/**
 * Drug Database
 *
 * Educational content about medications - mechanisms, effects, and clinical use.
 * Attending physician-level pharmacology understanding.
 */

import type {
  DrugEducation,
  DrugClassEducation,
  DrugInteraction,
} from './types.js';

// ============================================
// Drug Classes
// ============================================

export const DRUG_CLASSES: DrugClassEducation[] = [
  {
    id: 'statins',
    name: 'HMG-CoA Reductase Inhibitors (Statins)',
    category: 'cardiovascular',

    overview: 'Statins are the most important class of cholesterol-lowering medications. They reduce LDL cholesterol by 30-50% and have revolutionized cardiovascular disease prevention. They also have anti-inflammatory ("pleiotropic") effects beyond cholesterol lowering.',

    sharedMechanism: 'Inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis in the liver. This reduces hepatic cholesterol, causing upregulation of LDL receptors and increased LDL clearance from blood.',

    target: 'HMG-CoA reductase enzyme in hepatocytes',
    prototypeDrug: 'Atorvastatin',

    members: [
      {
        name: 'Atorvastatin (Lipitor)',
        distinguishingFeatures: ['High potency', 'Long half-life', 'Can be taken any time of day'],
        advantagesOverClass: ['Most potent LDL reduction', 'Extensive outcome data'],
        disadvantagesOverClass: ['More drug interactions via CYP3A4'],
      },
      {
        name: 'Rosuvastatin (Crestor)',
        distinguishingFeatures: ['Highest potency', 'Hydrophilic', 'Less CYP metabolism'],
        advantagesOverClass: ['Fewer drug interactions', 'Greatest LDL lowering per mg'],
        disadvantagesOverClass: ['More expensive'],
      },
      {
        name: 'Simvastatin (Zocor)',
        distinguishingFeatures: ['Prodrug', 'Moderate potency', 'Generic available'],
        advantagesOverClass: ['Inexpensive', 'Long track record'],
        disadvantagesOverClass: ['Many drug interactions', 'Myopathy risk at high doses'],
      },
      {
        name: 'Pravastatin (Pravachol)',
        distinguishingFeatures: ['Hydrophilic', 'Not CYP metabolized'],
        advantagesOverClass: ['Fewest drug interactions', 'Safer with other medications'],
        disadvantagesOverClass: ['Lower potency'],
      },
    ],

    classEffects: [
      {
        effect: 'LDL Cholesterol Reduction',
        mechanism: 'Decreased hepatic synthesis, increased LDL receptor expression',
        universalToClass: true,
      },
      {
        effect: 'Anti-inflammatory Effects',
        mechanism: 'Reduced CRP, decreased plaque inflammation',
        universalToClass: true,
      },
      {
        effect: 'Myopathy Risk',
        mechanism: 'Interference with mitochondrial function, CoQ10 depletion',
        universalToClass: true,
        exceptions: ['Less common with hydrophilic statins'],
      },
      {
        effect: 'Hepatotoxicity (rare)',
        mechanism: 'Direct hepatocyte toxicity, immune-mediated',
        universalToClass: true,
      },
      {
        effect: 'Diabetes Risk (slight)',
        mechanism: 'Impaired insulin secretion and sensitivity',
        universalToClass: true,
      },
    ],

    classWarnings: [
      'Monitor liver enzymes before starting and if symptoms develop',
      'Risk of myopathy increases with dose, interactions, hypothyroidism',
      'Contraindicated in pregnancy (category X)',
      'Drug interactions especially with CYP3A4 inhibitors',
    ],

    clinicalNiche: 'First-line therapy for primary and secondary prevention of atherosclerotic cardiovascular disease. Indicated for anyone with ASCVD, LDL ≥190, diabetes age 40-75, or elevated 10-year CV risk.',

    memberComparison: [
      {
        property: 'LDL Reduction (high dose)',
        drugComparisons: [
          { drug: 'Rosuvastatin 40mg', value: '55-60%' },
          { drug: 'Atorvastatin 80mg', value: '50-55%' },
          { drug: 'Simvastatin 40mg', value: '35-40%' },
          { drug: 'Pravastatin 40mg', value: '30-35%' },
        ],
      },
      {
        property: 'Half-life',
        drugComparisons: [
          { drug: 'Rosuvastatin', value: '19 hours' },
          { drug: 'Atorvastatin', value: '14 hours' },
          { drug: 'Simvastatin', value: '3 hours' },
          { drug: 'Pravastatin', value: '2 hours' },
        ],
      },
      {
        property: 'Drug Interactions',
        drugComparisons: [
          { drug: 'Pravastatin', value: 'Fewest' },
          { drug: 'Rosuvastatin', value: 'Few' },
          { drug: 'Atorvastatin', value: 'Moderate (CYP3A4)' },
          { drug: 'Simvastatin', value: 'Many (CYP3A4)' },
        ],
      },
    ],
  },
  {
    id: 'ace-inhibitors',
    name: 'ACE Inhibitors',
    category: 'cardiovascular',

    overview: 'ACE inhibitors block the renin-angiotensin-aldosterone system (RAAS), reducing blood pressure and protecting the heart and kidneys. They are cornerstone therapy for hypertension, heart failure, and diabetic nephropathy.',

    sharedMechanism: 'Inhibit angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This causes vasodilation, reduced aldosterone, and decreased sympathetic activity. Also prevents bradykinin breakdown (causes cough).',

    target: 'Angiotensin-converting enzyme',
    prototypeDrug: 'Lisinopril',

    members: [
      {
        name: 'Lisinopril (Prinivil, Zestril)',
        distinguishingFeatures: ['Once daily', 'No hepatic metabolism', 'Active drug (not prodrug)'],
        advantagesOverClass: ['Simple dosing', 'Renal excretion only'],
        disadvantagesOverClass: ['Renal adjustment needed'],
      },
      {
        name: 'Enalapril (Vasotec)',
        distinguishingFeatures: ['Prodrug', 'Twice daily often needed', 'IV form available'],
        advantagesOverClass: ['IV option for acute settings'],
        disadvantagesOverClass: ['BID dosing'],
      },
      {
        name: 'Ramipril (Altace)',
        distinguishingFeatures: ['Best outcome data in high-risk patients (HOPE trial)'],
        advantagesOverClass: ['Proven mortality benefit'],
        disadvantagesOverClass: ['Usually BID dosing'],
      },
      {
        name: 'Captopril (Capoten)',
        distinguishingFeatures: ['Original ACE inhibitor', 'Short-acting', 'TID dosing'],
        advantagesOverClass: ['Rapid onset, useful for dosing titration'],
        disadvantagesOverClass: ['Multiple daily doses needed'],
      },
    ],

    classEffects: [
      {
        effect: 'Blood Pressure Reduction',
        mechanism: 'Vasodilation, reduced sodium retention',
        universalToClass: true,
      },
      {
        effect: 'Cardiac Remodeling Prevention',
        mechanism: 'Reduced angiotensin II effects on heart',
        universalToClass: true,
      },
      {
        effect: 'Renal Protection',
        mechanism: 'Reduced intraglomerular pressure, decreased proteinuria',
        universalToClass: true,
      },
      {
        effect: 'Dry Cough',
        mechanism: 'Bradykinin accumulation irritates airways',
        universalToClass: true,
      },
      {
        effect: 'Hyperkalemia Risk',
        mechanism: 'Reduced aldosterone decreases potassium excretion',
        universalToClass: true,
      },
      {
        effect: 'Angioedema (rare)',
        mechanism: 'Bradykinin-mediated',
        universalToClass: true,
      },
    ],

    classWarnings: [
      'Contraindicated in pregnancy (teratogenic)',
      'Risk of hyperkalemia - monitor potassium',
      'Can cause acute kidney injury if bilateral renal artery stenosis',
      'Do not combine with ARBs (no benefit, more harm)',
      'Angioedema more common in Black patients',
    ],

    clinicalNiche: 'First-line for hypertension (especially with diabetes or CKD), heart failure with reduced ejection fraction (HFrEF), post-MI, diabetic nephropathy. Mortality benefit in heart failure.',

    memberComparison: [],
  },
  {
    id: 'beta-blockers',
    name: 'Beta-Adrenergic Blockers',
    category: 'cardiovascular',

    overview: 'Beta-blockers reduce heart rate and blood pressure by blocking beta-adrenergic receptors. They are essential for heart failure, post-MI, arrhythmias, and hypertension. Different agents have varying selectivity and additional properties.',

    sharedMechanism: 'Block beta-adrenergic receptors, reducing effects of catecholamines (norepinephrine, epinephrine). β1 blockade: decreases heart rate, contractility, and renin release. β2 blockade: can cause bronchoconstriction and vasoconstriction.',

    target: 'Beta-adrenergic receptors (β1 and/or β2)',
    prototypeDrug: 'Metoprolol',

    members: [
      {
        name: 'Metoprolol (Lopressor, Toprol-XL)',
        distinguishingFeatures: ['β1 selective', 'Available as tartrate (short-acting) and succinate (extended-release)'],
        advantagesOverClass: ['Heart failure data (succinate)', 'Relatively safe in mild asthma'],
        disadvantagesOverClass: ['CYP2D6 metabolism (genetic variability)'],
      },
      {
        name: 'Carvedilol (Coreg)',
        distinguishingFeatures: ['Non-selective β-blocker + α1 blocker', 'Additional vasodilation'],
        advantagesOverClass: ['Strong heart failure data', 'Additional BP lowering from α-blockade'],
        disadvantagesOverClass: ['More hypotension', 'Avoid in asthma'],
      },
      {
        name: 'Bisoprolol (Zebeta)',
        distinguishingFeatures: ['Highly β1 selective', 'Once daily'],
        advantagesOverClass: ['Heart failure proven', 'Good for COPD patients'],
        disadvantagesOverClass: ['Less commonly used in US'],
      },
      {
        name: 'Atenolol (Tenormin)',
        distinguishingFeatures: ['β1 selective', 'Renally excreted', 'Hydrophilic'],
        advantagesOverClass: ['Inexpensive', 'Fewer CNS effects'],
        disadvantagesOverClass: ['Less effective for mortality in hypertension vs other drugs'],
      },
      {
        name: 'Propranolol (Inderal)',
        distinguishingFeatures: ['Non-selective', 'Lipophilic (crosses BBB)', 'Original beta-blocker'],
        advantagesOverClass: ['Effective for tremor, migraines, anxiety', 'Performance anxiety'],
        disadvantagesOverClass: ['Avoid in asthma', 'More CNS effects', 'Masks hypoglycemia symptoms'],
      },
    ],

    classEffects: [
      {
        effect: 'Heart Rate Reduction',
        mechanism: 'β1 blockade reduces SA node automaticity and AV conduction',
        universalToClass: true,
      },
      {
        effect: 'Blood Pressure Reduction',
        mechanism: 'Reduced cardiac output, renin inhibition',
        universalToClass: true,
      },
      {
        effect: 'Anti-ischemic Effect',
        mechanism: 'Reduced myocardial oxygen demand',
        universalToClass: true,
      },
      {
        effect: 'Fatigue',
        mechanism: 'Reduced cardiac output, CNS effects',
        universalToClass: true,
      },
      {
        effect: 'Bronchoconstriction',
        mechanism: 'β2 blockade in airways',
        universalToClass: true,
        exceptions: ['β1 selective agents safer in mild asthma/COPD'],
      },
      {
        effect: 'Masking Hypoglycemia',
        mechanism: 'β2 blockade prevents tachycardia and tremor warning signs',
        universalToClass: true,
        exceptions: ['β1 selective agents less problematic'],
      },
    ],

    classWarnings: [
      'Do not stop abruptly (rebound hypertension, angina)',
      'Caution in asthma/COPD (use β1 selective if needed)',
      'Can worsen heart failure if not already on therapy (start low, go slow)',
      'Masks hypoglycemia symptoms in diabetics',
      'Sexual dysfunction common',
    ],

    clinicalNiche: 'Essential for heart failure (carvedilol, metoprolol succinate, bisoprolol), post-MI (mortality benefit), arrhythmias (rate control), angina, hypertension. Also migraine prophylaxis, essential tremor, performance anxiety.',

    memberComparison: [
      {
        property: 'β1 Selectivity',
        drugComparisons: [
          { drug: 'Bisoprolol', value: 'Highest' },
          { drug: 'Metoprolol', value: 'High' },
          { drug: 'Atenolol', value: 'Moderate' },
          { drug: 'Carvedilol', value: 'None (non-selective)' },
          { drug: 'Propranolol', value: 'None (non-selective)' },
        ],
      },
      {
        property: 'Heart Failure Evidence',
        drugComparisons: [
          { drug: 'Carvedilol', value: 'Strong (COPERNICUS)' },
          { drug: 'Metoprolol succinate', value: 'Strong (MERIT-HF)' },
          { drug: 'Bisoprolol', value: 'Strong (CIBIS-II)' },
          { drug: 'Atenolol', value: 'Not recommended' },
        ],
      },
    ],
  },
  {
    id: 'ssris',
    name: 'Selective Serotonin Reuptake Inhibitors (SSRIs)',
    category: 'psychiatric',

    overview: 'SSRIs are first-line antidepressants that work by increasing serotonin in the brain. They treat depression, anxiety disorders, OCD, and other conditions. Generally well-tolerated compared to older antidepressants.',

    sharedMechanism: 'Selectively inhibit serotonin reuptake transporter (SERT) in presynaptic neurons, increasing serotonin availability in synaptic cleft. Downstream effects include receptor downregulation and neuroplasticity changes that take weeks to develop.',

    target: 'Serotonin reuptake transporter (SERT)',
    prototypeDrug: 'Sertraline',

    members: [
      {
        name: 'Sertraline (Zoloft)',
        distinguishingFeatures: ['Most evidence in cardiac patients', 'Activating vs sedating neutral'],
        advantagesOverClass: ['Safe post-MI', 'Broad indication range'],
        disadvantagesOverClass: ['GI side effects common initially'],
      },
      {
        name: 'Escitalopram (Lexapro)',
        distinguishingFeatures: ['Most selective SSRI', 'S-enantiomer of citalopram'],
        advantagesOverClass: ['Fewest drug interactions', 'Well tolerated'],
        disadvantagesOverClass: ['QT prolongation at higher doses'],
      },
      {
        name: 'Fluoxetine (Prozac)',
        distinguishingFeatures: ['Very long half-life (4-6 days)', 'Original SSRI', 'Activating'],
        advantagesOverClass: ['Weekly formulation available', 'Less withdrawal if missed doses'],
        disadvantagesOverClass: ['Many drug interactions (CYP2D6)', 'Takes longer to clear'],
      },
      {
        name: 'Paroxetine (Paxil)',
        distinguishingFeatures: ['Most anticholinergic', 'Sedating', 'Short half-life'],
        advantagesOverClass: ['Effective for anxiety'],
        disadvantagesOverClass: ['Weight gain', 'Worst withdrawal syndrome', 'Pregnancy category D'],
      },
      {
        name: 'Citalopram (Celexa)',
        distinguishingFeatures: ['Racemic mixture', 'QT prolongation concern at >40mg'],
        advantagesOverClass: ['Inexpensive'],
        disadvantagesOverClass: ['Dose cap of 40mg (20mg in elderly) due to QT'],
      },
    ],

    classEffects: [
      {
        effect: 'Antidepressant Effect',
        mechanism: 'Increased serotonin transmission, downstream neuroplasticity',
        universalToClass: true,
      },
      {
        effect: 'Anxiolytic Effect',
        mechanism: 'Serotonin modulation in anxiety circuits',
        universalToClass: true,
      },
      {
        effect: 'GI Side Effects',
        mechanism: 'Serotonin effects on gut (most serotonin receptors are in GI)',
        universalToClass: true,
      },
      {
        effect: 'Sexual Dysfunction',
        mechanism: 'Serotonin inhibition of dopamine and nitric oxide',
        universalToClass: true,
      },
      {
        effect: 'Bleeding Risk',
        mechanism: 'Reduced platelet serotonin (needed for aggregation)',
        universalToClass: true,
      },
      {
        effect: 'Discontinuation Syndrome',
        mechanism: 'Receptor readjustment when drug stopped',
        universalToClass: true,
        exceptions: ['Less with fluoxetine due to long half-life'],
      },
    ],

    classWarnings: [
      'Black box warning: increased suicidality in young adults (monitor closely first weeks)',
      'Serotonin syndrome risk with other serotonergic drugs',
      'Discontinuation syndrome if stopped abruptly',
      'Bleeding risk, especially with NSAIDs or anticoagulants',
      'Hyponatremia (SIADH), especially in elderly',
    ],

    clinicalNiche: 'First-line for major depression, generalized anxiety disorder, panic disorder, social anxiety, OCD, PTSD. Preferred over older antidepressants due to safety and tolerability.',

    memberComparison: [
      {
        property: 'Half-life',
        drugComparisons: [
          { drug: 'Fluoxetine', value: '4-6 days (plus active metabolite)' },
          { drug: 'Sertraline', value: '26 hours' },
          { drug: 'Citalopram', value: '35 hours' },
          { drug: 'Escitalopram', value: '27-32 hours' },
          { drug: 'Paroxetine', value: '21 hours' },
        ],
      },
      {
        property: 'Drug Interactions',
        drugComparisons: [
          { drug: 'Escitalopram', value: 'Fewest' },
          { drug: 'Sertraline', value: 'Few' },
          { drug: 'Citalopram', value: 'Few' },
          { drug: 'Fluoxetine', value: 'Many (CYP2D6 inhibitor)' },
          { drug: 'Paroxetine', value: 'Many (CYP2D6 inhibitor)' },
        ],
      },
    ],
  },
  {
    id: 'ppis',
    name: 'Proton Pump Inhibitors (PPIs)',
    category: 'gastrointestinal',

    overview: 'PPIs are the most effective acid-suppressing medications, reducing gastric acid secretion by 90-95%. They treat GERD, peptic ulcers, and are used for H. pylori eradication and NSAID prophylaxis.',

    sharedMechanism: 'Irreversibly inhibit H+/K+-ATPase (proton pump) on parietal cell surface. This is the final common pathway for acid secretion. Because inhibition is irreversible, effect lasts until new pumps are synthesized (1-2 days).',

    target: 'H+/K+-ATPase (proton pump) on gastric parietal cells',
    prototypeDrug: 'Omeprazole',

    members: [
      {
        name: 'Omeprazole (Prilosec)',
        distinguishingFeatures: ['Original PPI', 'OTC available', 'CYP2C19 metabolism'],
        advantagesOverClass: ['Inexpensive', 'Well-studied'],
        disadvantagesOverClass: ['Drug interactions (CYP2C19)'],
      },
      {
        name: 'Esomeprazole (Nexium)',
        distinguishingFeatures: ['S-enantiomer of omeprazole', 'Slightly longer-acting'],
        advantagesOverClass: ['Possibly more consistent acid control'],
        disadvantagesOverClass: ['More expensive, minimal clinical advantage'],
      },
      {
        name: 'Pantoprazole (Protonix)',
        distinguishingFeatures: ['IV form available', 'Fewer drug interactions'],
        advantagesOverClass: ['Good for ICU use', 'Less CYP interaction'],
        disadvantagesOverClass: ['Cost'],
      },
      {
        name: 'Lansoprazole (Prevacid)',
        distinguishingFeatures: ['Orally disintegrating tablet available'],
        advantagesOverClass: ['Good for patients who cant swallow pills'],
        disadvantagesOverClass: ['CYP2C19 interactions'],
      },
    ],

    classEffects: [
      {
        effect: 'Profound Acid Suppression',
        mechanism: 'Irreversible proton pump inhibition',
        universalToClass: true,
      },
      {
        effect: 'Hypergastrinemia',
        mechanism: 'Loss of acid feedback → increased gastrin secretion',
        universalToClass: true,
      },
      {
        effect: 'Reduced B12 Absorption',
        mechanism: 'Acid needed to release B12 from food',
        universalToClass: true,
      },
      {
        effect: 'Reduced Calcium/Magnesium Absorption',
        mechanism: 'Acid facilitates mineral absorption',
        universalToClass: true,
      },
      {
        effect: 'C. difficile Risk',
        mechanism: 'Loss of acid barrier to ingested organisms',
        universalToClass: true,
      },
    ],

    classWarnings: [
      'Use lowest effective dose for shortest duration needed',
      'Long-term use: fracture risk, hypomagnesemia, B12 deficiency, C. diff',
      'May reduce clopidogrel effectiveness (especially omeprazole)',
      'Rebound acid hypersecretion when stopping',
      'Possible association with dementia, CKD (observational data)',
    ],

    clinicalNiche: 'GERD, peptic ulcer disease, H. pylori eradication (with antibiotics), NSAID-induced ulcer prophylaxis, Zollinger-Ellison syndrome, stress ulcer prophylaxis in ICU.',

    memberComparison: [],
  },
];

// ============================================
// Individual Drug Examples
// ============================================

export const DRUGS: DrugEducation[] = [
  {
    id: 'metformin',
    genericName: 'Metformin',
    brandNames: ['Glucophage', 'Glumetza', 'Fortamet'],
    drugClass: 'Biguanide',
    category: 'endocrine',

    overview: 'Metformin is the first-line medication for type 2 diabetes. It works primarily by reducing glucose production in the liver and improving insulin sensitivity. It does not cause hypoglycemia when used alone and may help with weight loss.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Mitochondrial complex I (indirectly activates AMPK)',
      targetLocation: 'Liver (primarily), muscle, fat',

      simpleExplanation: 'Metformin tells your liver to make less sugar and helps your body use insulin better. It\'s like turning down the sugar factory in your liver.',

      detailedMechanism: 'Metformin accumulates in hepatocytes where it inhibits mitochondrial respiratory chain complex I. This increases AMP:ATP ratio, activating AMPK (the cell\'s energy sensor). Activated AMPK suppresses gluconeogenesis and lipogenesis while increasing glucose uptake in muscle.',

      mechanismSteps: [
        {
          order: 1,
          location: 'Intestine',
          action: 'Absorbed from GI tract',
          result: 'Drug enters portal circulation to liver',
          timeframe: '2-3 hours to peak',
        },
        {
          order: 2,
          location: 'Hepatocyte mitochondria',
          action: 'Inhibits complex I of electron transport chain',
          result: 'Reduced ATP production, increased AMP:ATP ratio',
        },
        {
          order: 3,
          location: 'Hepatocyte cytoplasm',
          action: 'AMPK activated by increased AMP',
          result: 'Master metabolic regulator switched on',
        },
        {
          order: 4,
          location: 'Liver',
          action: 'AMPK inhibits gluconeogenic enzymes',
          result: 'Reduced glucose output from liver (main effect)',
        },
        {
          order: 5,
          location: 'Muscle',
          action: 'AMPK increases GLUT4 translocation',
          result: 'Improved glucose uptake',
        },
      ],

      physiologicalEffects: [
        {
          system: 'Hepatic',
          effect: 'Decreased gluconeogenesis',
          mechanism: 'AMPK inhibits CREB, reducing PEPCK and G6Pase',
          clinicalRelevance: 'Lowers fasting glucose',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Peripheral',
          effect: 'Improved insulin sensitivity',
          mechanism: 'Enhanced insulin signaling and GLUT4 trafficking',
          clinicalRelevance: 'Lowers postprandial glucose',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'GI upset',
          mechanism: 'Serotonin release, altered bile acid metabolism',
          clinicalRelevance: 'Nausea, diarrhea common initially',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Metabolic',
          effect: 'Weight neutral or slight loss',
          mechanism: 'Reduced appetite, altered gut hormones',
          clinicalRelevance: 'Advantage over many diabetes drugs',
          desiredOrAdverse: 'desired',
        },
      ],

      onsetOfAction: 'Days to weeks for full effect on glucose',
      durationOfEffect: '8-12 hours (immediate release)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '50-60%',
        route: ['oral'],
        factors: ['Decreased by food (delayed but not reduced total)'],
        timeToePeak: '2-3 hours (IR), 4-8 hours (ER)',
        foodEffect: 'Take with food to reduce GI effects',
      },
      distribution: {
        volumeOfDistribution: '654 L',
        proteinBinding: 'Negligible',
        tissueDistribution: ['Liver', 'Kidney', 'GI tract', 'Muscle'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (unchanged)',
        renalClearance: '510 mL/min',
        adjustmentNeeded: {
          renal: true,
          hepatic: false,
        },
      },
      halfLife: '6.2 hours',
      timeToSteadyState: '24-48 hours',
    },

    indications: [
      {
        condition: 'Type 2 Diabetes Mellitus',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line therapy per ADA guidelines',
      },
      {
        condition: 'Prediabetes',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Can delay progression to diabetes',
      },
      {
        condition: 'Polycystic Ovary Syndrome (PCOS)',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Improves insulin resistance, may help ovulation',
      },
      {
        condition: 'Gestational Diabetes',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Alternative to insulin in some cases',
      },
    ],

    dosing: {
      usualDose: {
        amount: '500-1000mg',
        frequency: 'Twice daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'eGFR 30-45',
          adjustment: 'Max 1000mg/day',
          rationale: 'Reduced clearance increases lactic acidosis risk',
        },
        {
          condition: 'eGFR <30',
          adjustment: 'Contraindicated',
          rationale: 'High risk of lactic acidosis',
        },
        {
          condition: 'Starting therapy',
          adjustment: 'Start 500mg daily, titrate slowly',
          rationale: 'Reduces GI side effects',
        },
      ],
      maxDose: '2550mg/day (2000mg more common)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: 'With meals',
        specialInstructions: [
          'Take with food to reduce GI upset',
          'Extended-release: swallow whole, do not crush',
          'Increase dose gradually over weeks',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'GI Upset (nausea, diarrhea)',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Direct GI effects, altered gut bacteria, bile acid changes',
        management: 'Take with food, titrate slowly, try extended-release',
        reversible: true,
        onsetTiming: 'First weeks of therapy',
      },
      {
        name: 'Vitamin B12 Deficiency',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Impaired B12 absorption in ileum',
        management: 'Monitor B12 levels, supplement if needed',
        reversible: true,
        onsetTiming: 'After years of use',
      },
      {
        name: 'Lactic Acidosis',
        frequency: 'very-rare',
        severity: 'life-threatening',
        mechanism: 'Inhibition of lactate gluconeogenesis with accumulation',
        management: 'Avoid in conditions with hypoxia or severe renal impairment',
        reversible: false,
        onsetTiming: 'Usually in setting of precipitant (dehydration, contrast)',
      },
      {
        name: 'Metallic Taste',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Unknown',
        management: 'Usually resolves with time',
        reversible: true,
        onsetTiming: 'Early in therapy',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Iodinated Contrast Dye',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Contrast can cause acute kidney injury, impairing metformin excretion',
        effect: 'Increased risk of lactic acidosis',
        management: 'Hold metformin before contrast, resume 48h after if renal function stable',
      },
      {
        interactingDrug: 'Alcohol',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Both inhibit gluconeogenesis',
        effect: 'Increased lactic acidosis risk and hypoglycemia',
        management: 'Limit alcohol use',
      },
      {
        interactingDrug: 'Cimetidine',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Competes for renal tubular secretion',
        effect: 'Increased metformin levels',
        management: 'Monitor or use alternative H2 blocker',
      },
    ],

    contraindications: [
      {
        condition: 'eGFR <30 mL/min',
        type: 'absolute',
        reason: 'Cannot be excreted, accumulates, lactic acidosis risk',
      },
      {
        condition: 'Metabolic acidosis',
        type: 'absolute',
        reason: 'Can worsen acidosis',
      },
      {
        condition: 'Severe hepatic impairment',
        type: 'relative',
        reason: 'Impaired lactate clearance',
      },
      {
        condition: 'Active alcohol abuse',
        type: 'relative',
        reason: 'Increased lactic acidosis risk',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Crosses placenta, no clear teratogenicity',
        recommendation: 'Can be continued in pregnancy if needed; insulin preferred by many',
        pregnancyCategory: 'B',
      },
      {
        population: 'geriatric',
        consideration: 'Reduced renal function more common',
        recommendation: 'Check and monitor eGFR, may need dose reduction',
      },
      {
        population: 'renal-impairment',
        consideration: 'Primary route of elimination',
        recommendation: 'Reduce dose if eGFR 30-45; contraindicated if <30',
      },
    ],

    monitoring: [
      {
        parameter: 'Renal function (eGFR)',
        frequency: 'At baseline, at least annually',
        rationale: 'Required for safe use',
        actionThreshold: 'Reduce dose if eGFR 30-45; stop if <30',
      },
      {
        parameter: 'Vitamin B12',
        frequency: 'Every 2-3 years with chronic use',
        rationale: 'Long-term use can cause deficiency',
        actionThreshold: 'Supplement if low',
      },
      {
        parameter: 'HbA1c',
        frequency: 'Every 3-6 months',
        rationale: 'Assess glycemic control',
        actionThreshold: 'Adjust therapy if not at goal',
      },
    ],

    patientEducation: [
      'Take with meals to reduce stomach upset',
      'Do not drink excessive alcohol',
      'Tell doctors you take metformin before any contrast dye procedures',
      'Does not usually cause low blood sugar by itself',
      'Diarrhea usually improves after a few weeks',
      'Extended-release tablets should not be crushed or chewed',
      'If you have severe vomiting or diarrhea, contact your doctor (dehydration risk)',
    ],

    clinicalPearls: [
      'First-line for type 2 diabetes regardless of weight',
      'Cardiovascular and possible mortality benefits',
      'Start low (500mg daily) and titrate slowly to minimize GI effects',
      'Extended-release formulation better tolerated GI-wise',
      'One of few diabetes drugs that doesn\'t cause weight gain',
      'No hypoglycemia when used alone',
      'Hold before surgery or procedures where kidney function might decline',
      'Ghost tablet in stool with ER formulation is normal',
    ],
  },

  // --------------------------------------------
  // LISINOPRIL
  // --------------------------------------------
  {
    id: 'lisinopril',
    genericName: 'Lisinopril',
    brandNames: ['Zestril', 'Prinivil'],
    drugClass: 'ACE Inhibitor',
    category: 'cardiovascular',

    overview: 'Lisinopril is an ACE inhibitor used to treat hypertension, heart failure, and post-MI LV dysfunction. It also protects kidneys in diabetic nephropathy. The distinctive "dry cough" side effect affects 5-20% of patients.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Angiotensin-Converting Enzyme (ACE)',
      targetLocation: 'Lungs (primarily), vascular endothelium, kidney',

      simpleExplanation: 'Lisinopril blocks an enzyme that makes a hormone that raises blood pressure. This relaxes blood vessels and reduces strain on the heart.',

      detailedMechanism: 'ACE converts angiotensin I to angiotensin II and degrades bradykinin. By inhibiting ACE, lisinopril reduces angiotensin II (a potent vasoconstrictor that also stimulates aldosterone release), leading to vasodilation and decreased sodium/water retention. Accumulated bradykinin contributes to vasodilation but also causes the characteristic dry cough and rare angioedema.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters systemic circulation', timeframe: '1-2 hours to peak' },
        { order: 2, location: 'Lungs/Vessels', action: 'Binds to ACE active site', result: 'ACE catalytic function blocked' },
        { order: 3, location: 'Systemic', action: 'Angiotensin I no longer converted to angiotensin II', result: 'Reduced vasoconstriction' },
        { order: 4, location: 'Adrenal gland', action: 'Less angiotensin II stimulation', result: 'Decreased aldosterone secretion' },
        { order: 5, location: 'Kidney', action: 'Reduced aldosterone effect', result: 'Decreased sodium and water retention' },
        { order: 6, location: 'Systemic', action: 'Bradykinin accumulates', result: 'Additional vasodilation; cough pathway activated' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Vasodilation', mechanism: 'Reduced angiotensin II', clinicalRelevance: 'Lowers blood pressure', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced cardiac remodeling', mechanism: 'Decreased angiotensin II-mediated fibrosis', clinicalRelevance: 'Heart failure benefit, post-MI protection', desiredOrAdverse: 'desired' },
        { system: 'Renal', effect: 'Reduced intraglomerular pressure', mechanism: 'Efferent arteriole dilation', clinicalRelevance: 'Protects kidneys in diabetes', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Dry cough', mechanism: 'Bradykinin accumulation in lungs', clinicalRelevance: 'Occurs in 5-20%, may require switching to ARB', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Hyperkalemia', mechanism: 'Reduced aldosterone', clinicalRelevance: 'Monitor potassium, especially with renal impairment', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours for BP effect; weeks for full heart failure/renal protection',
      durationOfEffect: '24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '25%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '6-8 hours',
        foodEffect: 'No significant effect',
      },
      distribution: {
        volumeOfDistribution: 'Minimal tissue distribution',
        proteinBinding: 'Minimal (0%)',
        tissueDistribution: ['Plasma', 'Kidney', 'Lung'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized (excreted unchanged)',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (100% unchanged)',
        renalClearance: '50 mL/min',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '12 hours',
      timeToSteadyState: '2-3 days',
    },

    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'First-line especially in diabetes, CKD, heart failure' },
      { condition: 'Heart Failure (HFrEF)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Mortality benefit in ATLAS, SOLVD trials' },
      { condition: 'Post-MI with LV dysfunction', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Diabetic Nephropathy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Slows progression of proteinuria' },
    ],

    dosing: {
      usualDose: { amount: '10-40 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'CrCl 10-30 mL/min', adjustment: 'Start 5 mg, max 40 mg', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl <10 or dialysis', adjustment: 'Start 2.5 mg', rationale: 'Severely reduced clearance' },
        { condition: 'Heart failure', adjustment: 'Start 2.5-5 mg', rationale: 'Higher risk of hypotension' },
      ],
      maxDose: '80 mg daily (40 mg for HTN)',
      administration: { route: 'oral', withFood: 'either', specialInstructions: ['Take at consistent time daily', 'Do not stop abruptly'] },
    },

    adverseEffects: [
      { name: 'Dry cough', frequency: 'common', severity: 'mild', mechanism: 'Bradykinin accumulation in lungs', management: 'Switch to ARB if intolerable', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Hyperkalemia', frequency: 'common', severity: 'moderate', mechanism: 'Reduced aldosterone', management: 'Monitor K+, limit K+ intake, avoid K-sparing diuretics', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Vasodilation', management: 'Start low dose, especially if volume depleted', reversible: true, onsetTiming: 'Hours' },
      { name: 'Acute kidney injury', frequency: 'uncommon', severity: 'severe', mechanism: 'Reduced GFR in bilateral renal artery stenosis', management: 'Check creatinine 1-2 weeks after starting', reversible: true, onsetTiming: 'Days' },
      { name: 'Angioedema', frequency: 'rare', severity: 'life-threatening', mechanism: 'Bradykinin accumulation', management: 'Discontinue immediately, never rechallenge', reversible: true, onsetTiming: 'Days to years' },
    ],

    interactions: [
      { interactingDrug: 'Potassium supplements', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both increase potassium', effect: 'Hyperkalemia risk', management: 'Monitor K+, avoid routine K+ supplementation' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs reduce renal prostaglandins', effect: 'Reduced antihypertensive effect, increased AKI risk', management: 'Use lowest NSAID dose, monitor BP and renal function' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced lithium excretion', effect: 'Lithium toxicity', management: 'Monitor lithium levels closely' },
    ],

    contraindications: [
      { condition: 'Pregnancy', type: 'absolute', reason: 'Fetal renal toxicity, oligohydramnios, fetal death', alternative: 'Labetalol, nifedipine, methyldopa for HTN in pregnancy' },
      { condition: 'History of ACE-I induced angioedema', type: 'absolute', reason: 'Life-threatening recurrence risk' },
      { condition: 'Bilateral renal artery stenosis', type: 'absolute', reason: 'Precipitates acute renal failure' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Teratogenic, especially 2nd and 3rd trimester', recommendation: 'Contraindicated - stop immediately if pregnancy detected', pregnancyCategory: 'D' },
      { population: 'geriatric', consideration: 'More sensitive to hypotension', recommendation: 'Start low dose, titrate slowly' },
      { population: 'renal-impairment', consideration: 'Accumulates in kidney disease', recommendation: 'Reduce dose based on CrCl' },
    ],

    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Initially at each visit, then per guidelines', rationale: 'Assess efficacy', actionThreshold: 'Titrate to goal' },
      { parameter: 'Potassium', frequency: 'Baseline, 1-2 weeks after start/dose change, then periodically', rationale: 'Risk of hyperkalemia', actionThreshold: 'K>5.5: reduce dose or discontinue' },
      { parameter: 'Creatinine/eGFR', frequency: 'Baseline, 1-2 weeks after start, then periodically', rationale: 'Assess for acute kidney injury', actionThreshold: 'Cr rise >30%: investigate renal artery stenosis' },
    ],

    patientEducation: [
      'May cause a dry cough - tell your doctor but do not stop without asking',
      'Avoid potassium supplements and salt substitutes (contain potassium)',
      'Report swelling of face, lips, or tongue immediately (angioedema)',
      'Do not use if pregnant or planning pregnancy',
      'Rise slowly to avoid dizziness from low blood pressure',
      'Stay well hydrated, especially in hot weather',
    ],

    clinicalPearls: [
      'ACE inhibitors reduce mortality in heart failure - titrate to target dose if tolerated',
      'Cough occurs in 5-20% - switching to ARB usually resolves it',
      'Angioedema can occur even after years of use - most common in Black patients',
      'Up to 30% creatinine rise is acceptable and may indicate the drug is working',
      'First-dose hypotension more common if volume depleted or on high-dose diuretics',
      'ARBs are NOT safe alternatives after ACE-I angioedema (some cross-reactivity)',
    ],
  },

  // --------------------------------------------
  // ATORVASTATIN
  // --------------------------------------------
  {
    id: 'atorvastatin',
    genericName: 'Atorvastatin',
    brandNames: ['Lipitor'],
    drugClass: 'HMG-CoA Reductase Inhibitor (Statin)',
    category: 'cardiovascular',

    overview: 'Atorvastatin is the most commonly prescribed statin, used to lower LDL cholesterol and reduce cardiovascular events. It offers potent LDL reduction (up to 50-60%) and has extensive clinical trial evidence for both primary and secondary prevention.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'HMG-CoA Reductase',
      targetLocation: 'Liver (hepatocytes)',

      simpleExplanation: 'Atorvastatin blocks an enzyme in the liver that makes cholesterol. When the liver makes less cholesterol, it pulls more LDL ("bad cholesterol") out of the blood to use.',

      detailedMechanism: 'HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis, converting HMG-CoA to mevalonate. Atorvastatin competitively inhibits this enzyme, reducing hepatic cholesterol synthesis. In response, hepatocytes upregulate LDL receptors, increasing LDL clearance from plasma. Statins also have pleiotropic effects including anti-inflammatory actions and improved endothelial function.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters portal circulation to liver', timeframe: '1-2 hours' },
        { order: 2, location: 'Hepatocyte', action: 'Binds to HMG-CoA reductase active site', result: 'Enzyme activity inhibited' },
        { order: 3, location: 'Hepatocyte', action: 'Reduced mevalonate and downstream cholesterol synthesis', result: 'Intracellular cholesterol decreases' },
        { order: 4, location: 'Hepatocyte membrane', action: 'SREBP activates LDL receptor gene', result: 'Increased LDL receptor expression' },
        { order: 5, location: 'Hepatocyte surface', action: 'More LDL receptors on cell surface', result: 'Increased LDL uptake from blood' },
        { order: 6, location: 'Plasma', action: 'LDL particles cleared by liver', result: 'Reduced LDL cholesterol in blood', timeframe: '2-4 weeks for full effect' },
      ],

      physiologicalEffects: [
        { system: 'Hepatic', effect: 'Reduced cholesterol synthesis', mechanism: 'HMG-CoA reductase inhibition', clinicalRelevance: 'Primary therapeutic effect', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Plaque stabilization', mechanism: 'Reduced inflammation, improved endothelial function', clinicalRelevance: 'Reduces cardiovascular events', desiredOrAdverse: 'desired' },
        { system: 'Musculoskeletal', effect: 'Myalgia/myopathy', mechanism: 'Mitochondrial dysfunction, CoQ10 depletion', clinicalRelevance: 'Muscle pain in 5-10%, rarely severe', desiredOrAdverse: 'adverse' },
        { system: 'Hepatic', effect: 'Transaminase elevation', mechanism: 'Direct hepatocyte toxicity', clinicalRelevance: 'Usually mild, rarely clinically significant', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Slight diabetes risk', mechanism: 'Impaired insulin secretion', clinicalRelevance: 'Small increase in new-onset diabetes, CV benefit outweighs', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '2-4 weeks for LDL reduction',
      durationOfEffect: '24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '14%',
        route: ['oral'],
        factors: ['Extensive first-pass metabolism'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Decreased absorption but not clinically significant',
      },
      distribution: {
        volumeOfDistribution: '381 L',
        proteinBinding: '>98%',
        tissueDistribution: ['Liver (high concentration)', 'Muscle', 'Adipose'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: ['ortho-hydroxy atorvastatin', 'para-hydroxy atorvastatin'],
        geneticVariability: 'CYP3A4 polymorphisms may affect levels',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Biliary (>98%)',
        biliaryClearance: 'Primary',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '14 hours (20-30 hours including active metabolites)',
      timeToSteadyState: '1-2 weeks',
    },

    indications: [
      { condition: 'Primary hyperlipidemia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'ASCVD (secondary prevention)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'High-intensity statin for all patients with ASCVD' },
      { condition: 'Primary prevention (high CV risk)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Based on 10-year ASCVD risk calculation' },
      { condition: 'Familial hypercholesterolemia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '10-80 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'High-intensity therapy needed', adjustment: '40-80 mg daily', rationale: 'ASCVD, LDL≥190, diabetes with CV risk' },
        { condition: 'Moderate-intensity needed', adjustment: '10-20 mg daily', rationale: 'Primary prevention with elevated risk' },
        { condition: 'With CYP3A4 inhibitors', adjustment: 'Max 20 mg with some inhibitors', rationale: 'Risk of myopathy' },
      ],
      maxDose: '80 mg daily',
      administration: { route: 'oral', withFood: 'either', timing: 'Can be taken any time of day (long half-life)', specialInstructions: ['Avoid grapefruit juice in large quantities'] },
    },

    adverseEffects: [
      { name: 'Myalgia', frequency: 'common', severity: 'mild', mechanism: 'Uncertain - possibly mitochondrial', management: 'Assess CK if severe; consider dose reduction, alternative statin, or non-statin', reversible: true, onsetTiming: 'Days to months' },
      { name: 'Transaminase elevation', frequency: 'uncommon', severity: 'mild', mechanism: 'Hepatocyte stress', management: 'Typically does not require discontinuation unless >3x ULN', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Rhabdomyolysis', frequency: 'very-rare', severity: 'life-threatening', mechanism: 'Severe muscle breakdown', management: 'Stop immediately, IV fluids, monitor renal function', reversible: true, onsetTiming: 'Weeks' },
      { name: 'New-onset diabetes', frequency: 'uncommon', severity: 'mild', mechanism: 'Impaired insulin secretion', management: 'Monitor glucose, CV benefit outweighs diabetes risk', reversible: false, onsetTiming: 'Months to years' },
    ],

    interactions: [
      { interactingDrug: 'Grapefruit juice (large amounts)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4 inhibition in gut', effect: 'Increased atorvastatin levels', management: 'Avoid large amounts of grapefruit' },
      { interactingDrug: 'Clarithromycin/Erythromycin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Strong CYP3A4 inhibition', effect: 'Markedly increased statin levels, myopathy risk', management: 'Temporarily hold statin or use azithromycin' },
      { interactingDrug: 'Cyclosporine', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 and OATP1B1 inhibition', effect: 'Greatly increased statin levels', management: 'Avoid combination or use very low dose' },
      { interactingDrug: 'Gemfibrozil', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Inhibits statin glucuronidation', effect: 'Increased myopathy risk', management: 'Avoid combination; fenofibrate safer with statins' },
    ],

    contraindications: [
      { condition: 'Active liver disease', type: 'absolute', reason: 'Risk of hepatotoxicity', alternative: 'Consider ezetimibe or other non-statin' },
      { condition: 'Pregnancy', type: 'absolute', reason: 'Theoretical teratogenicity', alternative: 'Stop before conception' },
      { condition: 'Breastfeeding', type: 'absolute', reason: 'Excreted in milk, potential harm to infant' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Contraindicated', recommendation: 'Discontinue before conception or immediately if pregnancy detected', pregnancyCategory: 'X' },
      { population: 'geriatric', consideration: 'Higher myopathy risk', recommendation: 'Consider lower doses, monitor for muscle symptoms' },
      { population: 'hepatic-impairment', consideration: 'Increased drug levels', recommendation: 'Avoid in active liver disease; caution in mild-moderate impairment' },
    ],

    monitoring: [
      { parameter: 'Lipid panel', frequency: 'Baseline, 4-12 weeks after starting, then annually', rationale: 'Assess efficacy', actionThreshold: 'Adjust therapy if not meeting goals' },
      { parameter: 'Liver enzymes (ALT)', frequency: 'Baseline, then if symptoms suggest hepatotoxicity', rationale: 'Routine monitoring no longer required per guidelines', actionThreshold: '>3x ULN: discontinue' },
      { parameter: 'Creatine kinase (CK)', frequency: 'Only if muscle symptoms develop', rationale: 'Assess for myopathy', actionThreshold: '>10x ULN or symptoms: discontinue' },
    ],

    patientEducation: [
      'Take once daily at any consistent time',
      'Report unexplained muscle pain, tenderness, or weakness promptly',
      'Avoid large quantities of grapefruit juice',
      'Do not take if pregnant or planning to become pregnant',
      'Statins work best with healthy lifestyle - diet and exercise still important',
      'Do not stop without talking to your doctor - cardiovascular benefits continue as long as you take it',
    ],

    clinicalPearls: [
      'Most potent statin per mg - high-intensity = 40-80 mg daily',
      'Long half-life allows dosing any time of day (unlike simvastatin)',
      'CYP3A4 substrate - watch for drug interactions',
      'LDL lowering roughly doubles with each doubling of dose (rule of 6%)',
      '80 mg dose has slightly higher adverse effect rate than 40 mg',
      'Generic widely available - excellent cost-effectiveness',
      'Statin "intolerance" is common but true intolerance is rare - often can rechallenge',
    ],
  },

  // --------------------------------------------
  // METOPROLOL
  // --------------------------------------------
  {
    id: 'metoprolol',
    genericName: 'Metoprolol',
    brandNames: ['Lopressor', 'Toprol-XL'],
    drugClass: 'Beta-1 Selective Blocker',
    category: 'cardiovascular',

    overview: 'Metoprolol is a cardioselective beta-blocker used for hypertension, heart failure, and angina. Available in immediate-release (tartrate) and extended-release (succinate) formulations. The succinate form has mortality benefit in heart failure.',

    mechanism: {
      type: 'receptor-antagonist',
      target: 'Beta-1 Adrenergic Receptors',
      targetLocation: 'Heart (primarily), kidney (JG cells)',

      simpleExplanation: 'Metoprolol blocks the receptors in your heart that respond to adrenaline. This slows your heart rate and reduces how hard your heart pumps, lowering blood pressure and oxygen demand.',

      detailedMechanism: 'Metoprolol selectively blocks beta-1 adrenergic receptors, which predominate in cardiac tissue. This antagonizes catecholamine effects on the heart, reducing heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity (negative dromotropy). It also reduces renin release from juxtaglomerular cells. At higher doses, some beta-2 blockade may occur.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters systemic circulation', timeframe: '1-2 hours (IR)' },
        { order: 2, location: 'Heart', action: 'Binds to beta-1 receptors', result: 'Prevents catecholamine binding' },
        { order: 3, location: 'SA node', action: 'Reduced cAMP signaling', result: 'Decreased heart rate' },
        { order: 4, location: 'Myocardium', action: 'Reduced calcium influx', result: 'Decreased contractility' },
        { order: 5, location: 'AV node', action: 'Reduced conduction velocity', result: 'Slowed AV conduction' },
        { order: 6, location: 'Kidney JG cells', action: 'Reduced renin release', result: 'Decreased angiotensin II, lower BP' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Reduced heart rate', mechanism: 'SA node beta-1 blockade', clinicalRelevance: 'Rate control, reduced oxygen demand', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced BP', mechanism: 'Decreased cardiac output and renin release', clinicalRelevance: 'Antihypertensive effect', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Negative inotropy', mechanism: 'Reduced contractility', clinicalRelevance: 'Paradoxically beneficial in HF (prevents remodeling)', desiredOrAdverse: 'both' },
        { system: 'Metabolic', effect: 'Masked hypoglycemia symptoms', mechanism: 'Blocked adrenergic warning signs', clinicalRelevance: 'Caution in insulin-treated diabetics', desiredOrAdverse: 'adverse' },
        { system: 'CNS', effect: 'Fatigue, depression', mechanism: 'Uncertain, possibly central beta blockade', clinicalRelevance: 'May affect quality of life', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1-2 hours (IR); 6-12 hours (ER)',
      durationOfEffect: '12-24 hours depending on formulation',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '50% (IR); variable ER',
        route: ['oral', 'IV'],
        factors: ['Food increases absorption of IR'],
        timeToePeak: '1-2 hours (IR); 6-12 hours (ER)',
        foodEffect: 'Take IR with food',
      },
      distribution: {
        volumeOfDistribution: '4.2 L/kg',
        proteinBinding: '12%',
        tissueDistribution: ['Heart', 'Liver', 'Lung'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2D6)',
        enzymes: ['CYP2D6'],
        activeMetabolites: [],
        geneticVariability: 'CYP2D6 poor metabolizers have higher levels',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (95% as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '3-7 hours (IR); effective half-life longer for ER',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Not first-line for uncomplicated HTN per JNC' },
      { condition: 'Heart Failure (HFrEF)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Metoprolol succinate only; mortality benefit (MERIT-HF)' },
      { condition: 'Angina pectoris', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Atrial fibrillation (rate control)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Post-MI', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '25-100 mg BID (IR) or 50-200 mg daily (ER)', frequency: 'varies by formulation', route: 'oral' },
      adjustments: [
        { condition: 'Heart failure initiation', adjustment: 'Start very low (12.5-25 mg ER), uptitrate slowly', rationale: 'Risk of decompensation if started too fast' },
        { condition: 'Hepatic impairment', adjustment: 'May need lower doses', rationale: 'Reduced metabolism' },
      ],
      maxDose: '400 mg daily (IR); 400 mg daily (ER)',
      administration: { route: 'oral', withFood: 'with-food', specialInstructions: ['IR should be taken with food', 'ER should not be crushed or chewed', 'Do not stop abruptly'] },
    },

    adverseEffects: [
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'SA node depression', management: 'Reduce dose if symptomatic; hold if HR<50', reversible: true, onsetTiming: 'Days' },
      { name: 'Fatigue', frequency: 'common', severity: 'mild', mechanism: 'Reduced cardiac output, possible CNS effects', management: 'Often improves with time; dose reduction if needed', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Cold extremities', frequency: 'common', severity: 'mild', mechanism: 'Some peripheral beta-2 blockade', management: 'Usually tolerable; consider vasodilating beta-blocker if severe', reversible: true, onsetTiming: 'Days' },
      { name: 'Depression', frequency: 'uncommon', severity: 'moderate', mechanism: 'CNS effects', management: 'Consider switching to more hydrophilic beta-blocker', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Bronchospasm', frequency: 'uncommon', severity: 'severe', mechanism: 'Beta-2 blockade (less than non-selective BBs)', management: 'Avoid in uncontrolled asthma; caution in COPD', reversible: true, onsetTiming: 'Hours to days' },
    ],

    interactions: [
      { interactingDrug: 'Verapamil/Diltiazem', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive cardiac depression', effect: 'Severe bradycardia, heart block', management: 'Avoid combination or use with extreme caution' },
      { interactingDrug: 'Clonidine', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Rebound hypertension if clonidine stopped', effect: 'Hypertensive crisis', management: 'Taper clonidine first if discontinuing both' },
      { interactingDrug: 'CYP2D6 inhibitors (fluoxetine, paroxetine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced metoprolol metabolism', effect: 'Increased metoprolol levels', management: 'Monitor HR and BP' },
    ],

    contraindications: [
      { condition: 'Severe bradycardia', type: 'absolute', reason: 'Will worsen' },
      { condition: 'Heart block (2nd or 3rd degree)', type: 'absolute', reason: 'Will worsen conduction' },
      { condition: 'Cardiogenic shock', type: 'absolute', reason: 'Negative inotropic effect dangerous' },
      { condition: 'Decompensated heart failure', type: 'absolute', reason: 'May precipitate further decompensation', alternative: 'Start only when euvolemic' },
      { condition: 'Sick sinus syndrome', type: 'absolute', reason: 'Without pacemaker' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'May cause fetal bradycardia, hypoglycemia', recommendation: 'Can be used if necessary; labetalol often preferred', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'More sensitive to bradycardia', recommendation: 'Start low, titrate slowly' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'Lower doses may be needed' },
    ],

    monitoring: [
      { parameter: 'Heart rate', frequency: 'Each visit', rationale: 'Assess for bradycardia', actionThreshold: 'HR<50: consider dose reduction' },
      { parameter: 'Blood pressure', frequency: 'Each visit', rationale: 'Assess efficacy', actionThreshold: 'Titrate to goal' },
      { parameter: 'Symptoms (fatigue, dizziness)', frequency: 'Each visit', rationale: 'Assess tolerability' },
    ],

    patientEducation: [
      'Do not stop this medication suddenly - can cause dangerous rebound effects',
      'Take with food for better absorption and to prevent stomach upset',
      'May cause tiredness, especially at first',
      'Check your pulse - contact doctor if consistently below 50',
      'Rise slowly to prevent dizziness',
      'May mask symptoms of low blood sugar if diabetic',
      'Extended-release tablets should not be crushed or chewed',
    ],

    clinicalPearls: [
      'Tartrate vs succinate: only succinate (Toprol-XL) has mortality benefit in HF',
      'Tartrate can be used for rate control and HTN but not for HF',
      'In HF, start very low and titrate slowly - "start low, go slow"',
      'Beta-blocker withdrawal can cause rebound angina, arrhythmia - always taper',
      'Cardioselective but selectivity decreases at higher doses',
      'CYP2D6 metabolism - watch for interactions with SSRIs',
      'Target HR in stable angina and HF is 55-60 bpm if tolerated',
    ],
  },

  // --------------------------------------------
  // OMEPRAZOLE
  // --------------------------------------------
  {
    id: 'omeprazole',
    genericName: 'Omeprazole',
    brandNames: ['Prilosec', 'Losec'],
    drugClass: 'Proton Pump Inhibitor (PPI)',
    category: 'gastrointestinal',

    overview: 'Omeprazole is a proton pump inhibitor that reduces stomach acid by irreversibly blocking the hydrogen-potassium ATPase enzyme in gastric parietal cells. It is one of the most prescribed medications worldwide for GERD, peptic ulcers, and acid-related disorders.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'H+/K+-ATPase (Proton Pump)',
      targetLocation: 'Gastric parietal cell canalicular membrane',

      simpleExplanation: 'Omeprazole turns off the acid pumps in your stomach. These pumps are what produce stomach acid, so blocking them dramatically reduces acid production.',

      detailedMechanism: 'Omeprazole is a prodrug that requires activation in the acidic environment of the parietal cell canaliculus. Once activated, it forms covalent disulfide bonds with cysteine residues on the H+/K+-ATPase, irreversibly inhibiting the enzyme. Since this is the final step in acid secretion, inhibition is profound (>90% reduction). New pumps must be synthesized for acid secretion to resume.',

      mechanismSteps: [
        { order: 1, location: 'Intestine', action: 'Absorbed as inactive prodrug', result: 'Drug enters systemic circulation', timeframe: '1-2 hours' },
        { order: 2, location: 'Parietal cell', action: 'Drug concentrates in acidic canaliculus', result: 'Prodrug accumulates near target' },
        { order: 3, location: 'Canaliculus', action: 'Acid-catalyzed conversion to active sulfenamide', result: 'Active metabolite formed' },
        { order: 4, location: 'Proton pump', action: 'Covalent binding to H+/K+-ATPase cysteines', result: 'Irreversible enzyme inhibition' },
        { order: 5, location: 'Gastric lumen', action: 'Reduced H+ secretion', result: 'Increased gastric pH', timeframe: '1-4 days for maximal effect' },
      ],

      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Reduced gastric acid', mechanism: 'Proton pump inhibition', clinicalRelevance: 'Heals ulcers, relieves GERD', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Hypergastrinemia', mechanism: 'Feedback from low acid', clinicalRelevance: 'Usually clinically insignificant', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Reduced B12/magnesium absorption', mechanism: 'Acid needed for absorption', clinicalRelevance: 'Monitor with long-term use', desiredOrAdverse: 'adverse' },
        { system: 'Skeletal', effect: 'Possible increased fracture risk', mechanism: 'Reduced calcium absorption', clinicalRelevance: 'Consider calcium supplementation, especially in elderly', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1-2 hours (acid suppression); 1-4 days for maximal effect',
      durationOfEffect: '24+ hours (irreversible binding)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '30-40% (increases with repeated dosing)',
        route: ['oral', 'IV'],
        factors: ['Food delays but does not reduce absorption', 'Enteric coating prevents inactivation in stomach'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Take 30-60 minutes before meals for best effect',
      },
      distribution: {
        volumeOfDistribution: '0.34 L/kg',
        proteinBinding: '95%',
        tissueDistribution: ['Parietal cells (concentrated)'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2C19, CYP3A4)',
        enzymes: ['CYP2C19', 'CYP3A4'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C19 poor metabolizers have higher levels and better efficacy',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (80%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '0.5-1 hour (but effect lasts 24+ hours due to irreversible binding)',
      timeToSteadyState: '3-5 days',
    },

    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Peptic ulcer disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'H. pylori eradication (with antibiotics)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Zollinger-Ellison syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Stress ulcer prophylaxis (ICU)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '20-40 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'Severe hepatic impairment', adjustment: 'Max 20 mg daily', rationale: 'Reduced metabolism' },
        { condition: 'H. pylori eradication', adjustment: '20 mg BID with antibiotics', rationale: 'Part of triple or quadruple therapy' },
      ],
      maxDose: '40 mg BID (higher in Zollinger-Ellison)',
      administration: { route: 'oral', withFood: 'without-food', timing: '30-60 minutes before breakfast', specialInstructions: ['Swallow whole, do not crush delayed-release capsules', 'Can open capsule and mix granules with applesauce'] },
    },

    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Uncertain', management: 'Usually resolves; standard headache treatment if needed', reversible: true, onsetTiming: 'Days' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora, reduced acid', management: 'Usually mild; rarely C. diff', reversible: true, onsetTiming: 'Days' },
      { name: 'C. difficile infection', frequency: 'uncommon', severity: 'severe', mechanism: 'Reduced gastric acid allows bacterial survival', management: 'Stop PPI if possible, treat C. diff', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Hypomagnesemia', frequency: 'rare', severity: 'moderate', mechanism: 'Reduced intestinal absorption', management: 'Monitor Mg with long-term use; supplement if low', reversible: true, onsetTiming: 'Months to years' },
      { name: 'B12 deficiency', frequency: 'rare', severity: 'moderate', mechanism: 'Reduced gastric acid for B12 release', management: 'Monitor B12 with long-term use; supplement if low', reversible: true, onsetTiming: 'Years' },
    ],

    interactions: [
      { interactingDrug: 'Clopidogrel', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C19 inhibition reduces clopidogrel activation', effect: 'Reduced antiplatelet effect', management: 'Consider pantoprazole (less CYP2C19 inhibition) or H2 blocker' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal elimination of methotrexate', effect: 'Increased methotrexate toxicity', management: 'Consider holding PPI with high-dose methotrexate' },
      { interactingDrug: 'Drugs requiring acid for absorption', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced gastric acid impairs absorption', effect: 'Reduced efficacy of ketoconazole, iron, etc.', management: 'Separate dosing or use different formulations' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity to PPIs', type: 'absolute', reason: 'Cross-reactivity between PPIs possible' },
      { condition: 'Rilpivirine use', type: 'relative', reason: 'Significant interaction - use H2 blocker instead' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but generally considered safe', recommendation: 'Use if clinically indicated', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Higher risk of fractures, B12/Mg deficiency', recommendation: 'Use lowest effective dose, reassess periodically' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Max 20 mg daily in severe impairment' },
    ],

    monitoring: [
      { parameter: 'Symptom relief', frequency: 'After 4-8 weeks', rationale: 'Assess need for continued therapy', actionThreshold: 'If no improvement, reconsider diagnosis' },
      { parameter: 'Magnesium', frequency: 'Periodically with long-term use', rationale: 'Risk of hypomagnesemia', actionThreshold: 'Supplement if low' },
      { parameter: 'B12', frequency: 'Consider every 1-2 years with chronic use', rationale: 'Risk of deficiency', actionThreshold: 'Supplement if deficient' },
    ],

    patientEducation: [
      'Take 30-60 minutes before eating for best effect',
      'Swallow capsules whole - do not crush or chew',
      'May take several days to feel full benefit',
      'Do not stop abruptly after long-term use - may have rebound acid',
      'Not intended for immediate heartburn relief - use antacids for that',
      'Tell your doctor about all medications, especially clopidogrel',
    ],

    clinicalPearls: [
      'Short half-life but long duration of action - once daily dosing works',
      'Takes 3-5 days for maximal acid suppression',
      'Clopidogrel interaction controversial but real - pantoprazole may be safer',
      'Deprescribing often possible - try stepping down after 8 weeks for GERD',
      'Morning dosing before breakfast is most effective',
      'Rebound acid hypersecretion can occur after stopping - taper if used >8 weeks',
    ],
  },

  // --------------------------------------------
  // SERTRALINE
  // --------------------------------------------
  {
    id: 'sertraline',
    genericName: 'Sertraline',
    brandNames: ['Zoloft'],
    drugClass: 'Selective Serotonin Reuptake Inhibitor (SSRI)',
    category: 'psychiatric',

    overview: 'Sertraline is an SSRI antidepressant that is one of the most prescribed medications for depression, anxiety disorders, OCD, PTSD, and other conditions. It has a favorable side effect profile and is generally well-tolerated.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin Reuptake Transporter (SERT)',
      targetLocation: 'Presynaptic neurons throughout CNS',

      simpleExplanation: 'Sertraline increases serotonin levels in the brain by preventing nerve cells from reabsorbing it. This helps improve mood, anxiety, and other symptoms over time.',

      detailedMechanism: 'Sertraline selectively inhibits the serotonin transporter (SERT), preventing reuptake of serotonin from the synaptic cleft into presynaptic neurons. This increases serotonin availability at post-synaptic receptors. The therapeutic effect takes weeks because downstream adaptations (receptor downregulation, neuroplasticity) are required for clinical benefit.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters systemic circulation', timeframe: '4-8 hours to peak' },
        { order: 2, location: 'CNS', action: 'Crosses blood-brain barrier', result: 'Drug reaches target neurons' },
        { order: 3, location: 'Synapse', action: 'Binds to SERT on presynaptic membrane', result: 'Serotonin reuptake blocked' },
        { order: 4, location: 'Synaptic cleft', action: 'Serotonin accumulates', result: 'Increased serotonergic neurotransmission' },
        { order: 5, location: 'Post-synaptic neuron', action: 'Receptor downregulation and adaptation', result: 'Therapeutic effect emerges', timeframe: '2-4 weeks' },
      ],

      physiologicalEffects: [
        { system: 'CNS', effect: 'Improved mood and reduced anxiety', mechanism: 'Enhanced serotonergic transmission', clinicalRelevance: 'Therapeutic effect for depression/anxiety', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Initial anxiety increase', mechanism: 'Acute serotonin increase before adaptation', clinicalRelevance: 'May worsen anxiety initially - warn patients', desiredOrAdverse: 'adverse' },
        { system: 'Gastrointestinal', effect: 'Nausea, diarrhea', mechanism: 'Serotonin receptors in GI tract', clinicalRelevance: 'Common at start, usually transient', desiredOrAdverse: 'adverse' },
        { system: 'Sexual', effect: 'Sexual dysfunction', mechanism: 'Serotonin effects on sexual function', clinicalRelevance: 'Very common, may persist', desiredOrAdverse: 'adverse' },
        { system: 'Hematologic', effect: 'Increased bleeding risk', mechanism: 'Serotonin in platelet function', clinicalRelevance: 'Caution with anticoagulants', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1-2 weeks for some effect; 4-6 weeks for full effect',
      durationOfEffect: 'Requires continuous dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: 'High (oral)',
        route: ['oral'],
        factors: ['Food slightly increases absorption'],
        timeToePeak: '4-8 hours',
        foodEffect: 'Can take with or without food',
      },
      distribution: {
        volumeOfDistribution: '20 L/kg',
        proteinBinding: '98%',
        tissueDistribution: ['CNS', 'Liver', 'Widely distributed'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4)',
        enzymes: ['CYP2B6', 'CYP2C19', 'CYP2D6', 'CYP3A4'],
        activeMetabolites: ['N-desmethylsertraline (weakly active)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal and renal',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '26 hours (66 hours for metabolite)',
      timeToSteadyState: '1 week',
    },

    indications: [
      { condition: 'Major Depressive Disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized Anxiety Disorder', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Panic Disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'PTSD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'OCD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Social Anxiety Disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Premenstrual Dysphoric Disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '50-200 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Lower doses, slower titration', rationale: 'Reduced metabolism' },
        { condition: 'Elderly', adjustment: 'Start 25 mg', rationale: 'More sensitive to side effects' },
        { condition: 'OCD', adjustment: 'May need higher doses (up to 200 mg)', rationale: 'Higher doses often needed' },
      ],
      maxDose: '200 mg daily',
      administration: { route: 'oral', withFood: 'either', timing: 'Morning or evening (consistent time)', specialInstructions: ['Start low and increase gradually', 'Do not stop abruptly'] },
    },

    adverseEffects: [
      { name: 'Nausea', frequency: 'very-common', severity: 'mild', mechanism: 'GI serotonin receptors', management: 'Take with food; usually resolves in 1-2 weeks', reversible: true, onsetTiming: 'Days' },
      { name: 'Sexual dysfunction', frequency: 'very-common', severity: 'moderate', mechanism: 'Serotonergic effect on sexual function', management: 'Dose reduction, drug holiday, add bupropion', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Insomnia or drowsiness', frequency: 'common', severity: 'mild', mechanism: 'Serotonin effects on sleep', management: 'Adjust timing; can take AM if causes insomnia', reversible: true, onsetTiming: 'Days' },
      { name: 'Weight changes', frequency: 'common', severity: 'mild', mechanism: 'Appetite changes', management: 'Monitor weight; diet and exercise', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Serotonin syndrome (with other serotonergics)', frequency: 'rare', severity: 'life-threatening', mechanism: 'Excessive serotonergic activity', management: 'Discontinue all serotonergics; supportive care', reversible: true, onsetTiming: 'Hours' },
    ],

    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Both increase serotonin', effect: 'Serotonin syndrome - potentially fatal', management: 'Wait 14 days between MAOI and SSRI' },
      { interactingDrug: 'Tramadol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both increase serotonin', effect: 'Increased serotonin syndrome risk', management: 'Avoid combination if possible' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'SSRIs affect platelet function', effect: 'Increased bleeding risk', management: 'Monitor INR; consider PPI for GI protection' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Both increase bleeding risk', effect: 'GI bleeding risk', management: 'Use PPI for protection if combination needed' },
    ],

    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Serotonin syndrome risk' },
      { condition: 'Concurrent pimozide use', type: 'absolute', reason: 'QT prolongation risk' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Generally considered safest SSRI in pregnancy', recommendation: 'Benefits usually outweigh risks for moderate-severe depression', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Low levels in breast milk', recommendation: 'Often considered compatible with breastfeeding' },
      { population: 'pediatric', consideration: 'FDA approved for OCD ages 6+', recommendation: 'Monitor closely for suicidal ideation (black box warning)' },
      { population: 'geriatric', consideration: 'Increased sensitivity, SIADH risk', recommendation: 'Start low (25 mg), monitor sodium' },
    ],

    monitoring: [
      { parameter: 'Depression/anxiety symptoms', frequency: 'Every 2-4 weeks initially', rationale: 'Assess response', actionThreshold: 'Adjust dose or switch if inadequate response by 6-8 weeks' },
      { parameter: 'Suicidal ideation', frequency: 'Weekly initially in youth', rationale: 'Black box warning for increased suicidality in young patients', actionThreshold: 'Immediate intervention if present' },
      { parameter: 'Sodium', frequency: 'Baseline and if symptoms (especially elderly)', rationale: 'SIADH risk', actionThreshold: 'Discontinue if significant hyponatremia' },
    ],

    patientEducation: [
      'May take 2-4 weeks or longer to feel the full benefit - do not give up too soon',
      'Do not stop suddenly - taper under doctor supervision to avoid withdrawal',
      'May increase anxiety initially - this usually improves',
      'Report worsening depression or suicidal thoughts immediately',
      'Sexual side effects are common - discuss with doctor',
      'Avoid alcohol - can worsen depression and increase side effects',
      'Tell your doctor about all other medications - many interactions possible',
    ],

    clinicalPearls: [
      'Sertraline is often preferred for cardiac patients - minimal cardiac effects',
      'May be preferred SSRI in pregnancy due to more safety data',
      'Therapeutic dose is typically 50-100 mg - 25 mg is usually subtherapeutic',
      'OCD often requires higher doses (150-200 mg) than depression',
      'Discontinuation syndrome can occur - taper over 2-4 weeks minimum',
      'Black box warning for suicidality applies mainly to young adults - risk is small',
      'Sexual dysfunction is very common but patients often dont report it - ask',
    ],
  },

  // --------------------------------------------
  // AMOXICILLIN
  // --------------------------------------------
  {
    id: 'amoxicillin',
    genericName: 'Amoxicillin',
    brandNames: ['Amoxil', 'Trimox'],
    drugClass: 'Aminopenicillin',
    category: 'antimicrobial',

    overview: 'Amoxicillin is a broad-spectrum, bactericidal beta-lactam antibiotic. It is one of the most commonly prescribed antibiotics worldwide, used for respiratory, ear, dental, and urinary tract infections. Better oral absorption than ampicillin.',

    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'Penicillin-Binding Proteins (PBPs)',
      targetLocation: 'Bacterial cell wall',

      simpleExplanation: 'Amoxicillin kills bacteria by preventing them from building their protective cell wall. Without this wall, the bacteria burst open and die.',

      detailedMechanism: 'Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of peptidoglycan cross-linking. This weakens the cell wall, leading to osmotic lysis and cell death. Amoxicillin is bactericidal and time-dependent (efficacy depends on time above MIC).',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Well absorbed from intestine', result: 'High oral bioavailability', timeframe: '1-2 hours' },
        { order: 2, location: 'Bacterial periplasm', action: 'Drug diffuses through porin channels', result: 'Reaches target site' },
        { order: 3, location: 'Bacterial membrane', action: 'Binds to PBPs', result: 'Transpeptidase enzyme inhibited' },
        { order: 4, location: 'Cell wall', action: 'Peptidoglycan cross-linking prevented', result: 'Weakened cell wall' },
        { order: 5, location: 'Bacterial cell', action: 'Osmotic pressure causes lysis', result: 'Bacterial death' },
      ],

      physiologicalEffects: [
        { system: 'Immune', effect: 'Bacterial killing', mechanism: 'Cell wall disruption', clinicalRelevance: 'Treats susceptible infections', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Diarrhea', mechanism: 'Alteration of gut flora', clinicalRelevance: 'Common, usually mild', desiredOrAdverse: 'adverse' },
        { system: 'Immune', effect: 'Allergic reactions', mechanism: 'Immune response to beta-lactam ring', clinicalRelevance: 'Rash common; anaphylaxis rare', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours (bacterial killing begins)',
      durationOfEffect: '6-8 hours (time-dependent killing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '74-92%',
        route: ['oral'],
        factors: ['Not significantly affected by food'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Can take with or without food',
      },
      distribution: {
        volumeOfDistribution: '0.3 L/kg',
        proteinBinding: '20%',
        tissueDistribution: ['Respiratory tract', 'Ear', 'Sinus', 'Urine', 'Bile'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (60-80% unchanged)',
        renalClearance: 'High',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '1-1.5 hours',
      timeToSteadyState: 'N/A (short course therapy)',
    },

    indications: [
      { condition: 'Strep pharyngitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Otitis media', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute bacterial sinusitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Often combined with macrolide for atypicals' },
      { condition: 'H. pylori eradication', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Part of triple therapy' },
      { condition: 'Dental infections', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'UTI (uncomplicated)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Not first-line; resistance common' },
    ],

    dosing: {
      usualDose: { amount: '250-500 mg', frequency: 'every 8 hours', route: 'oral' },
      adjustments: [
        { condition: 'CrCl 10-30 mL/min', adjustment: 'Every 12 hours', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl <10 mL/min', adjustment: 'Every 24 hours', rationale: 'Significantly reduced clearance' },
        { condition: 'High-dose for sinusitis/pneumonia', adjustment: '1000 mg every 8 hours or 875 mg every 12 hours', rationale: 'To overcome resistant organisms' },
      ],
      maxDose: '3 g/day (higher doses used in some protocols)',
      administration: { route: 'oral', withFood: 'either', specialInstructions: ['Complete full course even if feeling better', 'Shake suspension well before measuring dose'] },
    },

    adverseEffects: [
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually self-limited; probiotics may help', reversible: true, onsetTiming: 'Days' },
      { name: 'Rash', frequency: 'common', severity: 'mild', mechanism: 'Hypersensitivity or non-allergic', management: 'Discontinue if allergic; maculopapular rash common with EBV', reversible: true, onsetTiming: 'Days' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI irritation', management: 'Take with food', reversible: true, onsetTiming: 'Days' },
      { name: 'Anaphylaxis', frequency: 'rare', severity: 'life-threatening', mechanism: 'IgE-mediated allergy', management: 'Epinephrine, discontinue permanently, avoid all penicillins', reversible: true, onsetTiming: 'Minutes' },
      { name: 'C. difficile colitis', frequency: 'rare', severity: 'severe', mechanism: 'Gut flora disruption', management: 'Stop antibiotic, treat C. diff', reversible: true, onsetTiming: 'Days to weeks' },
    ],

    interactions: [
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal excretion of methotrexate', effect: 'Increased methotrexate toxicity', management: 'Monitor methotrexate levels if combination necessary' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Altered gut flora reduces vitamin K production', effect: 'Increased INR', management: 'Monitor INR' },
      { interactingDrug: 'Allopurinol', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Unknown', effect: 'Increased rash risk', management: 'Be aware; rash may occur' },
    ],

    contraindications: [
      { condition: 'History of anaphylaxis to penicillin', type: 'absolute', reason: 'Life-threatening reaction risk' },
      { condition: 'History of severe penicillin allergy', type: 'absolute', reason: 'High risk of serious reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Safe in pregnancy', recommendation: 'Can use when indicated', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Safe while breastfeeding', recommendation: 'Can use; small amounts in milk' },
      { population: 'pediatric', consideration: 'Commonly used', recommendation: 'Dose by weight; suspension available' },
      { population: 'renal-impairment', consideration: 'Reduced clearance', recommendation: 'Adjust dosing interval based on CrCl' },
    ],

    monitoring: [
      { parameter: 'Clinical response', frequency: 'After 48-72 hours', rationale: 'Assess if antibiotic is working', actionThreshold: 'Consider broader coverage if no improvement' },
      { parameter: 'Signs of allergic reaction', frequency: 'During treatment', rationale: 'Rash, itching, breathing difficulty', actionThreshold: 'Stop if allergic symptoms develop' },
    ],

    patientEducation: [
      'Take the full course even if you feel better - stopping early promotes resistance',
      'Can take with or without food',
      'Report any rash, itching, or difficulty breathing immediately',
      'Store suspension in refrigerator and discard after 14 days',
      'Shake suspension well before each dose',
      'May cause diarrhea - contact doctor if severe or bloody',
    ],

    clinicalPearls: [
      'Better oral absorption than ampicillin - preferred for oral therapy',
      'Time-dependent killing - dosing frequency matters more than peak level',
      'High-dose amoxicillin (1g TID) covers intermediate penicillin-resistant S. pneumoniae',
      'Maculopapular rash very common with EBV (mono) - not a true penicillin allergy',
      'Amoxicillin-clavulanate adds beta-lactamase coverage (Augmentin)',
      'About 10% of patients reporting penicillin allergy are truly allergic - skin testing can clarify',
      'For strep throat: 10 days is standard; some data support 5-day high-dose courses',
    ],
  },

  // --------------------------------------------
  // IBUPROFEN
  // --------------------------------------------
  {
    id: 'ibuprofen',
    genericName: 'Ibuprofen',
    brandNames: ['Advil', 'Motrin', 'Nurofen'],
    drugClass: 'Non-Steroidal Anti-Inflammatory Drug (NSAID)',
    category: 'analgesic',

    overview: 'Ibuprofen is one of the most widely used OTC and prescription medications for pain, fever, and inflammation. It works by inhibiting cyclooxygenase (COX) enzymes. Generally well-tolerated for short-term use but carries GI, cardiovascular, and renal risks with prolonged use.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase-1 and 2 (COX-1, COX-2)',
      targetLocation: 'Throughout body (all nucleated cells)',

      simpleExplanation: 'Ibuprofen blocks enzymes that produce prostaglandins - chemicals that cause pain, fever, and inflammation. By reducing prostaglandins, it relieves these symptoms.',

      detailedMechanism: 'Ibuprofen reversibly inhibits both COX-1 and COX-2 enzymes, which convert arachidonic acid to prostaglandins. COX-2 inhibition reduces prostaglandins at sites of inflammation (therapeutic), while COX-1 inhibition reduces prostaglandins in the stomach (causing GI risk) and kidneys (causing renal risk). Ibuprofen also affects platelet function by inhibiting thromboxane A2 synthesis.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Well absorbed from stomach and intestine', result: 'Drug enters systemic circulation', timeframe: '30-60 minutes' },
        { order: 2, location: 'Tissues', action: 'Distributed to sites of pain/inflammation', result: 'Drug reaches target' },
        { order: 3, location: 'Cell membrane', action: 'Binds to COX-1 and COX-2 active sites', result: 'Enzyme activity inhibited' },
        { order: 4, location: 'Tissues', action: 'Reduced prostaglandin synthesis', result: 'Decreased inflammation, pain, fever' },
        { order: 5, location: 'Hypothalamus', action: 'Reduced PGE2 in thermoregulatory center', result: 'Fever reduction' },
      ],

      physiologicalEffects: [
        { system: 'Musculoskeletal', effect: 'Analgesia and anti-inflammation', mechanism: 'Reduced prostaglandins at injury site', clinicalRelevance: 'Pain relief, reduced swelling', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Antipyretic', mechanism: 'Reduced PGE2 in hypothalamus', clinicalRelevance: 'Fever reduction', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'GI irritation and ulceration', mechanism: 'Reduced protective prostaglandins', clinicalRelevance: 'GI bleeding risk, especially with long-term use', desiredOrAdverse: 'adverse' },
        { system: 'Renal', effect: 'Reduced renal blood flow', mechanism: 'Prostaglandins maintain renal perfusion', clinicalRelevance: 'Acute kidney injury risk, especially in dehydration', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Increased cardiovascular risk', mechanism: 'COX-2 inhibition shifts prostanoid balance', clinicalRelevance: 'Increased MI/stroke risk with prolonged high-dose use', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '>80%',
        route: ['oral', 'IV', 'topical'],
        factors: ['Slowed but not reduced by food'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Take with food to reduce GI upset',
      },
      distribution: {
        volumeOfDistribution: '0.12 L/kg',
        proteinBinding: '99%',
        tissueDistribution: ['Synovial fluid', 'All tissues'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2C9)',
        enzymes: ['CYP2C9'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C9 polymorphisms may affect response',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (90% as metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '2-4 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Mild to moderate pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Fever', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Dysmenorrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Osteoarthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Rheumatoid arthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Headache/migraine', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '200-400 mg', frequency: 'every 4-6 hours', route: 'oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Lowest effective dose, shortest duration', rationale: 'Higher GI, CV, renal risk' },
        { condition: 'Mild renal impairment', adjustment: 'Caution; avoid if possible', rationale: 'Can worsen renal function' },
        { condition: 'Chronic use', adjustment: 'Consider PPI for GI protection', rationale: 'Reduced GI bleeding risk' },
      ],
      maxDose: '3200 mg/day (prescription); 1200 mg/day (OTC)',
      administration: { route: 'oral', withFood: 'with-food', specialInstructions: ['Take with food or milk to reduce GI upset', 'Use lowest effective dose for shortest duration'] },
    },

    adverseEffects: [
      { name: 'GI upset/dyspepsia', frequency: 'common', severity: 'mild', mechanism: 'Direct irritation and reduced protective prostaglandins', management: 'Take with food; add PPI if chronic use needed', reversible: true, onsetTiming: 'Days' },
      { name: 'GI bleeding/ulceration', frequency: 'uncommon', severity: 'severe', mechanism: 'Loss of mucosal protection', management: 'Stop NSAID; PPI for ulcer healing; may need hospitalization', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Acute kidney injury', frequency: 'uncommon', severity: 'severe', mechanism: 'Reduced renal prostaglandins and blood flow', management: 'Stop NSAID; IV fluids; usually reversible', reversible: true, onsetTiming: 'Days' },
      { name: 'Cardiovascular events', frequency: 'rare', severity: 'life-threatening', mechanism: 'COX-2 inhibition affects prostanoid balance', management: 'Use lowest dose, shortest duration; avoid in CV disease', reversible: false, onsetTiming: 'Months to years' },
      { name: 'Hypertension', frequency: 'common', severity: 'mild', mechanism: 'Sodium retention, vasoconstriction', management: 'Monitor BP; may need to adjust antihypertensives', reversible: true, onsetTiming: 'Days to weeks' },
    ],

    interactions: [
      { interactingDrug: 'Aspirin (cardioprotective)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Ibuprofen may block aspirin access to COX-1', effect: 'Reduced cardioprotective effect of aspirin', management: 'Take aspirin 30 min before or 8 hr after ibuprofen' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs reduce antihypertensive effect and worsen renal function', effect: 'Reduced BP control, increased AKI risk', management: 'Monitor BP and renal function' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'NSAID impairs platelet function and increases GI bleeding', effect: 'Significantly increased bleeding risk', management: 'Avoid combination; if needed, add PPI and monitor closely' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal lithium clearance', effect: 'Lithium toxicity', management: 'Monitor lithium levels; may need dose reduction' },
    ],

    contraindications: [
      { condition: 'Active GI bleeding or ulcer', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe renal impairment', type: 'absolute', reason: 'Risk of further damage' },
      { condition: 'Third trimester pregnancy', type: 'absolute', reason: 'Premature closure of ductus arteriosus' },
      { condition: 'CABG perioperative period', type: 'absolute', reason: 'Increased CV event risk' },
      { condition: 'History of aspirin-exacerbated respiratory disease', type: 'absolute', reason: 'Can trigger bronchospasm' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Avoid especially in third trimester', recommendation: 'Use acetaminophen instead if possible', pregnancyCategory: 'C (D in 3rd trimester)' },
      { population: 'geriatric', consideration: 'High risk for GI, renal, CV events', recommendation: 'Lowest dose, shortest duration; consider topical or acetaminophen' },
      { population: 'renal-impairment', consideration: 'Can precipitate AKI', recommendation: 'Avoid if possible; if used, monitor closely' },
    ],

    monitoring: [
      { parameter: 'GI symptoms', frequency: 'With chronic use', rationale: 'Assess for ulceration', actionThreshold: 'Stop if GI bleeding signs' },
      { parameter: 'Blood pressure', frequency: 'Periodically with chronic use', rationale: 'NSAIDs can raise BP', actionThreshold: 'Adjust antihypertensives if needed' },
      { parameter: 'Renal function', frequency: 'With chronic use, especially in at-risk patients', rationale: 'Risk of AKI', actionThreshold: 'Stop if creatinine rising' },
    ],

    patientEducation: [
      'Take with food or milk to protect your stomach',
      'Use the lowest dose that works for the shortest time needed',
      'Do not exceed recommended dose - more is not better and increases risk',
      'Avoid if you have kidney problems, stomach ulcers, or heart disease',
      'Do not take with other NSAIDs or aspirin without doctor approval',
      'Can raise blood pressure - tell your doctor if you have hypertension',
      'Avoid in late pregnancy',
      'Seek medical attention for stomach pain, black stools, or vomiting blood',
    ],

    clinicalPearls: [
      'Ibuprofen before aspirin can block aspirin\'s cardioprotective effect',
      'Ceiling effect for analgesia around 400-600 mg - higher doses mainly anti-inflammatory',
      'All NSAIDs have CV risk - ibuprofen is intermediate (naproxen may be lowest)',
      'Short half-life means more frequent dosing but faster recovery if adverse effect',
      'Topical formulations have lower systemic exposure',
      'Avoid "triple whammy" (NSAID + ACE-I + diuretic) - high AKI risk',
      'PPI reduces but does not eliminate GI risk with chronic NSAID use',
    ],
  },

  // --------------------------------------------
  // LEVOTHYROXINE
  // --------------------------------------------
  {
    id: 'levothyroxine',
    genericName: 'Levothyroxine',
    brandNames: ['Synthroid', 'Levoxyl', 'Tirosint'],
    drugClass: 'Thyroid Hormone',
    category: 'endocrine',

    overview: 'Levothyroxine is synthetic T4 (thyroxine) used to replace thyroid hormone in hypothyroidism. It is one of the most prescribed medications in the world. Proper dosing is critical - too little leaves patient symptomatic, too much causes hyperthyroid symptoms and bone/cardiac risks.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Thyroid Hormone Receptors (TR)',
      targetLocation: 'Nuclear receptors in virtually all cells',

      simpleExplanation: 'Levothyroxine replaces the thyroid hormone your body is not making enough of. Once in your body, it enters cells and controls how fast your metabolism runs.',

      detailedMechanism: 'Levothyroxine (T4) is converted to the active hormone triiodothyronine (T3) by deiodinases in peripheral tissues. T3 enters the nucleus and binds to thyroid hormone receptors, which are transcription factors that regulate expression of many genes involved in metabolism, growth, and development. Effects include increased metabolic rate, protein synthesis, and cardiovascular responsiveness.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from jejunum', result: 'Drug enters circulation', timeframe: '4-6 weeks for full effect' },
        { order: 2, location: 'Bloodstream', action: 'Circulates bound to TBG and albumin', result: 'Transported to tissues' },
        { order: 3, location: 'Peripheral tissues', action: 'Deiodinases convert T4 to T3', result: 'Active hormone formed' },
        { order: 4, location: 'Cell nucleus', action: 'T3 binds to thyroid hormone receptors', result: 'Gene transcription altered' },
        { order: 5, location: 'Throughout body', action: 'Increased expression of metabolic genes', result: 'Increased metabolic rate' },
      ],

      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Increased basal metabolic rate', mechanism: 'Enhanced mitochondrial activity', clinicalRelevance: 'Reverses hypothyroid symptoms', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Increased heart rate and contractility', mechanism: 'Enhanced beta-receptor sensitivity', clinicalRelevance: 'Excessive dose causes tachycardia, palpitations', desiredOrAdverse: 'both' },
        { system: 'CNS', effect: 'Improved cognition and mood', mechanism: 'Thyroid hormone needed for brain function', clinicalRelevance: 'Reverses "brain fog" of hypothyroidism', desiredOrAdverse: 'desired' },
        { system: 'Skeletal', effect: 'Increased bone turnover', mechanism: 'Enhanced osteoclast activity', clinicalRelevance: 'Excessive dose increases osteoporosis risk', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Days for biochemical effect; weeks for clinical improvement',
      durationOfEffect: 'Long half-life allows once-daily dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '40-80% (highly variable)',
        route: ['oral', 'IV'],
        factors: ['Fasting increases absorption', 'Many drugs and foods decrease absorption'],
        timeToePeak: '2-4 hours',
        foodEffect: 'Take on empty stomach, 30-60 min before food',
      },
      distribution: {
        volumeOfDistribution: '10-12 L',
        proteinBinding: '>99% (TBG, albumin, transthyretin)',
        tissueDistribution: ['All tissues'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Peripheral tissues (deiodination)',
        enzymes: ['Deiodinases (D1, D2, D3)'],
        activeMetabolites: ['T3 (triiodothyronine)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal and renal',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '6-7 days',
      timeToSteadyState: '4-6 weeks',
    },

    indications: [
      { condition: 'Hypothyroidism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'TSH suppression (thyroid cancer)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Myxedema coma', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV formulation' },
    ],

    dosing: {
      usualDose: { amount: '1.6 mcg/kg/day', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'Elderly or cardiac disease', adjustment: 'Start 12.5-25 mcg, increase slowly', rationale: 'Risk of cardiac events if increased too fast' },
        { condition: 'Pregnancy', adjustment: 'Increase dose 25-30% early in pregnancy', rationale: 'Increased requirement' },
        { condition: 'Subclinical hypothyroidism', adjustment: 'Lower doses may be appropriate', rationale: 'May not need full replacement' },
      ],
      maxDose: '300 mcg/day (rarely needed)',
      administration: { route: 'oral', withFood: 'without-food', timing: 'Morning, 30-60 min before breakfast', specialInstructions: ['Consistent timing important', 'Separate from calcium, iron, antacids by 4 hours'] },
    },

    adverseEffects: [
      { name: 'Palpitations/tachycardia (overdose)', frequency: 'common', severity: 'moderate', mechanism: 'Excess thyroid hormone', management: 'Reduce dose; check TSH', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Insomnia/anxiety (overdose)', frequency: 'common', severity: 'mild', mechanism: 'Excess thyroid hormone', management: 'Reduce dose', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Weight loss (overdose)', frequency: 'common', severity: 'mild', mechanism: 'Increased metabolic rate', management: 'Reduce dose', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Osteoporosis (chronic overdose)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Increased bone turnover', management: 'Maintain TSH in normal range; bone density monitoring', reversible: false, onsetTiming: 'Months to years' },
      { name: 'Atrial fibrillation (chronic overdose)', frequency: 'uncommon', severity: 'severe', mechanism: 'Thyroid hormone effects on heart', management: 'Maintain TSH in normal range', reversible: true, onsetTiming: 'Months' },
    ],

    interactions: [
      { interactingDrug: 'Calcium supplements', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Calcium binds levothyroxine in gut', effect: 'Reduced absorption', management: 'Separate by 4 hours' },
      { interactingDrug: 'Iron supplements', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Iron binds levothyroxine', effect: 'Reduced absorption', management: 'Separate by 4 hours' },
      { interactingDrug: 'PPIs/antacids', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Altered gastric pH affects absorption', effect: 'Reduced absorption', management: 'Separate by 4 hours; may need higher dose' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Thyroid hormone increases vitamin K clotting factor catabolism', effect: 'Increased anticoagulant effect', management: 'Monitor INR when starting or changing thyroid dose' },
    ],

    contraindications: [
      { condition: 'Uncorrected adrenal insufficiency', type: 'absolute', reason: 'Thyroid hormone increases cortisol clearance, can precipitate adrenal crisis' },
      { condition: 'Acute MI (relatively)', type: 'relative', reason: 'Increased cardiac demand may be dangerous' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Requirement increases 25-50%', recommendation: 'Increase dose early in pregnancy; check TSH every 4 weeks first trimester', pregnancyCategory: 'A' },
      { population: 'geriatric', consideration: 'Higher sensitivity to cardiac effects', recommendation: 'Start low (12.5-25 mcg), increase slowly' },
      { population: 'pediatric', consideration: 'Critical for brain development', recommendation: 'Early and adequate treatment essential' },
    ],

    monitoring: [
      { parameter: 'TSH', frequency: 'Every 6-8 weeks until stable, then every 6-12 months', rationale: 'Primary measure of adequate replacement', actionThreshold: 'Adjust dose to maintain TSH in target range' },
      { parameter: 'Free T4', frequency: 'With TSH or if pituitary disease suspected', rationale: 'Direct measure of hormone level', actionThreshold: 'Should be in upper half of normal range' },
      { parameter: 'Heart rate and symptoms', frequency: 'Each visit', rationale: 'Assess for over- or under-treatment' },
    ],

    patientEducation: [
      'Take on empty stomach in the morning, 30-60 minutes before eating',
      'Take at the same time every day for consistent levels',
      'Do not take with calcium, iron, or antacids - separate by 4 hours',
      'Do not change brands without telling your doctor - formulations vary',
      'Takes weeks to feel the full effect - be patient',
      'Tell your doctor if you experience palpitations, tremor, or weight loss (overdose signs)',
      'Do not stop taking without doctor supervision',
    ],

    clinicalPearls: [
      'TSH is the primary monitoring parameter - it takes 6-8 weeks to stabilize after dose change',
      'Brand-to-brand bioavailability varies - maintain consistency or recheck TSH',
      'Start low in elderly/cardiac patients - too rapid correction is dangerous',
      'Pregnancy increases requirement substantially - check TSH early and often',
      'Many absorption interactions - consistent timing matters',
      'Over-treatment increases atrial fibrillation and osteoporosis risk',
      'Full replacement dose is approximately 1.6 mcg/kg/day, but individual needs vary',
    ],
  },

  // --------------------------------------------
  // AMLODIPINE
  // --------------------------------------------
  {
    id: 'amlodipine',
    genericName: 'Amlodipine',
    brandNames: ['Norvasc', 'Katerzia'],
    drugClass: 'Dihydropyridine Calcium Channel Blocker',
    category: 'cardiovascular',

    overview: 'Amlodipine is a long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing peripheral vascular resistance and blood pressure. It is one of the most prescribed antihypertensive medications worldwide with unique 30-50 hour half-life allowing once-daily dosing.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'L-type voltage-gated calcium channels',
      targetLocation: 'Vascular smooth muscle (arterial > venous)',

      simpleExplanation: 'Amlodipine blocks calcium channels in blood vessel walls. When calcium cannot enter, the muscle relaxes and blood vessels widen, lowering blood pressure.',

      detailedMechanism: 'Amlodipine binds to the alpha-1 subunit of L-type calcium channels in vascular smooth muscle. This prevents calcium influx during depolarization, reducing intracellular calcium and preventing myosin light chain kinase activation. The result is arterial vasodilation with minimal effects on cardiac conduction or contractility (unlike non-dihydropyridine CCBs).',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters systemic circulation', timeframe: '6-12 hours to peak' },
        { order: 2, location: 'Vascular smooth muscle', action: 'Binds to alpha-1 subunit of L-type calcium channels', result: 'Channel pore blocked' },
        { order: 3, location: 'Cell membrane', action: 'Calcium influx prevented during depolarization', result: 'Intracellular calcium remains low' },
        { order: 4, location: 'Cytoplasm', action: 'Myosin light chain kinase not fully activated', result: 'Smooth muscle relaxation' },
        { order: 5, location: 'Arterioles', action: 'Arterial vasodilation', result: 'Reduced peripheral vascular resistance and blood pressure' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Arterial vasodilation', mechanism: 'Reduced calcium-mediated smooth muscle contraction', clinicalRelevance: 'Lowers blood pressure; reduces afterload', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Coronary vasodilation', mechanism: 'Relaxes coronary arterial smooth muscle', clinicalRelevance: 'Improves myocardial oxygen supply; treats angina', desiredOrAdverse: 'desired' },
        { system: 'Peripheral', effect: 'Peripheral edema', mechanism: 'Precapillary dilation increases capillary hydrostatic pressure', clinicalRelevance: 'Common side effect (5-10%); not due to fluid overload', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Reflex tachycardia (minimal)', mechanism: 'Baroreceptor response to vasodilation', clinicalRelevance: 'Less than short-acting CCBs due to gradual onset', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '6-12 hours (gradual)',
      durationOfEffect: '24+ hours (long half-life)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '64-90%',
        route: ['oral'],
        factors: ['Well absorbed regardless of food'],
        timeToePeak: '6-12 hours',
        foodEffect: 'No significant effect',
      },
      distribution: {
        volumeOfDistribution: '21 L/kg',
        proteinBinding: '93-97%',
        tissueDistribution: ['Vascular smooth muscle', 'Liver', 'Kidneys'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (60% as metabolites, 10% unchanged)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '30-50 hours (longest of all CCBs)',
      timeToSteadyState: '7-8 days',
    },

    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'First-line therapy; ALLHAT showed comparable outcomes to diuretics and ACE-I' },
      { condition: 'Chronic stable angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Reduces angina frequency and increases exercise tolerance' },
      { condition: 'Vasospastic (Prinzmetal) angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'CCBs are first-line for coronary spasm' },
      { condition: 'Raynaud phenomenon', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Reduces frequency and severity of attacks' },
    ],

    dosing: {
      usualDose: { amount: '5-10 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Start 2.5 mg', rationale: 'Reduced clearance' },
        { condition: 'Elderly', adjustment: 'Start 2.5 mg', rationale: 'More sensitive to hypotensive effects' },
        { condition: 'Small/frail patients', adjustment: 'Start 2.5 mg', rationale: 'Lower blood pressure baseline' },
      ],
      maxDose: '10 mg/day',
      administration: { route: 'oral', withFood: 'either', specialInstructions: ['Take at same time daily', 'Can take morning or evening'] },
    },

    adverseEffects: [
      { name: 'Peripheral edema', frequency: 'very-common', severity: 'mild', mechanism: 'Arteriolar dilation causes increased capillary hydrostatic pressure', management: 'Dose reduction; leg elevation; diuretics less helpful (not fluid overload); combine with ACE-I/ARB which reduces edema', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation and blood pressure reduction', management: 'Usually resolves with continued use; avoid rapid standing', reversible: true, onsetTiming: 'Days' },
      { name: 'Flushing', frequency: 'common', severity: 'mild', mechanism: 'Cutaneous vasodilation', management: 'Usually transient; dose reduction if bothersome', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Cerebral vasodilation', management: 'Often resolves with continued use', reversible: true, onsetTiming: 'Days' },
      { name: 'Gingival hyperplasia', frequency: 'uncommon', severity: 'mild', mechanism: 'Altered fibroblast metabolism', management: 'Good dental hygiene; may need to switch drugs', reversible: true, onsetTiming: 'Months' },
    ],

    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole, clarithromycin)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Inhibit amlodipine metabolism', effect: 'Increased amlodipine levels', management: 'Monitor for increased effect; may need dose reduction' },
      { interactingDrug: 'Simvastatin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Amlodipine inhibits CYP3A4', effect: 'Increased simvastatin levels', management: 'Limit simvastatin to 20 mg when combined' },
      { interactingDrug: 'Cyclosporine', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Amlodipine may increase cyclosporine levels', effect: 'Increased cyclosporine toxicity risk', management: 'Monitor cyclosporine levels' },
    ],

    contraindications: [
      { condition: 'Severe aortic stenosis', type: 'relative', reason: 'Afterload reduction may cause dangerous hypotension when cardiac output is fixed' },
      { condition: 'Cardiogenic shock', type: 'absolute', reason: 'Vasodilation worsens hypotension' },
      { condition: 'Unstable angina', type: 'relative', reason: 'May cause reflex tachycardia (though less than other CCBs)' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data; animal studies show fetal harm', recommendation: 'Use only if clearly needed; nifedipine preferred for hypertension in pregnancy', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Longer half-life; more sensitive to hypotension and edema', recommendation: 'Start 2.5 mg; excellent choice for isolated systolic hypertension' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'Start 2.5 mg; titrate slowly' },
    ],

    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Regularly until stable; periodic thereafter', rationale: 'Assess efficacy', actionThreshold: 'Adjust if not at goal' },
      { parameter: 'Heart rate', frequency: 'Periodic', rationale: 'Monitor for reflex tachycardia', actionThreshold: 'Usually not clinically significant' },
      { parameter: 'Peripheral edema', frequency: 'Each visit', rationale: 'Common dose-limiting adverse effect', actionThreshold: 'Reduce dose or add ACE-I/ARB' },
    ],

    patientEducation: [
      'Take at the same time each day; morning or evening is fine',
      'Swelling in ankles/feet is common - elevate legs; tell doctor if severe',
      'Do not stop suddenly even if you feel fine - blood pressure may spike',
      'Avoid grapefruit juice in large amounts (moderate amounts usually okay)',
      'May cause dizziness initially - avoid driving until you know how it affects you',
      'Full effect on blood pressure may take several weeks',
      'Report persistent headache, flushing, or palpitations',
    ],

    clinicalPearls: [
      'Longest half-life of any CCB - missing a dose rarely causes rebound hypertension',
      'Peripheral edema is due to arteriolar dilation, not fluid overload - diuretics help modestly but ACE-I/ARB addition is more effective',
      'Particularly effective in elderly, Black patients, and low-renin hypertension',
      'Unlike non-dihydropyridines (diltiazem, verapamil), does not slow heart rate or AV conduction',
      'Can be combined with any other antihypertensive class',
      'Gradual onset prevents reflex tachycardia seen with short-acting CCBs',
      'CAMELOT trial showed reduced cardiovascular events in CAD patients',
    ],
  },

  // --------------------------------------------
  // FUROSEMIDE
  // --------------------------------------------
  {
    id: 'furosemide',
    genericName: 'Furosemide',
    brandNames: ['Lasix'],
    drugClass: 'Loop Diuretic',
    category: 'cardiovascular',

    overview: 'Furosemide is a potent loop diuretic that inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle. It is the mainstay of therapy for acute decompensated heart failure and edematous states.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Na-K-2Cl cotransporter (NKCC2)',
      targetLocation: 'Thick ascending limb of loop of Henle',

      simpleExplanation: 'Furosemide blocks a pump in the kidney that normally reabsorbs salt. This causes the kidneys to remove much more salt and water, reducing fluid overload.',

      detailedMechanism: 'Furosemide inhibits NKCC2 in the thick ascending limb, preventing reabsorption of approximately 25% of filtered sodium. This causes massive natriuresis and diuresis. It also disrupts the medullary concentration gradient, impairing water reabsorption. IV furosemide has additional venodilatory effects.',

      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Secreted into tubular lumen via OAT transporters', result: 'Drug reaches site of action', timeframe: 'Minutes' },
        { order: 2, location: 'Thick ascending limb', action: 'Binds to chloride site of NKCC2', result: 'Transporter blocked' },
        { order: 3, location: 'Tubule', action: 'Na, K, Cl reabsorption blocked', result: 'Increased delivery to distal nephron' },
        { order: 4, location: 'Medulla', action: 'Concentration gradient disrupted', result: 'Impaired water reabsorption' },
        { order: 5, location: 'Collecting duct', action: 'Increased sodium delivery', result: 'Massive diuresis' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Reduced preload', mechanism: 'Volume depletion from diuresis', clinicalRelevance: 'Relieves pulmonary congestion in heart failure', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Venodilation (IV)', mechanism: 'Prostaglandin-mediated', clinicalRelevance: 'Rapid symptom relief before diuresis', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hypokalemia', mechanism: 'Increased K secretion in distal nephron', clinicalRelevance: 'Common; requires monitoring and often supplementation', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Metabolic alkalosis', mechanism: 'H+ loss; contraction alkalosis', clinicalRelevance: 'Usually mild', desiredOrAdverse: 'adverse' },
        { system: 'Auditory', effect: 'Ototoxicity (high dose IV)', mechanism: 'Direct toxic effect on hair cells', clinicalRelevance: 'Usually reversible; caution with aminoglycosides', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'IV: 5 minutes; PO: 30-60 minutes',
      durationOfEffect: 'IV: 2 hours; PO: 6-8 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '40-80% (variable, decreased with gut edema)',
        route: ['oral', 'IV', 'IM'],
        factors: ['Gut edema decreases absorption', 'Heart failure reduces bioavailability'],
        timeToePeak: '1-2 hours (oral)',
        foodEffect: 'Can take with or without food',
      },
      distribution: {
        volumeOfDistribution: '0.1-0.2 L/kg',
        proteinBinding: '91-99%',
        tissueDistribution: ['Kidney tubules', 'Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        geneticVariability: 'Glucuronidation pathway',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (60-90% unchanged)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '1-2 hours (prolonged in renal/hepatic impairment)',
      timeToSteadyState: 'Not applicable (usually used PRN or with variable dosing)',
    },

    indications: [
      { condition: 'Acute decompensated heart failure', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Standard of care for volume overload; rapid symptom relief' },
      { condition: 'Chronic heart failure with congestion', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Symptom control; does not improve mortality' },
      { condition: 'Edema from cirrhosis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Usually combined with spironolactone' },
      { condition: 'Nephrotic syndrome edema', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'May need high doses due to albumin binding in tubule' },
      { condition: 'Acute pulmonary edema', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV provides rapid preload reduction' },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Thiazides preferred; loop diuretics for resistant HTN or CKD' },
      { condition: 'Hypercalcemia', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Increases calcium excretion after volume repletion' },
    ],

    dosing: {
      usualDose: { amount: '20-80 mg', frequency: 'once or twice daily', route: 'oral or IV' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Higher doses needed; may need continuous infusion', rationale: 'Reduced secretion into tubule' },
        { condition: 'Hepatic impairment (cirrhosis)', adjustment: 'Use cautiously; combine with spironolactone', rationale: 'Risk of hepatic encephalopathy' },
        { condition: 'Elderly', adjustment: 'Start low', rationale: 'More susceptible to volume depletion' },
      ],
      maxDose: '600 mg/day PO; IV up to 200 mg bolus',
      administration: { route: 'oral or IV', withFood: 'either', timing: 'Morning preferred to avoid nocturia', specialInstructions: ['Double dose if inadequate response', 'Consider continuous infusion if boluses ineffective'] },
    },

    adverseEffects: [
      { name: 'Hypokalemia', frequency: 'very-common', severity: 'moderate', mechanism: 'Increased potassium excretion in distal nephron', management: 'Monitor potassium; supplement or add potassium-sparing diuretic', reversible: true, onsetTiming: 'Days' },
      { name: 'Hyponatremia', frequency: 'common', severity: 'moderate', mechanism: 'Sodium loss exceeds water loss', management: 'Fluid restriction; monitor sodium', reversible: true, onsetTiming: 'Days' },
      { name: 'Hypomagnesemia', frequency: 'common', severity: 'moderate', mechanism: 'Increased magnesium excretion', management: 'Monitor and supplement; often overlooked', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Volume depletion/hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Excessive diuresis', management: 'Monitor weight and volume status; adjust dose', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Ototoxicity', frequency: 'rare', severity: 'severe', mechanism: 'Direct toxic effect on inner ear hair cells', management: 'Avoid rapid IV push; caution with other ototoxic drugs (aminoglycosides)', reversible: true, onsetTiming: 'Hours (with rapid high-dose IV)' },
      { name: 'Hyperuricemia/gout', frequency: 'common', severity: 'mild', mechanism: 'Decreased uric acid excretion', management: 'Monitor uric acid; treat gout if occurs', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Metabolic alkalosis', frequency: 'common', severity: 'mild', mechanism: 'Contraction alkalosis; hydrogen loss', management: 'Usually mild; replace chloride', reversible: true, onsetTiming: 'Days' },
    ],

    interactions: [
      { interactingDrug: 'Aminoglycosides', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive ototoxicity', effect: 'Increased risk of hearing loss', management: 'Avoid combination if possible; if necessary, monitor hearing' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hypokalemia increases digoxin toxicity', effect: 'Increased risk of arrhythmias', management: 'Monitor and maintain potassium >4.0 mEq/L' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs inhibit prostaglandin-mediated renal blood flow', effect: 'Reduced diuretic efficacy', management: 'May need higher diuretic doses; avoid chronic NSAID use' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hypotension; risk of acute kidney injury in volume-depleted patients', effect: 'Hypotension, AKI', management: 'Start low; monitor kidney function; beneficial combination when euvolemic' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Volume depletion increases lithium reabsorption', effect: 'Lithium toxicity', management: 'Monitor lithium levels closely' },
    ],

    contraindications: [
      { condition: 'Anuria unresponsive to test dose', type: 'absolute', reason: 'Will not achieve diuresis; may worsen electrolyte abnormalities' },
      { condition: 'Severe hypokalemia or hyponatremia', type: 'relative', reason: 'Will worsen electrolyte derangements' },
      { condition: 'Hepatic coma', type: 'absolute', reason: 'Can precipitate or worsen hepatic encephalopathy' },
      { condition: 'Sulfonamide allergy', type: 'relative', reason: 'Furosemide contains sulfonamide moiety; cross-reactivity rare but possible' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Can decrease placental perfusion; crosses placenta', recommendation: 'Use only if clearly needed; avoid in pre-eclampsia (volume depletion harmful)', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'More sensitive to volume depletion, orthostatic hypotension, electrolyte abnormalities', recommendation: 'Start low; monitor carefully; adjust for renal function' },
      { population: 'renal-impairment', consideration: 'Need higher doses to achieve effect; non-renal clearance increases', recommendation: 'GFR 10-50: may need double doses; GFR <10: use IV; continuous infusion often needed' },
      { population: 'hepatic-impairment', consideration: 'Risk of hepatic encephalopathy; hypokalemia worsens encephalopathy', recommendation: 'Combine with spironolactone; maintain potassium' },
    ],

    monitoring: [
      { parameter: 'Weight', frequency: 'Daily in hospital; regularly at home', rationale: 'Best measure of volume status', actionThreshold: 'Adjust dose to achieve dry weight' },
      { parameter: 'Potassium', frequency: 'Within days of initiation; periodic ongoing', rationale: 'Hypokalemia common and dangerous', actionThreshold: 'Supplement if <3.5; maintain >4.0 if on digoxin' },
      { parameter: 'Sodium', frequency: 'Periodic', rationale: 'Hyponatremia possible', actionThreshold: '<130: reduce dose, fluid restrict' },
      { parameter: 'Creatinine/BUN', frequency: 'Periodic', rationale: 'Volume depletion can cause prerenal AKI', actionThreshold: 'Rising creatinine: assess volume status' },
      { parameter: 'Magnesium', frequency: 'Periodic', rationale: 'Often overlooked; causes refractory hypokalemia', actionThreshold: 'Supplement if low' },
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Monitor for hypotension', actionThreshold: 'Symptomatic hypotension: reduce dose' },
    ],

    patientEducation: [
      'Take in the morning to avoid nighttime urination',
      'Weigh yourself daily - report gain >2-3 lbs in a day or 5 lbs in a week',
      'You will urinate more frequently - this is expected',
      'Eat potassium-rich foods (bananas, oranges, potatoes) unless told otherwise',
      'Report muscle cramps, weakness, or irregular heartbeat (may indicate low potassium)',
      'Rise slowly from sitting/lying to avoid dizziness',
      'Limit salt intake for best effect',
      'Stay hydrated but follow fluid restrictions if prescribed',
      'Avoid NSAIDs (ibuprofen, naproxen) - they reduce effectiveness',
    ],

    clinicalPearls: [
      'Oral bioavailability is variable (40-80%) and decreases with gut edema - consider IV in decompensated heart failure',
      'If inadequate response to IV bolus, double the dose before switching to continuous infusion',
      'Continuous infusion (5-40 mg/hr) may be more effective than boluses in diuretic resistance',
      '"Diuretic resistance" often due to: inadequate dose, poor absorption, high sodium intake, NSAID use, or worsening renal function',
      'Hypokalemia is common - always check potassium and supplement proactively',
      'In cirrhosis, spironolactone should be first-line; add furosemide in ratio 100:40 (spironolactone:furosemide)',
      'Torsemide has more reliable oral bioavailability than furosemide',
      'Ototoxicity risk highest with rapid high-dose IV push - infuse over 1-2 minutes',
    ],
  },

  // --------------------------------------------
  // HYDROCHLOROTHIAZIDE
  // --------------------------------------------
  {
    id: 'hydrochlorothiazide',
    genericName: 'Hydrochlorothiazide',
    brandNames: ['Microzide', 'HydroDIURIL'],
    drugClass: 'Thiazide Diuretic',
    category: 'cardiovascular',

    overview: 'Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. First-line antihypertensive with proven cardiovascular outcomes benefits in ALLHAT trial.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Sodium-chloride cotransporter (NCC)',
      targetLocation: 'Distal convoluted tubule',

      simpleExplanation: 'HCTZ blocks a pump that normally reabsorbs salt in the kidney tubules. This causes the body to lose sodium and water through urine, lowering blood pressure.',

      detailedMechanism: 'Binds to chloride site of NCC, blocking sodium and chloride reabsorption. Initial effect is volume depletion from natriuresis. Chronic effect involves decreased peripheral vascular resistance through mechanisms not fully understood. Also increases calcium reabsorption, useful in osteoporosis.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Drug enters circulation', timeframe: '1-2 hours' },
        { order: 2, location: 'Distal convoluted tubule', action: 'Binds to chloride site of NCC', result: 'Transporter blocked' },
        { order: 3, location: 'Tubule', action: 'Sodium and chloride reabsorption blocked', result: 'Natriuresis and diuresis' },
        { order: 4, location: 'Systemic', action: 'Initial volume depletion', result: 'Blood pressure reduction', timeframe: 'Days to weeks' },
        { order: 5, location: 'Vasculature', action: 'Chronic vascular effect', result: 'Sustained BP reduction even after volume normalizes', timeframe: 'Weeks' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Blood pressure reduction', mechanism: 'Volume depletion then vascular resistance decrease', clinicalRelevance: 'First-line for hypertension', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hypokalemia', mechanism: 'Increased K secretion in collecting duct', clinicalRelevance: 'Common; requires monitoring', desiredOrAdverse: 'adverse' },
        { system: 'Renal', effect: 'Increased calcium reabsorption', mechanism: 'Enhanced proximal tubule calcium handling', clinicalRelevance: 'Useful for calcium stones and osteoporosis', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hyperglycemia', mechanism: 'Impaired insulin secretion and sensitivity', clinicalRelevance: 'May unmask diabetes', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '2 hours',
      durationOfEffect: '12-24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '65-75%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '4-6 hours',
        foodEffect: 'No significant effect',
      },
      distribution: {
        volumeOfDistribution: '0.8-1.0 L/kg',
        proteinBinding: '40-70%',
        tissueDistribution: ['Kidney', 'Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (95% unchanged)',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '6-15 hours',
      timeToSteadyState: '3-4 days',
    },

    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'ALLHAT: comparable outcomes to ACE-I and CCB' },
      { condition: 'Edema', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Less potent than loop diuretics' },
      { condition: 'Calcium kidney stones', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true, notes: 'Reduces urinary calcium excretion' },
      { condition: 'Nephrogenic diabetes insipidus', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Paradoxically reduces urine output' },
    ],

    dosing: {
      usualDose: { amount: '12.5-25 mg', frequency: 'once daily', route: 'oral' },
      adjustments: [
        { condition: 'Renal impairment (GFR <30)', adjustment: 'Less effective; consider loop diuretic', rationale: 'Requires tubular secretion' },
        { condition: 'Elderly', adjustment: 'Start 12.5 mg', rationale: 'Higher risk of electrolyte abnormalities' },
      ],
      maxDose: '50 mg/day (higher doses increase side effects without much added BP benefit)',
      administration: { route: 'oral', withFood: 'either', timing: 'Morning to avoid nocturia', specialInstructions: ['If inadequate response at 25 mg, add another agent rather than increasing dose'] },
    },

    adverseEffects: [
      { name: 'Hypokalemia', frequency: 'common', severity: 'moderate', mechanism: 'Increased potassium secretion in collecting duct', management: 'Monitor potassium; supplement or add K-sparing diuretic', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Hyponatremia', frequency: 'common', severity: 'moderate', mechanism: 'Enhanced free water retention relative to sodium', management: 'Monitor sodium; more common in elderly', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Hyperuricemia', frequency: 'common', severity: 'mild', mechanism: 'Decreased uric acid excretion', management: 'Monitor uric acid; treat gout if symptomatic', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Hyperglycemia', frequency: 'common', severity: 'mild', mechanism: 'Decreased insulin secretion', management: 'Monitor glucose in diabetics', reversible: true, onsetTiming: 'Months' },
      { name: 'Photosensitivity', frequency: 'uncommon', severity: 'mild', mechanism: 'Sulfonamide-related', management: 'Sun protection', reversible: true, onsetTiming: 'Days' },
    ],

    interactions: [
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Volume depletion increases lithium reabsorption', effect: 'Lithium toxicity', management: 'Monitor lithium levels closely; may need dose reduction' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hypokalemia increases digoxin toxicity', effect: 'Arrhythmias', management: 'Monitor and maintain potassium >4.0' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs cause sodium retention', effect: 'Reduced antihypertensive effect', management: 'May need higher doses; avoid chronic NSAIDs' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Risk of first-dose hypotension', effect: 'Hypotension when starting ACE-I/ARB', management: 'Start ACE-I/ARB at low dose; hold diuretic temporarily if hypotensive' },
    ],

    contraindications: [
      { condition: 'Anuria', type: 'absolute', reason: 'Will not produce diuresis' },
      { condition: 'Severe renal impairment (GFR <30)', type: 'relative', reason: 'Ineffective; may worsen renal function' },
      { condition: 'Hypersensitivity to sulfonamides', type: 'relative', reason: 'Cross-reactivity possible but rare' },
      { condition: 'Severe hypokalemia or hyponatremia', type: 'relative', reason: 'Will worsen' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta; may decrease placental perfusion', recommendation: 'Avoid; use methyldopa, labetalol, or nifedipine for gestational hypertension', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Higher risk of hyponatremia, hypokalemia, orthostatic hypotension', recommendation: 'Start 12.5 mg; monitor electrolytes closely' },
      { population: 'renal-impairment', consideration: 'Less effective as GFR declines', recommendation: 'Consider chlorthalidone or switch to loop diuretic if GFR <30' },
    ],

    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Assess efficacy', actionThreshold: 'Adjust or add therapy if not at goal' },
      { parameter: 'Potassium', frequency: 'Within 2-4 weeks of initiation; periodic ongoing', rationale: 'Hypokalemia common', actionThreshold: 'Supplement if <3.5 mEq/L' },
      { parameter: 'Sodium', frequency: 'Periodic', rationale: 'Hyponatremia risk especially in elderly', actionThreshold: '<130: reduce dose, fluid restrict' },
      { parameter: 'Creatinine', frequency: 'Baseline; periodic', rationale: 'Monitor renal function', actionThreshold: 'If declining, assess volume status' },
      { parameter: 'Glucose', frequency: 'Periodic', rationale: 'May worsen glucose tolerance', actionThreshold: 'Monitor more closely in diabetics' },
      { parameter: 'Uric acid', frequency: 'If history of gout', rationale: 'Can precipitate gout', actionThreshold: 'Treat if symptomatic' },
    ],

    patientEducation: [
      'Take in the morning to avoid nighttime urination',
      'Eat potassium-rich foods (bananas, oranges) unless told otherwise',
      'Report muscle cramps, weakness, or irregular heartbeat',
      'Use sunscreen - this medication can make you more sensitive to sun',
      'Rise slowly to avoid dizziness',
      'Do not stop taking even if you feel fine',
      'Limit salt intake for best effect',
      'Avoid excessive alcohol - increases blood pressure lowering effect',
    ],

    clinicalPearls: [
      'Antihypertensive effect maxes out at 25 mg - higher doses just increase side effects',
      'Chlorthalidone is more potent and has longer duration than HCTZ - preferred by some guidelines',
      'Initial BP reduction is from volume depletion; long-term effect is from decreased vascular resistance',
      'Hyponatremia is more common in elderly and with higher doses - a serious complication',
      'Excellent choice for Black patients and elderly - often better response than ACE-I alone',
      'Hypercalcemia effect makes it useful for calcium stones and osteoporosis',
      'Metabolic effects (glucose, lipids) are less pronounced at 12.5-25 mg',
      'Less effective when GFR <30 - switch to loop diuretic',
    ],
  },

  // ============================================
  // WARFARIN (Anticoagulant)
  // ============================================
  {
    id: 'warfarin',
    genericName: 'Warfarin',
    brandNames: ['Coumadin', 'Jantoven'],
    drugClass: 'Vitamin K Antagonist',
    category: 'hematologic',

    overview:
      'Warfarin is an oral anticoagulant that prevents blood clots by inhibiting vitamin K-dependent clotting factors. Despite the emergence of DOACs, it remains essential for mechanical heart valves and certain other conditions. Requires regular INR monitoring and has numerous drug/food interactions.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Vitamin K epoxide reductase (VKORC1)',
      targetLocation: 'Hepatocytes',
      simpleExplanation:
        'Warfarin blocks the enzyme that recycles vitamin K, which is needed to make several clotting factors. Without active vitamin K, the liver cannot produce functional clotting factors II, VII, IX, and X.',
      detailedMechanism:
        'Warfarin inhibits VKORC1, preventing the reduction of vitamin K epoxide back to its active hydroquinone form. This depletes active vitamin K needed for gamma-carboxylation of glutamate residues on clotting factors II (prothrombin), VII, IX, and X. Without carboxylation, these factors cannot bind calcium and phospholipid surfaces, rendering them non-functional.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Hepatocyte',
          action: 'Warfarin binds to and inhibits VKORC1 enzyme',
          result: 'Vitamin K cannot be recycled to active form',
        },
        {
          order: 2,
          location: 'Hepatocyte endoplasmic reticulum',
          action: 'Active vitamin K depleted',
          result: 'Clotting factors cannot be gamma-carboxylated',
        },
        {
          order: 3,
          location: 'Circulation',
          action:
            'Non-functional clotting factors released; functional factors degrade',
          result:
            'Reduced clotting ability as factor levels fall (VII first, then others)',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Coagulation',
          effect: 'Reduced clotting factor activity',
          mechanism: 'Depletion of factors II, VII, IX, X',
          clinicalRelevance: 'Prevents thrombus formation and extension',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Coagulation',
          effect: 'Reduced protein C and S activity',
          mechanism: 'Also vitamin K-dependent anticoagulant proteins',
          clinicalRelevance:
            'Initial hypercoagulable state possible; explains need for bridging',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '24-72 hours for initial effect; 5-7 days for full effect',
      durationOfEffect: '2-5 days after discontinuation',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~100%',
        route: ['oral'],
        factors: ['Rapid and complete absorption', 'Food may delay but not reduce absorption'],
        timeToePeak: '4 hours',
        foodEffect: 'Food delays absorption but does not affect extent',
      },
      distribution: {
        volumeOfDistribution: '0.14 L/kg (small, stays in blood)',
        proteinBinding: '99% (primarily albumin)',
        tissueDistribution: ['Primarily in plasma', 'Crosses placenta (teratogenic)'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C9 (S-warfarin, more potent)', 'CYP1A2, CYP3A4 (R-warfarin)'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C9 and VKORC1 polymorphisms significantly affect dosing',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (as metabolites)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: '20-60 hours (average 40 hours)',
      timeToSteadyState: '5-7 days',
    },

    indications: [
      {
        condition: 'Atrial fibrillation (stroke prevention)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'DOACs now preferred for most patients; warfarin for valvular AF',
      },
      {
        condition: 'Mechanical heart valve',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'DOACs contraindicated; warfarin remains standard of care',
      },
      {
        condition: 'Venous thromboembolism (DVT/PE)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'DOACs preferred for most; warfarin for antiphospholipid syndrome',
      },
      {
        condition: 'Antiphospholipid syndrome',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'DOACs inferior in this setting',
      },
    ],

    dosing: {
      usualDose: {
        amount: '2-10 mg daily (highly variable)',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Elderly',
          adjustment: 'Start with lower doses (2-5 mg)',
          rationale: 'Increased sensitivity',
        },
        {
          condition: 'CYP2C9/VKORC1 variants',
          adjustment: 'Use pharmacogenomic dosing algorithms',
          rationale: 'Genetic factors affect metabolism and sensitivity',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Reduce dose; enhanced effect',
          rationale: 'Decreased clotting factor synthesis',
        },
      ],
      maxDose: 'Dose-to-INR target (no fixed max)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Take at same time each day',
          'Consistent vitamin K intake crucial',
          'Do not double up on missed doses',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Bleeding',
        frequency: 'common',
        severity: 'severe',
        mechanism: 'Over-anticoagulation',
        management: 'Hold warfarin; vitamin K for reversal; 4-factor PCC for emergencies',
        reversible: true,
        onsetTiming: 'Any time; risk increases with INR',
      },
      {
        name: 'Warfarin-induced skin necrosis',
        frequency: 'rare',
        severity: 'severe',
        mechanism:
          'Protein C depletes faster than procoagulant factors; microthrombosis',
        management: 'Discontinue; heparin; possible protein C concentrate',
        reversible: false,
        onsetTiming: 'Days 3-8 of therapy',
      },
      {
        name: 'Purple toe syndrome',
        frequency: 'rare',
        severity: 'moderate',
        mechanism: 'Cholesterol embolization',
        management: 'Discontinue warfarin',
        reversible: true,
        onsetTiming: 'Weeks to months after starting',
      },
    ],

    interactions: [
      {
        interactingDrug: 'NSAIDs',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Antiplatelet effect + GI erosion',
        effect: 'Greatly increased bleeding risk',
        management: 'Avoid if possible; use PPI if needed',
      },
      {
        interactingDrug: 'Amiodarone',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP2C9 inhibition',
        effect: 'Increased INR 30-50%',
        management: 'Reduce warfarin dose 30-50%; monitor closely',
      },
      {
        interactingDrug: 'Rifampin',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP induction',
        effect: 'Dramatically reduced warfarin effect',
        management: 'Avoid combination; may need 2-3x warfarin dose',
      },
      {
        interactingDrug: 'Vitamin K (dietary)',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Provides substrate that warfarin blocks',
        effect: 'Reduced anticoagulant effect',
        management: 'Maintain consistent vitamin K intake',
      },
    ],

    contraindications: [
      {
        condition: 'Active bleeding',
        type: 'absolute',
        reason: 'Will worsen hemorrhage',
      },
      {
        condition: 'Pregnancy (especially 1st trimester)',
        type: 'absolute',
        reason: 'Teratogenic - warfarin embryopathy',
        alternative: 'LMWH',
      },
      {
        condition: 'Severe uncontrolled hypertension',
        type: 'relative',
        reason: 'Increased bleeding risk, especially intracranial',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Teratogenic; causes warfarin embryopathy (nasal hypoplasia, stippled epiphyses)',
        recommendation: 'Contraindicated; use LMWH instead',
        pregnancyCategory: 'X',
      },
      {
        population: 'geriatric',
        consideration: 'Increased sensitivity; higher bleeding risk',
        recommendation: 'Start low; target lower INR range if appropriate',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Enhanced effect due to decreased factor synthesis',
        recommendation: 'Use lower doses; monitor closely',
      },
    ],

    monitoring: [
      {
        parameter: 'INR',
        frequency: 'Daily during initiation; weekly during adjustment; monthly when stable',
        rationale: 'Assess anticoagulation intensity',
        actionThreshold: 'Target INR 2-3 for most indications; 2.5-3.5 for mechanical valves',
      },
      {
        parameter: 'Signs of bleeding',
        frequency: 'Every visit',
        rationale: 'Detect complications',
        actionThreshold: 'Hold dose, give vitamin K if significant',
      },
      {
        parameter: 'Hemoglobin/hematocrit',
        frequency: 'Periodic',
        rationale: 'Detect occult bleeding',
        actionThreshold: 'Investigate if dropping',
      },
    ],

    patientEducation: [
      'Take at the same time every day',
      'Maintain consistent vitamin K intake - do not suddenly increase or decrease green leafy vegetables',
      'Report any unusual bleeding or bruising immediately',
      'Inform all healthcare providers and dentists that you take warfarin',
      'Avoid contact sports and activities with high injury risk',
      'Do not take aspirin or NSAIDs without consulting your doctor',
      'Wear medical alert identification',
      'Never skip INR appointments',
      'Many medications and supplements interact - always check before starting anything new',
      'Alcohol can affect INR - limit and keep intake consistent',
    ],

    clinicalPearls: [
      'Loading doses are discouraged - increase risk of skin necrosis and overanticoagulation',
      'Factor VII has shortest half-life (6 hrs) - INR rises first but therapeutic anticoagulation takes 5-7 days',
      'Bridging with heparin needed if rapid anticoagulation required or high thrombotic risk',
      'CYP2C9 poor metabolizers and VKORC1 variants need significantly lower doses',
      'Vitamin K 1-2.5 mg PO reverses over-anticoagulation in 24-48 hours',
      '4-factor PCC provides immediate reversal for life-threatening bleeding',
      'DOACs have replaced warfarin for most indications except mechanical valves and APS',
      'Time in therapeutic range (TTR) >65-70% indicates good warfarin management',
      'Warfarin skin necrosis most common in protein C deficiency - overlap with heparin prevents this',
    ],
  },

  // ============================================
  // ACETAMINOPHEN (Analgesic/Antipyretic)
  // ============================================
  {
    id: 'acetaminophen',
    genericName: 'Acetaminophen (Paracetamol)',
    brandNames: ['Tylenol', 'Panadol', 'Ofirmev'],
    drugClass: 'Non-opioid Analgesic/Antipyretic',
    category: 'analgesic',

    overview:
      'Acetaminophen is the most commonly used over-the-counter analgesic and antipyretic worldwide. It provides effective pain relief and fever reduction without the GI, renal, or cardiovascular risks of NSAIDs. However, it is the leading cause of acute liver failure when overdosed.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'COX enzymes (central); endocannabinoid system',
      targetLocation: 'Central nervous system',
      simpleExplanation:
        'Acetaminophen works primarily in the brain to reduce pain signals and lower fever. Unlike NSAIDs, it has minimal effect on inflammation in the body because it works centrally, not peripherally.',
      detailedMechanism:
        'The exact mechanism remains debated. Proposed mechanisms include: (1) Inhibition of COX enzymes in the CNS, reducing prostaglandin synthesis and pain/fever signaling; (2) Activation of descending serotonergic pathways; (3) Metabolism to AM404, which inhibits anandamide reuptake and activates TRPV1 receptors in the endocannabinoid system.',
      mechanismSteps: [
        {
          order: 1,
          location: 'CNS',
          action: 'Acetaminophen crosses blood-brain barrier',
          result: 'Reaches central pain processing areas',
        },
        {
          order: 2,
          location: 'Brain (peroxidase-low environment)',
          action: 'Inhibits COX enzymes in CNS',
          result: 'Reduced central prostaglandin synthesis',
        },
        {
          order: 3,
          location: 'Hypothalamus',
          action: 'Lowers prostaglandin E2 setpoint',
          result: 'Reduced fever',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Analgesia',
          mechanism: 'Reduced central pain processing',
          clinicalRelevance: 'Effective for mild-moderate pain',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Thermoregulation',
          effect: 'Antipyresis',
          mechanism: 'Reset hypothalamic setpoint',
          clinicalRelevance: 'Reduces fever effectively',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Hepatic',
          effect: 'Hepatotoxicity (overdose)',
          mechanism: 'NAPQI accumulation depletes glutathione',
          clinicalRelevance: 'Leading cause of acute liver failure',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '30-60 minutes (oral); 5-15 minutes (IV)',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '85-90%',
        route: ['oral', 'rectal', 'intravenous'],
        factors: ['Rapid absorption from GI tract', 'Rectal absorption slower and less complete'],
        timeToePeak: '30-60 minutes (oral); immediate (IV)',
        foodEffect: 'Food may delay but does not reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '0.9 L/kg',
        proteinBinding: '10-25% (low)',
        tissueDistribution: ['Widely distributed', 'Crosses BBB well'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['UGT (glucuronidation 50%)', 'SULT (sulfation 30%)', 'CYP2E1 (NAPQI 5-10%)'],
        activeMetabolites: ['NAPQI (toxic, normally detoxified by glutathione)'],
        geneticVariability: 'CYP2E1 inducers increase NAPQI formation',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (90% as conjugates)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: '2-3 hours',
      timeToSteadyState: '8-12 hours',
    },

    indications: [
      {
        condition: 'Mild to moderate pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line for many pain conditions',
      },
      {
        condition: 'Fever',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line antipyretic',
      },
      {
        condition: 'Osteoarthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: true,
        notes: 'Less effective than NSAIDs but safer',
      },
    ],

    dosing: {
      usualDose: {
        amount: '325-1000 mg',
        frequency: 'Every 4-6 hours',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Hepatic impairment',
          adjustment: 'Reduce to max 2 g/day; avoid in severe disease',
          rationale: 'Decreased metabolism increases toxicity risk',
        },
        {
          condition: 'Chronic alcohol use',
          adjustment: 'Limit to 2 g/day',
          rationale: 'CYP2E1 induction and glutathione depletion',
        },
        {
          condition: 'Elderly',
          adjustment: 'Limit to 3 g/day',
          rationale: 'May have unrecognized liver disease',
        },
      ],
      maxDose: '4 g/day (3 g/day in elderly/alcohol use/liver disease)',
      administration: {
        route: 'Oral, rectal, or IV',
        withFood: 'either',
        specialInstructions: [
          'Check all medications for acetaminophen content',
          'Do not exceed daily maximum from all sources',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Hepatotoxicity',
        frequency: 'rare',
        severity: 'life-threatening',
        mechanism: 'NAPQI accumulation when glutathione depleted',
        management: 'N-acetylcysteine (NAC) within 8-10 hours of overdose',
        reversible: true,
        onsetTiming: '24-72 hours after overdose',
      },
      {
        name: 'Allergic reaction',
        frequency: 'rare',
        severity: 'moderate',
        mechanism: 'Hypersensitivity',
        management: 'Discontinue; supportive care',
        reversible: true,
        onsetTiming: 'Hours to days',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Alcohol (chronic)',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP2E1 induction increases NAPQI; glutathione depletion',
        effect: 'Increased hepatotoxicity risk',
        management: 'Limit to 2 g/day in chronic alcohol users',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'May inhibit warfarin metabolism at high doses',
        effect: 'Increased INR',
        management: 'Monitor INR with regular acetaminophen use',
      },
    ],

    contraindications: [
      {
        condition: 'Severe hepatic impairment',
        type: 'absolute',
        reason: 'Cannot safely metabolize; high toxicity risk',
      },
      {
        condition: 'Known hypersensitivity',
        type: 'absolute',
        reason: 'Risk of allergic reaction',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Extensive safety data; most commonly used analgesic in pregnancy',
        recommendation: 'First-line for pain/fever; use lowest effective dose',
        pregnancyCategory: 'B',
      },
      {
        population: 'breastfeeding',
        consideration: 'Minimal excretion in breast milk',
        recommendation: 'Safe to use',
      },
      {
        population: 'pediatric',
        consideration: 'Weight-based dosing essential',
        recommendation: '10-15 mg/kg every 4-6 hours; max 75 mg/kg/day',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Decreased glutathione; impaired metabolism',
        recommendation: 'Avoid in severe disease; max 2 g/day in mild-moderate',
      },
    ],

    monitoring: [
      {
        parameter: 'Liver function tests',
        frequency: 'If chronic high-dose use or risk factors',
        rationale: 'Detect hepatotoxicity',
        actionThreshold: 'Discontinue if ALT/AST significantly elevated',
      },
      {
        parameter: 'Total daily intake',
        frequency: 'Ongoing',
        rationale: 'Prevent inadvertent overdose from multiple products',
        actionThreshold: 'Never exceed 4 g/day from all sources',
      },
    ],

    patientEducation: [
      'Do not exceed 4000 mg (4 g) per day from ALL sources',
      'Many products contain acetaminophen - check labels on cold medicines, sleep aids, prescription pain medications',
      'Avoid or limit alcohol while taking acetaminophen',
      'Seek immediate medical attention if you may have taken too much',
      'Signs of liver problems: yellowing skin/eyes, dark urine, severe nausea, abdominal pain',
      'This medication does NOT reduce inflammation - NSAIDs needed for inflammatory conditions',
      'Safe in pregnancy and breastfeeding at recommended doses',
    ],

    clinicalPearls: [
      'Acetaminophen overdose is the leading cause of acute liver failure in the US',
      'NAC is the antidote - most effective within 8 hours but beneficial up to 24+ hours',
      'Rumack-Matthew nomogram guides treatment for acute single overdose',
      'No anti-inflammatory effect - ineffective for conditions like rheumatoid arthritis',
      'Safer than NSAIDs for patients with GI bleeding risk, cardiovascular disease, or renal impairment',
      'Chronic alcohol users and malnourished patients have depleted glutathione - higher risk',
      'IV acetaminophen provides opioid-sparing effect in postoperative multimodal analgesia',
      'Many combination products (Vicodin, Percocet, Norco) contain acetaminophen',
    ],
  },

  // ============================================
  // GABAPENTIN (Anticonvulsant/Neuropathic Pain)
  // ============================================
  {
    id: 'gabapentin',
    genericName: 'Gabapentin',
    brandNames: ['Neurontin', 'Gralise', 'Horizant'],
    drugClass: 'Gabapentinoid',
    category: 'neurological',

    overview:
      'Gabapentin is an anticonvulsant primarily used for neuropathic pain conditions such as diabetic neuropathy and postherpetic neuralgia. Despite its name suggesting GABA activity, it works by binding to calcium channels. It has a favorable safety profile but growing concerns about misuse potential.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'α2δ subunit of voltage-gated calcium channels',
      targetLocation: 'Presynaptic neurons in CNS and peripheral nerves',
      simpleExplanation:
        'Gabapentin binds to a specific part of calcium channels in nerves, reducing the release of excitatory neurotransmitters. This calms overactive nerve signals that cause neuropathic pain and seizures.',
      detailedMechanism:
        'Gabapentin binds to the α2δ-1 subunit of voltage-gated calcium channels (VGCCs). This reduces calcium channel trafficking to the plasma membrane and decreases presynaptic calcium influx. The result is reduced release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. Despite structural similarity to GABA, gabapentin does not bind to GABA receptors or affect GABA metabolism.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Presynaptic terminal',
          action: 'Binds to α2δ-1 subunit of VGCCs',
          result: 'Reduced calcium channel trafficking to membrane',
        },
        {
          order: 2,
          location: 'Presynaptic terminal',
          action: 'Decreased calcium influx during depolarization',
          result: 'Reduced neurotransmitter release',
        },
        {
          order: 3,
          location: 'Synapse',
          action: 'Decreased glutamate, norepinephrine, substance P release',
          result: 'Reduced neuronal excitability and pain transmission',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Nervous system (pain pathways)',
          effect: 'Reduced neuropathic pain',
          mechanism: 'Decreased ectopic firing and central sensitization',
          clinicalRelevance: 'First-line for diabetic neuropathy and PHN',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'CNS',
          effect: 'Anticonvulsant',
          mechanism: 'Reduced neuronal hyperexcitability',
          clinicalRelevance: 'Adjunctive therapy for partial seizures',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'CNS',
          effect: 'Sedation',
          mechanism: 'Reduced excitatory neurotransmission',
          clinicalRelevance: 'Common side effect; usually improves with time',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Days to weeks for neuropathic pain',
      durationOfEffect: '8-12 hours (requires TID dosing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '60% at 300 mg; decreases with higher doses (saturable)',
        route: ['oral'],
        factors: ['Absorbed via L-amino acid transporter (saturable)', 'Bioavailability inversely proportional to dose'],
        timeToePeak: '2-4 hours',
        foodEffect: 'Minimal effect',
      },
      distribution: {
        volumeOfDistribution: '0.6-0.8 L/kg',
        proteinBinding: '<3% (minimal)',
        tissueDistribution: ['CNS', 'Peripheral nerves'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (100% unchanged)',
        adjustmentNeeded: {
          renal: true,
          hepatic: false,
        },
      },
      halfLife: '5-7 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      {
        condition: 'Postherpetic neuralgia',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'NNT ~4 for 50% pain reduction',
      },
      {
        condition: 'Diabetic peripheral neuropathy',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line per ADA guidelines',
      },
      {
        condition: 'Partial seizures (adjunct)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Less potent than many newer agents',
      },
      {
        condition: 'Restless legs syndrome',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Gabapentin enacarbil (Horizant) approved',
      },
    ],

    dosing: {
      usualDose: {
        amount: '300-1200 mg TID',
        frequency: 'Three times daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Renal impairment (CrCl 30-59)',
          adjustment: '200-700 mg BID',
          rationale: 'Renally eliminated unchanged',
        },
        {
          condition: 'Renal impairment (CrCl 15-29)',
          adjustment: '200-700 mg daily',
          rationale: 'Renally eliminated unchanged',
        },
        {
          condition: 'Hemodialysis',
          adjustment: 'Supplemental dose after dialysis',
          rationale: 'Dialyzable',
        },
      ],
      maxDose: '3600 mg/day in divided doses',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Divide total dose into 3 doses (saturable absorption)',
          'Taper over at least 1 week to discontinue',
          'Take antacids 2 hours before gabapentin',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Somnolence/sedation',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'CNS depression',
        management: 'Start low, titrate slowly; usually improves with time',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Dizziness',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'CNS effect',
        management: 'Slow titration; usually improves',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Peripheral edema',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Unknown; not cardiac',
        management: 'Dose reduction if significant',
        reversible: true,
        onsetTiming: 'Weeks',
      },
      {
        name: 'Weight gain',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Increased appetite',
        management: 'Diet and exercise counseling',
        reversible: true,
        onsetTiming: 'Months',
      },
    ],

    interactions: [
      {
        interactingDrug: 'CNS depressants (opioids, benzodiazepines)',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS depression',
        effect: 'Increased sedation, respiratory depression',
        management: 'FDA boxed warning; use lower doses with caution',
      },
      {
        interactingDrug: 'Antacids',
        interactionType: 'pharmacokinetic',
        severity: 'minor',
        mechanism: 'Decreased gabapentin absorption',
        effect: 'Reduced efficacy',
        management: 'Take gabapentin 2 hours after antacids',
      },
    ],

    contraindications: [
      {
        condition: 'Hypersensitivity',
        type: 'absolute',
        reason: 'Risk of allergic reaction',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Limited data; some registry concerns',
        recommendation: 'Use only if benefit outweighs risk; register in pregnancy registry',
        pregnancyCategory: 'C',
      },
      {
        population: 'geriatric',
        consideration: 'Increased CNS sensitivity; often have reduced renal function',
        recommendation: 'Start low; adjust for renal function; fall risk assessment',
      },
      {
        population: 'renal-impairment',
        consideration: '100% renally eliminated unchanged',
        recommendation: 'Reduce dose based on CrCl; supplement after hemodialysis',
      },
    ],

    monitoring: [
      {
        parameter: 'Pain scores',
        frequency: 'Regular visits',
        rationale: 'Assess efficacy',
        actionThreshold: 'Allow 2-8 weeks at therapeutic dose before declaring failure',
      },
      {
        parameter: 'Renal function',
        frequency: 'Baseline and periodic',
        rationale: 'Dose adjustment needed for renal impairment',
        actionThreshold: 'Reduce dose if CrCl declines',
      },
      {
        parameter: 'Signs of misuse',
        frequency: 'Ongoing',
        rationale: 'Growing concerns about misuse potential',
        actionThreshold: 'Consider alternative if concerning',
      },
    ],

    patientEducation: [
      'May cause drowsiness - do not drive until you know how it affects you',
      'Do NOT stop suddenly - must taper to avoid withdrawal or seizures',
      'Full pain relief may take several weeks',
      'Report swelling in legs, unusual mood changes, or suicidal thoughts',
      'Avoid alcohol - increases sedation',
      'This medication may cause weight gain',
      'Take antacids 2 hours before gabapentin',
    ],

    clinicalPearls: [
      'Bioavailability decreases at higher doses - split into 3 doses rather than large single doses',
      'No CYP450 interactions - useful in patients on multiple medications',
      'Taper over at least 1 week - abrupt discontinuation can cause withdrawal',
      'Pregabalin (Lyrica) is more potent with linear absorption and BID dosing',
      'Schedule V in some states due to increasing misuse concerns',
      'Peripheral edema is not cardiac - does not require cardiac workup',
      'FDA boxed warning: serious breathing problems when used with CNS depressants',
      'For neuropathic pain, therapeutic dose often 1800-3600 mg/day',
    ],
  },

  // ============================================
  // PREDNISONE (Corticosteroid)
  // ============================================
  {
    id: 'prednisone',
    genericName: 'Prednisone',
    brandNames: ['Deltasone', 'Rayos', 'Prednisone Intensol'],
    drugClass: 'Glucocorticoid',
    category: 'immunologic',

    overview:
      'Prednisone is an intermediate-acting synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects. It is a prodrug converted to prednisolone in the liver. While highly effective for numerous inflammatory and autoimmune conditions, long-term use carries significant risks.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptor (GR)',
      targetLocation: 'Cytoplasm of virtually all cells',
      simpleExplanation:
        'Prednisone is converted to prednisolone in the liver, which then enters cells and binds to glucocorticoid receptors. This complex moves to the nucleus and turns off inflammatory genes while turning on anti-inflammatory genes.',
      detailedMechanism:
        'After hepatic conversion to prednisolone, the drug enters cells and binds cytoplasmic glucocorticoid receptors. The receptor-ligand complex translocates to the nucleus where it: (1) Binds glucocorticoid response elements (GREs) to increase anti-inflammatory gene transcription (annexin-1, IκB, IL-10); (2) Interacts with transcription factors (NF-κB, AP-1) to suppress pro-inflammatory gene expression (cytokines, COX-2, adhesion molecules).',
      mechanismSteps: [
        {
          order: 1,
          location: 'Liver',
          action: 'Prednisone converted to prednisolone by 11β-HSD1',
          result: 'Active drug formed',
        },
        {
          order: 2,
          location: 'Target cell cytoplasm',
          action: 'Prednisolone binds glucocorticoid receptor',
          result: 'Receptor-ligand complex forms',
        },
        {
          order: 3,
          location: 'Nucleus',
          action: 'Complex binds GREs and inhibits NF-κB/AP-1',
          result: 'Altered gene transcription - anti-inflammatory pattern',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Immune system',
          effect: 'Immunosuppression',
          mechanism: 'Reduced cytokine production, lymphocyte apoptosis',
          clinicalRelevance: 'Treats autoimmune diseases; increases infection risk',
          desiredOrAdverse: 'both',
        },
        {
          system: 'Metabolic',
          effect: 'Hyperglycemia',
          mechanism: 'Increased gluconeogenesis, decreased insulin sensitivity',
          clinicalRelevance: 'Can precipitate or worsen diabetes',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Musculoskeletal',
          effect: 'Bone loss',
          mechanism: 'Decreased osteoblast function, increased osteoclast activity',
          clinicalRelevance: 'Osteoporosis with long-term use',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '18-36 hours (intermediate-acting)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~80%',
        route: ['oral'],
        factors: ['Well absorbed from GI tract'],
        timeToePeak: '1-2 hours',
        foodEffect: 'May be taken with food to reduce GI upset',
      },
      distribution: {
        volumeOfDistribution: '0.4-1 L/kg',
        proteinBinding: '70-90%',
        tissueDistribution: ['Widely distributed', 'Crosses placenta minimally'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['11β-HSD1 (activation)', 'CYP3A4 (metabolism)'],
        activeMetabolites: ['Prednisolone (active form)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (as metabolites)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: 'Plasma: 2-4 hours; Biologic: 18-36 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      {
        condition: 'Asthma exacerbation',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Reduces hospitalization and relapse',
      },
      {
        condition: 'COPD exacerbation',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: '5-day course; speeds recovery',
      },
      {
        condition: 'Rheumatoid arthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Bridge therapy; long-term use avoided',
      },
      {
        condition: 'Inflammatory bowel disease',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Moderate-severe flares',
      },
      {
        condition: 'Giant cell arteritis',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'High-dose; prevents blindness',
      },
    ],

    dosing: {
      usualDose: {
        amount: '5-60 mg daily (varies by indication)',
        frequency: 'Once daily (usually morning)',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Hepatic impairment (severe)',
          adjustment: 'Use prednisolone instead',
          rationale: 'Prednisone requires hepatic conversion',
        },
        {
          condition: 'Concurrent CYP3A4 inducers',
          adjustment: 'May need higher doses',
          rationale: 'Increased metabolism',
        },
      ],
      maxDose: 'Variable; pulse doses up to 1 mg/kg for severe disease',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: [
          'Take in morning to mimic cortisol rhythm',
          'Taper gradually after prolonged use (>2-3 weeks)',
          'Never stop abruptly after chronic use',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Hyperglycemia',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'Increased gluconeogenesis; insulin resistance',
        management: 'Monitor glucose; adjust diabetes medications',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Osteoporosis',
        frequency: 'common',
        severity: 'severe',
        mechanism: 'Decreased bone formation; increased resorption',
        management: 'Calcium, vitamin D, bisphosphonates for chronic use',
        reversible: false,
        onsetTiming: 'Months to years',
      },
      {
        name: 'Adrenal suppression',
        frequency: 'common',
        severity: 'severe',
        mechanism: 'Exogenous steroids suppress HPA axis',
        management: 'Taper slowly; stress dosing during illness',
        reversible: true,
        onsetTiming: 'Weeks of use',
      },
      {
        name: 'Immunosuppression',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Decreased immune function',
        management: 'Monitor for infection; PJP prophylaxis if high-dose',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Mood changes',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'CNS effects',
        management: 'Dose reduction; psychiatric evaluation if severe',
        reversible: true,
        onsetTiming: 'Days to weeks',
      },
    ],

    interactions: [
      {
        interactingDrug: 'NSAIDs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Additive GI toxicity',
        effect: 'Increased GI bleeding risk',
        management: 'Use PPI if combination necessary',
      },
      {
        interactingDrug: 'CYP3A4 inducers (rifampin)',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Increased steroid metabolism',
        effect: 'Reduced efficacy',
        management: 'May need higher steroid doses',
      },
      {
        interactingDrug: 'Live vaccines',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Immunosuppression',
        effect: 'Vaccine virus may cause disease',
        management: 'Avoid live vaccines during immunosuppressive doses',
      },
    ],

    contraindications: [
      {
        condition: 'Systemic fungal infection',
        type: 'absolute',
        reason: 'Immunosuppression can cause dissemination',
      },
      {
        condition: 'Live vaccines',
        type: 'relative',
        reason: 'Contraindicated during immunosuppressive doses',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Crosses placenta minimally; prednisone preferred over dexamethasone',
        recommendation: 'Use when indicated; category C',
        pregnancyCategory: 'C',
      },
      {
        population: 'geriatric',
        consideration: 'Higher risk of osteoporosis, diabetes, delirium',
        recommendation: 'Use lowest effective dose; aggressive bone protection',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'May not convert prednisone to prednisolone',
        recommendation: 'Use prednisolone directly in severe disease',
      },
    ],

    monitoring: [
      {
        parameter: 'Blood glucose',
        frequency: 'Baseline; regular with long-term use',
        rationale: 'Hyperglycemia common',
        actionThreshold: 'Initiate diabetes therapy if persistent',
      },
      {
        parameter: 'Bone density',
        frequency: 'Baseline if >3 months anticipated',
        rationale: 'Osteoporosis prevention',
        actionThreshold: 'Start bisphosphonate for osteopenia/osteoporosis',
      },
      {
        parameter: 'Blood pressure',
        frequency: 'Regular',
        rationale: 'Sodium retention; hypertension',
        actionThreshold: 'Treat if elevated',
      },
    ],

    patientEducation: [
      'Take in the morning with food to mimic natural cortisol rhythm',
      'Do NOT stop suddenly after prolonged use - must taper gradually',
      'Carry a steroid card or medical alert identification',
      'Report signs of infection promptly',
      'May cause mood changes, insomnia, increased appetite',
      'Ensure adequate calcium and vitamin D intake',
      'Avoid live vaccines while on immunosuppressive doses',
      'Tell all healthcare providers you take steroids',
    ],

    clinicalPearls: [
      'Prednisone is a prodrug - use prednisolone in severe liver disease',
      'Biologic half-life (18-36 hrs) far exceeds plasma half-life (2-4 hrs)',
      'HPA suppression after 2-3 weeks of use - taper required',
      'Stress dosing: 50-100 mg hydrocortisone equivalent for major surgery',
      'Steroid equivalencies: prednisone 5 mg = hydrocortisone 20 mg = dexamethasone 0.75 mg',
      'Pneumocystis prophylaxis if ≥20 mg/day for ≥1 month with other immunosuppression',
      'Osteoporosis prevention: calcium 1200 mg + vitamin D 800 IU daily',
    ],
  },

  // ============================================
  // LOSARTAN (ARB)
  // ============================================
  {
    id: 'losartan',
    genericName: 'Losartan',
    brandNames: ['Cozaar'],
    drugClass: 'Angiotensin II Receptor Blocker (ARB)',
    category: 'cardiovascular',

    overview:
      'Losartan is an angiotensin II receptor blocker (ARB) that provides cardiovascular and renal protection similar to ACE inhibitors but without the common ACE-I side effect of cough. It has unique uricosuric properties among ARBs.',

    mechanism: {
      type: 'receptor-antagonist',
      target: 'Angiotensin II type 1 (AT1) receptor',
      targetLocation: 'Vascular smooth muscle, adrenal cortex, kidney',
      simpleExplanation:
        'Losartan blocks the receptor where angiotensin II normally acts. This prevents blood vessel constriction and reduces aldosterone release, lowering blood pressure and protecting the heart and kidneys.',
      detailedMechanism:
        'Losartan competitively antagonizes AT1 receptors, blocking the effects of angiotensin II including vasoconstriction, aldosterone secretion, sympathetic activation, and cell proliferation. Unlike ACE inhibitors, ARBs do not affect bradykinin metabolism, explaining the absence of cough.',
      mechanismSteps: [
        {
          order: 1,
          location: 'AT1 receptor',
          action: 'Losartan binds and blocks AT1 receptor',
          result: 'Angiotensin II cannot activate receptor',
        },
        {
          order: 2,
          location: 'Vascular smooth muscle',
          action: 'Blocked vasoconstriction signal',
          result: 'Vasodilation; reduced blood pressure',
        },
        {
          order: 3,
          location: 'Adrenal cortex',
          action: 'Blocked aldosterone release',
          result: 'Reduced sodium retention; cardioprotection',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Cardiovascular',
          effect: 'Vasodilation and BP reduction',
          mechanism: 'Blocked AT1-mediated vasoconstriction',
          clinicalRelevance: 'Treats hypertension',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Renal',
          effect: 'Reduced proteinuria; nephroprotection',
          mechanism: 'Decreased glomerular pressure',
          clinicalRelevance: 'Slows diabetic nephropathy',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Metabolic',
          effect: 'Uricosuric effect',
          mechanism: 'Inhibits uric acid reabsorption (unique to losartan)',
          clinicalRelevance: 'May benefit patients with gout',
          desiredOrAdverse: 'desired',
        },
      ],
      onsetOfAction: '1 hour; peak at 6 hours',
      durationOfEffect: '24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '33%',
        route: ['oral'],
        factors: ['First-pass metabolism'],
        timeToePeak: '1 hour (losartan); 3-4 hours (active metabolite)',
        foodEffect: 'Minimal effect',
      },
      distribution: {
        volumeOfDistribution: '34 L',
        proteinBinding: '98-99%',
        tissueDistribution: ['Does not readily cross BBB'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C9 (primary)', 'CYP3A4'],
        activeMetabolites: ['E-3174 (10-40x more potent than losartan)'],
        geneticVariability: 'CYP2C9 poor metabolizers have reduced active metabolite',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Biliary (60%) and renal (35%)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: 'Losartan: 2 hours; E-3174: 6-9 hours',
      timeToSteadyState: '3-5 days',
    },

    indications: [
      {
        condition: 'Hypertension',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line option',
      },
      {
        condition: 'Diabetic nephropathy (type 2 DM)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Slows progression to ESRD',
      },
      {
        condition: 'Heart failure with reduced EF',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Alternative if ACE-I not tolerated',
      },
      {
        condition: 'Stroke prevention in hypertension with LVH',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'LIFE trial data',
      },
    ],

    dosing: {
      usualDose: {
        amount: '50-100 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Hepatic impairment',
          adjustment: 'Start 25 mg daily',
          rationale: 'Reduced conversion to active metabolite',
        },
        {
          condition: 'Volume depletion',
          adjustment: 'Start 25 mg daily',
          rationale: 'Risk of hypotension',
        },
      ],
      maxDose: '100 mg daily',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Can be taken with or without food',
          'May take several weeks for full BP effect',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Hyperkalemia',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Reduced aldosterone',
        management: 'Monitor potassium; avoid K supplements',
        reversible: true,
        onsetTiming: 'Days to weeks',
      },
      {
        name: 'Hypotension',
        frequency: 'uncommon',
        severity: 'moderate',
        mechanism: 'Vasodilation',
        management: 'Start low in volume-depleted patients',
        reversible: true,
        onsetTiming: 'Hours',
      },
      {
        name: 'Acute kidney injury',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Reduced GFR in bilateral RAS',
        management: 'Monitor creatinine; caution in renovascular disease',
        reversible: true,
        onsetTiming: 'Days',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Potassium supplements/K-sparing diuretics',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive hyperkalemia risk',
        effect: 'Life-threatening hyperkalemia',
        management: 'Monitor potassium closely if combination needed',
      },
      {
        interactingDrug: 'NSAIDs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Reduced prostaglandin-mediated renal perfusion',
        effect: 'Reduced antihypertensive effect; AKI risk',
        management: 'Monitor BP and renal function',
      },
      {
        interactingDrug: 'Lithium',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Reduced lithium excretion',
        effect: 'Lithium toxicity',
        management: 'Monitor lithium levels',
      },
    ],

    contraindications: [
      {
        condition: 'Pregnancy',
        type: 'absolute',
        reason: 'Fetal toxicity - oligohydramnios, hypotension, renal failure',
      },
      {
        condition: 'Concurrent aliskiren (in diabetes)',
        type: 'absolute',
        reason: 'Increased adverse events without benefit',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Fetal toxicity in 2nd/3rd trimester; possible 1st trimester risk',
        recommendation: 'Contraindicated; discontinue immediately if pregnancy detected',
        pregnancyCategory: 'D',
      },
      {
        population: 'geriatric',
        consideration: 'No specific dose adjustment; monitor renal function',
        recommendation: 'Standard dosing; watch for orthostatic hypotension',
      },
      {
        population: 'renal-impairment',
        consideration: 'No dose adjustment needed; monitor for hyperkalemia',
        recommendation: 'Use with caution; monitor potassium and creatinine',
      },
    ],

    monitoring: [
      {
        parameter: 'Potassium',
        frequency: 'Baseline; 1-2 weeks after starting; periodically',
        rationale: 'Hyperkalemia risk',
        actionThreshold: 'Hold if K >5.5 mEq/L',
      },
      {
        parameter: 'Serum creatinine',
        frequency: 'Baseline; 1-2 weeks after starting; periodically',
        rationale: 'Detect AKI, especially in renovascular disease',
        actionThreshold: 'Hold if creatinine rises >30%',
      },
      {
        parameter: 'Blood pressure',
        frequency: 'Regular',
        rationale: 'Assess efficacy',
        actionThreshold: 'Adjust dose to meet BP goals',
      },
    ],

    patientEducation: [
      'Do not use if pregnant - can harm the baby',
      'May cause dizziness - rise slowly from sitting or lying',
      'Avoid potassium supplements and salt substitutes unless directed',
      'Report swelling of face, lips, or tongue immediately (rare angioedema)',
      'Continue taking even if you feel well',
      'Do not take NSAIDs (ibuprofen, naproxen) without asking your doctor',
    ],

    clinicalPearls: [
      'Unlike ACE inhibitors, ARBs rarely cause cough (bradykinin unaffected)',
      'Angioedema can still occur but is less common than with ACE-I',
      'Losartan has unique uricosuric effect - may benefit gout patients',
      'Active metabolite E-3174 is responsible for most antihypertensive effect',
      'Do not combine with ACE-I - no additional benefit, increased risk',
      'Black patients may have slightly reduced response - often combined with diuretic',
      'Full BP effect may take 3-6 weeks',
    ],
  },

  // ============================================
  // CLOPIDOGREL (Antiplatelet)
  // ============================================
  {
    id: 'clopidogrel',
    genericName: 'Clopidogrel',
    brandNames: ['Plavix'],
    drugClass: 'P2Y12 Inhibitor',
    category: 'cardiovascular',

    overview:
      'Clopidogrel is an antiplatelet agent that irreversibly inhibits ADP-mediated platelet aggregation. It is essential for preventing stent thrombosis after coronary intervention and is used in acute coronary syndromes and stroke prevention.',

    mechanism: {
      type: 'receptor-antagonist',
      target: 'P2Y12 ADP receptor on platelets',
      targetLocation: 'Platelet surface',
      simpleExplanation:
        'Clopidogrel is converted to an active form that permanently blocks the P2Y12 receptor on platelets. This prevents ADP from activating platelets, reducing clot formation.',
      detailedMechanism:
        'Clopidogrel is a prodrug requiring hepatic conversion to its active thiol metabolite via CYP2C19 and CYP3A4. The active metabolite irreversibly binds to the P2Y12 receptor, blocking ADP-mediated platelet activation and aggregation. This inhibition lasts for the platelet lifespan (7-10 days).',
      mechanismSteps: [
        {
          order: 1,
          location: 'Liver',
          action: 'CYP2C19 converts clopidogrel to active thiol metabolite',
          result: 'Active drug formed (only 15% of dose)',
        },
        {
          order: 2,
          location: 'Platelet surface',
          action: 'Active metabolite binds P2Y12 receptor irreversibly',
          result: 'ADP cannot activate platelet',
        },
        {
          order: 3,
          location: 'Platelet',
          action: 'Blocked amplification of platelet activation',
          result: 'Reduced platelet aggregation for platelet lifespan',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Hemostasis',
          effect: 'Reduced platelet aggregation',
          mechanism: 'Irreversible P2Y12 inhibition',
          clinicalRelevance: 'Prevents arterial thrombosis',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Hemostasis',
          effect: 'Increased bleeding risk',
          mechanism: 'Impaired platelet function',
          clinicalRelevance: 'Balance efficacy vs bleeding',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '2 hours (loading dose); days (maintenance)',
      durationOfEffect: '7-10 days (platelet lifespan)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~50% (prodrug)',
        route: ['oral'],
        factors: ['Rapid absorption'],
        timeToePeak: '0.5-1 hour',
        foodEffect: 'Minimal effect',
      },
      distribution: {
        volumeOfDistribution: 'Not well characterized',
        proteinBinding: '98%',
        tissueDistribution: ['Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19 (critical)', 'CYP3A4', 'CYP1A2'],
        activeMetabolites: ['Thiol metabolite (active)'],
        geneticVariability: 'CYP2C19 poor metabolizers have reduced response (boxed warning)',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (50%) and fecal (46%)',
        adjustmentNeeded: {
          renal: false,
          hepatic: false,
        },
      },
      halfLife: 'Parent: 6 hours; Active metabolite: 30 minutes',
      timeToSteadyState: '3-7 days (without loading dose)',
    },

    indications: [
      {
        condition: 'Acute coronary syndrome (NSTEMI/STEMI)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'With aspirin for 12 months post-ACS',
      },
      {
        condition: 'Post-PCI with stent',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'DAPT: 6-12 months (varies by stent type and risk)',
      },
      {
        condition: 'Recent MI, stroke, or PAD',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Secondary prevention',
      },
      {
        condition: 'Atrial fibrillation (if anticoagulation contraindicated)',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Inferior to anticoagulants for stroke prevention',
      },
    ],

    dosing: {
      usualDose: {
        amount: '75 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'ACS (loading)',
          adjustment: '300-600 mg loading dose',
          rationale: 'Rapid onset needed',
        },
        {
          condition: 'CYP2C19 poor metabolizer',
          adjustment: 'Consider alternative (prasugrel, ticagrelor)',
          rationale: 'Reduced activation to active metabolite',
        },
      ],
      maxDose: '75 mg daily maintenance',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Do not discontinue without consulting physician',
          'Hold 5-7 days before major surgery if possible',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Bleeding',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Impaired platelet function',
        management: 'Platelet transfusion for serious bleeding',
        reversible: false,
        onsetTiming: 'Any time during therapy',
      },
      {
        name: 'TTP (rare)',
        frequency: 'very-rare',
        severity: 'life-threatening',
        mechanism: 'Idiosyncratic',
        management: 'Plasma exchange; discontinue drug',
        reversible: true,
        onsetTiming: 'Usually first 2 weeks',
      },
      {
        name: 'GI upset',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Direct GI irritation',
        management: 'Take with food',
        reversible: true,
        onsetTiming: 'Early in therapy',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Omeprazole/esomeprazole',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'CYP2C19 inhibition reduces active metabolite',
        effect: 'Reduced antiplatelet effect',
        management: 'Use pantoprazole instead (less CYP2C19 inhibition)',
      },
      {
        interactingDrug: 'Aspirin',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Additive antiplatelet effect',
        effect: 'Increased efficacy and bleeding risk',
        management: 'Intended combination (DAPT); monitor for bleeding',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive antithrombotic effect',
        effect: 'Significantly increased bleeding risk',
        management: 'Avoid triple therapy when possible; use shortest duration if needed',
      },
    ],

    contraindications: [
      {
        condition: 'Active pathological bleeding',
        type: 'absolute',
        reason: 'Will worsen bleeding',
      },
      {
        condition: 'CYP2C19 poor metabolizer status',
        type: 'relative',
        reason: 'Reduced efficacy - consider alternative',
        alternative: 'Prasugrel or ticagrelor',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Limited data; use only if clearly needed',
        recommendation: 'Consider alternatives',
        pregnancyCategory: 'B',
      },
      {
        population: 'geriatric',
        consideration: 'No dose adjustment; increased bleeding risk',
        recommendation: 'Weigh bleeding vs thrombotic risk',
      },
      {
        population: 'renal-impairment',
        consideration: 'No dose adjustment needed',
        recommendation: 'Standard dosing',
      },
    ],

    monitoring: [
      {
        parameter: 'Signs of bleeding',
        frequency: 'Every visit',
        rationale: 'Detect complications',
        actionThreshold: 'Evaluate risk-benefit if significant bleeding',
      },
      {
        parameter: 'Platelet function testing (optional)',
        frequency: 'Consider in high-risk patients',
        rationale: 'Identify non-responders',
        actionThreshold: 'Consider alternative if high on-treatment platelet reactivity',
      },
    ],

    patientEducation: [
      'Do NOT stop taking without talking to your doctor - risk of stent thrombosis',
      'Tell all doctors and dentists you take this medication',
      'Report unusual bleeding or bruising',
      'Avoid NSAIDs (ibuprofen, naproxen) without asking your doctor',
      'Hold 5-7 days before surgery if your doctor advises',
      'Wear medical alert identification',
    ],

    clinicalPearls: [
      'FDA boxed warning: CYP2C19 poor metabolizers have reduced response - consider alternatives',
      'Genetic testing may guide therapy in high-risk patients',
      'Effect is irreversible - 5-7 days to recover platelet function after stopping',
      'Prasugrel and ticagrelor are more potent but have more bleeding',
      'DAPT duration depends on stent type, indication, and bleeding risk',
      'Omeprazole interaction: prefer pantoprazole if PPI needed',
      'Loading dose 300-600 mg achieves antiplatelet effect within 2 hours',
    ],
  },

  // ============================================
  // ALBUTEROL (Beta-2 Agonist)
  // ============================================
  {
    id: 'albuterol',
    genericName: 'Albuterol (Salbutamol)',
    brandNames: ['ProAir', 'Ventolin', 'Proventil'],
    drugClass: 'Short-Acting Beta-2 Agonist (SABA)',
    category: 'respiratory',

    overview:
      'Albuterol is the most commonly used rescue bronchodilator for asthma and COPD. It provides rapid relief of acute bronchospasm through beta-2 receptor activation, relaxing airway smooth muscle within minutes.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Beta-2 adrenergic receptors',
      targetLocation: 'Bronchial smooth muscle',
      simpleExplanation:
        'Albuterol activates beta-2 receptors on airway muscles, causing them to relax and open up the airways. This provides quick relief of breathing difficulty.',
      detailedMechanism:
        'Albuterol binds to beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP. This activates protein kinase A, leading to smooth muscle relaxation through: (1) decreased myosin light chain kinase activity, (2) calcium sequestration, (3) activation of potassium channels causing hyperpolarization.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Bronchial smooth muscle membrane',
          action: 'Albuterol binds beta-2 receptors',
          result: 'Gs protein activation; adenylyl cyclase stimulated',
        },
        {
          order: 2,
          location: 'Cytoplasm',
          action: 'Increased cAMP activates PKA',
          result: 'Phosphorylation of regulatory proteins',
        },
        {
          order: 3,
          location: 'Smooth muscle cells',
          action: 'Decreased calcium; hyperpolarization',
          result: 'Muscle relaxation; bronchodilation',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Respiratory',
          effect: 'Bronchodilation',
          mechanism: 'Airway smooth muscle relaxation',
          clinicalRelevance: 'Rapid relief of bronchospasm',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Cardiovascular',
          effect: 'Tachycardia',
          mechanism: 'Beta-1 spillover and reflex',
          clinicalRelevance: 'Usually mild; worse with high doses',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Metabolic',
          effect: 'Hypokalemia',
          mechanism: 'Beta-2 drives K+ into cells',
          clinicalRelevance: 'Monitor with frequent dosing',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '5-15 minutes (inhaled)',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~90% of inhaled dose deposited in oropharynx; ~10% reaches lungs',
        route: ['inhalation', 'nebulization', 'oral'],
        factors: ['Inhaler technique critical for lung deposition'],
        timeToePeak: '0.5-2 hours',
        foodEffect: 'Not applicable for inhaled',
      },
      distribution: {
        volumeOfDistribution: 'Not well characterized for inhaled',
        proteinBinding: 'Low',
        tissueDistribution: ['Airways', 'Systemic distribution minimal with proper technique'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['SULT1A3 (sulfation)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: {
          renal: false,
          hepatic: false,
        },
      },
      halfLife: '3-6 hours',
      timeToSteadyState: 'Not typically relevant for PRN use',
    },

    indications: [
      {
        condition: 'Acute bronchospasm (asthma/COPD)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Rescue inhaler; quick relief',
      },
      {
        condition: 'Exercise-induced bronchospasm (prevention)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Use 15-30 minutes before exercise',
      },
      {
        condition: 'Hyperkalemia (acute treatment)',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Drives K+ into cells; used with insulin/glucose',
      },
    ],

    dosing: {
      usualDose: {
        amount: '2 puffs (90 mcg/puff)',
        frequency: 'Every 4-6 hours as needed',
        route: 'Inhalation',
      },
      adjustments: [
        {
          condition: 'Acute severe asthma',
          adjustment: '4-8 puffs every 20 minutes x 3 doses',
          rationale: 'More aggressive dosing needed in acute exacerbation',
        },
      ],
      maxDose: '12 puffs/day (routine); higher in acute setting under supervision',
      administration: {
        route: 'Inhalation (MDI or nebulizer)',
        withFood: 'either',
        specialInstructions: [
          'Prime inhaler before first use',
          'Shake well before each use',
          'Use spacer if coordination difficult',
          'Rinse mouth after use',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Tremor',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Beta-2 stimulation of skeletal muscle',
        management: 'Usually mild; improves with continued use',
        reversible: true,
        onsetTiming: 'Minutes to hours',
      },
      {
        name: 'Tachycardia',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Beta-1 spillover; reflex from vasodilation',
        management: 'Usually mild; caution in cardiac disease',
        reversible: true,
        onsetTiming: 'Minutes',
      },
      {
        name: 'Hypokalemia',
        frequency: 'uncommon',
        severity: 'moderate',
        mechanism: 'Beta-2 drives potassium into cells',
        management: 'Monitor with frequent dosing; supplement if needed',
        reversible: true,
        onsetTiming: 'Hours',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Beta-blockers',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Antagonism of bronchodilation',
        effect: 'Reduced albuterol efficacy; possible bronchospasm',
        management: 'Avoid non-selective beta-blockers in asthma/COPD',
      },
      {
        interactingDrug: 'Diuretics',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Additive hypokalemia',
        effect: 'Increased hypokalemia risk',
        management: 'Monitor potassium with frequent SABA use',
      },
    ],

    contraindications: [
      {
        condition: 'Hypersensitivity to albuterol',
        type: 'absolute',
        reason: 'Risk of allergic reaction',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Limited data but extensive use; uncontrolled asthma is greater risk',
        recommendation: 'Use when indicated; preferred SABA in pregnancy',
        pregnancyCategory: 'C',
      },
      {
        population: 'geriatric',
        consideration: 'May have more cardiac sensitivity',
        recommendation: 'Use with caution; monitor for cardiac effects',
      },
      {
        population: 'pediatric',
        consideration: 'Approved for children; dose by weight/age',
        recommendation: 'Use appropriate pediatric dosing; spacer recommended',
      },
    ],

    monitoring: [
      {
        parameter: 'Symptom relief',
        frequency: 'Each use',
        rationale: 'Assess efficacy',
        actionThreshold: 'Seek care if not responding',
      },
      {
        parameter: 'Frequency of use',
        frequency: 'Ongoing',
        rationale: 'Overuse indicates poor asthma control',
        actionThreshold: '>2 days/week = step up controller therapy',
      },
    ],

    patientEducation: [
      'This is a rescue inhaler - use for quick relief of symptoms',
      'Shake well before each use',
      'Use a spacer for better medication delivery',
      'If using more than 2 days/week, your asthma may not be well controlled',
      'Seek immediate help if symptoms do not improve after multiple doses',
      'Keep track of doses remaining; replace before empty',
      'May cause tremor and fast heartbeat - usually mild',
    ],

    clinicalPearls: [
      'Overuse (>2 days/week) indicates need for controller therapy adjustment',
      'Using >1 canister/month associated with increased asthma mortality',
      'Spacer improves lung deposition and reduces side effects',
      'Nebulized albuterol delivers same medication, just different route',
      'Can be used for acute hyperkalemia (drives K+ into cells)',
      'Levalbuterol (Xopenex) is R-enantiomer only - similar efficacy, possibly less tachycardia',
    ],
  },

  // ============================================
  // PANTOPRAZOLE (PPI)
  // ============================================
  {
    id: 'pantoprazole',
    genericName: 'Pantoprazole',
    brandNames: ['Protonix'],
    drugClass: 'Proton Pump Inhibitor (PPI)',
    category: 'gastrointestinal',

    overview:
      'Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase pump. It is preferred in some settings due to fewer CYP2C19 interactions compared to omeprazole.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'H+/K+-ATPase (proton pump)',
      targetLocation: 'Gastric parietal cell canaliculus',
      simpleExplanation:
        'Pantoprazole blocks the proton pump in stomach cells that produces acid. It permanently shuts off acid production in those pumps, providing long-lasting acid suppression.',
      detailedMechanism:
        'Pantoprazole is a prodrug that accumulates in the acidic parietal cell canaliculus where it is protonated and converted to an active sulfenamide. This active form irreversibly binds to cysteine residues on the H+/K+-ATPase, blocking acid secretion until new pumps are synthesized (24-48 hours).',
      mechanismSteps: [
        {
          order: 1,
          location: 'Parietal cell',
          action: 'Pantoprazole enters and concentrates in acidic canaliculus',
          result: 'Drug accumulates where it is needed',
        },
        {
          order: 2,
          location: 'Canaliculus',
          action: 'Protonation converts to active sulfenamide',
          result: 'Active drug formed in acidic environment',
        },
        {
          order: 3,
          location: 'Proton pump',
          action: 'Irreversible covalent binding to H+/K+-ATPase',
          result: 'Pump permanently inactivated; no acid secretion',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Gastrointestinal',
          effect: 'Profound acid suppression',
          mechanism: 'Irreversible proton pump inhibition',
          clinicalRelevance: 'Heals ulcers; treats GERD',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Elevated gastric pH',
          mechanism: 'Reduced acid',
          clinicalRelevance: 'May affect drug absorption and infection risk',
          desiredOrAdverse: 'both',
        },
      ],
      onsetOfAction: '2.5 hours for maximal effect',
      durationOfEffect: '24 hours (until new pumps synthesized)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '77%',
        route: ['oral', 'intravenous'],
        factors: ['Should be taken before meals'],
        timeToePeak: '2-2.5 hours',
        foodEffect: 'Should take 30-60 minutes before meal',
      },
      distribution: {
        volumeOfDistribution: '11-24 L',
        proteinBinding: '98%',
        tissueDistribution: ['Concentrates in parietal cells'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19', 'CYP3A4'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C19 polymorphisms less clinically significant than omeprazole',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (71%) and fecal (18%)',
        adjustmentNeeded: {
          renal: false,
          hepatic: false,
        },
      },
      halfLife: '1 hour (but effect lasts 24 hours due to irreversible binding)',
      timeToSteadyState: '3-5 days',
    },

    indications: [
      {
        condition: 'GERD',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Both healing and maintenance',
      },
      {
        condition: 'Erosive esophagitis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Healing and maintenance',
      },
      {
        condition: 'H. pylori eradication (combination)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Part of triple/quadruple therapy',
      },
      {
        condition: 'Zollinger-Ellison syndrome',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'High doses often needed',
      },
      {
        condition: 'Stress ulcer prophylaxis (ICU)',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'IV formulation commonly used',
      },
    ],

    dosing: {
      usualDose: {
        amount: '40 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Erosive esophagitis (healing)',
          adjustment: '40 mg BID for 8 weeks',
          rationale: 'More severe disease needs more suppression',
        },
        {
          condition: 'Zollinger-Ellison',
          adjustment: '80-240 mg daily in divided doses',
          rationale: 'Hypersecretary conditions need higher doses',
        },
      ],
      maxDose: '240 mg/day (Zollinger-Ellison)',
      administration: {
        route: 'Oral or IV',
        withFood: 'without-food',
        specialInstructions: [
          'Take 30-60 minutes before breakfast',
          'Swallow tablets whole - do not crush or chew',
          'Granules for suspension must be given in apple juice or applesauce',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Headache',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Unknown',
        management: 'Usually mild; symptomatic treatment',
        reversible: true,
        onsetTiming: 'Early in therapy',
      },
      {
        name: 'C. difficile infection',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Reduced gastric acid barrier',
        management: 'Use lowest effective dose; discontinue if CDI',
        reversible: true,
        onsetTiming: 'Any time during therapy',
      },
      {
        name: 'Hypomagnesemia (long-term)',
        frequency: 'rare',
        severity: 'moderate',
        mechanism: 'Reduced magnesium absorption',
        management: 'Monitor Mg with long-term use; supplement if needed',
        reversible: true,
        onsetTiming: 'Months to years',
      },
      {
        name: 'Fracture risk (long-term)',
        frequency: 'rare',
        severity: 'moderate',
        mechanism: 'Possibly reduced calcium absorption',
        management: 'Use lowest effective dose; ensure adequate calcium/vitamin D',
        reversible: false,
        onsetTiming: 'Years',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Clopidogrel',
        interactionType: 'pharmacokinetic',
        severity: 'minor',
        mechanism: 'Less CYP2C19 inhibition than omeprazole',
        effect: 'Minimal effect on clopidogrel activation',
        management: 'Pantoprazole preferred PPI with clopidogrel',
      },
      {
        interactingDrug: 'Methotrexate',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Reduced renal clearance',
        effect: 'Increased methotrexate levels',
        management: 'Consider temporary discontinuation with high-dose MTX',
      },
    ],

    contraindications: [
      {
        condition: 'Hypersensitivity to PPIs',
        type: 'absolute',
        reason: 'Cross-reactivity possible between PPIs',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Limited human data; animal studies reassuring',
        recommendation: 'Use if indicated; one of preferred PPIs in pregnancy',
        pregnancyCategory: 'B',
      },
      {
        population: 'geriatric',
        consideration: 'No dose adjustment; concern for long-term risks',
        recommendation: 'Use lowest effective dose; review need periodically',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Clearance reduced in severe impairment',
        recommendation: 'No adjustment for mild-moderate; caution in severe',
      },
    ],

    monitoring: [
      {
        parameter: 'Symptom response',
        frequency: 'After 4-8 weeks',
        rationale: 'Assess efficacy',
        actionThreshold: 'Step down or discontinue if symptoms controlled',
      },
      {
        parameter: 'Magnesium (long-term use)',
        frequency: 'Periodically with long-term use',
        rationale: 'Risk of hypomagnesemia',
        actionThreshold: 'Supplement if low',
      },
    ],

    patientEducation: [
      'Take 30-60 minutes before breakfast',
      'Swallow tablets whole - do not crush or chew',
      'May take several days to feel full effect',
      'Report black stools or vomiting blood immediately',
      'Not for immediate heartburn relief - use antacids for that',
      'Long-term use should be reviewed periodically by your doctor',
    ],

    clinicalPearls: [
      'Less CYP2C19 inhibition than omeprazole - preferred with clopidogrel',
      'IV pantoprazole commonly used for stress ulcer prophylaxis in ICU',
      'PPIs work best when taken before meals (need active pumps to block)',
      'Takes 2-3 days for maximal effect (need to inhibit all active pumps)',
      'Rebound hypersecretion can occur after stopping - taper if long-term use',
      'All PPIs similar efficacy at equipotent doses',
      'Deprescribing PPIs is important - many patients on long-term therapy unnecessarily',
    ],
  },

  // ============================================
  // FLUOXETINE (SSRI)
  // ============================================
  {
    id: 'fluoxetine',
    genericName: 'Fluoxetine',
    brandNames: ['Prozac', 'Sarafem'],
    drugClass: 'Selective Serotonin Reuptake Inhibitor (SSRI)',
    category: 'psychiatric',

    overview:
      'Fluoxetine is the original SSRI antidepressant, notable for its very long half-life and active metabolite. Its extended duration makes it more forgiving of missed doses but requires a long washout before switching to MAOIs.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT)',
      targetLocation: 'Presynaptic serotonergic neurons',
      simpleExplanation:
        'Fluoxetine blocks the recycling of serotonin back into nerve cells, leaving more serotonin available in the synapse to activate receptors. Over time, this leads to brain changes that improve mood.',
      detailedMechanism:
        'Fluoxetine selectively inhibits the serotonin reuptake transporter (SERT), preventing presynaptic reuptake of serotonin. This increases synaptic serotonin levels. Long-term use leads to: (1) downregulation of postsynaptic 5-HT2 receptors, (2) desensitization of presynaptic 5-HT1A autoreceptors, (3) neuroplastic changes including increased BDNF.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Serotonergic synapse',
          action: 'Fluoxetine binds and blocks SERT',
          result: 'Serotonin cannot be taken back up into presynaptic neuron',
        },
        {
          order: 2,
          location: 'Synaptic cleft',
          action: 'Serotonin accumulates',
          result: 'Increased serotonin signaling (acute)',
        },
        {
          order: 3,
          location: 'Pre and postsynaptic neurons',
          action: 'Receptor adaptation and neuroplasticity (weeks)',
          result: 'Therapeutic antidepressant effect',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Antidepressant effect',
          mechanism: 'Enhanced serotonergic neurotransmission and neuroplasticity',
          clinicalRelevance: 'Treats depression, anxiety, OCD',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'GI',
          effect: 'Nausea',
          mechanism: 'Serotonin receptors in GI tract',
          clinicalRelevance: 'Usually improves after 1-2 weeks',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Sexual',
          effect: 'Sexual dysfunction',
          mechanism: 'Serotonin effects on sexual function',
          clinicalRelevance: 'Common; may persist',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '2-4 weeks for therapeutic effect',
      durationOfEffect: 'Days to weeks after stopping (long half-life)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '>70%',
        route: ['oral'],
        factors: ['Well absorbed; food does not significantly affect'],
        timeToePeak: '6-8 hours',
        foodEffect: 'Minimal',
      },
      distribution: {
        volumeOfDistribution: '20-45 L/kg (large)',
        proteinBinding: '95%',
        tissueDistribution: ['Widely distributed', 'CNS penetration'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2D6 (major)', 'CYP2C9', 'CYP3A4'],
        activeMetabolites: ['Norfluoxetine (active, t1/2 4-16 days)'],
        geneticVariability: 'CYP2D6 polymorphisms affect metabolism',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: 'Fluoxetine: 1-3 days; Norfluoxetine: 4-16 days',
      timeToSteadyState: '4-5 weeks',
    },

    indications: [
      {
        condition: 'Major depressive disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line SSRI',
      },
      {
        condition: 'Obsessive-compulsive disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Often needs higher doses',
      },
      {
        condition: 'Panic disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Start low to avoid initial anxiety',
      },
      {
        condition: 'Bulimia nervosa',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Higher doses (60 mg) used',
      },
      {
        condition: 'Premenstrual dysphoric disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'As Sarafem; can use intermittently',
      },
    ],

    dosing: {
      usualDose: {
        amount: '20 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'OCD',
          adjustment: '20-80 mg daily',
          rationale: 'Often needs higher doses for OCD',
        },
        {
          condition: 'Elderly',
          adjustment: 'Start 10 mg',
          rationale: 'Increased sensitivity',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Reduce dose or increase interval',
          rationale: 'Decreased clearance',
        },
      ],
      maxDose: '80 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'May take in morning or evening',
          'Long half-life means missed doses less critical',
          '5-week washout needed before starting MAOI',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Nausea',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI serotonin effects',
        management: 'Usually improves in 1-2 weeks; take with food',
        reversible: true,
        onsetTiming: 'First 1-2 weeks',
      },
      {
        name: 'Sexual dysfunction',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'Serotonergic effects on sexual function',
        management: 'May try dose reduction, drug holiday, or switch medications',
        reversible: true,
        onsetTiming: 'Weeks to months',
      },
      {
        name: 'Insomnia',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Activating serotonergic effects',
        management: 'Take in morning; consider sleep hygiene',
        reversible: true,
        onsetTiming: 'Early in therapy',
      },
      {
        name: 'Suicidal ideation (youth)',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Unknown; possibly activation before mood improvement',
        management: 'Close monitoring in first weeks, especially ages 18-24',
        reversible: true,
        onsetTiming: 'First 1-4 weeks',
      },
    ],

    interactions: [
      {
        interactingDrug: 'MAOIs',
        interactionType: 'pharmacodynamic',
        severity: 'contraindicated',
        mechanism: 'Serotonin syndrome',
        effect: 'Life-threatening hyperthermia, rigidity, autonomic instability',
        management: '5-week washout before or after MAOI due to long half-life',
      },
      {
        interactingDrug: 'CYP2D6 substrates (tamoxifen)',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP2D6 inhibition',
        effect: 'Reduced conversion of tamoxifen to active metabolite',
        management: 'Avoid combination; use different SSRI',
      },
      {
        interactingDrug: 'Tramadol',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive serotonergic effects',
        effect: 'Increased risk of serotonin syndrome and seizures',
        management: 'Avoid or use with caution',
      },
    ],

    contraindications: [
      {
        condition: 'Concurrent or recent MAOI use',
        type: 'absolute',
        reason: 'Serotonin syndrome risk; need 5-week washout',
      },
      {
        condition: 'Pimozide use',
        type: 'absolute',
        reason: 'QT prolongation and arrhythmia risk',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Crosses placenta; possible small increased risk of cardiac malformations',
        recommendation: 'Use if benefit outweighs risk; sertraline often preferred',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in milk; long half-life',
        recommendation: 'Sertraline preferred; monitor infant if used',
      },
      {
        population: 'pediatric',
        consideration: 'FDA approved for OCD and depression in children; boxed warning for suicidality',
        recommendation: 'Close monitoring required; start low',
      },
      {
        population: 'geriatric',
        consideration: 'Increased sensitivity; longer half-life',
        recommendation: 'Start at 10 mg; use lower doses',
      },
    ],

    monitoring: [
      {
        parameter: 'Depression/anxiety symptoms',
        frequency: 'Every 1-2 weeks initially; then monthly',
        rationale: 'Assess response',
        actionThreshold: 'Response expected by 4-6 weeks',
      },
      {
        parameter: 'Suicidal ideation',
        frequency: 'Every visit, especially early',
        rationale: 'FDA boxed warning for youth',
        actionThreshold: 'Immediate intervention if present',
      },
      {
        parameter: 'Sodium (elderly)',
        frequency: 'Consider checking in elderly',
        rationale: 'SIADH/hyponatremia risk',
        actionThreshold: 'Discontinue if symptomatic hyponatremia',
      },
    ],

    patientEducation: [
      'Takes 2-4 weeks to feel the full benefit',
      'Do not stop suddenly without talking to your doctor',
      'May cause nausea initially - usually improves',
      'Report any worsening mood or suicidal thoughts immediately',
      'Avoid alcohol',
      'Sexual side effects are common - discuss with doctor if troublesome',
      'Very long-acting - missing a dose is less critical but do not double up',
    ],

    clinicalPearls: [
      'Longest half-life of SSRIs - good for poor compliance, bad for rapid switching',
      '5-week washout needed before starting MAOI (due to norfluoxetine)',
      'Strong CYP2D6 inhibitor - avoid with tamoxifen, many opioids',
      'More activating than other SSRIs - can worsen anxiety/insomnia initially',
      'Weekly fluoxetine (90 mg) available for maintenance after initial stabilization',
      'One of few SSRIs FDA-approved for depression in children',
      'Hyponatremia risk, especially in elderly - check sodium if confusion develops',
    ],
  },

  // ============================================
  // ASPIRIN (NSAID/Antiplatelet)
  // ============================================
  {
    id: 'aspirin',
    genericName: 'Aspirin',
    brandNames: ['Bayer', 'Ecotrin', 'Bufferin'],
    drugClass: 'Nonsteroidal Anti-inflammatory Drug (NSAID) / Antiplatelet',
    category: 'cardiovascular',

    overview:
      'Aspirin (acetylsalicylic acid) is a unique NSAID that irreversibly inhibits cyclooxygenase, providing antiplatelet effects that last the life of the platelet (7-10 days). At low doses, it is a cornerstone of cardiovascular prevention; at higher doses, it provides analgesia and anti-inflammatory effects.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase (COX-1 and COX-2)',
      targetLocation: 'Platelets, vascular endothelium, inflammatory cells',
      simpleExplanation:
        'Aspirin permanently disables the COX enzyme by attaching a chemical group to it. In platelets, this stops production of thromboxane A2, which normally makes platelets stick together. Since platelets cannot make new enzymes, the antiplatelet effect lasts until new platelets are made.',
      detailedMechanism:
        'Aspirin irreversibly acetylates a serine residue in the active site of COX-1 (Ser530) and COX-2 (Ser516). This blocks arachidonic acid access and prevents prostaglandin and thromboxane synthesis. The irreversible nature is unique among NSAIDs. Low-dose aspirin preferentially affects platelet COX-1 (producing antithrombotic TXA2 inhibition) while preserving some vascular COX-2 prostacyclin production.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Aspirin absorbed and enters circulation',
          result: 'Drug reaches platelets and tissues',
          timeframe: '30-60 minutes',
        },
        {
          order: 2,
          location: 'Platelet',
          action: 'Acetyl group transferred to COX-1 serine residue',
          result: 'COX-1 permanently inactivated',
        },
        {
          order: 3,
          location: 'Platelet',
          action: 'No thromboxane A2 production',
          result: 'Platelet cannot aggregate normally',
        },
        {
          order: 4,
          location: 'Systemic',
          action: 'Effect persists for platelet lifespan',
          result: 'Antiplatelet effect lasts 7-10 days per platelet',
          timeframe: '7-10 days',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Hematologic',
          effect: 'Platelet inhibition',
          mechanism: 'Irreversible COX-1 inhibition prevents TXA2',
          clinicalRelevance: 'Cardiovascular protection; bleeding risk',
          desiredOrAdverse: 'both',
        },
        {
          system: 'Cardiovascular',
          effect: 'Reduced thrombosis',
          mechanism: 'Decreased platelet aggregation',
          clinicalRelevance: 'MI/stroke prevention',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'GI irritation and ulceration',
          mechanism: 'Loss of protective prostaglandins',
          clinicalRelevance: 'GI bleeding risk',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '15-30 minutes (analgesia); maximal platelet inhibition within hours',
      durationOfEffect: 'Platelet effect: 7-10 days; analgesic effect: 4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80-100%',
        route: ['oral', 'rectal'],
        factors: ['Enteric coating delays absorption', 'Food delays but may reduce GI upset'],
        timeToePeak: '1-2 hours (plain); 3-4 hours (enteric-coated)',
        foodEffect: 'Delays absorption; may reduce GI irritation',
      },
      distribution: {
        volumeOfDistribution: '0.1-0.2 L/kg',
        proteinBinding: '80-90% (dose-dependent)',
        tissueDistribution: ['Wide distribution', 'Crosses into synovial fluid', 'Crosses placenta'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver and tissues (esterases)',
        enzymes: ['Plasma esterases', 'CYP2C9 (minor)'],
        activeMetabolites: ['Salicylic acid (active)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: 'Dose-dependent: 2-3 hours (low dose); 15-30 hours (high dose)',
      timeToSteadyState: '5-7 days (low dose)',
    },

    indications: [
      {
        condition: 'Secondary prevention of MI',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Lifelong in most patients post-ACS',
      },
      {
        condition: 'Secondary prevention of ischemic stroke/TIA',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Alternative to clopidogrel',
      },
      {
        condition: 'Acute coronary syndrome',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Chewed immediately at onset',
      },
      {
        condition: 'Pain and fever',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Higher doses; largely supplanted by other NSAIDs/acetaminophen',
      },
      {
        condition: 'Primary prevention of cardiovascular disease',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Benefit limited to high-risk patients; weigh bleeding risk',
      },
    ],

    dosing: {
      usualDose: {
        amount: '81-325 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Acute MI/ACS',
          adjustment: '162-325 mg chewed immediately, then 81 mg daily',
          rationale: 'Chewing bypasses enteric coating for rapid effect',
        },
        {
          condition: 'Analgesia',
          adjustment: '325-650 mg every 4-6 hours',
          rationale: 'Higher doses for analgesic effect',
        },
      ],
      maxDose: '4 g/day (anti-inflammatory)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: [
          'Chew in acute MI for rapid effect',
          'Take with food to reduce GI upset',
          'Enteric coating should not be chewed',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'GI bleeding',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Loss of protective prostaglandins; antiplatelet effect',
        management: 'Use lowest effective dose; consider PPI',
        reversible: true,
        onsetTiming: 'Any time',
      },
      {
        name: 'Dyspepsia',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Direct irritation and prostaglandin inhibition',
        management: 'Take with food; enteric-coated formulation',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Tinnitus (high dose)',
        frequency: 'uncommon',
        severity: 'mild',
        mechanism: 'Ototoxicity at high salicylate levels',
        management: 'Reduce dose; reversible',
        reversible: true,
        onsetTiming: 'With high doses',
      },
      {
        name: 'Reye syndrome (children)',
        frequency: 'rare',
        severity: 'life-threatening',
        mechanism: 'Unknown; associated with viral illness',
        management: 'Contraindicated in children with viral illness',
        reversible: false,
        onsetTiming: 'During viral illness',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive bleeding risk',
        effect: 'Significantly increased bleeding',
        management: 'Avoid if possible; if necessary, use with PPI and close monitoring',
      },
      {
        interactingDrug: 'Other NSAIDs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Competitive COX binding; increased GI toxicity',
        effect: 'Ibuprofen may block aspirin from binding',
        management: 'Take aspirin 30 min before ibuprofen if both needed',
      },
      {
        interactingDrug: 'Methotrexate',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Reduced renal clearance of methotrexate',
        effect: 'Increased methotrexate toxicity',
        management: 'Avoid with high-dose methotrexate',
      },
    ],

    contraindications: [
      {
        condition: 'Active GI bleeding',
        type: 'absolute',
        reason: 'Will worsen bleeding',
      },
      {
        condition: 'Children with viral illness',
        type: 'absolute',
        reason: 'Risk of Reye syndrome',
      },
      {
        condition: 'Aspirin-exacerbated respiratory disease',
        type: 'absolute',
        reason: 'Can trigger severe bronchospasm',
      },
      {
        condition: 'Third trimester pregnancy',
        type: 'absolute',
        reason: 'Premature ductus closure; bleeding complications',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Low-dose aspirin may be used for preeclampsia prevention',
        recommendation: 'Avoid in third trimester; low-dose may be used earlier for specific indications',
        pregnancyCategory: 'C (D in third trimester)',
      },
      {
        population: 'pediatric',
        consideration: 'Risk of Reye syndrome with viral illness',
        recommendation: 'Avoid in children except specific indications (Kawasaki disease)',
      },
      {
        population: 'geriatric',
        consideration: 'Increased bleeding risk',
        recommendation: 'Use lowest effective dose; weigh benefits vs bleeding risk',
      },
    ],

    monitoring: [
      {
        parameter: 'Signs of bleeding',
        frequency: 'Ongoing',
        rationale: 'GI and other bleeding risk',
        actionThreshold: 'Any significant bleeding - hold and evaluate',
      },
      {
        parameter: 'Hemoglobin/stool guaiac',
        frequency: 'If symptoms suggest bleeding',
        rationale: 'Detect occult GI bleeding',
        actionThreshold: 'Drop in Hgb or positive guaiac - investigate',
      },
    ],

    patientEducation: [
      'Take with food to reduce stomach upset',
      'Report black tarry stools, blood in vomit, or unusual bleeding',
      'Tell all healthcare providers you take aspirin',
      'Do not give to children or teenagers with fever or flu symptoms',
      'Chew aspirin if having heart attack symptoms',
      'Avoid alcohol - increases stomach bleeding risk',
    ],

    clinicalPearls: [
      'Irreversible platelet inhibition distinguishes it from other NSAIDs',
      'Low-dose (81 mg) sufficient for antiplatelet effect',
      'If ibuprofen needed, take aspirin at least 30 min before to ensure platelet inhibition',
      'Enteric coating does not eliminate GI risk - just reduces local irritation',
      'Hold 7-10 days before surgery in most cases',
      'Aspirin resistance is real but testing not routinely recommended',
      'Primary prevention benefit now considered limited - USPSTF 2022 revised recommendations',
    ],
  },

  // ============================================
  // IBUPROFEN (NSAID)
  // ============================================
  {
    id: 'ibuprofen',
    genericName: 'Ibuprofen',
    brandNames: ['Advil', 'Motrin', 'Nuprin'],
    drugClass: 'Nonsteroidal Anti-inflammatory Drug (NSAID)',
    category: 'analgesic',

    overview:
      'Ibuprofen is a prototypical NSAID that reversibly inhibits cyclooxygenase enzymes, providing analgesic, anti-inflammatory, and antipyretic effects. Available OTC and by prescription, it is among the most commonly used pain relievers worldwide.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase-1 and Cyclooxygenase-2 (COX-1, COX-2)',
      targetLocation: 'Multiple tissues - inflammatory cells, vascular endothelium, kidneys, GI mucosa',
      simpleExplanation:
        'Ibuprofen blocks COX enzymes that make prostaglandins. Prostaglandins cause pain, fever, and inflammation. By blocking their production, ibuprofen reduces all three.',
      detailedMechanism:
        'Non-selective, reversible COX inhibitor. COX-1 is constitutively expressed and produces prostaglandins for gastric protection and platelet function. COX-2 is induced during inflammation. Ibuprofen blocks both, reducing prostaglandin E2 (pain sensitization, fever), prostacyclin (vasodilation), and thromboxane A2 (platelet aggregation).',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Rapid absorption',
          result: 'Drug enters circulation',
          timeframe: '30-60 minutes',
        },
        {
          order: 2,
          location: 'Inflammatory site',
          action: 'Reversibly binds to COX-1 and COX-2 active site',
          result: 'Prostaglandin synthesis blocked',
        },
        {
          order: 3,
          location: 'Peripheral nerves',
          action: 'Reduced PGE2',
          result: 'Decreased pain sensitization',
        },
        {
          order: 4,
          location: 'Hypothalamus',
          action: 'Reduced PGE2 at thermoregulatory center',
          result: 'Fever reduction',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Musculoskeletal',
          effect: 'Pain relief and reduced inflammation',
          mechanism: 'Decreased prostaglandin-mediated sensitization and inflammation',
          clinicalRelevance: 'Effective for inflammatory pain',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Reduced mucosal protection',
          mechanism: 'Loss of protective prostaglandins',
          clinicalRelevance: 'GI ulceration and bleeding risk',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Renal',
          effect: 'Decreased renal blood flow',
          mechanism: 'Loss of vasodilatory prostaglandins in kidney',
          clinicalRelevance: 'Can cause acute kidney injury, especially in dehydration',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Cardiovascular',
          effect: 'Sodium retention, possible increased BP',
          mechanism: 'Renal prostaglandin effects',
          clinicalRelevance: 'May worsen hypertension and heart failure',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80-100%',
        route: ['oral', 'IV', 'topical'],
        factors: ['Food delays but does not reduce absorption'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Delays peak but may reduce GI irritation',
      },
      distribution: {
        volumeOfDistribution: '0.12-0.2 L/kg',
        proteinBinding: '99%',
        tissueDistribution: ['Synovial fluid', 'Wide distribution'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C9', 'CYP2C8'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (90% as metabolites)',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '2-4 hours',
      timeToSteadyState: '1 day',
    },

    indications: [
      {
        condition: 'Mild to moderate pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'OTC and prescription',
      },
      {
        condition: 'Fever',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Alternative to acetaminophen',
      },
      {
        condition: 'Osteoarthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Intermittent use preferred',
      },
      {
        condition: 'Rheumatoid arthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Adjunct to DMARDs',
      },
      {
        condition: 'Dysmenorrhea',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Start at onset of menses',
      },
    ],

    dosing: {
      usualDose: {
        amount: '200-400 mg',
        frequency: 'Every 4-6 hours as needed',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Inflammatory conditions',
          adjustment: '400-800 mg three times daily',
          rationale: 'Higher doses for anti-inflammatory effect',
        },
        {
          condition: 'Elderly',
          adjustment: 'Start with lowest effective dose',
          rationale: 'Increased GI, renal, and cardiovascular risks',
        },
      ],
      maxDose: '3200 mg/day (prescription); 1200 mg/day (OTC)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: [
          'Take with food or milk to reduce stomach upset',
          'Take with full glass of water',
          'Do not lie down for 10 minutes after taking',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Dyspepsia/GI upset',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Direct irritation and prostaglandin inhibition',
        management: 'Take with food; consider H2 blocker or PPI',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'GI ulceration/bleeding',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Loss of mucosal protection',
        management: 'Use lowest dose, shortest duration; PPI if at risk',
        reversible: true,
        onsetTiming: 'Weeks to months',
      },
      {
        name: 'Acute kidney injury',
        frequency: 'uncommon',
        severity: 'moderate',
        mechanism: 'Loss of renal prostaglandin-mediated vasodilation',
        management: 'Avoid in dehydration; monitor creatinine in high-risk patients',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Cardiovascular events (long-term)',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Imbalance of prostacyclin/thromboxane',
        management: 'Use lowest effective dose for shortest duration',
        reversible: false,
        onsetTiming: 'Months to years',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Aspirin',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Ibuprofen can block aspirin binding to COX',
        effect: 'May reduce antiplatelet effect of aspirin',
        management: 'Take aspirin 30 min before ibuprofen',
      },
      {
        interactingDrug: 'ACE inhibitors/ARBs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'NSAIDs reduce renal prostaglandins; blunt antihypertensive effect',
        effect: 'Reduced BP lowering; increased AKI risk',
        management: 'Monitor BP and renal function; avoid chronic use if possible',
      },
      {
        interactingDrug: 'Lithium',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Reduced renal lithium clearance',
        effect: 'Increased lithium levels and toxicity',
        management: 'Monitor lithium levels; may need dose reduction',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive bleeding risk',
        effect: 'Increased bleeding',
        management: 'Avoid if possible; monitor INR closely',
      },
    ],

    contraindications: [
      {
        condition: 'Active GI bleeding or ulcer',
        type: 'absolute',
        reason: 'Will worsen bleeding',
      },
      {
        condition: 'CABG surgery (perioperative)',
        type: 'absolute',
        reason: 'FDA black box: increased MI and stroke risk',
      },
      {
        condition: 'Severe renal impairment',
        type: 'relative',
        reason: 'Risk of worsening renal function',
      },
      {
        condition: 'Third trimester pregnancy',
        type: 'absolute',
        reason: 'Premature ductus closure',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Contraindicated in third trimester; use caution earlier',
        recommendation: 'Avoid; if needed, use lowest dose for shortest time in first/second trimester',
        pregnancyCategory: 'C (D in third trimester)',
      },
      {
        population: 'geriatric',
        consideration: 'Higher risk of GI bleeding, renal impairment, cardiovascular events',
        recommendation: 'Use lowest effective dose for shortest duration; consider alternatives',
      },
      {
        population: 'renal-impairment',
        consideration: 'Can worsen renal function; accumulation possible',
        recommendation: 'Avoid if GFR <30; caution with moderate impairment',
      },
    ],

    monitoring: [
      {
        parameter: 'Blood pressure',
        frequency: 'Periodic with chronic use',
        rationale: 'NSAIDs can elevate BP',
        actionThreshold: 'Increase >5 mmHg - consider alternative',
      },
      {
        parameter: 'Renal function',
        frequency: 'Baseline and periodic if high-risk',
        rationale: 'NSAID-induced AKI',
        actionThreshold: 'Rising creatinine - discontinue',
      },
      {
        parameter: 'Signs of GI bleeding',
        frequency: 'Ongoing',
        rationale: 'GI toxicity',
        actionThreshold: 'Any symptoms - evaluate and consider stopping',
      },
    ],

    patientEducation: [
      'Take with food to reduce stomach upset',
      'Do not take more than directed',
      'Report black tarry stools or bloody vomit',
      'Tell your doctor about all medications including OTC',
      'Avoid alcohol - increases stomach bleeding risk',
      'Do not use long-term without doctor supervision',
      'Stay well hydrated, especially in hot weather',
    ],

    clinicalPearls: [
      'Ceiling effect for analgesia around 400 mg; higher doses mainly add anti-inflammatory effect',
      'Among the safer NSAIDs for cardiovascular risk at low doses',
      'Can interfere with antiplatelet effect of aspirin - dose aspirin first',
      'Triple whammy: NSAID + ACE-I/ARB + diuretic = high AKI risk',
      'Short half-life makes it good for PRN use',
      'IV ibuprofen available for PDA closure in premature infants',
    ],
  },

  // ============================================
  // NAPROXEN (NSAID)
  // ============================================
  {
    id: 'naproxen',
    genericName: 'Naproxen',
    brandNames: ['Aleve', 'Naprosyn', 'Anaprox'],
    drugClass: 'Nonsteroidal Anti-inflammatory Drug (NSAID)',
    category: 'analgesic',

    overview:
      'Naproxen is a long-acting NSAID that provides analgesic, anti-inflammatory, and antipyretic effects through COX inhibition. Its longer half-life allows twice-daily dosing, and it may have a better cardiovascular safety profile than some other NSAIDs.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase-1 and Cyclooxygenase-2 (COX-1, COX-2)',
      targetLocation: 'Inflammatory cells, vascular endothelium, kidneys, GI mucosa',
      simpleExplanation:
        'Naproxen blocks enzymes that produce prostaglandins - chemicals that cause pain, fever, and inflammation. Unlike ibuprofen, naproxen works longer so you take it less often.',
      detailedMechanism:
        'Non-selective, reversible COX inhibitor with slight COX-1 preference. Blocks prostaglandin synthesis at inflammatory sites, reducing pain and inflammation. The longer half-life (12-17 hours) compared to ibuprofen allows for sustained action and may contribute to better cardiovascular safety through more consistent platelet inhibition.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Complete absorption',
          result: 'Drug enters systemic circulation',
          timeframe: '2-4 hours',
        },
        {
          order: 2,
          location: 'Tissues',
          action: 'Reversibly inhibits COX-1 and COX-2',
          result: 'Prostaglandin synthesis blocked',
        },
        {
          order: 3,
          location: 'Inflammatory site',
          action: 'Sustained COX inhibition due to long half-life',
          result: 'Prolonged anti-inflammatory effect',
          timeframe: '12+ hours',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Musculoskeletal',
          effect: 'Pain relief and reduced inflammation',
          mechanism: 'Inhibition of prostaglandin-mediated inflammation',
          clinicalRelevance: 'Good for arthritis and inflammatory pain',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Hematologic',
          effect: 'Platelet inhibition',
          mechanism: 'COX-1 inhibition in platelets',
          clinicalRelevance: 'May contribute to better CV profile; increases bleeding risk',
          desiredOrAdverse: 'both',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Mucosal injury',
          mechanism: 'Loss of protective prostaglandins',
          clinicalRelevance: 'GI bleeding risk (similar to other NSAIDs)',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '12+ hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '95%',
        route: ['oral'],
        factors: ['Nearly complete absorption'],
        timeToePeak: '2-4 hours',
        foodEffect: 'Delays but does not reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '0.16 L/kg',
        proteinBinding: '>99%',
        tissueDistribution: ['Synovial fluid (good penetration)', 'Crosses placenta'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C9', 'CYP1A2'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (95%)',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '12-17 hours (allows BID dosing)',
      timeToSteadyState: '4-5 days',
    },

    indications: [
      {
        condition: 'Osteoarthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Long-acting allows BID dosing',
      },
      {
        condition: 'Rheumatoid arthritis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Adjunct to DMARDs',
      },
      {
        condition: 'Ankylosing spondylitis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'NSAIDs are first-line for AS',
      },
      {
        condition: 'Acute gout',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'High-dose initially',
      },
      {
        condition: 'Dysmenorrhea',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Loading dose then maintenance',
      },
      {
        condition: 'Mild to moderate pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'OTC (Aleve) and prescription',
      },
    ],

    dosing: {
      usualDose: {
        amount: '250-500 mg',
        frequency: 'Twice daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Acute gout',
          adjustment: '750 mg initially, then 250 mg every 8 hours',
          rationale: 'Loading dose for rapid effect',
        },
        {
          condition: 'OTC use (Aleve)',
          adjustment: '220 mg every 8-12 hours',
          rationale: 'Lower dose for OTC safety',
        },
        {
          condition: 'Elderly',
          adjustment: 'Start with lowest effective dose',
          rationale: 'Increased risk of adverse effects',
        },
      ],
      maxDose: '1500 mg/day (prescription); 660 mg/day (OTC)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: [
          'Take with food or milk to reduce GI upset',
          'Drink full glass of water',
          'Do not lie down for 30 minutes after taking',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'GI upset/dyspepsia',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Direct and prostaglandin-mediated',
        management: 'Take with food; consider GI protection',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'GI ulceration/bleeding',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Loss of mucosal protection',
        management: 'Use lowest effective dose; add PPI if high-risk',
        reversible: true,
        onsetTiming: 'Weeks to months',
      },
      {
        name: 'Edema',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Sodium retention from renal prostaglandin inhibition',
        management: 'Monitor weight; may need to discontinue',
        reversible: true,
        onsetTiming: 'Days to weeks',
      },
      {
        name: 'Renal impairment',
        frequency: 'uncommon',
        severity: 'moderate',
        mechanism: 'Reduced renal blood flow',
        management: 'Avoid in renal disease; hydrate adequately',
        reversible: true,
        onsetTiming: 'Days',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Lithium',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Reduced lithium clearance',
        effect: 'Lithium toxicity',
        management: 'Monitor lithium levels closely; reduce dose',
      },
      {
        interactingDrug: 'Methotrexate',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Reduced MTX clearance',
        effect: 'Methotrexate toxicity',
        management: 'Avoid with high-dose MTX; use caution with low-dose',
      },
      {
        interactingDrug: 'Antihypertensives',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'NSAIDs cause sodium retention and reduce vasodilatory prostaglandins',
        effect: 'Reduced antihypertensive effect',
        management: 'Monitor blood pressure',
      },
      {
        interactingDrug: 'SSRIs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Both affect platelet function',
        effect: 'Increased GI bleeding risk',
        management: 'Consider PPI if using both',
      },
    ],

    contraindications: [
      {
        condition: 'Active peptic ulcer or GI bleeding',
        type: 'absolute',
        reason: 'Will worsen bleeding',
      },
      {
        condition: 'Perioperative CABG',
        type: 'absolute',
        reason: 'FDA black box warning for CV events',
      },
      {
        condition: 'Severe renal impairment',
        type: 'relative',
        reason: 'May worsen kidney function',
      },
      {
        condition: 'Third trimester pregnancy',
        type: 'absolute',
        reason: 'Risk of premature ductus closure',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Third trimester contraindicated; caution earlier',
        recommendation: 'Avoid if possible; definitely avoid third trimester',
        pregnancyCategory: 'C (D in third trimester)',
      },
      {
        population: 'geriatric',
        consideration: 'Increased GI, renal, and CV risks',
        recommendation: 'Use with caution; lowest effective dose',
      },
      {
        population: 'renal-impairment',
        consideration: 'Long half-life increases accumulation risk',
        recommendation: 'Avoid if GFR <30; use with caution if moderate impairment',
      },
    ],

    monitoring: [
      {
        parameter: 'Blood pressure',
        frequency: 'Periodic',
        rationale: 'NSAIDs can raise BP',
        actionThreshold: 'Significant increase - consider alternative',
      },
      {
        parameter: 'Renal function',
        frequency: 'Baseline and periodic if at risk',
        rationale: 'NSAID nephrotoxicity',
        actionThreshold: 'Rising creatinine - discontinue',
      },
      {
        parameter: 'GI symptoms and occult blood',
        frequency: 'As needed',
        rationale: 'GI toxicity',
        actionThreshold: 'Symptoms or positive - investigate',
      },
    ],

    patientEducation: [
      'Take with food or milk',
      'Take at the same times each day for best effect',
      'Do not take more than prescribed',
      'Report stomach pain, black stools, or unusual bleeding',
      'Avoid alcohol',
      'Tell your doctor about all medications including OTC',
      'Do not use for more than 10 days (OTC) without medical advice',
    ],

    clinicalPearls: [
      'Long half-life allows twice daily dosing - good for compliance',
      'May have best cardiovascular safety profile among non-selective NSAIDs',
      'Naproxen sodium (Aleve) is salt form - 220 mg = 200 mg naproxen base',
      'Good choice for gout due to long duration and anti-inflammatory potency',
      'Like all NSAIDs, increases CV risk but may be less than others',
      'FDA-approved for JIA in children ≥2 years',
    ],
  },

  // ============================================
  // TRAMADOL (Opioid Analgesic)
  // ============================================
  {
    id: 'tramadol',
    genericName: 'Tramadol',
    brandNames: ['Ultram', 'ConZip', 'Ultram ER'],
    drugClass: 'Atypical Opioid Analgesic',
    category: 'analgesic',

    overview:
      'Tramadol is an atypical centrally-acting analgesic with dual mechanisms: weak mu-opioid agonism and inhibition of serotonin/norepinephrine reuptake. It is often considered a "safer" opioid but carries risks of seizures, serotonin syndrome, and still has abuse potential.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu-opioid receptors and monoamine reuptake transporters',
      targetLocation: 'Central nervous system',
      simpleExplanation:
        'Tramadol works through two mechanisms: it weakly activates opioid pain receptors and also blocks the reuptake of serotonin and norepinephrine, which helps with pain signaling. This dual action makes it effective but also causes unique side effects.',
      detailedMechanism:
        'Tramadol is a prodrug that undergoes CYP2D6 metabolism to O-desmethyltramadol (M1), which has 200x greater mu-opioid affinity than parent compound. Additionally, (+)-tramadol inhibits serotonin reuptake while (-)-tramadol inhibits norepinephrine reuptake. The analgesic effect comes from both opioid and monoaminergic mechanisms.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Tramadol absorbed',
          result: 'Parent drug enters circulation',
          timeframe: '1-2 hours',
        },
        {
          order: 2,
          location: 'Liver',
          action: 'CYP2D6 converts tramadol to M1 (active metabolite)',
          result: 'M1 has strong mu-opioid activity',
        },
        {
          order: 3,
          location: 'Spinal cord and brain',
          action: 'M1 activates mu-opioid receptors',
          result: 'Pain signal transmission inhibited',
        },
        {
          order: 4,
          location: 'Synapses',
          action: 'Tramadol blocks serotonin and NE reuptake',
          result: 'Enhanced descending pain inhibition',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Analgesia',
          mechanism: 'Mu-opioid agonism and monoamine modulation',
          clinicalRelevance: 'Effective for moderate pain',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Central nervous system',
          effect: 'Seizure threshold lowering',
          mechanism: 'Complex - related to monoaminergic effects',
          clinicalRelevance: 'Seizure risk especially at high doses or with other serotonergic drugs',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Central nervous system',
          effect: 'Serotonin effects',
          mechanism: 'SNRI-like action',
          clinicalRelevance: 'Serotonin syndrome risk with other serotonergic drugs',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '1 hour',
      durationOfEffect: '4-6 hours (immediate release)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '75%',
        route: ['oral'],
        factors: ['Food does not significantly affect'],
        timeToePeak: '2 hours (IR); 12 hours (ER)',
        foodEffect: 'Minimal effect',
      },
      distribution: {
        volumeOfDistribution: '2.6-2.9 L/kg',
        proteinBinding: '20%',
        tissueDistribution: ['CNS', 'Crosses placenta'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2D6 (M1 formation)', 'CYP3A4'],
        activeMetabolites: ['O-desmethyltramadol (M1) - more potent'],
        geneticVariability: 'CYP2D6 polymorphisms greatly affect efficacy - poor metabolizers get little benefit; ultra-rapid metabolizers may have toxicity',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (90%)',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '6-7 hours (parent); 7-9 hours (M1)',
      timeToSteadyState: '2 days',
    },

    indications: [
      {
        condition: 'Moderate to moderately severe pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Usually after non-opioid options tried',
      },
      {
        condition: 'Chronic pain (extended-release)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'For around-the-clock pain management',
      },
    ],

    dosing: {
      usualDose: {
        amount: '50-100 mg',
        frequency: 'Every 4-6 hours as needed',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Renal impairment (CrCl <30)',
          adjustment: 'Increase dosing interval to q12h; max 200 mg/day',
          rationale: 'Reduced clearance',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: '50 mg q12h',
          rationale: 'Reduced metabolism',
        },
        {
          condition: 'Elderly',
          adjustment: 'Start low, titrate slowly; max 300 mg/day if >75 years',
          rationale: 'Increased sensitivity, reduced clearance',
        },
      ],
      maxDose: '400 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'ER formulations must be swallowed whole - never crushed',
          'Start with lower doses and titrate',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Nausea/vomiting',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Opioid effect on CTZ',
        management: 'Take with food; antiemetics; usually improves',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Dizziness',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'CNS depression',
        management: 'Start low, go slow; usually improves',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Constipation',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Opioid effect on GI motility',
        management: 'Prophylactic bowel regimen',
        reversible: true,
        onsetTiming: 'Days',
      },
      {
        name: 'Seizures',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Lowered seizure threshold',
        management: 'Avoid in seizure history; avoid high doses; avoid with other seizure threshold-lowering drugs',
        reversible: true,
        onsetTiming: 'Any time',
      },
      {
        name: 'Serotonin syndrome',
        frequency: 'rare',
        severity: 'life-threatening',
        mechanism: 'SNRI activity combined with other serotonergic drugs',
        management: 'Avoid combinations; if occurs, stop drug and supportive care',
        reversible: true,
        onsetTiming: 'Hours to days after starting/increasing dose',
      },
    ],

    interactions: [
      {
        interactingDrug: 'SSRIs/SNRIs',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive serotonergic effects',
        effect: 'Serotonin syndrome and seizure risk',
        management: 'Use with extreme caution; monitor closely',
      },
      {
        interactingDrug: 'MAOIs',
        interactionType: 'pharmacodynamic',
        severity: 'contraindicated',
        mechanism: 'Severe serotonin excess',
        effect: 'Serotonin syndrome',
        management: 'Contraindicated - do not combine',
      },
      {
        interactingDrug: 'CYP2D6 inhibitors',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Reduced M1 formation',
        effect: 'Decreased efficacy',
        management: 'May need alternative analgesic',
      },
      {
        interactingDrug: 'Carbamazepine',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP3A4 induction increases tramadol metabolism; also lowers seizure threshold',
        effect: 'Reduced efficacy and increased seizure risk',
        management: 'Avoid combination',
      },
    ],

    contraindications: [
      {
        condition: 'Seizure disorder',
        type: 'relative',
        reason: 'Lowers seizure threshold',
      },
      {
        condition: 'Concurrent MAOI use',
        type: 'absolute',
        reason: 'Serotonin syndrome risk',
      },
      {
        condition: 'Acute intoxication (alcohol, sedatives, opioids)',
        type: 'absolute',
        reason: 'Additive CNS depression',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Neonatal opioid withdrawal syndrome; respiratory depression in newborn',
        recommendation: 'Avoid; if used, monitor neonate',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk; fatal events in ultra-rapid metabolizers',
        recommendation: 'Avoid breastfeeding while taking',
      },
      {
        population: 'geriatric',
        consideration: 'Increased CNS sensitivity; reduced clearance',
        recommendation: 'Start low, go slow; max 300 mg/day if >75 years',
      },
      {
        population: 'renal-impairment',
        consideration: 'Reduced clearance',
        recommendation: 'Reduce dose and extend interval',
      },
    ],

    monitoring: [
      {
        parameter: 'Pain control',
        frequency: 'Each visit',
        rationale: 'Assess efficacy',
        actionThreshold: 'If inadequate, consider alternative',
      },
      {
        parameter: 'Signs of dependence/misuse',
        frequency: 'Ongoing',
        rationale: 'Abuse potential (Schedule IV)',
        actionThreshold: 'Red flags - reassess treatment plan',
      },
      {
        parameter: 'Serotonin syndrome symptoms',
        frequency: 'With serotonergic comedication',
        rationale: 'Potentially fatal interaction',
        actionThreshold: 'Any symptoms - stop and evaluate',
      },
    ],

    patientEducation: [
      'May cause drowsiness - avoid driving until you know how it affects you',
      'Do not crush extended-release tablets',
      'Do not take more than prescribed',
      'Report seizure activity immediately',
      'Avoid alcohol',
      'Tell your doctor about all medications especially antidepressants',
      'Can cause dependence with long-term use',
    ],

    clinicalPearls: [
      'CYP2D6 poor metabolizers (7-10% of Caucasians) get little benefit',
      'Ultra-rapid CYP2D6 metabolizers can have excessive effects',
      'Seizure risk is dose-dependent - stay under 400 mg/day',
      'Still has abuse potential despite "atypical" classification - Schedule IV',
      'Serotonin syndrome can occur even at normal doses with SSRI combination',
      'Less effective than pure mu-agonists for severe pain',
      'Neonatal opioid withdrawal can occur with maternal use',
    ],
  },

  // ============================================
  // MORPHINE (Opioid Analgesic)
  // ============================================
  {
    id: 'morphine',
    genericName: 'Morphine',
    brandNames: ['MS Contin', 'Kadian', 'Avinza', 'Roxanol'],
    drugClass: 'Opioid Analgesic',
    category: 'analgesic',

    overview:
      'Morphine is the prototype opioid analgesic and the standard against which other opioids are compared. It provides potent analgesia through mu-opioid receptor activation in the CNS. Essential for severe acute pain and cancer pain, but carries significant risks of respiratory depression, dependence, and constipation.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu-opioid receptors (primary); kappa and delta opioid receptors (secondary)',
      targetLocation: 'Brain, spinal cord, peripheral tissues',
      simpleExplanation:
        'Morphine binds to opioid receptors in the brain and spinal cord, blocking pain signals and producing feelings of pain relief and sometimes euphoria. It mimics the body\'s natural pain-relieving endorphins.',
      detailedMechanism:
        'Morphine is a full agonist at mu-opioid receptors (MOR) with some activity at kappa and delta receptors. MOR activation couples to Gi proteins, inhibiting adenylyl cyclase, opening K+ channels (hyperpolarization), and closing voltage-gated Ca2+ channels. This reduces neurotransmitter release in pain pathways and activates descending inhibitory pathways. The result is profound analgesia, plus effects on mood, respiration, GI motility, and reward pathways.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Administration site',
          action: 'Morphine enters circulation',
          result: 'Drug distributed to CNS',
          timeframe: 'Minutes (IV) to 1 hour (oral)',
        },
        {
          order: 2,
          location: 'Spinal cord dorsal horn',
          action: 'Binds presynaptic and postsynaptic MOR',
          result: 'Inhibits pain signal transmission',
        },
        {
          order: 3,
          location: 'Brain (PAG, RVM)',
          action: 'Activates descending inhibitory pathways',
          result: 'Modulates pain perception at spinal level',
        },
        {
          order: 4,
          location: 'Limbic system',
          action: 'Activates reward pathways',
          result: 'Euphoria, reinforcement (addiction liability)',
        },
        {
          order: 5,
          location: 'Brainstem',
          action: 'Depresses respiratory center',
          result: 'Respiratory depression (major risk)',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Analgesia',
          mechanism: 'Mu-opioid receptor agonism',
          clinicalRelevance: 'Primary therapeutic effect',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Respiratory',
          effect: 'Respiratory depression',
          mechanism: 'Decreased CO2 sensitivity in brainstem',
          clinicalRelevance: 'Major cause of opioid-related death',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Constipation',
          mechanism: 'Decreased GI motility via enteric MOR',
          clinicalRelevance: 'Universal - does not develop tolerance',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Cardiovascular',
          effect: 'Hypotension, bradycardia',
          mechanism: 'Histamine release, vagal tone',
          clinicalRelevance: 'Monitor in hemodynamically unstable patients',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'IV: 5-10 min; PO: 30-60 min',
      durationOfEffect: 'IR: 4-5 hours; ER: 8-24 hours depending on formulation',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '25-30% (significant first-pass metabolism)',
        route: ['oral', 'IV', 'IM', 'SC', 'rectal', 'intrathecal', 'epidural'],
        factors: ['First-pass metabolism reduces oral bioavailability'],
        timeToePeak: '1 hour (IR oral); 4-5 hours (ER)',
        foodEffect: 'Food delays but does not reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '3-4 L/kg',
        proteinBinding: '35%',
        tissueDistribution: ['CNS (crosses BBB)', 'Skeletal muscle', 'Kidney', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['UGT2B7 (glucuronidation)'],
        activeMetabolites: ['Morphine-6-glucuronide (M6G) - more potent, renally cleared', 'Morphine-3-glucuronide (M3G) - neuroexcitatory'],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (90% as metabolites)',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '2-4 hours',
      timeToSteadyState: '1 day (IR); varies for ER',
    },

    indications: [
      {
        condition: 'Severe acute pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Post-surgical, trauma, acute MI',
      },
      {
        condition: 'Cancer pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Cornerstone of cancer pain management',
      },
      {
        condition: 'Chronic severe pain (ER formulations)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'When non-opioid options fail',
      },
      {
        condition: 'Dyspnea in terminal illness',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: true,
        notes: 'Palliative care',
      },
      {
        condition: 'Acute pulmonary edema',
        approvalStatus: 'off-label',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Reduces preload and anxiety',
      },
    ],

    dosing: {
      usualDose: {
        amount: '10-30 mg',
        frequency: 'Every 4 hours as needed (oral IR)',
        route: 'Oral, IV, SC',
      },
      adjustments: [
        {
          condition: 'Opioid-naive',
          adjustment: 'Start 5-10 mg PO or 2-4 mg IV',
          rationale: 'Avoid overdose in sensitive patients',
        },
        {
          condition: 'Renal impairment',
          adjustment: 'Reduce dose 50-75%; extend interval; avoid ER formulations',
          rationale: 'M6G accumulates and can cause prolonged sedation/respiratory depression',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Reduce dose; extend interval',
          rationale: 'Reduced metabolism',
        },
      ],
      maxDose: 'No ceiling for cancer pain when titrated; use caution with high doses',
      administration: {
        route: 'Multiple routes available',
        withFood: 'either',
        specialInstructions: [
          'ER formulations must be swallowed whole - crushing can cause fatal overdose',
          'IV push slowly over 4-5 minutes',
          'Rotate injection sites for SC administration',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Constipation',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'GI mu-opioid receptor activation',
        management: 'Prophylactic bowel regimen for all patients',
        reversible: true,
        onsetTiming: 'Early and persistent',
      },
      {
        name: 'Nausea/vomiting',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'CTZ stimulation, gastric stasis',
        management: 'Antiemetics; usually improves with continued use',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Sedation',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'CNS depression',
        management: 'Usually improves; reduce dose if persistent',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Respiratory depression',
        frequency: 'uncommon',
        severity: 'life-threatening',
        mechanism: 'Brainstem respiratory center depression',
        management: 'Naloxone reversal; careful dose titration',
        reversible: true,
        onsetTiming: 'Dose-related; peaks with Cmax',
      },
      {
        name: 'Pruritus',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Histamine release; central MOR effect',
        management: 'Antihistamines; opioid rotation if severe',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Physical dependence',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'Neuroadaptation',
        management: 'Taper when discontinuing; expected with chronic use',
        reversible: true,
        onsetTiming: 'Weeks of regular use',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Benzodiazepines',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS and respiratory depression',
        effect: 'Profound sedation, respiratory depression, death',
        management: 'FDA black box warning - avoid combination when possible',
      },
      {
        interactingDrug: 'Other CNS depressants',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS depression',
        effect: 'Increased sedation and respiratory depression',
        management: 'Reduce doses if combination necessary',
      },
      {
        interactingDrug: 'MAOIs',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Unpredictable - can cause excitation or depression',
        effect: 'Serotonin syndrome-like reaction or severe respiratory depression',
        management: 'Avoid within 14 days of MAOI',
      },
    ],

    contraindications: [
      {
        condition: 'Significant respiratory depression',
        type: 'absolute',
        reason: 'Will worsen respiratory failure',
      },
      {
        condition: 'Acute or severe bronchial asthma without monitoring',
        type: 'absolute',
        reason: 'Respiratory depression risk',
      },
      {
        condition: 'Paralytic ileus',
        type: 'absolute',
        reason: 'Morphine worsens GI stasis',
      },
      {
        condition: 'Concurrent MAOI use',
        type: 'relative',
        reason: 'Unpredictable severe reactions',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Neonatal opioid withdrawal syndrome with prolonged use',
        recommendation: 'Use only when benefits outweigh risks; monitor neonate',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk; can cause sedation in infant',
        recommendation: 'Use caution; monitor infant for sedation',
      },
      {
        population: 'geriatric',
        consideration: 'Increased sensitivity, reduced clearance',
        recommendation: 'Start with 50% of usual adult dose',
      },
      {
        population: 'renal-impairment',
        consideration: 'M6G accumulation can cause prolonged sedation and respiratory depression',
        recommendation: 'Significant dose reduction needed; consider alternative opioid',
      },
    ],

    monitoring: [
      {
        parameter: 'Respiratory rate',
        frequency: 'Hourly initially; with each dose adjustment',
        rationale: 'Respiratory depression is life-threatening',
        actionThreshold: '<10/min or oxygen saturation <92% - hold dose, consider naloxone',
      },
      {
        parameter: 'Pain level',
        frequency: 'With each dose',
        rationale: 'Assess efficacy',
        actionThreshold: 'Inadequate relief - titrate up cautiously',
      },
      {
        parameter: 'Sedation level',
        frequency: 'With each dose',
        rationale: 'Sedation precedes respiratory depression',
        actionThreshold: 'Excessive sedation - reduce dose',
      },
      {
        parameter: 'Bowel function',
        frequency: 'Daily',
        rationale: 'Constipation is universal',
        actionThreshold: 'No BM for 3 days - intensify bowel regimen',
      },
    ],

    patientEducation: [
      'Take exactly as prescribed - do not increase dose without doctor approval',
      'Do not crush, break, or chew extended-release tablets',
      'May cause drowsiness - do not drive or operate machinery',
      'Avoid alcohol - can cause severe respiratory depression',
      'Constipation is common - use stool softeners and increase fiber/fluids',
      'Rise slowly to prevent dizziness',
      'Store safely away from others, especially children',
      'Do not stop suddenly after prolonged use - may cause withdrawal',
      'Report difficulty breathing or severe drowsiness',
    ],

    clinicalPearls: [
      'M6G accumulation in renal failure can cause delayed toxicity',
      'No dose ceiling for cancer pain - titrate to effect',
      'Constipation does not develop tolerance - always needs prophylaxis',
      'Tolerance develops to nausea, sedation, respiratory depression but not constipation',
      'Pruritus is more common with neuraxial administration',
      'Histamine release more pronounced than with fentanyl - can cause flushing, hypotension',
      'MS Contin every 8-12h; Kadian every 12-24h - formulations not interchangeable',
    ],
  },

  // ============================================
  // OXYCODONE (Opioid Analgesic)
  // ============================================
  {
    id: 'oxycodone',
    genericName: 'Oxycodone',
    brandNames: ['OxyContin', 'Roxicodone', 'Oxaydo', 'Percocet (with acetaminophen)'],
    drugClass: 'Opioid Analgesic',
    category: 'analgesic',

    overview:
      'Oxycodone is a semi-synthetic opioid derived from thebaine with potent analgesic effects via mu-opioid receptor agonism. Available in immediate and extended-release formulations, it is commonly used for moderate to severe pain. Higher oral bioavailability than morphine but similar abuse potential.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu-opioid receptors (primary); kappa-opioid receptors (secondary)',
      targetLocation: 'Central nervous system - brain and spinal cord',
      simpleExplanation:
        'Oxycodone binds to opioid receptors in the brain and spinal cord to block pain signals. It works similarly to morphine but is absorbed better when taken by mouth.',
      detailedMechanism:
        'Oxycodone is a full mu-opioid receptor agonist with some kappa activity. MOR activation leads to Gi-coupled inhibition of adenylyl cyclase, K+ channel opening, and Ca2+ channel closing. This reduces neuronal excitability and neurotransmitter release in pain pathways. Oxycodone has higher oral bioavailability (60-87%) than morphine due to less first-pass metabolism.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Oxycodone absorbed',
          result: 'Higher bioavailability than morphine',
          timeframe: '30-60 minutes',
        },
        {
          order: 2,
          location: 'Liver',
          action: 'CYP3A4 and CYP2D6 metabolism',
          result: 'Metabolites (oxymorphone is active but minor contributor)',
        },
        {
          order: 3,
          location: 'Spinal cord',
          action: 'Mu-opioid receptor activation',
          result: 'Reduced pain signal transmission',
        },
        {
          order: 4,
          location: 'Supraspinal',
          action: 'Activation of descending inhibition',
          result: 'Pain modulation at multiple levels',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Analgesia',
          mechanism: 'Mu-opioid receptor agonism',
          clinicalRelevance: 'Primary therapeutic effect',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Central nervous system',
          effect: 'Euphoria',
          mechanism: 'Reward pathway activation',
          clinicalRelevance: 'High abuse potential',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Respiratory',
          effect: 'Respiratory depression',
          mechanism: 'Brainstem depression',
          clinicalRelevance: 'Major safety concern',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Constipation',
          mechanism: 'Decreased GI motility',
          clinicalRelevance: 'Universal adverse effect',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '15-30 minutes (IR)',
      durationOfEffect: '3-6 hours (IR); 12 hours (ER)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '60-87% (better than morphine)',
        route: ['oral'],
        factors: ['Food has minimal effect'],
        timeToePeak: '1-1.5 hours (IR); 4.5 hours (ER)',
        foodEffect: 'Minimal effect on absorption',
      },
      distribution: {
        volumeOfDistribution: '2.6 L/kg',
        proteinBinding: '45%',
        tissueDistribution: ['CNS', 'Wide distribution'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4 (major)', 'CYP2D6 (minor - forms oxymorphone)'],
        activeMetabolites: ['Oxymorphone (minor contributor to effect)'],
        geneticVariability: 'CYP2D6 polymorphisms have minor clinical impact unlike tramadol/codeine',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '3-5 hours',
      timeToSteadyState: '1 day (IR)',
    },

    indications: [
      {
        condition: 'Moderate to severe acute pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'When non-opioid options insufficient',
      },
      {
        condition: 'Chronic pain requiring opioids (ER formulation)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'For around-the-clock pain management',
      },
      {
        condition: 'Cancer pain',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Alternative to morphine',
      },
    ],

    dosing: {
      usualDose: {
        amount: '5-15 mg',
        frequency: 'Every 4-6 hours as needed',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Opioid-naive',
          adjustment: 'Start 5-10 mg IR',
          rationale: 'Avoid overdose',
        },
        {
          condition: 'Renal impairment',
          adjustment: 'Reduce dose by 50%; extend interval',
          rationale: 'Reduced clearance',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Start with 1/3 to 1/2 usual dose',
          rationale: 'Reduced metabolism',
        },
      ],
      maxDose: 'No defined ceiling; titrate to pain relief and tolerability',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'ER tablets must be swallowed whole - never crushed, broken, or chewed',
          'Crushing ER formulation can cause fatal overdose',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Constipation',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'GI mu-receptor activation',
        management: 'Prophylactic bowel regimen',
        reversible: true,
        onsetTiming: 'Early and persistent',
      },
      {
        name: 'Nausea/vomiting',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'CTZ stimulation',
        management: 'Antiemetics; usually improves',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Drowsiness',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'CNS depression',
        management: 'Usually improves with continued use',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Respiratory depression',
        frequency: 'uncommon',
        severity: 'life-threatening',
        mechanism: 'Brainstem respiratory center depression',
        management: 'Naloxone; careful dose titration',
        reversible: true,
        onsetTiming: 'Dose-related',
      },
      {
        name: 'Physical dependence',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'Neuroadaptation',
        management: 'Taper when discontinuing',
        reversible: true,
        onsetTiming: 'Weeks',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Benzodiazepines',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS and respiratory depression',
        effect: 'Profound sedation, respiratory depression, death',
        management: 'FDA black box - avoid if possible',
      },
      {
        interactingDrug: 'CYP3A4 inhibitors (ketoconazole, ritonavir)',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Increased oxycodone levels',
        effect: 'Enhanced opioid effect and toxicity',
        management: 'Reduce oxycodone dose; monitor closely',
      },
      {
        interactingDrug: 'CYP3A4 inducers (rifampin, carbamazepine)',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Decreased oxycodone levels',
        effect: 'Reduced efficacy; possible withdrawal',
        management: 'May need dose increase; monitor',
      },
      {
        interactingDrug: 'Alcohol',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS depression; ER may dump dose',
        effect: 'Respiratory depression, death',
        management: 'Absolute avoidance with ER formulations',
      },
    ],

    contraindications: [
      {
        condition: 'Significant respiratory depression',
        type: 'absolute',
        reason: 'Will worsen respiratory failure',
      },
      {
        condition: 'Acute or severe bronchial asthma without monitoring',
        type: 'absolute',
        reason: 'Respiratory depression risk',
      },
      {
        condition: 'GI obstruction',
        type: 'absolute',
        reason: 'Opioids worsen GI motility',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Neonatal opioid withdrawal syndrome',
        recommendation: 'Use only when benefits outweigh risks; monitor neonate',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk',
        recommendation: 'Use caution; monitor infant for sedation',
      },
      {
        population: 'geriatric',
        consideration: 'Increased sensitivity',
        recommendation: 'Start low, titrate slowly',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Reduced first-pass metabolism increases bioavailability',
        recommendation: 'Start with 1/3 to 1/2 usual dose',
      },
    ],

    monitoring: [
      {
        parameter: 'Respiratory rate and oxygen saturation',
        frequency: 'With dose changes; hourly initially',
        rationale: 'Respiratory depression is life-threatening',
        actionThreshold: 'RR <10 or SpO2 <92% - hold, consider naloxone',
      },
      {
        parameter: 'Pain control',
        frequency: 'Each visit',
        rationale: 'Assess efficacy',
        actionThreshold: 'Inadequate - consider titration or rotation',
      },
      {
        parameter: 'Signs of misuse/addiction',
        frequency: 'Each visit',
        rationale: 'High abuse potential',
        actionThreshold: 'Red flags - reassess treatment plan',
      },
    ],

    patientEducation: [
      'Take exactly as prescribed',
      'Never crush, break, or chew extended-release tablets - can be fatal',
      'Do not drink alcohol - dangerous interaction',
      'May cause drowsiness - avoid driving',
      'Constipation is common - use preventive measures',
      'Store securely away from others',
      'Do not stop suddenly - may cause withdrawal',
      'Report any difficulty breathing',
    ],

    clinicalPearls: [
      'Higher oral bioavailability (60-87%) vs morphine (25-30%) makes oral dosing more predictable',
      'OxyContin reformulated in 2010 to be abuse-deterrent (difficult to crush/inject)',
      'CYP2D6 polymorphisms less clinically relevant than for tramadol/codeine',
      'Percocet = oxycodone + acetaminophen - watch acetaminophen dosing',
      'No active metabolite accumulation in renal failure (unlike morphine M6G)',
      'Popular drug of abuse - contributed significantly to opioid epidemic',
      'Approximately 1.5x more potent than oral morphine',
    ],
  },

  // ============================================
  // AMOXICILLIN (Antibiotic)
  // ============================================
  {
    id: 'amoxicillin',
    genericName: 'Amoxicillin',
    brandNames: ['Amoxil', 'Moxatag', 'Trimox'],
    drugClass: 'Aminopenicillin',
    category: 'antimicrobial',

    overview:
      'Amoxicillin is a broad-spectrum aminopenicillin antibiotic that inhibits bacterial cell wall synthesis. It is one of the most commonly prescribed antibiotics, used for respiratory tract infections, otitis media, urinary tract infections, and as part of H. pylori eradication regimens.',

    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'Penicillin-binding proteins (PBPs)',
      targetLocation: 'Bacterial cell wall',
      simpleExplanation:
        'Amoxicillin kills bacteria by preventing them from building their protective cell wall. It binds to proteins that bacteria use to construct their cell wall, and without a complete wall, the bacteria burst open.',
      detailedMechanism:
        'Amoxicillin is a beta-lactam antibiotic that binds to PBPs (particularly PBP1A, PBP1B, PBP3) in bacterial cell membranes. This inhibits transpeptidase activity needed for peptidoglycan cross-linking during cell wall synthesis. The weakened cell wall cannot withstand osmotic pressure, leading to cell lysis. Amoxicillin is bactericidal.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Bacterial periplasm',
          action: 'Amoxicillin penetrates outer membrane (Gram-neg) or reaches cell membrane (Gram-pos)',
          result: 'Drug reaches PBPs',
        },
        {
          order: 2,
          location: 'Cell membrane',
          action: 'Beta-lactam ring binds to PBP active site',
          result: 'PBP acylated and inactivated',
        },
        {
          order: 3,
          location: 'Cell wall',
          action: 'Peptidoglycan cross-linking inhibited',
          result: 'Defective cell wall synthesis',
        },
        {
          order: 4,
          location: 'Bacterial cell',
          action: 'Osmotic pressure causes cell lysis',
          result: 'Bacterial death',
          timeframe: 'Hours',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Immune/Infectious',
          effect: 'Bacterial killing',
          mechanism: 'Cell wall disruption',
          clinicalRelevance: 'Treatment of susceptible infections',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'Disruption of gut flora',
          mechanism: 'Kills normal GI bacteria',
          clinicalRelevance: 'Diarrhea, C. difficile risk',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Clinical improvement 24-72 hours',
      durationOfEffect: 'Dose-dependent; 8-12 hours coverage per dose',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80-90%',
        route: ['oral'],
        factors: ['Stable in gastric acid', 'Food does not affect absorption'],
        timeToePeak: '1-2 hours',
        foodEffect: 'None significant',
      },
      distribution: {
        volumeOfDistribution: '0.3 L/kg',
        proteinBinding: '20%',
        tissueDistribution: ['Respiratory tract', 'Middle ear', 'Urinary tract', 'Bile'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (60% unchanged)',
        adjustmentNeeded: {
          renal: true,
          hepatic: false,
        },
      },
      halfLife: '1-1.5 hours',
      timeToSteadyState: '1 day',
    },

    indications: [
      {
        condition: 'Community-acquired pneumonia',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'High-dose for S. pneumoniae',
      },
      {
        condition: 'Acute otitis media',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line in children',
      },
      {
        condition: 'Streptococcal pharyngitis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Once or twice daily dosing effective',
      },
      {
        condition: 'H. pylori eradication',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Part of triple/quadruple therapy',
      },
      {
        condition: 'Urinary tract infection',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Only if susceptibility confirmed',
      },
    ],

    dosing: {
      usualDose: {
        amount: '500 mg',
        frequency: 'Every 8 hours',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Severe infections',
          adjustment: '875 mg every 12 hours or 1000 mg every 8 hours',
          rationale: 'Higher doses for resistant organisms',
        },
        {
          condition: 'Renal impairment (GFR 10-30)',
          adjustment: '250-500 mg every 12 hours',
          rationale: 'Reduced clearance',
        },
        {
          condition: 'Severe renal impairment (GFR <10)',
          adjustment: '250-500 mg every 24 hours',
          rationale: 'Accumulation risk',
        },
      ],
      maxDose: '3 g/day (adults)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Can be taken with or without food',
          'Shake suspension well before use',
          'Complete the full course even if feeling better',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Diarrhea',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Disruption of GI flora',
        management: 'Usually self-limiting; probiotics may help',
        reversible: true,
        onsetTiming: 'During treatment',
      },
      {
        name: 'Nausea/vomiting',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI irritation',
        management: 'Take with food',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Rash',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Hypersensitivity (not always true allergy)',
        management: 'Evaluate for true allergy vs. viral exanthem',
        reversible: true,
        onsetTiming: 'Days into treatment',
      },
      {
        name: 'Anaphylaxis',
        frequency: 'rare',
        severity: 'life-threatening',
        mechanism: 'IgE-mediated hypersensitivity',
        management: 'Epinephrine; never re-expose',
        reversible: true,
        onsetTiming: 'Minutes to hours of exposure',
      },
      {
        name: 'C. difficile colitis',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Overgrowth of C. difficile due to flora disruption',
        management: 'Stop antibiotic; treat with vancomycin or fidaxomicin',
        reversible: true,
        onsetTiming: 'During or up to 8 weeks after treatment',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Allopurinol',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Increased rash frequency',
        effect: 'Higher incidence of maculopapular rash',
        management: 'Monitor for rash; use alternative if possible',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Reduced vitamin K production by gut flora',
        effect: 'May increase INR',
        management: 'Monitor INR more frequently',
      },
      {
        interactingDrug: 'Methotrexate',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Reduced renal tubular secretion',
        effect: 'Increased methotrexate levels',
        management: 'Monitor for MTX toxicity',
      },
    ],

    contraindications: [
      {
        condition: 'Penicillin allergy (anaphylaxis)',
        type: 'absolute',
        reason: 'Risk of fatal reaction',
      },
      {
        condition: 'History of amoxicillin-induced hepatic dysfunction',
        type: 'absolute',
        reason: 'Risk of recurrence',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'No evidence of teratogenicity; commonly used',
        recommendation: 'Safe to use when indicated',
        pregnancyCategory: 'B',
      },
      {
        population: 'breastfeeding',
        consideration: 'Small amounts in breast milk; may cause GI upset in infant',
        recommendation: 'Generally safe; monitor infant for GI effects',
      },
      {
        population: 'pediatric',
        consideration: 'Frequently used; dosing by weight',
        recommendation: '25-50 mg/kg/day divided every 8-12 hours',
      },
      {
        population: 'renal-impairment',
        consideration: 'Renally excreted',
        recommendation: 'Reduce dose and/or extend interval',
      },
    ],

    monitoring: [
      {
        parameter: 'Clinical response',
        frequency: '48-72 hours',
        rationale: 'Assess efficacy',
        actionThreshold: 'No improvement - reassess diagnosis and susceptibility',
      },
      {
        parameter: 'Signs of allergic reaction',
        frequency: 'Throughout treatment',
        rationale: 'Hypersensitivity risk',
        actionThreshold: 'Rash, hives, swelling - evaluate for allergy',
      },
    ],

    patientEducation: [
      'Complete the full course even if you feel better',
      'Take with or without food',
      'Report any rash, hives, or difficulty breathing immediately',
      'Shake liquid suspension well before each dose',
      'Store suspension in refrigerator',
      'Contact doctor if severe diarrhea develops',
    ],

    clinicalPearls: [
      'Amoxicillin rash in EBV infection is not true allergy - 70-100% incidence',
      'Better absorbed than ampicillin, so preferred for oral use',
      'High-dose (90 mg/kg/day) overcomes some penicillin-resistant S. pneumoniae',
      'Combining with clavulanate extends spectrum to beta-lactamase producers',
      'Cross-reactivity with cephalosporins is low (~1%) despite historical concerns',
      'Good penetration to middle ear - first-line for otitis media',
    ],
  },

  // ============================================
  // AZITHROMYCIN (Antibiotic)
  // ============================================
  {
    id: 'azithromycin',
    genericName: 'Azithromycin',
    brandNames: ['Zithromax', 'Z-Pak', 'Zmax'],
    drugClass: 'Macrolide Antibiotic',
    category: 'antimicrobial',

    overview:
      'Azithromycin is a macrolide antibiotic with an exceptionally long half-life allowing short treatment courses. It covers atypicals (Mycoplasma, Chlamydia, Legionella) that beta-lactams miss, making it valuable for community-acquired pneumonia and sexually transmitted infections.',

    mechanism: {
      type: 'protein-synthesis-inhibitor',
      target: '50S ribosomal subunit',
      targetLocation: 'Bacterial ribosome',
      simpleExplanation:
        'Azithromycin stops bacteria from making proteins they need to survive and multiply. It binds to the bacterial ribosome (protein-making machinery) and blocks the assembly line.',
      detailedMechanism:
        'Azithromycin binds reversibly to the 23S rRNA of the 50S ribosomal subunit, blocking the exit tunnel and preventing the elongation of the nascent peptide chain. This inhibits translocation and protein synthesis. It is bacteriostatic at usual concentrations but can be bactericidal at high concentrations against certain organisms.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Bacterial cell',
          action: 'Azithromycin enters cell (concentrates in phagocytes)',
          result: 'High intracellular concentration',
        },
        {
          order: 2,
          location: 'Ribosome',
          action: 'Binds to 50S subunit 23S rRNA',
          result: 'Peptide exit tunnel blocked',
        },
        {
          order: 3,
          location: 'Ribosome',
          action: 'Translocation inhibited',
          result: 'Protein synthesis stops',
        },
        {
          order: 4,
          location: 'Bacterial cell',
          action: 'Unable to make essential proteins',
          result: 'Bacterial growth inhibited',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Immune/Infectious',
          effect: 'Bacterial growth inhibition',
          mechanism: 'Protein synthesis inhibition',
          clinicalRelevance: 'Treatment of susceptible infections',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Cardiovascular',
          effect: 'QT prolongation',
          mechanism: 'Potassium channel blockade',
          clinicalRelevance: 'Risk of torsades de pointes',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Clinical improvement 1-3 days',
      durationOfEffect: 'Tissue levels persist 5-7 days after last dose',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '37% (capsules); higher with suspension',
        route: ['oral', 'IV'],
        factors: ['Food decreases capsule absorption', 'Suspension not affected'],
        timeToePeak: '2-3 hours',
        foodEffect: 'Capsules: take on empty stomach; Tablets/suspension: with or without food',
      },
      distribution: {
        volumeOfDistribution: '31 L/kg (extensive tissue distribution)',
        proteinBinding: '7-50% (concentration dependent)',
        tissueDistribution: ['Concentrates in phagocytes', 'Lung', 'Tonsils', 'Prostate'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (demethylation)',
        enzymes: ['CYP3A4 (minor)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Biliary (major); renal (minor)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: '68 hours (allows 5-day course with 3-day dosing)',
      timeToSteadyState: 'Not relevant - concentrates in tissues',
    },

    indications: [
      {
        condition: 'Community-acquired pneumonia',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Covers atypicals; often combined with beta-lactam for severe cases',
      },
      {
        condition: 'Acute bacterial sinusitis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'moderate',
        firstLine: false,
        notes: 'Second-line; resistance increasing',
      },
      {
        condition: 'Chlamydia trachomatis infection',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Single 1g dose is standard treatment',
      },
      {
        condition: 'Traveler\'s diarrhea',
        approvalStatus: 'off-label',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Especially for Campylobacter-endemic areas',
      },
      {
        condition: 'MAC prophylaxis in HIV',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Weekly dosing for prophylaxis',
      },
    ],

    dosing: {
      usualDose: {
        amount: '500 mg day 1, then 250 mg',
        frequency: 'Days 2-5',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Chlamydia',
          adjustment: '1 g single dose',
          rationale: 'Long half-life allows single-dose treatment',
        },
        {
          condition: 'CAP (severe)',
          adjustment: '500 mg daily for 3-5 days',
          rationale: 'Higher dose for serious infection',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Use with caution; no specific guidelines',
          rationale: 'Biliary excretion',
        },
      ],
      maxDose: '500 mg/day for most indications',
      administration: {
        route: 'Oral or IV',
        withFood: 'either',
        specialInstructions: [
          'Tablets can be taken with or without food',
          'Capsules should be taken on empty stomach',
          'Do not take with antacids',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'GI upset (nausea, diarrhea, abdominal pain)',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI motility stimulation (motilin agonist effect)',
        management: 'Take with food; usually mild',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'QT prolongation',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Potassium channel blockade - risk of torsades de pointes',
        management: 'Avoid in patients with QT prolongation or hypokalemia',
        reversible: true,
        onsetTiming: 'During treatment',
      },
      {
        name: 'Hepatotoxicity',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Cholestatic hepatitis',
        management: 'Monitor for jaundice; discontinue if liver dysfunction',
        reversible: true,
        onsetTiming: 'Weeks',
      },
      {
        name: 'Hearing loss',
        frequency: 'rare',
        severity: 'moderate',
        mechanism: 'Ototoxicity',
        management: 'Usually reversible; report tinnitus',
        reversible: true,
        onsetTiming: 'High doses or prolonged use',
      },
    ],

    interactions: [
      {
        interactingDrug: 'QT-prolonging drugs (Class III antiarrhythmics)',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive QT prolongation',
        effect: 'Increased risk of torsades de pointes',
        management: 'Avoid combination; monitor ECG if necessary',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Possible inhibition of warfarin metabolism',
        effect: 'Increased INR',
        management: 'Monitor INR more frequently',
      },
      {
        interactingDrug: 'Nelfinavir',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Increased azithromycin levels',
        effect: 'Hepatotoxicity risk',
        management: 'Monitor for adverse effects',
      },
    ],

    contraindications: [
      {
        condition: 'History of cholestatic jaundice/hepatic dysfunction with azithromycin',
        type: 'absolute',
        reason: 'Risk of severe recurrence',
      },
      {
        condition: 'Known QT prolongation',
        type: 'relative',
        reason: 'Risk of arrhythmia',
      },
      {
        condition: 'Hypersensitivity to macrolides',
        type: 'absolute',
        reason: 'Cross-reactivity possible',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Limited data; generally considered safe',
        recommendation: 'Use when clearly needed',
        pregnancyCategory: 'B',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk',
        recommendation: 'Generally compatible; monitor infant for GI upset',
      },
      {
        population: 'geriatric',
        consideration: 'Higher risk of QT prolongation',
        recommendation: 'Assess cardiac risk; monitor electrolytes',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Biliary excretion',
        recommendation: 'Use with caution in severe impairment',
      },
    ],

    monitoring: [
      {
        parameter: 'Clinical response',
        frequency: '48-72 hours',
        rationale: 'Assess efficacy',
        actionThreshold: 'No improvement - reassess diagnosis',
      },
      {
        parameter: 'ECG (if risk factors)',
        frequency: 'Before treatment in high-risk patients',
        rationale: 'QT prolongation risk',
        actionThreshold: 'QTc >500ms - avoid use',
      },
      {
        parameter: 'Liver function (prolonged use)',
        frequency: 'If symptoms of hepatitis',
        rationale: 'Hepatotoxicity risk',
        actionThreshold: 'Elevated LFTs - consider discontinuation',
      },
    ],

    patientEducation: [
      'Complete full course even if feeling better',
      'Can take tablets with or without food',
      'Avoid antacids within 2 hours of dose',
      'Report irregular heartbeat, fainting, or dizziness',
      'Report yellowing of skin or eyes',
      'Long-acting - effects persist days after completing course',
    ],

    clinicalPearls: [
      'Tissue concentrations exceed serum concentrations by 10-100x',
      'Concentrates in phagocytes - delivers drug to infection sites',
      'Z-Pak (6 pills) achieves 10-day antibiotic exposure despite 5-day course',
      'Less GI upset than erythromycin due to reduced motilin effect',
      'Resistance increasing in S. pneumoniae - not reliable as sole agent for severe pneumonia',
      'Single-dose treatment for chlamydia improves adherence',
      'QT risk is real but low - FDA warning issued 2013',
    ],
  },

  // ============================================
  // CIPROFLOXACIN (Antibiotic)
  // ============================================
  {
    id: 'ciprofloxacin',
    genericName: 'Ciprofloxacin',
    brandNames: ['Cipro', 'Cipro XR'],
    drugClass: 'Fluoroquinolone Antibiotic',
    category: 'antimicrobial',

    overview:
      'Ciprofloxacin is a fluoroquinolone antibiotic with excellent gram-negative coverage, including Pseudomonas aeruginosa. While highly effective, serious adverse effects including tendon rupture, peripheral neuropathy, and CNS effects have led to FDA warnings restricting its use to when no alternatives exist.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'DNA gyrase (topoisomerase II) and topoisomerase IV',
      targetLocation: 'Bacterial DNA replication machinery',
      simpleExplanation:
        'Ciprofloxacin kills bacteria by interfering with enzymes they need to copy their DNA. Without being able to replicate DNA, bacteria cannot multiply and die.',
      detailedMechanism:
        'Ciprofloxacin inhibits bacterial DNA gyrase (primary target in gram-negatives) and topoisomerase IV (primary target in gram-positives). These enzymes are essential for DNA replication, transcription, and repair. Inhibition leads to double-stranded DNA breaks and rapid bacterial death. It is bactericidal with concentration-dependent killing.',
      mechanismSteps: [
        {
          order: 1,
          location: 'Bacterial cell',
          action: 'Ciprofloxacin enters through porins and efflux pumps',
          result: 'Drug reaches cytoplasm',
        },
        {
          order: 2,
          location: 'DNA',
          action: 'Binds to DNA-gyrase complex',
          result: 'Enzyme trapped on DNA',
        },
        {
          order: 3,
          location: 'Chromosome',
          action: 'Double-stranded DNA breaks accumulate',
          result: 'DNA replication and transcription halt',
        },
        {
          order: 4,
          location: 'Bacterial cell',
          action: 'SOS response overwhelmed',
          result: 'Rapid bacterial death',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Immune/Infectious',
          effect: 'Rapid bacterial killing',
          mechanism: 'DNA damage',
          clinicalRelevance: 'Effective for serious gram-negative infections',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Musculoskeletal',
          effect: 'Tendon damage',
          mechanism: 'Disruption of collagen synthesis and matrix metalloproteinases',
          clinicalRelevance: 'Risk of tendinitis and rupture (black box)',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Nervous system',
          effect: 'CNS effects and peripheral neuropathy',
          mechanism: 'GABA antagonism, mitochondrial toxicity',
          clinicalRelevance: 'Can be irreversible',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Rapid bactericidal activity',
      durationOfEffect: '12 hours (standard); 24 hours (XR)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '70-80%',
        route: ['oral', 'IV'],
        factors: ['Chelation with cations reduces absorption'],
        timeToePeak: '1-2 hours (IR); 1-4 hours (XR)',
        foodEffect: 'Dairy and minerals significantly reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '2-3 L/kg',
        proteinBinding: '20-40%',
        tissueDistribution: ['Urinary tract', 'Respiratory tract', 'Bone', 'Prostate'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (partial)',
        enzymes: ['CYP1A2 inhibitor'],
        activeMetabolites: ['Minor metabolites with some activity'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (40-50% unchanged) and biliary',
        adjustmentNeeded: {
          renal: true,
          hepatic: false,
        },
      },
      halfLife: '4-6 hours',
      timeToSteadyState: '2 days',
    },

    indications: [
      {
        condition: 'Complicated urinary tract infection',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Reserve for when no alternatives exist (FDA guidance)',
      },
      {
        condition: 'Acute bacterial prostatitis',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Good prostate penetration',
      },
      {
        condition: 'Intra-abdominal infections (with metronidazole)',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Usually reserved for penicillin-allergic patients',
      },
      {
        condition: 'Pseudomonas infections',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'One of few oral anti-pseudomonal options',
      },
      {
        condition: 'Anthrax prophylaxis/treatment',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Public health emergency use',
      },
    ],

    dosing: {
      usualDose: {
        amount: '500 mg',
        frequency: 'Every 12 hours',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Severe infections',
          adjustment: '750 mg every 12 hours',
          rationale: 'Higher doses for serious infections',
        },
        {
          condition: 'Renal impairment (CrCl 30-50)',
          adjustment: '250-500 mg every 12 hours',
          rationale: 'Reduced clearance',
        },
        {
          condition: 'Severe renal impairment (CrCl <30)',
          adjustment: '250-500 mg every 18-24 hours',
          rationale: 'Significant accumulation',
        },
      ],
      maxDose: '1500 mg/day',
      administration: {
        route: 'Oral or IV',
        withFood: 'either',
        specialInstructions: [
          'Avoid dairy products and calcium-fortified juices within 2 hours',
          'Avoid antacids, sucralfate, iron, zinc within 6 hours',
          'Maintain hydration to prevent crystalluria',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'GI upset (nausea, diarrhea)',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI irritation',
        management: 'Usually tolerable',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Tendinitis/tendon rupture',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Collagen disruption, MMP activation',
        management: 'STOP immediately; FDA black box warning',
        reversible: false,
        onsetTiming: 'Hours to months; can occur after completion',
      },
      {
        name: 'Peripheral neuropathy',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Mitochondrial toxicity',
        management: 'May be irreversible; discontinue immediately',
        reversible: false,
        onsetTiming: 'Any time',
      },
      {
        name: 'CNS effects (dizziness, confusion, seizures)',
        frequency: 'uncommon',
        severity: 'moderate',
        mechanism: 'GABA antagonism',
        management: 'Discontinue; caution in seizure history',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'QT prolongation',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Potassium channel blockade',
        management: 'Avoid in QT prolongation',
        reversible: true,
        onsetTiming: 'During treatment',
      },
      {
        name: 'C. difficile colitis',
        frequency: 'uncommon',
        severity: 'severe',
        mechanism: 'Flora disruption',
        management: 'Discontinue; treat CDI',
        reversible: true,
        onsetTiming: 'During or after treatment',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Tizanidine',
        interactionType: 'pharmacokinetic',
        severity: 'contraindicated',
        mechanism: 'CYP1A2 inhibition increases tizanidine levels 10x',
        effect: 'Severe hypotension, sedation',
        management: 'Contraindicated - do not combine',
      },
      {
        interactingDrug: 'Theophylline',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'CYP1A2 inhibition',
        effect: 'Theophylline toxicity',
        management: 'Reduce theophylline dose; monitor levels',
      },
      {
        interactingDrug: 'Antacids, calcium, iron, zinc',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Chelation reduces absorption',
        effect: 'Treatment failure',
        management: 'Separate by 2-6 hours',
      },
      {
        interactingDrug: 'Corticosteroids',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive tendon toxicity',
        effect: 'Increased tendon rupture risk',
        management: 'Avoid combination if possible',
      },
      {
        interactingDrug: 'NSAIDs',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Both lower seizure threshold',
        effect: 'Increased seizure risk',
        management: 'Use with caution',
      },
    ],

    contraindications: [
      {
        condition: 'Concurrent tizanidine use',
        type: 'absolute',
        reason: 'Dangerous interaction',
      },
      {
        condition: 'History of fluoroquinolone-associated tendon rupture',
        type: 'absolute',
        reason: 'High risk of recurrence',
      },
      {
        condition: 'Myasthenia gravis',
        type: 'absolute',
        reason: 'Can precipitate severe weakness/respiratory failure',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Animal data shows cartilage damage; limited human data',
        recommendation: 'Avoid; use only if no alternatives',
        pregnancyCategory: 'C',
      },
      {
        population: 'pediatric',
        consideration: 'Cartilage damage concern; limited indications',
        recommendation: 'Generally avoided; approved only for specific indications (anthrax, complicated UTI, CF)',
      },
      {
        population: 'geriatric',
        consideration: 'Higher risk of tendon rupture, CNS effects, QT prolongation',
        recommendation: 'Use only when no alternatives; lowest effective dose',
      },
      {
        population: 'renal-impairment',
        consideration: 'Accumulation and toxicity risk',
        recommendation: 'Dose reduce based on CrCl',
      },
    ],

    monitoring: [
      {
        parameter: 'Tendon symptoms',
        frequency: 'Throughout and after treatment',
        rationale: 'Black box warning for tendon rupture',
        actionThreshold: 'Any tendon pain - STOP immediately',
      },
      {
        parameter: 'Neurological symptoms',
        frequency: 'Throughout treatment',
        rationale: 'Peripheral neuropathy and CNS effects',
        actionThreshold: 'Numbness, tingling, confusion - discontinue',
      },
      {
        parameter: 'Clinical response',
        frequency: '48-72 hours',
        rationale: 'Assess efficacy',
        actionThreshold: 'No improvement - reassess',
      },
    ],

    patientEducation: [
      'STOP immediately and contact doctor if you have tendon pain, swelling, or rupture',
      'STOP if you experience numbness, tingling, or burning in hands/feet',
      'Avoid dairy and antacids within 2 hours of dose',
      'Stay well hydrated',
      'Avoid excessive sun exposure - can cause severe sunburn',
      'Report any irregular heartbeat',
      'Complete the full course unless told to stop',
    ],

    clinicalPearls: [
      'FDA black box warnings: tendon rupture, peripheral neuropathy, CNS effects, myasthenia gravis exacerbation',
      'Reserve for when no alternatives exist - not for uncomplicated UTI or sinusitis',
      'One of few oral options for Pseudomonas',
      'Excellent prostate penetration - good for prostatitis',
      'Resistance increasing in E. coli - check local susceptibility patterns',
      'Tendon rupture risk increased with steroids, age >60, and renal/cardiac/lung transplant',
      'Can cause false-positive urine screening for opioids',
    ],
  },

  // ============================================
  // SERTRALINE (Antidepressant)
  // ============================================
  {
    id: 'sertraline',
    genericName: 'Sertraline',
    brandNames: ['Zoloft'],
    drugClass: 'Selective Serotonin Reuptake Inhibitor (SSRI)',
    category: 'psychiatric',

    overview:
      'Sertraline is a widely prescribed SSRI antidepressant with a favorable side effect profile and extensive safety data. It is effective for depression, multiple anxiety disorders, PTSD, and OCD. Among SSRIs, it has a relatively low drug interaction potential.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT)',
      targetLocation: 'Presynaptic serotonergic neurons',
      simpleExplanation:
        'Sertraline blocks the recycling of serotonin in the brain, allowing serotonin to remain active longer in the synapse. This increased serotonin signaling over time helps improve mood and reduce anxiety.',
      detailedMechanism:
        'Sertraline selectively inhibits SERT, blocking presynaptic reuptake of serotonin. Acute inhibition increases synaptic serotonin, but therapeutic effects require weeks as downstream receptor adaptations occur (5-HT1A autoreceptor desensitization, BDNF upregulation). Sertraline also has mild dopamine reuptake inhibition, which may contribute to its activating profile.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Sertraline absorbed',
          result: 'Drug enters systemic circulation',
          timeframe: '4-8 hours',
        },
        {
          order: 2,
          location: 'Serotonergic synapse',
          action: 'Binds to and inhibits SERT',
          result: 'Serotonin reuptake blocked',
        },
        {
          order: 3,
          location: 'Synapse',
          action: 'Serotonin accumulates',
          result: 'Increased serotonergic neurotransmission',
        },
        {
          order: 4,
          location: 'Presynaptic neuron',
          action: '5-HT1A autoreceptors desensitize',
          result: 'Sustained serotonin release',
          timeframe: '2-4 weeks',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Mood improvement',
          mechanism: 'Enhanced serotonergic neurotransmission',
          clinicalRelevance: 'Antidepressant effect',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Central nervous system',
          effect: 'Anxiolytic effect',
          mechanism: 'Serotonin modulation of amygdala activity',
          clinicalRelevance: 'Effective for anxiety disorders',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Gastrointestinal',
          effect: 'GI upset',
          mechanism: 'Serotonin in gut (5-HT3/5-HT4 effects)',
          clinicalRelevance: 'Common initial side effect',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Sexual',
          effect: 'Sexual dysfunction',
          mechanism: 'Serotonin inhibits dopamine, affects spinal reflexes',
          clinicalRelevance: 'Common; may persist',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Clinical improvement: 2-4 weeks',
      durationOfEffect: 'Continuous with daily dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '44% (first-pass metabolism)',
        route: ['oral'],
        factors: ['Food increases absorption and reduces GI side effects'],
        timeToePeak: '4-8 hours',
        foodEffect: 'Take with food - improves absorption and tolerability',
      },
      distribution: {
        volumeOfDistribution: '20 L/kg (large)',
        proteinBinding: '98%',
        tissueDistribution: ['CNS', 'Widely distributed'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2B6', 'CYP2C9', 'CYP2C19', 'CYP2D6', 'CYP3A4'],
        activeMetabolites: ['N-desmethylsertraline (much less active)'],
        geneticVariability: 'CYP2C19 poor metabolizers have higher levels but clinical significance unclear',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Fecal (40-45%) and renal (40-45%)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: '26 hours (allows once daily dosing)',
      timeToSteadyState: '7 days',
    },

    indications: [
      {
        condition: 'Major depressive disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'First-line treatment option',
      },
      {
        condition: 'Generalized anxiety disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Effective for GAD',
      },
      {
        condition: 'Panic disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'May initially worsen panic; start low',
      },
      {
        condition: 'PTSD',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'One of only two SSRIs FDA-approved for PTSD',
      },
      {
        condition: 'OCD',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Often requires higher doses',
      },
      {
        condition: 'Social anxiety disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Effective for social phobia',
      },
    ],

    dosing: {
      usualDose: {
        amount: '50-200 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Depression starting dose',
          adjustment: '50 mg once daily',
          rationale: 'Typical starting dose',
        },
        {
          condition: 'OCD',
          adjustment: '50 mg initially; may need up to 200 mg',
          rationale: 'Higher doses often needed for OCD',
        },
        {
          condition: 'Panic disorder',
          adjustment: 'Start 25 mg; increase slowly',
          rationale: 'Panic patients sensitive to initial activation',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Reduce dose or use less frequent dosing',
          rationale: 'Reduced clearance',
        },
      ],
      maxDose: '200 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: 'Morning (can be activating) or evening',
        specialInstructions: [
          'Take with food to improve absorption and reduce GI upset',
          'Can be taken morning or evening consistently',
          'Oral concentrate should be diluted before use',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Nausea',
        frequency: 'very-common',
        severity: 'mild',
        mechanism: 'Serotonin effects on gut 5-HT3 receptors',
        management: 'Take with food; usually improves in 1-2 weeks',
        reversible: true,
        onsetTiming: 'First 1-2 weeks',
      },
      {
        name: 'Diarrhea',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI serotonin effects',
        management: 'Usually self-limiting',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Sexual dysfunction',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'Serotonin effects on sexual function',
        management: 'May try dose reduction, drug holiday (risky), add bupropion, or switch agents',
        reversible: true,
        onsetTiming: 'Can occur any time; may persist',
      },
      {
        name: 'Insomnia or somnolence',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'CNS effects variable by patient',
        management: 'Adjust timing of dose; usually improves',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Suicidal ideation (youth)',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Unclear - possibly activation before mood improvement',
        management: 'FDA black box warning in patients <25 years; close monitoring',
        reversible: true,
        onsetTiming: 'First weeks of treatment or dose changes',
      },
      {
        name: 'Serotonin syndrome',
        frequency: 'rare',
        severity: 'life-threatening',
        mechanism: 'Excessive serotonergic activity',
        management: 'Stop serotonergic drugs; supportive care',
        reversible: true,
        onsetTiming: 'Hours after starting/increasing serotonergic drug',
      },
    ],

    interactions: [
      {
        interactingDrug: 'MAOIs',
        interactionType: 'pharmacodynamic',
        severity: 'contraindicated',
        mechanism: 'Serotonin accumulation',
        effect: 'Serotonin syndrome',
        management: 'Contraindicated - wait 14 days between',
      },
      {
        interactingDrug: 'Pimozide',
        interactionType: 'pharmacokinetic',
        severity: 'contraindicated',
        mechanism: 'Increases pimozide levels',
        effect: 'QT prolongation',
        management: 'Contraindicated',
      },
      {
        interactingDrug: 'Tramadol',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive serotonergic effects',
        effect: 'Serotonin syndrome risk',
        management: 'Use with caution; monitor',
      },
      {
        interactingDrug: 'Warfarin',
        interactionType: 'pharmacodynamic',
        severity: 'moderate',
        mechanism: 'Platelet effects and possible PK interaction',
        effect: 'Increased bleeding risk',
        management: 'Monitor INR when starting/stopping',
      },
    ],

    contraindications: [
      {
        condition: 'Concurrent MAOI use',
        type: 'absolute',
        reason: 'Serotonin syndrome',
      },
      {
        condition: 'Pimozide use',
        type: 'absolute',
        reason: 'QT prolongation',
      },
      {
        condition: 'Disulfiram use (with oral concentrate)',
        type: 'absolute',
        reason: 'Concentrate contains alcohol',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Neonatal adaptation syndrome; possible PPHN with third trimester exposure',
        recommendation: 'Discuss risks/benefits; generally can continue if depression is severe',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Low levels in breast milk; sertraline often preferred SSRI',
        recommendation: 'Generally compatible; sertraline among preferred SSRIs in breastfeeding',
      },
      {
        population: 'pediatric',
        consideration: 'Black box warning for suicidality <25 years',
        recommendation: 'FDA-approved for OCD ages 6+; close monitoring required',
      },
      {
        population: 'geriatric',
        consideration: 'Increased bleeding risk, hyponatremia risk',
        recommendation: 'Start low; monitor sodium',
      },
    ],

    monitoring: [
      {
        parameter: 'Depression/anxiety symptoms',
        frequency: 'Baseline; weeks 2, 4, 6, then periodic',
        rationale: 'Assess efficacy',
        actionThreshold: 'No improvement by 6-8 weeks - reassess',
      },
      {
        parameter: 'Suicidal ideation (in youth)',
        frequency: 'Weekly for first 4 weeks, then periodic',
        rationale: 'Black box warning',
        actionThreshold: 'Any worsening - immediate evaluation',
      },
      {
        parameter: 'Sodium (in elderly)',
        frequency: 'Consider at 1-2 weeks',
        rationale: 'SIADH risk',
        actionThreshold: 'Symptomatic hyponatremia - discontinue',
      },
    ],

    patientEducation: [
      'May take 2-4 weeks to feel improvement',
      'Do not stop suddenly - taper under doctor supervision',
      'Take with food to reduce stomach upset',
      'Report worsening depression or suicidal thoughts immediately',
      'Sexual side effects are common - discuss with doctor',
      'Avoid alcohol',
      'Do not take with MAOIs or for 14 days after stopping',
    ],

    clinicalPearls: [
      'Among SSRIs with lowest drug interaction potential',
      'More activating - can help fatigue/hypersomnia but worsen insomnia/anxiety initially',
      'Mild dopamine reuptake inhibition may contribute to activating profile',
      'Oral concentrate contains alcohol - contraindicated with disulfiram',
      'Often preferred SSRI in breastfeeding due to low milk levels',
      'FDA-approved for more conditions than most SSRIs',
      'Generic widely available - cost-effective first-line option',
    ],
  },

  // ============================================
  // ESCITALOPRAM (Antidepressant)
  // ============================================
  {
    id: 'escitalopram',
    genericName: 'Escitalopram',
    brandNames: ['Lexapro'],
    drugClass: 'Selective Serotonin Reuptake Inhibitor (SSRI)',
    category: 'psychiatric',

    overview:
      'Escitalopram is the S-enantiomer of citalopram and is considered the most selective SSRI available. It has an excellent tolerability profile and is FDA-approved for depression and GAD. Often recommended as first-line due to efficacy, tolerability, and minimal drug interactions.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT)',
      targetLocation: 'Presynaptic serotonergic neurons',
      simpleExplanation:
        'Escitalopram is the most selective blocker of serotonin reuptake. By preventing serotonin from being recycled, it increases the amount of serotonin available to transmit signals in the brain.',
      detailedMechanism:
        'Escitalopram is the active S-enantiomer of racemic citalopram and is the most SERT-selective SSRI. It has minimal activity at other receptors (histamine, muscarinic, adrenergic), contributing to its favorable side effect profile. The R-enantiomer may actually inhibit binding of the S-enantiomer, so escitalopram is more potent than expected from citalopram.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Escitalopram absorbed',
          result: 'Drug enters circulation',
          timeframe: '4 hours',
        },
        {
          order: 2,
          location: 'SERT transporter',
          action: 'High-affinity binding to SERT',
          result: 'Serotonin reuptake blocked',
        },
        {
          order: 3,
          location: 'Synapse',
          action: 'Serotonin accumulates',
          result: 'Enhanced serotonergic transmission',
        },
        {
          order: 4,
          location: 'Neural circuits',
          action: 'Receptor adaptations occur',
          result: 'Clinical improvement',
          timeframe: '2-4 weeks',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Antidepressant effect',
          mechanism: 'Selective SERT inhibition',
          clinicalRelevance: 'Effective for depression',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Central nervous system',
          effect: 'Anxiolytic effect',
          mechanism: 'Serotonin modulation',
          clinicalRelevance: 'Effective for GAD',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Cardiovascular',
          effect: 'QT prolongation (dose-dependent)',
          mechanism: 'Cardiac ion channel effects',
          clinicalRelevance: 'Dose-dependent; max 20 mg',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: 'Clinical improvement: 1-4 weeks',
      durationOfEffect: 'Continuous with daily dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80%',
        route: ['oral'],
        factors: ['Not significantly affected by food'],
        timeToePeak: '5 hours',
        foodEffect: 'None significant',
      },
      distribution: {
        volumeOfDistribution: '12-26 L/kg',
        proteinBinding: '56%',
        tissueDistribution: ['CNS', 'Wide distribution'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19', 'CYP3A4'],
        activeMetabolites: ['S-desmethylcitalopram (less active)'],
        geneticVariability: 'CYP2C19 poor metabolizers have 2x higher levels',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (primarily as metabolites)',
        adjustmentNeeded: {
          renal: true,
          hepatic: true,
        },
      },
      halfLife: '27-32 hours',
      timeToSteadyState: '7 days',
    },

    indications: [
      {
        condition: 'Major depressive disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Often recommended first-line',
      },
      {
        condition: 'Generalized anxiety disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: true,
        notes: 'Effective for GAD',
      },
    ],

    dosing: {
      usualDose: {
        amount: '10-20 mg',
        frequency: 'Once daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Starting dose',
          adjustment: '10 mg once daily',
          rationale: 'Effective starting dose',
        },
        {
          condition: 'Elderly',
          adjustment: 'Max 10 mg/day',
          rationale: 'QT prolongation risk; reduced clearance',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: '10 mg/day max',
          rationale: 'Reduced clearance',
        },
        {
          condition: 'CYP2C19 poor metabolizers',
          adjustment: '10 mg/day max',
          rationale: '2x higher exposure',
        },
      ],
      maxDose: '20 mg/day (10 mg in elderly, hepatic impairment, or with CYP2C19 inhibitors)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'Can be taken with or without food',
          'Morning or evening dosing acceptable',
          'Do not exceed 20 mg due to QT prolongation',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Nausea',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'GI serotonin effects',
        management: 'Usually improves; take with food',
        reversible: true,
        onsetTiming: 'Early; improves',
      },
      {
        name: 'Headache',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'CNS serotonin effects',
        management: 'Usually transient',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'Sexual dysfunction',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Serotonin effects',
        management: 'Dose reduction, add bupropion, or switch',
        reversible: true,
        onsetTiming: 'Any time',
      },
      {
        name: 'Insomnia',
        frequency: 'common',
        severity: 'mild',
        mechanism: 'Activation',
        management: 'Take in morning',
        reversible: true,
        onsetTiming: 'Early',
      },
      {
        name: 'QT prolongation',
        frequency: 'rare',
        severity: 'severe',
        mechanism: 'Cardiac ion channel effects',
        management: 'Do not exceed 20 mg; 10 mg max in elderly',
        reversible: true,
        onsetTiming: 'Dose-dependent',
      },
    ],

    interactions: [
      {
        interactingDrug: 'MAOIs',
        interactionType: 'pharmacodynamic',
        severity: 'contraindicated',
        mechanism: 'Serotonin accumulation',
        effect: 'Serotonin syndrome',
        management: 'Contraindicated; 14-day washout required',
      },
      {
        interactingDrug: 'QT-prolonging drugs',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive QT prolongation',
        effect: 'Arrhythmia risk',
        management: 'Use with caution; consider alternatives',
      },
      {
        interactingDrug: 'CYP2C19 inhibitors (omeprazole)',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Increased escitalopram levels',
        effect: 'May increase adverse effects',
        management: 'Consider max 10 mg with strong inhibitors',
      },
    ],

    contraindications: [
      {
        condition: 'Concurrent MAOI use',
        type: 'absolute',
        reason: 'Serotonin syndrome',
      },
      {
        condition: 'Pimozide use',
        type: 'absolute',
        reason: 'QT prolongation',
      },
      {
        condition: 'Known QT prolongation',
        type: 'relative',
        reason: 'Dose-dependent QT effects',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Neonatal adaptation syndrome; possible PPHN',
        recommendation: 'Discuss risks/benefits with patient',
        pregnancyCategory: 'C',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk; low levels',
        recommendation: 'Generally compatible; sertraline may be preferred',
      },
      {
        population: 'pediatric',
        consideration: 'FDA-approved for MDD ages 12+; black box warning',
        recommendation: 'Close monitoring for suicidality required',
      },
      {
        population: 'geriatric',
        consideration: 'QT prolongation risk; SIADH risk',
        recommendation: 'Max 10 mg/day',
      },
    ],

    monitoring: [
      {
        parameter: 'Depression symptoms',
        frequency: 'Every 2-4 weeks initially',
        rationale: 'Assess efficacy',
        actionThreshold: 'No improvement by 6-8 weeks - reassess',
      },
      {
        parameter: 'ECG (if risk factors)',
        frequency: 'Before treatment if cardiac risk',
        rationale: 'QT prolongation',
        actionThreshold: 'QTc >500ms - avoid or discontinue',
      },
      {
        parameter: 'Suicidality (youth)',
        frequency: 'Weekly initially',
        rationale: 'Black box warning',
        actionThreshold: 'Any worsening - immediate evaluation',
      },
    ],

    patientEducation: [
      'May take 2-4 weeks to feel better',
      'Do not stop suddenly',
      'Do not exceed prescribed dose',
      'Report irregular heartbeat',
      'Report worsening depression or suicidal thoughts',
      'Avoid alcohol',
    ],

    clinicalPearls: [
      'Most selective SSRI - fewest off-target effects',
      'QT prolongation is dose-dependent - do not exceed 20 mg',
      'CYP2C19 poor metabolizers need max 10 mg',
      'Often better tolerated than other SSRIs',
      'Escitalopram 10 mg ≈ citalopram 20 mg in efficacy',
      'Generic now available - cost-effective option',
      'One of the most commonly prescribed antidepressants',
    ],
  },

  // ============================================
  // ALPRAZOLAM (Benzodiazepine)
  // ============================================
  {
    id: 'alprazolam',
    genericName: 'Alprazolam',
    brandNames: ['Xanax', 'Xanax XR', 'Niravam'],
    drugClass: 'Benzodiazepine',
    category: 'psychiatric',

    overview:
      'Alprazolam is a short-acting, high-potency benzodiazepine commonly prescribed for panic disorder and anxiety. Its rapid onset provides quick relief but creates significant risks of dependence, withdrawal, and abuse. Guidelines recommend limiting duration and preferring SSRIs for long-term anxiety treatment.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'GABA-A receptor (positive allosteric modulator)',
      targetLocation: 'CNS neurons',
      simpleExplanation:
        'Alprazolam enhances the effect of GABA, the brain\'s main calming chemical. When GABA binds its receptor, alprazolam makes the receptor open more often, allowing more chloride into neurons and making them less excitable.',
      detailedMechanism:
        'Alprazolam binds to the benzodiazepine site on GABA-A receptors, increasing the frequency of chloride channel opening in response to GABA binding. This enhances inhibitory neurotransmission throughout the CNS. It is a triazolobenzodiazepine with high receptor affinity and rapid absorption, leading to quick onset but also higher abuse potential.',
      mechanismSteps: [
        {
          order: 1,
          location: 'GI tract',
          action: 'Rapid absorption',
          result: 'Drug enters circulation quickly',
          timeframe: '15-30 minutes',
        },
        {
          order: 2,
          location: 'GABA-A receptor',
          action: 'Binds benzodiazepine site',
          result: 'Receptor conformation change',
        },
        {
          order: 3,
          location: 'GABA-A receptor',
          action: 'Increased frequency of chloride channel opening',
          result: 'Enhanced GABA effect',
        },
        {
          order: 4,
          location: 'Neurons',
          action: 'Hyperpolarization',
          result: 'CNS depression; anxiolytic effect',
        },
      ],
      physiologicalEffects: [
        {
          system: 'Central nervous system',
          effect: 'Anxiolysis',
          mechanism: 'Enhanced GABA-A inhibition in limbic system',
          clinicalRelevance: 'Rapid relief of anxiety and panic',
          desiredOrAdverse: 'desired',
        },
        {
          system: 'Central nervous system',
          effect: 'Sedation',
          mechanism: 'Global CNS depression',
          clinicalRelevance: 'Drowsiness; impaired function',
          desiredOrAdverse: 'both',
        },
        {
          system: 'Central nervous system',
          effect: 'Dependence and tolerance',
          mechanism: 'Neuroadaptive changes',
          clinicalRelevance: 'Major limitation for long-term use',
          desiredOrAdverse: 'adverse',
        },
        {
          system: 'Respiratory',
          effect: 'Respiratory depression (with other CNS depressants)',
          mechanism: 'Brainstem depression',
          clinicalRelevance: 'Dangerous with opioids/alcohol',
          desiredOrAdverse: 'adverse',
        },
      ],
      onsetOfAction: '15-30 minutes',
      durationOfEffect: '4-6 hours (IR)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80-100%',
        route: ['oral'],
        factors: ['Rapid absorption', 'Food delays but does not reduce absorption'],
        timeToePeak: '1-2 hours (IR); 9 hours (XR)',
        foodEffect: 'Delays peak but not extent',
      },
      distribution: {
        volumeOfDistribution: '0.8-1.2 L/kg',
        proteinBinding: '80%',
        tissueDistribution: ['CNS', 'Wide distribution'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4 (primary)'],
        activeMetabolites: ['Alpha-hydroxyalprazolam (minor activity)'],
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (as metabolites)',
        adjustmentNeeded: {
          renal: false,
          hepatic: true,
        },
      },
      halfLife: '11 hours (range 6-27 hours)',
      timeToSteadyState: '2-3 days',
    },

    indications: [
      {
        condition: 'Panic disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'SSRIs preferred first-line; alprazolam for acute/adjunctive use',
      },
      {
        condition: 'Generalized anxiety disorder',
        approvalStatus: 'FDA-approved',
        evidenceLevel: 'high',
        firstLine: false,
        notes: 'Short-term use only; SSRIs preferred',
      },
    ],

    dosing: {
      usualDose: {
        amount: '0.25-0.5 mg',
        frequency: 'Three times daily',
        route: 'Oral',
      },
      adjustments: [
        {
          condition: 'Panic disorder',
          adjustment: 'Start 0.5 mg TID; may increase every 3-4 days',
          rationale: 'Higher doses often needed for panic',
        },
        {
          condition: 'Elderly',
          adjustment: 'Start 0.25 mg BID-TID',
          rationale: 'Increased sensitivity and fall risk',
        },
        {
          condition: 'Hepatic impairment',
          adjustment: 'Start 0.25 mg BID-TID',
          rationale: 'Reduced clearance',
        },
      ],
      maxDose: '4 mg/day (anxiety); 10 mg/day (panic)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: [
          'XR tablets must be swallowed whole',
          'Use lowest effective dose for shortest duration',
          'Do not stop suddenly - taper required',
        ],
      },
    },

    adverseEffects: [
      {
        name: 'Sedation/drowsiness',
        frequency: 'very-common',
        severity: 'moderate',
        mechanism: 'CNS depression',
        management: 'Use lowest effective dose; avoid driving',
        reversible: true,
        onsetTiming: 'With each dose',
      },
      {
        name: 'Cognitive impairment',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'CNS depression; GABA effects on memory',
        management: 'May improve with tolerance; avoid in elderly',
        reversible: true,
        onsetTiming: 'During treatment',
      },
      {
        name: 'Physical dependence',
        frequency: 'very-common',
        severity: 'severe',
        mechanism: 'Neuroadaptation to enhanced GABA',
        management: 'Taper slowly; develops even at therapeutic doses',
        reversible: true,
        onsetTiming: 'Weeks of regular use',
      },
      {
        name: 'Withdrawal syndrome',
        frequency: 'very-common',
        severity: 'severe',
        mechanism: 'CNS hyperexcitability after neuroadaptation',
        management: 'Never stop suddenly; taper over weeks-months',
        reversible: true,
        onsetTiming: 'Within hours-days of stopping',
      },
      {
        name: 'Rebound anxiety',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Interdose withdrawal with short half-life',
        management: 'More frequent dosing or switch to longer-acting BZD',
        reversible: true,
        onsetTiming: 'Between doses',
      },
      {
        name: 'Falls (elderly)',
        frequency: 'common',
        severity: 'moderate',
        mechanism: 'Sedation, ataxia, cognitive impairment',
        management: 'Avoid in elderly if possible',
        reversible: true,
        onsetTiming: 'During treatment',
      },
    ],

    interactions: [
      {
        interactingDrug: 'Opioids',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS and respiratory depression',
        effect: 'Profound sedation, respiratory depression, death',
        management: 'FDA black box - avoid combination',
      },
      {
        interactingDrug: 'Alcohol',
        interactionType: 'pharmacodynamic',
        severity: 'major',
        mechanism: 'Additive CNS depression',
        effect: 'Respiratory depression, overdose death',
        management: 'Avoid alcohol completely',
      },
      {
        interactingDrug: 'CYP3A4 inhibitors (ketoconazole, itraconazole)',
        interactionType: 'pharmacokinetic',
        severity: 'major',
        mechanism: 'Increased alprazolam levels',
        effect: 'Excessive sedation',
        management: 'Reduce alprazolam dose 50%; avoid strong inhibitors',
      },
      {
        interactingDrug: 'CYP3A4 inducers (carbamazepine)',
        interactionType: 'pharmacokinetic',
        severity: 'moderate',
        mechanism: 'Decreased alprazolam levels',
        effect: 'Reduced efficacy; possible withdrawal',
        management: 'May need dose increase; monitor',
      },
    ],

    contraindications: [
      {
        condition: 'Acute narrow-angle glaucoma',
        type: 'absolute',
        reason: 'May precipitate acute attack',
      },
      {
        condition: 'Concurrent ketoconazole or itraconazole',
        type: 'absolute',
        reason: 'Dangerous increase in levels',
      },
      {
        condition: 'Severe respiratory insufficiency',
        type: 'relative',
        reason: 'Respiratory depression risk',
      },
    ],

    specialPopulations: [
      {
        population: 'pregnancy',
        consideration: 'Possible teratogenicity; neonatal withdrawal syndrome',
        recommendation: 'Avoid; if used chronically, taper before delivery',
        pregnancyCategory: 'D',
      },
      {
        population: 'breastfeeding',
        consideration: 'Excreted in breast milk; sedation in infant',
        recommendation: 'Avoid; if single dose, wait 8 hours before breastfeeding',
      },
      {
        population: 'geriatric',
        consideration: 'Beers Criteria - inappropriate due to fall/fracture risk, cognitive impairment',
        recommendation: 'Avoid if possible; if needed, use lowest dose for shortest time',
      },
      {
        population: 'hepatic-impairment',
        consideration: 'Reduced clearance',
        recommendation: 'Start with lower doses; titrate cautiously',
      },
    ],

    monitoring: [
      {
        parameter: 'Efficacy/anxiety symptoms',
        frequency: 'Each visit',
        rationale: 'Assess need for continued use',
        actionThreshold: 'Transition to SSRI if long-term needed',
      },
      {
        parameter: 'Signs of dependence/misuse',
        frequency: 'Each visit',
        rationale: 'High abuse potential',
        actionThreshold: 'Escalating doses, drug-seeking - reassess',
      },
      {
        parameter: 'Cognitive function (elderly)',
        frequency: 'Periodic',
        rationale: 'Cognitive impairment risk',
        actionThreshold: 'Any decline - consider discontinuation',
      },
    ],

    patientEducation: [
      'Do not stop suddenly - can cause dangerous withdrawal',
      'Avoid alcohol completely',
      'Do not drive or operate machinery until you know how it affects you',
      'Do not take with opioid medications',
      'This medication can be habit-forming',
      'Inform doctor of all other medications',
      'Keep medication secure - commonly misused',
    ],

    clinicalPearls: [
      'High potency + short half-life = highest abuse potential among benzodiazepines',
      'Interdose withdrawal ("clock-watching") common due to short half-life',
      'For long-term anxiety, SSRIs are preferred - alprazolam for acute/bridging',
      'Withdrawal can include seizures - never stop abruptly',
      'Beers Criteria lists as potentially inappropriate for elderly',
      'Schedule IV controlled substance but DEA monitoring shows high diversion',
      'Taper over weeks to months - 10-25% reduction per week typical',
    ],
  },

  // ============================================
  // Cardiovascular: Calcium Channel Blockers & Cardiac Glycosides
  // ============================================

  {
    id: 'diltiazem',
    genericName: 'Diltiazem',
    brandNames: ['Cardizem', 'Tiazac', 'Dilacor', 'Cartia XT'],
    drugClass: 'Calcium Channel Blocker (Non-dihydropyridine)',
    category: 'cardiovascular',

    overview: 'Diltiazem is a non-dihydropyridine calcium channel blocker used for rate control in atrial fibrillation, SVT termination, hypertension, and angina. Unlike dihydropyridines (amlodipine), it has significant effects on the heart in addition to blood vessels, making it useful for arrhythmias but requiring caution with heart failure.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'L-type calcium channels',
      targetLocation: 'Cardiac muscle (SA node, AV node, myocardium), vascular smooth muscle',

      simpleExplanation: 'Diltiazem blocks calcium from entering heart and blood vessel cells. This slows the heart rate, slows electrical conduction through the heart, and relaxes blood vessels.',

      detailedMechanism: 'Diltiazem blocks voltage-gated L-type calcium channels in both cardiac tissue and vascular smooth muscle. In the heart, this reduces SA node automaticity, slows AV nodal conduction (prolonging PR interval), and mildly decreases contractility. In blood vessels, it causes arterial vasodilation. The balance of cardiac and vascular effects distinguishes it from dihydropyridines.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed after oral administration', result: 'Drug enters systemic circulation', timeframe: '2-4 hours to peak' },
        { order: 2, location: 'SA node', action: 'Blocks L-type Ca2+ channels in pacemaker cells', result: 'Reduced automaticity, heart rate slows' },
        { order: 3, location: 'AV node', action: 'Blocks L-type Ca2+ channels', result: 'Slowed conduction, prolonged refractory period' },
        { order: 4, location: 'Myocardium', action: 'Reduced calcium influx during action potential', result: 'Mild negative inotropy' },
        { order: 5, location: 'Arteriolar smooth muscle', action: 'Blocks Ca2+ entry needed for contraction', result: 'Vasodilation, reduced blood pressure' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Heart rate reduction', mechanism: 'SA node suppression', clinicalRelevance: 'Rate control in AF/flutter', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'AV conduction slowing', mechanism: 'AV nodal Ca2+ channel blockade', clinicalRelevance: 'Terminates SVT, controls ventricular rate', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Blood pressure reduction', mechanism: 'Arterial vasodilation', clinicalRelevance: 'Treats hypertension', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Coronary vasodilation', mechanism: 'Smooth muscle relaxation', clinicalRelevance: 'Anti-anginal effect', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Negative inotropy', mechanism: 'Reduced myocardial calcium entry', clinicalRelevance: 'Caution in HFrEF', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'IV: 2-5 minutes; Oral: 30-60 minutes',
      durationOfEffect: 'IR: 6-8 hours; ER: 12-24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '40% (first-pass metabolism)',
        route: ['oral', 'intravenous'],
        factors: ['First-pass hepatic metabolism limits bioavailability'],
        timeToePeak: '2-4 hours (IR), 6-14 hours (ER)',
        foodEffect: 'Take with food; ER should not be crushed',
      },
      distribution: {
        volumeOfDistribution: '3-8 L/kg',
        proteinBinding: '70-80%',
        tissueDistribution: ['Heart', 'Vascular smooth muscle', 'Liver'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: ['Desacetyldiltiazem (25-50% activity)'],
        geneticVariability: 'CYP3A4 inhibitors significantly increase levels',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Hepatic metabolism then renal/fecal excretion',
        renalClearance: '35% of metabolites',
        biliaryClearance: '65% of metabolites',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '3.5-6 hours (IR), 5-8 hours (ER)',
      timeToSteadyState: '2-3 days',
    },

    indications: [
      { condition: 'Atrial fibrillation/flutter (rate control)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'First-line for acute and chronic rate control' },
      { condition: 'Supraventricular tachycardia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV diltiazem terminates AVNRT' },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Extended-release formulations' },
      { condition: 'Chronic stable angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Reduces myocardial O2 demand and coronary vasodilation' },
      { condition: 'Variant (Prinzmetal) angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Effective for coronary vasospasm' },
    ],

    dosing: {
      usualDose: { amount: '120-360 mg/day', frequency: 'Once daily (ER) or 3-4 times daily (IR)', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Start at 50% of usual dose', rationale: 'Increased bioavailability and half-life' },
        { condition: 'Elderly', adjustment: 'Start at lower doses', rationale: 'Increased sensitivity to bradycardia' },
        { condition: 'Acute AF (IV)', adjustment: '0.25 mg/kg bolus, may repeat 0.35 mg/kg', rationale: 'Rapid rate control needed' },
      ],
      maxDose: '540 mg/day (ER)',
      administration: { route: 'Oral or IV', withFood: 'with-food', timing: 'ER once daily, IR with meals', specialInstructions: ['Do not crush ER tablets', 'IV bolus over 2 minutes'] },
    },

    adverseEffects: [
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'SA and AV nodal suppression', management: 'Monitor HR; reduce dose if symptomatic', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Peripheral edema', frequency: 'common', severity: 'mild', mechanism: 'Arterial vasodilation with venous pooling', management: 'Not responsive to diuretics; may need dose reduction', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'GI smooth muscle relaxation', management: 'Fiber, stool softeners', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'AV block', frequency: 'uncommon', severity: 'severe', mechanism: 'Excessive AV nodal conduction depression', management: 'Stop drug; atropine or pacing if needed', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Heart failure exacerbation', frequency: 'uncommon', severity: 'severe', mechanism: 'Negative inotropic effect', management: 'Avoid in decompensated HF', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Gingival hyperplasia', frequency: 'rare', severity: 'mild', mechanism: 'Altered collagen metabolism', management: 'Dental hygiene; consider alternative', reversible: true, onsetTiming: 'Months' },
    ],

    interactions: [
      { interactingDrug: 'Beta-blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive negative chronotropic and inotropic effects', effect: 'Profound bradycardia, AV block, heart failure', management: 'Use with extreme caution; avoid in conduction disease' },
      { interactingDrug: 'Simvastatin/Lovastatin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Diltiazem inhibits CYP3A4', effect: 'Increased statin levels - myopathy/rhabdomyolysis risk', management: 'Limit simvastatin to 10 mg; use alternative statins' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced digoxin clearance', effect: 'Increased digoxin levels plus additive AV block', management: 'Reduce digoxin dose; monitor levels and HR' },
      { interactingDrug: 'Cyclosporine', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 inhibition', effect: 'Increased cyclosporine levels and nephrotoxicity', management: 'Reduce cyclosporine dose; monitor levels' },
    ],

    contraindications: [
      { condition: 'Sick sinus syndrome (without pacemaker)', type: 'absolute', reason: 'Risk of severe bradycardia and asystole' },
      { condition: 'Second or third-degree AV block (without pacemaker)', type: 'absolute', reason: 'Risk of complete heart block' },
      { condition: 'Hypotension (SBP < 90 mmHg)', type: 'absolute', reason: 'Worsening hemodynamic compromise' },
      { condition: 'Acute MI with pulmonary congestion', type: 'absolute', reason: 'Negative inotropy worsens failure' },
      { condition: 'Accessory pathway (WPW) with AF', type: 'absolute', reason: 'May accelerate conduction down bypass tract causing VF' },
      { condition: 'HFrEF', type: 'relative', reason: 'Negative inotropy may worsen heart failure' },
      { condition: 'Concurrent strong CYP3A4 inhibitors', type: 'relative', reason: 'Markedly increased diltiazem levels' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; crosses placenta', recommendation: 'Use only if benefit outweighs risk; nifedipine preferred for HTN', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Monitor infant for bradycardia; generally compatible' },
      { population: 'geriatric', consideration: 'Increased sensitivity; higher plasma levels', recommendation: 'Start low, titrate slowly; monitor for bradycardia' },
      { population: 'hepatic-impairment', consideration: 'Significantly increased bioavailability', recommendation: 'Start at 50% dose; titrate carefully' },
    ],

    monitoring: [
      { parameter: 'Heart rate', frequency: 'Baseline, during titration, periodically', rationale: 'Risk of bradycardia', actionThreshold: 'HR < 50 bpm - reduce/hold dose' },
      { parameter: 'Blood pressure', frequency: 'Regularly during titration', rationale: 'Hypotension risk', actionThreshold: 'SBP < 90 - hold dose' },
      { parameter: 'ECG (PR interval)', frequency: 'Baseline, with dose changes, if on beta-blocker', rationale: 'Risk of AV block', actionThreshold: 'PR > 240 ms or higher degree block - stop' },
      { parameter: 'LFTs', frequency: 'Baseline, periodically', rationale: 'Rare hepatotoxicity', actionThreshold: 'Significant elevation - consider discontinuation' },
    ],

    patientEducation: [
      'Take extended-release tablets whole - do not crush or chew',
      'Avoid grapefruit juice while taking this medication',
      'Rise slowly from sitting/lying to avoid dizziness',
      'Report slow heartbeat, dizziness, or fainting',
      'Ankle swelling may occur - report if worsening',
      'Do not stop abruptly - may worsen angina',
      'Tell doctor about all other medications - many interactions',
    ],

    clinicalPearls: [
      'Non-dihydropyridine CCB = significant cardiac effects (rate control)',
      'IV bolus very effective for acute AF rate control',
      'NEVER use with accessory pathway (WPW) - may cause VF',
      'Major CYP3A4 inhibitor - simvastatin max 10 mg',
      'Avoid combining with beta-blockers in conduction disease',
      'Different ER formulations are NOT interchangeable',
      'Relative contraindication in HFrEF due to negative inotropy',
    ],
  },

  {
    id: 'verapamil',
    genericName: 'Verapamil',
    brandNames: ['Calan', 'Verelan', 'Isoptin', 'Covera-HS'],
    drugClass: 'Calcium Channel Blocker (Non-dihydropyridine)',
    category: 'cardiovascular',

    overview: 'Verapamil is the most cardioselective non-dihydropyridine calcium channel blocker, with the strongest negative inotropic and chronotropic effects. It is highly effective for SVT and rate control but must be used cautiously due to significant effects on cardiac contractility and conduction.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'L-type calcium channels (highest cardiac affinity)',
      targetLocation: 'SA node, AV node, myocardium, vascular smooth muscle',

      simpleExplanation: 'Verapamil strongly blocks calcium channels in the heart, significantly slowing the heart rate and electrical conduction. It also relaxes blood vessels but has less vascular effect than diltiazem.',

      detailedMechanism: 'Verapamil is the most cardioselective non-DHP CCB, with highest affinity for cardiac L-type calcium channels. It causes marked negative chronotropy (SA node), dromotropy (AV node), and inotropy (myocardium). The strong AV nodal effects make it highly effective for arrhythmias but increase risk of heart block and heart failure.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed with extensive first-pass metabolism', result: 'Low bioavailability (20-35%)', timeframe: '1-2 hours to peak' },
        { order: 2, location: 'SA node', action: 'Strong blockade of pacemaker Ca2+ channels', result: 'Marked heart rate reduction' },
        { order: 3, location: 'AV node', action: 'Potent Ca2+ channel blockade', result: 'Significantly prolonged AV conduction' },
        { order: 4, location: 'Myocardium', action: 'Reduced calcium entry during contraction', result: 'Significant negative inotropy' },
        { order: 5, location: 'Arterial smooth muscle', action: 'Ca2+ channel blockade (less than cardiac)', result: 'Vasodilation, BP reduction' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Marked heart rate reduction', mechanism: 'Strong SA node suppression', clinicalRelevance: 'Very effective for SVT', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Prolonged AV conduction', mechanism: 'Potent AV nodal blockade', clinicalRelevance: 'Terminates and prevents AVNRT', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Significant negative inotropy', mechanism: 'Myocardial Ca2+ channel blockade', clinicalRelevance: 'Contraindicated in HFrEF', desiredOrAdverse: 'adverse' },
        { system: 'GI', effect: 'Constipation', mechanism: 'Smooth muscle relaxation in GI tract', clinicalRelevance: 'Most common among CCBs with verapamil', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'IV: 1-5 minutes; Oral: 1-2 hours',
      durationOfEffect: '6-8 hours (IR), 24 hours (ER)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '20-35% (extensive first-pass metabolism)',
        route: ['oral', 'intravenous'],
        factors: ['Extensive first-pass hepatic metabolism'],
        timeToePeak: '1-2 hours (IR), 7-9 hours (ER)',
        foodEffect: 'Food decreases rate but not extent',
      },
      distribution: {
        volumeOfDistribution: '3-5 L/kg',
        proteinBinding: '90%',
        tissueDistribution: ['Heart', 'Liver', 'Vascular tissue'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4, CYP1A2, CYP2C)',
        enzymes: ['CYP3A4', 'CYP1A2', 'CYP2C'],
        activeMetabolites: ['Norverapamil (20% activity)'],
        geneticVariability: 'CYP3A4 inhibitors increase levels significantly',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Hepatic metabolism',
        renalClearance: '70% as metabolites',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '6-8 hours (single dose), 12 hours (chronic)',
      timeToSteadyState: '3-4 days',
    },

    indications: [
      { condition: 'Supraventricular tachycardia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV verapamil very effective for AVNRT/AVRT' },
      { condition: 'Atrial fibrillation/flutter (rate control)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'More potent AV blocking than diltiazem' },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Extended-release formulations' },
      { condition: 'Angina pectoris', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Stable and variant angina' },
      { condition: 'Hypertrophic cardiomyopathy', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Improves diastolic function in obstructive HCM' },
      { condition: 'Migraine prophylaxis', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Some evidence for prevention' },
    ],

    dosing: {
      usualDose: { amount: '180-480 mg/day', frequency: 'Once daily (ER) or 3-4 times daily (IR)', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Use 20-50% of normal dose', rationale: 'Markedly reduced clearance' },
        { condition: 'Elderly', adjustment: 'Start at lower doses', rationale: 'Increased sensitivity' },
        { condition: 'SVT (IV)', adjustment: '5-10 mg over 2 min, may repeat 10 mg in 30 min', rationale: 'Acute arrhythmia termination' },
      ],
      maxDose: '480 mg/day',
      administration: { route: 'Oral or IV', withFood: 'either', timing: 'Consistent timing daily', specialInstructions: ['Do not crush ER tablets', 'IV bolus over 2 minutes', 'Never give IV with beta-blocker'] },
    },

    adverseEffects: [
      { name: 'Constipation', frequency: 'very-common', severity: 'mild', mechanism: 'GI smooth muscle inhibition - hallmark of verapamil', management: 'Fiber, fluids, stool softeners; may need stimulant laxatives', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'SA node suppression', management: 'Dose reduction; discontinue if symptomatic', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Vasodilation and negative inotropy', management: 'Dose reduction; rise slowly', reversible: true, onsetTiming: 'Hours' },
      { name: 'Heart failure exacerbation', frequency: 'uncommon', severity: 'severe', mechanism: 'Significant negative inotropic effect', management: 'Avoid in HFrEF; extreme caution with any LV dysfunction', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'AV block', frequency: 'uncommon', severity: 'severe', mechanism: 'AV nodal conduction delay', management: 'Stop drug; temporary pacing may be needed', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Gingival hyperplasia', frequency: 'rare', severity: 'mild', mechanism: 'Altered collagen metabolism', management: 'Dental hygiene; switch if needed', reversible: true, onsetTiming: 'Months' },
    ],

    interactions: [
      { interactingDrug: 'Beta-blockers (especially IV)', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Severe additive negative chronotropic and inotropic effects', effect: 'Asystole, severe heart failure, cardiogenic shock', management: 'IV verapamil + IV beta-blocker contraindicated; oral combo very risky' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased digoxin clearance plus additive AV block', effect: 'Digoxin toxicity; complete heart block', management: 'Reduce digoxin dose by 50%; monitor levels and HR' },
      { interactingDrug: 'Simvastatin/Lovastatin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 inhibition', effect: 'Myopathy/rhabdomyolysis from increased statin levels', management: 'Do not exceed simvastatin 10 mg' },
      { interactingDrug: 'Dantrolene', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both affect intracellular calcium', effect: 'Hyperkalemia, cardiovascular collapse', management: 'Avoid combination' },
    ],

    contraindications: [
      { condition: 'Severe LV dysfunction/heart failure', type: 'absolute', reason: 'Significant negative inotropy worsens HF' },
      { condition: 'Cardiogenic shock', type: 'absolute', reason: 'Cannot tolerate negative inotropy' },
      { condition: 'Sick sinus syndrome (without pacemaker)', type: 'absolute', reason: 'Risk of severe bradycardia/asystole' },
      { condition: 'Second or third-degree AV block (without pacemaker)', type: 'absolute', reason: 'Risk of complete heart block' },
      { condition: 'Hypotension (SBP < 90)', type: 'absolute', reason: 'Will worsen hypotension' },
      { condition: 'AF with accessory pathway (WPW)', type: 'absolute', reason: 'May accelerate conduction down bypass tract' },
      { condition: 'Concurrent IV beta-blocker', type: 'absolute', reason: 'Cardiac arrest risk' },
      { condition: 'Wide-complex tachycardia', type: 'absolute', reason: 'May be VT and will deteriorate' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; may decrease uterine blood flow', recommendation: 'Use only if clearly needed; nifedipine preferred for HTN', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Generally compatible; monitor infant' },
      { population: 'geriatric', consideration: 'Increased plasma levels and sensitivity', recommendation: 'Lower starting doses; monitor closely' },
      { population: 'hepatic-impairment', consideration: 'Markedly reduced clearance', recommendation: 'Use 20-50% of usual dose' },
    ],

    monitoring: [
      { parameter: 'Heart rate and rhythm', frequency: 'Baseline, during titration, regularly', rationale: 'Risk of bradycardia and AV block', actionThreshold: 'HR < 50 or new AV block - hold/reduce' },
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Hypotension risk', actionThreshold: 'SBP < 90 - hold dose' },
      { parameter: 'ECG', frequency: 'Baseline, with dose changes, with symptoms', rationale: 'Monitor PR interval and rhythm', actionThreshold: 'Significant PR prolongation or block' },
      { parameter: 'Signs of heart failure', frequency: 'Each visit', rationale: 'Negative inotropic effects', actionThreshold: 'New or worsening symptoms - stop' },
    ],

    patientEducation: [
      'Take with food if stomach upset occurs',
      'Do not crush or chew extended-release tablets',
      'Constipation is common - increase fiber and fluids',
      'Avoid grapefruit juice',
      'Rise slowly to avoid dizziness',
      'Report dizziness, fainting, or very slow heartbeat',
      'Report shortness of breath or ankle swelling',
      'Never take with beta-blocker without doctor supervision',
    ],

    clinicalPearls: [
      'Most cardioselective non-DHP CCB - strongest negative inotropy',
      'Constipation is hallmark side effect - often dose-limiting',
      'NEVER give IV verapamil with IV beta-blocker - cardiac arrest risk',
      'Absolutely avoid in HFrEF - negative inotropy worsens failure',
      'Do NOT use for wide-complex tachycardia - may be VT',
      'Useful off-label in hypertrophic cardiomyopathy',
      'Half-life increases with chronic dosing (saturable metabolism)',
    ],
  },

  {
    id: 'digoxin',
    genericName: 'Digoxin',
    brandNames: ['Lanoxin', 'Digitek', 'Digox'],
    drugClass: 'Cardiac Glycoside',
    category: 'cardiovascular',

    overview: 'Digoxin is a cardiac glycoside with a very narrow therapeutic index, used for rate control in atrial fibrillation and as adjunctive therapy in HFrEF. It increases cardiac contractility while slowing AV conduction. Toxicity is common and potentially fatal - careful monitoring is essential.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Na+/K+-ATPase (cardiac myocytes)',
      targetLocation: 'Cardiac muscle cell membrane; AV node (via vagal enhancement)',

      simpleExplanation: 'Digoxin blocks a pump in heart cells that normally moves sodium and potassium. This leads to more calcium inside the cells, making the heart squeeze stronger. It also activates the vagus nerve to slow the heart rate.',

      detailedMechanism: 'Digoxin inhibits the Na+/K+-ATPase pump on cardiac myocytes, increasing intracellular sodium. This reduces the sodium gradient that drives the Na+/Ca2+ exchanger, resulting in increased intracellular calcium during systole (positive inotropy). Additionally, digoxin enhances vagal tone (parasympathomimetic effect), slowing SA node firing and AV nodal conduction. The narrow therapeutic index means toxicity and efficacy are separated by small changes in drug level.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Enters systemic circulation', timeframe: '1-3 hours to peak' },
        { order: 2, location: 'Cardiac myocyte membrane', action: 'Binds to and inhibits Na+/K+-ATPase', result: 'Intracellular Na+ increases' },
        { order: 3, location: 'Cardiac myocyte', action: 'Na+/Ca2+ exchanger function reduced', result: 'Intracellular Ca2+ increases' },
        { order: 4, location: 'Myofilaments', action: 'More Ca2+ available for contraction', result: 'Increased contractile force (positive inotropy)' },
        { order: 5, location: 'Vagal nuclei/AV node', action: 'Enhanced vagal (parasympathetic) tone', result: 'Slowed AV conduction and SA rate' },
      ],

      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Positive inotropy', mechanism: 'Increased intracellular calcium', clinicalRelevance: 'Improves cardiac output in HF', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Negative chronotropy', mechanism: 'Enhanced vagal tone to SA node', clinicalRelevance: 'Slows heart rate', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Negative dromotropy', mechanism: 'AV nodal conduction slowing', clinicalRelevance: 'Rate control in AF', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Arrhythmias (toxicity)', mechanism: 'Increased automaticity, triggered activity', clinicalRelevance: 'Narrow therapeutic index - toxicity common', desiredOrAdverse: 'adverse' },
        { system: 'GI', effect: 'Nausea/vomiting', mechanism: 'CTZ stimulation', clinicalRelevance: 'Early sign of toxicity', desiredOrAdverse: 'adverse' },
        { system: 'Visual', effect: 'Yellow-green halos', mechanism: 'Retinal toxicity', clinicalRelevance: 'Classic toxicity sign', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Oral: 1-2 hours; IV: 5-30 minutes; Full effect: 6-8 hours (distribution)',
      durationOfEffect: '3-4 days (long half-life)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '60-80% (tablets), 90-100% (elixir)',
        route: ['oral', 'intravenous'],
        factors: ['High-fiber meals may reduce absorption'],
        timeToePeak: '1-3 hours',
        foodEffect: 'High-fiber may reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '5-7 L/kg (very large - tissue binding)',
        proteinBinding: '25%',
        tissueDistribution: ['Heart', 'Kidney', 'Skeletal muscle'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        geneticVariability: 'Some gut flora inactivate digoxin',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (60-80% unchanged)',
        renalClearance: 'Proportional to creatinine clearance',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '36-48 hours (normal renal function)',
      timeToSteadyState: '5-7 days',
    },

    indications: [
      { condition: 'Atrial fibrillation (rate control)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Second-line after beta-blockers/CCBs; useful in HFrEF' },
      { condition: 'Heart failure with reduced EF (HFrEF)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Reduces hospitalizations but NOT mortality; add-on therapy' },
      { condition: 'Atrial flutter (rate control)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Less effective than in AF' },
    ],

    dosing: {
      usualDose: { amount: '0.125-0.25 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment (CrCl 10-50)', adjustment: 'Reduce dose by 25-75%', rationale: 'Renal excretion - reduced clearance' },
        { condition: 'Renal impairment (CrCl < 10)', adjustment: '0.0625-0.125 mg daily or every other day', rationale: 'Markedly reduced clearance' },
        { condition: 'Elderly', adjustment: 'Start 0.125 mg daily or less', rationale: 'Often have reduced renal function' },
        { condition: 'Low body weight', adjustment: 'Use lower doses', rationale: 'Vd is reduced' },
      ],
      maxDose: '0.5 mg/day (rarely needed)',
      administration: { route: 'Oral or IV', withFood: 'either', timing: 'Same time each day', specialInstructions: ['Draw levels at least 6 hours post-dose', 'Loading dose rarely needed nowadays'] },
    },

    adverseEffects: [
      { name: 'Nausea/vomiting/anorexia', frequency: 'common', severity: 'mild', mechanism: 'Chemoreceptor trigger zone stimulation', management: 'Check level - may be early toxicity sign', reversible: true, onsetTiming: 'Variable' },
      { name: 'Visual disturbances (yellow-green halos)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Retinal cone cell toxicity', management: 'Classic toxicity sign - check level, hold drug', reversible: true, onsetTiming: 'With toxicity' },
      { name: 'Cardiac arrhythmias (multiple types)', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Increased automaticity, triggered activity, conduction blocks', management: 'Stop drug; correct K+/Mg2+; Fab fragments if severe', reversible: true, onsetTiming: 'Variable' },
      { name: 'AV block', frequency: 'uncommon', severity: 'severe', mechanism: 'Excessive AV nodal suppression', management: 'Hold drug; atropine; pacing; Fab if severe', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Confusion/delirium', frequency: 'uncommon', severity: 'moderate', mechanism: 'CNS toxicity especially in elderly', management: 'Check level; dose reduction or discontinuation', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Amiodarone', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased digoxin clearance via P-glycoprotein inhibition', effect: 'Digoxin levels increase 70-100%', management: 'Reduce digoxin dose by 50% when starting amiodarone' },
      { interactingDrug: 'Verapamil/Diltiazem', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced digoxin clearance plus additive AV block', effect: 'Increased digoxin levels 50-75%', management: 'Reduce digoxin dose; monitor levels and HR' },
      { interactingDrug: 'Diuretics (loop, thiazide)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hypokalemia and hypomagnesemia from diuretics', effect: 'Increased digoxin toxicity at same level', management: 'Monitor and maintain normal K+ (4-5 mEq/L) and Mg2+' },
      { interactingDrug: 'Quinidine', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Displacement from tissues; reduced renal clearance', effect: 'Digoxin levels approximately double', management: 'Reduce digoxin dose by 50%' },
    ],

    contraindications: [
      { condition: 'Ventricular fibrillation', type: 'absolute', reason: 'No role in VF treatment' },
      { condition: 'Second or third-degree AV block (without pacemaker)', type: 'absolute', reason: 'May cause complete heart block' },
      { condition: 'Accessory pathway (WPW) with AF', type: 'absolute', reason: 'May accelerate conduction down bypass tract causing VF' },
      { condition: 'Hypokalemia (uncorrected)', type: 'relative', reason: 'Greatly increases toxicity risk - correct before starting', alternative: 'Correct K+ first' },
      { condition: 'Acute MI', type: 'relative', reason: 'Increased risk of arrhythmias' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; crosses placenta, fetal levels approach maternal', recommendation: 'Use if maternal benefit outweighs fetal risk', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk in low levels', recommendation: 'Generally compatible; amounts too small to affect infant' },
      { population: 'geriatric', consideration: 'Decreased renal clearance and lean body mass', recommendation: 'Use 0.125 mg daily or less; monitor levels closely' },
      { population: 'renal-impairment', consideration: 'Primary elimination route; half-life markedly prolonged', recommendation: 'Reduce dose proportionally to CrCl' },
      { population: 'pediatric', consideration: 'Higher doses per kg needed (larger Vd, faster clearance)', recommendation: 'Weight-based dosing; same therapeutic levels' },
    ],

    monitoring: [
      { parameter: 'Serum digoxin level', frequency: 'At steady state (5-7 days), with dose changes, suspected toxicity', rationale: 'Narrow therapeutic index', actionThreshold: 'Therapeutic: 0.5-1.0 ng/mL (HF), 0.8-2.0 ng/mL (AF); lower targets preferred' },
      { parameter: 'Serum potassium', frequency: 'Baseline, regularly (especially with diuretics)', rationale: 'Hypokalemia increases toxicity', actionThreshold: 'Maintain K+ 4.0-5.0 mEq/L' },
      { parameter: 'Serum magnesium', frequency: 'Baseline, periodically', rationale: 'Hypomagnesemia increases toxicity', actionThreshold: 'Maintain normal levels' },
      { parameter: 'Renal function', frequency: 'Baseline, periodically', rationale: 'Primary elimination route', actionThreshold: 'Adjust dose with declining function' },
      { parameter: 'Heart rate and rhythm', frequency: 'Each visit', rationale: 'Detect toxicity or excess effect', actionThreshold: 'New arrhythmias, bradycardia, AV block - check level' },
    ],

    patientEducation: [
      'Take at the same time each day',
      'Do not take double dose if missed',
      'Report nausea, vomiting, loss of appetite - may be toxicity',
      'Report any visual changes (blurring, yellow/green halos)',
      'Report very slow or irregular heartbeat',
      'Eat potassium-rich foods; maintain consistent intake',
      'Tell all healthcare providers you take digoxin',
      'Keep all appointments for blood tests',
    ],

    clinicalPearls: [
      'Very narrow therapeutic index - small margin between therapy and toxicity',
      'Draw level at least 6 hours post-dose (after distribution phase)',
      'Current target levels LOWER than historical: 0.5-1.0 ng/mL for HF',
      'DIG trial: reduces HF hospitalizations but NOT mortality',
      'Hypokalemia sensitizes heart to digoxin - toxicity at "normal" levels',
      'Classic toxicity triad: GI (N/V), visual (halos), cardiac (arrhythmias)',
      'Digoxin Immune Fab (Digibind) is antidote for severe toxicity',
      'Half-life 36-48 hours means steady state takes ~1 week',
    ],
  },

  // ============================================
  // Anticoagulants
  // ============================================

  {
    id: 'apixaban',
    genericName: 'Apixaban',
    brandNames: ['Eliquis'],
    drugClass: 'Direct Oral Anticoagulant (DOAC) - Factor Xa Inhibitor',
    category: 'hematologic',

    overview: 'Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, a key enzyme in the coagulation cascade. It is used for stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism. Among DOACs, it has favorable bleeding profiles and does not require routine monitoring.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Factor Xa',
      targetLocation: 'Coagulation cascade (common pathway)',

      simpleExplanation: 'Apixaban blocks factor Xa, an enzyme that helps form blood clots. By blocking this, it prevents harmful blood clots from forming while still allowing some clotting ability for wound healing.',

      detailedMechanism: 'Factor Xa converts prothrombin to thrombin in the coagulation cascade. By directly and reversibly inhibiting free and clot-bound factor Xa, apixaban prevents thrombin generation. One molecule of factor Xa catalyzes formation of ~1000 thrombin molecules, making Xa inhibition highly efficient. Unlike warfarin, it has predictable pharmacokinetics and does not require monitoring.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed from intestine', result: 'Reaches systemic circulation', timeframe: '3-4 hours to peak' },
        { order: 2, location: 'Blood/clot', action: 'Binds directly to factor Xa active site', result: 'Factor Xa catalytic activity blocked' },
        { order: 3, location: 'Coagulation cascade', action: 'Factor Xa cannot convert prothrombin to thrombin', result: 'Reduced thrombin generation' },
        { order: 4, location: 'Systemic', action: 'Less thrombin available for fibrin formation', result: 'Anticoagulant effect - clot prevention' },
      ],

      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Factor Xa inhibition', clinicalRelevance: 'Prevents stroke in AF, treats VTE', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Impaired clot formation', clinicalRelevance: 'Main adverse effect - lower than warfarin in trials', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '3-4 hours (peak anticoagulant effect)',
      durationOfEffect: '12 hours (BID dosing maintains effect)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '50% (not affected by food)',
        route: ['oral'],
        factors: ['Can be crushed and given via NG tube'],
        timeToePeak: '3-4 hours',
        foodEffect: 'No significant effect',
      },
      distribution: {
        volumeOfDistribution: '21 L',
        proteinBinding: '87%',
        tissueDistribution: ['Plasma', 'Tissues'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4, CYP3A5) - partial',
        enzymes: ['CYP3A4', 'CYP3A5'],
        activeMetabolites: [],
        geneticVariability: 'CYP3A4/P-gp inhibitors increase levels',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal 56%, Renal 27%',
        renalClearance: '27% of total clearance',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '12 hours',
      timeToSteadyState: '3 days',
    },

    indications: [
      { condition: 'Stroke prevention in atrial fibrillation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'ARISTOTLE trial: superior to warfarin for stroke prevention with less bleeding' },
      { condition: 'Treatment of DVT and PE', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'AMPLIFY: non-inferior to warfarin with less bleeding' },
      { condition: 'VTE prophylaxis after hip/knee replacement', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'ADVANCE trials' },
      { condition: 'Recurrent VTE prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'AMPLIFY-EXT' },
    ],

    dosing: {
      usualDose: { amount: '5 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'AF with 2+ of: age ≥80, weight ≤60 kg, Cr ≥1.5', adjustment: '2.5 mg BID', rationale: 'Reduced clearance in these populations' },
        { condition: 'VTE treatment', adjustment: '10 mg BID x 7 days, then 5 mg BID', rationale: 'Higher initial dose for acute treatment' },
        { condition: 'ESRD on dialysis', adjustment: '5 mg BID (or 2.5 mg if other criteria met)', rationale: 'Limited data; dialysis removes minimal drug' },
        { condition: 'Strong CYP3A4 + P-gp inhibitors', adjustment: '2.5 mg BID or avoid', rationale: 'Significantly increased levels' },
      ],
      maxDose: '10 mg BID (acute VTE treatment only)',
      administration: { route: 'Oral', withFood: 'either', timing: 'Consistent timing, BID', specialInstructions: ['Can crush and mix with water or applesauce', 'Can give via NG/G-tube'] },
    },

    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulant effect', management: 'Hold drug; consider andexanet alfa (Andexxa) for reversal', reversible: true, onsetTiming: 'Variable' },
      { name: 'Major bleeding', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Excessive anticoagulation', management: 'Discontinue; andexanet alfa, 4-factor PCC, supportive care', reversible: true, onsetTiming: 'Variable' },
      { name: 'GI upset', frequency: 'common', severity: 'mild', mechanism: 'Direct GI effect', management: 'Take with food if needed', reversible: true, onsetTiming: 'Early' },
    ],

    interactions: [
      { interactingDrug: 'Strong CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased apixaban levels', effect: 'Increased bleeding risk', management: 'Reduce dose or avoid combination' },
      { interactingDrug: 'Strong CYP3A4/P-gp inducers (rifampin, phenytoin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased apixaban levels', effect: 'Reduced efficacy - clot risk', management: 'Avoid combination' },
      { interactingDrug: 'Antiplatelet agents (aspirin, clopidogrel)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects on hemostasis', effect: 'Increased bleeding risk', management: 'Use lowest effective doses; monitor for bleeding' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Antiplatelet and GI effects of NSAIDs', effect: 'Increased bleeding, especially GI', management: 'Avoid chronic NSAID use' },
    ],

    contraindications: [
      { condition: 'Active pathological bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe hypersensitivity to apixaban', type: 'absolute', reason: 'Anaphylaxis risk' },
      { condition: 'Prosthetic heart valve', type: 'absolute', reason: 'Not studied; use warfarin', alternative: 'Warfarin' },
      { condition: 'Triple positive antiphospholipid syndrome', type: 'absolute', reason: 'Inferior to warfarin', alternative: 'Warfarin' },
      { condition: 'Moderate-severe hepatic impairment', type: 'relative', reason: 'Coagulopathy; altered metabolism' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data; likely crosses placenta', recommendation: 'Avoid - use LMWH if anticoagulation needed', pregnancyCategory: 'Not established' },
      { population: 'breastfeeding', consideration: 'Unknown excretion in breast milk', recommendation: 'Not recommended' },
      { population: 'geriatric', consideration: 'Dose reduction criteria include age ≥80', recommendation: 'Use standard dosing unless meets dose reduction criteria' },
      { population: 'renal-impairment', consideration: 'Only 27% renally cleared', recommendation: 'Dose adjust per criteria; usable even in ESRD on dialysis' },
      { population: 'hepatic-impairment', consideration: 'Coagulation factor production impaired', recommendation: 'Avoid in moderate-severe impairment (Child-Pugh B or C)' },
    ],

    monitoring: [
      { parameter: 'Signs/symptoms of bleeding', frequency: 'Ongoing', rationale: 'Primary adverse effect', actionThreshold: 'New bleeding - evaluate and consider holding' },
      { parameter: 'Renal function', frequency: 'Annually, or more often if unstable', rationale: 'Affects dosing', actionThreshold: 'Reassess dose if significant change' },
      { parameter: 'Hemoglobin/Hematocrit', frequency: 'As needed clinically', rationale: 'Detect occult bleeding', actionThreshold: 'Unexplained drop - evaluate for bleeding' },
    ],

    patientEducation: [
      'Take twice daily at the same times each day',
      'Do not stop taking without consulting your doctor - risk of stroke/clot',
      'Report any unusual bleeding (blood in urine/stool, nosebleeds, bruising)',
      'Tell all doctors and dentists you take a blood thinner',
      'Carry a card stating you take apixaban',
      'Avoid activities with high injury risk',
      'If you miss a dose, take it as soon as remembered; skip if <6 hours until next',
      'Reversal agent (andexanet alfa) exists for emergencies',
    ],

    clinicalPearls: [
      'ARISTOTLE: Superior to warfarin for stroke prevention with less major bleeding',
      'Only DOAC with dose reduction criteria based on clinical factors, not renal function alone',
      'Usable in ESRD on dialysis (unlike dabigatran)',
      'BID dosing - some patients prefer once-daily rivaroxaban',
      'Can crush tablets - useful for patients with dysphagia',
      'Andexanet alfa (Andexxa) is specific reversal agent',
      'No routine monitoring needed - big advantage over warfarin',
    ],
  },

  {
    id: 'rivaroxaban',
    genericName: 'Rivaroxaban',
    brandNames: ['Xarelto'],
    drugClass: 'Direct Oral Anticoagulant (DOAC) - Factor Xa Inhibitor',
    category: 'hematologic',

    overview: 'Rivaroxaban is a direct factor Xa inhibitor used for stroke prevention in atrial fibrillation, VTE treatment and prevention, and secondary prevention in coronary/peripheral artery disease. It offers once-daily dosing for most indications but has more GI bleeding than some alternatives.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Factor Xa',
      targetLocation: 'Coagulation cascade (common pathway)',

      simpleExplanation: 'Rivaroxaban directly blocks factor Xa, an essential enzyme for blood clotting. This prevents the formation of harmful clots while the effect is predictable and reversible.',

      detailedMechanism: 'Like apixaban, rivaroxaban directly inhibits factor Xa, preventing thrombin generation. It is highly selective for factor Xa with >10,000-fold selectivity over other serine proteases. Unlike warfarin, it has rapid onset/offset and predictable anticoagulation without routine monitoring.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed (bioavailability depends on dose and food)', result: 'Enters systemic circulation', timeframe: '2-4 hours to peak' },
        { order: 2, location: 'Blood', action: 'Binds directly to factor Xa', result: 'Factor Xa activity inhibited' },
        { order: 3, location: 'Coagulation cascade', action: 'Prothrombin cannot be converted to thrombin', result: 'Anticoagulation' },
      ],

      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Factor Xa inhibition', clinicalRelevance: 'Stroke/VTE prevention', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Impaired clotting', clinicalRelevance: 'Higher GI bleeding than apixaban', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '2-4 hours',
      durationOfEffect: '24 hours (once daily dosing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '80-100% with food (15-20 mg doses require food)',
        route: ['oral'],
        factors: ['Food required for full absorption at higher doses'],
        timeToePeak: '2-4 hours',
        foodEffect: 'MUST take 15-20 mg doses with food',
      },
      distribution: {
        volumeOfDistribution: '50 L',
        proteinBinding: '92-95%',
        tissueDistribution: ['Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4, CYP2J2)',
        enzymes: ['CYP3A4', 'CYP2J2'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal 36% (unchanged), fecal 28%',
        renalClearance: '36% of total',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '5-9 hours (young), 11-13 hours (elderly)',
      timeToSteadyState: '3 days',
    },

    indications: [
      { condition: 'Stroke prevention in atrial fibrillation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'ROCKET-AF: non-inferior to warfarin' },
      { condition: 'DVT/PE treatment', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'EINSTEIN trials' },
      { condition: 'VTE prophylaxis after hip/knee surgery', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Secondary CV prevention (CAD/PAD)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'COMPASS: 2.5 mg BID with aspirin reduces CV events' },
    ],

    dosing: {
      usualDose: { amount: '20 mg', frequency: 'Once daily', route: 'Oral (with dinner)' },
      adjustments: [
        { condition: 'AF with CrCl 15-50 mL/min', adjustment: '15 mg once daily with dinner', rationale: 'Reduced clearance' },
        { condition: 'AF with CrCl <15 mL/min', adjustment: 'Avoid (insufficient data)', rationale: 'Not studied in severe CKD' },
        { condition: 'VTE treatment (initial)', adjustment: '15 mg BID x 21 days, then 20 mg daily', rationale: 'Higher initial dosing for acute VTE' },
        { condition: 'CAD/PAD secondary prevention', adjustment: '2.5 mg BID with aspirin 100 mg', rationale: 'COMPASS regimen' },
      ],
      maxDose: '20 mg/day (VTE/AF); 30 mg/day (initial VTE)',
      administration: { route: 'Oral', withFood: 'with-food', timing: 'With largest meal (usually dinner)', specialInstructions: ['15-20 mg doses MUST be taken with food', 'Can crush and mix with applesauce'] },
    },

    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Hold; andexanet alfa for reversal', reversible: true, onsetTiming: 'Variable' },
      { name: 'GI bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Local GI effect plus anticoagulation', management: 'Higher than apixaban; consider PPI', reversible: true, onsetTiming: 'Variable' },
      { name: 'Major bleeding', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Excessive anticoagulation', management: 'Discontinue; reversal agent; supportive care', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Strong CYP3A4/P-gp inhibitors', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased rivaroxaban levels', effect: 'Increased bleeding', management: 'Avoid combination' },
      { interactingDrug: 'Strong CYP3A4/P-gp inducers', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased rivaroxaban levels', effect: 'Reduced efficacy', management: 'Avoid combination' },
      { interactingDrug: 'Antiplatelet agents', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive bleeding risk', effect: 'Increased bleeding', management: 'Minimize duration; use lowest doses' },
    ],

    contraindications: [
      { condition: 'Active bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe hepatic impairment (Child-Pugh C)', type: 'absolute', reason: 'Coagulopathy' },
      { condition: 'Prosthetic heart valves', type: 'absolute', reason: 'Not studied; use warfarin' },
      { condition: 'CrCl <15 (for AF indication)', type: 'relative', reason: 'Insufficient data' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta', recommendation: 'Avoid - use LMWH' },
      { population: 'geriatric', consideration: 'Longer half-life', recommendation: 'Use standard dosing; adjust for renal function' },
      { population: 'renal-impairment', consideration: '36% renal elimination', recommendation: 'Reduce dose if CrCl 15-50; avoid if <15' },
    ],

    monitoring: [
      { parameter: 'Signs of bleeding', frequency: 'Ongoing', rationale: 'Primary adverse effect', actionThreshold: 'New bleeding - evaluate' },
      { parameter: 'Renal function', frequency: 'Annually minimum', rationale: 'Determines dosing', actionThreshold: 'Dose adjust per CrCl' },
    ],

    patientEducation: [
      'Take with food (especially 15-20 mg doses)',
      'Take at the same time daily with your largest meal',
      'Do not stop without doctor approval - stroke risk',
      'Report unusual bleeding immediately',
      'Inform all providers you take rivaroxaban',
    ],

    clinicalPearls: [
      'Once-daily dosing preferred by some patients vs BID apixaban',
      'MUST take higher doses with food - absorption significantly reduced without',
      'More GI bleeding than apixaban in head-to-head comparison (limited data)',
      'COMPASS regimen (2.5 mg BID + ASA) for secondary CV prevention unique to rivaroxaban',
      'Andexanet alfa is reversal agent',
      'Avoid in severe renal impairment (unlike apixaban)',
    ],
  },

  {
    id: 'warfarin',
    genericName: 'Warfarin',
    brandNames: ['Coumadin', 'Jantoven'],
    drugClass: 'Vitamin K Antagonist',
    category: 'hematologic',

    overview: 'Warfarin is the oldest oral anticoagulant, working by inhibiting vitamin K-dependent clotting factor synthesis. It requires regular INR monitoring and has many drug/food interactions, but remains preferred for mechanical heart valves and antiphospholipid syndrome. Being replaced by DOACs for most other indications.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Vitamin K epoxide reductase (VKORC1)',
      targetLocation: 'Hepatocytes',

      simpleExplanation: 'Warfarin blocks vitamin K recycling in the liver. Vitamin K is needed to make several clotting factors, so blocking it reduces these factors and prevents clots.',

      detailedMechanism: 'Warfarin inhibits VKORC1, preventing reduction of vitamin K epoxide back to active vitamin K. Without active vitamin K, the liver cannot carboxylate factors II (prothrombin), VII, IX, and X, as well as proteins C and S. These factors are synthesized but non-functional. The anticoagulant effect depends on depletion of existing functional factors (half-lives: VII ~6h, IX ~24h, X ~36h, II ~72h).',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Near-complete absorption', result: 'Enters systemic circulation', timeframe: '1-3 hours' },
        { order: 2, location: 'Hepatocyte', action: 'Inhibits VKORC1', result: 'Vitamin K cannot be recycled' },
        { order: 3, location: 'Hepatocyte', action: 'Vitamin K-dependent factors not carboxylated', result: 'Non-functional factors II, VII, IX, X produced' },
        { order: 4, location: 'Blood', action: 'Existing functional factors depleted', result: 'Anticoagulation (takes days)', timeframe: '3-5 days for full effect' },
      ],

      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Reduced functional clotting factors', clinicalRelevance: 'Prevents stroke/VTE', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Impaired clotting', clinicalRelevance: 'Main adverse effect', desiredOrAdverse: 'adverse' },
        { system: 'Hematologic', effect: 'Skin necrosis (early)', mechanism: 'Protein C depleted faster than procoagulant factors', clinicalRelevance: 'Rare; bridge with heparin', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '3-5 days for full anticoagulant effect (requires factor depletion)',
      durationOfEffect: '2-5 days after stopping (depends on factor synthesis)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '>90%',
        route: ['oral', 'intravenous'],
        factors: ['Completely absorbed'],
        timeToePeak: '1-4 hours',
        foodEffect: 'High vitamin K foods antagonize effect',
      },
      distribution: {
        volumeOfDistribution: '0.14 L/kg (small - stays in plasma)',
        proteinBinding: '99% (albumin)',
        tissueDistribution: ['Plasma', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP2C9, CYP3A4, CYP1A2)',
        enzymes: ['CYP2C9 (primary)', 'CYP3A4', 'CYP1A2'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C9, VKORC1 polymorphisms significantly affect dosing',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (metabolites)',
        renalClearance: 'Metabolites excreted renally',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '20-60 hours (mean ~40 hours)',
      timeToSteadyState: '5-7 days',
    },

    indications: [
      { condition: 'Mechanical heart valve', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'DOACs contraindicated - warfarin remains standard' },
      { condition: 'Stroke prevention in atrial fibrillation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'DOACs preferred unless valve disease or cost prohibitive' },
      { condition: 'VTE treatment/prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'DOACs preferred for most; warfarin for severe renal impairment' },
      { condition: 'Antiphospholipid syndrome', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true, notes: 'DOACs inferior in APS - use warfarin' },
    ],

    dosing: {
      usualDose: { amount: 'Variable (typically 2-10 mg)', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Initial dosing', adjustment: 'Start 5 mg daily (or 2.5-7.5 mg based on age, weight, genetics)', rationale: 'Individualized based on patient factors' },
        { condition: 'CYP2C9/VKORC1 variants', adjustment: 'Use pharmacogenomic dosing if available', rationale: 'Genetic variants significantly affect dose requirements' },
        { condition: 'Elderly/malnourished', adjustment: 'Start lower (2.5-5 mg)', rationale: 'Increased sensitivity' },
        { condition: 'Target INR', adjustment: 'Adjust to achieve goal INR 2-3 (or 2.5-3.5 for mechanical mitral valve)', rationale: 'INR-based dosing' },
      ],
      maxDose: 'No fixed max - guided by INR',
      administration: { route: 'Oral', withFood: 'either', timing: 'Same time daily; evening preferred', specialInstructions: ['Monitor INR regularly', 'Maintain consistent vitamin K intake'] },
    },

    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Hold drug; vitamin K for reversal; FFP/PCC for severe', reversible: true, onsetTiming: 'Variable' },
      { name: 'Major/life-threatening bleeding', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Excessive anticoagulation', management: 'Stop drug; vitamin K 10 mg IV; 4-factor PCC', reversible: true, onsetTiming: 'Variable' },
      { name: 'Skin necrosis', frequency: 'rare', severity: 'severe', mechanism: 'Protein C depletion before other factors (hypercoagulable state)', management: 'Stop warfarin; heparin; may need skin grafts', reversible: false, onsetTiming: 'Days 3-8 of initiation' },
      { name: 'Purple toe syndrome', frequency: 'rare', severity: 'moderate', mechanism: 'Cholesterol embolization', management: 'Stop warfarin', reversible: true, onsetTiming: 'Weeks after starting' },
    ],

    interactions: [
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Antiplatelet effect plus GI erosion', effect: 'Markedly increased bleeding', management: 'Avoid or use with extreme caution; add PPI' },
      { interactingDrug: 'Amiodarone', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP2C9 inhibition', effect: 'INR increases 30-50%', management: 'Reduce warfarin dose 30-50%; monitor closely' },
      { interactingDrug: 'Rifampin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP induction', effect: 'INR drops dramatically', management: 'Avoid if possible; need much higher warfarin doses' },
      { interactingDrug: 'Antibiotics', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Variable - altered gut flora, CYP effects', effect: 'Unpredictable INR changes', management: 'Monitor INR more frequently during antibiotic use' },
      { interactingDrug: 'Vitamin K (diet)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Vitamin K opposes warfarin effect', effect: 'INR decreases', management: 'Maintain consistent vitamin K intake' },
    ],

    contraindications: [
      { condition: 'Pregnancy (especially first trimester)', type: 'absolute', reason: 'Teratogenic - warfarin embryopathy', alternative: 'LMWH' },
      { condition: 'Active bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe hepatic disease', type: 'relative', reason: 'Already coagulopathic' },
      { condition: 'Uncontrolled hypertension', type: 'relative', reason: 'Increased bleeding risk' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Teratogenic - causes warfarin embryopathy', recommendation: 'CONTRAINDICATED especially first trimester; use LMWH', pregnancyCategory: 'X' },
      { population: 'breastfeeding', consideration: 'Minimal excretion in breast milk', recommendation: 'Compatible with breastfeeding' },
      { population: 'geriatric', consideration: 'Increased sensitivity', recommendation: 'Start lower doses; more frequent INR monitoring' },
      { population: 'hepatic-impairment', consideration: 'Already reduced clotting factor synthesis', recommendation: 'Use with caution; may need lower doses; INR less reliable' },
    ],

    monitoring: [
      { parameter: 'INR', frequency: 'Daily during initiation, weekly until stable, monthly when stable', rationale: 'Warfarin requires INR monitoring for safe use', actionThreshold: 'Goal INR 2-3 (or 2.5-3.5 for mechanical valves)' },
      { parameter: 'Signs of bleeding', frequency: 'Ongoing', rationale: 'Primary adverse effect', actionThreshold: 'New bleeding - check INR, evaluate' },
      { parameter: 'Drug interactions', frequency: 'Each visit/med change', rationale: 'Numerous interactions affect INR', actionThreshold: 'New med - increase INR monitoring' },
    ],

    patientEducation: [
      'Take at the same time daily (evening preferred)',
      'Regular INR blood tests are essential - never skip',
      'Keep vitamin K intake consistent (green leafy vegetables)',
      'Avoid alcohol or drink only in moderation',
      'Many medications interact - always check before starting new drugs',
      'Carry an anticoagulant card',
      'Report bleeding, bruising, blood in urine/stool immediately',
      'Use a soft toothbrush; avoid contact sports',
    ],

    clinicalPearls: [
      'Still preferred for mechanical heart valves - DOACs are contraindicated',
      'Still preferred for antiphospholipid syndrome - DOACs are inferior',
      'Takes 3-5 days for full effect - bridge with heparin if immediate anticoagulation needed',
      'Reversal: Vitamin K (slow), FFP (volume issues), 4-factor PCC (preferred)',
      'CYP2C9/VKORC1 pharmacogenomics can guide initial dosing',
      'INR goal 2-3 for most indications; 2.5-3.5 for mechanical mitral valve',
      'Teratogenic - absolutely avoid in pregnancy (warfarin embryopathy)',
      'Most drug interactions of any anticoagulant',
    ],
  },

  // ============================================
  // Endocrine Medications
  // ============================================

  {
    id: 'levothyroxine',
    genericName: 'Levothyroxine',
    brandNames: ['Synthroid', 'Levoxyl', 'Unithroid', 'Tirosint'],
    drugClass: 'Thyroid hormone',
    category: 'endocrine',

    overview: 'Levothyroxine is synthetic thyroid hormone (T4) used to replace deficient thyroid hormone in hypothyroidism. It is the most commonly prescribed medication for thyroid disorders and one of the most prescribed drugs overall.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Thyroid hormone receptors (nuclear)',
      targetLocation: 'Intracellular (nucleus of target cells)',

      simpleExplanation: 'Levothyroxine is identical to the T4 hormone your thyroid normally makes. When you take it, your body converts some to T3, and both hormones enter cells to turn on genes that control metabolism, energy, and growth.',

      detailedMechanism: 'Levothyroxine (T4) is a prohormone that is converted to triiodothyronine (T3) by deiodinase enzymes (primarily D1 and D2) in peripheral tissues. T3 (and to a lesser extent T4) enters cells, binds to nuclear thyroid hormone receptors (TRα and TRβ), which form heterodimers with retinoid X receptors. This complex binds to thyroid response elements (TREs) on DNA, recruiting coactivators and activating transcription of thyroid hormone-responsive genes that regulate metabolic rate, protein synthesis, and development.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorption (40-80%, requires fasting)', result: 'T4 enters circulation', timeframe: '30-60 minutes to peak' },
        { order: 2, location: 'Peripheral tissues', action: 'Deiodinases convert T4 to T3', result: 'Active hormone produced' },
        { order: 3, location: 'Target cells', action: 'T3/T4 enter cells via transporters', result: 'Hormones reach nucleus' },
        { order: 4, location: 'Nucleus', action: 'Bind thyroid hormone receptors', result: 'Gene transcription activated' },
        { order: 5, location: 'Cells', action: 'Increased protein synthesis, metabolic enzymes', result: 'Restoration of normal metabolism' },
      ],

      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Increased basal metabolic rate', mechanism: 'Enhanced mitochondrial activity and Na/K-ATPase', clinicalRelevance: 'Corrects hypothyroid symptoms', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Increased heart rate and contractility', mechanism: 'Increased cardiac β-receptor expression', clinicalRelevance: 'Risk of cardiac effects if overreplaced', desiredOrAdverse: 'both' },
        { system: 'Neurological', effect: 'Improved cognition and mood', mechanism: 'Critical for brain function', clinicalRelevance: 'Resolves brain fog of hypothyroidism', desiredOrAdverse: 'desired' },
        { system: 'Skeletal', effect: 'Bone turnover', mechanism: 'Increased osteoclast activity', clinicalRelevance: 'Overtreatment increases fracture risk', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Days to weeks (T4 half-life 7 days; full effect at steady state)',
      durationOfEffect: 'Effects persist for weeks after stopping',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '40-80% (highly variable; better when fasting)',
        route: ['oral'],
        factors: ['Empty stomach critical', 'Coffee/fiber/calcium/iron reduce absorption'],
        timeToePeak: '2-4 hours',
        foodEffect: 'Food reduces absorption 40-80%; take 30-60 min before breakfast',
      },
      distribution: {
        volumeOfDistribution: '~10 L (low - highly protein bound)',
        proteinBinding: '>99% (TBG, albumin, transthyretin)',
        tissueDistribution: ['All tissues', 'Higher in liver, kidney'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Peripheral tissues (deiodination)',
        enzymes: ['Deiodinase D1', 'Deiodinase D2', 'Deiodinase D3'],
        activeMetabolites: ['T3 (triiodothyronine)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Hepatic (biliary)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '6-7 days',
      timeToSteadyState: '4-6 weeks',
    },

    indications: [
      { condition: 'Primary hypothyroidism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Secondary hypothyroidism (pituitary)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'TSH suppression (thyroid cancer)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Myxedema coma', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true, notes: 'IV formulation; often combined with T3' },
    ],

    dosing: {
      usualDose: { amount: '1.6 mcg/kg/day (typically 50-200 mcg)', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly or cardiac disease', adjustment: 'Start 12.5-25 mcg daily, increase slowly', rationale: 'Avoid precipitating cardiac events' },
        { condition: 'Severe hypothyroidism', adjustment: 'Start low despite high TSH', rationale: 'Rapid correction risks cardiac events' },
        { condition: 'Pregnancy', adjustment: 'Increase dose 25-50% early in pregnancy', rationale: 'Increased TBG and fetal requirements' },
      ],
      maxDose: 'No fixed max; guided by TSH (usually <300 mcg)',
      administration: { route: 'Oral', withFood: 'without-food', timing: '30-60 minutes before breakfast', specialInstructions: ['Take on empty stomach', 'Separate from calcium, iron, antacids by 4 hours'] },
    },

    adverseEffects: [
      { name: 'Symptoms of hyperthyroidism (if overdosed)', frequency: 'common', severity: 'moderate', mechanism: 'Excess thyroid hormone', management: 'Reduce dose based on TSH', reversible: true, onsetTiming: 'Weeks after dose increase' },
      { name: 'Palpitations/tachycardia', frequency: 'common', severity: 'mild', mechanism: 'Increased cardiac sensitivity', management: 'Check TSH; reduce dose', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Weight loss', frequency: 'common', severity: 'mild', mechanism: 'Increased metabolism', management: 'Generally desired effect', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Bone loss (with long-term overtreatment)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Increased bone turnover', management: 'Maintain TSH in target range', reversible: false, onsetTiming: 'Years' },
      { name: 'Angina/MI (if underlying CAD)', frequency: 'rare', severity: 'severe', mechanism: 'Increased cardiac demand', management: 'Start very low dose in cardiac patients', reversible: false, onsetTiming: 'Days to weeks after starting' },
    ],

    interactions: [
      { interactingDrug: 'Calcium supplements', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Forms insoluble complexes in gut', effect: 'Reduced levothyroxine absorption', management: 'Separate by at least 4 hours' },
      { interactingDrug: 'Iron supplements', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Forms insoluble complexes', effect: 'Reduced absorption', management: 'Separate by at least 4 hours' },
      { interactingDrug: 'Proton pump inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Altered gastric pH', effect: 'May reduce absorption', management: 'Monitor TSH; may need dose increase' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Thyroid hormone increases vitamin K-dependent factor catabolism', effect: 'Increased anticoagulant effect', management: 'Monitor INR when adjusting levothyroxine' },
    ],

    contraindications: [
      { condition: 'Uncorrected adrenal insufficiency', type: 'absolute', reason: 'Thyroid hormone increases cortisol metabolism; can precipitate adrenal crisis', alternative: 'Treat adrenal insufficiency first' },
      { condition: 'Acute myocardial infarction', type: 'relative', reason: 'Increased cardiac demand', alternative: 'Start only if severe hypothyroidism contributing' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Increased requirements due to increased TBG', recommendation: 'Increase dose 25-50% early; monitor TSH monthly', pregnancyCategory: 'A' },
      { population: 'breastfeeding', consideration: 'Minimal excretion in breast milk', recommendation: 'Safe - continue replacement' },
      { population: 'geriatric', consideration: 'Increased sensitivity; cardiac risk', recommendation: 'Start low (12.5-25 mcg), increase slowly' },
    ],

    monitoring: [
      { parameter: 'TSH', frequency: 'Every 6-8 weeks until stable, then annually', rationale: 'Primary marker for dose adequacy', actionThreshold: 'Adjust dose if outside 0.4-4.0 mIU/L (or target range)' },
      { parameter: 'Free T4', frequency: 'With TSH initially; when secondary hypothyroidism', rationale: 'TSH unreliable in pituitary disease', actionThreshold: 'Should be in upper half of normal' },
      { parameter: 'Heart rate/symptoms', frequency: 'Each visit', rationale: 'Detect over-replacement', actionThreshold: 'Persistent tachycardia or hyperthyroid symptoms' },
    ],

    patientEducation: [
      'Take on an empty stomach, 30-60 minutes before breakfast',
      'Take at the same time every day',
      'Separate from calcium, iron, antacids by at least 4 hours',
      'Do not switch brands without consulting your doctor',
      'It takes 4-6 weeks to see full effect of dose changes',
      'Report palpitations, chest pain, or hyperthyroid symptoms',
    ],

    clinicalPearls: [
      'Most patients need lifelong therapy - this is hormone replacement, not cure',
      'Full equilibration takes 6 weeks - wait before rechecking TSH after dose change',
      'Brand switching can cause fluctuations - try to maintain same brand',
      'In elderly/cardiac patients: "start low, go slow" - rapid correction is dangerous',
      'In pregnancy: increase dose early (week 4-6) - fetal brain development depends on maternal T4',
      'TSH alone is insufficient in secondary hypothyroidism - use free T4',
      'Absorption is highly variable - empty stomach is critical',
    ],
  },

  {
    id: 'insulin-glargine',
    genericName: 'Insulin glargine',
    brandNames: ['Lantus', 'Basaglar', 'Toujeo', 'Semglee'],
    drugClass: 'Long-acting insulin',
    category: 'endocrine',

    overview: 'Insulin glargine is a long-acting insulin analog providing basal insulin coverage for approximately 24 hours. It is a cornerstone of insulin therapy for type 1 and type 2 diabetes.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Insulin receptor (tyrosine kinase)',
      targetLocation: 'Cell surface of insulin-sensitive tissues',

      simpleExplanation: 'Insulin glargine is a modified insulin that works the same way as natural insulin but releases slowly from the injection site over 24 hours. It helps cells take up glucose from the blood and use it for energy or storage.',

      detailedMechanism: 'Insulin glargine binds to the insulin receptor, activating its tyrosine kinase domain. This triggers autophosphorylation and activation of downstream signaling cascades including PI3K-Akt (mediating glucose uptake via GLUT4 translocation, glycogen synthesis) and MAPK pathways (mediating growth effects). The glargine molecule has amino acid substitutions (A21 asparagine→glycine; B-chain extended by 2 arginines) that shift the isoelectric point to neutral pH, causing microprecipitation at physiological pH in subcutaneous tissue, resulting in slow, prolonged release.',

      mechanismSteps: [
        { order: 1, location: 'Subcutaneous tissue', action: 'Forms microprecipitates at neutral pH', result: 'Slow dissolution and absorption', timeframe: 'Over 24 hours' },
        { order: 2, location: 'Bloodstream', action: 'Insulin glargine circulates', result: 'Steady basal insulin level' },
        { order: 3, location: 'Target cell membrane', action: 'Binds insulin receptor α-subunit', result: 'Receptor conformational change' },
        { order: 4, location: 'Intracellular', action: 'Tyrosine kinase activation → PI3K-Akt signaling', result: 'GLUT4 translocation to membrane' },
        { order: 5, location: 'Cells', action: 'Glucose uptake and anabolic processes', result: 'Blood glucose lowered' },
      ],

      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Glucose uptake by muscle/adipose', mechanism: 'GLUT4 translocation', clinicalRelevance: 'Primary mechanism of glucose lowering', desiredOrAdverse: 'desired' },
        { system: 'Hepatic', effect: 'Suppresses gluconeogenesis', mechanism: 'Insulin signaling in liver', clinicalRelevance: 'Controls fasting glucose', desiredOrAdverse: 'desired' },
        { system: 'Adipose', effect: 'Inhibits lipolysis', mechanism: 'Suppresses hormone-sensitive lipase', clinicalRelevance: 'Reduces free fatty acids', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hypoglycemia', mechanism: 'Excessive glucose lowering', clinicalRelevance: 'Main adverse effect', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1-2 hours (gradual)',
      durationOfEffect: '~24 hours (peakless profile)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~60% (subcutaneous)',
        route: ['subcutaneous'],
        factors: ['Injection site', 'Exercise', 'Temperature'],
        timeToePeak: 'No pronounced peak (plateau over 24 hours)',
        foodEffect: 'Not applicable (injectable)',
      },
      distribution: {
        volumeOfDistribution: '~0.15 L/kg',
        proteinBinding: 'Minimal',
        tissueDistribution: ['All tissues with insulin receptors'],
        crossesBBB: false,
        crossesPlacenta: false,
      },
      metabolism: {
        primarySite: 'Proteolytic degradation in tissues',
        enzymes: ['Insulin-degrading enzyme'],
        activeMetabolites: ['M1 and M2 metabolites (active)'],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Metabolic degradation',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: 'Not applicable (effect is absorption-limited)',
      timeToSteadyState: '2-4 days',
    },

    indications: [
      { condition: 'Type 1 diabetes mellitus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Basal component of basal-bolus regimen' },
      { condition: 'Type 2 diabetes mellitus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'When basal insulin added to oral agents' },
    ],

    dosing: {
      usualDose: { amount: '10 units or 0.1-0.2 units/kg', frequency: 'Once daily', route: 'Subcutaneous', duration: 'Ongoing' },
      adjustments: [
        { condition: 'Type 1 diabetes', adjustment: 'Basal is typically 40-50% of total daily dose', rationale: 'Remainder is bolus insulin' },
        { condition: 'Renal impairment (eGFR <30)', adjustment: 'Reduce dose; increased hypoglycemia risk', rationale: 'Reduced insulin clearance' },
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose', rationale: 'Reduced gluconeogenesis capacity' },
        { condition: 'Elderly', adjustment: 'Start low, titrate carefully', rationale: 'Increased hypoglycemia risk' },
      ],
      maxDose: 'No fixed max - titrate to fasting glucose target',
      administration: { route: 'Subcutaneous', withFood: 'either', timing: 'Same time daily (bedtime or morning)', specialInstructions: ['Do not mix with other insulins', 'Rotate injection sites'] },
    },

    adverseEffects: [
      { name: 'Hypoglycemia', frequency: 'common', severity: 'moderate', mechanism: 'Excessive glucose lowering', management: 'Glucose tablets, adjust dose', reversible: true, onsetTiming: 'Variable' },
      { name: 'Weight gain', frequency: 'common', severity: 'mild', mechanism: 'Anabolic effects', management: 'Diet and exercise', reversible: true, onsetTiming: 'Months' },
      { name: 'Injection site reactions', frequency: 'common', severity: 'mild', mechanism: 'Local reaction', management: 'Rotate sites', reversible: true, onsetTiming: 'With injection' },
      { name: 'Lipohypertrophy', frequency: 'uncommon', severity: 'mild', mechanism: 'Repeated injection at same site', management: 'Rotate injection sites', reversible: false, onsetTiming: 'Months to years' },
    ],

    interactions: [
      { interactingDrug: 'Beta-blockers', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Mask hypoglycemic symptoms (except sweating)', effect: 'May not recognize hypoglycemia', management: 'Educate patient; monitor more closely' },
      { interactingDrug: 'Thiazolidinediones', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive glucose lowering; TZDs cause fluid retention', effect: 'Increased hypoglycemia; edema', management: 'Monitor; may need to reduce doses' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Alcohol inhibits gluconeogenesis', effect: 'Delayed hypoglycemia', management: 'Eat when drinking; monitor glucose' },
    ],

    contraindications: [
      { condition: 'Hypoglycemia', type: 'absolute', reason: 'Will worsen hypoglycemia' },
      { condition: 'Hypersensitivity to insulin glargine', type: 'absolute', reason: 'Risk of anaphylaxis' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Insulin is treatment of choice for diabetes in pregnancy', recommendation: 'Use when needed; adjust doses frequently', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Endogenous insulin normal in breast milk', recommendation: 'Safe' },
      { population: 'renal-impairment', consideration: 'Reduced insulin clearance', recommendation: 'Reduce dose; monitor closely' },
      { population: 'geriatric', consideration: 'Increased hypoglycemia risk', recommendation: 'Conservative targets; start low' },
    ],

    monitoring: [
      { parameter: 'Fasting blood glucose', frequency: 'Daily during titration; less often when stable', rationale: 'Guide dose adjustments', actionThreshold: 'Target typically 80-130 mg/dL' },
      { parameter: 'HbA1c', frequency: 'Every 3 months until at target, then every 6 months', rationale: 'Overall glycemic control', actionThreshold: 'Target <7% for most; individualize' },
      { parameter: 'Hypoglycemia frequency', frequency: 'Ongoing', rationale: 'Safety', actionThreshold: 'Recurrent hypoglycemia - reduce dose' },
    ],

    patientEducation: [
      'Inject at the same time every day',
      'Do not mix with other insulins in the same syringe',
      'Rotate injection sites to prevent lumps',
      'Know the signs of low blood sugar and always carry glucose tablets',
      'Do not skip meals if taking insulin',
      'Store unopened vials in refrigerator; once opened, can keep at room temperature for 28 days',
    ],

    clinicalPearls: [
      'Truly peakless profile - lower nocturnal hypoglycemia risk than NPH',
      'Clear solution - if cloudy, discard',
      'Cannot be mixed with other insulins - the low pH will alter other insulin',
      'Toujeo (U-300) is 3x concentrated - longer duration but may need higher dose',
      'Start with 10 units or 0.1-0.2 units/kg; titrate based on fasting glucose',
      'Typical titration: increase 2 units every 3 days until fasting glucose at target',
    ],
  },

  {
    id: 'prednisone',
    genericName: 'Prednisone',
    brandNames: ['Deltasone', 'Rayos', 'Prednisone Intensol'],
    drugClass: 'Glucocorticoid (corticosteroid)',
    category: 'endocrine',

    overview: 'Prednisone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects. It is widely used for numerous inflammatory and autoimmune conditions but carries significant risks with long-term use.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptor (nuclear)',
      targetLocation: 'Cytoplasm → Nucleus of target cells',

      simpleExplanation: 'Prednisone is converted in the liver to prednisolone, which then enters cells and binds to a receptor. This receptor-drug complex moves to the nucleus and turns off inflammatory genes while turning on anti-inflammatory genes, reducing inflammation throughout the body.',

      detailedMechanism: 'Prednisone is a prodrug that is hepatically converted to prednisolone by 11β-hydroxysteroid dehydrogenase. Prednisolone enters cells and binds the cytoplasmic glucocorticoid receptor (GR), causing heat shock protein dissociation. The drug-receptor complex translocates to the nucleus where it: 1) Binds glucocorticoid response elements (GREs) to induce anti-inflammatory proteins (lipocortin-1, IL-10), and 2) Trans-represses pro-inflammatory transcription factors (NF-κB, AP-1), suppressing cytokines (IL-1, IL-6, TNF-α), prostaglandins, and leukotrienes.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Prednisone absorbed', result: 'Enters portal circulation', timeframe: '1-2 hours' },
        { order: 2, location: 'Liver', action: '11β-HSD converts prednisone to prednisolone', result: 'Active metabolite formed' },
        { order: 3, location: 'Target cell cytoplasm', action: 'Prednisolone binds glucocorticoid receptor', result: 'HSP90 released; receptor activated' },
        { order: 4, location: 'Nucleus', action: 'GR-drug complex binds DNA (GREs) and transcription factors', result: 'Anti-inflammatory genes on; inflammatory genes off' },
        { order: 5, location: 'Systemically', action: 'Reduced cytokines, prostaglandins, leukocyte migration', result: 'Inflammation suppressed' },
      ],

      physiologicalEffects: [
        { system: 'Immune', effect: 'Immunosuppression', mechanism: 'Reduced T-cell activation, cytokines', clinicalRelevance: 'Treats autoimmune diseases', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hyperglycemia', mechanism: 'Gluconeogenesis; insulin resistance', clinicalRelevance: 'Can cause/worsen diabetes', desiredOrAdverse: 'adverse' },
        { system: 'Musculoskeletal', effect: 'Bone loss (osteoporosis)', mechanism: 'Osteoblast suppression; calcium absorption reduced', clinicalRelevance: 'Major long-term toxicity', desiredOrAdverse: 'adverse' },
        { system: 'Adrenal', effect: 'HPA axis suppression', mechanism: 'Negative feedback on ACTH', clinicalRelevance: 'Cannot stop abruptly after chronic use', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Fluid retention, hypertension', mechanism: 'Mineralocorticoid effects', clinicalRelevance: 'Monitor blood pressure', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours for anti-inflammatory effect; days for full immunosuppression',
      durationOfEffect: '12-36 hours (intermediate-acting)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~80%',
        route: ['oral'],
        factors: ['Well absorbed regardless of food'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Minimal',
      },
      distribution: {
        volumeOfDistribution: '0.5-1 L/kg',
        proteinBinding: '70-90% (transcortin, albumin)',
        tissueDistribution: ['All tissues'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic',
        enzymes: ['11β-HSD (prodrug activation)', 'CYP3A4'],
        activeMetabolites: ['Prednisolone (active form)'],
        geneticVariability: 'Rare 11β-HSD deficiency - use prednisolone instead',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '2-3 hours (biological effect lasts longer)',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Inflammatory conditions (many)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Autoimmune diseases', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Often used as bridge to steroid-sparing agents' },
      { condition: 'Asthma exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Short course for acute exacerbations' },
      { condition: 'COPD exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Allergic reactions', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Organ transplant rejection prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Part of immunosuppressive regimen' },
    ],

    dosing: {
      usualDose: { amount: 'Highly variable (5-60 mg/day)', frequency: 'Once daily or divided', route: 'Oral' },
      adjustments: [
        { condition: 'Acute conditions', adjustment: 'Higher doses (40-60 mg) for short courses', rationale: 'Rapid control of inflammation' },
        { condition: 'Chronic conditions', adjustment: 'Lowest effective dose; consider alternate-day dosing', rationale: 'Minimize long-term toxicity' },
        { condition: 'Tapering', adjustment: 'Gradual reduction if >2-3 weeks of use', rationale: 'Prevent adrenal insufficiency' },
        { condition: 'Hepatic impairment', adjustment: 'Consider prednisolone (no hepatic activation needed)', rationale: 'Prednisone requires hepatic conversion' },
      ],
      maxDose: 'No fixed max for short-term; minimize for chronic use',
      administration: { route: 'Oral', withFood: 'with-food', timing: 'Morning to mimic cortisol rhythm', specialInstructions: ['Take with food to reduce GI upset', 'Morning dosing preferred'] },
    },

    adverseEffects: [
      { name: 'Insomnia, mood changes', frequency: 'very-common', severity: 'mild', mechanism: 'CNS effects', management: 'Morning dosing; short course', reversible: true, onsetTiming: 'Days' },
      { name: 'Hyperglycemia', frequency: 'common', severity: 'moderate', mechanism: 'Gluconeogenesis; insulin resistance', management: 'Monitor glucose; may need diabetes meds', reversible: true, onsetTiming: 'Days' },
      { name: 'Weight gain, fluid retention', frequency: 'common', severity: 'mild', mechanism: 'Sodium/water retention; appetite increase', management: 'Low-sodium diet; minimize dose', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Osteoporosis', frequency: 'common', severity: 'severe', mechanism: 'Osteoblast suppression', management: 'Calcium, vitamin D, bisphosphonate if chronic use', reversible: false, onsetTiming: 'Months to years' },
      { name: 'Adrenal suppression', frequency: 'common', severity: 'severe', mechanism: 'HPA axis suppression', management: 'Taper slowly; stress-dose steroids if needed', reversible: true, onsetTiming: 'Weeks of use' },
      { name: 'Infection risk', frequency: 'common', severity: 'moderate', mechanism: 'Immunosuppression', management: 'Avoid live vaccines; watch for infections', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Cushing syndrome (chronic use)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Sustained glucocorticoid excess', management: 'Minimize dose; taper when possible', reversible: true, onsetTiming: 'Months' },
      { name: 'Avascular necrosis', frequency: 'rare', severity: 'severe', mechanism: 'Vascular compromise to bone', management: 'May require surgery', reversible: false, onsetTiming: 'Months to years' },
    ],

    interactions: [
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive GI toxicity', effect: 'Increased GI ulcer/bleeding risk', management: 'Use PPI prophylaxis if combination needed' },
      { interactingDrug: 'Rifampin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 induction', effect: 'Reduced prednisone levels', management: 'May need to increase prednisone dose' },
      { interactingDrug: 'Diabetes medications', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Prednisone raises glucose', effect: 'Worsened glycemic control', management: 'Increase diabetes medication doses' },
      { interactingDrug: 'Vaccines (live)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Immunosuppression', effect: 'Risk of vaccine-associated infection', management: 'Avoid live vaccines during therapy' },
    ],

    contraindications: [
      { condition: 'Systemic fungal infections', type: 'absolute', reason: 'Immunosuppression will worsen infection' },
      { condition: 'Live vaccines during immunosuppressive doses', type: 'absolute', reason: 'Risk of vaccine-strain infection' },
      { condition: 'Untreated infection', type: 'relative', reason: 'May mask/worsen infection', alternative: 'Treat infection first' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta; risk of cleft palate in first trimester', recommendation: 'Use only if clearly needed; lowest effective dose', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Small amounts in breast milk', recommendation: 'Low doses generally safe; high doses - wait 4 hours after dose' },
      { population: 'geriatric', consideration: 'Increased osteoporosis, infection, glucose effects', recommendation: 'Minimize dose and duration' },
      { population: 'pediatric', consideration: 'Growth suppression with chronic use', recommendation: 'Alternate-day dosing when possible' },
    ],

    monitoring: [
      { parameter: 'Blood glucose', frequency: 'Weekly during high-dose therapy; with changes', rationale: 'Steroid-induced hyperglycemia common', actionThreshold: 'Glucose >180 - consider treatment' },
      { parameter: 'Blood pressure', frequency: 'Each visit', rationale: 'Fluid retention, hypertension', actionThreshold: 'HTN - sodium restriction, treat if persistent' },
      { parameter: 'Bone density (DEXA)', frequency: 'Baseline and annually if chronic use', rationale: 'Osteoporosis prevention', actionThreshold: 'T-score <-1.0 - consider bisphosphonate' },
      { parameter: 'Potassium', frequency: 'Periodically', rationale: 'Hypokalemia possible', actionThreshold: '<3.5 - supplement' },
      { parameter: 'Signs of infection', frequency: 'Ongoing', rationale: 'Immunosuppression masks signs', actionThreshold: 'Fever or other signs - evaluate promptly' },
    ],

    patientEducation: [
      'Take with food in the morning',
      'Do not stop suddenly after more than 2 weeks of use - must taper',
      'Carry a medical alert card if on long-term steroids',
      'Report signs of infection, even minor ones',
      'Avoid people with chickenpox or measles',
      'Do not receive live vaccines while taking this medication',
      'Report unusual weight gain, swelling, or mood changes',
    ],

    clinicalPearls: [
      'Prednisone is a prodrug - requires hepatic conversion to prednisolone (active)',
      'In liver failure, use prednisolone directly',
      'HPA suppression occurs with >7.5 mg/day for >3 weeks - taper required',
      'Short courses (<2 weeks) usually do not require taper',
      'Morning dosing mimics physiological cortisol rhythm - less HPA suppression',
      'Alternate-day dosing minimizes HPA suppression and growth effects in children',
      'Always consider osteoporosis prophylaxis (calcium, vitamin D, possibly bisphosphonate) for chronic use',
      '"Steroid psychosis" can occur at high doses - usually resolves with dose reduction',
    ],
  },

  // ============================================
  // Respiratory Medications
  // ============================================

  {
    id: 'albuterol',
    genericName: 'Albuterol (salbutamol)',
    brandNames: ['ProAir', 'Ventolin', 'Proventil'],
    drugClass: 'Short-acting beta-2 agonist (SABA)',
    category: 'respiratory',

    overview: 'Albuterol is a short-acting bronchodilator that rapidly relieves acute bronchospasm. It is the most commonly used rescue inhaler for asthma and COPD exacerbations.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Beta-2 adrenergic receptor',
      targetLocation: 'Airway smooth muscle',

      simpleExplanation: 'Albuterol attaches to beta-2 receptors on the muscles surrounding your airways. This causes the muscles to relax and the airways to open wider, making it easier to breathe within minutes.',

      detailedMechanism: 'Albuterol selectively binds β2-adrenergic receptors coupled to Gs proteins. Activation increases adenylyl cyclase activity, raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets: myosin light chain kinase (inhibited → relaxation), calcium-activated potassium channels (opened → hyperpolarization), and reduces intracellular calcium. The net effect is bronchial smooth muscle relaxation. β2 receptors are also present on mast cells (inhibiting mediator release) and mucociliary epithelium (enhanced clearance).',

      mechanismSteps: [
        { order: 1, location: 'Airways', action: 'Inhaled albuterol deposits on airway epithelium', result: 'Drug reaches β2 receptors', timeframe: '1-5 minutes' },
        { order: 2, location: 'Smooth muscle cell', action: 'β2 receptor activated → Gs → adenylyl cyclase', result: 'cAMP increases' },
        { order: 3, location: 'Intracellular', action: 'cAMP activates PKA', result: 'MLCK inhibited; Ca2+ channels closed' },
        { order: 4, location: 'Smooth muscle', action: 'Muscle relaxation', result: 'Bronchodilation', timeframe: '5-15 minutes peak' },
      ],

      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'Smooth muscle relaxation', clinicalRelevance: 'Relieves bronchospasm', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Improved mucociliary clearance', mechanism: 'β2 stimulation of cilia', clinicalRelevance: 'Helps clear secretions', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Tachycardia', mechanism: 'β2 (some β1) stimulation', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Hypokalemia', mechanism: 'β2-mediated K+ shift into cells', clinicalRelevance: 'Monitor with high doses', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '5-15 minutes (inhaled)',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~10-20% reaches lungs via inhaler; rest swallowed',
        route: ['inhalation', 'oral', 'nebulized'],
        factors: ['Inhaler technique critical', 'Spacer improves delivery'],
        timeToePeak: '0.5-2 hours (plasma); effect immediate locally',
        foodEffect: 'Not applicable (inhaled)',
      },
      distribution: {
        volumeOfDistribution: '2.5 L/kg',
        proteinBinding: '~10%',
        tissueDistribution: ['Lungs (topical)', 'Systemically distributed'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (sulfation)',
        enzymes: ['Sulfotransferase'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '4-6 hours',
      timeToSteadyState: 'Not applicable (used as needed)',
    },

    indications: [
      { condition: 'Acute bronchospasm relief', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Asthma (rescue therapy)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'COPD exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Exercise-induced bronchospasm prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: '15-30 minutes before exercise' },
      { condition: 'Hyperkalemia (adjunct)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Nebulized; shifts K+ into cells' },
    ],

    dosing: {
      usualDose: { amount: '1-2 puffs (90-180 mcg)', frequency: 'Every 4-6 hours as needed', route: 'Inhalation' },
      adjustments: [
        { condition: 'Acute severe asthma', adjustment: '4-8 puffs every 20 min for 3 doses, then q1-4h', rationale: 'Higher doses in emergencies' },
        { condition: 'Nebulizer', adjustment: '2.5-5 mg nebulized q20min x3, then q1-4h', rationale: 'Equivalent to MDI with spacer' },
      ],
      maxDose: 'No fixed max in emergencies; frequent use suggests need for controller',
      administration: { route: 'Inhalation', withFood: 'either', timing: 'As needed; before exercise for prevention', specialInstructions: ['Shake well', 'Use spacer if available', 'Rinse mouth after'] },
    },

    adverseEffects: [
      { name: 'Tremor', frequency: 'common', severity: 'mild', mechanism: 'β2 stimulation of skeletal muscle', management: 'Usually lessens with use', reversible: true, onsetTiming: 'Minutes' },
      { name: 'Tachycardia/palpitations', frequency: 'common', severity: 'mild', mechanism: 'β stimulation of heart', management: 'Reduce dose; use spacer', reversible: true, onsetTiming: 'Minutes' },
      { name: 'Nervousness/anxiety', frequency: 'common', severity: 'mild', mechanism: 'Sympathomimetic effect', management: 'Usually mild', reversible: true, onsetTiming: 'Minutes' },
      { name: 'Hypokalemia', frequency: 'uncommon', severity: 'moderate', mechanism: 'β2-mediated K+ shift', management: 'Monitor K+ with frequent use', reversible: true, onsetTiming: 'Hours' },
      { name: 'Paradoxical bronchospasm', frequency: 'rare', severity: 'severe', mechanism: 'Unknown; possibly excipients', management: 'Stop; use alternative bronchodilator', reversible: true, onsetTiming: 'Immediately' },
    ],

    interactions: [
      { interactingDrug: 'Beta-blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Antagonize bronchodilating effect', effect: 'Reduced albuterol efficacy; bronchospasm risk', management: 'Use cardioselective β-blockers if needed; avoid non-selective' },
      { interactingDrug: 'Diuretics (loop, thiazide)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Both cause hypokalemia', effect: 'Additive hypokalemia', management: 'Monitor potassium' },
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Enhanced sympathomimetic effect', effect: 'Increased cardiovascular effects', management: 'Use with caution' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity to albuterol', type: 'absolute', reason: 'Allergic reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but long experience with safe use', recommendation: 'Use when needed - uncontrolled asthma is greater risk', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Unknown excretion; likely minimal systemic absorption', recommendation: 'Probably safe' },
      { population: 'geriatric', consideration: 'Increased cardiovascular sensitivity', recommendation: 'Use lower doses; monitor heart rate' },
      { population: 'pediatric', consideration: 'Well established in children', recommendation: 'Appropriate weight-based dosing' },
    ],

    monitoring: [
      { parameter: 'Symptom relief', frequency: 'With each use', rationale: 'Assess effectiveness', actionThreshold: 'No relief after 3 treatments - seek emergency care' },
      { parameter: 'Frequency of use', frequency: 'Ongoing', rationale: 'Frequent rescue use indicates uncontrolled asthma', actionThreshold: '>2 days/week - need controller therapy' },
      { parameter: 'Heart rate', frequency: 'If cardiovascular concerns', rationale: 'Tachycardia common', actionThreshold: 'Sustained HR >120 - evaluate' },
    ],

    patientEducation: [
      'This is a rescue inhaler - use it when you have symptoms',
      'Keep it with you at all times',
      'Shake well before each use',
      'Use a spacer if you have one - improves delivery',
      'If you need it more than twice a week, your asthma is not controlled',
      'If 2 puffs do not help within 15-20 minutes, seek medical attention',
      'Check expiration date and get refills before running out',
    ],

    clinicalPearls: [
      'MDI with spacer is as effective as nebulizer in most situations',
      'Frequent rescue use (>2 days/week) indicates need for controller therapy',
      'Tremor and tachycardia are common - reassure patients',
      'In severe asthma: continuous nebulization or frequent MDI (4-8 puffs q20min)',
      'Hypokalemia can be significant with high-dose nebulization - monitor',
      'Paradoxical bronchospasm is rare but important - switch to different formulation',
      'Use 15-30 minutes before exercise for exercise-induced bronchospasm prevention',
    ],
  },

  {
    id: 'fluticasone-propionate',
    genericName: 'Fluticasone propionate',
    brandNames: ['Flovent', 'Flonase', 'ArmonAir'],
    drugClass: 'Inhaled corticosteroid (ICS)',
    category: 'respiratory',

    overview: 'Fluticasone is a potent inhaled corticosteroid used as maintenance therapy for asthma and allergic rhinitis. It reduces airway inflammation and is the cornerstone of persistent asthma management.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptor (nuclear)',
      targetLocation: 'Airway epithelial and inflammatory cells',

      simpleExplanation: 'Fluticasone enters airway cells and turns off genes that cause inflammation. Over days to weeks of regular use, it reduces swelling and mucus in the airways, preventing asthma symptoms and attacks.',

      detailedMechanism: 'Fluticasone binds the glucocorticoid receptor in airway cells. The drug-receptor complex translocates to the nucleus, where it trans-represses pro-inflammatory transcription factors (NF-κB, AP-1), suppressing cytokines (IL-1, IL-4, IL-5, IL-13), chemokines, and adhesion molecules. It also induces anti-inflammatory proteins including lipocortin-1, β2-receptor expression (restoring β-agonist sensitivity), and secretory leukoprotease inhibitor. The net effect is reduced eosinophilic inflammation, mucus hypersecretion, and airway hyperresponsiveness.',

      mechanismSteps: [
        { order: 1, location: 'Airways', action: 'Inhaled fluticasone deposits on airway epithelium', result: 'Topical delivery to inflamed tissue', timeframe: 'Immediate deposition' },
        { order: 2, location: 'Epithelial/inflammatory cells', action: 'Fluticasone binds glucocorticoid receptor', result: 'Receptor activation' },
        { order: 3, location: 'Nucleus', action: 'Gene transcription modified', result: 'Pro-inflammatory genes suppressed; anti-inflammatory genes induced' },
        { order: 4, location: 'Airways', action: 'Reduced inflammation over time', result: 'Less swelling, mucus, hyperresponsiveness', timeframe: 'Days to weeks for full effect' },
      ],

      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Reduced airway inflammation', mechanism: 'Suppressed eosinophils, cytokines', clinicalRelevance: 'Prevents asthma symptoms/exacerbations', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced airway hyperresponsiveness', mechanism: 'Anti-inflammatory effect', clinicalRelevance: 'Less sensitivity to triggers', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Upregulated β2 receptors', mechanism: 'Gene induction', clinicalRelevance: 'Maintains β-agonist efficacy', desiredOrAdverse: 'desired' },
        { system: 'Oropharyngeal', effect: 'Oral candidiasis', mechanism: 'Local immunosuppression', clinicalRelevance: 'Common local side effect', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Days for improvement; 1-2 weeks for significant effect',
      durationOfEffect: 'Continued effect with regular use',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~10-30% reaches lungs; swallowed portion has <1% bioavailability',
        route: ['inhalation', 'intranasal'],
        factors: ['Inhaler technique', 'Spacer use'],
        timeToePeak: '0.5-1 hour (plasma)',
        foodEffect: 'Not applicable (inhaled)',
      },
      distribution: {
        volumeOfDistribution: '4 L/kg',
        proteinBinding: '91%',
        tissueDistribution: ['Lungs (topical)', 'Minimal systemic'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal (biliary)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '~8 hours (plasma); prolonged pulmonary retention',
      timeToSteadyState: '3-5 days (plasma)',
    },

    indications: [
      { condition: 'Persistent asthma maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Intranasal formulation (Flonase)' },
      { condition: 'COPD (with frequent exacerbations)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Usually combined with LABA' },
    ],

    dosing: {
      usualDose: { amount: '88-440 mcg', frequency: 'Twice daily', route: 'Inhalation' },
      adjustments: [
        { condition: 'Mild asthma', adjustment: 'Low dose (88-220 mcg/day)', rationale: 'Step 2 therapy' },
        { condition: 'Moderate asthma', adjustment: 'Medium dose (220-440 mcg/day)', rationale: 'Step 3-4 therapy' },
        { condition: 'Severe asthma', adjustment: 'High dose (440-880 mcg/day)', rationale: 'Step 4-5 therapy' },
        { condition: 'Allergic rhinitis', adjustment: '1-2 sprays per nostril daily', rationale: 'Intranasal dosing' },
      ],
      maxDose: '880 mcg twice daily (inhaled); higher doses increase systemic effects',
      administration: { route: 'Inhalation', withFood: 'either', timing: 'Same times daily; rinse mouth after', specialInstructions: ['Rinse mouth after each use to prevent thrush', 'Use spacer with MDI'] },
    },

    adverseEffects: [
      { name: 'Oral candidiasis (thrush)', frequency: 'common', severity: 'mild', mechanism: 'Local immunosuppression in mouth', management: 'Rinse mouth after use; use spacer', reversible: true, onsetTiming: 'Weeks of use' },
      { name: 'Dysphonia (hoarseness)', frequency: 'common', severity: 'mild', mechanism: 'Local laryngeal effect', management: 'Use spacer; try DPI instead of MDI', reversible: true, onsetTiming: 'Variable' },
      { name: 'Pharyngitis', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Rinse mouth after use', reversible: true, onsetTiming: 'Variable' },
      { name: 'Adrenal suppression (high doses)', frequency: 'rare', severity: 'severe', mechanism: 'Systemic absorption', management: 'Use lowest effective dose', reversible: true, onsetTiming: 'Months of high-dose use' },
      { name: 'Growth suppression in children', frequency: 'uncommon', severity: 'moderate', mechanism: 'Systemic corticosteroid effect', management: 'Monitor growth; use lowest effective dose', reversible: true, onsetTiming: 'Months to years' },
    ],

    interactions: [
      { interactingDrug: 'Ritonavir and strong CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 inhibition increases systemic fluticasone', effect: 'Cushing syndrome, adrenal suppression reported', management: 'Avoid combination; use alternative steroid (beclomethasone)' },
      { interactingDrug: 'Ketoconazole', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4 inhibition', effect: 'Increased fluticasone levels', management: 'Use caution; monitor for systemic effects' },
    ],

    contraindications: [
      { condition: 'Primary treatment of acute bronchospasm', type: 'absolute', reason: 'Not a rescue medication; does not work acutely' },
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'ICS use recommended - uncontrolled asthma is greater risk', recommendation: 'Continue at lowest effective dose', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Minimal systemic absorption', recommendation: 'Safe to use' },
      { population: 'pediatric', consideration: 'Potential growth effects', recommendation: 'Use lowest effective dose; monitor growth' },
      { population: 'geriatric', consideration: 'Osteoporosis risk with high doses', recommendation: 'Use lowest effective dose' },
    ],

    monitoring: [
      { parameter: 'Asthma control', frequency: 'Every 1-3 months initially', rationale: 'Assess symptom control and adjust dose', actionThreshold: 'Uncontrolled - step up therapy' },
      { parameter: 'Growth (children)', frequency: 'Annually', rationale: 'ICS can slow growth velocity', actionThreshold: 'Significant growth deceleration - evaluate' },
      { parameter: 'Oral cavity', frequency: 'Periodically', rationale: 'Check for thrush', actionThreshold: 'Thrush - treat with antifungal, improve technique' },
    ],

    patientEducation: [
      'This is a controller medication - use every day, even when feeling well',
      'It does not work immediately for acute symptoms - use rescue inhaler for those',
      'Rinse your mouth with water after each use to prevent thrush',
      'Use a spacer with the metered-dose inhaler if possible',
      'Do not stop suddenly - talk to your doctor first',
      'It may take 1-2 weeks to feel the full benefit',
    ],

    clinicalPearls: [
      'ICS is the most effective controller therapy for persistent asthma',
      'Not for acute symptoms - this is maintenance therapy',
      'Rinsing mouth and using spacer dramatically reduces local side effects',
      'AVOID with ritonavir - documented Cushing syndrome/adrenal suppression',
      'Step down therapy after 3 months of good control',
      'Fluticasone is one of the most potent ICS - lower doses needed vs budesonide',
      'Monitor growth in children - effect is small (0.5 cm/year) and not progressive',
    ],
  },

  {
    id: 'montelukast',
    genericName: 'Montelukast',
    brandNames: ['Singulair'],
    drugClass: 'Leukotriene receptor antagonist (LTRA)',
    category: 'respiratory',

    overview: 'Montelukast blocks leukotriene receptors, reducing inflammation and bronchoconstriction in asthma and allergic rhinitis. It is an oral alternative or add-on to inhaled corticosteroids, though less effective as monotherapy.',

    mechanism: {
      type: 'receptor-antagonist',
      target: 'Cysteinyl leukotriene receptor 1 (CysLT1)',
      targetLocation: 'Airway smooth muscle, inflammatory cells, vascular endothelium',

      simpleExplanation: 'Montelukast blocks the effects of leukotrienes, which are inflammatory chemicals that cause airway swelling, mucus production, and tightening of airway muscles. By blocking these, it reduces asthma and allergy symptoms.',

      detailedMechanism: 'Montelukast selectively antagonizes the CysLT1 receptor, blocking the effects of cysteinyl leukotrienes (LTC4, LTD4, LTE4). These leukotrienes, produced via the 5-lipoxygenase pathway from arachidonic acid, are potent bronchoconstrictors and pro-inflammatory mediators. CysLT1 receptor blockade inhibits: smooth muscle contraction (bronchodilation), vascular permeability (reduced edema), eosinophil recruitment, and mucus secretion. Leukotrienes are particularly important in aspirin-exacerbated respiratory disease and exercise-induced bronchospasm.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Montelukast absorbed orally', result: 'Systemic distribution', timeframe: '3-4 hours to peak' },
        { order: 2, location: 'Airway tissues', action: 'Binds CysLT1 receptor', result: 'Receptor blocked' },
        { order: 3, location: 'CysLT1 receptor', action: 'Prevents leukotriene binding', result: 'No downstream signaling' },
        { order: 4, location: 'Airways', action: 'Reduced bronchoconstriction, inflammation, mucus', result: 'Improved symptoms' },
      ],

      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'Blocks LT-induced bronchoconstriction', clinicalRelevance: 'Modest improvement in FEV1', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced airway inflammation', mechanism: 'Blocks LT-mediated inflammation', clinicalRelevance: 'Reduces eosinophils, symptoms', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced nasal congestion', mechanism: 'Blocks LT effects in nasal mucosa', clinicalRelevance: 'Helps allergic rhinitis', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Neuropsychiatric effects (rare)', mechanism: 'CysLT1 receptors in brain', clinicalRelevance: 'FDA boxed warning', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours to days for full effect',
      durationOfEffect: '24 hours (once daily dosing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '64% (tablet); 73% (chewable)',
        route: ['oral'],
        factors: ['Food minimally affects absorption'],
        timeToePeak: '3-4 hours (tablet); 2-2.5 hours (chewable)',
        foodEffect: 'Can be taken with or without food',
      },
      distribution: {
        volumeOfDistribution: '8-11 L',
        proteinBinding: '>99%',
        tissueDistribution: ['Minimal CNS penetration', 'Lung distribution'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4, 2C8, 2C9)',
        enzymes: ['CYP3A4', 'CYP2C8', 'CYP2C9'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Biliary/fecal (86%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '2.7-5.5 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Asthma (prophylaxis and maintenance)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Alternative to ICS for mild persistent; add-on for moderate-severe' },
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Alternative to antihistamines' },
      { condition: 'Exercise-induced bronchospasm prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Aspirin-exacerbated respiratory disease (AERD)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Leukotrienes are key in AERD pathophysiology' },
    ],

    dosing: {
      usualDose: { amount: '10 mg', frequency: 'Once daily in evening', route: 'Oral' },
      adjustments: [
        { condition: 'Children 6-14 years', adjustment: '5 mg chewable tablet daily', rationale: 'Pediatric dosing' },
        { condition: 'Children 2-5 years', adjustment: '4 mg chewable or granules daily', rationale: 'Pediatric dosing' },
        { condition: 'Children 12-23 months (asthma only)', adjustment: '4 mg granules daily', rationale: 'Young pediatric dosing' },
      ],
      maxDose: '10 mg daily',
      administration: { route: 'Oral', withFood: 'either', timing: 'Evening (for asthma); any time for allergic rhinitis', specialInstructions: ['Chewable tablets should not be swallowed whole'] },
    },

    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually resolves', reversible: true, onsetTiming: 'Variable' },
      { name: 'Abdominal pain', frequency: 'common', severity: 'mild', mechanism: 'GI effect', management: 'Usually mild', reversible: true, onsetTiming: 'Variable' },
      { name: 'Neuropsychiatric effects (FDA boxed warning)', frequency: 'rare', severity: 'severe', mechanism: 'CysLT1 receptors in CNS', management: 'Stop drug; monitor closely', reversible: true, onsetTiming: 'Variable' },
      { name: 'Upper respiratory infection', frequency: 'common', severity: 'mild', mechanism: 'Unknown (may be coincidental)', management: 'Supportive care', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Phenobarbital and other CYP inducers', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP induction', effect: 'Reduced montelukast levels', management: 'Monitor efficacy' },
      { interactingDrug: 'Gemfibrozil', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C8 inhibition', effect: 'Increased montelukast levels', management: 'Usually no dose adjustment needed' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data; crosses placenta', recommendation: 'Use if benefits outweigh risks; consider ICS as first-line', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Unknown excretion', recommendation: 'Use with caution' },
      { population: 'pediatric', consideration: 'Approved down to 12 months for asthma', recommendation: 'Age-appropriate dosing' },
      { population: 'hepatic-impairment', consideration: 'Hepatically metabolized', recommendation: 'No adjustment for mild-moderate; use caution in severe' },
    ],

    monitoring: [
      { parameter: 'Asthma control', frequency: 'Every 1-3 months', rationale: 'Assess efficacy', actionThreshold: 'Poor control - step up (ICS preferred)' },
      { parameter: 'Neuropsychiatric symptoms', frequency: 'Ongoing', rationale: 'FDA boxed warning', actionThreshold: 'Any mood/behavior changes - consider stopping' },
    ],

    patientEducation: [
      'Take every day, even when feeling well',
      'This is not a rescue medication - use rescue inhaler for acute symptoms',
      'Take in the evening for asthma',
      'Report any changes in mood, behavior, or sleep',
      'Do not stop suddenly without talking to your doctor',
    ],

    clinicalPearls: [
      'FDA boxed warning (2020) for neuropsychiatric events - discuss with patients',
      'ICS is more effective than montelukast monotherapy for most asthma patients',
      'Particularly useful in aspirin-exacerbated respiratory disease (AERD)',
      'Good add-on to ICS for patients with concomitant allergic rhinitis',
      'Exercise-induced bronchospasm: effective prevention taken daily or before exercise',
      'Not for acute bronchospasm - no rescue role',
      'Consider for patients refusing or unable to use inhalers',
    ],
  },

  // ============================================
  // Gastrointestinal Medications
  // ============================================

  {
    id: 'omeprazole',
    genericName: 'Omeprazole',
    brandNames: ['Prilosec', 'Losec'],
    drugClass: 'Proton pump inhibitor (PPI)',
    category: 'gastrointestinal',

    overview: 'Omeprazole is a proton pump inhibitor that profoundly suppresses gastric acid secretion. It is widely used for GERD, peptic ulcer disease, and Helicobacter pylori eradication.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'H+/K+-ATPase (proton pump)',
      targetLocation: 'Gastric parietal cell canaliculus',

      simpleExplanation: 'Omeprazole permanently shuts off the acid pumps in your stomach lining. It gets absorbed, travels to the stomach cells, and irreversibly blocks the pump that releases acid, reducing acid production by over 90%.',

      detailedMechanism: 'Omeprazole is a prodrug that accumulates in the acidic environment of the parietal cell canaliculus (pH <2), where it is protonated and converted to the active sulfenamide form. This active metabolite covalently binds to cysteine residues on the H+/K+-ATPase enzyme (primarily Cys813), irreversibly inhibiting acid secretion. Since the binding is covalent, acid suppression persists until new proton pumps are synthesized (~24-48 hours for full recovery). The drug preferentially concentrates in actively secreting parietal cells.',

      mechanismSteps: [
        { order: 1, location: 'Small intestine', action: 'Omeprazole absorbed (enteric-coated)', result: 'Enters systemic circulation', timeframe: '1-2 hours' },
        { order: 2, location: 'Parietal cell canaliculus', action: 'Accumulates in acidic environment', result: 'Protonated and activated' },
        { order: 3, location: 'Proton pump', action: 'Active sulfenamide binds cysteine residues', result: 'Irreversible enzyme inhibition' },
        { order: 4, location: 'Stomach', action: 'Acid secretion blocked', result: 'Gastric pH rises', timeframe: '1-3 days for maximum effect' },
      ],

      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Profound acid suppression', mechanism: 'Proton pump inhibition', clinicalRelevance: 'Heals ulcers and erosions', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Hypergastrinemia', mechanism: 'Negative feedback from low acid', clinicalRelevance: 'May cause rebound on stopping', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Reduced mineral absorption', mechanism: 'pH-dependent absorption impaired', clinicalRelevance: 'Mg, Ca, B12 deficiency risk', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1 hour for plasma levels; 1-3 days for maximum acid suppression',
      durationOfEffect: '72+ hours (until new pumps synthesized)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '30-40% (increases with repeated dosing)',
        route: ['oral', 'intravenous'],
        factors: ['Enteric coating protects from gastric acid', 'Food delays absorption'],
        timeToePeak: '0.5-3.5 hours',
        foodEffect: 'Take before meals for best effect (pumps must be active)',
      },
      distribution: {
        volumeOfDistribution: '0.4 L/kg',
        proteinBinding: '95%',
        tissueDistribution: ['Concentrates in parietal cells'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP2C19, CYP3A4)',
        enzymes: ['CYP2C19 (primary)', 'CYP3A4'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C19 poor metabolizers have higher drug exposure',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (80% as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '0.5-1 hour (but effect persists much longer)',
      timeToSteadyState: '3-5 days for full acid suppression',
    },

    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Peptic ulcer disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'H. pylori eradication (with antibiotics)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Zollinger-Ellison syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'NSAID ulcer prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Stress ulcer prophylaxis (ICU)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '20-40 mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'GERD healing', adjustment: '20 mg daily x 4-8 weeks', rationale: 'Standard healing dose' },
        { condition: 'Erosive esophagitis', adjustment: '40 mg daily', rationale: 'More severe disease' },
        { condition: 'H. pylori', adjustment: '20-40 mg twice daily with antibiotics', rationale: 'Part of triple/quadruple therapy' },
        { condition: 'Zollinger-Ellison', adjustment: '60 mg daily; may need much higher', rationale: 'Titrate to gastric acid output' },
      ],
      maxDose: '120 mg twice daily (Zollinger-Ellison); usually 40 mg daily',
      administration: { route: 'Oral', withFood: 'without-food', timing: '30-60 minutes before meals', specialInstructions: ['Take before first meal of day', 'Swallow whole - do not crush delayed-release'] },
    },

    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually resolves', reversible: true, onsetTiming: 'Days' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually mild', reversible: true, onsetTiming: 'Variable' },
      { name: 'Hypomagnesemia (long-term)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Impaired intestinal absorption', management: 'Monitor Mg; supplement if needed', reversible: true, onsetTiming: 'Months to years' },
      { name: 'Vitamin B12 deficiency (long-term)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Reduced acid-dependent absorption', management: 'Monitor B12; supplement if needed', reversible: true, onsetTiming: 'Years' },
      { name: 'Increased fracture risk (long-term)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Impaired calcium absorption', management: 'Ensure adequate calcium/vitamin D', reversible: false, onsetTiming: 'Years' },
      { name: 'C. difficile infection', frequency: 'rare', severity: 'severe', mechanism: 'Altered gut flora from reduced acid', management: 'Treat C. diff; consider stopping PPI', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Clopidogrel', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C19 inhibition reduces clopidogrel activation', effect: 'Reduced antiplatelet effect', management: 'Use pantoprazole (less CYP2C19 interaction) or consider H2RA' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced renal clearance of methotrexate', effect: 'Increased methotrexate toxicity', management: 'Monitor methotrexate levels; consider holding PPI' },
      { interactingDrug: 'Drugs requiring acid for absorption', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced gastric acidity', effect: 'Reduced absorption of ketoconazole, iron, B12', management: 'Separate dosing; monitor levels' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity to PPIs', type: 'absolute', reason: 'Cross-reactivity possible between PPIs' },
      { condition: 'Co-administration with rilpivirine', type: 'absolute', reason: 'Rilpivirine requires acid for absorption' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but generally considered safe', recommendation: 'Use if clearly needed', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Use with caution' },
      { population: 'geriatric', consideration: 'Increased fracture and B12 deficiency risk', recommendation: 'Use lowest effective dose; monitor for long-term effects' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Consider dose reduction in severe impairment' },
    ],

    monitoring: [
      { parameter: 'Symptom resolution', frequency: 'After 4-8 weeks of therapy', rationale: 'Assess need for continued use', actionThreshold: 'Symptoms persist - evaluate for other causes' },
      { parameter: 'Magnesium (long-term use)', frequency: 'Periodically', rationale: 'Hypomagnesemia risk', actionThreshold: '<1.0 mg/dL - supplement and consider stopping' },
      { parameter: 'B12 (long-term use)', frequency: 'Annually if on years of therapy', rationale: 'Malabsorption risk', actionThreshold: 'Low B12 - supplement' },
    ],

    patientEducation: [
      'Take 30-60 minutes before your first meal of the day',
      'Swallow the capsule whole - do not crush or chew',
      'It may take a few days to feel the full effect',
      'Do not use for more than 14 days for heartburn without consulting a doctor',
      'Long-term use requires periodic reassessment',
      'Report any muscle cramps, irregular heartbeat, or persistent diarrhea',
    ],

    clinicalPearls: [
      'Take before meals - proton pumps must be active for drug to work',
      'Full acid suppression takes 3-5 days - not for immediate relief',
      'Deprescribe when possible - many patients can step down to H2RA or stop',
      'Rebound hypersecretion can occur when stopping - consider tapering',
      'Clopidogrel interaction: pantoprazole has less CYP2C19 inhibition',
      'Long-term use: watch for hypomagnesemia, B12 deficiency, fractures',
      'OTC omeprazole is the same drug - ask about self-medication',
    ],
  },

  {
    id: 'ondansetron',
    genericName: 'Ondansetron',
    brandNames: ['Zofran', 'Zuplenz'],
    drugClass: '5-HT3 receptor antagonist',
    category: 'gastrointestinal',

    overview: 'Ondansetron is a highly effective antiemetic that blocks serotonin receptors in the gut and brain. It is first-line for chemotherapy-induced and postoperative nausea/vomiting.',

    mechanism: {
      type: 'receptor-antagonist',
      target: '5-HT3 (serotonin type 3) receptor',
      targetLocation: 'Vagal afferents in GI tract and chemoreceptor trigger zone',

      simpleExplanation: 'Ondansetron blocks serotonin from triggering nausea. Chemotherapy and surgery cause cells to release serotonin, which normally activates the vomiting center. By blocking this signal, ondansetron prevents nausea and vomiting.',

      detailedMechanism: 'Ondansetron selectively antagonizes 5-HT3 receptors. Cytotoxic chemotherapy, radiation, and surgery trigger release of serotonin from enterochromaffin cells in the GI mucosa. Serotonin activates 5-HT3 receptors on vagal afferents, which project to the nucleus tractus solitarius and vomiting center in the brainstem. 5-HT3 receptors are also present in the chemoreceptor trigger zone (area postrema). Blocking these receptors interrupts the emetic signal cascade. Ondansetron does not affect dopamine receptors (unlike older antiemetics).',

      mechanismSteps: [
        { order: 1, location: 'GI tract/systemic', action: 'Ondansetron administered', result: 'Reaches 5-HT3 receptors', timeframe: '30-60 minutes' },
        { order: 2, location: 'GI tract enterochromaffin cells', action: 'Chemotherapy triggers serotonin release', result: 'Serotonin released' },
        { order: 3, location: 'Vagal afferents', action: 'Ondansetron blocks 5-HT3 receptors', result: 'Signal to vomiting center blocked' },
        { order: 4, location: 'Brainstem', action: 'Chemoreceptor trigger zone 5-HT3 blocked', result: 'Nausea/vomiting prevented' },
      ],

      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Antiemetic', mechanism: '5-HT3 blockade', clinicalRelevance: 'Prevents nausea/vomiting', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Constipation', mechanism: 'Serotonin role in GI motility', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Cardiac ion channel effects', clinicalRelevance: 'FDA warning; dose-dependent', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '30 minutes (oral); faster IV',
      durationOfEffect: '4-8 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~60%',
        route: ['oral', 'intravenous', 'intramuscular', 'sublingual'],
        factors: ['Well absorbed orally'],
        timeToePeak: '1-2 hours (oral)',
        foodEffect: 'Slightly increased bioavailability with food',
      },
      distribution: {
        volumeOfDistribution: '1.9 L/kg',
        proteinBinding: '70-76%',
        tissueDistribution: ['Crosses blood-brain barrier'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4, CYP2D6, CYP1A2)',
        enzymes: ['CYP3A4', 'CYP2D6', 'CYP1A2'],
        activeMetabolites: [],
        geneticVariability: 'CYP2D6 poor metabolizers have higher exposure',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (5% unchanged)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '3-6 hours',
      timeToSteadyState: 'Single doses; not typically used at steady state',
    },

    indications: [
      { condition: 'Chemotherapy-induced nausea/vomiting (CINV)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Postoperative nausea/vomiting (PONV)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Radiation-induced nausea/vomiting', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Nausea/vomiting of pregnancy', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Second-line after vitamin B6/doxylamine' },
      { condition: 'Gastroenteritis', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Often used in pediatrics and adults' },
    ],

    dosing: {
      usualDose: { amount: '4-8 mg', frequency: 'Every 8 hours as needed', route: 'Oral/IV' },
      adjustments: [
        { condition: 'CINV - highly emetogenic', adjustment: '8 mg twice daily + dexamethasone + NK1 antagonist', rationale: 'Triple therapy for highly emetogenic chemo' },
        { condition: 'PONV prevention', adjustment: '4 mg IV at end of surgery', rationale: 'Single dose often sufficient' },
        { condition: 'Hepatic impairment (severe)', adjustment: 'Max 8 mg/day', rationale: 'Reduced clearance' },
        { condition: 'Pediatric', adjustment: '0.1-0.15 mg/kg (max 4 mg per dose)', rationale: 'Weight-based dosing' },
      ],
      maxDose: '8 mg IV single dose (FDA); 24 mg/day oral',
      administration: { route: 'Oral/IV', withFood: 'either', specialInstructions: ['ODT: place on tongue and let dissolve', 'IV: give over 15 minutes'] },
    },

    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Symptomatic treatment', reversible: true, onsetTiming: 'Hours' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Serotonin effects on gut motility', management: 'Stool softeners if needed', reversible: true, onsetTiming: 'Days' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Cardiac ion channel blockade', management: 'Avoid in QT prolongation; limit IV dose to 16 mg', reversible: true, onsetTiming: 'Hours' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Usually mild', reversible: true, onsetTiming: 'Hours' },
    ],

    interactions: [
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT prolongation', effect: 'Increased arrhythmia risk', management: 'Avoid combination if possible; monitor ECG' },
      { interactingDrug: 'Apomorphine', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Profound hypotension and LOC reported', effect: 'Severe hypotension', management: 'Contraindicated combination' },
      { interactingDrug: 'CYP3A4 inducers (rifampin)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased ondansetron metabolism', effect: 'Reduced antiemetic effect', management: 'May need higher doses' },
    ],

    contraindications: [
      { condition: 'Concomitant apomorphine', type: 'absolute', reason: 'Severe hypotension and loss of consciousness' },
      { condition: 'Congenital long QT syndrome', type: 'absolute', reason: 'QT prolongation risk' },
      { condition: 'Hypersensitivity to ondansetron or other 5-HT3 antagonists', type: 'absolute', reason: 'Cross-reactivity possible' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Some studies suggest slightly increased cleft palate risk', recommendation: 'Use other antiemetics first; ondansetron if refractory', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Unknown excretion', recommendation: 'Probably safe given short-term use' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'Max 8 mg/day in severe impairment' },
      { population: 'geriatric', consideration: 'More susceptible to QT prolongation', recommendation: 'Use lowest effective dose; monitor ECG if risk factors' },
    ],

    monitoring: [
      { parameter: 'Nausea/vomiting control', frequency: 'Ongoing', rationale: 'Assess effectiveness', actionThreshold: 'Inadequate control - add other antiemetics' },
      { parameter: 'ECG (if risk factors)', frequency: 'Baseline', rationale: 'QT prolongation risk', actionThreshold: 'QTc >500 ms - avoid or use alternative' },
    ],

    patientEducation: [
      'Take 30-60 minutes before chemotherapy or as directed',
      'The dissolving tablet (ODT) can be taken without water',
      'May cause constipation - increase fluids and fiber',
      'Report any irregular heartbeat or fainting',
      'Do not take more than prescribed - higher doses increase heart rhythm risk',
    ],

    clinicalPearls: [
      'Most effective for acute CINV (first 24 hours) - less effective for delayed',
      'FDA reduced max IV dose to 16 mg due to QT prolongation concerns',
      'For highly emetogenic chemo: combine with dexamethasone and NK1 antagonist',
      'ODT formulation useful when patient cannot swallow pills',
      'Contraindicated with apomorphine - severe hypotension reported',
      'Constipation is common - counsel patients',
      'Does not work well for motion sickness (different mechanism)',
    ],
  },

  {
    id: 'lactulose',
    genericName: 'Lactulose',
    brandNames: ['Enulose', 'Kristalose', 'Generlac'],
    drugClass: 'Osmotic laxative / Ammonia-lowering agent',
    category: 'gastrointestinal',

    overview: 'Lactulose is a synthetic disaccharide with two distinct uses: as an osmotic laxative for constipation, and to lower blood ammonia in hepatic encephalopathy. Humans cannot digest it, so it reaches the colon intact.',

    mechanism: {
      type: 'other',
      target: 'Colonic bacteria / Osmotic gradient',
      targetLocation: 'Colon',

      simpleExplanation: 'Lactulose is a sugar that humans cannot digest. It passes to the colon where bacteria ferment it into acids. This creates an osmotic effect that draws water into the stool (laxative effect) and traps ammonia by converting it to ammonium, which cannot be absorbed (hepatic encephalopathy treatment).',

      detailedMechanism: 'Lactulose is not absorbed in the small intestine because humans lack the enzyme to hydrolyze it. In the colon, bacteria (primarily Lactobacillus, Bacteroides) ferment lactulose to short-chain fatty acids (lactic acid, acetic acid), lowering colonic pH. This has two effects: 1) Osmotic - the acids and lactulose draw water into the colon, increasing stool volume and stimulating peristalsis. 2) Ammonia trapping - the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is charged and cannot cross the intestinal epithelium, so it is excreted in stool rather than absorbed systemically.',

      mechanismSteps: [
        { order: 1, location: 'Small intestine', action: 'Lactulose not absorbed (no enzyme)', result: 'Reaches colon intact' },
        { order: 2, location: 'Colon', action: 'Bacteria ferment lactulose', result: 'Produces organic acids; pH drops' },
        { order: 3, location: 'Colon (laxative effect)', action: 'Osmotic gradient created', result: 'Water drawn into stool', timeframe: '24-48 hours' },
        { order: 4, location: 'Colon (ammonia effect)', action: 'NH3 → NH4+ in acidic environment', result: 'Ammonia trapped and excreted' },
      ],

      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Increased stool water content', mechanism: 'Osmotic effect', clinicalRelevance: 'Treats constipation', desiredOrAdverse: 'desired' },
        { system: 'Neurological', effect: 'Reduced serum ammonia', mechanism: 'Ammonia trapping in colon', clinicalRelevance: 'Treats hepatic encephalopathy', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Bloating and flatulence', mechanism: 'Bacterial fermentation produces gas', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '24-48 hours (laxative); 24-48 hours (ammonia lowering)',
      durationOfEffect: 'As long as continued',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '<3% absorbed systemically',
        route: ['oral', 'rectal'],
        factors: ['Not absorbed - acts locally in colon'],
        timeToePeak: 'Not applicable (minimal absorption)',
        foodEffect: 'None',
      },
      distribution: {
        volumeOfDistribution: 'Not applicable (minimal systemic exposure)',
        proteinBinding: 'Not applicable',
        tissueDistribution: ['Remains in GI tract'],
        crossesBBB: false,
        crossesPlacenta: false,
      },
      metabolism: {
        primarySite: 'Colon (bacterial fermentation)',
        enzymes: ['Bacterial enzymes'],
        activeMetabolites: ['Lactic acid', 'Acetic acid'],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Fecal (mostly as organic acids)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: 'Not applicable',
      timeToSteadyState: 'Not applicable',
    },

    indications: [
      { condition: 'Constipation', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Second-line after lifestyle/fiber' },
      { condition: 'Hepatic encephalopathy treatment', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Hepatic encephalopathy prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Portal systemic encephalopathy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '15-30 mL (10-20 g)', frequency: 'Daily to three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Constipation', adjustment: '15-30 mL once daily', rationale: 'Titrate to 2-3 soft stools daily' },
        { condition: 'Hepatic encephalopathy (acute)', adjustment: '30-45 mL every hour until bowel movement, then titrate', rationale: 'Goal: 2-3 soft stools daily' },
        { condition: 'Hepatic encephalopathy (maintenance)', adjustment: '15-30 mL 2-4 times daily', rationale: 'Titrate to stool output' },
        { condition: 'Rectal (if unable to take oral)', adjustment: '300 mL in 700 mL water as retention enema', rationale: 'Alternative route in severe HE' },
      ],
      maxDose: 'No fixed max; titrate to stool output',
      administration: { route: 'Oral/Rectal', withFood: 'either', specialInstructions: ['Can mix with juice or water to improve taste', 'Titrate to 2-3 soft stools daily'] },
    },

    adverseEffects: [
      { name: 'Bloating and flatulence', frequency: 'very-common', severity: 'mild', mechanism: 'Bacterial fermentation produces gas', management: 'Usually improves over time', reversible: true, onsetTiming: 'Days' },
      { name: 'Abdominal cramps', frequency: 'common', severity: 'mild', mechanism: 'Increased motility', management: 'Reduce dose', reversible: true, onsetTiming: 'Hours to days' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Osmotic effect (if overdosed)', management: 'Reduce dose', reversible: true, onsetTiming: 'Hours' },
      { name: 'Electrolyte imbalances (with excessive dosing)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Excessive diarrhea', management: 'Monitor electrolytes; reduce dose', reversible: true, onsetTiming: 'Days' },
      { name: 'Hypernatremia (with certain preparations)', frequency: 'rare', severity: 'moderate', mechanism: 'Some formulations contain sodium', management: 'Use low-sodium preparation', reversible: true, onsetTiming: 'Days' },
    ],

    interactions: [
      { interactingDrug: 'Antacids (aluminum/magnesium)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'May neutralize acidic environment in colon', effect: 'Reduced ammonia-lowering effect', management: 'Avoid concurrent use in hepatic encephalopathy' },
      { interactingDrug: 'Oral antibiotics (neomycin, metronidazole)', interactionType: 'pharmacodynamic', severity: 'minor', mechanism: 'May alter colonic flora needed for lactulose fermentation', effect: 'Variable effect on lactulose efficacy', management: 'Often used together in hepatic encephalopathy - monitor response' },
    ],

    contraindications: [
      { condition: 'Galactosemia', type: 'absolute', reason: 'Contains galactose' },
      { condition: 'Patients requiring low-galactose diet', type: 'relative', reason: 'Contains galactose' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Minimal absorption; long safety history', recommendation: 'Safe to use', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Not absorbed systemically', recommendation: 'Safe to use' },
      { population: 'pediatric', consideration: 'Used for constipation in children', recommendation: 'Appropriate age-based dosing' },
      { population: 'geriatric', consideration: 'Watch for dehydration and electrolyte imbalances', recommendation: 'Monitor hydration status' },
    ],

    monitoring: [
      { parameter: 'Stool frequency', frequency: 'Daily initially', rationale: 'Titrate to 2-3 soft stools per day', actionThreshold: 'Diarrhea - reduce dose; constipation - increase dose' },
      { parameter: 'Mental status (for HE)', frequency: 'Ongoing', rationale: 'Assess encephalopathy improvement', actionThreshold: 'No improvement - add rifaximin; worsening - evaluate for precipitants' },
      { parameter: 'Electrolytes (if excessive diarrhea)', frequency: 'Periodically', rationale: 'Diarrhea can cause electrolyte loss', actionThreshold: 'Abnormal - correct and reduce dose' },
    ],

    patientEducation: [
      'May take 24-48 hours to work',
      'Bloating and gas are common initially and usually improve',
      'For hepatic encephalopathy: adjust dose to have 2-3 soft bowel movements daily',
      'Can mix with juice or water to improve the sweet taste',
      'Do not take if you have galactosemia',
      'Drink plenty of fluids',
    ],

    clinicalPearls: [
      'Goal in hepatic encephalopathy: 2-3 soft stools per day',
      'Works by bacterial fermentation - acts in colon, not absorbed',
      'Sweet taste may cause nausea - mixing with juice helps',
      'Can be given as retention enema if patient cannot take oral',
      'Often combined with rifaximin for refractory hepatic encephalopathy',
      'Avoid antacids in HE patients - they can neutralize the colonic acidity',
      'Patients with galactosemia cannot use lactulose (metabolized to galactose)',
    ],
  },

  // ============================================
  // Additional Psychiatric Medications
  // ============================================

  {
    id: 'bupropion',
    genericName: 'Bupropion',
    brandNames: ['Wellbutrin', 'Wellbutrin XL', 'Zyban', 'Forfivo'],
    drugClass: 'Norepinephrine-dopamine reuptake inhibitor (NDRI)',
    category: 'psychiatric',

    overview: 'Bupropion is a unique antidepressant that inhibits norepinephrine and dopamine reuptake, with no direct serotonergic effects. It is used for depression, smoking cessation, and as an adjunct for weight management.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Norepinephrine transporter (NET) and dopamine transporter (DAT)',
      targetLocation: 'Presynaptic neurons in CNS',

      simpleExplanation: 'Bupropion blocks the recycling of norepinephrine and dopamine in the brain, allowing these chemicals to stay active longer in the synapse. This differs from most antidepressants which primarily affect serotonin.',

      detailedMechanism: 'Bupropion and its active metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion) inhibit the reuptake of norepinephrine and dopamine by blocking NET and DAT. This increases synaptic concentrations of these neurotransmitters, particularly in the nucleus accumbens and prefrontal cortex. Notably, bupropion has minimal effect on serotonin reuptake and does not significantly affect muscarinic, histaminergic, or α-adrenergic receptors, explaining its favorable side effect profile.',

      mechanismSteps: [
        { order: 1, location: 'GI tract/systemic', action: 'Bupropion absorbed', result: 'Reaches CNS', timeframe: '3 hours to peak' },
        { order: 2, location: 'Liver', action: 'CYP2B6 metabolism', result: 'Active metabolites formed' },
        { order: 3, location: 'Presynaptic terminal', action: 'NET and DAT blocked', result: 'Reduced reuptake of NE and DA' },
        { order: 4, location: 'Synapse', action: 'Increased NE and DA', result: 'Enhanced neurotransmission', timeframe: 'Weeks for clinical effect' },
      ],

      physiologicalEffects: [
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Increased NE/DA signaling', clinicalRelevance: 'Treats depression', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Reduced nicotine craving', mechanism: 'Dopamine in reward circuits; nicotinic receptor antagonism', clinicalRelevance: 'Smoking cessation', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Seizure risk', mechanism: 'Dose-dependent lowering of seizure threshold', clinicalRelevance: 'Key safety concern', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Weight neutral or loss', mechanism: 'NE/DA effects on appetite', clinicalRelevance: 'Advantage over other antidepressants', desiredOrAdverse: 'desired' },
      ],

      onsetOfAction: '2-4 weeks for antidepressant effect',
      durationOfEffect: 'Continuous with regular dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~90%',
        route: ['oral'],
        factors: ['Well absorbed; food has minimal effect'],
        timeToePeak: '3 hours (IR); 5 hours (XL)',
        foodEffect: 'Minimal',
      },
      distribution: {
        volumeOfDistribution: '20-47 L/kg',
        proteinBinding: '84%',
        tissueDistribution: ['Crosses blood-brain barrier'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP2B6)',
        enzymes: ['CYP2B6 (primary)'],
        activeMetabolites: ['Hydroxybupropion', 'Threohydrobupropion', 'Erythrohydrobupropion'],
        geneticVariability: 'CYP2B6 polymorphisms affect metabolism',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (87% as metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '21 hours (parent); metabolites 20-37 hours',
      timeToSteadyState: '8 days',
    },

    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Seasonal affective disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Smoking cessation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Marketed as Zyban' },
      { condition: 'ADHD (adult)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],

    dosing: {
      usualDose: { amount: '150-300 mg', frequency: 'Daily (XL) or twice daily (SR)', route: 'Oral' },
      adjustments: [
        { condition: 'Initial dosing', adjustment: 'Start 150 mg daily x 3-7 days, then increase', rationale: 'Minimize seizure risk' },
        { condition: 'Smoking cessation', adjustment: '150 mg daily x 3 days, then 150 mg twice daily', rationale: 'Start 1-2 weeks before quit date' },
        { condition: 'Renal impairment (eGFR <90)', adjustment: 'Reduce dose and frequency', rationale: 'Metabolite accumulation' },
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose; avoid in severe impairment', rationale: 'Reduced clearance' },
      ],
      maxDose: '450 mg/day (single dose max 150 mg IR, 200 mg SR, 450 mg XL)',
      administration: { route: 'Oral', withFood: 'either', timing: 'Morning (or morning and early afternoon for twice daily); avoid evening to reduce insomnia', specialInstructions: ['Do not crush or chew extended-release', 'Maintain 8+ hours between doses if twice daily'] },
    },

    adverseEffects: [
      { name: 'Insomnia', frequency: 'common', severity: 'mild', mechanism: 'Activating NE/DA effects', management: 'Take early in day; avoid evening dosing', reversible: true, onsetTiming: 'Days' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Unknown (minimal anticholinergic activity)', management: 'Hydration, sugar-free gum', reversible: true, onsetTiming: 'Days' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually resolves', reversible: true, onsetTiming: 'Days' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Take with food; usually improves', reversible: true, onsetTiming: 'Days' },
      { name: 'Seizures', frequency: 'rare', severity: 'severe', mechanism: 'Dose-dependent lowering of seizure threshold', management: 'Contraindicated in seizure disorders; do not exceed max dose', reversible: true, onsetTiming: 'Variable' },
      { name: 'Hypertension', frequency: 'uncommon', severity: 'moderate', mechanism: 'NE effects', management: 'Monitor BP', reversible: true, onsetTiming: 'Weeks' },
    ],

    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Risk of hypertensive crisis', effect: 'Severe hypertension', management: '14-day washout required' },
      { interactingDrug: 'Drugs that lower seizure threshold', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive seizure risk', effect: 'Increased seizure risk', management: 'Use with caution; consider alternatives' },
      { interactingDrug: 'CYP2D6 substrates', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Bupropion inhibits CYP2D6', effect: 'Increased levels of CYP2D6 substrates', management: 'Reduce dose of affected drug' },
    ],

    contraindications: [
      { condition: 'Seizure disorder', type: 'absolute', reason: 'Lowers seizure threshold' },
      { condition: 'Eating disorders (anorexia, bulimia)', type: 'absolute', reason: 'Increased seizure risk' },
      { condition: 'Abrupt alcohol or sedative withdrawal', type: 'absolute', reason: 'Increased seizure risk' },
      { condition: 'MAOIs within 14 days', type: 'absolute', reason: 'Hypertensive crisis risk' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data; consider risk/benefit', recommendation: 'Use if clearly needed', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Use with caution; monitor infant' },
      { population: 'geriatric', consideration: 'Increased sensitivity', recommendation: 'Start at lower dose' },
      { population: 'renal-impairment', consideration: 'Metabolite accumulation', recommendation: 'Reduce dose frequency' },
    ],

    monitoring: [
      { parameter: 'Depression symptoms', frequency: 'Every 1-4 weeks initially', rationale: 'Assess response and suicidality', actionThreshold: 'No improvement by 4-6 weeks - reevaluate' },
      { parameter: 'Blood pressure', frequency: 'Periodically', rationale: 'Can cause hypertension', actionThreshold: 'Sustained HTN - evaluate' },
      { parameter: 'Seizure history/risk factors', frequency: 'Baseline', rationale: 'Contraindicated in seizure disorders', actionThreshold: 'Seizure risk factors - consider alternative' },
    ],

    patientEducation: [
      'May take 2-4 weeks to feel full benefit',
      'Take in the morning to avoid insomnia',
      'Do not crush or chew extended-release tablets',
      'Avoid alcohol (increases seizure risk)',
      'Do not exceed prescribed dose (seizure risk increases with dose)',
      'Report any seizures, severe headaches, or changes in mood',
      'For smoking cessation: start 1-2 weeks before quit date',
    ],

    clinicalPearls: [
      'No sexual dysfunction - advantage over SSRIs',
      'Weight neutral or slight weight loss - good choice for patients concerned about weight',
      'Seizure risk is dose-dependent - never exceed 450 mg/day',
      'Avoid in eating disorders, seizure history, alcohol withdrawal',
      'Potent CYP2D6 inhibitor - watch for interactions',
      'For smoking cessation: combines well with nicotine replacement',
      'Not effective for anxiety - may worsen it initially (activating)',
    ],
  },

  {
    id: 'duloxetine',
    genericName: 'Duloxetine',
    brandNames: ['Cymbalta', 'Irenka'],
    drugClass: 'Serotonin-norepinephrine reuptake inhibitor (SNRI)',
    category: 'psychiatric',

    overview: 'Duloxetine is an SNRI antidepressant that also has FDA approval for chronic pain conditions including diabetic neuropathy and fibromyalgia. Its dual mechanism makes it particularly useful when depression and chronic pain coexist.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT) and norepinephrine transporter (NET)',
      targetLocation: 'Presynaptic neurons in CNS and descending pain pathways',

      simpleExplanation: 'Duloxetine blocks the recycling of both serotonin and norepinephrine in the brain and spinal cord. The serotonin effect helps mood, while the norepinephrine effect also modulates pain pathways, making it effective for both depression and chronic pain.',

      detailedMechanism: 'Duloxetine potently inhibits both SERT and NET, increasing synaptic concentrations of serotonin and norepinephrine. In the brain, this modulates mood and anxiety circuits. Importantly, norepinephrine and serotonin also play key roles in descending inhibitory pain pathways from the brainstem to the spinal cord dorsal horn. By enhancing these neurotransmitters, duloxetine augments endogenous pain inhibition, explaining its efficacy in neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Duloxetine absorbed (enteric-coated)', result: 'Enters systemic circulation', timeframe: '6-10 hours to peak' },
        { order: 2, location: 'CNS - presynaptic', action: 'SERT and NET inhibited', result: 'Increased synaptic 5-HT and NE' },
        { order: 3, location: 'Brain mood circuits', action: 'Enhanced serotonergic/noradrenergic signaling', result: 'Antidepressant effect', timeframe: 'Weeks' },
        { order: 4, location: 'Spinal cord', action: 'Descending inhibitory pathways enhanced', result: 'Pain modulation' },
      ],

      physiologicalEffects: [
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Increased 5-HT and NE', clinicalRelevance: 'Treats depression and anxiety', desiredOrAdverse: 'desired' },
        { system: 'Peripheral nervous system', effect: 'Analgesia', mechanism: 'Descending pain pathway modulation', clinicalRelevance: 'Treats neuropathic pain, fibromyalgia', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Blood pressure increase', mechanism: 'NE effects', clinicalRelevance: 'Monitor BP', desiredOrAdverse: 'adverse' },
        { system: 'CNS', effect: 'Discontinuation syndrome', mechanism: 'Receptor adaptation', clinicalRelevance: 'Taper slowly when stopping', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: '1-2 weeks for pain; 2-4 weeks for depression',
      durationOfEffect: 'Continuous with regular dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~50% (enteric-coated to prevent degradation)',
        route: ['oral'],
        factors: ['Delayed-release capsule', 'High-fat meal delays absorption'],
        timeToePeak: '6-10 hours',
        foodEffect: 'Delays but does not reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '1640 L',
        proteinBinding: '>90%',
        tissueDistribution: ['Widely distributed', 'CNS'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP1A2, CYP2D6)',
        enzymes: ['CYP1A2', 'CYP2D6'],
        activeMetabolites: [],
        geneticVariability: 'CYP2D6 poor metabolizers have higher exposure',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (70% as metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '~12 hours (range 8-17 hours)',
      timeToSteadyState: '3 days',
    },

    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Diabetic peripheral neuropathic pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Fibromyalgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic musculoskeletal pain', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],

    dosing: {
      usualDose: { amount: '60 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Initial dosing (depression/anxiety)', adjustment: 'Start 30 mg daily x 1-2 weeks, then increase to 60 mg', rationale: 'Improve tolerability' },
        { condition: 'Pain conditions', adjustment: '30-60 mg daily', rationale: 'May not need higher doses for pain' },
        { condition: 'Renal impairment (CrCl <30)', adjustment: 'Not recommended', rationale: 'Significant accumulation' },
        { condition: 'Hepatic impairment', adjustment: 'Avoid in moderate-severe', rationale: 'Reduced clearance' },
      ],
      maxDose: '120 mg/day',
      administration: { route: 'Oral', withFood: 'either', timing: 'Same time daily', specialInstructions: ['Swallow whole - do not crush or open capsule', 'Can take with or without food'] },
    },

    adverseEffects: [
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'Serotonergic GI effects', management: 'Take with food; usually improves', reversible: true, onsetTiming: 'Days' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Noradrenergic effects', management: 'Hydration, sugar-free gum', reversible: true, onsetTiming: 'Days' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Noradrenergic GI effects', management: 'Fiber, fluids, stool softeners', reversible: true, onsetTiming: 'Days' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'Days' },
      { name: 'Sexual dysfunction', frequency: 'common', severity: 'moderate', mechanism: 'Serotonergic effects', management: 'Dose reduction; consider switch', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Blood pressure increase', frequency: 'uncommon', severity: 'moderate', mechanism: 'NE effects', management: 'Monitor BP; may need treatment', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Discontinuation syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Receptor adaptation', management: 'Taper slowly over weeks', reversible: true, onsetTiming: 'Days after stopping' },
      { name: 'Hepatotoxicity', frequency: 'rare', severity: 'severe', mechanism: 'Idiosyncratic', management: 'Monitor LFTs; discontinue if elevated', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome risk', effect: 'Potentially fatal serotonin syndrome', management: '14-day washout required' },
      { interactingDrug: 'CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced duloxetine metabolism', effect: 'Increased duloxetine levels', management: 'Avoid fluvoxamine; use caution with others' },
      { interactingDrug: 'Serotonergic drugs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive serotonergic effects', effect: 'Serotonin syndrome risk', management: 'Monitor for serotonin syndrome' },
      { interactingDrug: 'Heavy alcohol use', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hepatotoxicity risk', effect: 'Increased liver damage risk', management: 'Avoid in heavy drinkers' },
    ],

    contraindications: [
      { condition: 'MAOIs within 14 days', type: 'absolute', reason: 'Serotonin syndrome risk' },
      { condition: 'Uncontrolled narrow-angle glaucoma', type: 'absolute', reason: 'May increase intraocular pressure' },
      { condition: 'Severe renal impairment (CrCl <30)', type: 'absolute', reason: 'Significant accumulation' },
      { condition: 'Moderate-severe hepatic impairment', type: 'absolute', reason: 'Hepatotoxicity risk' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Third trimester use may cause neonatal complications', recommendation: 'Weigh risks vs benefits; taper if possible before delivery', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Use with caution' },
      { population: 'geriatric', consideration: 'Increased sensitivity; falls risk', recommendation: 'Start low; monitor closely' },
      { population: 'renal-impairment', consideration: 'Accumulates significantly', recommendation: 'Avoid if CrCl <30' },
    ],

    monitoring: [
      { parameter: 'Depression/anxiety symptoms', frequency: 'Every 1-4 weeks initially', rationale: 'Assess response and suicidality', actionThreshold: 'No improvement by 4-6 weeks - reevaluate' },
      { parameter: 'Blood pressure', frequency: 'Baseline and periodically', rationale: 'NE effects can raise BP', actionThreshold: 'Sustained HTN - evaluate' },
      { parameter: 'Liver function', frequency: 'If symptoms develop', rationale: 'Rare hepatotoxicity', actionThreshold: 'ALT >3x ULN - discontinue' },
    ],

    patientEducation: [
      'May take 2-4 weeks to feel full benefit',
      'Swallow capsules whole - do not crush or open',
      'Do not stop suddenly - must taper slowly to avoid withdrawal',
      'Report any nausea, dizziness, or changes in mood',
      'Avoid alcohol',
      'Report signs of liver problems: yellowing skin, dark urine, abdominal pain',
    ],

    clinicalPearls: [
      'Excellent choice when depression and chronic pain coexist',
      'Discontinuation syndrome is common - taper slowly over 2+ weeks',
      'Contraindicated in severe renal impairment - metabolites accumulate',
      'Avoid fluvoxamine - dramatic increase in duloxetine levels',
      'Check blood pressure - can cause hypertension',
      'Sexual side effects occur (like SSRIs) due to serotonergic activity',
      'Delayed-release capsule - must swallow whole',
    ],
  },

  {
    id: 'quetiapine',
    genericName: 'Quetiapine',
    brandNames: ['Seroquel', 'Seroquel XR'],
    drugClass: 'Atypical antipsychotic',
    category: 'psychiatric',

    overview: 'Quetiapine is a second-generation antipsychotic with broad receptor activity. It is FDA-approved for schizophrenia, bipolar disorder, and adjunctive treatment of major depression. Low doses are commonly used off-label for insomnia.',

    mechanism: {
      type: 'receptor-antagonist',
      target: 'Multiple receptors: D2, 5-HT2A, H1, α1, others',
      targetLocation: 'CNS',

      simpleExplanation: 'Quetiapine blocks multiple receptors in the brain. Blocking D2 dopamine receptors helps with psychotic symptoms. Blocking serotonin 5-HT2A receptors improves mood and reduces side effects. Blocking histamine H1 receptors causes sedation.',

      detailedMechanism: 'Quetiapine has complex receptor pharmacology: D2 antagonism (moderate affinity with fast dissociation - explaining low EPS) provides antipsychotic effect. 5-HT2A antagonism modulates dopamine release in cortex (cognitive/mood benefits) and reduces EPS. 5-HT1A partial agonism may contribute to anxiolytic/antidepressant effects. H1 antagonism causes sedation and weight gain. α1 antagonism causes orthostatic hypotension. The active metabolite norquetiapine has NET inhibition (NE reuptake inhibition), contributing to antidepressant effects.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Quetiapine absorbed', result: 'Reaches CNS', timeframe: '1.5 hours to peak' },
        { order: 2, location: 'Liver', action: 'CYP3A4 metabolism', result: 'Norquetiapine (active metabolite) formed' },
        { order: 3, location: 'Mesolimbic pathway', action: 'D2 receptor blockade', result: 'Antipsychotic effect' },
        { order: 4, location: 'Multiple CNS regions', action: '5-HT2A, H1, α1 blockade', result: 'Sedation, mood effects, side effects' },
      ],

      physiologicalEffects: [
        { system: 'CNS', effect: 'Antipsychotic', mechanism: 'D2 blockade in mesolimbic pathway', clinicalRelevance: 'Treats schizophrenia, bipolar mania', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'H1 antagonism', clinicalRelevance: 'Can be therapeutic or adverse', desiredOrAdverse: 'both' },
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Norquetiapine NET inhibition; 5-HT1A agonism', clinicalRelevance: 'Adjunctive depression treatment', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Weight gain', mechanism: 'H1 and 5-HT2C effects', clinicalRelevance: 'Major long-term concern', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Orthostatic hypotension', mechanism: 'α1 antagonism', clinicalRelevance: 'Risk of falls', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Sedation: hours; Antipsychotic: days to weeks',
      durationOfEffect: 'Continuous with regular dosing',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~100%',
        route: ['oral'],
        factors: ['Food increases AUC by 25%'],
        timeToePeak: '1.5 hours (IR); 6 hours (XR)',
        foodEffect: 'XR should be taken without food or with light meal (<300 cal)',
      },
      distribution: {
        volumeOfDistribution: '10 L/kg',
        proteinBinding: '83%',
        tissueDistribution: ['Widely distributed', 'CNS'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: ['Norquetiapine (active)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (73%) and fecal (20%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '~6 hours (parent); ~12 hours (norquetiapine)',
      timeToSteadyState: '2 days',
    },

    indications: [
      { condition: 'Schizophrenia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar mania (acute)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar depression', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Major depression (adjunctive)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'XR formulation' },
      { condition: 'Insomnia', approvalStatus: 'off-label', evidenceLevel: 'low', firstLine: false, notes: 'Common but not recommended due to metabolic risks' },
    ],

    dosing: {
      usualDose: { amount: '150-800 mg', frequency: 'Daily (XR) or divided (IR)', route: 'Oral' },
      adjustments: [
        { condition: 'Schizophrenia', adjustment: 'Start 25 mg twice daily; titrate to 300-800 mg/day', rationale: 'Gradual titration for tolerability' },
        { condition: 'Bipolar mania', adjustment: '100 mg day 1, 200 mg day 2, 300 mg day 3, then 400-800 mg', rationale: 'Faster titration often needed' },
        { condition: 'Bipolar depression', adjustment: '50 mg day 1, 100 mg day 2, 200 mg day 3, then 300 mg', rationale: 'Target 300 mg for depression' },
        { condition: 'MDD adjunct (XR)', adjustment: '50-300 mg at bedtime', rationale: 'Lower doses for depression' },
        { condition: 'Hepatic impairment', adjustment: 'Start 25 mg, titrate slowly', rationale: 'Reduced clearance' },
      ],
      maxDose: '800 mg/day',
      administration: { route: 'Oral', withFood: 'either', timing: 'XR at bedtime (sedating); IR in divided doses', specialInstructions: ['XR: take without food or light meal (<300 cal)', 'Swallow XR whole'] },
    },

    adverseEffects: [
      { name: 'Sedation/somnolence', frequency: 'very-common', severity: 'moderate', mechanism: 'H1 antagonism', management: 'Take at bedtime; may improve over time', reversible: true, onsetTiming: 'Immediate' },
      { name: 'Weight gain', frequency: 'common', severity: 'moderate', mechanism: 'H1/5-HT2C effects', management: 'Diet/exercise; consider metabolically neutral alternative', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Orthostatic hypotension', frequency: 'common', severity: 'moderate', mechanism: 'α1 antagonism', management: 'Rise slowly; adequate hydration; slower titration', reversible: true, onsetTiming: 'Days' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic-like effect', management: 'Hydration, sugar-free gum', reversible: true, onsetTiming: 'Days' },
      { name: 'Dyslipidemia', frequency: 'common', severity: 'moderate', mechanism: 'Metabolic effects', management: 'Monitor lipids; lifestyle; may need statins', reversible: true, onsetTiming: 'Months' },
      { name: 'Hyperglycemia/diabetes', frequency: 'uncommon', severity: 'severe', mechanism: 'Metabolic effects', management: 'Monitor glucose; may need to switch drugs', reversible: true, onsetTiming: 'Months' },
      { name: 'QT prolongation', frequency: 'rare', severity: 'severe', mechanism: 'Cardiac ion channel effects', management: 'Avoid in QT prolongation; monitor ECG', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Strong CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced quetiapine metabolism', effect: 'Increased quetiapine levels 6-fold', management: 'Reduce quetiapine dose to 1/6' },
      { interactingDrug: 'Strong CYP3A4 inducers (rifampin, phenytoin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased quetiapine metabolism', effect: 'Reduced quetiapine levels 5-fold', management: 'Increase quetiapine dose up to 5-fold' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Excessive sedation', management: 'Use caution; reduce doses' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Third trimester: risk of EPS/withdrawal in neonate', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Not recommended' },
      { population: 'geriatric', consideration: 'Increased mortality in dementia-related psychosis (black box); orthostatic hypotension', recommendation: 'Start very low; titrate slowly; not for dementia-related psychosis' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'Start 25 mg; titrate slowly' },
    ],

    monitoring: [
      { parameter: 'Metabolic panel (fasting glucose, lipids)', frequency: 'Baseline, 12 weeks, then annually', rationale: 'Metabolic syndrome risk', actionThreshold: 'Significant changes - lifestyle intervention or switch' },
      { parameter: 'Weight/BMI', frequency: 'Baseline, then at each visit', rationale: 'Weight gain common', actionThreshold: '>7% gain - evaluate' },
      { parameter: 'Blood pressure', frequency: 'Baseline and periodically', rationale: 'Orthostatic hypotension', actionThreshold: 'Symptomatic - slow titration, hydration' },
    ],

    patientEducation: [
      'Take at the same time each day',
      'Rise slowly from sitting or lying to avoid dizziness',
      'May cause significant drowsiness - do not drive until you know how it affects you',
      'Weight gain is common - maintain healthy diet and exercise',
      'Do not drink alcohol',
      'Do not stop suddenly - must taper',
      'Report any involuntary movements, high fever, or muscle stiffness',
    ],

    clinicalPearls: [
      'Low EPS risk due to fast D2 dissociation and 5-HT2A blockade',
      'Significant metabolic effects - monitor weight, glucose, lipids',
      'Low doses for insomnia expose patients to metabolic risks without clear benefit',
      'Black box warning: increased mortality in elderly with dementia-related psychosis',
      'CYP3A4 interactions are significant - check for inducers/inhibitors',
      'Norquetiapine (metabolite) has norepinephrine reuptake inhibition - antidepressant effect',
      'XR formulation has lower peak levels - may reduce sedation',
    ],
  },

  // ============================================
  // Antimicrobial Medications
  // ============================================

  {
    id: 'amoxicillin',
    genericName: 'Amoxicillin',
    brandNames: ['Amoxil', 'Trimox'],
    drugClass: 'Aminopenicillin (beta-lactam antibiotic)',
    category: 'antimicrobial',

    overview: 'Amoxicillin is a broad-spectrum penicillin-class antibiotic that is one of the most commonly prescribed antibiotics worldwide. It is well-absorbed orally and is first-line for many common infections.',

    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'Penicillin-binding proteins (PBPs)',
      targetLocation: 'Bacterial cell wall',

      simpleExplanation: 'Amoxicillin kills bacteria by preventing them from building their cell walls. It binds to enzymes that bacteria need to construct their protective outer wall, causing the wall to weaken and the bacteria to burst.',

      detailedMechanism: 'Amoxicillin is a bactericidal beta-lactam that inhibits bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), which are transpeptidases that catalyze the final cross-linking step of peptidoglycan synthesis. By inhibiting this cross-linking, the cell wall becomes structurally weak. Combined with continued autolytic enzyme activity, this leads to cell lysis and death. Amoxicillin has better gram-negative coverage than penicillin but is susceptible to beta-lactamases produced by resistant bacteria.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Amoxicillin absorbed', result: 'High bioavailability (~90%)', timeframe: '1-2 hours to peak' },
        { order: 2, location: 'Bacterial periplasm', action: 'Drug penetrates outer membrane', result: 'Reaches PBPs' },
        { order: 3, location: 'Cell wall synthesis site', action: 'Binds PBPs (transpeptidases)', result: 'Peptidoglycan cross-linking inhibited' },
        { order: 4, location: 'Bacterial cell wall', action: 'Wall weakens; autolysins activated', result: 'Cell lysis and death' },
      ],

      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bactericidal', mechanism: 'Cell wall disruption', clinicalRelevance: 'Kills susceptible bacteria', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Diarrhea', mechanism: 'Disruption of normal gut flora', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Immune', effect: 'Allergic reaction', mechanism: 'Beta-lactam ring is immunogenic', clinicalRelevance: 'Penicillin allergy', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours to days (depending on infection)',
      durationOfEffect: 'Serum concentration-dependent; dosed every 8-12 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~90% (excellent oral absorption)',
        route: ['oral', 'intravenous'],
        factors: ['Not significantly affected by food'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Minimal - can take with or without food',
      },
      distribution: {
        volumeOfDistribution: '0.3-0.4 L/kg',
        proteinBinding: '~20%',
        tissueDistribution: ['Good penetration to respiratory tract, ENT, urinary tract', 'Poor CNS penetration unless meninges inflamed'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (60-80% unchanged)',
        renalClearance: 'High - secreted into tubules',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '1-1.5 hours (prolonged in renal failure)',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Strep pharyngitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute otitis media', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Community-acquired pneumonia (mild)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute bacterial sinusitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'H. pylori eradication (with other agents)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Dental infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '500 mg', frequency: 'Every 8-12 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Severe infections', adjustment: '875 mg every 12 hours or 500 mg every 8 hours', rationale: 'Higher doses for serious infections' },
        { condition: 'Strep pharyngitis', adjustment: '500 mg twice daily x 10 days (or 1000 mg once daily)', rationale: 'Standard treatment course' },
        { condition: 'Renal impairment (CrCl 10-30)', adjustment: '250-500 mg every 12 hours', rationale: 'Reduced clearance' },
        { condition: 'Renal impairment (CrCl <10)', adjustment: '250-500 mg every 24 hours', rationale: 'Significant accumulation' },
        { condition: 'Pediatric', adjustment: '25-50 mg/kg/day divided every 8-12 hours', rationale: 'Weight-based dosing' },
      ],
      maxDose: '3 g/day (adults)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Complete full course even if feeling better', 'Shake suspension well before use'] },
    },

    adverseEffects: [
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Gut flora disruption', management: 'Probiotics; usually self-limited', reversible: true, onsetTiming: 'Days' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI irritation', management: 'Take with food', reversible: true, onsetTiming: 'Days' },
      { name: 'Rash (non-allergic)', frequency: 'common', severity: 'mild', mechanism: 'Unknown; more common in EBV/CMV infection', management: 'Usually benign; distinguish from allergy', reversible: true, onsetTiming: 'Days' },
      { name: 'Allergic reaction', frequency: 'uncommon', severity: 'moderate', mechanism: 'IgE-mediated', management: 'Stop drug; antihistamines; epinephrine if severe', reversible: true, onsetTiming: 'Minutes to hours' },
      { name: 'Anaphylaxis', frequency: 'rare', severity: 'life-threatening', mechanism: 'IgE-mediated', management: 'Epinephrine; emergency care', reversible: true, onsetTiming: 'Minutes' },
      { name: 'C. difficile colitis', frequency: 'rare', severity: 'severe', mechanism: 'Gut flora disruption', management: 'Stop antibiotic; treat C. diff', reversible: true, onsetTiming: 'Days to weeks' },
    ],

    interactions: [
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced renal clearance of methotrexate', effect: 'Increased methotrexate toxicity', management: 'Monitor methotrexate levels' },
      { interactingDrug: 'Allopurinol', interactionType: 'pharmacodynamic', severity: 'minor', mechanism: 'Unknown mechanism', effect: 'Increased rash risk', management: 'Be aware of increased rash risk' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Altered gut flora affecting vitamin K', effect: 'Increased INR', management: 'Monitor INR closely' },
    ],

    contraindications: [
      { condition: 'Penicillin allergy (IgE-mediated/anaphylaxis)', type: 'absolute', reason: 'Risk of anaphylaxis' },
      { condition: 'History of amoxicillin-associated hepatic impairment', type: 'absolute', reason: 'Risk of recurrent hepatotoxicity' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta but long safety history', recommendation: 'Safe - first-line for many infections', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk in small amounts', recommendation: 'Safe to use' },
      { population: 'renal-impairment', consideration: 'Renally excreted', recommendation: 'Reduce dose/frequency based on CrCl' },
      { population: 'pediatric', consideration: 'Well-established safety', recommendation: 'Weight-based dosing' },
    ],

    monitoring: [
      { parameter: 'Clinical response', frequency: 'After 2-3 days of therapy', rationale: 'Ensure infection responding', actionThreshold: 'No improvement - reassess diagnosis and coverage' },
      { parameter: 'Allergic symptoms', frequency: 'Throughout course', rationale: 'Monitor for allergic reaction', actionThreshold: 'Rash, hives, breathing difficulty - stop and evaluate' },
    ],

    patientEducation: [
      'Complete the full course of antibiotics even if you feel better',
      'Take doses evenly spaced throughout the day',
      'Can be taken with or without food',
      'Stop and seek medical attention if you develop a rash, hives, or difficulty breathing',
      'Diarrhea is common - contact your doctor if it is severe or bloody',
    ],

    clinicalPearls: [
      'High oral bioavailability makes it interchangeable with IV in many situations',
      'Mononucleosis: amoxicillin causes rash in EBV infection - not true allergy',
      'Combine with clavulanate (Augmentin) for beta-lactamase coverage',
      'Excellent coverage: Strep, E. coli, Proteus, H. influenzae, H. pylori',
      'Not effective: MRSA, Pseudomonas, beta-lactamase producers',
      'Cross-reactivity with cephalosporins ~1-2% (historical 10% is overstated)',
    ],
  },

  {
    id: 'azithromycin',
    genericName: 'Azithromycin',
    brandNames: ['Zithromax', 'Z-Pak', 'Zmax'],
    drugClass: 'Macrolide antibiotic',
    category: 'antimicrobial',

    overview: 'Azithromycin is a macrolide antibiotic with excellent tissue penetration and a long half-life allowing short treatment courses. It is commonly used for respiratory tract infections, STIs, and as an alternative in penicillin-allergic patients.',

    mechanism: {
      type: 'protein-synthesis-inhibitor',
      target: '50S ribosomal subunit',
      targetLocation: 'Bacterial ribosome',

      simpleExplanation: 'Azithromycin stops bacteria from making essential proteins by binding to their ribosomes. Without new proteins, bacteria cannot grow or repair themselves, leading to their death.',

      detailedMechanism: 'Azithromycin binds to the 50S ribosomal subunit, specifically to the 23S rRNA component. This binding blocks the exit tunnel through which nascent polypeptide chains emerge, inhibiting translocation and causing premature dissociation of peptidyl-tRNA. The result is inhibition of protein synthesis. Azithromycin is generally bacteriostatic but can be bactericidal at high concentrations against susceptible organisms. It concentrates heavily in phagocytes and tissues, with intracellular levels 10-100 times higher than serum.',

      mechanismSteps: [
        { order: 1, location: 'GI tract/systemic', action: 'Azithromycin absorbed', result: 'Tissue distribution begins', timeframe: '2-3 hours to peak' },
        { order: 2, location: 'Tissues', action: 'Concentrated in phagocytes', result: 'Delivered to infection site' },
        { order: 3, location: 'Bacterial ribosome', action: 'Binds 50S subunit (23S rRNA)', result: 'Exit tunnel blocked' },
        { order: 4, location: 'Bacterial cell', action: 'Protein synthesis halted', result: 'Bacteriostatic/bactericidal effect' },
      ],

      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bacteriostatic (bactericidal at high concentrations)', mechanism: 'Protein synthesis inhibition', clinicalRelevance: 'Treats many respiratory and STI pathogens', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'GI upset/diarrhea', mechanism: 'Motilin agonism (prokinetic effect)', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Cardiac ion channel effects', clinicalRelevance: 'FDA warning', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours to days',
      durationOfEffect: 'Tissue levels persist for days after last dose',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '37% (capsules); improved with tablets',
        route: ['oral', 'intravenous'],
        factors: ['Capsules: food reduces absorption; Tablets: minimal food effect'],
        timeToePeak: '2-3 hours',
        foodEffect: 'Variable - tablets can be taken with or without food',
      },
      distribution: {
        volumeOfDistribution: '31 L/kg (extensive tissue distribution)',
        proteinBinding: '7-50%',
        tissueDistribution: ['Lungs 10-100x serum', 'Phagocytes 50-100x serum', 'Skin', 'Prostate'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (minor)',
        enzymes: ['CYP3A4 (minor)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Biliary/fecal (majority)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '68 hours (tissue retention even longer)',
      timeToSteadyState: 'Not typically relevant (short courses)',
    },

    indications: [
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Alternative to beta-lactam or for atypicals' },
      { condition: 'Acute bacterial sinusitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Chlamydia trachomatis infection', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Single 1 g dose' },
      { condition: 'Gonorrhea (with ceftriaxone)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'COPD exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'MAC prophylaxis (HIV)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '500 mg day 1, then 250 mg', frequency: 'Daily x 4 more days (Z-Pak)', route: 'Oral' },
      adjustments: [
        { condition: 'Chlamydia', adjustment: '1 g single dose', rationale: 'Single-dose cure' },
        { condition: 'Community-acquired pneumonia', adjustment: '500 mg day 1, then 250 mg days 2-5', rationale: 'Standard 5-day course' },
        { condition: 'Zmax extended release', adjustment: '2 g single dose', rationale: 'Extended-release one-time dosing' },
        { condition: 'Hepatic impairment', adjustment: 'Use caution', rationale: 'Hepatic excretion; monitor for toxicity' },
      ],
      maxDose: '500 mg/day (after loading dose)',
      administration: { route: 'Oral', withFood: 'either', timing: 'Same time daily', specialInstructions: ['Complete full course', 'Tablets can be taken with or without food'] },
    },

    adverseEffects: [
      { name: 'Diarrhea/GI upset', frequency: 'common', severity: 'mild', mechanism: 'Motilin agonism (prokinetic)', management: 'Usually self-limited', reversible: true, onsetTiming: 'Days' },
      { name: 'Nausea/vomiting', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Take with food if needed', reversible: true, onsetTiming: 'Days' },
      { name: 'Abdominal pain', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Usually self-limited', reversible: true, onsetTiming: 'Days' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Cardiac ion channel effects', management: 'Avoid in QT prolongation; use caution with other QT-prolonging drugs', reversible: true, onsetTiming: 'Variable' },
      { name: 'Hepatotoxicity', frequency: 'rare', severity: 'severe', mechanism: 'Idiosyncratic', management: 'Monitor LFTs if symptoms', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT prolongation', effect: 'Increased arrhythmia risk', management: 'Avoid combination if possible' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Altered gut flora; possible P-gp inhibition', effect: 'Increased INR', management: 'Monitor INR' },
      { interactingDrug: 'Nelfinavir', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased azithromycin levels', effect: 'Increased side effects', management: 'Monitor for toxicity' },
    ],

    contraindications: [
      { condition: 'History of cholestatic jaundice/hepatic dysfunction with azithromycin', type: 'absolute', reason: 'Risk of recurrent hepatotoxicity' },
      { condition: 'Hypersensitivity to macrolides', type: 'absolute', reason: 'Allergic reaction' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but generally considered safe', recommendation: 'Use if clearly needed', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Use with caution' },
      { population: 'geriatric', consideration: 'Increased QT prolongation risk', recommendation: 'Caution in cardiac disease' },
      { population: 'hepatic-impairment', consideration: 'Hepatic excretion', recommendation: 'Use with caution' },
    ],

    monitoring: [
      { parameter: 'Clinical response', frequency: 'After 2-3 days', rationale: 'Ensure infection responding', actionThreshold: 'No improvement - reassess' },
      { parameter: 'ECG (if cardiac risk factors)', frequency: 'Baseline', rationale: 'QT prolongation risk', actionThreshold: 'Prolonged QT - avoid use' },
    ],

    patientEducation: [
      'Complete the full course even if you feel better',
      'Can be taken with or without food',
      'Report any irregular heartbeat, fainting, or palpitations',
      'Diarrhea is common and usually mild',
      'For chlamydia: partners should also be treated',
    ],

    clinicalPearls: [
      'Long half-life allows short 3-5 day courses',
      'Tissue levels persist for days after last dose - why 5 days = 10 days of coverage',
      'Single dose 1 g for chlamydia - excellent for compliance',
      'QT prolongation risk - FDA warning; avoid in cardiac patients',
      'Not reliable for strep pharyngitis due to resistance',
      'Good atypical coverage: Mycoplasma, Legionella, Chlamydophila',
      'Low drug interaction potential compared to other macrolides',
    ],
  },

  {
    id: 'ciprofloxacin',
    genericName: 'Ciprofloxacin',
    brandNames: ['Cipro', 'Cipro XR'],
    drugClass: 'Fluoroquinolone antibiotic',
    category: 'antimicrobial',

    overview: 'Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic with excellent gram-negative coverage. It has FDA boxed warnings for serious adverse effects and should be reserved for infections without safer alternatives.',

    mechanism: {
      type: 'dna-modifier',
      target: 'DNA gyrase (topoisomerase II) and topoisomerase IV',
      targetLocation: 'Bacterial chromosome',

      simpleExplanation: 'Ciprofloxacin kills bacteria by blocking enzymes they need to copy and repair their DNA. Without functional DNA gyrase and topoisomerase IV, bacterial DNA becomes damaged and the bacteria die.',

      detailedMechanism: 'Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II, primary target in gram-negatives) and topoisomerase IV (primary target in gram-positives). DNA gyrase introduces negative supercoils and relieves positive supercoiling during DNA replication. Topoisomerase IV separates daughter chromosomes. By inhibiting these enzymes, ciprofloxacin causes accumulation of positive supercoils, double-stranded DNA breaks, and inhibition of DNA replication and repair, resulting in rapid bactericidal activity.',

      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Ciprofloxacin absorbed', result: 'Systemic distribution', timeframe: '1-2 hours to peak' },
        { order: 2, location: 'Bacterial cell', action: 'Drug penetrates cell', result: 'Reaches DNA enzymes' },
        { order: 3, location: 'Bacterial chromosome', action: 'Inhibits DNA gyrase/topoisomerase IV', result: 'DNA supercoiling disrupted; breaks accumulate' },
        { order: 4, location: 'Bacterial cell', action: 'DNA replication halted; SOS response triggered', result: 'Bactericidal cell death' },
      ],

      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bactericidal', mechanism: 'DNA damage', clinicalRelevance: 'Rapid killing of susceptible bacteria', desiredOrAdverse: 'desired' },
        { system: 'Musculoskeletal', effect: 'Tendinopathy/tendon rupture', mechanism: 'Unclear - possibly collagen damage', clinicalRelevance: 'FDA boxed warning', desiredOrAdverse: 'adverse' },
        { system: 'Neurological', effect: 'CNS effects (seizures, peripheral neuropathy)', mechanism: 'GABA receptor inhibition; mitochondrial toxicity', clinicalRelevance: 'FDA boxed warning', desiredOrAdverse: 'adverse' },
      ],

      onsetOfAction: 'Hours',
      durationOfEffect: 'Serum half-life based; dosed every 12 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '70-80%',
        route: ['oral', 'intravenous'],
        factors: ['Reduced by divalent cations (Ca, Mg, Fe, Zn)'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Dairy products and antacids significantly reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '2-3 L/kg',
        proteinBinding: '20-40%',
        tissueDistribution: ['Excellent prostate penetration', 'Good bone penetration', 'Lungs', 'Urine'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (partial)',
        enzymes: ['CYP1A2 (minor)'],
        activeMetabolites: ['Metabolites have some activity'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (40-50% unchanged)',
        renalClearance: 'Tubular secretion and glomerular filtration',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '4 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Complicated UTI/pyelonephritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Use only when no alternatives' },
      { condition: 'Infectious diarrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'For serious bacterial gastroenteritis' },
      { condition: 'Anthrax (post-exposure)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Pseudomonas infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'One of few oral anti-pseudomonal options' },
      { condition: 'Osteomyelitis (gram-negative)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],

    dosing: {
      usualDose: { amount: '250-750 mg', frequency: 'Every 12 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Simple UTI', adjustment: '250 mg every 12 hours x 3 days', rationale: 'Short course for uncomplicated infection' },
        { condition: 'Complicated UTI', adjustment: '500 mg every 12 hours x 7-14 days', rationale: 'Longer course for complicated infections' },
        { condition: 'Severe infections', adjustment: '750 mg every 12 hours', rationale: 'Maximum oral dosing' },
        { condition: 'Renal impairment (CrCl <30)', adjustment: 'Reduce dose by 50%', rationale: 'Reduced clearance' },
      ],
      maxDose: '1500 mg/day oral; 1200 mg/day IV',
      administration: { route: 'Oral/IV', withFood: 'without-food', timing: 'Avoid dairy and antacids within 2 hours', specialInstructions: ['Do not take with dairy products, antacids, or iron/zinc supplements', 'Maintain hydration'] },
    },

    adverseEffects: [
      { name: 'Nausea/GI upset', frequency: 'common', severity: 'mild', mechanism: 'GI irritation', management: 'Take with non-dairy food', reversible: true, onsetTiming: 'Days' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Gut flora disruption', management: 'Usually self-limited', reversible: true, onsetTiming: 'Days' },
      { name: 'Tendinopathy/tendon rupture (BOXED WARNING)', frequency: 'uncommon', severity: 'severe', mechanism: 'Collagen damage; MMP activation', management: 'Stop immediately if tendon pain; avoid in high-risk patients', reversible: false, onsetTiming: 'Days to months' },
      { name: 'Peripheral neuropathy (BOXED WARNING)', frequency: 'uncommon', severity: 'severe', mechanism: 'Mitochondrial toxicity', management: 'Stop immediately; may be permanent', reversible: false, onsetTiming: 'Variable' },
      { name: 'CNS effects (headache, dizziness, seizures)', frequency: 'uncommon', severity: 'moderate', mechanism: 'GABA receptor inhibition', management: 'Caution in seizure disorders', reversible: true, onsetTiming: 'Days' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Cardiac ion channel effects', management: 'Avoid in QT prolongation', reversible: true, onsetTiming: 'Variable' },
      { name: 'Aortic aneurysm/dissection (BOXED WARNING)', frequency: 'rare', severity: 'life-threatening', mechanism: 'Collagen damage in vessel wall', management: 'Avoid in aortic aneurysm patients', reversible: false, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Antacids, dairy, iron, zinc', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Chelation reduces absorption', effect: 'Dramatically reduced ciprofloxacin levels', management: 'Separate by 2-4 hours' },
      { interactingDrug: 'Theophylline', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP1A2 inhibition', effect: 'Increased theophylline levels/toxicity', management: 'Reduce theophylline dose; monitor levels' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP1A2 inhibition; gut flora effects', effect: 'Increased INR', management: 'Monitor INR closely' },
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT prolongation', effect: 'Increased arrhythmia risk', management: 'Avoid combination' },
      { interactingDrug: 'Tizanidine', interactionType: 'pharmacokinetic', severity: 'contraindicated', mechanism: 'CYP1A2 inhibition', effect: 'Dramatically increased tizanidine levels', management: 'Contraindicated' },
    ],

    contraindications: [
      { condition: 'Concurrent tizanidine', type: 'absolute', reason: 'Severe tizanidine toxicity' },
      { condition: 'Myasthenia gravis', type: 'absolute', reason: 'May exacerbate muscle weakness' },
      { condition: 'History of tendon disorders with fluoroquinolones', type: 'absolute', reason: 'Risk of recurrence' },
    ],

    specialPopulations: [
      { population: 'pregnancy', consideration: 'Animal data show cartilage damage', recommendation: 'Avoid unless no alternatives', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Avoid if possible' },
      { population: 'pediatric', consideration: 'Risk of cartilage damage (animal data)', recommendation: 'Not first-line in children <18; use when no alternatives' },
      { population: 'geriatric', consideration: 'Increased tendon rupture, CNS effects, aortic risks', recommendation: 'Avoid when possible; high-risk population' },
    ],

    monitoring: [
      { parameter: 'Clinical response', frequency: 'After 2-3 days', rationale: 'Ensure infection responding', actionThreshold: 'No improvement - reassess' },
      { parameter: 'Tendon symptoms', frequency: 'Throughout and after treatment', rationale: 'FDA boxed warning', actionThreshold: 'Any tendon pain - stop immediately' },
      { parameter: 'Neurological symptoms', frequency: 'Throughout treatment', rationale: 'FDA boxed warning', actionThreshold: 'Numbness, tingling, weakness - stop immediately' },
    ],

    patientEducation: [
      'Do not take with dairy products, antacids, or iron/calcium supplements',
      'Stop immediately and call your doctor if you experience tendon pain, swelling, or rupture',
      'Stop and call if you develop numbness, tingling, or weakness',
      'Drink plenty of fluids',
      'Avoid excessive sun exposure',
      'Complete the full course of treatment',
    ],

    clinicalPearls: [
      'FDA boxed warnings: tendon rupture, peripheral neuropathy, CNS effects, aortic aneurysm, myasthenia gravis exacerbation',
      'Reserve for infections without safer alternatives',
      'Excellent gram-negative coverage including Pseudomonas',
      'Poor gram-positive coverage - not for strep or staph',
      'Chelation with divalent cations dramatically reduces absorption',
      'Tendon rupture risk higher in: elderly, steroids, kidney/heart/lung transplant',
      'One of few oral options for Pseudomonas',
    ],
  },

  // ============================================
  // Neurological/Anticonvulsant Medications
  // ============================================

  {
    id: 'gabapentin',
    genericName: 'Gabapentin',
    brandNames: ['Neurontin', 'Gralise', 'Horizant'],
    drugClass: 'Gabapentinoid (anticonvulsant)',
    category: 'neurological',

    overview: 'Gabapentin is a GABA analog that paradoxically does not work on GABA receptors. It binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing neurotransmitter release. Used for epilepsy and neuropathic pain. Widely prescribed for various pain syndromes, though evidence varies.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'Alpha-2-delta subunit of voltage-gated calcium channels',
      targetLocation: 'Presynaptic nerve terminals in CNS',
      simpleExplanation: 'Reduces the release of excitatory neurotransmitters by blocking calcium channels involved in neurotransmission.',
      detailedMechanism: 'Gabapentin binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels. This binding reduces calcium influx at nerve terminals, decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. Despite being a GABA analog, it has no direct effect on GABA receptors or metabolism.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Gabapentin absorbed (saturable)', result: 'Drug enters systemic circulation' },
        { order: 2, location: 'CNS', action: 'Crosses blood-brain barrier', result: 'Distributed to nerve terminals' },
        { order: 3, location: 'Presynaptic terminals', action: 'Binds alpha-2-delta subunit of calcium channels', result: 'Reduced calcium channel function' },
        { order: 4, location: 'Synapse', action: 'Decreased calcium influx', result: 'Reduced neurotransmitter release' },
        { order: 5, location: 'Neural circuits', action: 'Reduced excitatory transmission', result: 'Decreased neuronal hyperexcitability and pain signaling' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Decreased neuronal excitability', mechanism: 'Reduced presynaptic calcium influx', clinicalRelevance: 'Anticonvulsant effect', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Reduced pain transmission', mechanism: 'Decreased substance P and glutamate release', clinicalRelevance: 'Neuropathic pain relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'CNS depression from reduced excitatory transmission', clinicalRelevance: 'Drowsiness, especially initially', desiredOrAdverse: 'adverse' },
        { system: 'Peripheral', effect: 'Edema', mechanism: 'Calcium channel effects on vascular tone', clinicalRelevance: 'Swelling in extremities', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-4 weeks for neuropathic pain; days for seizure control',
      durationOfEffect: '6-8 hours (requires TID dosing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '60% at 300mg, 35% at 1600mg (saturable)',
        route: ['oral'],
        factors: ['Absorption decreases at higher doses due to saturable transport'],
        timeToePeak: '2-3 hours',
      },
      distribution: {
        volumeOfDistribution: '0.8 L/kg',
        proteinBinding: 'Negligible (<3%)',
        tissueDistribution: ['CNS', 'Peripheral nerves'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (unchanged)',
        renalClearance: '190 mL/min',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '5-7 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Partial seizures (adjunctive)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Add-on therapy for partial seizures in adults and children 3+' },
      { condition: 'Postherpetic neuralgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'First-line treatment option' },
      { condition: 'Diabetic peripheral neuropathy', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Very commonly used though technically off-label' },
      { condition: 'Restless legs syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Gabapentin enacarbil (Horizant) specifically approved' },
    ],

    dosing: {
      usualDose: { amount: '300-600mg', frequency: 'Three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 30-60 mL/min', adjustment: '200-700mg BID', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl 15-30 mL/min', adjustment: '200-700mg once daily', rationale: 'Significantly reduced clearance' },
        { condition: 'CrCl <15 mL/min', adjustment: '100-300mg once daily', rationale: 'Severely impaired clearance' },
        { condition: 'Hemodialysis', adjustment: 'Supplemental 125-350mg after dialysis', rationale: 'Drug removed by dialysis' },
      ],
      maxDose: '3600mg/day',
      administration: { route: 'Oral', withFood: 'either', timing: 'Evenly spaced doses TID', specialInstructions: ['Start low (100-300mg at bedtime)', 'Titrate slowly over weeks', 'Split doses to maximize absorption'] },
    },

    adverseEffects: [
      { name: 'Somnolence/sedation', frequency: 'very-common', severity: 'mild', mechanism: 'CNS depression', management: 'Start low, titrate slowly; often improves with time', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Dizziness', frequency: 'very-common', severity: 'mild', mechanism: 'CNS effect', management: 'Slow titration; usually improves over weeks', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Peripheral edema', frequency: 'common', severity: 'mild', mechanism: 'Calcium channel effects on vascular tone', management: 'Monitor weight; may require diuretics or dose reduction', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Weight gain', frequency: 'common', severity: 'mild', mechanism: 'Appetite stimulation and edema', management: 'Dietary counseling; consider alternative if problematic', reversible: true, onsetTiming: 'Gradual over months' },
      { name: 'Respiratory depression', frequency: 'rare', severity: 'severe', mechanism: 'CNS depression, especially with opioids', management: 'FDA warning about use with opioids; monitor carefully', reversible: true, onsetTiming: 'Usually with concomitant opioids' },
    ],

    interactions: [
      { interactingDrug: 'Opioids', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Increased risk of respiratory depression, sedation, death', management: 'FDA boxed warning; use lowest effective doses, monitor closely' },
      { interactingDrug: 'Antacids (aluminum/magnesium)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced GI absorption', effect: 'Reduced gabapentin absorption by 20%', management: 'Give gabapentin at least 2 hours after antacids' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive CNS effects', effect: 'Enhanced sedation', management: 'Use caution; may need dose adjustment' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity to gabapentin', type: 'absolute', reason: 'Risk of serious allergic reaction' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Increased sensitivity; higher fall risk', recommendation: 'Start at lowest dose, titrate slowly. Adjust for renal function.' },
      { population: 'renal-impairment', consideration: 'Exclusively renally eliminated', recommendation: 'Must reduce dose - see dosing adjustments' },
      { population: 'pregnancy', consideration: 'Limited human data; crosses placenta', recommendation: 'Use only if benefits outweigh risks', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Pain scores/seizure frequency', frequency: 'At each visit', rationale: 'Assess efficacy' },
      { parameter: 'Sedation, dizziness', frequency: 'Especially during titration', rationale: 'Common side effects; assess tolerability' },
      { parameter: 'Renal function', frequency: 'Baseline and periodically', rationale: 'Required for dose adjustment' },
      { parameter: 'Weight, edema', frequency: 'Periodically', rationale: 'Common side effects' },
    ],

    patientEducation: [
      'May cause drowsiness - avoid driving until you know how it affects you',
      'Do not stop suddenly - taper gradually to avoid withdrawal or seizures',
      'Avoid alcohol - increases sedation',
      'Take regularly for best effect - may take weeks to see full benefit',
      'Report suicidal thoughts or mood changes immediately',
    ],

    clinicalPearls: [
      'Despite GABA in the name, does not work on GABA receptors',
      'Absorption is saturable - splitting doses increases total absorption',
      'No hepatic metabolism - useful in liver disease',
      'Has abuse potential - some states now schedule as controlled substance',
      'FDA warns about serious breathing problems when combined with opioids',
    ],
  },

  {
    id: 'levetiracetam',
    genericName: 'Levetiracetam',
    brandNames: ['Keppra', 'Spritam', 'Elepsia XR'],
    drugClass: 'Pyrrolidone derivative (anticonvulsant)',
    category: 'neurological',

    overview: 'Levetiracetam is a newer anticonvulsant with a unique mechanism involving synaptic vesicle protein 2A (SV2A). It has minimal drug interactions, is renally eliminated, and is well-tolerated, making it a popular first-line choice for many seizure types. Main limitation is behavioral side effects.',

    mechanism: {
      type: 'other',
      target: 'Synaptic vesicle protein 2A (SV2A)',
      targetLocation: 'Presynaptic vesicles in neurons',
      simpleExplanation: 'Binds to a protein on vesicles that store neurotransmitters, modulating their release and reducing excessive neuronal firing.',
      detailedMechanism: 'Levetiracetam binds to SV2A, a transmembrane protein in synaptic vesicles that modulates neurotransmitter release. The exact mechanism of anticonvulsant action is not fully understood, but SV2A binding correlates with anticonvulsant potency. It may also have minor effects on GABA and glycine receptors.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Rapid complete absorption', result: 'Drug enters systemic circulation' },
        { order: 2, location: 'CNS', action: 'Crosses blood-brain barrier', result: 'Distributed to neurons' },
        { order: 3, location: 'Presynaptic terminals', action: 'Binds to SV2A protein', result: 'Modulated vesicle function' },
        { order: 4, location: 'Synapse', action: 'Altered neurotransmitter release', result: 'Reduced excessive neuronal firing' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Reduced seizure activity', mechanism: 'SV2A modulation decreases hyperexcitability', clinicalRelevance: 'Anticonvulsant effect', desiredOrAdverse: 'desired' },
        { system: 'Behavioral', effect: 'Irritability/mood changes', mechanism: 'Unknown; possibly related to SV2A effects', clinicalRelevance: '"Keppra rage" in some patients', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Rapid (hours to days for seizure control)',
      durationOfEffect: '12 hours (requires BID dosing)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~100%',
        route: ['oral', 'IV'],
        factors: ['Food does not significantly affect absorption'],
        timeToePeak: '1 hour',
      },
      distribution: {
        volumeOfDistribution: '0.5-0.7 L/kg',
        proteinBinding: '<10%',
        tissueDistribution: ['CNS', 'CSF'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal (blood hydrolysis)',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (66% unchanged)',
        renalClearance: '0.6 mL/min/kg',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '6-8 hours',
      timeToSteadyState: '2 days',
    },

    indications: [
      { condition: 'Partial-onset seizures', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Monotherapy age 4+; adjunctive age 1 month+' },
      { condition: 'Myoclonic seizures (JME)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Adjunctive therapy age 12+' },
      { condition: 'Primary generalized tonic-clonic seizures', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Adjunctive therapy age 6+' },
      { condition: 'Status epilepticus', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'IV form used as second-line agent' },
    ],

    dosing: {
      usualDose: { amount: '500-1500mg', frequency: 'Twice daily', route: 'Oral or IV' },
      adjustments: [
        { condition: 'CrCl 50-80 mL/min', adjustment: '500-1000mg BID', rationale: 'Mild renal impairment' },
        { condition: 'CrCl 30-50 mL/min', adjustment: '250-750mg BID', rationale: 'Moderate renal impairment' },
        { condition: 'CrCl <30 mL/min', adjustment: '250-500mg BID', rationale: 'Severe renal impairment' },
        { condition: 'Hemodialysis', adjustment: 'Supplemental 250-500mg after dialysis', rationale: 'Drug removed by dialysis' },
      ],
      maxDose: '3000mg/day',
      administration: { route: 'Oral or IV', withFood: 'either', timing: 'BID, 12 hours apart', specialInstructions: ['IV and oral bioequivalent', 'Can titrate rapidly if needed'] },
    },

    adverseEffects: [
      { name: 'Somnolence', frequency: 'very-common', severity: 'mild', mechanism: 'CNS effect', management: 'Often improves over time; slower titration may help', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Behavioral changes (irritability, aggression)', frequency: 'common', severity: 'moderate', mechanism: 'Unknown; possibly related to SV2A effects', management: 'May require dose reduction or discontinuation; pyridoxine (B6) may help', reversible: true, onsetTiming: 'Variable' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Usually mild and transient', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Depression/suicidal ideation', frequency: 'uncommon', severity: 'severe', mechanism: 'Unknown', management: 'FDA warning for all AEDs; monitor mood closely', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'minor', mechanism: 'Additive CNS effects', effect: 'Additive sedation', management: 'Use caution; generally minor interaction' },
    ],

    contraindications: [
      { condition: 'Hypersensitivity to levetiracetam', type: 'absolute', reason: 'Risk of serious allergic reaction' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Reduced renal function common', recommendation: 'Adjust dose for renal function. More susceptible to sedation.' },
      { population: 'renal-impairment', consideration: 'Primarily renally eliminated', recommendation: 'Dose reduction required - see adjustments' },
      { population: 'pregnancy', consideration: 'Considered relatively safe for epilepsy', recommendation: 'Monitor levels - clearance increases during pregnancy', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'Approved down to 1 month for adjunctive therapy', recommendation: 'Watch for behavioral side effects' },
    ],

    monitoring: [
      { parameter: 'Seizure frequency', frequency: 'Ongoing', rationale: 'Assess efficacy' },
      { parameter: 'Mood and behavior', frequency: 'At each visit, especially early', rationale: 'Behavioral side effects are significant limitation' },
      { parameter: 'Renal function', frequency: 'Baseline and periodically', rationale: 'Dose adjustment needed for renal impairment' },
    ],

    patientEducation: [
      'May cause drowsiness initially - avoid driving until adjusted',
      'Report mood changes, irritability, or unusual behavior immediately',
      'Do not stop suddenly - may cause seizures',
      'Take consistently - twice daily with or without food',
      'Vitamin B6 (pyridoxine) may help with irritability - discuss with doctor',
    ],

    clinicalPearls: [
      'Excellent pharmacokinetic profile: almost no drug interactions',
      'Main limitation is behavioral side effects - "Keppra rage" in some patients',
      'Can titrate rapidly when needed (status epilepticus)',
      'No hepatic metabolism - safe in liver disease',
      'Pyridoxine (B6) may help prevent or treat behavioral side effects',
      'IV and oral forms are bioequivalent - easy IV-to-PO transition',
      'Generic widely available and inexpensive',
    ],
  },

  // ============================================
  // Additional Cardiovascular Medications
  // ============================================

  {
    id: 'amlodipine',
    genericName: 'Amlodipine',
    brandNames: ['Norvasc'],
    drugClass: 'Dihydropyridine Calcium Channel Blocker',
    category: 'cardiovascular',

    overview: 'Amlodipine is a long-acting calcium channel blocker used primarily for hypertension and angina. It has a very long half-life allowing once-daily dosing and causes less reflex tachycardia than shorter-acting agents. Peripheral edema is the main dose-limiting side effect.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'L-type voltage-gated calcium channels',
      targetLocation: 'Vascular smooth muscle and cardiac muscle',
      simpleExplanation: 'Blocks calcium from entering blood vessel cells, causing them to relax and widen, which lowers blood pressure.',
      detailedMechanism: 'Amlodipine selectively inhibits L-type calcium channels in vascular smooth muscle, preventing calcium influx needed for contraction. This causes vasodilation, reducing peripheral vascular resistance. It has minimal effect on cardiac conduction due to vascular selectivity.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Slowly absorbed', result: 'Gradual rise in blood levels' },
        { order: 2, location: 'Vascular smooth muscle', action: 'Binds L-type calcium channels', result: 'Blocks calcium entry' },
        { order: 3, location: 'Arterioles', action: 'Reduced calcium influx', result: 'Smooth muscle relaxation' },
        { order: 4, location: 'Systemic circulation', action: 'Vasodilation', result: 'Decreased peripheral resistance and BP' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Vasodilation', mechanism: 'Calcium channel blockade in vessels', clinicalRelevance: 'Blood pressure reduction', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced afterload', mechanism: 'Lower peripheral resistance', clinicalRelevance: 'Decreased cardiac workload', desiredOrAdverse: 'desired' },
        { system: 'Peripheral', effect: 'Ankle edema', mechanism: 'Precapillary dilation without venous dilation', clinicalRelevance: 'Common dose-limiting side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '6-12 hours; full effect 6-9 days',
      durationOfEffect: '24+ hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '64-90%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '6-12 hours',
      },
      distribution: {
        volumeOfDistribution: '21 L/kg',
        proteinBinding: '93-98%',
        tissueDistribution: ['Vascular smooth muscle', 'Heart'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (inactive metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '30-50 hours',
      timeToSteadyState: '7-8 days',
    },

    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Excellent first-line option' },
      { condition: 'Chronic stable angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Reduces myocardial oxygen demand' },
      { condition: 'Vasospastic (Prinzmetal) angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Prevents coronary vasospasm' },
    ],

    dosing: {
      usualDose: { amount: '5-10mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 2.5mg daily', rationale: 'Increased sensitivity, slower clearance' },
        { condition: 'Hepatic impairment', adjustment: 'Start 2.5mg daily', rationale: 'Reduced hepatic metabolism' },
      ],
      maxDose: '10mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Take at same time daily', 'Do not stop abruptly'] },
    },

    adverseEffects: [
      { name: 'Peripheral edema', frequency: 'very-common', severity: 'mild', mechanism: 'Precapillary vasodilation causing fluid extravasation', management: 'Dose reduction; adding ACE-I may help', reversible: true, onsetTiming: 'Dose-related, weeks' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation', management: 'Usually transient; analgesics if needed', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Flushing', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation', management: 'Usually decreases with continued use', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'Blood pressure lowering', management: 'Avoid sudden position changes', reversible: true, onsetTiming: 'After doses' },
    ],

    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (clarithromycin, ketoconazole)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Inhibited metabolism', effect: 'Increased amlodipine levels', management: 'May need dose reduction' },
      { interactingDrug: 'Simvastatin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Amlodipine increases simvastatin levels', effect: 'Increased myopathy risk', management: 'Limit simvastatin to 20mg daily' },
    ],

    contraindications: [
      { condition: 'Severe hypotension', type: 'absolute', reason: 'Will worsen hypotension' },
      { condition: 'Severe aortic stenosis', type: 'relative', reason: 'Afterload reduction may cause syncope' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Slower clearance, increased sensitivity', recommendation: 'Start 2.5mg daily' },
      { population: 'hepatic-impairment', consideration: 'Hepatically metabolized', recommendation: 'Start 2.5mg, titrate slowly' },
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Other agents preferred', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Regular monitoring', rationale: 'Assess efficacy' },
      { parameter: 'Peripheral edema', frequency: 'At each visit', rationale: 'Common dose-limiting effect' },
      { parameter: 'Heart rate', frequency: 'Periodically', rationale: 'Monitor for reflex tachycardia' },
    ],

    patientEducation: [
      'May take 1-2 weeks for full blood pressure effect',
      'Ankle swelling is common - not dangerous but may limit dose',
      'Do not stop suddenly',
      'Avoid grapefruit juice in large quantities',
      'Report dizziness or fainting',
    ],

    clinicalPearls: [
      'Very long half-life allows forgiveness for missed doses',
      'Peripheral edema is dose-dependent and may improve by adding ACE-I/ARB',
      'Less reflex tachycardia than shorter-acting dihydropyridines',
      'Good choice for patients with both hypertension and angina',
      'Safe in patients with heart failure (unlike non-dihydropyridines)',
    ],
  },

  {
    id: 'furosemide',
    genericName: 'Furosemide',
    brandNames: ['Lasix'],
    drugClass: 'Loop Diuretic',
    category: 'cardiovascular',

    overview: 'Furosemide is a potent loop diuretic that acts on the thick ascending limb of the loop of Henle. It is the workhorse diuretic for acute decompensated heart failure and edematous states. Requires monitoring for electrolyte disturbances, particularly hypokalemia.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Na-K-2Cl cotransporter (NKCC2)',
      targetLocation: 'Thick ascending limb of loop of Henle',
      simpleExplanation: 'Blocks sodium and chloride reabsorption in the kidney, causing the body to excrete more water and salt in urine.',
      detailedMechanism: 'Furosemide inhibits NKCC2 in the thick ascending limb, blocking reabsorption of sodium, potassium, and chloride. This disrupts the countercurrent concentrating mechanism, preventing water reabsorption and producing a powerful diuresis. Also causes venodilation, providing rapid symptomatic relief in pulmonary edema.',
      mechanismSteps: [
        { order: 1, location: 'Proximal tubule', action: 'Secreted into tubular fluid', result: 'Drug reaches site of action' },
        { order: 2, location: 'Thick ascending limb', action: 'Binds and inhibits NKCC2', result: 'Blocks Na/K/2Cl reabsorption' },
        { order: 3, location: 'Collecting duct', action: 'Increased sodium delivery', result: 'Increased K+ and H+ secretion' },
        { order: 4, location: 'Collecting duct', action: 'Reduced medullary gradient', result: 'Impaired water reabsorption' },
      ],
      physiologicalEffects: [
        { system: 'Renal', effect: 'Diuresis', mechanism: 'Blocked sodium reabsorption', clinicalRelevance: 'Volume reduction', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Venodilation', mechanism: 'Direct effect, prostaglandin-mediated', clinicalRelevance: 'Rapid preload reduction in pulmonary edema', desiredOrAdverse: 'desired' },
        { system: 'Electrolyte', effect: 'Hypokalemia', mechanism: 'Increased K+ secretion in collecting duct', clinicalRelevance: 'Must supplement potassium', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'PO: 30-60 min; IV: 5 min',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '10-100% (average 50%)',
        route: ['oral', 'IV', 'IM'],
        factors: ['Highly variable oral absorption', 'Edema reduces absorption'],
        timeToePeak: '1-2 hours (oral)',
      },
      distribution: {
        volumeOfDistribution: '0.1-0.2 L/kg',
        proteinBinding: '91-99%',
        tissueDistribution: ['Kidney', 'Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Hepatic (minimal)',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (65% unchanged)',
        renalClearance: 'Actively secreted',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '1-2 hours (prolonged in renal failure)',
      timeToSteadyState: 'N/A (used as needed)',
    },

    indications: [
      { condition: 'Acute decompensated heart failure', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV for rapid diuresis' },
      { condition: 'Chronic heart failure with volume overload', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Oral maintenance' },
      { condition: 'Edema (hepatic, renal, cardiac)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Not first-line; thiazides preferred' },
    ],

    dosing: {
      usualDose: { amount: '20-80mg', frequency: 'Once or twice daily', route: 'Oral or IV' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Higher doses needed', rationale: 'Reduced tubular secretion requires more drug' },
        { condition: 'Acute pulmonary edema', adjustment: 'IV 40-80mg bolus', rationale: 'Rapid onset needed' },
        { condition: 'Diuretic resistance', adjustment: 'Continuous IV infusion', rationale: 'Avoids post-dose sodium retention' },
      ],
      maxDose: '600mg/day',
      administration: { route: 'Oral or IV', withFood: 'either', timing: 'Morning to avoid nocturia', specialInstructions: ['IV: give slowly over 1-2 min', 'Can split to BID for better 24h coverage'] },
    },

    adverseEffects: [
      { name: 'Hypokalemia', frequency: 'very-common', severity: 'moderate', mechanism: 'Increased K+ secretion in collecting duct', management: 'Monitor K+, supplement, consider K-sparing diuretic', reversible: true, onsetTiming: 'Within days' },
      { name: 'Hyponatremia', frequency: 'common', severity: 'moderate', mechanism: 'Sodium loss exceeds water loss', management: 'Monitor sodium levels', reversible: true, onsetTiming: 'Variable' },
      { name: 'Hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Volume depletion', management: 'Monitor BP, adjust dose', reversible: true, onsetTiming: 'With overdiuresis' },
      { name: 'Ototoxicity', frequency: 'rare', severity: 'severe', mechanism: 'Electrolyte changes in inner ear', management: 'Avoid rapid IV boluses; caution with aminoglycosides', reversible: true, onsetTiming: 'Usually with rapid IV or high doses' },
    ],

    interactions: [
      { interactingDrug: 'Aminoglycosides', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive ototoxicity', effect: 'Increased hearing loss risk', management: 'Avoid combination if possible; monitor hearing' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hypokalemia increases digoxin toxicity', effect: 'Arrhythmia risk', management: 'Maintain potassium >4.0 mEq/L' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs reduce prostaglandin-mediated renal blood flow', effect: 'Reduced diuretic efficacy', management: 'Monitor response, may need higher doses' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced lithium clearance with volume depletion', effect: 'Lithium toxicity', management: 'Monitor lithium levels closely' },
    ],

    contraindications: [
      { condition: 'Anuria', type: 'absolute', reason: 'Drug requires functional kidneys' },
      { condition: 'Severe hypovolemia', type: 'absolute', reason: 'Will worsen dehydration' },
      { condition: 'Sulfonamide allergy', type: 'relative', reason: 'Structural similarity; cross-reactivity possible but rare' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'More susceptible to electrolyte abnormalities', recommendation: 'Start low, monitor closely' },
      { population: 'renal-impairment', consideration: 'Higher doses needed for effect', recommendation: 'May need 80-200mg or continuous infusion' },
      { population: 'pregnancy', consideration: 'Crosses placenta', recommendation: 'Use only if clearly needed', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Electrolytes (K+, Na+, Mg2+)', frequency: 'Before starting, then regularly', rationale: 'Common and dangerous abnormalities', actionThreshold: 'Supplement if K+ <3.5' },
      { parameter: 'Renal function (BUN, Cr)', frequency: 'Regularly', rationale: 'Can cause prerenal azotemia', actionThreshold: 'Rising creatinine may indicate overdiuresis' },
      { parameter: 'Weight, fluid status', frequency: 'Daily in hospital', rationale: 'Assess diuretic response' },
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Avoid hypotension' },
    ],

    patientEducation: [
      'Take in the morning to avoid nighttime urination',
      'You may need potassium supplements or potassium-rich foods',
      'Weigh yourself daily - report sudden weight gain (>2 lbs/day)',
      'Report dizziness, muscle cramps, or irregular heartbeat',
      'Avoid excessive sun exposure (photosensitivity)',
    ],

    clinicalPearls: [
      'Oral bioavailability is highly variable (10-100%); if poor response, switch to IV',
      'In acute heart failure, IV furosemide provides venodilation within minutes (before diuresis)',
      '"Ceiling effect" - doubling dose above threshold does not increase effect',
      'For diuretic resistance, consider continuous infusion or adding thiazide',
      'Hypokalemia increases digoxin toxicity - critical interaction',
      'Torsemide has more predictable oral absorption',
    ],
  },

  {
    id: 'warfarin',
    genericName: 'Warfarin',
    brandNames: ['Coumadin', 'Jantoven'],
    drugClass: 'Vitamin K Antagonist',
    category: 'hematologic',

    overview: 'Warfarin is an oral anticoagulant that inhibits vitamin K-dependent clotting factors. Despite the advent of DOACs, it remains important for mechanical heart valves and some other conditions. Requires careful monitoring with INR and has numerous food and drug interactions.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Vitamin K epoxide reductase (VKORC1)',
      targetLocation: 'Liver',
      simpleExplanation: 'Blocks vitamin K recycling in the liver, preventing the production of clotting factors that need vitamin K to work.',
      detailedMechanism: 'Warfarin inhibits VKORC1, preventing regeneration of reduced vitamin K needed as a cofactor for gamma-carboxylation of clotting factors II, VII, IX, and X (and proteins C and S). This produces inactive clotting factors, prolonging coagulation time.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Complete absorption', result: 'Drug enters circulation' },
        { order: 2, location: 'Liver', action: 'Inhibits VKORC1 enzyme', result: 'Vitamin K cannot be recycled' },
        { order: 3, location: 'Liver', action: 'Clotting factors produced without carboxylation', result: 'Non-functional factors II, VII, IX, X' },
        { order: 4, location: 'Circulation', action: 'Existing factors depleted over days', result: 'Anticoagulant effect after 3-5 days' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Reduced functional clotting factors', clinicalRelevance: 'Prevention of thrombosis', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Over-anticoagulation', clinicalRelevance: 'Major adverse effect requiring monitoring', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '24-72 hours; full effect 5-7 days',
      durationOfEffect: '2-5 days after discontinuation',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~100%',
        route: ['oral'],
        factors: ['Well absorbed'],
        timeToePeak: '4 hours',
      },
      distribution: {
        volumeOfDistribution: '0.14 L/kg',
        proteinBinding: '99%',
        tissueDistribution: ['Plasma', 'Liver'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2C9, CYP3A4, CYP1A2)',
        enzymes: ['CYP2C9', 'CYP3A4', 'CYP1A2'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C9 and VKORC1 polymorphisms affect dosing',
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (inactive metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '20-60 hours (mean 40 hours)',
      timeToSteadyState: '5-7 days',
    },

    indications: [
      { condition: 'Mechanical heart valve', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'DOACs contraindicated; warfarin required' },
      { condition: 'Atrial fibrillation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'DOACs often preferred; warfarin still used' },
      { condition: 'Venous thromboembolism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'DOACs often preferred for DVT/PE' },
      { condition: 'Antiphospholipid syndrome', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true, notes: 'DOACs may be inferior' },
    ],

    dosing: {
      usualDose: { amount: '2-10mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Initiation', adjustment: '5mg daily typical start', rationale: 'Higher doses may overcorrect initially' },
        { condition: 'CYP2C9 poor metabolizer', adjustment: 'Reduce dose 50%+', rationale: 'Slower metabolism, higher levels' },
        { condition: 'VKORC1 variant', adjustment: 'Reduce dose', rationale: 'More sensitive to warfarin' },
        { condition: 'Elderly', adjustment: 'Lower starting dose', rationale: 'Increased sensitivity' },
      ],
      maxDose: 'Titrated to INR',
      administration: { route: 'Oral', withFood: 'either', timing: 'Same time daily', specialInstructions: ['Consistent vitamin K intake', 'INR monitoring required'] },
    },

    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'life-threatening', mechanism: 'Over-anticoagulation', management: 'Hold warfarin, vitamin K, FFP/PCC for severe bleeding', reversible: true, onsetTiming: 'Risk increases with INR' },
      { name: 'Skin necrosis', frequency: 'rare', severity: 'severe', mechanism: 'Protein C depletes faster than factors, causing hypercoagulable state early', management: 'Bridge with heparin; genetic testing', reversible: false, onsetTiming: 'Days 3-8 of therapy' },
      { name: 'Purple toe syndrome', frequency: 'rare', severity: 'moderate', mechanism: 'Cholesterol emboli', management: 'Discontinue warfarin', reversible: true, onsetTiming: 'Weeks after initiation' },
    ],

    interactions: [
      { interactingDrug: 'CYP2C9 inhibitors (fluconazole, amiodarone)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Inhibited warfarin metabolism', effect: 'Increased INR, bleeding risk', management: 'Reduce warfarin dose, monitor INR frequently' },
      { interactingDrug: 'Vitamin K (dietary or supplements)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Reverses warfarin effect', effect: 'Decreased INR', management: 'Consistent vitamin K intake; avoid supplements' },
      { interactingDrug: 'Aspirin/NSAIDs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive bleeding risk, NSAIDs also inhibit warfarin metabolism', effect: 'Increased bleeding', management: 'Avoid if possible; use acetaminophen' },
      { interactingDrug: 'Antibiotics', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Kill gut bacteria that produce vitamin K; some inhibit CYP enzymes', effect: 'Usually increased INR', management: 'Monitor INR more frequently during antibiotics' },
    ],

    contraindications: [
      { condition: 'Active major bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Pregnancy', type: 'absolute', reason: 'Teratogenic (warfarin embryopathy)', alternative: 'LMWH in pregnancy' },
      { condition: 'Severe uncontrolled hypertension', type: 'relative', reason: 'Increased intracranial bleeding risk' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Increased sensitivity, bleeding risk', recommendation: 'Lower starting doses, target lower INR if appropriate' },
      { population: 'pregnancy', consideration: 'Teratogenic, causes fetal bleeding', recommendation: 'Contraindicated; use LMWH', pregnancyCategory: 'X' },
      { population: 'hepatic-impairment', consideration: 'Reduced clotting factor synthesis', recommendation: 'May need lower doses; enhanced sensitivity' },
    ],

    monitoring: [
      { parameter: 'INR', frequency: 'Initially every 2-3 days, then weekly, then monthly when stable', rationale: 'Tight therapeutic window', actionThreshold: 'Adjust dose to maintain target INR (usually 2-3)' },
      { parameter: 'Signs of bleeding', frequency: 'Ongoing', rationale: 'Major adverse effect' },
      { parameter: 'Hemoglobin', frequency: 'Periodically', rationale: 'Detect occult bleeding' },
    ],

    patientEducation: [
      'Maintain consistent vitamin K intake - do not suddenly eat more or less green vegetables',
      'Take at the same time every day',
      'Report any unusual bleeding (gums, nosebleeds, dark stool, excessive bruising)',
      'Many medications and foods interact - tell all providers you take warfarin',
      'Wear medical alert identification',
      'Avoid contact sports and activities with high bleeding risk',
    ],

    clinicalPearls: [
      'INR goal 2.5 (range 2-3) for most indications; 3.0 (range 2.5-3.5) for mechanical mitral valve',
      'Still required for mechanical heart valves - DOACs are contraindicated',
      'CYP2C9 and VKORC1 pharmacogenomics can guide dosing',
      'Bridge with heparin when starting (especially with protein C/S deficiency)',
      'Vitamin K reversal: 1-2.5mg oral for elevated INR; 10mg IV for life-threatening bleeding',
      'Has antidote (vitamin K, 4-factor PCC) unlike some DOACs initially did',
    ],
  },

  // ============================================
  // Pain Management Medications
  // ============================================

  {
    id: 'acetaminophen',
    genericName: 'Acetaminophen',
    brandNames: ['Tylenol', 'Panadol'],
    drugClass: 'Analgesic/Antipyretic',
    category: 'analgesic',

    overview: 'Acetaminophen (paracetamol) is a widely used analgesic and antipyretic. Unlike NSAIDs, it has no significant anti-inflammatory activity and no GI or platelet effects. Hepatotoxicity is the major concern, especially with excessive doses or in liver disease.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'COX enzymes (central, not peripheral)',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Works in the brain to reduce pain signals and lower body temperature. Unlike ibuprofen, it does not reduce inflammation.',
      detailedMechanism: 'Exact mechanism unclear. Inhibits central COX enzymes (COX-3 or a COX-1 variant) in the CNS, reducing prostaglandin synthesis involved in pain and fever. May also affect serotonergic, cannabinoid, and vanilloid systems. Has no peripheral anti-inflammatory effect.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Rapid absorption', result: 'Drug enters circulation' },
        { order: 2, location: 'CNS', action: 'Crosses blood-brain barrier', result: 'Reaches central targets' },
        { order: 3, location: 'CNS', action: 'Inhibits central COX activity', result: 'Reduced prostaglandin synthesis' },
        { order: 4, location: 'Hypothalamus', action: 'Lowers thermoregulatory set point', result: 'Antipyretic effect' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Analgesia', mechanism: 'Central COX inhibition, serotonergic pathways', clinicalRelevance: 'Pain relief', desiredOrAdverse: 'desired' },
        { system: 'Thermoregulatory', effect: 'Antipyresis', mechanism: 'Hypothalamic prostaglandin inhibition', clinicalRelevance: 'Fever reduction', desiredOrAdverse: 'desired' },
        { system: 'Hepatic', effect: 'Hepatotoxicity (overdose)', mechanism: 'NAPQI metabolite depletes glutathione', clinicalRelevance: 'Liver failure risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '85-100%',
        route: ['oral', 'IV', 'rectal'],
        factors: ['Food slightly delays but does not reduce absorption'],
        timeToePeak: '30-60 minutes (oral)',
      },
      distribution: {
        volumeOfDistribution: '0.9 L/kg',
        proteinBinding: '10-25%',
        tissueDistribution: ['CNS', 'Throughout body'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (glucuronidation, sulfation, CYP2E1)',
        enzymes: ['CYP2E1'],
        activeMetabolites: ['NAPQI (toxic)'],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (conjugates)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '1.5-3 hours',
      timeToSteadyState: '8-12 hours',
    },

    indications: [
      { condition: 'Mild to moderate pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Safe for most patients' },
      { condition: 'Fever', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Osteoarthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true, notes: 'First-line analgesic option' },
    ],

    dosing: {
      usualDose: { amount: '325-1000mg', frequency: 'Every 4-6 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Max 2g/day', rationale: 'Reduced hepatic metabolism increases toxicity risk' },
        { condition: 'Chronic alcohol use', adjustment: 'Max 2g/day', rationale: 'CYP2E1 induction increases toxic metabolite' },
      ],
      maxDose: '4g/day (3g/day in elderly or hepatic impairment)',
      administration: { route: 'Oral, IV, rectal', withFood: 'either', specialInstructions: ['Check all medications for hidden acetaminophen', 'Do not exceed maximum dose'] },
    },

    adverseEffects: [
      { name: 'Hepatotoxicity (overdose)', frequency: 'rare', severity: 'life-threatening', mechanism: 'NAPQI metabolite depletes glutathione, causes hepatocyte necrosis', management: 'N-acetylcysteine is antidote; must give early', reversible: true, onsetTiming: 'Within 24-72 hours of overdose' },
      { name: 'Allergic reactions', frequency: 'rare', severity: 'moderate', mechanism: 'Hypersensitivity', management: 'Discontinue, supportive care', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'May increase INR at high doses (>4g/week)', effect: 'Increased bleeding risk', management: 'Monitor INR, prefer low doses' },
      { interactingDrug: 'Alcohol (chronic use)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Induces CYP2E1, increasing toxic NAPQI formation', effect: 'Increased hepatotoxicity risk', management: 'Limit to 2g/day maximum' },
    ],

    contraindications: [
      { condition: 'Severe hepatic impairment', type: 'relative', reason: 'Increased toxicity risk' },
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Risk of allergic reaction' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'May have reduced hepatic function', recommendation: 'Use lower maximum dose (3g/day)' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism, increased toxicity risk', recommendation: 'Maximum 2g/day; avoid if severe' },
      { population: 'pregnancy', consideration: 'Generally considered safe', recommendation: 'Preferred analgesic in pregnancy', pregnancyCategory: 'B' },
      { population: 'pediatric', consideration: 'Weight-based dosing', recommendation: '10-15 mg/kg every 4-6 hours' },
    ],

    monitoring: [
      { parameter: 'Hepatic function', frequency: 'If high-dose chronic use', rationale: 'Detect hepatotoxicity' },
      { parameter: 'Total daily dose', frequency: 'Ongoing', rationale: 'Ensure not exceeding max from all sources' },
    ],

    patientEducation: [
      'Do not exceed 4 grams (4000mg) per day from all sources',
      'Check other medications - many contain hidden acetaminophen',
      'Avoid alcohol while taking, or limit to moderate amounts',
      'Does not reduce inflammation like ibuprofen',
      'Call poison control immediately if you take too much',
    ],

    clinicalPearls: [
      'Safest analgesic for patients on anticoagulation or with GI concerns',
      'Hidden in many combination products - always check total daily dose',
      'N-acetylcysteine most effective if given within 8 hours of overdose',
      'Rumack-Matthew nomogram guides treatment in overdose',
      'No anti-inflammatory effect - not useful for inflammatory conditions',
    ],
  },

  {
    id: 'ibuprofen',
    genericName: 'Ibuprofen',
    brandNames: ['Advil', 'Motrin', 'Nuprin'],
    drugClass: 'NSAID (Propionic acid derivative)',
    category: 'analgesic',

    overview: 'Ibuprofen is a commonly used NSAID with analgesic, antipyretic, and anti-inflammatory properties. It works by inhibiting COX enzymes. GI and cardiovascular risks are key concerns, particularly with chronic use.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)',
      targetLocation: 'Throughout body (peripheral and central)',
      simpleExplanation: 'Blocks enzymes that make prostaglandins - chemicals that cause pain, fever, and inflammation.',
      detailedMechanism: 'Ibuprofen reversibly inhibits both COX-1 and COX-2 isoforms. COX-2 inhibition reduces prostaglandins involved in pain and inflammation. COX-1 inhibition affects protective prostaglandins in GI mucosa and platelet thromboxane.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Rapid absorption', result: 'Drug enters circulation' },
        { order: 2, location: 'Peripheral tissues', action: 'Binds and inhibits COX-1 and COX-2', result: 'Reduced prostaglandin synthesis' },
        { order: 3, location: 'Sites of inflammation', action: 'Decreased PGE2 and PGI2', result: 'Reduced inflammation, pain, and fever' },
        { order: 4, location: 'GI tract', action: 'Reduced protective prostaglandins', result: 'GI mucosal vulnerability (adverse effect)' },
      ],
      physiologicalEffects: [
        { system: 'Inflammatory', effect: 'Anti-inflammation', mechanism: 'Reduced prostaglandin synthesis', clinicalRelevance: 'Reduces swelling and pain', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Analgesia', mechanism: 'Peripheral and central prostaglandin inhibition', clinicalRelevance: 'Pain relief', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Mucosal injury', mechanism: 'Loss of protective prostaglandins', clinicalRelevance: 'Ulcers and GI bleeding', desiredOrAdverse: 'adverse' },
        { system: 'Renal', effect: 'Reduced renal blood flow', mechanism: 'Prostaglandin-mediated renal vasodilation impaired', clinicalRelevance: 'Can worsen kidney function', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-6 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '>80%',
        route: ['oral', 'IV', 'topical'],
        factors: ['Food delays but does not reduce absorption'],
        timeToePeak: '1-2 hours',
      },
      distribution: {
        volumeOfDistribution: '0.12-0.2 L/kg',
        proteinBinding: '90-99%',
        tissueDistribution: ['Synovial fluid', 'Throughout body'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2C9)',
        enzymes: ['CYP2C9'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '2-4 hours',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Mild to moderate pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Fever', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Inflammatory conditions (arthritis)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Dysmenorrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],

    dosing: {
      usualDose: { amount: '200-400mg', frequency: 'Every 4-6 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Use lowest effective dose', rationale: 'Increased GI and CV risk' },
        { condition: 'Renal impairment', adjustment: 'Avoid if CrCl <30', rationale: 'Can worsen kidney function' },
      ],
      maxDose: '3200mg/day (prescription); 1200mg/day (OTC)',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Take with food or milk to reduce stomach upset'] },
    },

    adverseEffects: [
      { name: 'GI upset/ulceration', frequency: 'common', severity: 'moderate', mechanism: 'COX-1 inhibition reduces protective prostaglandins', management: 'Take with food; consider PPI prophylaxis', reversible: true, onsetTiming: 'With chronic use' },
      { name: 'Cardiovascular events', frequency: 'rare', severity: 'severe', mechanism: 'Prostaglandin imbalance favors thrombosis', management: 'Avoid in high CV risk; use lowest dose/shortest duration', reversible: false, onsetTiming: 'With chronic high-dose use' },
      { name: 'Acute kidney injury', frequency: 'uncommon', severity: 'moderate', mechanism: 'Reduced renal prostaglandins impair blood flow', management: 'Avoid in dehydration or renal disease', reversible: true, onsetTiming: 'Usually early, especially if dehydrated' },
    ],

    interactions: [
      { interactingDrug: 'Aspirin (cardioprotective)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Ibuprofen competes for COX-1 binding, reducing aspirin efficacy', effect: 'Reduced cardioprotection', management: 'Take aspirin 30 min before ibuprofen' },
      { interactingDrug: 'Anticoagulants', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive bleeding risk, inhibits platelet function', effect: 'Increased bleeding', management: 'Avoid if possible; monitor closely' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal lithium clearance', effect: 'Lithium toxicity', management: 'Monitor lithium levels; avoid if possible' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'NSAIDs reduce renal prostaglandins needed for drug effect', effect: 'Reduced antihypertensive efficacy, AKI risk', management: 'Monitor BP and renal function' },
    ],

    contraindications: [
      { condition: 'Active GI bleeding or ulcer', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe renal impairment', type: 'absolute', reason: 'Can precipitate renal failure' },
      { condition: 'Post-CABG surgery', type: 'absolute', reason: 'Black box warning - increased CV events' },
      { condition: 'Third trimester pregnancy', type: 'absolute', reason: 'Premature closure of ductus arteriosus' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Increased GI and CV risk', recommendation: 'Use lowest dose for shortest duration; add PPI if needed' },
      { population: 'renal-impairment', consideration: 'Can worsen kidney function', recommendation: 'Avoid or use with extreme caution' },
      { population: 'pregnancy', consideration: 'Risk varies by trimester', recommendation: 'Avoid in third trimester (contraindicated); use cautiously earlier', pregnancyCategory: 'D (third trimester)' },
    ],

    monitoring: [
      { parameter: 'GI symptoms', frequency: 'Ongoing', rationale: 'Early detection of ulcer/bleeding' },
      { parameter: 'Renal function', frequency: 'With chronic use', rationale: 'NSAIDs can impair kidney function' },
      { parameter: 'Blood pressure', frequency: 'Periodically', rationale: 'NSAIDs can raise BP' },
    ],

    patientEducation: [
      'Take with food to reduce stomach upset',
      'Do not exceed recommended dose',
      'Report black or bloody stools, abdominal pain',
      'Avoid if you have heart disease, kidney disease, or history of ulcers',
      'Not safe in third trimester of pregnancy',
    ],

    clinicalPearls: [
      'If patient needs cardioprotective aspirin, take aspirin 30 min before ibuprofen',
      'GI risk lower than naproxen, higher than celecoxib',
      'CV risk increases with dose and duration - use lowest effective dose',
      'FDA black box warning for CV and GI risks',
      'Consider misoprostol or PPI for GI protection in high-risk patients',
    ],
  },

  {
    id: 'tramadol',
    genericName: 'Tramadol',
    brandNames: ['Ultram', 'ConZip'],
    drugClass: 'Atypical Opioid Analgesic',
    category: 'analgesic',

    overview: 'Tramadol is a centrally acting analgesic with dual mechanism: weak mu-opioid agonism and inhibition of norepinephrine/serotonin reuptake. It provides moderate pain relief with lower (but not zero) abuse potential than typical opioids. Seizure risk and serotonin syndrome are unique concerns.',

    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu-opioid receptors; serotonin and norepinephrine transporters',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Works on opioid receptors in the brain (like a weak morphine) and also increases brain chemicals that reduce pain signals.',
      detailedMechanism: 'Tramadol has dual mechanism: (1) the M1 metabolite is a mu-opioid agonist providing opioid analgesia, and (2) the parent drug inhibits reuptake of serotonin and norepinephrine, providing additional analgesia via descending pain modulation pathways.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed', result: 'Parent drug enters circulation' },
        { order: 2, location: 'Liver', action: 'CYP2D6 converts to M1 metabolite', result: 'Active opioid metabolite formed' },
        { order: 3, location: 'CNS', action: 'M1 activates mu-opioid receptors', result: 'Opioid analgesia' },
        { order: 4, location: 'CNS', action: 'Parent drug inhibits SNRI', result: 'Enhanced descending pain inhibition' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Analgesia', mechanism: 'Opioid receptor activation plus SNRI effects', clinicalRelevance: 'Moderate pain relief', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Seizures', mechanism: 'Lowers seizure threshold (SNRI effect)', clinicalRelevance: 'Risk especially at high doses or with other serotonergic drugs', desiredOrAdverse: 'adverse' },
        { system: 'Nervous', effect: 'Serotonin syndrome', mechanism: 'Serotonin reuptake inhibition', clinicalRelevance: 'Risk with other serotonergic drugs', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-6 hours (IR); 12-24 hours (ER)',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '70-75%',
        route: ['oral'],
        factors: ['Not significantly affected by food'],
        timeToePeak: '2 hours (IR)',
      },
      distribution: {
        volumeOfDistribution: '2.5-3 L/kg',
        proteinBinding: '20%',
        tissueDistribution: ['CNS', 'Throughout body'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2D6, CYP3A4)',
        enzymes: ['CYP2D6', 'CYP3A4'],
        activeMetabolites: ['O-desmethyltramadol (M1) - 6x more potent opioid'],
        geneticVariability: 'CYP2D6 polymorphism affects efficacy',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '6 hours (parent); 7 hours (M1)',
      timeToSteadyState: '2 days',
    },

    indications: [
      { condition: 'Moderate to moderately severe pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Step 2 analgesic option' },
    ],

    dosing: {
      usualDose: { amount: '50-100mg', frequency: 'Every 4-6 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment (CrCl <30)', adjustment: '50-100mg every 12 hours', rationale: 'Reduced clearance' },
        { condition: 'Hepatic impairment', adjustment: '50mg every 12 hours', rationale: 'Reduced metabolism' },
        { condition: 'CYP2D6 poor metabolizers', adjustment: 'May have reduced efficacy', rationale: 'Less M1 metabolite formed' },
        { condition: 'CYP2D6 ultra-rapid metabolizers', adjustment: 'Increased toxicity risk', rationale: 'Excessive M1 formation' },
      ],
      maxDose: '400mg/day (300mg in elderly)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not crush ER formulations', 'Titrate slowly'] },
    },

    adverseEffects: [
      { name: 'Nausea/vomiting', frequency: 'very-common', severity: 'mild', mechanism: 'Opioid effect on CTZ', management: 'Take with food; antiemetics if needed', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Dizziness/sedation', frequency: 'common', severity: 'mild', mechanism: 'CNS depression', management: 'Avoid driving until adjusted', reversible: true, onsetTiming: 'With doses' },
      { name: 'Seizures', frequency: 'rare', severity: 'severe', mechanism: 'SNRI effect lowers seizure threshold', management: 'Avoid exceeding 400mg/day; avoid in seizure history', reversible: true, onsetTiming: 'Usually at high doses or with drug interactions' },
      { name: 'Serotonin syndrome', frequency: 'rare', severity: 'life-threatening', mechanism: 'Serotonin accumulation with other serotonergic drugs', management: 'Avoid combinations; recognize early symptoms', reversible: true, onsetTiming: 'With drug combinations' },
    ],

    interactions: [
      { interactingDrug: 'SSRIs/SNRIs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive serotonergic effects', effect: 'Serotonin syndrome risk', management: 'Avoid combination if possible; monitor closely' },
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Severe serotonergic toxicity', effect: 'Life-threatening serotonin syndrome', management: 'Absolutely contraindicated' },
      { interactingDrug: 'CYP2D6 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced conversion to active M1 metabolite', effect: 'Reduced analgesic efficacy', management: 'May need higher doses or alternative agent' },
      { interactingDrug: 'Carbamazepine', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4 induction', effect: 'Reduced tramadol levels', management: 'May need dose adjustment' },
    ],

    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Risk of serotonin syndrome' },
      { condition: 'Seizure disorder', type: 'relative', reason: 'Lowers seizure threshold' },
      { condition: 'Acute intoxication (alcohol, sedatives, opioids)', type: 'absolute', reason: 'Additive CNS depression' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Increased sensitivity; higher seizure risk', recommendation: 'Max 300mg/day; start low' },
      { population: 'renal-impairment', consideration: 'Reduced clearance', recommendation: 'Extend dosing interval' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: '50mg every 12 hours' },
      { population: 'pregnancy', consideration: 'Opioid; can cause neonatal withdrawal', recommendation: 'Avoid; use alternatives', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Pain relief', frequency: 'With each prescription', rationale: 'Assess efficacy' },
      { parameter: 'Signs of misuse', frequency: 'Ongoing', rationale: 'Has abuse potential (Schedule IV)' },
      { parameter: 'Serotonergic symptoms', frequency: 'If on multiple serotonergic drugs', rationale: 'Early detection of serotonin syndrome' },
    ],

    patientEducation: [
      'Can cause drowsiness - avoid driving until you know how it affects you',
      'Risk of seizures especially at higher doses',
      'Tell your doctor about all medications - serious interactions possible',
      'Do not take with alcohol or sleeping pills',
      'Can cause dependence - take only as prescribed',
    ],

    clinicalPearls: [
      'Dual mechanism: weak opioid + SNRI effects',
      'CYP2D6 poor metabolizers get less benefit (can not convert to active M1)',
      'Unique seizure risk among opioids - avoid if seizure history',
      'Schedule IV - lower abuse potential than typical opioids but still present',
      'Maximum 400mg/day due to seizure risk at higher doses',
      'Avoid with other serotonergic drugs (SSRIs, SNRIs, triptans)',
    ],
  },

  // ============================================
  // Additional Diabetes/Endocrine Medications
  // ============================================

  {
    id: 'glipizide',
    genericName: 'Glipizide',
    brandNames: ['Glucotrol', 'Glucotrol XL'],
    drugClass: 'Sulfonylurea (Second Generation)',
    category: 'endocrine',

    overview: 'Glipizide is a second-generation sulfonylurea that stimulates insulin release from pancreatic beta cells. Effective for type 2 diabetes but carries hypoglycemia risk. Shorter half-life than glyburide makes it somewhat safer in elderly.',

    mechanism: {
      type: 'ion-channel-blocker',
      target: 'ATP-sensitive potassium channels on pancreatic beta cells',
      targetLocation: 'Pancreatic islet beta cells',
      simpleExplanation: 'Blocks potassium channels on insulin-producing cells, triggering them to release more insulin.',
      detailedMechanism: 'Glipizide binds to SUR1 subunit of ATP-sensitive potassium channels on beta cells. Channel closure leads to membrane depolarization, calcium influx, and insulin exocytosis. Effect is glucose-independent, meaning insulin is released regardless of blood sugar level.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed', result: 'Drug enters circulation' },
        { order: 2, location: 'Beta cell membrane', action: 'Binds SUR1 subunit of KATP channel', result: 'Channel closure' },
        { order: 3, location: 'Beta cell', action: 'Membrane depolarization', result: 'Voltage-gated Ca2+ channel opening' },
        { order: 4, location: 'Beta cell', action: 'Calcium influx', result: 'Insulin vesicle exocytosis' },
      ],
      physiologicalEffects: [
        { system: 'Endocrine', effect: 'Increased insulin secretion', mechanism: 'KATP channel blockade', clinicalRelevance: 'Lowers blood glucose', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Hypoglycemia', mechanism: 'Insulin release independent of glucose', clinicalRelevance: 'Major adverse effect', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Weight gain', mechanism: 'Anabolic effect of insulin', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30 minutes to 1 hour',
      durationOfEffect: '12-24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '90-100%',
        route: ['oral'],
        factors: ['Delayed by food - take 30 min before meals'],
        timeToePeak: '1-3 hours',
      },
      distribution: {
        volumeOfDistribution: '0.2 L/kg',
        proteinBinding: '98-99%',
        tissueDistribution: ['Pancreas', 'Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP2C9)',
        enzymes: ['CYP2C9'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (inactive metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '2-4 hours (shorter than glyburide)',
      timeToSteadyState: '1-2 days',
    },

    indications: [
      { condition: 'Type 2 Diabetes Mellitus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Second-line after or with metformin' },
    ],

    dosing: {
      usualDose: { amount: '5-10mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 2.5mg daily', rationale: 'Higher hypoglycemia risk' },
        { condition: 'Renal impairment', adjustment: 'Start low, monitor closely', rationale: 'Increased hypoglycemia risk (though less than glyburide)' },
        { condition: 'Hepatic impairment', adjustment: 'Start low, titrate carefully', rationale: 'Reduced metabolism' },
      ],
      maxDose: '40mg/day',
      administration: { route: 'Oral', withFood: 'without-food', timing: '30 minutes before meals', specialInstructions: ['Take before meals to match insulin release with food', 'ER formulation: once daily'] },
    },

    adverseEffects: [
      { name: 'Hypoglycemia', frequency: 'common', severity: 'moderate', mechanism: 'Glucose-independent insulin release', management: 'Treat with glucose; educate patient on symptoms', reversible: true, onsetTiming: 'With missed meals or excessive dose' },
      { name: 'Weight gain', frequency: 'common', severity: 'mild', mechanism: 'Anabolic effects of insulin', management: 'Diet counseling; consider alternative agents', reversible: true, onsetTiming: 'Gradual' },
      { name: 'GI upset', frequency: 'uncommon', severity: 'mild', mechanism: 'Direct GI effect', management: 'Take with meals if persistent', reversible: true, onsetTiming: 'Early' },
    ],

    interactions: [
      { interactingDrug: 'CYP2C9 inhibitors (fluconazole)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Inhibited metabolism', effect: 'Increased glipizide levels, hypoglycemia', management: 'Monitor glucose closely; may need dose reduction' },
      { interactingDrug: 'Beta-blockers', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Mask hypoglycemia symptoms (tachycardia)', effect: 'Delayed recognition of hypoglycemia', management: 'Educate patient on neuroglycopenic symptoms' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hypoglycemia; disulfiram-like reaction possible', effect: 'Hypoglycemia, flushing', management: 'Limit alcohol; avoid on empty stomach' },
    ],

    contraindications: [
      { condition: 'Type 1 diabetes', type: 'absolute', reason: 'No functioning beta cells' },
      { condition: 'Diabetic ketoacidosis', type: 'absolute', reason: 'Requires insulin' },
      { condition: 'Sulfa allergy', type: 'relative', reason: 'Structural similarity; cross-reactivity uncommon but possible' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'High hypoglycemia risk', recommendation: 'Start 2.5mg; consider alternative agents (DPP4i, SGLT2i)' },
      { population: 'renal-impairment', consideration: 'Increased hypoglycemia risk', recommendation: 'Start low; prefer shorter-acting sulfonylureas' },
      { population: 'pregnancy', consideration: 'Limited data; crosses placenta', recommendation: 'Insulin preferred; some use glyburide off-label', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Blood glucose', frequency: 'SMBG as directed', rationale: 'Assess efficacy and detect hypoglycemia' },
      { parameter: 'HbA1c', frequency: 'Every 3 months initially, then every 6 months', rationale: 'Long-term glycemic control' },
      { parameter: 'Hypoglycemia symptoms', frequency: 'Ongoing', rationale: 'Major risk of sulfonylureas' },
    ],

    patientEducation: [
      'Take 30 minutes before meals',
      'Know the symptoms of low blood sugar (sweating, shaking, hunger, confusion)',
      'Always carry glucose tablets or candy',
      'Do not skip meals',
      'Limit alcohol intake',
      'This medication can cause weight gain',
    ],

    clinicalPearls: [
      'Shorter half-life than glyburide makes it safer in elderly',
      'Requires functioning beta cells - will not work in advanced disease',
      'Weight gain and hypoglycemia limit use compared to newer agents',
      'Take 30 minutes before meals to time insulin release with food',
      'Falls out of favor to newer agents (DPP4i, GLP-1 RA, SGLT2i) with better safety profiles',
    ],
  },

  {
    id: 'sitagliptin',
    genericName: 'Sitagliptin',
    brandNames: ['Januvia'],
    drugClass: 'Dipeptidyl Peptidase-4 (DPP-4) Inhibitor',
    category: 'endocrine',

    overview: 'Sitagliptin inhibits DPP-4, prolonging the action of incretin hormones (GLP-1, GIP). This enhances glucose-dependent insulin secretion. Weight-neutral with low hypoglycemia risk. Well-tolerated but modest efficacy.',

    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Dipeptidyl peptidase-4 (DPP-4)',
      targetLocation: 'Plasma and tissue membranes',
      simpleExplanation: 'Blocks an enzyme that normally breaks down gut hormones that stimulate insulin. By preserving these hormones, insulin release is enhanced when blood sugar is high.',
      detailedMechanism: 'DPP-4 rapidly degrades incretin hormones (GLP-1 and GIP) that are released after meals. Sitagliptin inhibits DPP-4, increasing incretin levels 2-3 fold. Higher GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed', result: 'Drug enters circulation' },
        { order: 2, location: 'Plasma/tissues', action: 'Inhibits DPP-4 enzyme', result: 'Reduced incretin degradation' },
        { order: 3, location: 'Circulation', action: 'GLP-1 and GIP levels rise', result: '2-3 fold increase in active incretins' },
        { order: 4, location: 'Pancreas', action: 'Enhanced insulin secretion (glucose-dependent)', result: 'Lower postprandial glucose' },
      ],
      physiologicalEffects: [
        { system: 'Endocrine', effect: 'Glucose-dependent insulin secretion', mechanism: 'Increased GLP-1 action', clinicalRelevance: 'Lowers blood sugar with low hypoglycemia risk', desiredOrAdverse: 'desired' },
        { system: 'Endocrine', effect: 'Suppressed glucagon', mechanism: 'GLP-1 inhibits alpha cells', clinicalRelevance: 'Reduced hepatic glucose output', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '87%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '1-4 hours',
      },
      distribution: {
        volumeOfDistribution: '198 L',
        proteinBinding: '38%',
        tissueDistribution: ['Widely distributed'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal metabolism (CYP3A4, CYP2C8 minor)',
        enzymes: ['CYP3A4', 'CYP2C8'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (79% unchanged)',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '12 hours',
      timeToSteadyState: '3 days',
    },

    indications: [
      { condition: 'Type 2 Diabetes Mellitus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Second-line; good add-on option' },
    ],

    dosing: {
      usualDose: { amount: '100mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 30-45 mL/min', adjustment: '50mg once daily', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl <30 mL/min', adjustment: '25mg once daily', rationale: 'Severely reduced clearance' },
        { condition: 'ESRD/dialysis', adjustment: '25mg once daily', rationale: 'Not removed by dialysis' },
      ],
      maxDose: '100mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Once daily, any time'] },
    },

    adverseEffects: [
      { name: 'Upper respiratory infection', frequency: 'common', severity: 'mild', mechanism: 'Possibly DPP-4 role in immune function', management: 'Supportive care', reversible: true, onsetTiming: 'Variable' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Analgesics if needed', reversible: true, onsetTiming: 'Variable' },
      { name: 'Pancreatitis', frequency: 'rare', severity: 'severe', mechanism: 'Uncertain; possibly GLP-1 effects on pancreas', management: 'Discontinue; do not rechallenge', reversible: true, onsetTiming: 'Variable' },
      { name: 'Joint pain', frequency: 'uncommon', severity: 'moderate', mechanism: 'Unknown', management: 'May need to discontinue', reversible: true, onsetTiming: 'Variable' },
    ],

    interactions: [
      { interactingDrug: 'Insulin/sulfonylureas', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hypoglycemic effect', effect: 'Increased hypoglycemia risk', management: 'May need to reduce insulin/SU dose when adding sitagliptin' },
    ],

    contraindications: [
      { condition: 'History of pancreatitis', type: 'relative', reason: 'Possible increased risk' },
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Anaphylaxis and angioedema reported' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Often have renal impairment', recommendation: 'Adjust dose for renal function; otherwise well-tolerated' },
      { population: 'renal-impairment', consideration: 'Renally excreted', recommendation: 'Reduce dose based on eGFR' },
      { population: 'pregnancy', consideration: 'Limited human data', recommendation: 'Insulin preferred', pregnancyCategory: 'B' },
    ],

    monitoring: [
      { parameter: 'Blood glucose/HbA1c', frequency: 'Per diabetes guidelines', rationale: 'Assess efficacy' },
      { parameter: 'Renal function', frequency: 'At baseline and periodically', rationale: 'Dose adjustment needed' },
      { parameter: 'Signs of pancreatitis', frequency: 'Ongoing', rationale: 'Rare but serious' },
    ],

    patientEducation: [
      'Take once daily at any time, with or without food',
      'Low risk of causing low blood sugar when used alone',
      'Report severe abdominal pain (possible pancreatitis)',
      'Does not cause weight gain',
    ],

    clinicalPearls: [
      'Modest HbA1c reduction (0.5-0.8%) but excellent tolerability',
      'Weight-neutral, low hypoglycemia risk (unless combined with SU/insulin)',
      'Requires dose adjustment for renal impairment',
      'Good option for elderly patients who cannot tolerate other agents',
      'Class concerns about pancreatitis - monitor for symptoms',
    ],
  },

  {
    id: 'empagliflozin',
    genericName: 'Empagliflozin',
    brandNames: ['Jardiance'],
    drugClass: 'Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor',
    category: 'endocrine',

    overview: 'Empagliflozin inhibits SGLT2 in the kidney, reducing glucose reabsorption and causing glucosuria. Beyond glucose lowering, it has proven cardiovascular and renal benefits, making it preferred in patients with heart failure or CKD. Weight loss and blood pressure reduction are additional benefits.',

    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Sodium-glucose cotransporter-2 (SGLT2)',
      targetLocation: 'Proximal renal tubule',
      simpleExplanation: 'Blocks glucose from being reabsorbed by the kidney, so excess sugar is excreted in urine. This lowers blood sugar and provides heart and kidney benefits.',
      detailedMechanism: 'SGLT2 is responsible for 90% of glucose reabsorption in the kidney. Empagliflozin inhibits SGLT2, lowering the renal threshold for glucose and inducing glucosuria (~70g/day). This causes caloric loss (weight loss), osmotic diuresis (lower BP), and natriuresis (hemodynamic benefits).',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed', result: 'Drug enters circulation' },
        { order: 2, location: 'Proximal tubule', action: 'Inhibits SGLT2 transporter', result: 'Blocked glucose reabsorption' },
        { order: 3, location: 'Nephron', action: 'Glucose remains in tubular fluid', result: 'Glucosuria (~70g/day)' },
        { order: 4, location: 'Systemic', action: 'Caloric loss, osmotic diuresis, natriuresis', result: 'Weight loss, lower BP, hemodynamic benefits' },
      ],
      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Glucosuria', mechanism: 'Blocked renal glucose reabsorption', clinicalRelevance: 'Lowers blood glucose', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced CV events', mechanism: 'Likely multifactorial: hemodynamic, metabolic', clinicalRelevance: 'Major benefit in heart failure', desiredOrAdverse: 'desired' },
        { system: 'Renal', effect: 'Nephroprotection', mechanism: 'Reduced intraglomerular pressure, hemodynamic effects', clinicalRelevance: 'Slows CKD progression', desiredOrAdverse: 'desired' },
        { system: 'Genitourinary', effect: 'Genital mycotic infections', mechanism: 'Glucose in urine promotes yeast growth', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '24 hours',
    },

    pharmacokinetics: {
      absorption: {
        bioavailability: '~78%',
        route: ['oral'],
        factors: ['Not clinically affected by food'],
        timeToePeak: '1.5 hours',
      },
      distribution: {
        volumeOfDistribution: '73.8 L',
        proteinBinding: '86%',
        tissueDistribution: ['Kidney', 'Plasma'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (glucuronidation)',
        enzymes: ['UGT2B7', 'UGT1A3', 'UGT1A8', 'UGT1A9'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (54%) and fecal (41%)',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '12 hours',
      timeToSteadyState: '5 days',
    },

    indications: [
      { condition: 'Type 2 Diabetes Mellitus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Preferred if ASCVD, HF, or CKD' },
      { condition: 'Heart failure (HFrEF and HFpEF)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Regardless of diabetes status' },
      { condition: 'Chronic kidney disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Slows progression' },
    ],

    dosing: {
      usualDose: { amount: '10-25mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'eGFR 30-45', adjustment: 'Can continue if already on; may not start for glucose only', rationale: 'Reduced glucose-lowering efficacy' },
        { condition: 'eGFR <30', adjustment: 'Do not start for glucose; may continue for HF/CKD', rationale: 'CV/renal benefits persist' },
        { condition: 'ESRD', adjustment: 'Not recommended', rationale: 'No data' },
      ],
      maxDose: '25mg/day',
      administration: { route: 'Oral', withFood: 'either', timing: 'Morning preferred', specialInstructions: ['Can take with or without food', 'Continue despite reduced eGFR for HF/CKD benefits'] },
    },

    adverseEffects: [
      { name: 'Genital mycotic infections', frequency: 'common', severity: 'mild', mechanism: 'Glucosuria promotes yeast', management: 'Good hygiene; antifungal treatment', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Urinary tract infections', frequency: 'common', severity: 'mild', mechanism: 'Glucosuria', management: 'Treat with antibiotics; maintain hydration', reversible: true, onsetTiming: 'Variable' },
      { name: 'Volume depletion/hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Osmotic diuresis', management: 'Monitor volume status; may need diuretic adjustment', reversible: true, onsetTiming: 'Early, especially in elderly on diuretics' },
      { name: 'Diabetic ketoacidosis (euglycemic)', frequency: 'rare', severity: 'severe', mechanism: 'Glucosuria masks hyperglycemia; ketogenesis from low insulin', management: 'Hold during illness/surgery; check ketones if symptoms', reversible: true, onsetTiming: 'During illness or stress' },
    ],

    interactions: [
      { interactingDrug: 'Diuretics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive volume depletion', effect: 'Hypotension, dehydration', management: 'May need to reduce diuretic dose' },
      { interactingDrug: 'Insulin/sulfonylureas', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive glucose lowering', effect: 'Hypoglycemia risk', management: 'May need to reduce insulin/SU dose' },
    ],

    contraindications: [
      { condition: 'Type 1 diabetes', type: 'absolute', reason: 'High risk of DKA' },
      { condition: 'ESRD or dialysis', type: 'absolute', reason: 'No efficacy data' },
      { condition: 'History of recurrent UTIs', type: 'relative', reason: 'May worsen infections' },
    ],

    specialPopulations: [
      { population: 'geriatric', consideration: 'Higher risk of volume depletion', recommendation: 'Monitor volume status; start at lower dose' },
      { population: 'renal-impairment', consideration: 'Glucose-lowering reduced; CV/renal benefits persist', recommendation: 'Can continue for HF/CKD even with low eGFR' },
      { population: 'pregnancy', consideration: 'Affects fetal kidney development', recommendation: 'Discontinue; use insulin', pregnancyCategory: 'C' },
    ],

    monitoring: [
      { parameter: 'Blood glucose/HbA1c', frequency: 'Per guidelines', rationale: 'Assess glycemic efficacy' },
      { parameter: 'Renal function', frequency: 'Baseline and periodically', rationale: 'For dosing and monitoring' },
      { parameter: 'Volume status, blood pressure', frequency: 'Periodically', rationale: 'Monitor for dehydration' },
      { parameter: 'Signs of DKA', frequency: 'During illness', rationale: 'Can occur even with normal glucose' },
    ],

    patientEducation: [
      'Take in the morning',
      'Causes increased urination - stay well hydrated',
      'May increase risk of yeast infections - practice good hygiene',
      'Stop taking during severe illness, vomiting, or before surgery',
      'Report symptoms of DKA: nausea, vomiting, abdominal pain, fatigue',
      'This medication protects your heart and kidneys beyond just lowering sugar',
    ],

    clinicalPearls: [
      'EMPA-REG OUTCOME: 38% reduction in CV death in T2DM with ASCVD',
      'EMPEROR trials: benefits in both HFrEF and HFpEF, regardless of diabetes',
      'Euglycemic DKA can occur - hold during illness, surgery, fasting',
      'Continue for HF/CKD benefits even if eGFR drops below glucose-lowering threshold',
      'Causes 2-3 kg weight loss and 3-5 mmHg systolic BP reduction',
      'Genital infections more common in women than men',
    ],
  },

  // ============================================
  // Antimicrobials
  // ============================================

  {
    id: 'amoxicillin',
    genericName: 'Amoxicillin',
    brandNames: ['Amoxil', 'Trimox', 'Moxatag'],
    drugClass: 'Aminopenicillin (beta-lactam antibiotic)',
    category: 'antimicrobial',
    overview: 'Amoxicillin is an aminopenicillin antibiotic with a broad spectrum of activity against many gram-positive and some gram-negative bacteria. It is one of the most commonly prescribed antibiotics worldwide due to its excellent oral bioavailability, safety profile, and effectiveness against common respiratory and urinary tract pathogens.',
    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'Penicillin-binding proteins (PBPs)',
      targetLocation: 'Bacterial cell wall',
      simpleExplanation: 'Amoxicillin blocks the enzymes that bacteria need to build their cell walls. Without a strong cell wall, bacteria cannot survive osmotic pressure and they burst.',
      detailedMechanism: 'Amoxicillin binds to penicillin-binding proteins (PBPs), particularly PBP1 and PBP3, which are transpeptidase enzymes essential for the final cross-linking step of peptidoglycan synthesis in the bacterial cell wall. This inhibition prevents the formation of the rigid cell wall structure, leading to cell lysis due to osmotic instability. The drug is bactericidal against susceptible organisms.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial periplasm', action: 'Amoxicillin enters through porin channels', result: 'Drug reaches target site' },
        { order: 2, location: 'Cell wall synthesis site', action: 'Binds to PBP1 and PBP3', result: 'Transpeptidase activity inhibited' },
        { order: 3, location: 'Peptidoglycan layer', action: 'Cross-linking prevented', result: 'Weak cell wall forms' },
        { order: 4, location: 'Bacterial cell', action: 'Osmotic pressure causes lysis', result: 'Bacterial death' },
      ],
      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bacterial killing', mechanism: 'Cell wall disruption and lysis', clinicalRelevance: 'Treatment of susceptible infections', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Altered gut flora', mechanism: 'Killing of normal intestinal bacteria', clinicalRelevance: 'Diarrhea, C. diff risk', desiredOrAdverse: 'adverse' },
        { system: 'Immune', effect: 'Allergic potential', mechanism: 'Beta-lactam ring acts as hapten', clinicalRelevance: 'Hypersensitivity reactions', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Peak levels in 1-2 hours; clinical effect 24-72 hours',
      durationOfEffect: '8 hours per dose',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '74-92%',
        route: ['oral'],
        factors: ['Food does not significantly affect absorption'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Minimal effect on absorption',
      },
      distribution: {
        volumeOfDistribution: '0.3-0.4 L/kg',
        proteinBinding: '17-20%',
        tissueDistribution: ['Middle ear', 'Sinuses', 'Respiratory tract', 'Urinary tract', 'Skin'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (60-70% unchanged)',
        renalClearance: '250-300 mL/min',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '1-1.3 hours (prolonged in renal impairment)',
      timeToSteadyState: '1-2 days',
    },
    indications: [
      { condition: 'Acute otitis media', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Streptococcal pharyngitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute sinusitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Urinary tract infection', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'H. pylori eradication', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Part of triple therapy' },
    ],
    dosing: {
      usualDose: { amount: '500 mg', frequency: 'Every 8 hours', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 10-30 mL/min', adjustment: '250-500 mg every 12 hours', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl <10 mL/min', adjustment: '250-500 mg every 24 hours', rationale: 'Severely reduced clearance' },
        { condition: 'High-dose for respiratory', adjustment: '1g every 8 hours', rationale: 'Achieve higher tissue levels' },
      ],
      maxDose: '3 g/day in divided doses',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: ['Complete full course even if feeling better', 'Can be taken with or without food'],
      },
    },
    adverseEffects: [
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Disruption of gut flora', management: 'Usually self-limited; consider probiotics', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI irritation', management: 'Take with food', reversible: true, onsetTiming: 'First few days' },
      { name: 'Rash', frequency: 'common', severity: 'mild', mechanism: 'Allergic or non-allergic', management: 'Distinguish from true allergy; may need to stop', reversible: true, onsetTiming: 'Days 5-14' },
      { name: 'Hypersensitivity reaction', frequency: 'uncommon', severity: 'severe', mechanism: 'IgE-mediated allergy', management: 'Stop immediately; never rechallenge', reversible: true, onsetTiming: 'Minutes to hours' },
      { name: 'C. difficile colitis', frequency: 'rare', severity: 'severe', mechanism: 'Overgrowth of C. diff due to flora disruption', management: 'Stop amoxicillin; treat C. diff', reversible: true, onsetTiming: 'During or weeks after therapy' },
    ],
    interactions: [
      { interactingDrug: 'Probenecid', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreased renal tubular secretion', effect: 'Increased amoxicillin levels', management: 'May use intentionally to boost levels' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced vitamin K production by gut flora', effect: 'Increased INR', management: 'Monitor INR more frequently' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased renal clearance of MTX', effect: 'Increased MTX toxicity', management: 'Monitor closely; may need MTX dose reduction' },
    ],
    contraindications: [
      { condition: 'Penicillin allergy with anaphylaxis', type: 'absolute', reason: 'Risk of fatal anaphylaxis' },
      { condition: 'History of amoxicillin-induced cholestatic jaundice', type: 'absolute', reason: 'Risk of recurrence' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category B - commonly used in pregnancy', recommendation: 'Generally considered safe', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk in small amounts', recommendation: 'Compatible with breastfeeding' },
      { population: 'pediatric', consideration: 'Commonly used in children', recommendation: 'Weight-based dosing: 25-50 mg/kg/day divided q8h' },
      { population: 'renal-impairment', consideration: 'Renally cleared', recommendation: 'Extend dosing interval based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: 'Day 2-3 of therapy', rationale: 'Assess for improvement', actionThreshold: 'No improvement by 72 hours - reassess' },
      { parameter: 'Signs of allergy', frequency: 'Throughout therapy', rationale: 'Early detection of hypersensitivity', actionThreshold: 'Stop if rash with systemic symptoms' },
    ],
    patientEducation: [
      'Complete the full course of antibiotics even if you feel better',
      'Take all doses at evenly spaced intervals',
      'Can be taken with or without food',
      'Stop and seek care immediately if you develop rash with fever, joint pain, or difficulty breathing',
      'Diarrhea is common - contact doctor if severe or bloody',
    ],
    clinicalPearls: [
      'The "amoxicillin rash" in EBV/mononucleosis is not a true allergy - occurs in 70-100% of patients',
      'Adding clavulanate extends spectrum to beta-lactamase producing organisms',
      'High-dose amoxicillin (90 mg/kg/day) overcomes some resistant S. pneumoniae',
      '10% cross-reactivity with cephalosporins is largely a myth - true cross-reactivity is ~1%',
      'Unlike ampicillin, amoxicillin absorption is not significantly reduced by food',
    ],
  },

  {
    id: 'azithromycin',
    genericName: 'Azithromycin',
    brandNames: ['Zithromax', 'Z-Pak', 'Zmax'],
    drugClass: 'Azalide (macrolide antibiotic)',
    category: 'antimicrobial',
    overview: 'Azithromycin is a macrolide antibiotic with a unique pharmacokinetic profile featuring high tissue penetration and a long half-life allowing for short-course therapy. It covers atypical pathogens (Mycoplasma, Chlamydia, Legionella) better than beta-lactams and is important for treating community-acquired pneumonia and STIs.',
    mechanism: {
      type: 'protein-synthesis-inhibitor',
      target: '50S ribosomal subunit',
      targetLocation: 'Bacterial ribosome',
      simpleExplanation: 'Azithromycin attaches to the bacterial ribosome and prevents bacteria from making proteins they need to survive and multiply.',
      detailedMechanism: 'Azithromycin binds to the 23S rRNA of the 50S ribosomal subunit, blocking the exit tunnel through which nascent peptide chains emerge. This inhibits translocation of peptidyl-tRNA and prevents elongation of the protein chain. The effect is bacteriostatic at usual concentrations but may be bactericidal at high concentrations achieved in tissues.',
      mechanismSteps: [
        { order: 1, location: 'Cell entry', action: 'Azithromycin crosses bacterial membrane', result: 'Drug reaches cytoplasm' },
        { order: 2, location: '50S ribosome', action: 'Binds to 23S rRNA in exit tunnel', result: 'Peptide chain cannot exit' },
        { order: 3, location: 'Ribosome', action: 'Translocation blocked', result: 'Protein synthesis stalls' },
        { order: 4, location: 'Bacterial cell', action: 'Essential proteins not made', result: 'Bacterial growth inhibited' },
      ],
      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bacterial growth inhibition', mechanism: 'Protein synthesis blockade', clinicalRelevance: 'Treatment of susceptible infections', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Potassium channel blockade', clinicalRelevance: 'Risk of torsades de pointes', desiredOrAdverse: 'adverse' },
        { system: 'Gastrointestinal', effect: 'Prokinetic effect', mechanism: 'Motilin receptor agonism', clinicalRelevance: 'Nausea, diarrhea', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Peak tissue levels in 2-3 days',
      durationOfEffect: 'Tissue levels persist 5-7 days after last dose',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '37% (reduced by food with immediate-release)',
        route: ['oral', 'intravenous'],
        factors: ['Food decreases rate but not extent for capsules', 'Tablets unaffected by food'],
        timeToePeak: '2-3 hours',
        foodEffect: 'Take capsules on empty stomach; tablets can be taken with food',
      },
      distribution: {
        volumeOfDistribution: '31 L/kg (extensive tissue distribution)',
        proteinBinding: '7-50% (concentration dependent)',
        tissueDistribution: ['Lungs (100x plasma)', 'Tonsils', 'Prostate', 'Macrophages', 'Fibroblasts'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (minimal)',
        enzymes: ['CYP3A4 (minor)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Biliary (major), Renal (minor)',
        biliaryClearance: '50% unchanged in bile',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '68 hours (terminal)',
      timeToSteadyState: 'N/A - single dose or short course typical',
    },
    indications: [
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Covers atypicals' },
      { condition: 'Acute bacterial exacerbation of COPD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chlamydia trachomatis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Single 1g dose' },
      { condition: 'Travelers diarrhea', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'MAC prophylaxis in HIV', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Pertussis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '500 mg day 1, then 250 mg', frequency: 'Daily for 4 days (Z-Pak)', route: 'Oral' },
      adjustments: [
        { condition: 'Chlamydia', adjustment: '1 g single dose', rationale: 'High tissue penetration maintains effect' },
        { condition: 'CAP', adjustment: '500 mg daily x 3 days', rationale: 'Equivalent to longer courses' },
        { condition: 'MAC prophylaxis', adjustment: '1200 mg weekly', rationale: 'Long half-life allows weekly dosing' },
      ],
      maxDose: '500 mg/day for multi-day regimens',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Consistent timing each day',
        specialInstructions: ['Capsules: take on empty stomach', 'Tablets/suspension: can take with food'],
      },
    },
    adverseEffects: [
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Motilin receptor agonism + flora disruption', management: 'Usually self-limited', reversible: true, onsetTiming: 'First few days' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI prokinetic effect', management: 'Take with food if using tablets', reversible: true, onsetTiming: 'First dose' },
      { name: 'QT prolongation', frequency: 'rare', severity: 'severe', mechanism: 'IKr potassium channel blockade', management: 'Avoid in patients with risk factors; monitor ECG if concerned', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Hepatotoxicity', frequency: 'rare', severity: 'severe', mechanism: 'Idiosyncratic', management: 'Stop if LFTs significantly elevated', reversible: true, onsetTiming: 'During or shortly after therapy' },
    ],
    interactions: [
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT prolongation', effect: 'Increased risk of torsades', management: 'Avoid combination if possible; monitor ECG' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced gut flora vitamin K synthesis', effect: 'Increased INR', management: 'Monitor INR' },
      { interactingDrug: 'Cyclosporine', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4/P-gp inhibition (less than other macrolides)', effect: 'Increased cyclosporine levels', management: 'Monitor levels' },
    ],
    contraindications: [
      { condition: 'History of cholestatic jaundice/hepatic dysfunction with azithromycin', type: 'absolute', reason: 'Risk of recurrence' },
      { condition: 'Hypersensitivity to macrolides', type: 'absolute', reason: 'Risk of allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category B', recommendation: 'Generally considered safe; preferred macrolide in pregnancy', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Excreted in breast milk', recommendation: 'Use with caution' },
      { population: 'hepatic-impairment', consideration: 'Primarily biliary excretion', recommendation: 'Use with caution in severe hepatic disease' },
      { population: 'geriatric', consideration: 'Higher risk of QT prolongation', recommendation: 'Consider baseline ECG; avoid with other QT-prolonging drugs' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: 'Day 3-5', rationale: 'Assess improvement', actionThreshold: 'No improvement - consider alternative diagnosis/therapy' },
      { parameter: 'ECG', frequency: 'If risk factors present', rationale: 'QT prolongation risk', actionThreshold: 'QTc > 500 ms - discontinue' },
    ],
    patientEducation: [
      'Complete all doses even though it is a short course',
      'The medicine continues to work in your body for several days after your last dose',
      'Report any heart palpitations, fainting, or irregular heartbeat immediately',
      'Diarrhea is common but should improve after finishing the medicine',
    ],
    clinicalPearls: [
      'The long tissue half-life means 3-5 day courses are equivalent to 10 days of other antibiotics',
      'Concentrates in macrophages - gets "delivered" to sites of infection',
      'Lower GI side effects than erythromycin due to less motilin agonism',
      'Does NOT require renal dose adjustment unlike many antibiotics',
      'QT prolongation risk lower than erythromycin or fluoroquinolones but still present',
      'Poor activity against H. influenzae compared to other macrolides',
    ],
  },

  {
    id: 'ciprofloxacin',
    genericName: 'Ciprofloxacin',
    brandNames: ['Cipro', 'Ciloxan', 'Cipro XR'],
    drugClass: 'Fluoroquinolone antibiotic',
    category: 'antimicrobial',
    overview: 'Ciprofloxacin is a second-generation fluoroquinolone with excellent gram-negative coverage, including Pseudomonas aeruginosa. It has broad indications but carries significant warnings including tendon rupture, QT prolongation, and peripheral neuropathy. Reserve for infections where benefits outweigh risks.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'DNA gyrase (gram-negative) and Topoisomerase IV (gram-positive)',
      targetLocation: 'Bacterial chromosome',
      simpleExplanation: 'Ciprofloxacin blocks the enzymes bacteria need to unwind and copy their DNA. Without being able to replicate DNA, bacteria cannot divide and die.',
      detailedMechanism: 'Fluoroquinolones inhibit bacterial type II topoisomerases - DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase introduces negative supercoils needed for DNA replication and transcription, while topoisomerase IV separates daughter chromosomes. Inhibition leads to DNA strand breaks and rapid bactericidal effect. Ciprofloxacin has relatively balanced activity against both targets.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial cell', action: 'Ciprofloxacin enters through porins', result: 'Drug reaches chromosome' },
        { order: 2, location: 'DNA-enzyme complex', action: 'Binds to gyrase-DNA or TopoIV-DNA complex', result: 'Enzyme trapped on DNA' },
        { order: 3, location: 'Chromosome', action: 'Double-strand breaks accumulate', result: 'DNA fragmentation' },
        { order: 4, location: 'Bacterial cell', action: 'SOS response overwhelmed', result: 'Rapid bacterial death' },
      ],
      physiologicalEffects: [
        { system: 'Infectious', effect: 'Rapid bactericidal killing', mechanism: 'DNA fragmentation', clinicalRelevance: 'Effective against susceptible gram-negatives', desiredOrAdverse: 'desired' },
        { system: 'Musculoskeletal', effect: 'Tendon damage', mechanism: 'Collagen degradation, MMP upregulation', clinicalRelevance: 'Risk of tendinitis/rupture', desiredOrAdverse: 'adverse' },
        { system: 'Nervous', effect: 'CNS effects', mechanism: 'GABA antagonism, glutamate effects', clinicalRelevance: 'Seizures, confusion, neuropathy', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Potassium channel blockade', clinicalRelevance: 'Arrhythmia risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Bactericidal within hours',
      durationOfEffect: '12 hours per dose',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '70-80%',
        route: ['oral', 'intravenous', 'ophthalmic', 'otic'],
        factors: ['Significantly reduced by divalent cations (Ca, Mg, Fe, Zn)'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Dairy products and antacids significantly reduce absorption',
      },
      distribution: {
        volumeOfDistribution: '2-3 L/kg',
        proteinBinding: '20-40%',
        tissueDistribution: ['Prostate', 'Lungs', 'Bone', 'Urinary tract', 'GI tract'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (partial)',
        enzymes: ['CYP1A2 (inhibitor)'],
        activeMetabolites: ['Desethyleneciprofloxacin (minor)'],
        geneticVariability: 'CYP1A2 polymorphisms affect drug interactions',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (40-50% unchanged)',
        renalClearance: '300 mL/min',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '4-6 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Complicated UTI/pyelonephritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Reserve due to resistance/toxicity' },
      { condition: 'Acute bacterial prostatitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Excellent prostate penetration' },
      { condition: 'Infectious diarrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Pseudomonas infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Anthrax (post-exposure)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bone and joint infections', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Oral option for osteomyelitis' },
    ],
    dosing: {
      usualDose: { amount: '500 mg', frequency: 'Every 12 hours', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 30-50 mL/min', adjustment: '250-500 mg q12h', rationale: 'Reduced clearance' },
        { condition: 'CrCl <30 mL/min', adjustment: '250-500 mg q18-24h', rationale: 'Significantly reduced clearance' },
        { condition: 'Severe infection/Pseudomonas', adjustment: '750 mg q12h', rationale: 'Higher levels needed' },
      ],
      maxDose: '1500 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Take 2 hours before or 6 hours after antacids, dairy, calcium, iron',
        specialInstructions: ['Avoid dairy products within 2 hours of dose', 'Stay well hydrated to prevent crystalluria'],
      },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI irritation', management: 'Take with food (non-dairy)', reversible: true, onsetTiming: 'First few doses' },
      { name: 'Tendinitis/rupture', frequency: 'uncommon', severity: 'severe', mechanism: 'MMP upregulation, collagen damage', management: 'Stop immediately at first sign of tendon pain; avoid exercise during therapy', reversible: false, onsetTiming: 'Days to months after starting' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Potassium channel inhibition', management: 'Avoid in patients with risk factors', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Peripheral neuropathy', frequency: 'rare', severity: 'severe', mechanism: 'Mitochondrial toxicity in neurons', management: 'Stop at first symptom; may be irreversible', reversible: false, onsetTiming: 'Days to weeks' },
      { name: 'CNS effects (confusion, seizures)', frequency: 'uncommon', severity: 'moderate', mechanism: 'GABA antagonism', management: 'Avoid in seizure history; stop if symptoms occur', reversible: true, onsetTiming: 'First few days' },
    ],
    interactions: [
      { interactingDrug: 'Theophylline', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP1A2 inhibition', effect: 'Increased theophylline levels and toxicity', management: 'Reduce theophylline dose 30-50%; monitor levels' },
      { interactingDrug: 'Tizanidine', interactionType: 'pharmacokinetic', severity: 'contraindicated', mechanism: 'CYP1A2 inhibition', effect: '10-fold increase in tizanidine levels', management: 'Contraindicated - do not use together' },
      { interactingDrug: 'Antacids/dairy', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Chelation with divalent cations', effect: 'Reduced ciprofloxacin absorption', management: 'Separate by 2 hours before or 6 hours after' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP1A2 inhibition of warfarin metabolism', effect: 'Increased INR', management: 'Monitor INR closely' },
    ],
    contraindications: [
      { condition: 'Concurrent tizanidine use', type: 'absolute', reason: 'Dangerous CYP1A2 interaction' },
      { condition: 'History of tendon disorder with fluoroquinolone', type: 'absolute', reason: 'High risk of recurrence' },
      { condition: 'Myasthenia gravis', type: 'relative', reason: 'May exacerbate weakness', alternative: 'Use only if no alternative' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C - cartilage toxicity in animals', recommendation: 'Avoid unless no alternative', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'Risk of cartilage damage', recommendation: 'Generally avoided; some exceptions (anthrax, Pseudomonas in CF)' },
      { population: 'geriatric', consideration: 'Higher risk of tendon rupture, QT prolongation, CNS effects', recommendation: 'Use with caution; consider alternatives' },
      { population: 'renal-impairment', consideration: 'Renally cleared', recommendation: 'Dose reduction based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: 'Days 2-3', rationale: 'Assess improvement', actionThreshold: 'Switch therapy if no improvement' },
      { parameter: 'Tendon symptoms', frequency: 'Throughout therapy', rationale: 'Early detection', actionThreshold: 'Stop immediately if pain/swelling' },
      { parameter: 'Neurological symptoms', frequency: 'Throughout therapy', rationale: 'Detect neuropathy', actionThreshold: 'Stop if numbness/tingling' },
    ],
    patientEducation: [
      'Avoid dairy products, antacids, and vitamins with calcium/iron near your doses',
      'Stop the medication and call your doctor immediately if you have tendon pain or swelling',
      'Report numbness, tingling, or burning sensations right away - these may be permanent',
      'Stay well hydrated while taking this medication',
      'Avoid excessive sun exposure - this medication increases sunburn risk',
    ],
    clinicalPearls: [
      'FDA Black Box Warning for tendon rupture, peripheral neuropathy, and CNS effects',
      'Reserve for infections where benefits clearly outweigh risks',
      'Oral bioavailability is excellent - IV-to-PO switch is straightforward',
      'One of few oral antibiotics with Pseudomonas coverage',
      'CYP1A2 inhibition strongest among fluoroquinolones',
      'Resistance increasing rapidly - check susceptibilities',
      'Tendon rupture risk highest in patients >60, on corticosteroids, or with renal/heart/lung transplant',
    ],
  },

  // ============================================
  // Psychiatric Medications
  // ============================================

  {
    id: 'sertraline',
    genericName: 'Sertraline',
    brandNames: ['Zoloft'],
    drugClass: 'Selective serotonin reuptake inhibitor (SSRI)',
    category: 'psychiatric',
    overview: 'Sertraline is a widely prescribed SSRI antidepressant with a favorable side effect profile and extensive evidence base. It is first-line treatment for major depressive disorder, multiple anxiety disorders, PTSD, and OCD. Its relatively low drug interaction potential makes it a preferred choice in medically complex patients.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT)',
      targetLocation: 'Presynaptic serotonergic neurons',
      simpleExplanation: 'Sertraline blocks the recycling of serotonin from the synapse back into the nerve cell, leaving more serotonin available to signal the next neuron. Over time, this helps regulate mood and anxiety.',
      detailedMechanism: 'Sertraline is a potent and selective inhibitor of the presynaptic serotonin transporter (SERT). By blocking reuptake, serotonin accumulates in the synaptic cleft, enhancing serotonergic neurotransmission. The acute effect is increased serotonin availability, but therapeutic effects require 2-4 weeks due to downstream adaptive changes including receptor downregulation and neuroplasticity effects.',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic terminal', action: 'Sertraline binds to SERT', result: 'Serotonin reuptake blocked' },
        { order: 2, location: 'Synapse', action: 'Serotonin accumulates', result: 'Enhanced postsynaptic signaling' },
        { order: 3, location: 'Postsynaptic neuron', action: '5-HT receptors activated', result: 'Initial effects (may worsen anxiety)' },
        { order: 4, location: 'Multiple brain regions', action: 'Receptor adaptation over weeks', result: 'Therapeutic antidepressant/anxiolytic effect', timeframe: '2-4 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Mood stabilization', mechanism: 'Enhanced serotonergic transmission', clinicalRelevance: 'Antidepressant effect', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Reduced anxiety', mechanism: 'Serotonin modulation of amygdala', clinicalRelevance: 'Anxiolytic effect', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'GI upset', mechanism: '90% of serotonin in gut', clinicalRelevance: 'Nausea, diarrhea', desiredOrAdverse: 'adverse' },
        { system: 'Reproductive', effect: 'Sexual dysfunction', mechanism: 'Serotonin inhibits dopamine/NO', clinicalRelevance: 'Delayed orgasm, reduced libido', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Initial effects 1-2 weeks; full effect 4-6 weeks',
      durationOfEffect: '24 hours (dosed once daily)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '44% (first-pass metabolism)',
        route: ['oral'],
        factors: ['Food increases absorption'],
        timeToePeak: '4.5-8.4 hours',
        foodEffect: 'Take with food to enhance absorption',
      },
      distribution: {
        volumeOfDistribution: '20 L/kg',
        proteinBinding: '98%',
        tissueDistribution: ['Brain', 'Liver', 'Lungs'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2D6', 'CYP2C19', 'CYP3A4', 'CYP2B6'],
        activeMetabolites: ['Desmethylsertraline (weak activity)'],
        geneticVariability: 'CYP2C19 poor metabolizers may have higher levels',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Fecal (40-45%), Renal (40-45%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '26 hours (36 hours for desmethylsertraline)',
      timeToSteadyState: '1 week',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Panic disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'PTSD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'OCD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Higher doses often needed' },
      { condition: 'Social anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Premenstrual dysphoric disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '50-100 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Start 25 mg; slower titration', rationale: 'Reduced metabolism' },
        { condition: 'OCD', adjustment: 'May need 150-200 mg daily', rationale: 'Higher doses often required' },
        { condition: 'Elderly', adjustment: 'Start 25 mg', rationale: 'Increased sensitivity' },
      ],
      maxDose: '200 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: 'Morning or evening (consistent time)',
        specialInstructions: ['Take with food', 'Do not stop abruptly - taper to avoid discontinuation syndrome'],
      },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'very-common', severity: 'mild', mechanism: 'GI serotonin effects', management: 'Take with food; usually improves in 1-2 weeks', reversible: true, onsetTiming: 'First 1-2 weeks' },
      { name: 'Sexual dysfunction', frequency: 'common', severity: 'moderate', mechanism: 'Serotonin inhibition of dopamine/NO', management: 'May try dose reduction, drug holiday, or adjunctive therapy', reversible: true, onsetTiming: 'Within first month' },
      { name: 'Insomnia', frequency: 'common', severity: 'mild', mechanism: 'Serotonergic activation', management: 'Take in morning; may add low-dose trazodone', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Serotonergic effects on vasculature', management: 'Usually transient', reversible: true, onsetTiming: 'First 1-2 weeks' },
      { name: 'Discontinuation syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Sudden serotonin drop', management: 'Taper slowly over weeks', reversible: true, onsetTiming: 'Within days of stopping' },
      { name: 'Serotonin syndrome', frequency: 'rare', severity: 'life-threatening', mechanism: 'Excessive serotonergic activity', management: 'Stop drug; supportive care; cyproheptadine', reversible: true, onsetTiming: 'Usually with drug interactions' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Severe serotonin excess', effect: 'Serotonin syndrome', management: 'Wait 14 days between agents' },
      { interactingDrug: 'Other serotonergic drugs (tramadol, triptans)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive serotonin effects', effect: 'Increased serotonin syndrome risk', management: 'Use caution; monitor for symptoms' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'SSRIs inhibit platelet aggregation', effect: 'Increased bleeding risk', management: 'Monitor INR; consider GI protection' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Both impair hemostasis', effect: 'Increased GI bleeding risk', management: 'Use PPI if needed' },
    ],
    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Risk of serotonin syndrome' },
      { condition: 'Concurrent pimozide', type: 'absolute', reason: 'Risk of QT prolongation' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; possible PPHN risk in 3rd trimester', recommendation: 'Weigh risks vs benefits; sertraline relatively well-studied', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Low levels in breast milk', recommendation: 'Generally considered compatible; preferred SSRI for breastfeeding' },
      { population: 'pediatric', consideration: 'FDA approved for OCD ages 6+', recommendation: 'Black box warning for suicidality; close monitoring required' },
      { population: 'geriatric', consideration: 'Increased fall risk, hyponatremia risk', recommendation: 'Start low, go slow; monitor sodium' },
    ],
    monitoring: [
      { parameter: 'Depression/anxiety symptoms', frequency: 'Every 1-2 weeks initially', rationale: 'Assess response and suicidality', actionThreshold: 'Worsening symptoms or suicidal thoughts' },
      { parameter: 'Sodium', frequency: 'Within first few weeks, especially elderly', rationale: 'Risk of SIADH', actionThreshold: 'Sodium <130 mEq/L' },
    ],
    patientEducation: [
      'It takes 2-4 weeks to feel the full benefit - do not give up too soon',
      'Do not stop suddenly - this can cause withdrawal symptoms',
      'Report any thoughts of self-harm immediately, especially in first weeks',
      'Avoid alcohol - it can worsen depression and increase side effects',
      'Sexual side effects are common - talk to your doctor about options',
      'Take at the same time each day for best results',
    ],
    clinicalPearls: [
      'Black box warning for suicidality in children, adolescents, young adults <25 (close monitoring required)',
      'Lowest CYP450 interaction potential among SSRIs - good choice for medically complex patients',
      'The only SSRI FDA-approved for use in children with OCD (age 6+)',
      'Preferred SSRI in breastfeeding due to low milk transfer',
      'Can worsen anxiety initially - start low in anxious patients',
      'Discontinuation syndrome less severe than paroxetine but still taper',
    ],
  },

  {
    id: 'escitalopram',
    genericName: 'Escitalopram',
    brandNames: ['Lexapro'],
    drugClass: 'Selective serotonin reuptake inhibitor (SSRI)',
    category: 'psychiatric',
    overview: 'Escitalopram is the S-enantiomer of citalopram and is considered one of the most selective SSRIs available. It has an excellent tolerability profile with minimal drug interactions, making it a first-line choice for depression and generalized anxiety disorder.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin transporter (SERT)',
      targetLocation: 'Presynaptic serotonergic neurons',
      simpleExplanation: 'Escitalopram selectively blocks serotonin reuptake, increasing serotonin levels in the brain to improve mood and reduce anxiety.',
      detailedMechanism: 'Escitalopram is the therapeutically active S-enantiomer of citalopram. It binds to the primary and allosteric sites on SERT with high affinity and selectivity. The R-enantiomer (in racemic citalopram) actually inhibits the binding of S-citalopram, so escitalopram may be more potent at lower doses than the racemic mixture.',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic terminal', action: 'Escitalopram binds SERT at primary and allosteric sites', result: 'Highly selective reuptake inhibition' },
        { order: 2, location: 'Synapse', action: 'Serotonin accumulates', result: 'Enhanced neurotransmission' },
        { order: 3, location: 'Postsynaptic neuron', action: '5-HT receptor activation', result: 'Acute effects' },
        { order: 4, location: 'Limbic system', action: 'Neuroadaptation occurs', result: 'Antidepressant/anxiolytic effect', timeframe: '2-4 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Antidepressant effect', mechanism: 'Increased serotonergic neurotransmission', clinicalRelevance: 'Improved mood', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Anxiolytic effect', mechanism: 'Serotonin modulation of limbic circuits', clinicalRelevance: 'Reduced anxiety', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'hERG channel inhibition', clinicalRelevance: 'Dose-dependent risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-4 weeks for therapeutic effect',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '80%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '5 hours',
      },
      distribution: {
        volumeOfDistribution: '12-26 L/kg',
        proteinBinding: '56%',
        tissueDistribution: ['Brain', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19 (primary)', 'CYP3A4'],
        activeMetabolites: ['S-desmethylcitalopram (weak)'],
        geneticVariability: 'CYP2C19 poor metabolizers have 2x exposure',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (8% unchanged), Fecal',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '27-32 hours',
      timeToSteadyState: '1 week',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Social anxiety disorder', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Panic disorder', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '10-20 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Max 10 mg daily', rationale: 'Reduced metabolism' },
        { condition: 'Elderly (>65)', adjustment: 'Max 10 mg daily', rationale: 'QT prolongation risk' },
        { condition: 'CYP2C19 poor metabolizers', adjustment: 'Max 10 mg daily', rationale: 'Reduced metabolism' },
      ],
      maxDose: '20 mg/day (10 mg in elderly/hepatic impairment)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Morning or evening',
        specialInstructions: ['Can be taken with or without food', 'Taper when discontinuing'],
      },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI serotonin effects', management: 'Usually transient; take with food', reversible: true, onsetTiming: 'First 1-2 weeks' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Serotonergic effects', management: 'Usually resolves', reversible: true, onsetTiming: 'First week' },
      { name: 'Sexual dysfunction', frequency: 'common', severity: 'moderate', mechanism: 'Serotonin effects on sexual function', management: 'Dose reduction or adjunctive therapy', reversible: true, onsetTiming: 'Within first month' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'hERG potassium channel inhibition', management: 'Avoid doses >20 mg; ECG if risk factors', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Hyponatremia', frequency: 'uncommon', severity: 'moderate', mechanism: 'SIADH', management: 'Monitor sodium, especially in elderly', reversible: true, onsetTiming: 'First few weeks' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome risk', effect: 'Potentially fatal reaction', management: '14-day washout between drugs' },
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT effects', effect: 'Increased arrhythmia risk', management: 'Avoid combination; monitor ECG' },
      { interactingDrug: 'Omeprazole/CYP2C19 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C19 inhibition', effect: 'Increased escitalopram levels', management: 'Consider dose reduction' },
    ],
    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Serotonin syndrome' },
      { condition: 'Concurrent pimozide', type: 'absolute', reason: 'QT prolongation' },
      { condition: 'Congenital long QT syndrome', type: 'absolute', reason: 'QT prolongation risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Consider risks vs benefits; some data available', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'QT prolongation risk', recommendation: 'Max 10 mg daily' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Max 10 mg daily' },
    ],
    monitoring: [
      { parameter: 'Depression/anxiety symptoms', frequency: 'Every 2-4 weeks initially', rationale: 'Assess response', actionThreshold: 'No improvement by 6-8 weeks' },
      { parameter: 'ECG', frequency: 'Baseline if risk factors', rationale: 'QT prolongation', actionThreshold: 'QTc >500 ms' },
      { parameter: 'Sodium', frequency: 'First few weeks in elderly', rationale: 'SIADH risk', actionThreshold: 'Na <130' },
    ],
    patientEducation: [
      'Full effects take 2-4 weeks - be patient',
      'Do not stop suddenly to avoid withdrawal symptoms',
      'Report palpitations or fainting (could indicate heart rhythm issue)',
      'Can be taken morning or evening at the same time daily',
    ],
    clinicalPearls: [
      'Often considered the best-tolerated SSRI with fewest drug interactions',
      'QT prolongation is dose-dependent - do not exceed 20 mg (10 mg in elderly)',
      'Half the dose of citalopram (10 mg escitalopram ≈ 20 mg citalopram)',
      'CYP2C19 poor metabolizers (2-3% of Caucasians) should not exceed 10 mg',
      'Minimal CYP450 inhibition - good for patients on multiple medications',
    ],
  },

  {
    id: 'bupropion',
    genericName: 'Bupropion',
    brandNames: ['Wellbutrin', 'Wellbutrin SR', 'Wellbutrin XL', 'Zyban', 'Aplenzin'],
    drugClass: 'Norepinephrine-dopamine reuptake inhibitor (NDRI)',
    category: 'psychiatric',
    overview: 'Bupropion is unique among antidepressants in that it works primarily on norepinephrine and dopamine rather than serotonin. This gives it a distinct side effect profile - notably no sexual dysfunction or weight gain. It is also FDA-approved for smoking cessation.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Norepinephrine and dopamine transporters (NET, DAT)',
      targetLocation: 'Presynaptic catecholaminergic neurons',
      simpleExplanation: 'Bupropion blocks the reuptake of norepinephrine and dopamine, increasing their levels in the brain. This provides an energizing antidepressant effect without the sexual side effects of serotonin-based drugs.',
      detailedMechanism: 'Bupropion and its active metabolites inhibit the reuptake of norepinephrine and dopamine by blocking NET and DAT. It has minimal effect on serotonin reuptake. The drug is also a non-competitive antagonist at nicotinic acetylcholine receptors, which contributes to its efficacy in smoking cessation.',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic terminals', action: 'Bupropion blocks NET and DAT', result: 'NE and dopamine reuptake inhibited' },
        { order: 2, location: 'Synapse', action: 'Catecholamines accumulate', result: 'Enhanced adrenergic/dopaminergic signaling' },
        { order: 3, location: 'Nicotinic receptors', action: 'Non-competitive antagonism', result: 'Reduced nicotine craving' },
        { order: 4, location: 'Prefrontal cortex', action: 'Enhanced catecholamine tone', result: 'Improved mood and concentration', timeframe: '2-4 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Antidepressant/activating', mechanism: 'Enhanced NE/DA neurotransmission', clinicalRelevance: 'Improved mood and energy', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Reduced nicotine craving', mechanism: 'nAChR antagonism', clinicalRelevance: 'Smoking cessation aid', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Seizure risk', mechanism: 'Lowered seizure threshold', clinicalRelevance: 'Dose-dependent seizure risk', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Increased blood pressure', mechanism: 'Noradrenergic activation', clinicalRelevance: 'Hypertension risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 weeks for some effect; 4-6 weeks for full effect',
      durationOfEffect: '12-24 hours depending on formulation',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '87%',
        route: ['oral'],
        factors: ['Food has minimal effect'],
        timeToePeak: '2 hours (IR), 3 hours (SR), 5 hours (XL)',
      },
      distribution: {
        volumeOfDistribution: '20-47 L/kg',
        proteinBinding: '84%',
        tissueDistribution: ['Brain', 'Liver', 'Adipose tissue'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2B6 (primary)'],
        activeMetabolites: ['Hydroxybupropion (potent)', 'Threohydrobupropion', 'Erythrohydrobupropion'],
        geneticVariability: 'CYP2B6 polymorphisms affect levels',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (87%)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '21 hours (parent); 20-37 hours (metabolites)',
      timeToSteadyState: '5-8 days',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Seasonal affective disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'XL formulation' },
      { condition: 'Smoking cessation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'As Zyban' },
      { condition: 'ADHD', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'SSRI-induced sexual dysfunction', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Augmentation' },
    ],
    dosing: {
      usualDose: { amount: '150-300 mg', frequency: 'XL once daily; SR twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Reduce dose and frequency', rationale: 'Metabolite accumulation' },
        { condition: 'Hepatic impairment', adjustment: '75-150 mg daily', rationale: 'Reduced metabolism' },
        { condition: 'Smoking cessation', adjustment: '150 mg daily x 3 days, then 150 mg BID', rationale: 'Standard Zyban dosing' },
      ],
      maxDose: '450 mg/day (300 mg/dose max)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Morning (to avoid insomnia); if BID, doses 8 hours apart',
        specialInstructions: ['Do not crush/chew SR/XL formulations', 'Single doses should not exceed 150 mg (SR) or 300 mg (XL)'],
      },
    },
    adverseEffects: [
      { name: 'Insomnia', frequency: 'common', severity: 'mild', mechanism: 'Catecholaminergic activation', management: 'Take morning dose; avoid evening dosing', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic-like effect', management: 'Sugarless gum, hydration', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Agitation/anxiety', frequency: 'common', severity: 'mild', mechanism: 'Activating effects', management: 'May diminish over time; consider dose reduction', reversible: true, onsetTiming: 'First 1-2 weeks' },
      { name: 'Seizures', frequency: 'rare', severity: 'severe', mechanism: 'Lowered seizure threshold', management: 'Do not exceed 450 mg/day; avoid in seizure risk', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Hypertension', frequency: 'uncommon', severity: 'moderate', mechanism: 'Noradrenergic effects', management: 'Monitor BP; treat if needed', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Hypertensive crisis risk', effect: 'Severe hypertension', management: '14-day washout' },
      { interactingDrug: 'CYP2B6 inhibitors (ticlopidine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased bupropion levels', effect: 'Toxicity risk', management: 'Consider dose reduction' },
      { interactingDrug: 'CYP2D6 substrates', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Bupropion inhibits CYP2D6', effect: 'Increased levels of 2D6 substrates', management: 'Monitor for toxicity of 2D6 drugs' },
      { interactingDrug: 'Drugs lowering seizure threshold', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive seizure risk', effect: 'Increased seizure risk', management: 'Avoid combination if possible' },
    ],
    contraindications: [
      { condition: 'Seizure disorder', type: 'absolute', reason: 'Increased seizure risk' },
      { condition: 'Bulimia/anorexia nervosa', type: 'absolute', reason: 'Increased seizure risk with eating disorders' },
      { condition: 'Concurrent MAOIs', type: 'absolute', reason: 'Hypertensive crisis' },
      { condition: 'Abrupt alcohol or benzo withdrawal', type: 'absolute', reason: 'Seizure risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Limited data; consider if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in milk; seizure reported in infant', recommendation: 'Use with caution' },
      { population: 'renal-impairment', consideration: 'Metabolites accumulate', recommendation: 'Reduce dose/frequency' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Max 75-150 mg daily' },
    ],
    monitoring: [
      { parameter: 'Depression symptoms', frequency: 'Every 2-4 weeks initially', rationale: 'Assess response', actionThreshold: 'No improvement by 6-8 weeks' },
      { parameter: 'Blood pressure', frequency: 'Baseline and periodically', rationale: 'HTN risk', actionThreshold: 'Significant elevation' },
      { parameter: 'Seizure risk factors', frequency: 'Ongoing', rationale: 'Safety', actionThreshold: 'New risk factors' },
    ],
    patientEducation: [
      'This medication does not typically cause sexual dysfunction or weight gain like other antidepressants',
      'Take doses at least 8 hours apart if on twice-daily dosing',
      'Do not crush or chew extended-release tablets',
      'Avoid alcohol - increases seizure risk',
      'Do not exceed prescribed dose - seizure risk increases at higher doses',
      'Report any seizure activity immediately',
    ],
    clinicalPearls: [
      'Only antidepressant without sexual side effects - often used as add-on for SSRI-induced dysfunction',
      'Often causes weight loss rather than gain - useful in overweight/obese patients',
      'Seizure risk is dose-dependent: 0.1% at 300 mg, 0.4% at 400 mg',
      'Contraindicated in eating disorders due to electrolyte-related seizure risk',
      'Also marketed as Zyban for smoking cessation - do not combine with Wellbutrin',
      'Strong CYP2D6 inhibitor - watch for interactions with metoprolol, codeine, etc.',
      'Activating profile makes it good for low-energy depression, poor for anxious depression',
    ],
  },

  // ============================================
  // Respiratory Medications
  // ============================================

  {
    id: 'albuterol',
    genericName: 'Albuterol',
    brandNames: ['ProAir', 'Ventolin', 'Proventil'],
    drugClass: 'Short-acting beta-2 agonist (SABA)',
    category: 'respiratory',
    overview: 'Albuterol is the most commonly used rescue inhaler for asthma and COPD. It works within minutes to relax airway smooth muscle and relieve bronchospasm. It is essential for acute symptom relief but should not be used as maintenance therapy.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Beta-2 adrenergic receptors',
      targetLocation: 'Bronchial smooth muscle',
      simpleExplanation: 'Albuterol activates beta-2 receptors on airway muscles, causing them to relax and open up the airways. This makes it easier to breathe during an asthma attack or COPD flare.',
      detailedMechanism: 'Albuterol is a selective beta-2 adrenergic receptor agonist. When it binds to beta-2 receptors on bronchial smooth muscle, it activates adenylyl cyclase, increasing intracellular cAMP. This leads to activation of protein kinase A, which phosphorylates proteins that promote smooth muscle relaxation. The result is bronchodilation within minutes.',
      mechanismSteps: [
        { order: 1, location: 'Airways', action: 'Albuterol inhaled and deposited on airway epithelium', result: 'Drug reaches smooth muscle' },
        { order: 2, location: 'Smooth muscle', action: 'Binds to beta-2 receptors', result: 'Receptor activation' },
        { order: 3, location: 'Cell membrane', action: 'Adenylyl cyclase activated', result: 'cAMP increases' },
        { order: 4, location: 'Cytoplasm', action: 'PKA phosphorylates myosin light chain kinase', result: 'Smooth muscle relaxation', timeframe: '5-15 minutes' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'Smooth muscle relaxation', clinicalRelevance: 'Relief of bronchospasm', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Tachycardia', mechanism: 'Beta-1 cross-reactivity', clinicalRelevance: 'Palpitations, tremor', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Hypokalemia', mechanism: 'K+ driven into cells', clinicalRelevance: 'Monitor in high-dose use', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '5-15 minutes',
      durationOfEffect: '4-6 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '10-20% reaches lungs (inhaled)',
        route: ['inhalation', 'oral', 'nebulization'],
        factors: ['Proper inhaler technique critical for delivery'],
        timeToePeak: '5-15 minutes (inhaled)',
      },
      distribution: {
        volumeOfDistribution: '2.5 L/kg',
        proteinBinding: '10%',
        tissueDistribution: ['Lungs', 'Heart', 'Skeletal muscle'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (GI tract for swallowed portion)',
        enzymes: ['SULT1A3 (sulfation)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (80% as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '4-6 hours',
      timeToSteadyState: 'N/A - used as needed',
    },
    indications: [
      { condition: 'Acute asthma exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'COPD exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Exercise-induced bronchospasm', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Use 15-30 min before exercise' },
      { condition: 'Hyperkalemia', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: false, notes: 'Drives K+ into cells' },
    ],
    dosing: {
      usualDose: { amount: '2 puffs (90 mcg each)', frequency: 'Every 4-6 hours as needed', route: 'Inhalation' },
      adjustments: [
        { condition: 'Acute severe asthma', adjustment: '4-8 puffs every 20 min x 3', rationale: 'Higher doses needed in severe exacerbation' },
        { condition: 'Nebulizer', adjustment: '2.5 mg in 3 mL saline', rationale: 'Alternative delivery for severe cases' },
      ],
      maxDose: 'Generally 8-12 puffs/day (chronic use suggests poor control)',
      administration: {
        route: 'Inhalation',
        withFood: 'either',
        specialInstructions: ['Shake inhaler before each use', 'Use spacer for better lung deposition', 'Rinse mouth after if using frequently'],
      },
    },
    adverseEffects: [
      { name: 'Tremor', frequency: 'common', severity: 'mild', mechanism: 'Beta-2 stimulation of skeletal muscle', management: 'Usually diminishes with continued use', reversible: true, onsetTiming: 'Within minutes of dose' },
      { name: 'Tachycardia', frequency: 'common', severity: 'mild', mechanism: 'Beta-1 cross-reactivity', management: 'Reduce dose if bothersome', reversible: true, onsetTiming: 'Within minutes' },
      { name: 'Hypokalemia', frequency: 'uncommon', severity: 'moderate', mechanism: 'Intracellular K+ shift', management: 'Monitor K+ with frequent use', reversible: true, onsetTiming: 'With high doses' },
      { name: 'Paradoxical bronchospasm', frequency: 'rare', severity: 'severe', mechanism: 'Propellant/preservative reaction', management: 'Stop use; use alternative', reversible: true, onsetTiming: 'Immediately after inhalation' },
    ],
    interactions: [
      { interactingDrug: 'Beta-blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Antagonism of bronchodilation', effect: 'Reduced efficacy; may worsen bronchospasm', management: 'Use cardioselective beta-blockers if needed' },
      { interactingDrug: 'Diuretics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hypokalemia', effect: 'Worsened K+ depletion', management: 'Monitor potassium' },
      { interactingDrug: 'MAOIs/TCAs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Enhanced cardiovascular effects', effect: 'Increased BP, arrhythmia risk', management: 'Use with caution' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to albuterol', type: 'absolute', reason: 'Allergic reaction risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C but widely used', recommendation: 'Benefits of asthma control outweigh risks; well-established safety', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'Safe in children', recommendation: 'Same mechanism; dose by age/weight' },
      { population: 'geriatric', consideration: 'More sensitive to cardiovascular effects', recommendation: 'Start with lower doses' },
    ],
    monitoring: [
      { parameter: 'Frequency of use', frequency: 'Each visit', rationale: 'Increased use indicates poor control', actionThreshold: '>2 days/week suggests need for controller therapy' },
      { parameter: 'Heart rate', frequency: 'If symptoms', rationale: 'Tachycardia', actionThreshold: 'Sustained >120 bpm' },
    ],
    patientEducation: [
      'This is a rescue inhaler - use for quick relief of symptoms',
      'If you need it more than twice a week, your asthma may not be well controlled',
      'Shake well before each use',
      'Use a spacer if you have one - it helps more medicine reach your lungs',
      'Keep track of doses remaining in the inhaler',
      'Always carry your rescue inhaler with you',
    ],
    clinicalPearls: [
      'Needing rescue inhaler >2 days/week indicates need for step-up therapy',
      'Frequent albuterol use associated with worse asthma outcomes',
      'Always prescribe with a controller (ICS) if patient has persistent asthma',
      'Can cause significant hypokalemia when nebulized repeatedly in ED',
      'Beta-blocker use in asthma: if needed, use cardioselective (metoprolol) and monitor',
    ],
  },

  {
    id: 'fluticasone',
    genericName: 'Fluticasone',
    brandNames: ['Flovent', 'Flonase', 'ArmonAir', 'Arnuity'],
    drugClass: 'Inhaled corticosteroid (ICS)',
    category: 'respiratory',
    overview: 'Fluticasone is a potent inhaled corticosteroid used as controller therapy for asthma and allergic rhinitis. It reduces airway inflammation and is the foundation of asthma maintenance therapy. Unlike rescue inhalers, it does not provide immediate relief but prevents symptoms when used regularly.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptors',
      targetLocation: 'Airway epithelium, inflammatory cells',
      simpleExplanation: 'Fluticasone enters airway cells and turns off the genes that cause inflammation. This reduces swelling, mucus production, and sensitivity of the airways over time.',
      detailedMechanism: 'Fluticasone binds to intracellular glucocorticoid receptors (GR) in airway epithelial cells, eosinophils, and other inflammatory cells. The activated GR-drug complex translocates to the nucleus and modulates gene transcription - suppressing inflammatory cytokines (IL-4, IL-5, IL-13) while enhancing anti-inflammatory proteins. This reduces eosinophil recruitment, mucus production, and airway hyperreactivity.',
      mechanismSteps: [
        { order: 1, location: 'Airways', action: 'Fluticasone deposited on airway surface', result: 'Drug absorbed into epithelial cells' },
        { order: 2, location: 'Cytoplasm', action: 'Binds to glucocorticoid receptor', result: 'Receptor activation and dimerization' },
        { order: 3, location: 'Nucleus', action: 'GR-drug complex binds DNA', result: 'Gene transcription modulated' },
        { order: 4, location: 'Airway tissues', action: 'Inflammatory mediators suppressed', result: 'Reduced inflammation over days-weeks', timeframe: '1-4 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Reduced airway inflammation', mechanism: 'Cytokine suppression', clinicalRelevance: 'Asthma control', desiredOrAdverse: 'desired' },
        { system: 'Immune', effect: 'Local immunosuppression', mechanism: 'Suppressed immune cell function', clinicalRelevance: 'Oral candidiasis risk', desiredOrAdverse: 'adverse' },
        { system: 'Endocrine', effect: 'HPA axis suppression', mechanism: 'Systemic absorption', clinicalRelevance: 'Adrenal suppression at high doses', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '24 hours for some effect; full effect in 1-4 weeks',
      durationOfEffect: '12-24 hours (requires daily use)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '~1% systemic (oral deposition swallowed/inactivated)',
        route: ['inhalation', 'intranasal'],
        factors: ['Spacer reduces oropharyngeal deposition'],
        timeToePeak: '1-2 hours',
      },
      distribution: {
        volumeOfDistribution: '4.2 L/kg',
        proteinBinding: '91%',
        tissueDistribution: ['Lungs (primary)', 'Systemic distribution limited'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver (CYP3A4)',
        enzymes: ['CYP3A4'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal (majority), Renal (<5%)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '7.8 hours',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Persistent asthma', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'COPD maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Usually combined with LABA' },
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Intranasal formulation' },
      { condition: 'Eosinophilic esophagitis', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Swallowed inhaler' },
    ],
    dosing: {
      usualDose: { amount: '88-440 mcg', frequency: 'Twice daily', route: 'Inhalation' },
      adjustments: [
        { condition: 'Low-dose (mild persistent)', adjustment: '88-264 mcg/day', rationale: 'Step 2 therapy' },
        { condition: 'Medium-dose (moderate)', adjustment: '264-440 mcg/day', rationale: 'Step 3-4 therapy' },
        { condition: 'High-dose (severe)', adjustment: '440-880 mcg/day', rationale: 'Step 4-5 therapy' },
      ],
      maxDose: '880 mcg twice daily (adults)',
      administration: {
        route: 'Inhalation',
        withFood: 'either',
        specialInstructions: ['Rinse mouth after each use to prevent thrush', 'Use spacer with MDI', 'Do not use for acute symptoms'],
      },
    },
    adverseEffects: [
      { name: 'Oral candidiasis (thrush)', frequency: 'common', severity: 'mild', mechanism: 'Local immunosuppression', management: 'Rinse mouth after use; treat with nystatin if occurs', reversible: true, onsetTiming: 'After weeks of use' },
      { name: 'Dysphonia (hoarseness)', frequency: 'common', severity: 'mild', mechanism: 'Local steroid effect on vocal cords', management: 'Use spacer; technique review', reversible: true, onsetTiming: 'During therapy' },
      { name: 'HPA axis suppression', frequency: 'uncommon', severity: 'moderate', mechanism: 'Systemic absorption at high doses', management: 'Use lowest effective dose', reversible: true, onsetTiming: 'With prolonged high-dose use' },
      { name: 'Growth suppression in children', frequency: 'uncommon', severity: 'moderate', mechanism: 'Systemic steroid effect', management: 'Monitor growth; use lowest dose', reversible: true, onsetTiming: 'Cumulative over years' },
    ],
    interactions: [
      { interactingDrug: 'Ritonavir/CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased systemic fluticasone exposure', effect: 'Cushing syndrome, adrenal suppression', management: 'Avoid combination; use beclomethasone instead' },
      { interactingDrug: 'Ketoconazole', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP3A4 inhibition', effect: 'Increased steroid levels', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'Primary treatment of acute bronchospasm', type: 'absolute', reason: 'Does not provide immediate relief' },
      { condition: 'Hypersensitivity to fluticasone or milk proteins', type: 'absolute', reason: 'Some formulations contain lactose' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Poorly controlled asthma more dangerous than ICS', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'May affect growth velocity', recommendation: 'Use lowest effective dose; monitor height' },
      { population: 'geriatric', consideration: 'Osteoporosis risk with long-term use', recommendation: 'Monitor bone density; ensure adequate calcium/vitamin D' },
    ],
    monitoring: [
      { parameter: 'Asthma control', frequency: 'Every 1-3 months', rationale: 'Assess if at correct step', actionThreshold: 'Step down if controlled 3 months' },
      { parameter: 'Growth in children', frequency: 'Regular intervals', rationale: 'Growth suppression risk', actionThreshold: 'Growth velocity decreasing' },
      { parameter: 'Oral thrush', frequency: 'Each visit', rationale: 'Common local effect', actionThreshold: 'Presence of white patches' },
    ],
    patientEducation: [
      'This is a controller inhaler - use every day even when feeling well',
      'It will not help during an asthma attack - keep your rescue inhaler handy',
      'Rinse your mouth with water after each use and spit it out',
      'It may take several weeks to feel the full benefit',
      'Do not stop suddenly - talk to your doctor about tapering if needed',
    ],
    clinicalPearls: [
      'ICS is the most effective controller for asthma - reduces exacerbations, hospitalizations, and death',
      'The ritonavir-fluticasone interaction is notorious - causes Cushing syndrome',
      'Beclomethasone is preferred when CYP3A4 inhibitors are needed',
      'Growth effect is ~0.5-1 cm in first year but does not affect final adult height',
      'Combination ICS/LABA inhalers improve adherence vs separate inhalers',
    ],
  },

  // ============================================
  // Gastrointestinal Medications
  // ============================================

  {
    id: 'omeprazole',
    genericName: 'Omeprazole',
    brandNames: ['Prilosec', 'Zegerid'],
    drugClass: 'Proton pump inhibitor (PPI)',
    category: 'gastrointestinal',
    overview: 'Omeprazole was the first proton pump inhibitor and remains one of the most prescribed medications worldwide. It irreversibly blocks gastric acid production and is highly effective for GERD, peptic ulcers, and acid-related conditions. Long-term use carries some risks that require monitoring.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'H+/K+-ATPase (proton pump)',
      targetLocation: 'Gastric parietal cell canaliculus',
      simpleExplanation: 'Omeprazole permanently shuts off the acid pumps in your stomach cells. This dramatically reduces stomach acid production, allowing ulcers to heal and reducing heartburn.',
      detailedMechanism: 'Omeprazole is a prodrug that becomes activated in the acidic environment of the parietal cell canaliculus. The active form covalently binds to cysteine residues on the H+/K+-ATPase (proton pump), causing irreversible inhibition. Since the pump is permanently disabled, acid secretion only returns as new pumps are synthesized (half-life of pump recovery ~54 hours). Maximum effect requires 2-5 days of dosing.',
      mechanismSteps: [
        { order: 1, location: 'Stomach', action: 'Omeprazole absorbed and reaches parietal cells', result: 'Prodrug enters canaliculus' },
        { order: 2, location: 'Acidic canaliculus', action: 'Protonation activates omeprazole', result: 'Active sulfenamide formed' },
        { order: 3, location: 'Proton pump', action: 'Covalent binding to H+/K+-ATPase', result: 'Irreversible pump inhibition' },
        { order: 4, location: 'Parietal cell', action: 'Acid secretion blocked', result: 'Gastric pH rises to >4', timeframe: '1 hour' },
      ],
      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Suppressed acid secretion', mechanism: 'Proton pump inhibition', clinicalRelevance: 'Healing of acid-related conditions', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Hypergastrinemia', mechanism: 'Feedback from reduced acid', clinicalRelevance: 'Potential for rebound, polyps', desiredOrAdverse: 'adverse' },
        { system: 'Skeletal', effect: 'Reduced calcium absorption', mechanism: 'Requires acid for absorption', clinicalRelevance: 'Fracture risk with long-term use', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1 hour (peak effect 2-4 hours)',
      durationOfEffect: '24 hours (irreversible inhibition)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '30-40% (acid labile - enteric coated)',
        route: ['oral', 'intravenous'],
        factors: ['Enteric coating protects from gastric degradation', 'Food may delay absorption'],
        timeToePeak: '0.5-3.5 hours',
        foodEffect: 'Best taken 30-60 min before meals',
      },
      distribution: {
        volumeOfDistribution: '0.4 L/kg',
        proteinBinding: '95%',
        tissueDistribution: ['Concentrates in parietal cells'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19 (major)', 'CYP3A4 (minor)'],
        activeMetabolites: [],
        geneticVariability: 'CYP2C19 poor metabolizers have 5x exposure',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (77% as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '0.5-1 hour (but effect lasts 24 hours due to irreversible binding)',
      timeToSteadyState: '4-5 days for maximum effect',
    },
    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Peptic ulcer disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'H. pylori eradication', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Part of triple/quadruple therapy' },
      { condition: 'Zollinger-Ellison syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Erosive esophagitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'NSAID gastroprotection', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '20-40 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Severe hepatic impairment', adjustment: 'Max 20 mg daily', rationale: 'Reduced metabolism' },
        { condition: 'Erosive esophagitis healing', adjustment: '20 mg daily x 4-8 weeks', rationale: 'Standard course' },
        { condition: 'H. pylori', adjustment: '20 mg BID x 10-14 days', rationale: 'Part of combination therapy' },
      ],
      maxDose: '40 mg twice daily (Zollinger-Ellison)',
      administration: {
        route: 'Oral',
        withFood: 'without-food',
        timing: '30-60 minutes before first meal of the day',
        specialInstructions: ['Swallow capsules whole - do not crush enteric-coated forms', 'Take before breakfast for best effect'],
      },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'First few days' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually mild', reversible: true, onsetTiming: 'During therapy' },
      { name: 'C. difficile infection', frequency: 'uncommon', severity: 'severe', mechanism: 'Reduced gastric acid barrier', management: 'Discontinue PPI if C. diff develops', reversible: true, onsetTiming: 'During or after therapy' },
      { name: 'Hypomagnesemia', frequency: 'rare', severity: 'moderate', mechanism: 'Impaired intestinal absorption', management: 'Monitor Mg with long-term use', reversible: true, onsetTiming: 'After months-years of use' },
      { name: 'Vitamin B12 deficiency', frequency: 'uncommon', severity: 'mild', mechanism: 'Reduced acid-dependent absorption', management: 'Monitor B12 in long-term use', reversible: true, onsetTiming: 'After years of use' },
      { name: 'Fracture risk', frequency: 'uncommon', severity: 'moderate', mechanism: 'Reduced calcium absorption', management: 'Ensure adequate calcium/vitamin D', reversible: false, onsetTiming: 'Long-term risk' },
    ],
    interactions: [
      { interactingDrug: 'Clopidogrel', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP2C19 inhibition blocks clopidogrel activation', effect: 'Reduced antiplatelet effect', management: 'Use pantoprazole instead if PPI needed' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced MTX renal clearance', effect: 'Increased MTX toxicity', management: 'Consider holding PPI with high-dose MTX' },
      { interactingDrug: 'Drugs requiring acid for absorption', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced gastric acid', effect: 'Decreased absorption (ketoconazole, iron, B12)', management: 'Separate dosing or use alternatives' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to PPIs', type: 'absolute', reason: 'Cross-reactivity among PPIs possible' },
      { condition: 'Concurrent rilpivirine', type: 'absolute', reason: 'Dramatically reduced rilpivirine levels' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Generally considered safe based on extensive experience', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Higher fracture risk, B12/Mg concerns', recommendation: 'Use lowest effective dose; limit duration when possible' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Max 20 mg daily in severe impairment' },
    ],
    monitoring: [
      { parameter: 'Symptoms', frequency: 'Every 4-8 weeks initially', rationale: 'Assess response', actionThreshold: 'No improvement - consider alternative diagnosis' },
      { parameter: 'Magnesium', frequency: 'Periodically with long-term use', rationale: 'Hypomagnesemia risk', actionThreshold: 'Mg <1.5 mg/dL' },
      { parameter: 'B12', frequency: 'Annually if long-term use', rationale: 'Deficiency risk', actionThreshold: 'B12 <200 pg/mL' },
    ],
    patientEducation: [
      'Take 30-60 minutes before your first meal for best effect',
      'Swallow capsules whole - do not chew or crush',
      'This medication works best when taken regularly, not just when you have symptoms',
      'It may take several days to feel full relief',
      'Talk to your doctor about how long you need to take this - long-term use has some risks',
    ],
    clinicalPearls: [
      'Omeprazole-clopidogrel interaction is clinically significant - use pantoprazole if PPI needed',
      'PPI deprescribing should be attempted when used >8 weeks without clear indication',
      'Rebound acid hypersecretion can cause symptom recurrence after stopping',
      'Morning dosing before breakfast provides best acid control',
      'CYP2C19 poor metabolizers may have better H. pylori eradication rates',
      'Do not use long-term for mild/occasional heartburn - try H2 blockers or antacids',
    ],
  },

  {
    id: 'ondansetron',
    genericName: 'Ondansetron',
    brandNames: ['Zofran', 'Zuplenz'],
    drugClass: '5-HT3 receptor antagonist (serotonin antagonist)',
    category: 'gastrointestinal',
    overview: 'Ondansetron is a powerful antiemetic that blocks serotonin-induced nausea and vomiting. Originally developed for chemotherapy-induced nausea, it is now widely used for postoperative nausea, gastroenteritis, and pregnancy-related nausea. It is generally well-tolerated with QT prolongation as the main safety concern.',
    mechanism: {
      type: 'receptor-antagonist',
      target: '5-HT3 (serotonin) receptors',
      targetLocation: 'Chemoreceptor trigger zone and vagal afferents',
      simpleExplanation: 'Ondansetron blocks serotonin receptors in the brain and gut that trigger nausea and vomiting. By blocking these signals, it prevents the vomiting reflex.',
      detailedMechanism: 'Chemotherapy, radiation, and GI irritants release serotonin from enterochromaffin cells in the gut. This serotonin activates 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone (CTZ), triggering the vomiting reflex. Ondansetron competitively blocks these 5-HT3 receptors, preventing serotonin from initiating the emetic cascade.',
      mechanismSteps: [
        { order: 1, location: 'GI tract/CTZ', action: 'Ondansetron binds to 5-HT3 receptors', result: 'Receptors blocked' },
        { order: 2, location: 'Vagal afferents', action: 'Serotonin signal blocked', result: 'No nerve impulse to vomiting center' },
        { order: 3, location: 'CTZ', action: 'Serotonin effects inhibited', result: 'Central nausea pathway blocked' },
        { order: 4, location: 'Medulla', action: 'Vomiting center not activated', result: 'Nausea and vomiting prevented', timeframe: '30-60 minutes' },
      ],
      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Antiemetic', mechanism: '5-HT3 blockade', clinicalRelevance: 'Prevention/treatment of nausea/vomiting', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Constipation', mechanism: 'Reduced GI motility', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Potassium channel blockade', clinicalRelevance: 'Dose-dependent arrhythmia risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30 minutes (oral); immediate (IV)',
      durationOfEffect: '8-12 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '60% (first-pass metabolism)',
        route: ['oral', 'intravenous', 'sublingual', 'intramuscular'],
        factors: ['Food slightly decreases absorption but not clinically significant'],
        timeToePeak: '1.5-2 hours (oral)',
      },
      distribution: {
        volumeOfDistribution: '1.9 L/kg',
        proteinBinding: '70-76%',
        tissueDistribution: ['Widely distributed'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP1A2', 'CYP2D6'],
        activeMetabolites: [],
        geneticVariability: 'CYP2D6 poor metabolizers may have altered exposure',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (5% unchanged)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '3-5 hours (prolonged in hepatic impairment)',
      timeToSteadyState: '1-2 days',
    },
    indications: [
      { condition: 'Chemotherapy-induced nausea/vomiting', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Postoperative nausea/vomiting', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Radiation-induced nausea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Nausea/vomiting of pregnancy', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute gastroenteritis', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Common use in children' },
    ],
    dosing: {
      usualDose: { amount: '4-8 mg', frequency: 'Every 8 hours as needed', route: 'Oral' },
      adjustments: [
        { condition: 'Severe hepatic impairment', adjustment: 'Max 8 mg/day', rationale: 'Reduced metabolism' },
        { condition: 'CINV prevention', adjustment: '8 mg 30 min before chemo, then q8h', rationale: 'Prevention protocol' },
        { condition: 'PONV prevention', adjustment: '4 mg IV at induction', rationale: 'Single dose often sufficient' },
      ],
      maxDose: '24 mg/day (oral); 16 mg IV single dose',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: ['ODT formulation dissolves on tongue', 'Can be given IV slowly over 2-5 minutes'],
      },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually mild and transient', reversible: true, onsetTiming: 'First few doses' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Reduced GI motility via 5-HT3 blockade', management: 'Increase fluids; stool softeners if needed', reversible: true, onsetTiming: 'During therapy' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Potassium channel blockade', management: 'Avoid in long QT; limit IV to 16 mg', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Serotonin syndrome', frequency: 'rare', severity: 'severe', mechanism: 'With other serotonergic drugs', management: 'Monitor with SSRIs/SNRIs', reversible: true, onsetTiming: 'With drug combinations' },
    ],
    interactions: [
      { interactingDrug: 'Apomorphine', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Profound hypotension', effect: 'Severe hypotension and loss of consciousness', management: 'Do not use together' },
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive QT effects', effect: 'Increased arrhythmia risk', management: 'Avoid combination if possible' },
      { interactingDrug: 'Serotonergic drugs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive serotonin effects', effect: 'Serotonin syndrome risk', management: 'Monitor for symptoms' },
    ],
    contraindications: [
      { condition: 'Concurrent apomorphine', type: 'absolute', reason: 'Severe hypotension' },
      { condition: 'Congenital long QT syndrome', type: 'absolute', reason: 'QT prolongation risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category B', recommendation: 'Generally considered safe; widely used for hyperemesis', pregnancyCategory: 'B' },
      { population: 'pediatric', consideration: 'Safe and effective', recommendation: 'Weight-based dosing' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'Max 8 mg/day in severe impairment' },
    ],
    monitoring: [
      { parameter: 'Nausea/vomiting control', frequency: 'Each use', rationale: 'Assess efficacy', actionThreshold: 'Inadequate control - consider adding other antiemetics' },
      { parameter: 'ECG', frequency: 'If risk factors', rationale: 'QT prolongation', actionThreshold: 'QTc >500 ms' },
    ],
    patientEducation: [
      'Can be taken with or without food',
      'The dissolving tablet should be placed on the tongue and allowed to dissolve',
      'Constipation is common - drink plenty of fluids',
      'Tell your doctor about all medications to avoid interactions',
      'If nausea persists, contact your healthcare provider',
    ],
    clinicalPearls: [
      'IV doses >16 mg are associated with QT prolongation - limit to 16 mg max single IV dose',
      'More effective for acute nausea than delayed nausea (add dexamethasone for delayed)',
      'Works well in combination with other antiemetics for highly emetogenic chemo',
      'Constipation is the trade-off - especially problematic with opioids',
      'ODT formulation is good for patients who cannot swallow pills',
      'Oral bioavailability is ~60% - IV may be more reliable in severe vomiting',
    ],
  },

  // ============================================
  // More Cardiovascular Medications
  // ============================================

  {
    id: 'carvedilol',
    genericName: 'Carvedilol',
    brandNames: ['Coreg', 'Coreg CR'],
    drugClass: 'Non-selective beta-blocker with alpha-1 blocking activity',
    category: 'cardiovascular',
    overview: 'Carvedilol is a unique beta-blocker that also blocks alpha-1 receptors, providing both heart rate control and vasodilation. It is one of only three beta-blockers proven to reduce mortality in heart failure (along with metoprolol succinate and bisoprolol) and is first-line therapy for HFrEF.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Beta-1, Beta-2, and Alpha-1 adrenergic receptors',
      targetLocation: 'Heart, blood vessels, bronchi',
      simpleExplanation: 'Carvedilol blocks stress hormone receptors in your heart (slowing it down and reducing workload) and in blood vessels (relaxing them to lower blood pressure). This dual action is particularly helpful for heart failure.',
      detailedMechanism: 'Carvedilol competitively antagonizes beta-1 receptors (heart), beta-2 receptors (bronchi, blood vessels), and alpha-1 receptors (blood vessels). The beta blockade reduces heart rate, contractility, and renin release. The alpha-1 blockade causes vasodilation, reducing afterload. Additionally, carvedilol has antioxidant properties that may provide cardioprotection beyond receptor blockade.',
      mechanismSteps: [
        { order: 1, location: 'Heart', action: 'Beta-1 receptor blockade', result: 'Reduced heart rate and contractility' },
        { order: 2, location: 'Blood vessels', action: 'Alpha-1 blockade', result: 'Vasodilation and reduced afterload' },
        { order: 3, location: 'Kidney', action: 'Reduced renin release', result: 'Decreased RAAS activation' },
        { order: 4, location: 'Myocardium', action: 'Antioxidant effects', result: 'Cardioprotection', timeframe: 'Weeks to months' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Reduced heart rate', mechanism: 'Beta-1 blockade', clinicalRelevance: 'Rate control, reduced oxygen demand', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Vasodilation', mechanism: 'Alpha-1 blockade', clinicalRelevance: 'Blood pressure reduction', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Hypotension', mechanism: 'Combined alpha/beta blockade', clinicalRelevance: 'Dizziness, especially initially', desiredOrAdverse: 'adverse' },
        { system: 'Respiratory', effect: 'Bronchospasm', mechanism: 'Beta-2 blockade', clinicalRelevance: 'Caution in asthma', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '12 hours (immediate release), 24 hours (CR)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '25-35% (significant first-pass metabolism)',
        route: ['oral'],
        factors: ['Food slows absorption but increases bioavailability'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Take with food to reduce orthostatic hypotension',
      },
      distribution: {
        volumeOfDistribution: '115 L',
        proteinBinding: '98%',
        tissueDistribution: ['Heart', 'Blood vessels', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2D6 (primary)', 'CYP2C9', 'CYP1A2'],
        activeMetabolites: ['4-hydroxyphenyl metabolite (13x more potent beta-blocker)'],
        geneticVariability: 'CYP2D6 poor metabolizers have 2-3x higher levels',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal (60%), Renal (16%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '7-10 hours',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Heart failure with reduced EF', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Mortality benefit proven' },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Post-MI LV dysfunction', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Atrial fibrillation rate control', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '3.125-25 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Heart failure initiation', adjustment: 'Start 3.125 mg BID, double every 2 weeks', rationale: 'Avoid decompensation' },
        { condition: 'Hepatic impairment', adjustment: 'Contraindicated in severe', rationale: 'Extensive hepatic metabolism' },
        { condition: 'CR formulation', adjustment: '10-80 mg once daily', rationale: 'Extended release allows daily dosing' },
      ],
      maxDose: '25 mg BID (50 mg BID if >85 kg)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: ['Take with food to reduce dizziness', 'Do not crush CR tablets', 'Rise slowly from sitting'],
      },
    },
    adverseEffects: [
      { name: 'Dizziness/hypotension', frequency: 'very-common', severity: 'moderate', mechanism: 'Alpha-1 and beta blockade', management: 'Take with food; rise slowly; titrate gradually', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Fatigue', frequency: 'common', severity: 'mild', mechanism: 'Beta blockade', management: 'Often improves with time', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Weight gain/edema', frequency: 'common', severity: 'mild', mechanism: 'Fluid retention', management: 'May need diuretic adjustment', reversible: true, onsetTiming: 'During titration' },
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'Beta-1 blockade', management: 'Hold if HR <50', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Worsening heart failure', frequency: 'uncommon', severity: 'severe', mechanism: 'Negative inotropic effect', management: 'Slower titration; optimize diuretics', reversible: true, onsetTiming: 'During initiation/titration' },
    ],
    interactions: [
      { interactingDrug: 'CYP2D6 inhibitors (fluoxetine, paroxetine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased carvedilol levels', effect: 'Enhanced effects and side effects', management: 'Monitor for hypotension/bradycardia' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased digoxin levels', effect: 'Digoxin toxicity risk', management: 'Monitor digoxin levels' },
      { interactingDrug: 'Insulin/oral hypoglycemics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Masked hypoglycemia symptoms', effect: 'Delayed recognition of low blood sugar', management: 'Educate patient; monitor closely' },
      { interactingDrug: 'Calcium channel blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive negative chronotropic/inotropic effects', effect: 'Severe bradycardia, heart block', management: 'Avoid verapamil/diltiazem combination' },
    ],
    contraindications: [
      { condition: 'Decompensated heart failure requiring IV inotropes', type: 'absolute', reason: 'Negative inotropic effect' },
      { condition: 'Second/third-degree heart block without pacemaker', type: 'absolute', reason: 'Risk of complete block' },
      { condition: 'Severe bradycardia', type: 'absolute', reason: 'Further rate reduction' },
      { condition: 'Severe hepatic impairment', type: 'absolute', reason: 'Extensive hepatic metabolism' },
      { condition: 'Asthma', type: 'relative', reason: 'Beta-2 blockade may cause bronchospasm', alternative: 'Metoprolol succinate may be safer' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Use if benefits outweigh risks; monitor newborn', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'More sensitive to hypotensive effects', recommendation: 'Start low and titrate slowly' },
      { population: 'hepatic-impairment', consideration: 'Contraindicated in severe', recommendation: 'Avoid in severe; caution in moderate' },
    ],
    monitoring: [
      { parameter: 'Heart rate', frequency: 'Each visit during titration', rationale: 'Avoid excessive bradycardia', actionThreshold: 'HR <50 bpm' },
      { parameter: 'Blood pressure', frequency: 'Each visit', rationale: 'Hypotension risk', actionThreshold: 'SBP <90 mmHg with symptoms' },
      { parameter: 'Symptoms of HF', frequency: 'Each visit', rationale: 'Watch for decompensation', actionThreshold: 'Increased edema, dyspnea' },
      { parameter: 'Weight', frequency: 'Daily during titration', rationale: 'Fluid retention', actionThreshold: 'Gain >3 lbs in 1 day or 5 lbs in 1 week' },
    ],
    patientEducation: [
      'Take with food to reduce dizziness',
      'Rise slowly from sitting or lying down to prevent falls',
      'Weigh yourself daily - call if you gain 3+ pounds in a day',
      'Do not stop suddenly - this can cause rebound effects',
      'This medication helps your heart work more efficiently over time',
      'You may feel more tired initially, but this usually improves',
    ],
    clinicalPearls: [
      'One of only 3 beta-blockers with mortality benefit in HFrEF (COPERNICUS, CAPRICORN trials)',
      'Start low (3.125 mg BID) and titrate slowly in HF - "start low, go slow"',
      'Alpha blockade provides vasodilation without reflex tachycardia',
      'More hypotension than metoprolol due to alpha blockade',
      'Non-selective - caution in asthma/COPD (metoprolol succinate often preferred)',
      'CR formulation allows once-daily dosing but cannot be crushed',
    ],
  },

  {
    id: 'spironolactone',
    genericName: 'Spironolactone',
    brandNames: ['Aldactone', 'CaroSpir'],
    drugClass: 'Mineralocorticoid receptor antagonist (potassium-sparing diuretic)',
    category: 'cardiovascular',
    overview: 'Spironolactone blocks aldosterone, which causes the body to retain sodium and excrete potassium. By blocking this hormone, it helps remove excess fluid while preserving potassium. It has proven mortality benefit in heart failure and is also used for resistant hypertension, cirrhotic ascites, and hormonal conditions like acne and hirsutism.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Mineralocorticoid (aldosterone) receptors',
      targetLocation: 'Collecting duct of kidney, heart, blood vessels',
      simpleExplanation: 'Spironolactone blocks the hormone aldosterone, which normally tells your kidneys to hold onto salt and water. By blocking it, your body releases extra fluid and keeps potassium. It also protects the heart from harmful effects of aldosterone.',
      detailedMechanism: 'Spironolactone competitively inhibits aldosterone at mineralocorticoid receptors in the distal convoluted tubule and collecting duct. This prevents aldosterone-induced sodium reabsorption and potassium excretion, resulting in natriuresis and potassium retention. Beyond the kidney, aldosterone blockade prevents cardiac fibrosis, vascular remodeling, and endothelial dysfunction - mechanisms that contribute to its mortality benefit in heart failure.',
      mechanismSteps: [
        { order: 1, location: 'Collecting duct', action: 'Blocks mineralocorticoid receptor', result: 'Aldosterone effects inhibited' },
        { order: 2, location: 'Principal cells', action: 'ENaC channels not upregulated', result: 'Sodium excreted, potassium retained' },
        { order: 3, location: 'Heart', action: 'Prevents aldosterone-mediated fibrosis', result: 'Reduced cardiac remodeling', timeframe: 'Weeks to months' },
        { order: 4, location: 'Blood vessels', action: 'Reduced vascular stiffness', result: 'Improved endothelial function' },
      ],
      physiologicalEffects: [
        { system: 'Renal', effect: 'Mild diuresis with K+ retention', mechanism: 'Aldosterone blockade', clinicalRelevance: 'Potassium-sparing effect', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced cardiac fibrosis', mechanism: 'Blocks aldosterone in heart', clinicalRelevance: 'Mortality benefit in HF', desiredOrAdverse: 'desired' },
        { system: 'Endocrine', effect: 'Antiandrogenic effects', mechanism: 'Also blocks androgen receptors', clinicalRelevance: 'Gynecomastia, menstrual irregularities; useful for acne/hirsutism', desiredOrAdverse: 'both' },
      ],
      onsetOfAction: '24-48 hours (diuretic); weeks for full cardiovascular effect',
      durationOfEffect: '48-72 hours (prolonged due to active metabolite)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '73%',
        route: ['oral'],
        factors: ['Food increases absorption'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Take with food to enhance absorption',
      },
      distribution: {
        volumeOfDistribution: '0.05 L/kg',
        proteinBinding: '>90%',
        tissueDistribution: ['Kidney', 'Heart', 'Liver'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['Deacetylation to canrenone'],
        activeMetabolites: ['Canrenone (major active metabolite)', '7-alpha-thiomethylspironolactone'],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (47-57%)',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '1.4 hours (parent); 10-35 hours (canrenone)',
      timeToSteadyState: '5-7 days',
    },
    indications: [
      { condition: 'Heart failure with reduced EF', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'RALES trial - 30% mortality reduction' },
      { condition: 'Resistant hypertension', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true, notes: 'Often 4th agent' },
      { condition: 'Cirrhotic ascites', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Primary hyperaldosteronism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acne in women', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Hirsutism/PCOS', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '25-50 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Heart failure', adjustment: '12.5-25 mg daily', rationale: 'Low dose for mortality benefit' },
        { condition: 'Cirrhotic ascites', adjustment: '100-400 mg daily', rationale: 'Higher doses needed' },
        { condition: 'Renal impairment (eGFR <30)', adjustment: 'Avoid or use with extreme caution', rationale: 'Hyperkalemia risk' },
      ],
      maxDose: '400 mg/day (ascites); 50 mg/day (HF)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        specialInstructions: ['Take with food', 'Best in morning to avoid nocturia'],
      },
    },
    adverseEffects: [
      { name: 'Hyperkalemia', frequency: 'common', severity: 'severe', mechanism: 'Reduced potassium excretion', management: 'Monitor K+; avoid K+ supplements and high-K+ foods', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Gynecomastia', frequency: 'common', severity: 'moderate', mechanism: 'Antiandrogenic/estrogenic effects', management: 'Switch to eplerenone if intolerable', reversible: true, onsetTiming: 'After weeks-months' },
      { name: 'Menstrual irregularities', frequency: 'common', severity: 'mild', mechanism: 'Hormonal effects', management: 'Often resolves; may need alternative', reversible: true, onsetTiming: 'First few months' },
      { name: 'Erectile dysfunction', frequency: 'uncommon', severity: 'moderate', mechanism: 'Antiandrogenic effect', management: 'Consider eplerenone', reversible: true, onsetTiming: 'Variable' },
      { name: 'GI upset', frequency: 'common', severity: 'mild', mechanism: 'Direct GI irritation', management: 'Take with food', reversible: true, onsetTiming: 'Early in therapy' },
    ],
    interactions: [
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive hyperkalemia', effect: 'Severe hyperkalemia', management: 'Monitor K+ closely; use low doses' },
      { interactingDrug: 'Potassium supplements', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive hyperkalemia', effect: 'Dangerous hyperkalemia', management: 'Avoid concurrent use' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced diuretic effect; hyperkalemia', effect: 'Fluid retention; hyperkalemia', management: 'Avoid if possible; monitor' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased digoxin levels', effect: 'Digoxin toxicity risk', management: 'Monitor digoxin levels' },
    ],
    contraindications: [
      { condition: 'Severe hyperkalemia', type: 'absolute', reason: 'Will worsen hyperkalemia' },
      { condition: 'Acute renal failure', type: 'absolute', reason: 'Cannot excrete potassium' },
      { condition: 'Addison disease', type: 'absolute', reason: 'Already deficient in aldosterone' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; antiandrogenic effects concerning', recommendation: 'Avoid - can feminize male fetus', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Hyperkalemia risk increases', recommendation: 'Avoid if eGFR <30; extreme caution if 30-45' },
      { population: 'geriatric', consideration: 'Higher hyperkalemia risk', recommendation: 'Start low; monitor K+ frequently' },
    ],
    monitoring: [
      { parameter: 'Potassium', frequency: 'Within 1 week of starting, then regularly', rationale: 'Hyperkalemia risk', actionThreshold: 'K+ >5.5 mEq/L - reduce dose or stop' },
      { parameter: 'Creatinine', frequency: 'Within 1 week, then regularly', rationale: 'Renal function decline', actionThreshold: 'Creatinine rise >30%' },
      { parameter: 'Sodium', frequency: 'Periodically', rationale: 'Hyponatremia possible', actionThreshold: 'Na <130 mEq/L' },
    ],
    patientEducation: [
      'This medication can cause high potassium - avoid salt substitutes and potassium supplements',
      'Take with food to improve absorption and reduce stomach upset',
      'Men may notice breast tenderness - tell your doctor if bothersome',
      'Have regular blood tests to check potassium and kidney function',
      'Report muscle weakness, irregular heartbeat, or numbness',
    ],
    clinicalPearls: [
      'RALES trial showed 30% mortality reduction in severe HF at just 25 mg daily',
      'Eplerenone is more selective (fewer hormonal side effects) but more expensive',
      'Hyperkalemia risk highest when combined with ACE-I/ARB - monitor closely',
      'Gynecomastia occurs in up to 10% of men - switch to eplerenone if problematic',
      'Very effective 4th agent for resistant hypertension (PATHWAY-2 trial)',
      'In cirrhosis, ratio of spironolactone to furosemide should be 100:40',
    ],
  },

  {
    id: 'apixaban',
    genericName: 'Apixaban',
    brandNames: ['Eliquis'],
    drugClass: 'Direct oral anticoagulant (DOAC) - Factor Xa inhibitor',
    category: 'cardiovascular',
    overview: 'Apixaban is a direct Factor Xa inhibitor used for stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism. It has the best safety profile among DOACs with lower bleeding rates in trials, making it often preferred, especially in elderly patients.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Factor Xa',
      targetLocation: 'Coagulation cascade',
      simpleExplanation: 'Apixaban directly blocks Factor Xa, a key enzyme in blood clotting. By blocking this factor, it prevents the formation of blood clots that could cause strokes or block blood vessels.',
      detailedMechanism: 'Apixaban is a direct, selective, reversible inhibitor of Factor Xa in both free and clot-bound forms. Factor Xa is the point of convergence of the intrinsic and extrinsic coagulation pathways and is required for the conversion of prothrombin to thrombin. By inhibiting Factor Xa, apixaban reduces thrombin generation and clot formation without directly affecting existing thrombin or requiring antithrombin as a cofactor.',
      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Apixaban binds to Factor Xa active site', result: 'Factor Xa inhibited' },
        { order: 2, location: 'Coagulation cascade', action: 'Prothrombin cannot convert to thrombin', result: 'Reduced thrombin generation' },
        { order: 3, location: 'Blood', action: 'Less fibrin formation', result: 'Reduced clot formation' },
        { order: 4, location: 'Clinical effect', action: 'Maintained anticoagulation', result: 'Prevention of thromboembolism', timeframe: '1-3 hours' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Factor Xa inhibition', clinicalRelevance: 'Stroke/VTE prevention', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Impaired clotting', clinicalRelevance: 'Risk of hemorrhage', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-3 hours',
      durationOfEffect: '12 hours (dosed twice daily)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '50%',
        route: ['oral'],
        factors: ['Not affected by food'],
        timeToePeak: '3-4 hours',
      },
      distribution: {
        volumeOfDistribution: '21 L',
        proteinBinding: '87%',
        tissueDistribution: ['Broadly distributed'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4 (25%)', 'Sulfation'],
        activeMetabolites: [],
        geneticVariability: 'Minimal',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal (56%), Renal (27%)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '12 hours',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Stroke prevention in nonvalvular AF', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'ARISTOTLE trial' },
      { condition: 'Treatment of DVT/PE', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'VTE prophylaxis after hip/knee replacement', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Secondary prevention of VTE', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '5 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'AF with 2 of: age ≥80, weight ≤60 kg, Cr ≥1.5', adjustment: '2.5 mg BID', rationale: 'Reduced clearance' },
        { condition: 'VTE treatment', adjustment: '10 mg BID x 7 days, then 5 mg BID', rationale: 'Loading dose then maintenance' },
        { condition: 'VTE prophylaxis hip/knee', adjustment: '2.5 mg BID', rationale: 'Lower dose for prophylaxis' },
        { condition: 'CrCl 15-29 mL/min', adjustment: 'Use with caution; limited data', rationale: 'Increased exposure' },
      ],
      maxDose: '10 mg twice daily (during VTE treatment loading)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: ['Can be taken with or without food', 'Can be crushed and mixed with applesauce', 'Take at consistent times'],
      },
    },
    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Andexanet alfa reversal if severe', reversible: true, onsetTiming: 'Throughout therapy' },
      { name: 'Major bleeding', frequency: 'uncommon', severity: 'severe', mechanism: 'Excessive anticoagulation', management: 'Hold drug; supportive care; andexanet alfa', reversible: true, onsetTiming: 'Any time' },
      { name: 'GI bleeding', frequency: 'uncommon', severity: 'moderate', mechanism: 'Topical anticoagulant effect', management: 'May need endoscopy; consider GI protection', reversible: true, onsetTiming: 'Throughout therapy' },
      { name: 'Anemia', frequency: 'uncommon', severity: 'mild', mechanism: 'Occult bleeding', management: 'Check for bleeding source', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Strong CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased apixaban levels', effect: 'Increased bleeding risk', management: 'Reduce dose 50% if on 5 mg BID; avoid if on 2.5 mg' },
      { interactingDrug: 'Strong CYP3A4/P-gp inducers (rifampin, phenytoin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased apixaban levels', effect: 'Reduced efficacy; thrombosis risk', management: 'Avoid combination' },
      { interactingDrug: 'Antiplatelet agents (aspirin, clopidogrel)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive bleeding risk', effect: 'Increased hemorrhage', management: 'Use only if clearly indicated; lowest aspirin dose' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive bleeding + GI toxicity', effect: 'Increased GI bleeding', management: 'Avoid if possible' },
    ],
    contraindications: [
      { condition: 'Active pathological bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Severe hypersensitivity to apixaban', type: 'absolute', reason: 'Allergic reaction' },
      { condition: 'Mechanical heart valve', type: 'absolute', reason: 'Not studied; warfarin required' },
      { condition: 'Moderate-severe mitral stenosis', type: 'absolute', reason: 'Not studied' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category B but limited data', recommendation: 'Avoid - use LMWH if anticoagulation needed', pregnancyCategory: 'B' },
      { population: 'renal-impairment', consideration: 'Partial renal elimination', recommendation: 'Dose reduce per criteria; avoid if CrCl <15' },
      { population: 'hepatic-impairment', consideration: 'Partially metabolized in liver', recommendation: 'Avoid in severe (Child-Pugh C)' },
      { population: 'geriatric', consideration: 'Age is dose reduction criterion', recommendation: 'Use 2.5 mg BID if ≥80 with another criterion' },
    ],
    monitoring: [
      { parameter: 'Hemoglobin/hematocrit', frequency: 'Baseline, then if bleeding suspected', rationale: 'Detect occult bleeding', actionThreshold: 'Unexplained drop >2 g/dL' },
      { parameter: 'Renal function', frequency: 'At least annually; more if impaired', rationale: 'Affects dosing', actionThreshold: 'CrCl <25 - reassess' },
      { parameter: 'Signs of bleeding', frequency: 'Each visit', rationale: 'Safety', actionThreshold: 'Any significant bleeding' },
    ],
    patientEducation: [
      'Take at the same times each day - consistency is important',
      'Do not stop without talking to your doctor - stroke risk increases',
      'Report any unusual bleeding: nosebleeds, blood in urine/stool, excessive bruising',
      'Tell all healthcare providers you take a blood thinner before procedures',
      'Carry a card or wear a bracelet indicating you take an anticoagulant',
      'Can be crushed and mixed with applesauce if needed',
    ],
    clinicalPearls: [
      'ARISTOTLE trial: apixaban beat warfarin for efficacy AND safety in AF',
      'Lowest bleeding rates among DOACs - often preferred in elderly/high bleeding risk',
      'Has specific reversal agent: andexanet alfa (expensive but available)',
      'Dose reduction criteria: need 2 of 3 (age ≥80, weight ≤60 kg, Cr ≥1.5)',
      'Unlike rivaroxaban, apixaban requires BID dosing',
      'Can crush and mix with applesauce - helpful for patients with swallowing difficulty',
      'No routine monitoring needed, but anti-Xa levels can assess effect if needed',
    ],
  },

  // ============================================
  // More Psychiatric Medications
  // ============================================

  {
    id: 'quetiapine',
    genericName: 'Quetiapine',
    brandNames: ['Seroquel', 'Seroquel XR'],
    drugClass: 'Atypical antipsychotic',
    category: 'psychiatric',
    overview: 'Quetiapine is an atypical antipsychotic with a broad receptor profile that gives it sedating, antipsychotic, and mood-stabilizing properties. It is FDA-approved for schizophrenia, bipolar disorder, and as adjunctive treatment for depression. Off-label, it is widely used for insomnia and anxiety, though this use is controversial.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Dopamine D2, Serotonin 5-HT2A, Histamine H1, Alpha-1, and 5-HT1A receptors',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Quetiapine blocks multiple brain receptors. By blocking dopamine and serotonin receptors, it reduces psychotic symptoms and stabilizes mood. Its antihistamine effect causes sedation, which can help with sleep.',
      detailedMechanism: 'Quetiapine has moderate D2 and 5-HT2A antagonism (antipsychotic effect), strong H1 antagonism (sedation, weight gain), alpha-1 antagonism (orthostatic hypotension), and partial 5-HT1A agonism (anxiolytic). Its active metabolite norquetiapine inhibits the norepinephrine transporter (NET), contributing to antidepressant effects. The rapid D2 dissociation minimizes extrapyramidal symptoms.',
      mechanismSteps: [
        { order: 1, location: 'Mesolimbic pathway', action: 'D2 receptor blockade', result: 'Reduced positive psychotic symptoms' },
        { order: 2, location: 'Prefrontal cortex', action: '5-HT2A blockade + 5-HT1A partial agonism', result: 'Improved negative symptoms and cognition' },
        { order: 3, location: 'Hypothalamus', action: 'H1 receptor blockade', result: 'Sedation and increased appetite' },
        { order: 4, location: 'Locus coeruleus (norquetiapine)', action: 'NET inhibition', result: 'Antidepressant effect', timeframe: 'Days to weeks' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Antipsychotic effect', mechanism: 'D2/5-HT2A blockade', clinicalRelevance: 'Treats psychosis', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Sedation', mechanism: 'H1 blockade', clinicalRelevance: 'Useful for sleep; problematic for alertness', desiredOrAdverse: 'both' },
        { system: 'Metabolic', effect: 'Weight gain', mechanism: 'H1 blockade, 5-HT2C effects', clinicalRelevance: 'Metabolic syndrome risk', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'Orthostatic hypotension', mechanism: 'Alpha-1 blockade', clinicalRelevance: 'Falls risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Sedation: 30-60 min; Antipsychotic: days to weeks',
      durationOfEffect: '6-12 hours (IR); 12-24 hours (XR)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '100% (oral)',
        route: ['oral'],
        factors: ['High-fat food increases Cmax by 25%'],
        timeToePeak: '1.5 hours (IR); 6 hours (XR)',
        foodEffect: 'XR should be taken without food or with light meal',
      },
      distribution: {
        volumeOfDistribution: '10 L/kg',
        proteinBinding: '83%',
        tissueDistribution: ['Brain', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4 (major)'],
        activeMetabolites: ['Norquetiapine (NET inhibitor)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (73%), Fecal (20%)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '6-7 hours (parent); 12 hours (norquetiapine)',
      timeToSteadyState: '2 days',
    },
    indications: [
      { condition: 'Schizophrenia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Bipolar disorder (acute mania, depression, maintenance)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Adjunctive treatment of MDD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'XR formulation' },
      { condition: 'Insomnia', approvalStatus: 'off-label', evidenceLevel: 'low', firstLine: false, notes: 'Controversial - metabolic risks' },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '150-800 mg', frequency: 'Daily (XR) or divided (IR)', route: 'Oral' },
      adjustments: [
        { condition: 'Schizophrenia', adjustment: '150-750 mg/day', rationale: 'Higher doses needed' },
        { condition: 'Bipolar depression', adjustment: '300 mg at bedtime (XR)', rationale: 'Monotherapy dose' },
        { condition: 'Adjunctive for MDD', adjustment: '50-300 mg at bedtime (XR)', rationale: 'Lower adjunctive dose' },
        { condition: 'Hepatic impairment', adjustment: 'Start 25 mg, titrate slowly', rationale: 'Reduced clearance' },
        { condition: 'Elderly', adjustment: 'Start 25-50 mg', rationale: 'Increased sensitivity' },
      ],
      maxDose: '800 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Usually at bedtime due to sedation',
        specialInstructions: ['XR tablets should not be crushed', 'Can cause significant sedation - take at bedtime'],
      },
    },
    adverseEffects: [
      { name: 'Sedation/somnolence', frequency: 'very-common', severity: 'moderate', mechanism: 'H1 antagonism', management: 'Take at bedtime; may improve over time', reversible: true, onsetTiming: 'First dose' },
      { name: 'Weight gain', frequency: 'very-common', severity: 'moderate', mechanism: 'H1/5-HT2C effects', management: 'Average 2-3 kg; diet/exercise counseling', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Orthostatic hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Alpha-1 blockade', management: 'Rise slowly; hydration', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Metabolic syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Multiple receptor effects', management: 'Monitor glucose, lipids; lifestyle', reversible: true, onsetTiming: 'Months' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Potassium channel effects', management: 'ECG if risk factors', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Tardive dyskinesia', frequency: 'rare', severity: 'severe', mechanism: 'Chronic D2 blockade', management: 'Lower risk than typical antipsychotics but possible', reversible: false, onsetTiming: 'Months to years' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased quetiapine levels', effect: 'Enhanced sedation and side effects', management: 'Reduce quetiapine dose' },
      { interactingDrug: 'CYP3A4 inducers (phenytoin, carbamazepine)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased quetiapine levels', effect: 'Reduced efficacy', management: 'May need higher doses' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Excessive drowsiness', management: 'Use caution; warn patient' },
      { interactingDrug: 'Antihypertensives', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hypotension', effect: 'Orthostatic hypotension', management: 'Monitor BP' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to quetiapine', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C; potential for EPS in newborn', recommendation: 'Use only if clearly needed; register in pregnancy registry', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Black box warning: increased mortality in dementia-related psychosis', recommendation: 'Avoid for dementia-related psychosis; start very low if used' },
      { population: 'hepatic-impairment', consideration: 'CYP3A4 metabolism', recommendation: 'Start 25 mg; titrate cautiously' },
    ],
    monitoring: [
      { parameter: 'Fasting glucose', frequency: 'Baseline, 12 weeks, then annually', rationale: 'Diabetes risk', actionThreshold: 'Glucose >126 mg/dL' },
      { parameter: 'Lipid panel', frequency: 'Baseline, 12 weeks, then annually', rationale: 'Dyslipidemia risk', actionThreshold: 'Abnormal lipids' },
      { parameter: 'Weight/BMI', frequency: 'Each visit', rationale: 'Weight gain monitoring', actionThreshold: '>5% weight gain' },
      { parameter: 'Blood pressure', frequency: 'Baseline and during titration', rationale: 'Orthostatic hypotension', actionThreshold: 'Symptomatic hypotension' },
    ],
    patientEducation: [
      'Take at bedtime to minimize daytime drowsiness',
      'Rise slowly from bed to prevent dizziness',
      'This medication may increase appetite and cause weight gain',
      'Do not drive until you know how this medication affects you',
      'Have regular blood tests to monitor blood sugar and cholesterol',
      'Do not stop suddenly without talking to your doctor',
    ],
    clinicalPearls: [
      'Black box warning: increased mortality in elderly with dementia-related psychosis',
      'Low-dose quetiapine for insomnia is controversial due to metabolic risks without FDA approval',
      'Lower EPS risk than other antipsychotics due to rapid D2 dissociation',
      'Norquetiapine metabolite has NET inhibition - contributes to antidepressant effect',
      'Common "PRN" on psychiatry units for agitation - sedation is predictable',
      'Metabolic monitoring essential - can cause diabetes and dyslipidemia',
    ],
  },

  {
    id: 'trazodone',
    genericName: 'Trazodone',
    brandNames: ['Desyrel', 'Oleptro'],
    drugClass: 'Serotonin antagonist and reuptake inhibitor (SARI)',
    category: 'psychiatric',
    overview: 'Trazodone is an antidepressant that is now more commonly used at low doses for insomnia than for depression. It blocks serotonin receptors and inhibits serotonin reuptake. Its sedating properties make it popular for sleep, with less dependence risk than benzodiazepines or Z-drugs.',
    mechanism: {
      type: 'receptor-antagonist',
      target: '5-HT2A receptors, serotonin transporter, alpha-1 receptors, H1 receptors',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Trazodone blocks certain serotonin receptors and prevents serotonin reuptake. The receptor blockade causes sedation, making it useful for sleep. At higher doses, the combined effects help with depression.',
      detailedMechanism: 'Trazodone is a SARI (serotonin antagonist and reuptake inhibitor). It potently antagonizes 5-HT2A receptors, which contributes to sleep enhancement and anxiolysis. It moderately inhibits SERT (serotonin reuptake), providing antidepressant effect at higher doses. It also blocks alpha-1 (hypotension, priapism) and H1 (sedation) receptors. Its metabolite mCPP is a 5-HT2C agonist that may contribute to anxiogenic effects in some patients.',
      mechanismSteps: [
        { order: 1, location: 'CNS', action: '5-HT2A receptor blockade', result: 'Sedation, enhanced slow-wave sleep' },
        { order: 2, location: 'Synapse', action: 'Serotonin reuptake inhibition', result: 'Increased serotonin (at higher doses)' },
        { order: 3, location: 'CNS', action: 'H1 receptor blockade', result: 'Additional sedation' },
        { order: 4, location: 'Blood vessels', action: 'Alpha-1 blockade', result: 'Vasodilation, orthostatic hypotension' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Sedation', mechanism: '5-HT2A and H1 blockade', clinicalRelevance: 'Sleep promotion', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Antidepressant', mechanism: 'SERT inhibition + 5-HT2A blockade', clinicalRelevance: 'Depression treatment at high doses', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Orthostatic hypotension', mechanism: 'Alpha-1 blockade', clinicalRelevance: 'Falls risk', desiredOrAdverse: 'adverse' },
        { system: 'Genitourinary', effect: 'Priapism', mechanism: 'Alpha-1 blockade affecting erectile tissue', clinicalRelevance: 'Rare but serious', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '30-60 minutes (sedation)',
      durationOfEffect: '5-9 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '65%',
        route: ['oral'],
        factors: ['Food increases absorption and delays peak'],
        timeToePeak: '1-2 hours (fasting); 2.5 hours (with food)',
        foodEffect: 'Take after meal or snack to reduce dizziness',
      },
      distribution: {
        volumeOfDistribution: '0.5-1.5 L/kg',
        proteinBinding: '89-95%',
        tissueDistribution: ['Brain', 'Liver'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4'],
        activeMetabolites: ['mCPP (5-HT2C agonist)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (70-75%)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '5-9 hours (biphasic)',
      timeToSteadyState: '3-5 days',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Requires higher doses' },
      { condition: 'Insomnia', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Most common use' },
      { condition: 'Anxiety', approvalStatus: 'off-label', evidenceLevel: 'low', firstLine: false },
      { condition: 'SSRI-induced insomnia', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Common adjunct' },
    ],
    dosing: {
      usualDose: { amount: '50-100 mg', frequency: 'At bedtime', route: 'Oral' },
      adjustments: [
        { condition: 'Insomnia', adjustment: '25-100 mg at bedtime', rationale: 'Low dose effective for sleep' },
        { condition: 'Depression', adjustment: '150-400 mg/day in divided doses', rationale: 'Higher doses needed for antidepressant effect' },
        { condition: 'Elderly', adjustment: 'Start 25 mg', rationale: 'Increased sensitivity' },
      ],
      maxDose: '400 mg/day (outpatient); 600 mg/day (inpatient)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: 'At bedtime for insomnia',
        specialInstructions: ['Take after a meal or snack', 'May cause next-day drowsiness at higher doses'],
      },
    },
    adverseEffects: [
      { name: 'Sedation/drowsiness', frequency: 'very-common', severity: 'mild', mechanism: '5-HT2A and H1 blockade', management: 'Take at bedtime', reversible: true, onsetTiming: 'First dose' },
      { name: 'Orthostatic hypotension', frequency: 'common', severity: 'moderate', mechanism: 'Alpha-1 blockade', management: 'Rise slowly; take with food', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'Alpha-1 blockade', management: 'Take with food; avoid alcohol', reversible: true, onsetTiming: 'Early in therapy' },
      { name: 'Priapism', frequency: 'rare', severity: 'severe', mechanism: 'Alpha-1 blockade in erectile tissue', management: 'Seek immediate medical attention - urological emergency', reversible: false, onsetTiming: 'Any time' },
      { name: 'Next-day drowsiness', frequency: 'common', severity: 'mild', mechanism: 'Long half-life metabolites', management: 'Lower dose', reversible: true, onsetTiming: 'Morning after dose' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome risk', effect: 'Potentially fatal', management: '14-day washout' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased trazodone levels', effect: 'Enhanced sedation and side effects', management: 'Consider dose reduction' },
      { interactingDrug: 'CNS depressants/alcohol', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Excessive drowsiness', management: 'Avoid or use caution' },
      { interactingDrug: 'Other serotonergic drugs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Serotonin syndrome risk', effect: 'Serotonin toxicity', management: 'Monitor for symptoms' },
    ],
    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Serotonin syndrome risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category C', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Falls risk from orthostatic hypotension', recommendation: 'Start 25 mg; monitor closely' },
      { population: 'pediatric', consideration: 'Not approved in children', recommendation: 'Avoid; increased suicidality risk' },
    ],
    monitoring: [
      { parameter: 'Sleep quality', frequency: 'Each visit', rationale: 'Assess efficacy', actionThreshold: 'No improvement' },
      { parameter: 'Orthostatic BP', frequency: 'Early in therapy', rationale: 'Hypotension risk', actionThreshold: 'Symptomatic drops' },
      { parameter: 'Priapism warning', frequency: 'At start of therapy', rationale: 'Patient education critical', actionThreshold: 'Any prolonged erection - emergency' },
    ],
    patientEducation: [
      'Take at bedtime with a light snack to reduce dizziness',
      'Rise slowly from bed to prevent falls',
      'Men: Seek immediate medical attention for any prolonged erection (priapism)',
      'Avoid alcohol - it increases drowsiness',
      'May cause morning grogginess - avoid driving until you know how it affects you',
      'This medication is non-habit forming',
    ],
    clinicalPearls: [
      'Most commonly prescribed for insomnia, not depression',
      'Low-dose (25-100 mg) for insomnia; 150-400 mg for depression',
      'Priapism is rare but a urological emergency - warn male patients',
      'No dependence/tolerance like benzodiazepines - good choice for chronic insomnia',
      'Often added to SSRIs when insomnia is a problem',
      'The mCPP metabolite may cause anxiety in some patients',
      '5-HT2A blockade may enhance antidepressant effect of SSRIs',
    ],
  },

  {
    id: 'lorazepam',
    genericName: 'Lorazepam',
    brandNames: ['Ativan'],
    drugClass: 'Benzodiazepine',
    category: 'psychiatric',
    overview: 'Lorazepam is an intermediate-acting benzodiazepine commonly used for anxiety, insomnia, seizures, and procedural sedation. It is metabolized by glucuronidation (not CYP450), making it preferred in patients with liver disease or on multiple medications. It is one of the most commonly used benzodiazepines in hospitals.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'GABA-A receptor (benzodiazepine binding site)',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Lorazepam enhances the effect of GABA, the brain\'s main calming chemical. It makes GABA receptors more sensitive, increasing inhibition in the brain and producing relaxation, sedation, and reduced anxiety.',
      detailedMechanism: 'Lorazepam binds to the benzodiazepine site on GABA-A receptors, which are ligand-gated chloride channels. This binding increases the frequency of chloride channel opening when GABA binds, hyperpolarizing neurons and reducing their excitability. The result is anxiolytic, sedative, anticonvulsant, and muscle relaxant effects. Unlike barbiturates, benzodiazepines cannot directly open the channel - they require GABA.',
      mechanismSteps: [
        { order: 1, location: 'GABA-A receptor', action: 'Lorazepam binds to benzodiazepine site', result: 'Allosteric modulation of receptor' },
        { order: 2, location: 'Chloride channel', action: 'Increased GABA-induced Cl- flux', result: 'Neuronal hyperpolarization' },
        { order: 3, location: 'Limbic system', action: 'Enhanced GABAergic inhibition', result: 'Reduced anxiety', timeframe: '15-30 minutes' },
        { order: 4, location: 'Cortex', action: 'Generalized CNS depression', result: 'Sedation' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Anxiolysis', mechanism: 'Enhanced GABA inhibition in limbic system', clinicalRelevance: 'Anxiety relief', desiredOrAdverse: 'desired' },
        { system: 'Nervous', effect: 'Sedation', mechanism: 'Generalized CNS depression', clinicalRelevance: 'Sleep induction; impaired alertness', desiredOrAdverse: 'both' },
        { system: 'Nervous', effect: 'Anterograde amnesia', mechanism: 'Hippocampal GABA enhancement', clinicalRelevance: 'Useful for procedures; problematic otherwise', desiredOrAdverse: 'both' },
        { system: 'Respiratory', effect: 'Respiratory depression', mechanism: 'Brainstem depression', clinicalRelevance: 'Risk with other CNS depressants/overdose', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'PO: 20-30 min; IM: 15-30 min; IV: 1-5 min',
      durationOfEffect: '6-8 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '90% (oral), 85% (IM)',
        route: ['oral', 'intramuscular', 'intravenous', 'sublingual'],
        factors: ['Food may slow absorption'],
        timeToePeak: '2 hours (oral)',
      },
      distribution: {
        volumeOfDistribution: '1-1.3 L/kg',
        proteinBinding: '85%',
        tissueDistribution: ['Brain', 'Fat'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['Glucuronidation (UGT) - NOT CYP450'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (88% as glucuronide)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '12-16 hours',
      timeToSteadyState: '3-5 days',
    },
    indications: [
      { condition: 'Anxiety disorders', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Short-term only' },
      { condition: 'Status epilepticus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Insomnia (short-term)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Procedural sedation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Alcohol withdrawal', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute agitation', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chemotherapy-induced nausea (anticipatory)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '0.5-2 mg', frequency: 'Two to three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Anxiety', adjustment: '0.5-1 mg BID-TID', rationale: 'Start low' },
        { condition: 'Insomnia', adjustment: '0.5-2 mg at bedtime', rationale: 'Single nightly dose' },
        { condition: 'Status epilepticus', adjustment: '4 mg IV (may repeat)', rationale: 'Rapid seizure control needed' },
        { condition: 'Elderly', adjustment: 'Start 0.5 mg; max 2 mg/day', rationale: 'Increased sensitivity, falls risk' },
        { condition: 'Alcohol withdrawal', adjustment: '1-4 mg IV/IM/PO q1h PRN', rationale: 'Symptom-triggered protocol' },
      ],
      maxDose: '10 mg/day (anxiety); varies for seizures/withdrawal',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: ['For anxiety, use short-term only (<4 weeks)', 'IV must be diluted 1:1 with saline', 'SL tablets can be given sublingually'],
      },
    },
    adverseEffects: [
      { name: 'Sedation', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Start low; avoid driving', reversible: true, onsetTiming: 'First dose' },
      { name: 'Cognitive impairment', frequency: 'common', severity: 'moderate', mechanism: 'Hippocampal GABA effects', management: 'Problematic especially in elderly', reversible: true, onsetTiming: 'During use' },
      { name: 'Dependence/tolerance', frequency: 'common', severity: 'severe', mechanism: 'GABA receptor adaptation', management: 'Limit to short-term use', reversible: true, onsetTiming: 'After weeks of regular use' },
      { name: 'Paradoxical disinhibition', frequency: 'uncommon', severity: 'moderate', mechanism: 'Unknown', management: 'Stop medication', reversible: true, onsetTiming: 'Variable' },
      { name: 'Respiratory depression', frequency: 'rare', severity: 'severe', mechanism: 'Brainstem depression', management: 'Flumazenil reversal; avoid with opioids', reversible: true, onsetTiming: 'High doses or combinations' },
    ],
    interactions: [
      { interactingDrug: 'Opioids', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS/respiratory depression', effect: 'Fatal overdose risk', management: 'FDA black box warning - avoid if possible' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Fatal overdose risk', management: 'Contraindicated' },
      { interactingDrug: 'Other CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Excessive sedation', management: 'Reduce doses' },
    ],
    contraindications: [
      { condition: 'Acute narrow-angle glaucoma', type: 'absolute', reason: 'May increase intraocular pressure' },
      { condition: 'Severe respiratory insufficiency', type: 'relative', reason: 'Respiratory depression risk' },
      { condition: 'Sleep apnea (untreated)', type: 'relative', reason: 'Worsened airway obstruction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Category D - fetal risk', recommendation: 'Avoid - risk of neonatal withdrawal and floppy infant syndrome', pregnancyCategory: 'D' },
      { population: 'geriatric', consideration: 'Beers criteria - avoid', recommendation: 'Increased falls, cognitive impairment; if used, half the adult dose' },
      { population: 'hepatic-impairment', consideration: 'Glucuronidated - not CYP dependent', recommendation: 'Preferred benzodiazepine in liver disease' },
    ],
    monitoring: [
      { parameter: 'Sedation level', frequency: 'Each visit', rationale: 'Avoid over-sedation', actionThreshold: 'Excessive daytime sedation' },
      { parameter: 'Cognitive function', frequency: 'Periodically', rationale: 'Especially in elderly', actionThreshold: 'New confusion' },
      { parameter: 'Signs of dependence', frequency: 'Each visit', rationale: 'Develop with regular use', actionThreshold: 'Using more than prescribed, anxiety about refills' },
      { parameter: 'Respiratory status', frequency: 'When combined with opioids', rationale: 'Fatal interaction', actionThreshold: 'RR <12 or SpO2 <90%' },
    ],
    patientEducation: [
      'This medication can be habit-forming - use only as prescribed',
      'Do not drink alcohol while taking this medication',
      'Do not drive or operate machinery until you know how it affects you',
      'Do not stop suddenly after regular use - this can cause seizures',
      'This is intended for short-term use only',
      'Tell your doctor if you are taking any opioid pain medications',
    ],
    clinicalPearls: [
      'FDA black box warning for combined use with opioids',
      'Preferred benzodiazepine in liver disease (glucuronidated, not CYP-metabolized)',
      'Only benzodiazepine with reliable IM absorption - good for acute agitation',
      'IV lorazepam contains propylene glycol - watch for toxicity with high doses',
      'Beers criteria: avoid in elderly due to falls and cognitive decline',
      'Flumazenil reverses effects but can precipitate seizures in dependent patients',
      'For alcohol withdrawal: symptom-triggered dosing preferred over fixed schedule',
    ],
  },

  // ============================================
  // Thyroid & Endocrine Medications
  // ============================================

  {
    id: 'levothyroxine',
    genericName: 'Levothyroxine',
    brandNames: ['Synthroid', 'Levoxyl', 'Tirosint', 'Unithroid'],
    drugClass: 'Thyroid Hormone',
    category: 'endocrine',
    overview: 'Levothyroxine is synthetic T4 (thyroxine) used to replace deficient thyroid hormone in hypothyroidism. It is converted to T3 in peripheral tissues and has a long half-life allowing once-daily dosing. Key considerations include absorption interactions and the need for consistent dosing.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Thyroid hormone receptors (nuclear receptors)',
      targetLocation: 'Cell nuclei throughout the body',
      simpleExplanation: 'Levothyroxine provides the T4 that your thyroid gland cannot make. Your body converts T4 to active T3, which controls metabolism, heart rate, and energy.',
      detailedMechanism: 'Levothyroxine provides exogenous T4 that is deiodinated to T3 in peripheral tissues. T3 enters cells, binds nuclear thyroid hormone receptors, and modulates transcription of genes involved in metabolism, growth, development, and thermogenesis.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Levothyroxine absorbed', result: 'T4 enters bloodstream', timeframe: '30-60 min' },
        { order: 2, location: 'Peripheral tissues', action: 'T4 deiodinated to T3', result: 'Active hormone formed' },
        { order: 3, location: 'Cell cytoplasm', action: 'T3 enters cells', result: 'Hormone reaches target' },
        { order: 4, location: 'Cell nucleus', action: 'T3 binds thyroid hormone receptor', result: 'Gene transcription altered', timeframe: 'Hours to days' },
      ],
      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Increased basal metabolic rate', mechanism: 'Gene transcription changes', clinicalRelevance: 'Restores normal metabolism in hypothyroidism', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Increased heart rate and contractility', mechanism: 'Upregulation of cardiac beta receptors', clinicalRelevance: 'Can worsen angina if dose too high', desiredOrAdverse: 'both' },
        { system: 'Bone', effect: 'Increased bone turnover', mechanism: 'Stimulates osteoclasts', clinicalRelevance: 'Overreplacement causes osteoporosis', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Days to weeks for full clinical effect',
      durationOfEffect: 'Long half-life (6-7 days) allows once-daily dosing',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '40-80%',
        route: ['oral', 'intravenous'],
        factors: ['Empty stomach increases absorption', 'Calcium, iron, PPIs decrease absorption'],
        timeToePeak: '2-4 hours',
        foodEffect: 'Food reduces absorption; take 30-60 min before breakfast',
      },
      distribution: {
        volumeOfDistribution: '10-12 L',
        proteinBinding: '>99% (TBG, albumin, transthyretin)',
        tissueDistribution: ['Thyroid', 'Liver', 'Kidney', 'All tissues'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Peripheral tissues (liver, kidney, muscle)',
        enzymes: ['Deiodinases (D1, D2, D3)'],
        activeMetabolites: ['T3 (active)', 'rT3 (inactive)'],
        geneticVariability: 'Deiodinase polymorphisms may affect T3 conversion',
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Fecal and renal (as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '6-7 days (allows weekly dosing errors without major impact)',
      timeToSteadyState: '4-6 weeks',
    },
    indications: [
      { condition: 'Hypothyroidism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'TSH suppression in thyroid cancer', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Myxedema coma', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV formulation' },
      { condition: 'Subclinical hypothyroidism', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false, notes: 'Treat if TSH >10 or symptomatic' },
    ],
    dosing: {
      usualDose: { amount: '1.6 mcg/kg/day', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly or cardiac disease', adjustment: 'Start 12.5-25 mcg daily', rationale: 'Avoid cardiac stress' },
        { condition: 'Pregnancy', adjustment: 'Increase dose 25-50%', rationale: 'Increased thyroid hormone requirements' },
        { condition: 'Post-thyroidectomy', adjustment: 'Full replacement immediately', rationale: 'No endogenous production' },
      ],
      maxDose: '200-300 mcg/day (rarely needed)',
      administration: {
        route: 'Oral',
        withFood: 'without-food',
        timing: '30-60 minutes before breakfast',
        specialInstructions: ['Take consistently at same time', 'Separate from calcium/iron by 4 hours', 'Gel caps (Tirosint) may be taken with food'],
      },
    },
    adverseEffects: [
      { name: 'Tachycardia/palpitations', frequency: 'common', severity: 'moderate', mechanism: 'Overreplacement increases cardiac activity', management: 'Reduce dose; check TSH', reversible: true, onsetTiming: 'With overreplacement' },
      { name: 'Weight loss', frequency: 'common', severity: 'mild', mechanism: 'Increased metabolic rate', management: 'Usually desired in hypothyroidism', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Insomnia/anxiety', frequency: 'common', severity: 'mild', mechanism: 'CNS stimulation from excess thyroid hormone', management: 'Reduce dose if TSH suppressed', reversible: true, onsetTiming: 'Variable' },
      { name: 'Osteoporosis', frequency: 'uncommon', severity: 'moderate', mechanism: 'Chronic overreplacement increases bone turnover', management: 'Monitor bone density with suppressive therapy', reversible: false, onsetTiming: 'Years of overreplacement' },
      { name: 'Atrial fibrillation', frequency: 'uncommon', severity: 'severe', mechanism: 'Thyroid excess shortens atrial refractory period', management: 'Keep TSH in normal range, especially in elderly', reversible: true, onsetTiming: 'With chronic overreplacement' },
    ],
    interactions: [
      { interactingDrug: 'Calcium/Iron supplements', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Chelation reduces levothyroxine absorption', effect: 'Decreased thyroid hormone levels', management: 'Separate by 4 hours' },
      { interactingDrug: 'Proton pump inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Altered gastric pH affects absorption', effect: 'Decreased absorption', management: 'Separate dosing or use gel cap formulation' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Thyroid hormone increases warfarin sensitivity', effect: 'Increased INR', management: 'Monitor INR when adjusting levothyroxine' },
    ],
    contraindications: [
      { condition: 'Untreated adrenal insufficiency', type: 'absolute', reason: 'Thyroid hormone increases cortisol clearance - can precipitate adrenal crisis' },
      { condition: 'Acute MI', type: 'absolute', reason: 'Thyroid hormone increases cardiac work' },
      { condition: 'Thyrotoxicosis', type: 'absolute', reason: 'Would worsen hyperthyroid state' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Requirements increase 25-50%', recommendation: 'Increase dose early; monitor TSH monthly', pregnancyCategory: 'A' },
      { population: 'breastfeeding', consideration: 'Minimal excretion in milk', recommendation: 'Safe - continue normal dosing' },
      { population: 'geriatric', consideration: 'Increased cardiac sensitivity', recommendation: 'Start low (12.5-25 mcg), titrate slowly' },
      { population: 'pediatric', consideration: 'Critical for neurodevelopment', recommendation: 'Treat congenital hypothyroidism within 2 weeks' },
    ],
    monitoring: [
      { parameter: 'TSH', frequency: 'Every 4-6 weeks until stable, then every 6-12 months', rationale: 'Primary monitoring parameter', actionThreshold: 'Adjust dose to TSH 0.5-2.5' },
      { parameter: 'Free T4', frequency: 'If TSH abnormal or secondary hypothyroidism', rationale: 'Confirms thyroid status', actionThreshold: 'Target mid-normal range' },
      { parameter: 'Heart rate/symptoms', frequency: 'Each visit', rationale: 'Detect overreplacement', actionThreshold: 'Reduce dose if tachycardia or hyperthyroid symptoms' },
    ],
    patientEducation: [
      'Take on empty stomach 30-60 minutes before breakfast',
      'Do not take with calcium, iron, antacids, or coffee',
      'Take at the same time every day for consistency',
      'This is a lifelong medication - do not stop without consulting doctor',
      'Report racing heart, chest pain, or tremors (too much medication)',
      'It takes 4-6 weeks to see full effect of dose changes',
    ],
    clinicalPearls: [
      'TSH goal for most patients is 0.5-2.5 mU/L; higher (4-6) may be acceptable in very elderly',
      'Separate from ALL absorption-impairing substances by 4 hours',
      'Pregnancy increases requirements 25-50% - often add 2 extra doses/week empirically',
      'Generic vs brand may have absorption differences - maintain consistency',
      'Tirosint (gel cap) preferred in malabsorption or multiple interacting drugs',
      'Myxedema coma: IV levothyroxine + hydrocortisone (treat adrenal crisis risk)',
    ],
  },

  {
    id: 'prednisone',
    genericName: 'Prednisone',
    brandNames: ['Deltasone', 'Rayos', 'Prednisone Intensol'],
    drugClass: 'Corticosteroid (Glucocorticoid)',
    category: 'endocrine',
    overview: 'Prednisone is an oral corticosteroid used for its anti-inflammatory and immunosuppressive effects. It is a prodrug converted to prednisolone in the liver. Used for a wide range of inflammatory and autoimmune conditions, but long-term use carries significant risks.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptors',
      targetLocation: 'Cytoplasm of all nucleated cells',
      simpleExplanation: 'Prednisone mimics cortisol, your body\'s natural stress hormone. It powerfully reduces inflammation and suppresses immune responses, which helps in conditions where inflammation is harmful.',
      detailedMechanism: 'Prednisone is converted to prednisolone in the liver. Prednisolone binds cytoplasmic glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription - upregulating anti-inflammatory genes and downregulating pro-inflammatory cytokines, adhesion molecules, and enzymes.',
      mechanismSteps: [
        { order: 1, location: 'Liver', action: 'Prednisone converted to prednisolone', result: 'Active drug formed', timeframe: '1-2 hours' },
        { order: 2, location: 'Cell cytoplasm', action: 'Prednisolone binds glucocorticoid receptor', result: 'Receptor-drug complex forms' },
        { order: 3, location: 'Cell nucleus', action: 'Complex modulates gene transcription', result: 'Anti-inflammatory protein production', timeframe: 'Hours' },
        { order: 4, location: 'Inflammatory site', action: 'Cytokines and inflammation reduced', result: 'Clinical improvement', timeframe: 'Days' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Immunosuppression', mechanism: 'Reduced cytokine production', clinicalRelevance: 'Treats autoimmune conditions but increases infection risk', desiredOrAdverse: 'both' },
        { system: 'Metabolic', effect: 'Hyperglycemia', mechanism: 'Gluconeogenesis stimulation', clinicalRelevance: 'May cause or worsen diabetes', desiredOrAdverse: 'adverse' },
        { system: 'Musculoskeletal', effect: 'Bone loss', mechanism: 'Decreased osteoblast activity', clinicalRelevance: 'Osteoporosis with chronic use', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 hours (plasma), but clinical effect over days',
      durationOfEffect: 'Intermediate-acting (18-36 hour biological half-life)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '~80%',
        route: ['oral'],
        factors: ['Well absorbed regardless of food'],
        timeToePeak: '1-2 hours',
        foodEffect: 'Minimal - can take with food to reduce GI upset',
      },
      distribution: {
        volumeOfDistribution: '0.5-1.5 L/kg',
        proteinBinding: '65-91%',
        tissueDistribution: ['Widely distributed', 'Crosses placenta'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['Hepatic 11β-hydroxysteroid dehydrogenase'],
        activeMetabolites: ['Prednisolone (active form)'],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '2-4 hours (drug), 18-36 hours (biological)',
      timeToSteadyState: '1-2 days',
    },
    indications: [
      { condition: 'Asthma exacerbation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Autoimmune diseases', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Inflammatory conditions', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'COPD exacerbation', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Cancer adjunct therapy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '5-60 mg/day', frequency: 'Once daily or divided', route: 'Oral' },
      adjustments: [
        { condition: 'Asthma exacerbation', adjustment: '40-60 mg x 5-7 days', rationale: 'Burst therapy' },
        { condition: 'Rheumatoid arthritis', adjustment: '5-10 mg daily', rationale: 'Lowest effective dose' },
        { condition: 'Severe hepatic impairment', adjustment: 'Use prednisolone instead', rationale: 'May not convert to active form' },
      ],
      maxDose: 'No absolute maximum; limited by adverse effects',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Morning dosing preferred (mimics cortisol rhythm)',
        specialInstructions: ['Take with food to reduce GI upset', 'Never stop abruptly after chronic use - taper required'],
      },
    },
    adverseEffects: [
      { name: 'Hyperglycemia', frequency: 'very-common', severity: 'moderate', mechanism: 'Gluconeogenesis stimulation', management: 'Monitor glucose; may need diabetes medications', reversible: true, onsetTiming: 'Days' },
      { name: 'Weight gain/fluid retention', frequency: 'very-common', severity: 'moderate', mechanism: 'Mineralocorticoid effects', management: 'Sodium restriction; diuretics if needed', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Insomnia/mood changes', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS effects', management: 'Morning dosing; psychiatric support if severe', reversible: true, onsetTiming: 'Days' },
      { name: 'Osteoporosis', frequency: 'common', severity: 'severe', mechanism: 'Decreased bone formation', management: 'Calcium, vitamin D, bisphosphonates for chronic use', reversible: false, onsetTiming: 'Months' },
      { name: 'Adrenal suppression', frequency: 'common', severity: 'severe', mechanism: 'HPA axis suppression', management: 'Taper slowly; stress dose coverage', reversible: true, onsetTiming: 'After >3 weeks' },
      { name: 'Increased infection risk', frequency: 'common', severity: 'severe', mechanism: 'Immunosuppression', management: 'Avoid live vaccines; infection precautions', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive GI toxicity', effect: 'Increased ulcer risk', management: 'Avoid combination; PPI prophylaxis if must use' },
      { interactingDrug: 'CYP3A4 inducers (rifampin)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased steroid metabolism', effect: 'Reduced efficacy', management: 'May need higher steroid doses' },
      { interactingDrug: 'Live vaccines', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Immunosuppression allows vaccine virus replication', effect: 'Disseminated vaccine infection', management: 'Contraindicated at immunosuppressive doses' },
    ],
    contraindications: [
      { condition: 'Systemic fungal infection', type: 'absolute', reason: 'Immunosuppression worsens disseminated fungal disease' },
      { condition: 'Live vaccine administration', type: 'relative', reason: 'Risk of disseminated infection at high doses' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Can cause cleft palate in first trimester', recommendation: 'Use when benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Excreted in milk', recommendation: 'Compatible at low doses; wait 4h after high doses' },
      { population: 'geriatric', consideration: 'Very high complication risk', recommendation: 'Use lowest dose, shortest duration' },
      { population: 'pediatric', consideration: 'Growth suppression risk', recommendation: 'Monitor growth with chronic use' },
    ],
    monitoring: [
      { parameter: 'Blood glucose', frequency: 'Baseline then regularly', rationale: 'Hyperglycemia risk', actionThreshold: 'Treat if fasting glucose >126' },
      { parameter: 'Blood pressure', frequency: 'Regular monitoring', rationale: 'May increase BP', actionThreshold: 'Treat elevated BP' },
      { parameter: 'Bone density', frequency: 'Baseline if >3 months anticipated', rationale: 'Osteoporosis prevention', actionThreshold: 'T-score <-2.5' },
      { parameter: 'Signs of infection', frequency: 'Ongoing', rationale: 'Steroids mask symptoms', actionThreshold: 'Low threshold to treat' },
    ],
    patientEducation: [
      'Take with food in the morning',
      'Do NOT stop suddenly - it must be tapered if used >2-3 weeks',
      'Carry medical ID stating you take steroids',
      'Tell all healthcare providers before surgery or if ill',
      'Report signs of infection - steroids can mask fever',
      'You may have increased appetite and weight gain',
    ],
    clinicalPearls: [
      'HPA suppression occurs with >3 weeks of supraphysiologic doses - always taper',
      'Steroid equivalency: 5 mg prednisone = 4 mg methylprednisolone = 0.75 mg dexamethasone',
      'Osteoporosis prevention: calcium + vitamin D + bisphosphonate for chronic use',
      'PJP prophylaxis with TMP-SMX if ≥20 mg/day for ≥4 weeks with other immunosuppression',
      'Steroid psychosis occurs in up to 5% at high doses',
      'For stress dosing: hydrocortisone 50-100 mg IV preferred',
    ],
  },

  // ============================================
  // Antihistamines & Allergy
  // ============================================

  {
    id: 'cetirizine',
    genericName: 'Cetirizine',
    brandNames: ['Zyrtec', 'All Day Allergy'],
    drugClass: 'Second-generation H1 antihistamine',
    category: 'respiratory',
    overview: 'Cetirizine is a second-generation antihistamine that blocks histamine H1 receptors with minimal sedation and anticholinergic effects compared to first-generation agents. It provides 24-hour relief of allergy symptoms and is available over-the-counter.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Histamine H1 receptors',
      targetLocation: 'Peripheral tissues (skin, airways, vasculature)',
      simpleExplanation: 'Cetirizine blocks histamine, the chemical released during allergic reactions. By blocking histamine from binding to its receptors, it prevents sneezing, itching, runny nose, and hives.',
      detailedMechanism: 'Cetirizine is a selective peripheral H1-receptor antagonist with minimal CNS penetration. It competitively inhibits histamine binding to H1 receptors on smooth muscle, vascular endothelium, and sensory nerve endings, preventing histamine-mediated allergic symptoms.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Cetirizine absorbed', result: 'Drug enters bloodstream', timeframe: '20-60 min' },
        { order: 2, location: 'Peripheral tissues', action: 'Cetirizine binds H1 receptors', result: 'Histamine binding blocked' },
        { order: 3, location: 'Target tissues', action: 'Allergic cascade interrupted', result: 'Reduced inflammation and symptoms', timeframe: '1-3 hours' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Reduced nasal congestion and sneezing', mechanism: 'H1 blockade in nasal mucosa', clinicalRelevance: 'Relieves allergic rhinitis', desiredOrAdverse: 'desired' },
        { system: 'Skin', effect: 'Reduced itching and hives', mechanism: 'H1 blockade in skin', clinicalRelevance: 'Treats urticaria', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Mild sedation', mechanism: 'Some CNS H1 receptor activity', clinicalRelevance: 'Less sedating than first-gen but more than fexofenadine', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '20-60 minutes',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '~70%',
        route: ['oral'],
        factors: ['Food does not significantly affect absorption'],
        timeToePeak: '1-3 hours',
      },
      distribution: {
        volumeOfDistribution: '0.56 L/kg',
        proteinBinding: '93%',
        tissueDistribution: ['Minimal CNS penetration', 'Concentrates in skin'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal hepatic metabolism',
        enzymes: ['Not significantly CYP-dependent'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (unchanged)',
        renalClearance: '~60%',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '8-9 hours',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Seasonal allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Perennial allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic urticaria', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Atopic dermatitis (pruritus)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '5-10 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment (CrCl <31)', adjustment: '5 mg daily', rationale: 'Reduced clearance' },
        { condition: 'Elderly', adjustment: 'Start with 5 mg', rationale: 'May have increased sedation' },
        { condition: 'Hemodialysis', adjustment: '5 mg after dialysis', rationale: 'Not significantly dialyzed' },
      ],
      maxDose: '10 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Can be morning or evening; bedtime if causes drowsiness',
        specialInstructions: ['Available in tablet, chewable, and liquid forms'],
      },
    },
    adverseEffects: [
      { name: 'Somnolence', frequency: 'common', severity: 'mild', mechanism: 'Some CNS H1 receptor activity', management: 'Take at bedtime if bothersome', reversible: true, onsetTiming: 'First doses' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Mild anticholinergic effect', management: 'Stay hydrated; sugarless gum', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Fatigue', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Usually mild and transient', reversible: true, onsetTiming: 'First few days' },
      { name: 'Headache', frequency: 'uncommon', severity: 'mild', mechanism: 'Unknown', management: 'Symptomatic treatment', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'CNS depressants (alcohol)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive CNS depression', effect: 'Increased sedation', management: 'Avoid alcohol; use caution' },
      { interactingDrug: 'Theophylline', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Slight decrease in cetirizine clearance', effect: 'Slightly increased levels', management: 'Not clinically significant' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to cetirizine or hydroxyzine', type: 'absolute', reason: 'Cross-reactivity (cetirizine is hydroxyzine metabolite)' },
      { condition: 'Severe renal impairment (CrCl <10)', type: 'relative', reason: 'Reduced clearance; avoid or give after dialysis' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Extensive use data', recommendation: 'Preferred antihistamine in pregnancy (Category B)', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Low levels in breast milk', recommendation: 'Compatible; monitor infant for irritability' },
      { population: 'geriatric', consideration: 'May have more sedation', recommendation: 'Start with 5 mg daily' },
      { population: 'pediatric', consideration: 'Approved for 6 months and older', recommendation: 'Weight/age-based dosing' },
    ],
    monitoring: [
      { parameter: 'Symptom relief', frequency: 'As needed', rationale: 'Assess efficacy', actionThreshold: 'Switch agent if no relief' },
      { parameter: 'Sedation', frequency: 'Initial therapy', rationale: 'May affect driving/work', actionThreshold: 'Try bedtime dosing or switch to fexofenadine' },
    ],
    patientEducation: [
      'Can be taken once daily, morning or evening',
      'May cause drowsiness - avoid driving until you know how it affects you',
      'Avoid alcohol as it increases drowsiness',
      'Works best when taken regularly during allergy season',
      'Available over-the-counter in various forms',
    ],
    clinicalPearls: [
      'Cetirizine is the active metabolite of hydroxyzine',
      'More sedating than fexofenadine/loratadine, less than first-generation',
      'Fast onset makes it good for as-needed use',
      'No significant CYP interactions - advantage over many drugs',
      'Cetirizine accumulates in skin - particularly good for urticaria',
      'OTC availability - patients may not report use to providers',
    ],
  },

  // ============================================
  // GI Medications - Additional
  // ============================================

  {
    id: 'loperamide',
    genericName: 'Loperamide',
    brandNames: ['Imodium', 'Imodium A-D'],
    drugClass: 'Antidiarrheal (Peripheral Opioid)',
    category: 'gastrointestinal',
    overview: 'Loperamide is a peripheral-acting mu-opioid agonist used for acute and chronic diarrhea. It acts on intestinal opioid receptors to slow motility and does not cross the blood-brain barrier at therapeutic doses, avoiding CNS effects and addiction potential.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu-opioid receptors in intestinal wall',
      targetLocation: 'Myenteric plexus of GI tract',
      simpleExplanation: 'Loperamide slows down intestinal movement by activating opioid receptors in the gut. Unlike other opioids, it does not enter the brain at normal doses, so it does not cause sedation or addiction.',
      detailedMechanism: 'Loperamide binds mu-opioid receptors in the intestinal myenteric plexus, inhibiting acetylcholine release and reducing peristalsis. This increases intestinal transit time and enhances fluid and electrolyte absorption. P-glycoprotein efflux at the BBB prevents CNS penetration.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Loperamide absorbed and acts locally', result: 'Binds intestinal mu receptors' },
        { order: 2, location: 'Myenteric plexus', action: 'Inhibits acetylcholine release', result: 'Reduced peristalsis' },
        { order: 3, location: 'Intestinal lumen', action: 'Transit time increased', result: 'More fluid absorption', timeframe: '1-3 hours' },
      ],
      physiologicalEffects: [
        { system: 'Gastrointestinal', effect: 'Reduced motility', mechanism: 'Opioid receptor activation', clinicalRelevance: 'Treats diarrhea', desiredOrAdverse: 'desired' },
        { system: 'Gastrointestinal', effect: 'Constipation', mechanism: 'Excessive slowing', clinicalRelevance: 'Can occur with overuse', desiredOrAdverse: 'adverse' },
        { system: 'Cardiovascular', effect: 'QT prolongation', mechanism: 'Ion channel blockade at high doses', clinicalRelevance: 'Only with massive overdose/abuse', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1 hour',
      durationOfEffect: 'Up to 24 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '0.3% (extensive first-pass)',
        route: ['oral'],
        factors: ['High first-pass metabolism limits systemic exposure'],
        timeToePeak: '4-5 hours',
      },
      distribution: {
        volumeOfDistribution: 'Limited systemic distribution',
        proteinBinding: '97%',
        tissueDistribution: ['Primarily GI tract'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP2C8'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Fecal',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '10-14 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Acute nonspecific diarrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic diarrhea (IBS-D)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Traveler\'s diarrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true, notes: 'With antibiotics' },
    ],
    dosing: {
      usualDose: { amount: '4 mg initially, then 2 mg', frequency: 'After each loose stool', route: 'Oral' },
      adjustments: [
        { condition: 'Maximum daily dose', adjustment: '16 mg/day (OTC), up to 16 mg/day (Rx)', rationale: 'Safety ceiling' },
        { condition: 'Acute diarrhea', adjustment: 'Max 48 hours of self-treatment', rationale: 'Seek care if no improvement' },
      ],
      maxDose: '16 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        specialInstructions: ['Do not exceed max dose', 'Stop if no improvement in 48 hours'],
      },
    },
    adverseEffects: [
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Excessive GI slowing', management: 'Reduce dose or stop', reversible: true, onsetTiming: 'With overuse' },
      { name: 'Abdominal cramping', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Usually self-limiting', reversible: true, onsetTiming: 'During use' },
      { name: 'Nausea', frequency: 'uncommon', severity: 'mild', mechanism: 'GI effects', management: 'Symptomatic', reversible: true, onsetTiming: 'Early' },
      { name: 'Cardiac arrhythmias', frequency: 'rare', severity: 'life-threatening', mechanism: 'Ion channel blockade at supratherapeutic doses', management: 'Only with massive overdose - FDA warning', reversible: true, onsetTiming: 'With overdose/abuse' },
    ],
    interactions: [
      { interactingDrug: 'P-glycoprotein inhibitors (quinidine)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Allows CNS penetration', effect: 'CNS opioid effects, respiratory depression', management: 'Avoid combination' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Increased levels', effect: 'Usually not significant at therapeutic doses', management: 'Use with caution' },
    ],
    contraindications: [
      { condition: 'Acute dysentery (bloody diarrhea with fever)', type: 'absolute', reason: 'May prolong infection - need antibiotics' },
      { condition: 'Acute ulcerative colitis flare', type: 'absolute', reason: 'Risk of toxic megacolon' },
      { condition: 'C. difficile colitis', type: 'absolute', reason: 'May worsen infection' },
      { condition: 'Children under 2 years', type: 'absolute', reason: 'Risk of CNS depression' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use if needed; prefer oral rehydration first', pregnancyCategory: 'B' },
      { population: 'breastfeeding', consideration: 'Minimal excretion', recommendation: 'Compatible for short-term use' },
      { population: 'geriatric', consideration: 'More prone to constipation', recommendation: 'Use cautiously; monitor for impaction' },
      { population: 'pediatric', consideration: 'Not for <2 years', recommendation: 'Age-appropriate dosing for older children' },
    ],
    monitoring: [
      { parameter: 'Stool frequency', frequency: 'Daily during use', rationale: 'Assess efficacy', actionThreshold: 'Seek care if no improvement in 48 hours' },
      { parameter: 'Hydration status', frequency: 'Ongoing', rationale: 'Diarrhea causes dehydration', actionThreshold: 'Ensure adequate fluid intake' },
    ],
    patientEducation: [
      'Take after each loose stool - not on a fixed schedule',
      'Do not exceed 8 caplets (16 mg) in 24 hours',
      'Stay hydrated - drink plenty of clear fluids',
      'Stop and see a doctor if diarrhea continues >48 hours or if you have fever/bloody stools',
      'Not for children under 2 years',
    ],
    clinicalPearls: [
      'Does not cross BBB at therapeutic doses due to P-glycoprotein efflux',
      'At supratherapeutic doses (abuse), can cause fatal cardiac arrhythmias',
      'Contraindicated in bloody diarrhea - infection needs treatment',
      'Oral rehydration is always first-line for diarrhea',
      'OTC strength same as prescription - no advantage to Rx',
      'For traveler\'s diarrhea: can use with antibiotics to reduce symptoms',
    ],
  },

  {
    id: 'metoclopramide',
    genericName: 'Metoclopramide',
    brandNames: ['Reglan', 'Metozolv ODT'],
    drugClass: 'Prokinetic/Antiemetic',
    category: 'gastrointestinal',
    overview: 'Metoclopramide is a dopamine D2 antagonist and 5-HT4 agonist used for gastroparesis and nausea/vomiting. It has FDA black box warning for tardive dyskinesia risk with prolonged use. Treatment should not exceed 12 weeks.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Dopamine D2 receptors (CTZ, GI tract) and 5-HT4 receptors (GI tract)',
      targetLocation: 'Chemoreceptor trigger zone and gastrointestinal tract',
      simpleExplanation: 'Metoclopramide blocks dopamine to reduce nausea and activates serotonin receptors to speed up stomach emptying. This helps food move through faster and reduces the urge to vomit.',
      detailedMechanism: 'D2 receptor blockade in the CTZ produces antiemetic effects. In the GI tract, D2 blockade and 5-HT4 agonism enhance acetylcholine release from the myenteric plexus, increasing LES tone, gastric emptying, and small bowel transit.',
      mechanismSteps: [
        { order: 1, location: 'CTZ', action: 'D2 receptor blockade', result: 'Antiemetic effect', timeframe: '30-60 min' },
        { order: 2, location: 'GI tract', action: 'D2 blockade + 5-HT4 agonism', result: 'Increased ACh release' },
        { order: 3, location: 'Stomach', action: 'Enhanced gastric contractions', result: 'Faster emptying', timeframe: '30-60 min' },
      ],
      physiologicalEffects: [
        { system: 'GI', effect: 'Accelerated gastric emptying', mechanism: 'Prokinetic activity', clinicalRelevance: 'Treats gastroparesis', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Antiemetic', mechanism: 'CTZ D2 blockade', clinicalRelevance: 'Reduces nausea/vomiting', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Extrapyramidal symptoms', mechanism: 'D2 blockade in basal ganglia', clinicalRelevance: 'Tardive dyskinesia risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-3 minutes (IV); 30-60 minutes (oral)',
      durationOfEffect: '1-2 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '80%',
        route: ['oral', 'intravenous', 'intramuscular'],
        factors: ['Rapidly absorbed'],
        timeToePeak: '1-2 hours',
      },
      distribution: {
        volumeOfDistribution: '3.5 L/kg',
        proteinBinding: '30%',
        tissueDistribution: ['Widely distributed', 'Crosses BBB'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2D6'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal',
        renalClearance: '~85%',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '5-6 hours (prolonged in renal impairment)',
      timeToSteadyState: '2 days',
    },
    indications: [
      { condition: 'Diabetic gastroparesis', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true, notes: 'Max 12 weeks' },
      { condition: 'PONV/CINV prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Facilitate small bowel intubation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '10 mg', frequency: 'QID 30 min before meals and at bedtime', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment (CrCl <40)', adjustment: 'Reduce dose by 50%', rationale: 'Reduced clearance' },
        { condition: 'Duration', adjustment: 'Maximum 12 weeks', rationale: 'FDA black box - TD risk' },
      ],
      maxDose: '40 mg/day; max 12 weeks duration',
      administration: {
        route: 'Oral',
        withFood: 'without-food',
        timing: '30 minutes before meals',
        specialInstructions: ['Limit to 12 weeks', 'IV: give slowly over 1-2 minutes'],
      },
    },
    adverseEffects: [
      { name: 'Tardive dyskinesia', frequency: 'uncommon', severity: 'severe', mechanism: 'Chronic D2 blockade', management: 'May be irreversible - limit to 12 weeks; stop at first sign', reversible: false, onsetTiming: 'Usually after prolonged use' },
      { name: 'Drowsiness', frequency: 'common', severity: 'mild', mechanism: 'CNS D2 blockade', management: 'Use lower doses; take at bedtime', reversible: true, onsetTiming: 'Early' },
      { name: 'Restlessness/akathisia', frequency: 'common', severity: 'moderate', mechanism: 'D2 blockade', management: 'Reduce dose or stop', reversible: true, onsetTiming: 'Early' },
      { name: 'Acute dystonia', frequency: 'uncommon', severity: 'moderate', mechanism: 'D2 blockade', management: 'Treat with diphenhydramine; more common in young adults', reversible: true, onsetTiming: 'First 24-48 hours' },
    ],
    interactions: [
      { interactingDrug: 'Dopamine agonists (levodopa)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Opposing D2 effects', effect: 'Reduced antiparkinsonian effect', management: 'Avoid in Parkinson disease' },
      { interactingDrug: 'Antipsychotics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive D2 blockade', effect: 'Increased EPS risk', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'GI obstruction/perforation', type: 'absolute', reason: 'Prokinetics dangerous with obstruction' },
      { condition: 'Pheochromocytoma', type: 'absolute', reason: 'Hypertensive crisis risk' },
      { condition: 'Parkinson disease', type: 'relative', reason: 'D2 blockade worsens symptoms' },
      { condition: 'Seizure disorder', type: 'relative', reason: 'May lower seizure threshold' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Used for hyperemesis', recommendation: 'Generally considered safe', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Highest TD risk', recommendation: 'Avoid if possible; if needed, very short course' },
      { population: 'pediatric', consideration: 'Higher dystonia risk', recommendation: 'Avoid in <1 year; use cautiously in children' },
    ],
    monitoring: [
      { parameter: 'Extrapyramidal symptoms', frequency: 'Each visit', rationale: 'TD screening', actionThreshold: 'Stop at first sign of involuntary movements' },
      { parameter: 'Duration of therapy', frequency: 'Ongoing', rationale: 'Do not exceed 12 weeks', actionThreshold: 'Discontinue at 12 weeks' },
    ],
    patientEducation: [
      'This medication should NOT be used for more than 12 weeks',
      'Take 30 minutes before meals',
      'Report any involuntary movements of face, tongue, or limbs immediately',
      'May cause drowsiness - avoid driving until you know how it affects you',
    ],
    clinicalPearls: [
      'FDA black box for tardive dyskinesia - strict 12-week limit',
      'Elderly women at highest TD risk',
      'Acute dystonia: treat with IV diphenhydramine 25-50 mg',
      'Not effective for opioid-induced constipation',
      'Can be used safely for single-dose procedural use',
    ],
  },

  // ============================================
  // Cardiovascular - Additional
  // ============================================

  {
    id: 'digoxin',
    genericName: 'Digoxin',
    brandNames: ['Lanoxin', 'Digitek'],
    drugClass: 'Cardiac Glycoside',
    category: 'cardiovascular',
    overview: 'Digoxin inhibits sodium-potassium ATPase, increasing cardiac contractility and slowing AV conduction. Used for heart failure with reduced ejection fraction and atrial fibrillation rate control. Has narrow therapeutic index requiring level monitoring.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Sodium-potassium ATPase',
      targetLocation: 'Cardiac myocytes',
      simpleExplanation: 'Digoxin makes the heart beat stronger and slower. It increases calcium inside heart cells (stronger contraction) and slows the electrical signals through the heart (controls fast heart rhythms).',
      detailedMechanism: 'Digoxin inhibits Na+/K+-ATPase, increasing intracellular sodium. This reduces the sodium gradient driving the Na+/Ca2+ exchanger, increasing intracellular calcium and contractility. Vagomimetic effects slow AV nodal conduction.',
      mechanismSteps: [
        { order: 1, location: 'Cardiac myocyte', action: 'Na+/K+-ATPase inhibition', result: 'Increased intracellular Na+' },
        { order: 2, location: 'Cell membrane', action: 'Reduced Na+/Ca2+ exchange', result: 'Increased intracellular Ca2+' },
        { order: 3, location: 'Sarcomere', action: 'More Ca2+ for contraction', result: 'Positive inotropy', timeframe: 'Hours' },
        { order: 4, location: 'AV node', action: 'Enhanced vagal tone', result: 'Slowed conduction', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Positive inotropy', mechanism: 'Increased intracellular calcium', clinicalRelevance: 'Improves symptoms in HFrEF', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Negative chronotropy (AV node)', mechanism: 'Vagomimetic effects', clinicalRelevance: 'Rate control in AF', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Arrhythmias', mechanism: 'Toxicity increases automaticity', clinicalRelevance: 'Toxicity sign - check level', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '0.5-2 hours (oral)',
      durationOfEffect: 'Days (long half-life)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '60-80%',
        route: ['oral', 'intravenous'],
        factors: ['High fiber diet decreases absorption'],
        timeToePeak: '2-6 hours',
      },
      distribution: {
        volumeOfDistribution: '6-7 L/kg (large)',
        proteinBinding: '25%',
        tissueDistribution: ['Skeletal muscle', 'Heart', 'Kidney'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Minimal metabolism',
        enzymes: ['Some gut bacterial metabolism'],
        activeMetabolites: [],
        drugInteractionRisk: 'high',
      },
      excretion: {
        primaryRoute: 'Renal (60-80% unchanged)',
        renalClearance: 'Proportional to CrCl',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '36-48 hours (normal renal function)',
      timeToSteadyState: '5-7 days',
    },
    indications: [
      { condition: 'Heart failure with reduced EF', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Add-on therapy' },
      { condition: 'Atrial fibrillation rate control', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false, notes: 'Usually with beta-blocker' },
    ],
    dosing: {
      usualDose: { amount: '0.125-0.25 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Reduce dose; CrCl 25-50: 0.125 mg/day', rationale: 'Reduced clearance' },
        { condition: 'Elderly', adjustment: '0.0625-0.125 mg daily', rationale: 'Reduced renal function' },
        { condition: 'Amiodarone coadministration', adjustment: 'Reduce digoxin by 50%', rationale: 'Interaction doubles levels' },
      ],
      maxDose: '0.25 mg/day for most patients',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Same time daily; hold if HR <60',
        specialInstructions: ['Check pulse before taking', 'IV dose = 0.8 × oral dose'],
      },
    },
    adverseEffects: [
      { name: 'Nausea/vomiting/anorexia', frequency: 'common', severity: 'moderate', mechanism: 'CTZ and GI effects', management: 'Early toxicity sign - check level', reversible: true, onsetTiming: 'With toxicity' },
      { name: 'Visual disturbances (yellow halos)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Retinal effects', management: 'Classic toxicity sign - check level', reversible: true, onsetTiming: 'With toxicity' },
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'Vagal effects on SA/AV node', management: 'Hold if HR <60', reversible: true, onsetTiming: 'Variable' },
      { name: 'Cardiac arrhythmias', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Toxicity increases automaticity', management: 'Digoxin immune Fab for severe toxicity', reversible: true, onsetTiming: 'With toxicity' },
    ],
    interactions: [
      { interactingDrug: 'Amiodarone', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'P-gp inhibition, reduced clearance', effect: 'Digoxin levels double', management: 'Reduce digoxin by 50%' },
      { interactingDrug: 'Verapamil/Diltiazem', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'P-gp inhibition + additive AV blockade', effect: 'Increased digoxin + bradycardia', management: 'Reduce digoxin; monitor HR' },
      { interactingDrug: 'Diuretics (causing hypokalemia)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Hypokalemia enhances toxicity', effect: 'Arrhythmias at normal levels', management: 'Maintain K+ 4-5 mEq/L' },
    ],
    contraindications: [
      { condition: 'Ventricular fibrillation', type: 'absolute', reason: 'Ineffective and dangerous' },
      { condition: 'WPW with AF', type: 'absolute', reason: 'May accelerate accessory pathway conduction causing VF' },
      { condition: 'Hypertrophic cardiomyopathy with obstruction', type: 'relative', reason: 'Inotropy worsens obstruction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Used for fetal SVT', recommendation: 'Use if needed; monitor levels', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Reduced renal function', recommendation: 'Lower doses; target level 0.5-0.9' },
      { population: 'renal-impairment', consideration: 'Major route of elimination', recommendation: 'Reduce dose; extend interval' },
    ],
    monitoring: [
      { parameter: 'Serum digoxin level', frequency: 'At steady state, then periodically', rationale: 'Narrow therapeutic index', actionThreshold: 'Target 0.5-0.9 ng/mL for HF' },
      { parameter: 'Potassium', frequency: 'Regular', rationale: 'Hypokalemia increases toxicity', actionThreshold: 'Maintain 4-5 mEq/L' },
      { parameter: 'Heart rate and rhythm', frequency: 'Each visit', rationale: 'Detect toxicity', actionThreshold: 'Hold if HR <60 or arrhythmia' },
      { parameter: 'Creatinine', frequency: 'Periodically', rationale: 'Renal function affects clearance', actionThreshold: 'Adjust dose if worsening' },
    ],
    patientEducation: [
      'Check your pulse before taking - call doctor if <60 or irregular',
      'Take at the same time each day',
      'Report nausea, vomiting, vision changes, or palpitations',
      'Do not stop without talking to your doctor',
      'Keep follow-up appointments for blood tests',
    ],
    clinicalPearls: [
      'Target level 0.5-0.9 ng/mL - lower than historical targets',
      'DIG trial: reduces HF hospitalizations but no mortality benefit',
      'Toxicity enhanced by hypokalemia - maintain K+ 4-5',
      'Classic toxicity arrhythmia: regularized AF (accelerated junctional)',
      'Yellow-green vision (xanthopsia) is pathognomonic of toxicity',
      'Digoxin immune Fab (Digibind) for severe toxicity',
    ],
  },

  // ============================================
  // Anticoagulants - Additional
  // ============================================

  {
    id: 'rivaroxaban',
    genericName: 'Rivaroxaban',
    brandNames: ['Xarelto'],
    drugClass: 'Direct Oral Anticoagulant (DOAC)',
    category: 'hematologic',
    overview: 'Rivaroxaban is a direct Factor Xa inhibitor used for stroke prevention in atrial fibrillation, VTE treatment/prevention, and CAD/PAD. Unlike warfarin, it requires no routine monitoring and has fewer drug interactions, but has no widely available reversal agent.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Factor Xa',
      targetLocation: 'Coagulation cascade',
      simpleExplanation: 'Rivaroxaban blocks Factor Xa, a key enzyme in blood clotting. By blocking this enzyme, it prevents the formation of blood clots that can cause strokes and DVTs.',
      detailedMechanism: 'Rivaroxaban is a direct, selective, reversible inhibitor of Factor Xa. It inhibits both free and clot-bound Factor Xa, preventing conversion of prothrombin to thrombin and subsequent fibrin clot formation.',
      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Rivaroxaban binds Factor Xa', result: 'Enzyme inhibition' },
        { order: 2, location: 'Coagulation cascade', action: 'Prothrombin conversion blocked', result: 'Reduced thrombin generation' },
        { order: 3, location: 'Fibrin pathway', action: 'Less fibrin produced', result: 'Reduced clot formation', timeframe: '2-4 hours' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Factor Xa inhibition', clinicalRelevance: 'Prevents thromboembolic events', desiredOrAdverse: 'desired' },
        { system: 'Hematologic', effect: 'Bleeding', mechanism: 'Anticoagulant effect', clinicalRelevance: 'Major adverse effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '2-4 hours',
      durationOfEffect: 'Once or twice daily depending on indication',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '80-100% (15-20 mg doses require food)',
        route: ['oral'],
        factors: ['Food increases absorption of higher doses'],
        timeToePeak: '2-4 hours',
        foodEffect: '15-20 mg doses MUST be taken with food',
      },
      distribution: {
        volumeOfDistribution: '50 L',
        proteinBinding: '92-95%',
        tissueDistribution: ['Widely distributed'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP2J2'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (36% unchanged) and biliary (36%)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '5-9 hours (11-13 hours in elderly)',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Stroke prevention in nonvalvular AF', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'DVT/PE treatment and prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'VTE prophylaxis (hip/knee replacement)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'CAD/PAD secondary prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Vascular dose 2.5 mg BID' },
    ],
    dosing: {
      usualDose: { amount: '20 mg', frequency: 'Once daily with food', route: 'Oral' },
      adjustments: [
        { condition: 'AF with CrCl 15-50', adjustment: '15 mg daily', rationale: 'Reduced clearance' },
        { condition: 'DVT/PE treatment', adjustment: '15 mg BID x 21 days, then 20 mg daily', rationale: 'Lead-in period' },
        { condition: 'CAD/PAD (COMPASS regimen)', adjustment: '2.5 mg BID + aspirin', rationale: 'Vascular dose' },
      ],
      maxDose: '20 mg/day (AF/VTE); 5 mg/day (CAD/PAD)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: '15-20 mg doses MUST be taken with food',
        specialInstructions: ['Can crush and mix with applesauce', 'Can give via NG tube with enteral feeding'],
      },
    },
    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'severe', mechanism: 'Anticoagulant effect', management: 'Andexanet alfa for life-threatening; supportive care', reversible: true, onsetTiming: 'Any time' },
      { name: 'GI bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Topical + systemic effect', management: 'May be higher than warfarin; PPI if risk factors', reversible: true, onsetTiming: 'Variable' },
      { name: 'Anemia', frequency: 'common', severity: 'moderate', mechanism: 'Blood loss', management: 'Investigate source; transfuse if needed', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Strong CYP3A4/P-gp inhibitors', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased rivaroxaban levels', effect: 'Increased bleeding risk', management: 'Avoid ketoconazole, ritonavir' },
      { interactingDrug: 'Strong CYP3A4 inducers (rifampin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased rivaroxaban levels', effect: 'Reduced efficacy, thrombosis risk', management: 'Avoid combination' },
      { interactingDrug: 'Antiplatelet agents', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive bleeding', effect: 'Increased bleeding risk', management: 'Use only when indicated; lowest doses' },
    ],
    contraindications: [
      { condition: 'Active pathological bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'Mechanical heart valve', type: 'absolute', reason: 'Not studied; use warfarin' },
      { condition: 'Moderate-severe hepatic impairment', type: 'absolute', reason: 'Coagulopathy' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta', recommendation: 'Avoid - bleeding risk', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Higher bleeding risk', recommendation: 'Assess renal function; standard dosing if CrCl >50' },
      { population: 'renal-impairment', consideration: 'Partially renally cleared', recommendation: 'CrCl 15-50: reduce dose; <15: avoid' },
    ],
    monitoring: [
      { parameter: 'Renal function', frequency: 'Annually; more often if unstable', rationale: 'Dose adjustment needed', actionThreshold: 'Reduce dose if CrCl <50' },
      { parameter: 'Hemoglobin', frequency: 'Periodically', rationale: 'Detect bleeding', actionThreshold: 'Investigate if dropping' },
      { parameter: 'No routine coagulation monitoring needed', frequency: 'N/A', rationale: 'Major advantage over warfarin', actionThreshold: 'N/A' },
    ],
    patientEducation: [
      'Take 15 mg and 20 mg doses WITH FOOD',
      'Take at the same time each day',
      'Report any unusual bleeding',
      'Tell all doctors and dentists you take a blood thinner',
      'Do not stop without talking to your doctor',
      'Wear medical ID bracelet',
    ],
    clinicalPearls: [
      'Reversal agent: andexanet alfa (Andexxa)',
      'No routine monitoring needed - major advantage',
      'GI bleeding may be higher than warfarin',
      '15-20 mg doses MUST be taken with food (66-100% higher absorption)',
      'Not for mechanical heart valves',
      'COMPASS trial: 2.5 mg BID + aspirin for stable CAD/PAD',
    ],
  },

  // ============================================
  // Pain Management - Additional
  // ============================================

  {
    id: 'naproxen',
    genericName: 'Naproxen',
    brandNames: ['Aleve', 'Naprosyn', 'Anaprox'],
    drugClass: 'NSAID (Propionic Acid Derivative)',
    category: 'analgesic',
    overview: 'Naproxen is a non-selective COX inhibitor with anti-inflammatory, analgesic, and antipyretic properties. It has a longer half-life than ibuprofen allowing twice-daily dosing. May have lower cardiovascular risk than some other NSAIDs.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Cyclooxygenase-1 and -2 (COX-1, COX-2)',
      targetLocation: 'Throughout body (sites of inflammation)',
      simpleExplanation: 'Naproxen blocks enzymes that make prostaglandins, chemicals that cause pain, inflammation, and fever. By reducing prostaglandins, it relieves these symptoms.',
      detailedMechanism: 'Naproxen non-selectively inhibits COX-1 and COX-2, blocking conversion of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. This reduces inflammation, pain, and fever but also affects GI protection and platelet function.',
      mechanismSteps: [
        { order: 1, location: 'Cell membrane', action: 'Naproxen enters tissue', result: 'Reaches inflammatory site' },
        { order: 2, location: 'COX enzymes', action: 'Blocks COX-1 and COX-2', result: 'Prostaglandin synthesis inhibited' },
        { order: 3, location: 'Inflammatory site', action: 'Reduced prostaglandins', result: 'Less pain, swelling, fever', timeframe: '1-2 hours' },
      ],
      physiologicalEffects: [
        { system: 'Musculoskeletal', effect: 'Anti-inflammatory', mechanism: 'COX-2 inhibition', clinicalRelevance: 'Treats arthritis and pain', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Reduced mucosal protection', mechanism: 'COX-1 inhibition', clinicalRelevance: 'GI bleeding/ulcer risk', desiredOrAdverse: 'adverse' },
        { system: 'Renal', effect: 'Reduced renal blood flow', mechanism: 'Prostaglandin inhibition', clinicalRelevance: 'AKI risk especially with dehydration', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1 hour',
      durationOfEffect: '8-12 hours (allows BID dosing)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '95%',
        route: ['oral'],
        factors: ['Food delays but does not reduce absorption'],
        timeToePeak: '2-4 hours',
      },
      distribution: {
        volumeOfDistribution: '0.16 L/kg',
        proteinBinding: '>99%',
        tissueDistribution: ['Widely distributed', 'Concentrates in inflamed tissue'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C9 (minor)'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal',
        renalClearance: '95% as metabolites',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '12-17 hours',
      timeToSteadyState: '4-5 days',
    },
    indications: [
      { condition: 'Osteoarthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Rheumatoid arthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Dysmenorrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute gout', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '250-500 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Use lowest effective dose', rationale: 'Higher GI/CV risk' },
        { condition: 'Renal impairment', adjustment: 'Avoid if CrCl <30', rationale: 'Further renal impairment' },
      ],
      maxDose: '1500 mg/day (Rx); 660 mg/day (OTC)',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: 'With food or milk to reduce GI upset',
        specialInstructions: ['Take with full glass of water', 'Do not lie down for 15-30 min after'],
      },
    },
    adverseEffects: [
      { name: 'GI upset/dyspepsia', frequency: 'very-common', severity: 'mild', mechanism: 'COX-1 inhibition', management: 'Take with food; consider PPI', reversible: true, onsetTiming: 'Early' },
      { name: 'GI bleeding/ulceration', frequency: 'common', severity: 'severe', mechanism: 'Loss of mucosal protection', management: 'PPI prophylaxis if risk factors', reversible: true, onsetTiming: 'Any time' },
      { name: 'Cardiovascular events', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'COX-2 inhibition affects vascular homeostasis', management: 'Naproxen may have lower CV risk than other NSAIDs', reversible: false, onsetTiming: 'Risk increases with duration' },
      { name: 'Renal impairment', frequency: 'common', severity: 'moderate', mechanism: 'Reduced renal prostaglandins', management: 'Avoid in CKD; monitor creatinine', reversible: true, onsetTiming: 'Days to weeks' },
    ],
    interactions: [
      { interactingDrug: 'Anticoagulants (warfarin, DOACs)', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Antiplatelet effect + anticoagulation', effect: 'Greatly increased bleeding', management: 'Avoid; use acetaminophen' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Antagonizes antihypertensive effect', effect: 'Reduced BP control; AKI risk', management: 'Monitor BP and renal function' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced lithium clearance', effect: 'Lithium toxicity', management: 'Monitor lithium levels' },
    ],
    contraindications: [
      { condition: 'NSAID or aspirin allergy', type: 'absolute', reason: 'Cross-reactivity; bronchospasm' },
      { condition: 'Active GI bleeding/ulcer', type: 'absolute', reason: 'Will worsen' },
      { condition: 'CABG surgery (perioperative)', type: 'absolute', reason: 'Increased CV events (FDA)' },
      { condition: 'Third trimester pregnancy', type: 'absolute', reason: 'Premature ductus closure' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Avoid after 30 weeks', recommendation: 'Risk of premature DA closure', pregnancyCategory: 'C/D' },
      { population: 'geriatric', consideration: 'Highest GI/CV risk', recommendation: 'Avoid if possible; if needed, lowest dose + PPI' },
      { population: 'renal-impairment', consideration: 'Further impairment risk', recommendation: 'Avoid if CrCl <30' },
    ],
    monitoring: [
      { parameter: 'GI symptoms', frequency: 'Ongoing', rationale: 'Detect bleeding early', actionThreshold: 'Black stools - stop and evaluate' },
      { parameter: 'Blood pressure', frequency: 'Periodically', rationale: 'May increase BP', actionThreshold: 'Treat if elevated' },
      { parameter: 'Renal function', frequency: 'Baseline and periodic', rationale: 'AKI risk', actionThreshold: 'Stop if rising creatinine' },
    ],
    patientEducation: [
      'Take with food or milk to protect stomach',
      'Avoid alcohol - increases stomach bleeding risk',
      'Report black or bloody stools immediately',
      'Do not take other NSAIDs at the same time',
      'Tell your doctor if you have heart or kidney disease',
    ],
    clinicalPearls: [
      'May have lower CV risk than other NSAIDs (PRECISION trial)',
      'Long half-life allows twice-daily dosing',
      'Triple whammy: NSAID + ACE-I/ARB + diuretic = high AKI risk',
      'PPI co-therapy if >65, prior ulcer, anticoagulant, or steroid',
      'OTC Aleve = 220 mg naproxen sodium',
    ],
  },

  {
    id: 'cyclobenzaprine',
    genericName: 'Cyclobenzaprine',
    brandNames: ['Flexeril', 'Amrix'],
    drugClass: 'Skeletal Muscle Relaxant',
    category: 'musculoskeletal',
    overview: 'Cyclobenzaprine is a centrally acting muscle relaxant structurally related to tricyclic antidepressants. Used short-term for acute musculoskeletal conditions. Has significant anticholinergic effects and is on the Beers criteria for elderly.',
    mechanism: {
      type: 'other',
      target: 'Brainstem alpha and gamma motor neurons',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Cyclobenzaprine relaxes muscles by acting in the brain and spinal cord, not directly on muscles. It reduces the signals that cause muscle spasm.',
      detailedMechanism: 'Cyclobenzaprine acts centrally at the brainstem to reduce tonic somatic motor activity by influencing alpha and gamma motor neurons. Structurally similar to TCAs, it has anticholinergic, antihistaminic, and sedative properties.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed orally', result: 'Drug enters bloodstream' },
        { order: 2, location: 'Brainstem', action: 'Modulates motor neuron activity', result: 'Reduced muscle tone' },
        { order: 3, location: 'Spinal cord', action: 'Decreased motor activity', result: 'Muscle relaxation', timeframe: '1-4 hours' },
      ],
      physiologicalEffects: [
        { system: 'Musculoskeletal', effect: 'Muscle relaxation', mechanism: 'Central motor neuron modulation', clinicalRelevance: 'Relieves muscle spasm', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'Antihistaminic effects', clinicalRelevance: 'Can be therapeutic for sleep', desiredOrAdverse: 'both' },
        { system: 'Autonomic', effect: 'Anticholinergic effects', mechanism: 'Muscarinic blockade', clinicalRelevance: 'Dry mouth, urinary retention', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1 hour',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '33-55%',
        route: ['oral'],
        factors: ['Food does not significantly affect absorption'],
        timeToePeak: '4 hours',
      },
      distribution: {
        volumeOfDistribution: 'Large',
        proteinBinding: '93%',
        tissueDistribution: ['Widely distributed'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP1A2', 'CYP2D6'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: true },
      },
      halfLife: '18 hours (range 8-37)',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Acute musculoskeletal spasm', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true, notes: 'Short-term use only (2-3 weeks)' },
    ],
    dosing: {
      usualDose: { amount: '5-10 mg', frequency: 'Three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 5 mg once at bedtime; avoid if possible', rationale: 'Anticholinergic effects - Beers criteria' },
        { condition: 'Hepatic impairment', adjustment: 'Start 5 mg; avoid in severe', rationale: 'Reduced metabolism' },
      ],
      maxDose: '30 mg/day; max 2-3 weeks duration',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Often taken at bedtime due to sedation',
        specialInstructions: ['Short-term use only', 'Do not stop abruptly after regular use'],
      },
    },
    adverseEffects: [
      { name: 'Drowsiness', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Take at bedtime; avoid driving', reversible: true, onsetTiming: 'First dose' },
      { name: 'Dry mouth', frequency: 'very-common', severity: 'mild', mechanism: 'Anticholinergic', management: 'Sugarless gum; good oral hygiene', reversible: true, onsetTiming: 'First dose' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Rise slowly; falls precautions', reversible: true, onsetTiming: 'Early' },
      { name: 'Urinary retention', frequency: 'uncommon', severity: 'moderate', mechanism: 'Anticholinergic', management: 'Avoid in BPH; monitor', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'MAO inhibitors', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Hyperpyretic crisis', effect: 'Severe hypertension, hyperthermia', management: 'Contraindicated within 14 days' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive CNS depression', effect: 'Enhanced sedation', management: 'Avoid alcohol; use caution' },
      { interactingDrug: 'Anticholinergic drugs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Increased dry mouth, urinary retention', management: 'Avoid combinations in elderly' },
    ],
    contraindications: [
      { condition: 'MAO inhibitor use within 14 days', type: 'absolute', reason: 'Hyperpyretic crisis' },
      { condition: 'Acute MI or heart block', type: 'absolute', reason: 'TCA-like cardiac effects' },
      { condition: 'Hyperthyroidism', type: 'absolute', reason: 'Enhanced cardiac effects' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use only if clearly needed', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Beers criteria - avoid', recommendation: 'High anticholinergic burden; falls risk' },
    ],
    monitoring: [
      { parameter: 'Symptom relief', frequency: 'During therapy', rationale: 'Assess efficacy', actionThreshold: 'Limited to 2-3 weeks' },
      { parameter: 'Sedation level', frequency: 'Ongoing', rationale: 'May impair function', actionThreshold: 'Reduce dose if excessive' },
    ],
    patientEducation: [
      'This is for short-term use only (2-3 weeks maximum)',
      'Causes drowsiness - do not drive until you know how it affects you',
      'Do not drink alcohol',
      'May cause dry mouth',
      'Report difficulty urinating or fast heartbeat',
    ],
    clinicalPearls: [
      'Structurally related to TCAs - similar side effects',
      'Most effective with rest, PT, and NSAIDs',
      'Limited evidence for efficacy beyond 2-3 weeks',
      'Sedation can be therapeutic for sleep in acute back pain',
      'Beers criteria: strongly avoid in elderly',
      '5 mg TID may be as effective as 10 mg TID with fewer side effects',
    ],
  },

  // ============================================
  // Psychiatric - Additional
  // ============================================

  {
    id: 'duloxetine',
    genericName: 'Duloxetine',
    brandNames: ['Cymbalta', 'Irenka'],
    drugClass: 'Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)',
    category: 'psychiatric',
    overview: 'Duloxetine is an SNRI used for depression, anxiety, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain. Its dual reuptake inhibition provides both antidepressant and analgesic effects.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin and norepinephrine transporters',
      targetLocation: 'Presynaptic nerve terminals',
      simpleExplanation: 'Duloxetine increases serotonin and norepinephrine in the brain by preventing their reuptake. Higher levels of these chemicals improve mood and also help with pain signals.',
      detailedMechanism: 'Duloxetine potently inhibits presynaptic reuptake of both serotonin and norepinephrine, increasing their synaptic concentrations. The dual mechanism provides antidepressant effects and also modulates descending pain inhibitory pathways for analgesic benefit.',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic terminal', action: 'Blocks SERT and NET', result: 'Reduced reuptake' },
        { order: 2, location: 'Synapse', action: 'Increased 5-HT and NE', result: 'Enhanced neurotransmission' },
        { order: 3, location: 'Descending pathways', action: 'Modulated pain signals', result: 'Analgesic effect', timeframe: 'Days to weeks' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Increased serotonin/NE', clinicalRelevance: 'Treats depression and anxiety', desiredOrAdverse: 'desired' },
        { system: 'Pain pathways', effect: 'Analgesia', mechanism: 'Descending inhibitory modulation', clinicalRelevance: 'Treats neuropathic pain', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Nausea', mechanism: '5-HT3 stimulation', clinicalRelevance: 'Common initial side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Days (side effects), 2-4 weeks (antidepressant)',
      durationOfEffect: 'Requires daily dosing',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '~50% (after first-pass)',
        route: ['oral'],
        factors: ['Food delays absorption but does not affect total amount'],
        timeToePeak: '6 hours',
      },
      distribution: {
        volumeOfDistribution: '1640 L',
        proteinBinding: '>90%',
        tissueDistribution: ['Widely distributed'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP1A2 (major)', 'CYP2D6 (minor)'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (70% as metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '12 hours',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Diabetic peripheral neuropathy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Fibromyalgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic musculoskeletal pain', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '60 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Depression/anxiety', adjustment: 'Start 30 mg, increase to 60 mg after 1 week', rationale: 'Reduce initial nausea' },
        { condition: 'Diabetic neuropathy', adjustment: '60 mg daily', rationale: 'Target dose for pain' },
        { condition: 'Severe renal impairment', adjustment: 'Avoid if CrCl <30', rationale: 'Reduced clearance' },
      ],
      maxDose: '120 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'With or without food; same time daily',
        specialInstructions: ['Swallow whole - do not crush or chew', 'Taper to discontinue - do not stop abruptly'],
      },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'very-common', severity: 'mild', mechanism: '5-HT3 stimulation', management: 'Take with food; usually improves over time', reversible: true, onsetTiming: 'First 1-2 weeks' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Noradrenergic effect', management: 'Sugarless gum; good oral hygiene', reversible: true, onsetTiming: 'Early' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic-like effects', management: 'Fiber, fluids', reversible: true, onsetTiming: 'Early' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Rise slowly', reversible: true, onsetTiming: 'Early' },
      { name: 'Discontinuation syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Serotonergic withdrawal', management: 'Taper over at least 2 weeks', reversible: true, onsetTiming: 'With abrupt discontinuation' },
    ],
    interactions: [
      { interactingDrug: 'MAO inhibitors', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome', effect: 'Life-threatening hyperthermia, rigidity', management: 'Contraindicated within 14 days of MAOI' },
      { interactingDrug: 'Serotonergic drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive serotonin effects', effect: 'Serotonin syndrome risk', management: 'Use cautiously; monitor symptoms' },
      { interactingDrug: 'CYP1A2 inhibitors (fluvoxamine)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased duloxetine levels', effect: 'Enhanced toxicity', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'MAO inhibitor use within 14 days', type: 'absolute', reason: 'Serotonin syndrome risk' },
      { condition: 'Uncontrolled narrow-angle glaucoma', type: 'absolute', reason: 'May increase intraocular pressure' },
      { condition: 'Severe hepatic impairment', type: 'absolute', reason: 'Reduced metabolism' },
      { condition: 'Severe renal impairment (CrCl <30)', type: 'absolute', reason: 'Accumulation' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Third trimester: neonatal withdrawal', recommendation: 'Weigh risks vs untreated depression', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'May have more falls, hyponatremia', recommendation: 'Start low; monitor sodium' },
    ],
    monitoring: [
      { parameter: 'Depression/anxiety symptoms', frequency: 'Every 1-2 weeks initially', rationale: 'Assess response', actionThreshold: 'No improvement by 4-6 weeks - reassess' },
      { parameter: 'Blood pressure', frequency: 'Baseline and periodic', rationale: 'Can increase BP', actionThreshold: 'Treat if sustained elevation' },
      { parameter: 'Suicidality', frequency: 'Closely initially', rationale: 'FDA black box warning', actionThreshold: 'Immediate evaluation if worsening' },
    ],
    patientEducation: [
      'Takes 2-4 weeks to feel the full effect on mood',
      'Do not stop suddenly - taper to avoid withdrawal symptoms',
      'Report worsening depression or thoughts of self-harm immediately',
      'May cause nausea initially - this often improves',
      'Avoid alcohol',
    ],
    clinicalPearls: [
      'FDA black box warning for suicidality in young adults',
      'Good choice when depression + chronic pain coexist',
      'More norepinephrine activity than venlafaxine at low doses',
      'Discontinuation syndrome common - always taper',
      'Enteric coating - must swallow whole',
      'Avoid in severe renal or hepatic impairment',
    ],
  },

  {
    id: 'tamsulosin',
    genericName: 'Tamsulosin',
    brandNames: ['Flomax', 'Flomaxtra'],
    drugClass: 'Alpha-1 Adrenergic Blocker',
    category: 'urologic',
    overview: 'Tamsulosin is a selective alpha-1A adrenergic receptor antagonist used for benign prostatic hyperplasia (BPH). Its selectivity for the alpha-1A subtype in the prostate provides symptomatic relief with less hypotension than non-selective alpha blockers.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Alpha-1A adrenergic receptors',
      targetLocation: 'Prostate, bladder neck, urethra',
      simpleExplanation: 'Tamsulosin relaxes the muscles in the prostate and bladder neck by blocking specific nerve signals. This makes it easier to urinate by reducing the obstruction caused by an enlarged prostate.',
      detailedMechanism: 'Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation. This reduces urethral resistance and improves urine flow without significant effects on blood pressure.',
      mechanismSteps: [
        { order: 1, location: 'Prostate/bladder neck', action: 'Alpha-1A receptor blockade', result: 'Smooth muscle relaxation' },
        { order: 2, location: 'Urethra', action: 'Reduced urethral pressure', result: 'Decreased obstruction' },
        { order: 3, location: 'Bladder', action: 'Improved emptying', result: 'Better urine flow', timeframe: '1-2 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Urinary', effect: 'Improved urine flow', mechanism: 'Prostatic smooth muscle relaxation', clinicalRelevance: 'Relieves BPH symptoms', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Orthostatic hypotension', mechanism: 'Some alpha-1B vascular effect', clinicalRelevance: 'Less than non-selective blockers', desiredOrAdverse: 'adverse' },
        { system: 'Ocular', effect: 'Intraoperative floppy iris syndrome', mechanism: 'Alpha blockade in iris dilator', clinicalRelevance: 'Complicates cataract surgery', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Days; maximum effect 2-4 weeks',
      durationOfEffect: 'Requires daily dosing',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '~90% in fasting state',
        route: ['oral'],
        factors: ['Food decreases bioavailability 30%'],
        timeToePeak: '4-5 hours (fasting); 6-7 hours (fed)',
        foodEffect: 'Take 30 minutes after same meal daily',
      },
      distribution: {
        volumeOfDistribution: '16 L',
        proteinBinding: '94-99%',
        tissueDistribution: ['Concentrates in prostate'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP2D6'],
        activeMetabolites: [],
        drugInteractionRisk: 'moderate',
      },
      excretion: {
        primaryRoute: 'Renal (76% as metabolites)',
        adjustmentNeeded: { renal: true, hepatic: true },
      },
      halfLife: '9-13 hours',
      timeToSteadyState: '4-5 days',
    },
    indications: [
      { condition: 'Benign prostatic hyperplasia (BPH)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Ureteral stone passage', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true, notes: 'Medical expulsive therapy' },
    ],
    dosing: {
      usualDose: { amount: '0.4 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Inadequate response', adjustment: 'May increase to 0.8 mg daily', rationale: 'Higher dose for refractory cases' },
        { condition: 'Severe renal impairment (CrCl <10)', adjustment: 'Not studied; use with caution', rationale: 'Limited data' },
      ],
      maxDose: '0.8 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'with-food',
        timing: '30 minutes after the same meal each day',
        specialInstructions: ['Do not crush or chew capsule', 'First dose at bedtime to minimize dizziness'],
      },
    },
    adverseEffects: [
      { name: 'Dizziness/lightheadedness', frequency: 'common', severity: 'mild', mechanism: 'Mild orthostatic effect', management: 'First dose at bedtime; rise slowly', reversible: true, onsetTiming: 'First few doses' },
      { name: 'Abnormal ejaculation', frequency: 'common', severity: 'mild', mechanism: 'Alpha blockade affects vas deferens', management: 'Discuss with patient; reversible if stopped', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Intraoperative floppy iris syndrome (IFIS)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Alpha blockade in iris dilator muscle', management: 'Inform ophthalmologist before cataract surgery - even if stopped', reversible: false, onsetTiming: 'At surgery' },
      { name: 'Nasal congestion', frequency: 'common', severity: 'mild', mechanism: 'Vascular smooth muscle relaxation', management: 'Usually tolerable', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased tamsulosin levels', effect: 'Enhanced hypotension', management: 'Avoid strong inhibitors' },
      { interactingDrug: 'Other alpha blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive alpha blockade', effect: 'Severe hypotension', management: 'Do not combine' },
      { interactingDrug: 'PDE5 inhibitors (sildenafil)', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive vasodilation', effect: 'Hypotension', management: 'Caution; use lowest PDE5 dose' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to tamsulosin or sulfonamides', type: 'absolute', reason: 'Allergic reaction' },
      { condition: 'Concurrent use of other alpha blockers', type: 'absolute', reason: 'Additive hypotension' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Main population; fall risk', recommendation: 'Start at bedtime; assess orthostatic BP' },
    ],
    monitoring: [
      { parameter: 'BPH symptoms (AUA score)', frequency: 'Baseline and periodic', rationale: 'Assess efficacy', actionThreshold: 'No improvement - consider adding 5-ARI or surgery' },
      { parameter: 'Blood pressure', frequency: 'Baseline; periodic if symptomatic', rationale: 'Orthostatic hypotension', actionThreshold: 'Symptomatic hypotension' },
    ],
    patientEducation: [
      'Take 30 minutes after the same meal each day',
      'The first dose may cause dizziness - take at bedtime',
      'Rise slowly from sitting or lying positions',
      'Tell your eye doctor you take this medication before cataract surgery',
      'May cause abnormal ejaculation - this is reversible if you stop',
    ],
    clinicalPearls: [
      'More selective for prostate (alpha-1A) than vascular (alpha-1B) receptors',
      'IFIS risk persists even after stopping - always inform ophthalmologist',
      'Can combine with 5-alpha reductase inhibitor for larger prostates',
      'Medical expulsive therapy: helps pass ureteral stones <10mm',
      'Less orthostatic hypotension than older alpha blockers (doxazosin)',
    ],
  },

  {
    id: 'montelukast',
    genericName: 'Montelukast',
    brandNames: ['Singulair'],
    drugClass: 'Leukotriene Receptor Antagonist',
    category: 'respiratory',
    overview: 'Montelukast blocks cysteinyl leukotriene receptors, reducing bronchoconstriction and inflammation in asthma and allergic rhinitis. FDA black box warning for neuropsychiatric events limits its use to patients who cannot tolerate or fail other therapies.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Cysteinyl leukotriene receptor 1 (CysLT1)',
      targetLocation: 'Airways, nasal mucosa',
      simpleExplanation: 'Montelukast blocks leukotrienes, chemicals that cause airway tightening and inflammation in asthma and allergies. By blocking these chemicals, it helps keep airways open and reduces allergy symptoms.',
      detailedMechanism: 'Montelukast selectively antagonizes the CysLT1 receptor, blocking the actions of cysteinyl leukotrienes (LTC4, LTD4, LTE4) which are potent bronchoconstrictors and pro-inflammatory mediators released from mast cells and eosinophils.',
      mechanismSteps: [
        { order: 1, location: 'Airways', action: 'CysLT1 receptor blockade', result: 'Leukotriene effects blocked' },
        { order: 2, location: 'Bronchial smooth muscle', action: 'Reduced bronchoconstriction', result: 'Easier breathing' },
        { order: 3, location: 'Airway mucosa', action: 'Reduced inflammation', result: 'Less swelling and mucus', timeframe: 'Hours to days' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'CysLT1 blockade', clinicalRelevance: 'Prevents asthma symptoms', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced nasal symptoms', mechanism: 'CysLT1 blockade in nasal mucosa', clinicalRelevance: 'Treats allergic rhinitis', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Neuropsychiatric effects', mechanism: 'Unknown - CysLT receptors in brain', clinicalRelevance: 'FDA black box warning', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '2 hours',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '64% (tablet)',
        route: ['oral'],
        factors: ['Food does not affect tablet absorption'],
        timeToePeak: '3-4 hours',
      },
      distribution: {
        volumeOfDistribution: '8-11 L',
        proteinBinding: '>99%',
        tissueDistribution: ['Concentrates in airways'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP3A4', 'CYP2C8', 'CYP2C9'],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Biliary (86%)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '2.7-5.5 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Asthma prophylaxis (≥1 year)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Reserve for ICS failure/intolerance' },
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Exercise-induced bronchoconstriction', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '10 mg', frequency: 'Once daily in evening', route: 'Oral' },
      adjustments: [
        { condition: 'Pediatric 6-14 years', adjustment: '5 mg chewable daily', rationale: 'Age-appropriate dosing' },
        { condition: 'Pediatric 1-5 years', adjustment: '4 mg chewable or granules daily', rationale: 'Age-appropriate dosing' },
        { condition: 'Exercise-induced', adjustment: '10 mg 2 hours before exercise', rationale: 'Preventive use' },
      ],
      maxDose: '10 mg/day',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Evening for asthma; any time for allergic rhinitis',
        specialInstructions: ['Chewable tablets should be chewed', 'Granules can be mixed with soft food', 'Not for acute bronchospasm'],
      },
    },
    adverseEffects: [
      { name: 'Neuropsychiatric effects', frequency: 'uncommon', severity: 'severe', mechanism: 'CysLT receptors in brain', management: 'FDA black box - discontinue immediately if symptoms; monitor closely', reversible: true, onsetTiming: 'Any time during therapy' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually self-limiting', reversible: true, onsetTiming: 'Early' },
      { name: 'Abdominal pain', frequency: 'common', severity: 'mild', mechanism: 'GI effect', management: 'Take with food', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inducers (phenobarbital)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased metabolism', effect: 'Reduced efficacy', management: 'Monitor effectiveness' },
      { interactingDrug: 'Gemfibrozil', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C8 inhibition', effect: 'Increased montelukast levels', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'Acute asthma attack', type: 'relative', reason: 'Not a rescue medication' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Continue if needed for asthma control', pregnancyCategory: 'B' },
      { population: 'pediatric', consideration: 'Neuropsychiatric risk', recommendation: 'Monitor behavior closely; different formulations by age' },
    ],
    monitoring: [
      { parameter: 'Asthma control', frequency: 'Ongoing', rationale: 'Assess efficacy', actionThreshold: 'ICS preferred if inadequate control' },
      { parameter: 'Neuropsychiatric symptoms', frequency: 'Each visit; caregiver reports', rationale: 'FDA black box warning', actionThreshold: 'Discontinue if any mood/behavioral changes' },
    ],
    patientEducation: [
      'This is NOT a rescue inhaler - do not use for sudden breathing problems',
      'Take every day even when feeling well',
      'Report any changes in mood, behavior, or sleep immediately',
      'Continue your other asthma medications unless told to stop',
      'For children: watch for behavioral changes and report immediately',
    ],
    clinicalPearls: [
      'FDA black box warning (2020) for neuropsychiatric events - reserve for ICS failure/intolerance',
      'Less effective than inhaled corticosteroids as monotherapy',
      'Good for aspirin-exacerbated respiratory disease',
      'Exercise-induced bronchospasm: take 2 hours before exercise',
      'Churg-Strauss reports may be unmasking when steroids reduced',
    ],
  },

  {
    id: 'gabapentin',
    genericName: 'Gabapentin',
    brandNames: ['Neurontin', 'Gralise', 'Horizant'],
    drugClass: 'Anticonvulsant (Gabapentinoid)',
    category: 'neurological',
    overview: 'Gabapentin is an anticonvulsant used for seizures, neuropathic pain, and postherpetic neuralgia. Though structurally related to GABA, it does not act on GABA receptors but binds alpha-2-delta calcium channel subunits. Has potential for misuse.',
    mechanism: {
      type: 'ion-channel-blocker',
      target: 'Alpha-2-delta subunit of voltage-gated calcium channels',
      targetLocation: 'CNS neurons',
      simpleExplanation: 'Gabapentin calms overactive nerve signals by binding to calcium channels in the brain and nerves. This reduces seizures and nerve pain without directly affecting the main brain chemicals.',
      detailedMechanism: 'Gabapentin binds the alpha-2-delta subunit of presynaptic voltage-gated calcium channels, reducing calcium influx and subsequent release of excitatory neurotransmitters. This dampens neuronal excitability without direct effects on GABA or glutamate receptors.',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic terminal', action: 'Binds alpha-2-delta subunit', result: 'Calcium channel modulation' },
        { order: 2, location: 'Presynaptic terminal', action: 'Reduced calcium influx', result: 'Less neurotransmitter release' },
        { order: 3, location: 'Synapse', action: 'Decreased excitatory transmission', result: 'Reduced seizures/pain', timeframe: 'Days to weeks' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Anticonvulsant', mechanism: 'Reduced neuronal excitability', clinicalRelevance: 'Adjunct for partial seizures', desiredOrAdverse: 'desired' },
        { system: 'Peripheral nerves', effect: 'Analgesia', mechanism: 'Modulation of pain signaling', clinicalRelevance: 'Treats neuropathic pain', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'CNS depression', clinicalRelevance: 'Dose-limiting side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Days to weeks for full effect',
      durationOfEffect: 'Requires multiple daily doses',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '27-60% (dose-dependent - decreases at higher doses)',
        route: ['oral'],
        factors: ['Saturable absorption - bioavailability decreases at higher doses'],
        timeToePeak: '2-3 hours',
      },
      distribution: {
        volumeOfDistribution: '58 L',
        proteinBinding: '<3%',
        tissueDistribution: ['CNS'],
        crossesBBB: true,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Not metabolized',
        enzymes: [],
        activeMetabolites: [],
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (unchanged)',
        renalClearance: 'Proportional to CrCl',
        adjustmentNeeded: { renal: true, hepatic: false },
      },
      halfLife: '5-7 hours',
      timeToSteadyState: '1-2 days',
    },
    indications: [
      { condition: 'Postherpetic neuralgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Partial seizures (adjunct)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Diabetic neuropathy', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Restless legs syndrome', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '300-600 mg', frequency: 'Three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Start low', adjustment: 'Day 1: 300 mg; Day 2: 300 mg BID; Day 3: 300 mg TID', rationale: 'Minimize sedation' },
        { condition: 'Renal impairment', adjustment: 'CrCl 30-60: 200-700 mg BID; CrCl 15-30: 200-700 mg daily; CrCl <15: reduce proportionally', rationale: 'Renally cleared' },
      ],
      maxDose: '3600 mg/day (in divided doses)',
      administration: {
        route: 'Oral',
        withFood: 'either',
        timing: 'Three times daily with maximum interval of 12 hours',
        specialInstructions: ['Taper to discontinue - do not stop abruptly', 'Divide doses to maximize absorption'],
      },
    },
    adverseEffects: [
      { name: 'Somnolence', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Take at bedtime initially; tolerance may develop', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Dizziness', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS effect', management: 'Rise slowly; falls precautions', reversible: true, onsetTiming: 'First few weeks' },
      { name: 'Peripheral edema', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'May need diuretics; rule out other causes', reversible: true, onsetTiming: 'Variable' },
      { name: 'Weight gain', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Monitor; diet/exercise', reversible: true, onsetTiming: 'Months' },
    ],
    interactions: [
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive CNS depression', effect: 'Enhanced sedation', management: 'Use caution; reduce doses' },
      { interactingDrug: 'Antacids', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Reduced gabapentin absorption', effect: 'Lower levels', management: 'Separate by 2 hours' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to gabapentin', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Weigh benefits vs risks for seizure control', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Higher fall risk; more sedation', recommendation: 'Start low, go slow; adjust for renal function' },
      { population: 'renal-impairment', consideration: 'Renally cleared', recommendation: 'Reduce dose based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Pain or seizure control', frequency: 'Ongoing', rationale: 'Assess efficacy', actionThreshold: 'Titrate to effect' },
      { parameter: 'Sedation', frequency: 'Initial weeks', rationale: 'May affect function', actionThreshold: 'Slow titration if problematic' },
      { parameter: 'Renal function', frequency: 'Baseline and periodic', rationale: 'Affects dosing', actionThreshold: 'Adjust dose for CrCl' },
    ],
    patientEducation: [
      'Start at a low dose and increase slowly',
      'May cause drowsiness - avoid driving until you know how it affects you',
      'Do not stop suddenly - taper slowly to avoid seizures',
      'Take doses no more than 12 hours apart',
      'May cause weight gain',
    ],
    clinicalPearls: [
      'Bioavailability decreases at higher doses - must use TID dosing',
      'Not metabolized - no CYP interactions; renally cleared',
      'Potential for misuse - some states require PDMP check',
      'Pregabalin has linear absorption and can be dosed BID',
      'Gabapentin enacarbil (Horizant) has improved absorption',
      'Titrate slowly to minimize sedation',
    ],
  },

  {
    id: 'pantoprazole',
    genericName: 'Pantoprazole',
    brandNames: ['Protonix', 'Protonix IV'],
    drugClass: 'Proton Pump Inhibitor',
    category: 'gastrointestinal',
    overview: 'Pantoprazole irreversibly inhibits the gastric H+/K+-ATPase proton pump, reducing gastric acid secretion. It is preferred over omeprazole when patients are on clopidogrel due to fewer CYP2C19 interactions.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Gastric H+/K+-ATPase (proton pump)',
      targetLocation: 'Parietal cell canaliculus',
      simpleExplanation: 'Pantoprazole turns off the acid pumps in your stomach. It irreversibly blocks the enzyme that produces stomach acid, providing long-lasting acid reduction.',
      detailedMechanism: 'Pantoprazole is a prodrug that accumulates in the acidic parietal cell canaliculus, where it is converted to an active sulfenamide. This active form irreversibly binds and inhibits the H+/K+-ATPase proton pump, blocking the final step of acid secretion.',
      mechanismSteps: [
        { order: 1, location: 'Parietal cell', action: 'Pantoprazole absorbed into canaliculus', result: 'Accumulates in acidic environment' },
        { order: 2, location: 'Canaliculus', action: 'Converted to active sulfenamide', result: 'Active drug formed' },
        { order: 3, location: 'Proton pump', action: 'Irreversible covalent binding', result: 'Pump inactivated', timeframe: '1 hour' },
        { order: 4, location: 'Stomach', action: 'Acid secretion blocked', result: 'Increased gastric pH', timeframe: '24+ hours' },
      ],
      physiologicalEffects: [
        { system: 'GI', effect: 'Reduced gastric acid', mechanism: 'Proton pump inhibition', clinicalRelevance: 'Treats GERD, ulcers', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Increased gastric pH', mechanism: 'Acid suppression', clinicalRelevance: 'May affect drug absorption', desiredOrAdverse: 'both' },
        { system: 'Bone', effect: 'Fracture risk', mechanism: 'Reduced calcium absorption', clinicalRelevance: 'Long-term concern', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 hours (effect lasts 24+ hours due to irreversible inhibition)',
      durationOfEffect: '24 hours (new pump synthesis required for recovery)',
    },
    pharmacokinetics: {
      absorption: {
        bioavailability: '77%',
        route: ['oral', 'intravenous'],
        factors: ['Food may delay but does not reduce absorption'],
        timeToePeak: '2-2.5 hours',
      },
      distribution: {
        volumeOfDistribution: '11-24 L',
        proteinBinding: '98%',
        tissueDistribution: ['Concentrates in parietal cells'],
        crossesBBB: false,
        crossesPlacenta: true,
      },
      metabolism: {
        primarySite: 'Liver',
        enzymes: ['CYP2C19 (minimal)', 'CYP3A4'],
        activeMetabolites: [],
        geneticVariability: 'Less affected by CYP2C19 status than omeprazole',
        drugInteractionRisk: 'low',
      },
      excretion: {
        primaryRoute: 'Renal (71% as metabolites)',
        adjustmentNeeded: { renal: false, hepatic: false },
      },
      halfLife: '1 hour (but effect lasts 24+ hours)',
      timeToSteadyState: '5-7 days for maximal acid suppression',
    },
    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Erosive esophagitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Zollinger-Ellison syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'GI bleeding prophylaxis (stress ulcer)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '40 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'GERD', adjustment: '40 mg daily x 8 weeks', rationale: 'Standard course' },
        { condition: 'Zollinger-Ellison', adjustment: '40 mg BID, may increase', rationale: 'Higher acid output' },
        { condition: 'IV for GI bleed', adjustment: '80 mg bolus, then 8 mg/hr infusion', rationale: 'Rapid acid control' },
      ],
      maxDose: '240 mg/day (Zollinger-Ellison)',
      administration: {
        route: 'Oral',
        withFood: 'without-food',
        timing: '30-60 minutes before breakfast',
        specialInstructions: ['Do not crush or chew tablets', 'IV: can give as push or infusion'],
      },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually mild', reversible: true, onsetTiming: 'During therapy' },
      { name: 'C. difficile infection', frequency: 'uncommon', severity: 'severe', mechanism: 'Altered gastric pH', management: 'Consider discontinuing if C. diff develops', reversible: true, onsetTiming: 'During or after therapy' },
      { name: 'Hypomagnesemia', frequency: 'rare', severity: 'moderate', mechanism: 'Reduced intestinal absorption', management: 'Monitor Mg with long-term use', reversible: true, onsetTiming: 'After months-years' },
    ],
    interactions: [
      { interactingDrug: 'Clopidogrel', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Minimal CYP2C19 inhibition', effect: 'Less interaction than omeprazole', management: 'Pantoprazole preferred PPI with clopidogrel' },
      { interactingDrug: 'Drugs requiring acid for absorption', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased gastric pH', effect: 'Reduced absorption (ketoconazole, iron)', management: 'Separate dosing' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity to PPIs', type: 'absolute', reason: 'Cross-reactivity possible' },
      { condition: 'Concurrent rilpivirine', type: 'absolute', reason: 'Reduced rilpivirine levels' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use if clearly needed', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Higher fracture, B12, Mg risk', recommendation: 'Use lowest dose, shortest duration' },
      { population: 'hepatic-impairment', consideration: 'Reduced clearance', recommendation: 'No adjustment typically needed; max 40 mg/day in severe' },
    ],
    monitoring: [
      { parameter: 'Symptom improvement', frequency: 'Every 4-8 weeks', rationale: 'Assess response', actionThreshold: 'No improvement - consider alternative diagnosis' },
      { parameter: 'Magnesium', frequency: 'Periodically with long-term use', rationale: 'Hypomagnesemia risk', actionThreshold: 'Mg <1.5 mg/dL' },
    ],
    patientEducation: [
      'Take 30-60 minutes before breakfast',
      'Swallow tablet whole - do not crush or chew',
      'Works best when taken regularly, not just when you have symptoms',
      'Talk to your doctor about how long you need to take this',
      'Long-term use has some risks - use lowest effective dose',
    ],
    clinicalPearls: [
      'Preferred PPI with clopidogrel - minimal CYP2C19 interaction',
      'Less affected by CYP2C19 genetic polymorphisms than omeprazole',
      'Same PPI class effects: C. diff, fractures, B12/Mg deficiency',
      'IV pantoprazole for GI bleeding: 80 mg bolus then 8 mg/hr infusion',
      'Consider PPI deprescribing after 8+ weeks without clear indication',
    ],
  },

  // ============================================
  // NEW DRUGS - Batch 1
  // ============================================

  {
    id: 'cephalexin',
    genericName: 'Cephalexin',
    brandNames: ['Keflex'],
    drugClass: 'First-Generation Cephalosporin',
    category: 'antimicrobial',
    overview: 'Cephalexin is a first-generation cephalosporin antibiotic with excellent coverage against gram-positive bacteria, particularly Staphylococcus and Streptococcus. It is commonly used for skin/soft tissue infections, pharyngitis, and urinary tract infections.',
    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'Penicillin-binding proteins (PBPs)',
      targetLocation: 'Bacterial cell wall',
      simpleExplanation: 'Cephalexin weakens the bacterial cell wall by blocking the proteins that build it, causing the bacteria to burst open and die.',
      detailedMechanism: 'Cephalexin binds to penicillin-binding proteins (PBPs) in the bacterial cell wall, inhibiting transpeptidation and cross-linking of peptidoglycan. This weakens the cell wall, leading to osmotic lysis and cell death.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial periplasm', action: 'Drug enters through porins', result: 'Access to PBPs' },
        { order: 2, location: 'Cell wall', action: 'Binds to PBPs', result: 'Inhibits transpeptidation' },
        { order: 3, location: 'Cell wall', action: 'Peptidoglycan cross-linking blocked', result: 'Weakened cell wall' },
        { order: 4, location: 'Bacterium', action: 'Osmotic pressure imbalance', result: 'Cell lysis and death', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Microbial', effect: 'Bactericidal', mechanism: 'Cell wall disruption', clinicalRelevance: 'Kills susceptible bacteria', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Diarrhea', mechanism: 'Disruption of gut flora', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Peak levels in 1 hour',
      durationOfEffect: '6-8 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '95%', route: ['oral'], factors: ['Food delays but does not reduce absorption'], timeToePeak: '1 hour' },
      distribution: { volumeOfDistribution: '0.26 L/kg', proteinBinding: '10-15%', tissueDistribution: ['Widely distributed', 'Poor CNS penetration'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Minimal', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (80-90% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '0.9-1.2 hours',
      timeToSteadyState: '1 day',
    },
    indications: [
      { condition: 'Skin and soft tissue infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Streptococcal pharyngitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Alternative to penicillin' },
      { condition: 'Urinary tract infections', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '500 mg', frequency: 'Every 6-12 hours', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 10-50', adjustment: '500 mg q8-12h', rationale: 'Reduced renal clearance' },
        { condition: 'CrCl <10', adjustment: '250 mg q12h', rationale: 'Severe renal impairment' },
      ],
      maxDose: '4 g/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Complete full course'] },
    },
    adverseEffects: [
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually self-limiting', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Allergic reaction', frequency: 'uncommon', severity: 'moderate', mechanism: 'Hypersensitivity', management: 'Discontinue if rash/hives', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Probenecid', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Decreased renal tubular secretion', effect: 'Increased cephalexin levels', management: 'Monitor' },
    ],
    contraindications: [
      { condition: 'Cephalosporin allergy', type: 'absolute', reason: 'Cross-reactivity' },
      { condition: 'Severe penicillin allergy', type: 'relative', reason: '5-10% cross-reactivity', alternative: 'Clindamycin or macrolide' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Generally safe', recommendation: 'Can use', pregnancyCategory: 'B' },
      { population: 'renal-impairment', consideration: 'Accumulation', recommendation: 'Dose adjust based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: '48-72 hours', rationale: 'Assess improvement' },
    ],
    patientEducation: ['Complete full course even if feeling better', 'Report rash or difficulty breathing immediately', 'Can take with or without food'],
    clinicalPearls: ['First-gen cephalosporins: excellent gram-positive, limited gram-negative', '~5-10% cross-reactivity with penicillin allergy', 'No MRSA coverage', 'Pregnancy-safe antibiotic'],
  },

  {
    id: 'doxycycline',
    genericName: 'Doxycycline',
    brandNames: ['Vibramycin', 'Doryx', 'Monodox'],
    drugClass: 'Tetracycline',
    category: 'antimicrobial',
    overview: 'Doxycycline is a broad-spectrum tetracycline antibiotic effective against many gram-positive, gram-negative, and atypical bacteria. It is the tetracycline of choice due to better absorption and less renal excretion.',
    mechanism: {
      type: 'protein-synthesis-inhibitor',
      target: '30S ribosomal subunit',
      targetLocation: 'Bacterial ribosome',
      simpleExplanation: 'Doxycycline stops bacteria from making proteins they need to survive by blocking their protein-making machinery.',
      detailedMechanism: 'Doxycycline enters bacteria and binds reversibly to the 30S ribosomal subunit, blocking attachment of aminoacyl-tRNA to the mRNA-ribosome complex. This inhibits protein synthesis, resulting in bacteriostatic activity.',
      mechanismSteps: [
        { order: 1, location: 'Cell membrane', action: 'Active transport into bacteria', result: 'Intracellular accumulation' },
        { order: 2, location: '30S ribosome', action: 'Binds to A-site', result: 'Blocks aminoacyl-tRNA attachment' },
        { order: 3, location: 'Ribosome', action: 'Protein synthesis halted', result: 'Bacteriostatic effect' },
      ],
      physiologicalEffects: [
        { system: 'Microbial', effect: 'Bacteriostatic', mechanism: 'Protein synthesis inhibition', clinicalRelevance: 'Stops bacterial growth', desiredOrAdverse: 'desired' },
        { system: 'Skin', effect: 'Photosensitivity', mechanism: 'Drug accumulation in skin', clinicalRelevance: 'Increased sunburn risk', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Hours',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '93%', route: ['oral', 'intravenous'], factors: ['Avoid dairy and antacids'], timeToePeak: '2-3 hours' },
      distribution: { volumeOfDistribution: '0.7 L/kg', proteinBinding: '93%', tissueDistribution: ['Wide distribution', 'Concentrates in teeth/bones'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Partial hepatic', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Fecal (primarily), some renal', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '18-22 hours',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Covers atypicals' },
      { condition: 'Chlamydia/gonorrhea', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acne vulgaris', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Lyme disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Malaria prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '100 mg', frequency: 'Every 12 hours', route: 'Oral' },
      adjustments: [],
      maxDose: '200 mg/day for most indications',
      administration: { route: 'Oral', withFood: 'either', timing: 'Take with plenty of water', specialInstructions: ['Avoid lying down for 30 min after dose', 'Avoid dairy/antacids within 2 hours'] },
    },
    adverseEffects: [
      { name: 'Photosensitivity', frequency: 'common', severity: 'mild', mechanism: 'Drug accumulation in skin', management: 'Sun protection', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Esophageal irritation', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Take with water, stay upright', reversible: true, onsetTiming: 'After dosing' },
      { name: 'Tooth discoloration', frequency: 'common', severity: 'moderate', mechanism: 'Binds to developing teeth', management: 'Avoid in children <8 years', reversible: false, onsetTiming: 'With use in children' },
    ],
    interactions: [
      { interactingDrug: 'Antacids/calcium/iron', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Chelation', effect: 'Reduced doxycycline absorption', management: 'Separate by 2-4 hours' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced vitamin K flora', effect: 'Increased INR', management: 'Monitor INR' },
    ],
    contraindications: [
      { condition: 'Pregnancy (2nd-3rd trimester)', type: 'absolute', reason: 'Tooth discoloration, bone effects' },
      { condition: 'Children <8 years', type: 'relative', reason: 'Permanent tooth discoloration', alternative: 'Amoxicillin' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Avoid after 1st trimester', recommendation: 'Use alternatives', pregnancyCategory: 'D' },
      { population: 'renal-impairment', consideration: 'No adjustment needed', recommendation: 'Preferred tetracycline in renal failure' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: '48-72 hours', rationale: 'Assess improvement' },
    ],
    patientEducation: ['Avoid sun exposure - use sunscreen', 'Take with full glass of water', 'Do not lie down for 30 minutes after taking', 'Avoid antacids, dairy, and iron supplements close to dosing'],
    clinicalPearls: ['Does NOT require renal adjustment - can use in kidney disease', 'Excellent atypical coverage (Mycoplasma, Chlamydia)', 'Photosensitivity common - warn patients', 'Avoid in pregnancy and children <8'],
  },

  {
    id: 'metronidazole',
    genericName: 'Metronidazole',
    brandNames: ['Flagyl', 'Metrogel'],
    drugClass: 'Nitroimidazole',
    category: 'antimicrobial',
    overview: 'Metronidazole is an antibiotic and antiprotozoal agent with excellent activity against anaerobic bacteria and certain parasites. It is first-line for C. difficile, bacterial vaginosis, and parasitic infections like giardiasis.',
    mechanism: {
      type: 'dna-modifier',
      target: 'DNA',
      targetLocation: 'Bacterial/protozoal nucleus',
      simpleExplanation: 'Metronidazole is converted inside anaerobic bacteria into a toxic form that damages their DNA, killing the organism.',
      detailedMechanism: 'Inside anaerobic cells, metronidazole is reduced by ferredoxin to form reactive intermediates that cause DNA strand breakage, inhibiting DNA synthesis and resulting in cell death.',
      mechanismSteps: [
        { order: 1, location: 'Anaerobic cell', action: 'Drug enters via diffusion', result: 'Intracellular accumulation' },
        { order: 2, location: 'Cytoplasm', action: 'Nitro group reduced by ferredoxin', result: 'Cytotoxic intermediates formed' },
        { order: 3, location: 'Nucleus', action: 'Reactive species damage DNA', result: 'DNA strand breaks' },
        { order: 4, location: 'Cell', action: 'DNA synthesis stops', result: 'Cell death', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Microbial', effect: 'Bactericidal/antiprotozoal', mechanism: 'DNA damage', clinicalRelevance: 'Kills anaerobes and protozoa', desiredOrAdverse: 'desired' },
        { system: 'GI', effect: 'Metallic taste', mechanism: 'Drug accumulation in saliva', clinicalRelevance: 'Common side effect', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: 'Hours',
      durationOfEffect: '8 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '95-100%', route: ['oral', 'intravenous', 'topical'], factors: ['Food slightly delays absorption'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '0.55 L/kg', proteinBinding: '<20%', tissueDistribution: ['Wide distribution', 'Excellent CNS penetration'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2A6'], activeMetabolites: ['Hydroxy metabolite (some activity)'], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (60-80%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '8 hours',
      timeToSteadyState: '2 days',
    },
    indications: [
      { condition: 'C. difficile infection', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'First episode, non-severe' },
      { condition: 'Bacterial vaginosis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Anaerobic infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Giardiasis/amebiasis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'H. pylori (triple therapy)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '500 mg', frequency: 'Every 8 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Severe hepatic impairment', adjustment: 'Reduce dose by 50%', rationale: 'Reduced metabolism' },
      ],
      maxDose: '4 g/day',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Avoid alcohol during and 48 hours after'] },
    },
    adverseEffects: [
      { name: 'Metallic taste', frequency: 'common', severity: 'mild', mechanism: 'Drug in saliva', management: 'Temporary', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Disulfiram-like reaction', frequency: 'uncommon', severity: 'moderate', mechanism: 'Acetaldehyde accumulation with alcohol', management: 'Avoid all alcohol', reversible: true, onsetTiming: 'With alcohol' },
      { name: 'Peripheral neuropathy', frequency: 'rare', severity: 'moderate', mechanism: 'Neurotoxicity with prolonged use', management: 'Discontinue; usually reversible', reversible: true, onsetTiming: 'With prolonged use' },
    ],
    interactions: [
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Disulfiram-like reaction', effect: 'Nausea, vomiting, flushing', management: 'Avoid alcohol during and 48h after' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP inhibition', effect: 'Increased INR/bleeding risk', management: 'Monitor INR closely' },
    ],
    contraindications: [
      { condition: 'First trimester pregnancy', type: 'relative', reason: 'Potential teratogenicity (controversial)' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Avoid first trimester if possible', recommendation: 'Use after first trimester if needed', pregnancyCategory: 'B' },
      { population: 'hepatic-impairment', consideration: 'Reduced metabolism', recommendation: 'Reduce dose in severe impairment' },
    ],
    monitoring: [
      { parameter: 'Clinical response', frequency: '48-72 hours', rationale: 'Assess improvement' },
      { parameter: 'Neurological symptoms', frequency: 'With prolonged use', rationale: 'Peripheral neuropathy risk' },
    ],
    patientEducation: ['Do NOT drink alcohol during treatment or for 48 hours after', 'May cause metallic taste', 'Take with food to reduce stomach upset', 'Report numbness/tingling'],
    clinicalPearls: ['Excellent anaerobic coverage - "below the diaphragm"', 'Disulfiram reaction with alcohol - absolute avoidance', 'Crosses BBB - can treat CNS infections', 'First-line for C. diff (non-severe)'],
  },

  {
    id: 'venlafaxine',
    genericName: 'Venlafaxine',
    brandNames: ['Effexor', 'Effexor XR'],
    drugClass: 'Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)',
    category: 'psychiatric',
    overview: 'Venlafaxine is an SNRI antidepressant that inhibits reuptake of both serotonin and norepinephrine. It is used for major depression, generalized anxiety disorder, panic disorder, and social anxiety. Higher doses provide more norepinephrine effect.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Serotonin and norepinephrine transporters (SERT/NET)',
      targetLocation: 'Presynaptic nerve terminals',
      simpleExplanation: 'Venlafaxine increases the levels of two mood chemicals (serotonin and norepinephrine) in your brain by preventing their removal from the space between nerve cells.',
      detailedMechanism: 'Venlafaxine inhibits presynaptic reuptake of serotonin at low-moderate doses and norepinephrine at higher doses. This increases synaptic concentrations of these neurotransmitters, enhancing their signaling.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed orally', result: 'Enters bloodstream', timeframe: '2-4 hours' },
        { order: 2, location: 'Presynaptic terminals', action: 'Binds to SERT (all doses) and NET (higher doses)', result: 'Reuptake blocked' },
        { order: 3, location: 'Synapse', action: 'Serotonin/NE accumulate', result: 'Enhanced neurotransmission' },
        { order: 4, location: 'Brain', action: 'Receptor downregulation over time', result: 'Antidepressant effect', timeframe: '2-4 weeks' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Increased serotonin/NE signaling', clinicalRelevance: 'Mood improvement', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Increased blood pressure', mechanism: 'Norepinephrine effect', clinicalRelevance: 'Monitor BP especially at higher doses', desiredOrAdverse: 'adverse' },
        { system: 'GI', effect: 'Nausea', mechanism: 'Serotonin effect', clinicalRelevance: 'Common initially', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '2-4 weeks for antidepressant effect',
      durationOfEffect: '24 hours with XR formulation',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '45%', route: ['oral'], factors: ['Food does not significantly affect'], timeToePeak: '2-3 hours (IR), 5-9 hours (XR)' },
      distribution: { volumeOfDistribution: '7.5 L/kg', proteinBinding: '27%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6 (primarily)', 'CYP3A4'], activeMetabolites: ['O-desmethylvenlafaxine (desvenlafaxine)'], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (87%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '5 hours (parent), 11 hours (active metabolite)',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Social anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Panic disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Neuropathic pain', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '75-225 mg', frequency: 'Once daily (XR)', route: 'Oral' },
      adjustments: [
        { condition: 'Start', adjustment: '37.5-75 mg daily', rationale: 'Titrate to minimize side effects' },
        { condition: 'CrCl <30', adjustment: 'Reduce dose by 50%', rationale: 'Reduced renal clearance' },
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose by 50%', rationale: 'Reduced metabolism' },
      ],
      maxDose: '375 mg/day (225 mg for XR)',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Do not crush or chew XR capsules', 'Taper gradually when discontinuing'] },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'very-common', severity: 'mild', mechanism: 'Serotonin effect', management: 'Take with food; often improves', reversible: true, onsetTiming: 'Early' },
      { name: 'Hypertension', frequency: 'common', severity: 'moderate', mechanism: 'Norepinephrine effect', management: 'Monitor BP; dose-dependent', reversible: true, onsetTiming: 'Dose-dependent' },
      { name: 'Sexual dysfunction', frequency: 'common', severity: 'moderate', mechanism: 'Serotonergic', management: 'Dose adjustment or switch', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Discontinuation syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Short half-life', management: 'Must taper gradually', reversible: true, onsetTiming: 'Upon stopping' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome', effect: 'Life-threatening', management: '14-day washout required' },
      { interactingDrug: 'Other serotonergic drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive serotonin', effect: 'Serotonin syndrome risk', management: 'Monitor or avoid' },
    ],
    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Serotonin syndrome' },
      { condition: 'Uncontrolled hypertension', type: 'relative', reason: 'Can worsen BP' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Risk of neonatal withdrawal', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Start lower, titrate slowly', recommendation: 'Monitor BP and fall risk' },
    ],
    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Baseline and periodically', rationale: 'Dose-dependent hypertension' },
      { parameter: 'Depression/suicidality', frequency: 'Closely initially', rationale: 'Black box warning' },
    ],
    patientEducation: ['Do not stop suddenly - taper gradually', 'May take 2-4 weeks to feel better', 'Report suicidal thoughts immediately', 'Take with food to reduce nausea'],
    clinicalPearls: ['Higher doses = more NE effect, also more BP elevation', 'Short half-life means significant discontinuation syndrome', 'CYP2D6 poor metabolizers may have higher levels', 'Active metabolite is desvenlafaxine (Pristiq)'],
  },

  {
    id: 'mirtazapine',
    genericName: 'Mirtazapine',
    brandNames: ['Remeron', 'Remeron SolTab'],
    drugClass: 'Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)',
    category: 'psychiatric',
    overview: 'Mirtazapine is a unique antidepressant that works by blocking alpha-2 adrenergic autoreceptors (increasing NE/5-HT release) and selectively blocking 5-HT2 and 5-HT3 receptors. It is notable for causing sedation and appetite stimulation.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Alpha-2 adrenergic, 5-HT2, 5-HT3, H1 receptors',
      targetLocation: 'CNS presynaptic and postsynaptic neurons',
      simpleExplanation: 'Mirtazapine increases the release of mood chemicals (serotonin and norepinephrine) in the brain while blocking receptors that cause certain side effects like nausea and sexual dysfunction.',
      detailedMechanism: 'Mirtazapine blocks presynaptic alpha-2 autoreceptors, increasing NE and serotonin release. It also blocks 5-HT2A/2C and 5-HT3 receptors (avoiding sexual dysfunction and nausea), and strongly blocks H1 histamine receptors (causing sedation/appetite).',
      mechanismSteps: [
        { order: 1, location: 'Presynaptic neurons', action: 'Blocks alpha-2 autoreceptors', result: 'Increased NE and 5-HT release' },
        { order: 2, location: 'Postsynaptic neurons', action: 'Blocks 5-HT2 and 5-HT3', result: 'Avoids sexual dysfunction and nausea' },
        { order: 3, location: 'CNS', action: 'Strong H1 blockade', result: 'Sedation and appetite stimulation' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antidepressant', mechanism: 'Enhanced NE/5-HT transmission', clinicalRelevance: 'Mood improvement', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'H1 antagonism', clinicalRelevance: 'Helps insomnia but may cause daytime drowsiness', desiredOrAdverse: 'both' },
        { system: 'Metabolic', effect: 'Appetite increase/weight gain', mechanism: 'H1 and 5-HT2C antagonism', clinicalRelevance: 'May help or worsen depending on patient', desiredOrAdverse: 'both' },
      ],
      onsetOfAction: '1-2 weeks (may see sleep improvement earlier)',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '50%', route: ['oral'], factors: ['Food does not significantly affect'], timeToePeak: '2 hours' },
      distribution: { volumeOfDistribution: '4.5 L/kg', proteinBinding: '85%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6', 'CYP3A4', 'CYP1A2'], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (75%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '20-40 hours',
      timeToSteadyState: '5 days',
    },
    indications: [
      { condition: 'Major depressive disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Insomnia (with depression)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Appetite stimulation', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '15-45 mg', frequency: 'Once daily at bedtime', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 7.5 mg', rationale: 'Increased sensitivity' },
        { condition: 'Renal impairment (CrCl <40)', adjustment: 'Consider lower dose', rationale: 'Reduced clearance' },
      ],
      maxDose: '45 mg/day',
      administration: { route: 'Oral', withFood: 'either', timing: 'Bedtime (due to sedation)', specialInstructions: ['SolTab dissolves on tongue'] },
    },
    adverseEffects: [
      { name: 'Sedation', frequency: 'very-common', severity: 'moderate', mechanism: 'H1 antagonism', management: 'Take at bedtime; often improves', reversible: true, onsetTiming: 'Immediate' },
      { name: 'Weight gain', frequency: 'common', severity: 'moderate', mechanism: 'H1/5-HT2C antagonism', management: 'Monitor weight; diet/exercise', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic-like', management: 'Oral hygiene', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'MAOIs', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Serotonin syndrome', effect: 'Life-threatening', management: '14-day washout' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Increased drowsiness', management: 'Use caution' },
    ],
    contraindications: [
      { condition: 'Concurrent MAOI use', type: 'absolute', reason: 'Serotonin syndrome' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Increased sensitivity', recommendation: 'Start 7.5 mg' },
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
    ],
    monitoring: [
      { parameter: 'Weight', frequency: 'Monthly initially', rationale: 'Weight gain common' },
      { parameter: 'Depression/suicidality', frequency: 'Closely initially', rationale: 'Black box warning' },
    ],
    patientEducation: ['Take at bedtime - causes drowsiness', 'May increase appetite and cause weight gain', 'Do not stop suddenly', 'Avoid alcohol'],
    clinicalPearls: ['Paradoxical dosing: lower doses MORE sedating (H1 dominates)', 'No sexual dysfunction - good for patients with this on other antidepressants', 'Weight gain and appetite stimulation useful in cancer/geriatric cachexia', 'SolTab useful for patients with swallowing difficulty'],
  },

  {
    id: 'famotidine',
    genericName: 'Famotidine',
    brandNames: ['Pepcid', 'Pepcid AC'],
    drugClass: 'H2 Receptor Antagonist',
    category: 'gastrointestinal',
    overview: 'Famotidine is an H2 blocker that reduces gastric acid secretion by blocking histamine receptors on parietal cells. It is less potent than PPIs but has faster onset and fewer long-term risks.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Histamine H2 receptors',
      targetLocation: 'Gastric parietal cells',
      simpleExplanation: 'Famotidine blocks histamine from telling your stomach cells to make acid, resulting in less acid production.',
      detailedMechanism: 'Famotidine competitively inhibits histamine at the H2 receptors of gastric parietal cells, reducing both basal and stimulated gastric acid secretion.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed orally', result: 'Enters bloodstream' },
        { order: 2, location: 'Parietal cells', action: 'Blocks H2 receptors', result: 'Histamine cannot stimulate acid secretion' },
        { order: 3, location: 'Stomach', action: 'Reduced acid production', result: 'Decreased gastric acidity', timeframe: '1-3 hours' },
      ],
      physiologicalEffects: [
        { system: 'GI', effect: 'Reduced gastric acid', mechanism: 'H2 blockade', clinicalRelevance: 'Relieves heartburn/GERD', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-3 hours',
      durationOfEffect: '10-12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '40-45%', route: ['oral', 'intravenous'], factors: ['Food slightly decreases absorption'], timeToePeak: '1-3 hours' },
      distribution: { volumeOfDistribution: '1.1-1.3 L/kg', proteinBinding: '15-20%', tissueDistribution: ['Widely distributed'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Minimal hepatic', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (65-70% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '2.5-4 hours',
      timeToSteadyState: '2 days',
    },
    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'PPIs more effective' },
      { condition: 'Peptic ulcer disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Stress ulcer prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '20-40 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl <50', adjustment: 'Reduce dose by 50% or extend interval', rationale: 'Reduced renal clearance' },
      ],
      maxDose: '160 mg/day (in divided doses)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Can take as needed for heartburn'] },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Constipation', frequency: 'uncommon', severity: 'mild', mechanism: 'Reduced motility', management: 'Dietary fiber', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'Drugs requiring acid for absorption', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Increased gastric pH', effect: 'Reduced absorption (ketoconazole)', management: 'Separate dosing' },
    ],
    contraindications: [
      { condition: 'Hypersensitivity', type: 'absolute', reason: 'Prior reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Generally safe', recommendation: 'Can use', pregnancyCategory: 'B' },
      { population: 'renal-impairment', consideration: 'Accumulation', recommendation: 'Reduce dose' },
    ],
    monitoring: [
      { parameter: 'Symptom improvement', frequency: 'As needed', rationale: 'Assess response' },
    ],
    patientEducation: ['Works within 1-3 hours', 'Less potent than PPIs but fewer long-term risks', 'Can take as needed for heartburn'],
    clinicalPearls: ['Faster onset than PPIs (1-3 hours vs 2-3 days)', 'Less acid suppression = fewer long-term risks', 'Tolerance can develop with continuous use', 'Good for intermittent/PRN use'],
  },

  {
    id: 'enalapril',
    genericName: 'Enalapril',
    brandNames: ['Vasotec'],
    drugClass: 'ACE Inhibitor',
    category: 'cardiovascular',
    overview: 'Enalapril is an ACE inhibitor prodrug that blocks the conversion of angiotensin I to angiotensin II, reducing blood pressure and cardiac workload. It is used for hypertension, heart failure, and diabetic nephropathy.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Angiotensin-converting enzyme (ACE)',
      targetLocation: 'Lungs (primarily), vascular endothelium',
      simpleExplanation: 'Enalapril blocks an enzyme that makes a hormone (angiotensin II) that raises blood pressure. By blocking this enzyme, blood vessels relax and blood pressure decreases.',
      detailedMechanism: 'Enalapril is converted to enalaprilat in the liver. Enalaprilat competitively inhibits ACE, preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and cardiac remodeling.',
      mechanismSteps: [
        { order: 1, location: 'Liver', action: 'Enalapril hydrolyzed to enalaprilat', result: 'Active drug formed', timeframe: '1 hour' },
        { order: 2, location: 'Lungs/vessels', action: 'Enalaprilat inhibits ACE', result: 'Blocked Ang I to Ang II conversion' },
        { order: 3, location: 'Vasculature', action: 'Reduced angiotensin II', result: 'Vasodilation, reduced BP' },
        { order: 4, location: 'Adrenals', action: 'Decreased aldosterone', result: 'Natriuresis, reduced fluid retention' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Vasodilation', mechanism: 'Reduced Ang II', clinicalRelevance: 'Lowers blood pressure', desiredOrAdverse: 'desired' },
        { system: 'Renal', effect: 'Efferent arteriole dilation', mechanism: 'Reduced Ang II', clinicalRelevance: 'Nephroprotection but watch creatinine', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Dry cough', mechanism: 'Bradykinin accumulation', clinicalRelevance: 'Class effect, ~10%', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-4 hours',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '60%', route: ['oral', 'intravenous'], factors: ['Food does not significantly affect'], timeToePeak: '3-4 hours (enalaprilat)' },
      distribution: { volumeOfDistribution: '1.7 L/kg', proteinBinding: '50-60%', tissueDistribution: ['Widely distributed'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['Esterases (prodrug activation)'], activeMetabolites: ['Enalaprilat'], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (60%)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '11 hours (enalaprilat)',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Heart failure', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Diabetic nephropathy', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '5-40 mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl <30', adjustment: 'Start 2.5 mg', rationale: 'Reduced clearance' },
        { condition: 'Heart failure', adjustment: 'Start 2.5 mg BID', rationale: 'Risk of hypotension' },
      ],
      maxDose: '40 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['IV form is enalaprilat'] },
    },
    adverseEffects: [
      { name: 'Dry cough', frequency: 'common', severity: 'mild', mechanism: 'Bradykinin accumulation', management: 'Switch to ARB if intolerable', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Hyperkalemia', frequency: 'uncommon', severity: 'moderate', mechanism: 'Reduced aldosterone', management: 'Monitor K+; dietary modification', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Angioedema', frequency: 'rare', severity: 'life-threatening', mechanism: 'Bradykinin effect', management: 'Discontinue immediately; never rechallenge', reversible: true, onsetTiming: 'Can occur anytime' },
    ],
    interactions: [
      { interactingDrug: 'K+-sparing diuretics', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive hyperkalemia', effect: 'Dangerous hyperkalemia', management: 'Monitor K+ closely or avoid' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Reduced prostaglandins', effect: 'Reduced antihypertensive effect, AKI risk', management: 'Monitor BP and renal function' },
    ],
    contraindications: [
      { condition: 'Pregnancy', type: 'absolute', reason: 'Fetotoxicity (2nd/3rd trimester)' },
      { condition: 'History of ACE inhibitor angioedema', type: 'absolute', reason: 'Recurrence risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Contraindicated', recommendation: 'Discontinue immediately if pregnant', pregnancyCategory: 'D' },
      { population: 'renal-impairment', consideration: 'Reduced clearance', recommendation: 'Start low, monitor creatinine/K+' },
    ],
    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Therapeutic response' },
      { parameter: 'Potassium', frequency: 'Baseline and periodically', rationale: 'Hyperkalemia risk' },
      { parameter: 'Creatinine', frequency: 'Baseline, 1-2 weeks, then periodically', rationale: 'Can worsen renal function initially' },
    ],
    patientEducation: ['Do not use if pregnant or planning pregnancy', 'Report swelling of face/lips/tongue immediately', 'Rise slowly to avoid dizziness', 'Dry cough is a known side effect - talk to doctor if bothersome'],
    clinicalPearls: ['ACE inhibitors reduce mortality in HFrEF', 'Small creatinine rise (up to 30%) acceptable and expected', 'Cough is class effect; switch to ARB if intolerable', 'Angioedema can occur even after years of use'],
  },

  {
    id: 'atenolol',
    genericName: 'Atenolol',
    brandNames: ['Tenormin'],
    drugClass: 'Beta-1 Selective Blocker',
    category: 'cardiovascular',
    overview: 'Atenolol is a cardioselective beta-1 blocker used for hypertension, angina, and post-MI. It has less effect on beta-2 receptors (bronchial, vascular) making it safer in patients with reactive airway disease.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Beta-1 adrenergic receptors',
      targetLocation: 'Heart (primarily)',
      simpleExplanation: 'Atenolol blocks the effects of adrenaline on the heart, slowing heart rate and reducing blood pressure.',
      detailedMechanism: 'Atenolol competitively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, contractility, and AV conduction. This decreases cardiac output and oxygen demand.',
      mechanismSteps: [
        { order: 1, location: 'Heart', action: 'Blocks beta-1 receptors', result: 'Reduced catecholamine effects' },
        { order: 2, location: 'SA node', action: 'Decreased automaticity', result: 'Reduced heart rate' },
        { order: 3, location: 'Myocardium', action: 'Reduced contractility', result: 'Decreased oxygen demand' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Reduced heart rate', mechanism: 'Beta-1 blockade', clinicalRelevance: 'Controls rate, reduces oxygen demand', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reduced blood pressure', mechanism: 'Decreased cardiac output', clinicalRelevance: 'Antihypertensive effect', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Masked hypoglycemia', mechanism: 'Blocked catecholamine response', clinicalRelevance: 'Caution in diabetics', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '50%', route: ['oral', 'intravenous'], factors: ['Food reduces absorption'], timeToePeak: '2-4 hours' },
      distribution: { volumeOfDistribution: '0.7 L/kg', proteinBinding: '6-16%', tissueDistribution: ['Low lipid solubility', 'Less CNS penetration'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Minimal', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (40-50% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '6-7 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Not first-line per guidelines' },
      { condition: 'Angina pectoris', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Post-MI', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '50-100 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 15-35', adjustment: '50 mg daily', rationale: 'Reduced clearance' },
        { condition: 'CrCl <15', adjustment: '50 mg every other day', rationale: 'Severe renal impairment' },
      ],
      maxDose: '100 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not stop abruptly'] },
    },
    adverseEffects: [
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'Beta-1 blockade', management: 'Monitor HR; reduce dose if symptomatic', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Fatigue', frequency: 'common', severity: 'mild', mechanism: 'Reduced cardiac output', management: 'May improve over time', reversible: true, onsetTiming: 'During therapy' },
      { name: 'Cold extremities', frequency: 'common', severity: 'mild', mechanism: 'Reduced cardiac output', management: 'Dress warmly', reversible: true, onsetTiming: 'During therapy' },
    ],
    interactions: [
      { interactingDrug: 'Verapamil/diltiazem', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive AV block', effect: 'Severe bradycardia/heart block', management: 'Avoid combination or use cautiously' },
      { interactingDrug: 'Clonidine', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Rebound hypertension if clonidine stopped', effect: 'Hypertensive crisis', management: 'Stop beta-blocker first' },
    ],
    contraindications: [
      { condition: 'Severe bradycardia', type: 'absolute', reason: 'Will worsen' },
      { condition: 'Heart block (2nd/3rd degree)', type: 'absolute', reason: 'Will worsen' },
      { condition: 'Decompensated heart failure', type: 'absolute', reason: 'Negative inotropic effect' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'May cause fetal bradycardia', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'D' },
      { population: 'renal-impairment', consideration: 'Accumulation', recommendation: 'Reduce dose' },
    ],
    monitoring: [
      { parameter: 'Heart rate', frequency: 'Regularly', rationale: 'Avoid excessive bradycardia' },
      { parameter: 'Blood pressure', frequency: 'Regularly', rationale: 'Therapeutic response' },
    ],
    patientEducation: ['Do not stop suddenly - can cause rebound', 'May cause fatigue initially', 'Rise slowly from sitting/lying', 'May mask symptoms of low blood sugar'],
    clinicalPearls: ['Cardioselective - safer in mild asthma/COPD than non-selective', 'Less CNS effects (fatigue, depression) than lipophilic beta-blockers', 'Not first-line for HTN in most patients (per guidelines)', 'Must taper when discontinuing'],
  },

  {
    id: 'hydrocodone',
    genericName: 'Hydrocodone',
    brandNames: ['Vicodin', 'Norco', 'Lortab'],
    drugClass: 'Opioid Analgesic',
    category: 'analgesic',
    overview: 'Hydrocodone is an opioid analgesic commonly combined with acetaminophen for moderate to moderately severe pain. It is a Schedule II controlled substance with significant abuse potential.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Mu opioid receptors',
      targetLocation: 'CNS (brain, spinal cord)',
      simpleExplanation: 'Hydrocodone activates opioid receptors in the brain and spinal cord, reducing pain perception and causing euphoria.',
      detailedMechanism: 'Hydrocodone is a mu-opioid receptor agonist. Binding to mu receptors in the CNS inhibits ascending pain pathways, alters pain perception and response, and produces analgesia.',
      mechanismSteps: [
        { order: 1, location: 'GI tract', action: 'Absorbed orally', result: 'Enters bloodstream' },
        { order: 2, location: 'CNS', action: 'Binds to mu opioid receptors', result: 'Receptor activation' },
        { order: 3, location: 'Pain pathways', action: 'Inhibits pain transmission', result: 'Analgesia' },
        { order: 4, location: 'Limbic system', action: 'Activates reward pathways', result: 'Euphoria (abuse potential)' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Analgesia', mechanism: 'Mu receptor activation', clinicalRelevance: 'Pain relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'CNS depression', clinicalRelevance: 'May impair function', desiredOrAdverse: 'adverse' },
        { system: 'Respiratory', effect: 'Respiratory depression', mechanism: 'Brainstem mu receptor activation', clinicalRelevance: 'Main cause of opioid death', desiredOrAdverse: 'adverse' },
        { system: 'GI', effect: 'Constipation', mechanism: 'Gut mu receptor activation', clinicalRelevance: 'Universal with opioids', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '20-30 minutes',
      durationOfEffect: '4-6 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '~50%', route: ['oral'], factors: ['Food delays but does not reduce'], timeToePeak: '1.3 hours' },
      distribution: { volumeOfDistribution: '3.3-4.7 L/kg', proteinBinding: '20-50%', tissueDistribution: ['Wide distribution', 'Crosses BBB'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6', 'CYP3A4'], activeMetabolites: ['Hydromorphone (minor)'], geneticVariability: 'CYP2D6 poor metabolizers have reduced effect', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '3.8 hours',
      timeToSteadyState: '1 day',
    },
    indications: [
      { condition: 'Moderate to severe pain', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Use when non-opioids inadequate' },
    ],
    dosing: {
      usualDose: { amount: '5-10 mg', frequency: 'Every 4-6 hours as needed', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Start lower, extend interval', rationale: 'Accumulation risk' },
        { condition: 'Hepatic impairment', adjustment: 'Start lower', rationale: 'Reduced metabolism' },
        { condition: 'Opioid naive', adjustment: 'Start at lowest dose', rationale: 'Avoid overdose' },
      ],
      maxDose: 'Varies; limited by acetaminophen (4g/day) in combo products',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not exceed acetaminophen limits', 'Do not crush ER formulations'] },
    },
    adverseEffects: [
      { name: 'Constipation', frequency: 'very-common', severity: 'moderate', mechanism: 'GI mu receptor activation', management: 'Prophylactic bowel regimen', reversible: false, onsetTiming: 'Immediate' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'CTZ stimulation', management: 'Often improves; antiemetics', reversible: true, onsetTiming: 'Early' },
      { name: 'Sedation', frequency: 'common', severity: 'moderate', mechanism: 'CNS depression', management: 'Caution with driving/machinery', reversible: true, onsetTiming: 'Immediate' },
      { name: 'Respiratory depression', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Brainstem depression', management: 'Naloxone for overdose', reversible: true, onsetTiming: 'With overdose' },
    ],
    interactions: [
      { interactingDrug: 'Benzodiazepines', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Additive CNS/respiratory depression', effect: 'Overdose death', management: 'Avoid combination - FDA black box warning' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased opioid levels', effect: 'Enhanced effects/toxicity', management: 'Reduce opioid dose' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Respiratory depression', management: 'Avoid' },
    ],
    contraindications: [
      { condition: 'Severe respiratory depression', type: 'absolute', reason: 'Will worsen' },
      { condition: 'Acute/severe asthma', type: 'absolute', reason: 'Respiratory depression risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Neonatal withdrawal if used chronically', recommendation: 'Use only if necessary; avoid chronic use', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Increased sensitivity', recommendation: 'Start low, go slow' },
    ],
    monitoring: [
      { parameter: 'Pain level', frequency: 'Each visit', rationale: 'Assess efficacy' },
      { parameter: 'Signs of misuse', frequency: 'Each visit', rationale: 'Abuse potential' },
      { parameter: 'Respiratory status', frequency: 'When initiating/increasing', rationale: 'Respiratory depression' },
    ],
    patientEducation: ['Take exactly as prescribed', 'Do not take with alcohol or benzodiazepines', 'May cause constipation - take stool softeners', 'Keep in secure location', 'Do not share medication'],
    clinicalPearls: ['Schedule II controlled substance', 'Constipation does not improve with tolerance - always treat', 'Watch for acetaminophen toxicity in combo products', 'CYP2D6 poor metabolizers may have reduced analgesic effect'],
  },

  {
    id: 'aripiprazole',
    genericName: 'Aripiprazole',
    brandNames: ['Abilify', 'Abilify Maintena'],
    drugClass: 'Atypical Antipsychotic (Dopamine Partial Agonist)',
    category: 'psychiatric',
    overview: 'Aripiprazole is an atypical antipsychotic with a unique mechanism as a dopamine D2 partial agonist. It has a favorable metabolic profile compared to other antipsychotics and is used for schizophrenia, bipolar disorder, and as augmentation for depression.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Dopamine D2 receptors (partial agonist), 5-HT1A (partial agonist), 5-HT2A (antagonist)',
      targetLocation: 'CNS',
      simpleExplanation: 'Aripiprazole acts as a "dopamine stabilizer" - increasing dopamine activity where it is too low and decreasing it where it is too high.',
      detailedMechanism: 'Aripiprazole is a dopamine D2 partial agonist that provides ~30% activation compared to full agonist. In hyperdopaminergic states (psychosis), it acts as functional antagonist; in hypodopaminergic states, it provides agonist activity. It also antagonizes 5-HT2A and partially agonizes 5-HT1A receptors.',
      mechanismSteps: [
        { order: 1, location: 'Mesolimbic pathway', action: 'D2 partial agonism in high-dopamine state', result: 'Functional antagonism, reduces psychosis' },
        { order: 2, location: 'Mesocortical pathway', action: 'D2 partial agonism in low-dopamine state', result: 'Functional agonism, improves cognition/mood' },
        { order: 3, location: 'Cortex', action: '5-HT2A antagonism', result: 'Reduced negative symptoms, less EPS' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antipsychotic', mechanism: 'D2 partial agonism', clinicalRelevance: 'Treats psychosis/mania', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Akathisia', mechanism: 'Dopamine effects', clinicalRelevance: 'Most common side effect', desiredOrAdverse: 'adverse' },
        { system: 'Metabolic', effect: 'Weight neutral', mechanism: 'Minimal H1/5-HT2C antagonism', clinicalRelevance: 'Advantage over other antipsychotics', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 weeks for antipsychotic effect',
      durationOfEffect: '24+ hours (long half-life)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '87%', route: ['oral', 'intramuscular'], factors: ['Food does not significantly affect'], timeToePeak: '3-5 hours' },
      distribution: { volumeOfDistribution: '4.9 L/kg', proteinBinding: '>99%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6', 'CYP3A4'], activeMetabolites: ['Dehydro-aripiprazole'], geneticVariability: 'CYP2D6 poor metabolizers have higher levels', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Fecal (55%), renal (25%)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '75 hours (parent), 94 hours (metabolite)',
      timeToSteadyState: '14 days',
    },
    indications: [
      { condition: 'Schizophrenia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Major depression (augmentation)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Irritability in autism', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '10-30 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'CYP2D6 poor metabolizers', adjustment: 'Reduce dose by 50%', rationale: 'Increased levels' },
        { condition: 'With strong CYP2D6/3A4 inhibitors', adjustment: 'Reduce dose by 50%', rationale: 'Drug interaction' },
      ],
      maxDose: '30 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Long-acting injection available monthly'] },
    },
    adverseEffects: [
      { name: 'Akathisia', frequency: 'common', severity: 'moderate', mechanism: 'Dopamine effects', management: 'Reduce dose; add beta-blocker or benzodiazepine', reversible: true, onsetTiming: 'Early' },
      { name: 'Insomnia/activation', frequency: 'common', severity: 'mild', mechanism: 'Dopamine partial agonism', management: 'Take in morning; may improve', reversible: true, onsetTiming: 'Early' },
      { name: 'Nausea', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'CYP2D6 inhibitors (fluoxetine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased aripiprazole levels', effect: 'Enhanced effects', management: 'Reduce aripiprazole dose by 50%' },
      { interactingDrug: 'CYP3A4 inducers (carbamazepine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreased aripiprazole levels', effect: 'Reduced efficacy', management: 'Double aripiprazole dose' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Black box warning for dementia-related psychosis', recommendation: 'Not approved for dementia psychosis' },
      { population: 'pregnancy', consideration: 'Extrapyramidal symptoms in neonates', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
    ],
    monitoring: [
      { parameter: 'Symptoms/response', frequency: 'Every visit', rationale: 'Assess efficacy' },
      { parameter: 'Weight/metabolic parameters', frequency: 'Baseline and periodically', rationale: 'Metabolic monitoring (though lower risk)' },
      { parameter: 'Akathisia assessment', frequency: 'At each visit initially', rationale: 'Most common side effect' },
    ],
    patientEducation: ['Take once daily, with or without food', 'Report restlessness (akathisia) immediately', 'May cause insomnia - take in morning', 'Do not stop suddenly'],
    clinicalPearls: ['Unique partial agonist mechanism - "dopamine stabilizer"', 'Most activating antipsychotic - akathisia is main side effect', 'Weight neutral compared to other antipsychotics', 'Very long half-life (75h) - steady state takes 2 weeks'],
  },

  // Levofloxacin - Fluoroquinolone Antibiotic
  {
    id: 'levofloxacin',
    genericName: 'Levofloxacin',
    brandNames: ['Levaquin'],
    drugClass: 'Fluoroquinolone',
    category: 'antimicrobial',
    overview: 'Levofloxacin is a broad-spectrum fluoroquinolone antibiotic used for respiratory, urinary, and skin infections. It works by inhibiting bacterial DNA synthesis.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'DNA gyrase and topoisomerase IV',
      targetLocation: 'Bacterial cells',
      simpleExplanation: 'Blocks enzymes bacteria need to copy their DNA, stopping them from multiplying.',
      detailedMechanism: 'Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, essential for bacterial DNA replication, transcription, repair, and recombination.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial cell', action: 'Drug enters through porins', result: 'Intracellular accumulation', timeframe: 'Minutes' },
        { order: 2, location: 'DNA', action: 'Binds to DNA-enzyme complex', result: 'Stabilizes cleaved DNA', timeframe: 'Minutes' },
        { order: 3, location: 'DNA', action: 'Prevents DNA resealing', result: 'Double-strand breaks accumulate', timeframe: 'Minutes to hours' },
      ],
      physiologicalEffects: [
        { system: 'Bacterial', effect: 'Bactericidal activity', mechanism: 'DNA fragmentation', clinicalRelevance: 'Kills bacteria', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 hours to peak',
      durationOfEffect: '24 hours (once daily dosing)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '99%', route: ['oral', 'IV'], factors: ['Excellent oral absorption'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '1.1 L/kg', proteinBinding: '24-38%', tissueDistribution: ['Lung', 'Prostate', 'Skin', 'Bone'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Minimal metabolism', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (87% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '6-8 hours',
      timeToSteadyState: '48 hours',
    },
    indications: [
      { condition: 'Community-acquired pneumonia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Reserve due to resistance concerns' },
      { condition: 'Complicated UTI', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Acute bacterial sinusitis', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '500-750 mg', frequency: 'Once daily', route: 'Oral or IV' },
      adjustments: [
        { condition: 'CrCl 20-49', adjustment: '250-500 mg q24h', rationale: 'Renal clearance' },
        { condition: 'CrCl 10-19', adjustment: '250-500 mg q48h', rationale: 'Renal clearance' },
      ],
      maxDose: '750 mg/day',
      administration: { route: 'Oral or IV', withFood: 'either', specialInstructions: ['Avoid antacids/dairy 2 hours before or after', 'Hydrate well to prevent crystalluria'] },
    },
    adverseEffects: [
      { name: 'Tendinitis/tendon rupture', frequency: 'rare', severity: 'severe', mechanism: 'Collagen damage', management: 'Black box warning - discontinue at first sign', reversible: false, onsetTiming: 'Variable' },
      { name: 'QT prolongation', frequency: 'uncommon', severity: 'severe', mechanism: 'Cardiac ion channel effects', management: 'Avoid in patients with risk factors', reversible: true, onsetTiming: 'Variable' },
      { name: 'CNS effects', frequency: 'uncommon', severity: 'moderate', mechanism: 'GABA antagonism', management: 'Discontinue if severe', reversible: true, onsetTiming: 'Early' },
      { name: 'GI upset', frequency: 'common', severity: 'mild', mechanism: 'Direct irritation and dysbiosis', management: 'Take with food', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Antacids/iron/calcium', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Chelation reduces absorption', effect: 'Decreased efficacy', management: 'Separate by 2 hours' },
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Inhibits warfarin metabolism', effect: 'Increased INR', management: 'Monitor INR closely' },
      { interactingDrug: 'QT-prolonging drugs', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive QT effects', effect: 'Arrhythmia risk', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'History of tendon disorders with fluoroquinolones', type: 'absolute', reason: 'Increased rupture risk' },
      { condition: 'Myasthenia gravis', type: 'absolute', reason: 'May exacerbate weakness' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Higher tendon rupture risk', recommendation: 'Use alternatives when possible' },
      { population: 'pregnancy', consideration: 'Potential cartilage damage in fetus', recommendation: 'Avoid', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'Cartilage toxicity concerns', recommendation: 'Generally avoid under 18' },
    ],
    monitoring: [
      { parameter: 'Signs of tendinitis', frequency: 'Throughout therapy', rationale: 'Black box warning' },
      { parameter: 'Renal function', frequency: 'Before and during therapy', rationale: 'Dose adjustment needed' },
    ],
    patientEducation: ['Stop and call doctor for tendon pain or swelling', 'Avoid excessive sun exposure', 'Take 2 hours away from antacids/vitamins', 'Stay well hydrated'],
    clinicalPearls: ['FDA black box warning: tendinitis, nerve damage, CNS effects', 'Reserve for when no alternatives - not first-line', 'Excellent bioavailability - IV to PO switch easy', 'Covers atypicals (Legionella, Mycoplasma) for pneumonia'],
  },

  // Clindamycin - Lincosamide Antibiotic
  {
    id: 'clindamycin',
    genericName: 'Clindamycin',
    brandNames: ['Cleocin', 'Dalacin'],
    drugClass: 'Lincosamide',
    category: 'antimicrobial',
    overview: 'Clindamycin is an antibiotic effective against gram-positive bacteria and anaerobes. It is used for skin infections, bone infections, and as an alternative for penicillin-allergic patients.',
    mechanism: {
      type: 'protein-synthesis-inhibitor',
      target: '50S ribosomal subunit',
      targetLocation: 'Bacterial ribosomes',
      simpleExplanation: 'Blocks the part of bacteria that makes proteins, stopping bacterial growth.',
      detailedMechanism: 'Binds to the 50S ribosomal subunit at the 23S rRNA, inhibiting peptidyl transferase and blocking bacterial protein synthesis. Bacteriostatic at usual doses.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial ribosome', action: 'Binds to 50S subunit', result: 'Blocks peptide bond formation', timeframe: 'Minutes' },
        { order: 2, location: 'Ribosome', action: 'Inhibits translocation', result: 'Protein synthesis stops', timeframe: 'Minutes' },
      ],
      physiologicalEffects: [
        { system: 'Bacterial', effect: 'Bacteriostatic', mechanism: 'Protein synthesis inhibition', clinicalRelevance: 'Stops bacterial growth', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-3 hours',
      durationOfEffect: '6-8 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '90%', route: ['oral', 'IV', 'topical'], factors: ['Food delays but does not reduce absorption'], timeToePeak: '45-60 minutes' },
      distribution: { volumeOfDistribution: '0.6-1.2 L/kg', proteinBinding: '60-95%', tissueDistribution: ['Bone', 'Abscess', 'Skin'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: ['N-demethyl-clindamycin'], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Biliary (active) and renal', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '2-3 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Skin and soft tissue infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Good MRSA coverage' },
      { condition: 'Bone and joint infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bacterial vaginosis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Dental infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '300-450 mg', frequency: 'Every 6 hours', route: 'Oral' },
      adjustments: [
        { condition: 'Severe hepatic impairment', adjustment: 'Reduce dose', rationale: 'Hepatic metabolism' },
      ],
      maxDose: '1800 mg/day oral',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Take with full glass of water', 'May be taken with food to reduce GI upset'] },
    },
    adverseEffects: [
      { name: 'C. difficile colitis', frequency: 'uncommon', severity: 'severe', mechanism: 'Disrupts gut flora', management: 'Stop drug immediately if diarrhea develops', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Gut flora disruption', management: 'Monitor closely for C. diff', reversible: true, onsetTiming: 'Early' },
      { name: 'Rash', frequency: 'uncommon', severity: 'mild', mechanism: 'Hypersensitivity', management: 'Discontinue if severe', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Neuromuscular blocking agents', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Enhances neuromuscular blockade', effect: 'Prolonged paralysis', management: 'Monitor closely in surgery' },
      { interactingDrug: 'Erythromycin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Compete for same ribosomal binding site', effect: 'Antagonism', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'History of C. difficile colitis', type: 'relative', reason: 'High recurrence risk' },
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta', recommendation: 'Use when benefits outweigh risks', pregnancyCategory: 'B' },
      { population: 'hepatic-impairment', consideration: 'Hepatic metabolism', recommendation: 'Reduce dose in severe impairment' },
    ],
    monitoring: [
      { parameter: 'Bowel function', frequency: 'Throughout therapy', rationale: 'C. diff risk' },
      { parameter: 'Liver function', frequency: 'For prolonged therapy', rationale: 'Hepatotoxicity rare but possible' },
    ],
    patientEducation: ['Report diarrhea immediately - even mild cases', 'Complete full course even if feeling better', 'Take with water to prevent esophageal irritation'],
    clinicalPearls: ['Strong association with C. difficile - highest risk antibiotic', 'Excellent bone penetration - good for osteomyelitis', 'Covers CA-MRSA skin infections', 'Does NOT cross blood-brain barrier'],
  },

  // Nitrofurantoin - UTI Antibiotic
  {
    id: 'nitrofurantoin',
    genericName: 'Nitrofurantoin',
    brandNames: ['Macrobid', 'Macrodantin'],
    drugClass: 'Nitrofuran',
    category: 'antimicrobial',
    overview: 'Nitrofurantoin is an antibiotic specifically for urinary tract infections. It concentrates in urine and is not effective for infections outside the urinary tract.',
    mechanism: {
      type: 'dna-modifier',
      target: 'Multiple bacterial targets',
      targetLocation: 'Bacterial cells',
      simpleExplanation: 'Damages bacterial DNA and proteins, killing bacteria in the urine.',
      detailedMechanism: 'Reduced by bacterial flavoproteins to reactive intermediates that damage DNA, inhibit protein synthesis, and disrupt cell wall formation. Multiple mechanisms reduce resistance development.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial cell', action: 'Reduced to reactive intermediates', result: 'Multiple reactive species formed', timeframe: 'Minutes' },
        { order: 2, location: 'DNA/proteins', action: 'Damages multiple targets', result: 'Bacterial death', timeframe: 'Minutes to hours' },
      ],
      physiologicalEffects: [
        { system: 'Urinary', effect: 'Concentrated bactericidal action', mechanism: 'Multiple mechanism attack', clinicalRelevance: 'Effective for UTI only', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '30 minutes',
      durationOfEffect: '6-12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '90% (macrocrystalline)', route: ['oral'], factors: ['Food increases absorption'], timeToePeak: '4-5 hours' },
      distribution: { volumeOfDistribution: 'Low (concentrates in urine)', proteinBinding: '60%', tissueDistribution: ['Urine', 'Minimal serum levels'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Tissues', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (30-50% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '20-60 minutes',
      timeToSteadyState: 'N/A (short course)',
    },
    indications: [
      { condition: 'Uncomplicated UTI', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'UTI prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '100 mg', frequency: 'Twice daily', route: 'Oral', duration: '5-7 days' },
      adjustments: [
        { condition: 'CrCl < 30', adjustment: 'Contraindicated', rationale: 'Inadequate urine concentration and toxicity risk' },
      ],
      maxDose: '400 mg/day',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Take with food to increase absorption and reduce GI upset'] },
    },
    adverseEffects: [
      { name: 'GI upset/nausea', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Take with food; macrocrystalline form better tolerated', reversible: true, onsetTiming: 'Early' },
      { name: 'Pulmonary toxicity', frequency: 'rare', severity: 'severe', mechanism: 'Hypersensitivity/oxidative damage', management: 'Discontinue immediately', reversible: true, onsetTiming: 'Acute or chronic' },
      { name: 'Peripheral neuropathy', frequency: 'rare', severity: 'moderate', mechanism: 'Toxic to nerves', management: 'Avoid prolonged use', reversible: false, onsetTiming: 'Chronic use' },
    ],
    interactions: [
      { interactingDrug: 'Antacids with magnesium', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreased absorption', effect: 'Reduced efficacy', management: 'Separate administration' },
      { interactingDrug: 'Probenecid', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreases renal excretion', effect: 'Reduced urine levels', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'CrCl < 30 mL/min', type: 'absolute', reason: 'Inadequate urine concentration' },
      { condition: 'G6PD deficiency', type: 'absolute', reason: 'Hemolytic anemia risk' },
      { condition: 'Pregnancy at term', type: 'absolute', reason: 'Neonatal hemolysis risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Avoid at term (38+ weeks)', recommendation: 'Safe earlier in pregnancy', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Higher pulmonary toxicity risk', recommendation: 'Avoid long-term use' },
      { population: 'renal-impairment', consideration: 'Contraindicated in CrCl < 30', recommendation: 'Use alternatives' },
    ],
    monitoring: [
      { parameter: 'Pulmonary symptoms', frequency: 'Throughout therapy', rationale: 'Pulmonary toxicity' },
      { parameter: 'Renal function', frequency: 'Before starting', rationale: 'Contraindicated if CrCl < 30' },
    ],
    patientEducation: ['Take with food', 'Urine may turn brown - this is harmless', 'Report breathing problems immediately', 'Only works for bladder infections'],
    clinicalPearls: ['Only for cystitis - NO systemic activity', 'First-line for uncomplicated UTI (IDSA guidelines)', 'Contraindicated if CrCl < 30 - inadequate urine levels', 'Low resistance rates due to multiple mechanisms'],
  },

  // Trimethoprim-Sulfamethoxazole (TMP-SMX)
  {
    id: 'trimethoprim-sulfamethoxazole',
    genericName: 'Trimethoprim-Sulfamethoxazole',
    brandNames: ['Bactrim', 'Septra'],
    drugClass: 'Folate Antagonist Combination',
    category: 'antimicrobial',
    overview: 'TMP-SMX is a combination antibiotic that blocks two steps in bacterial folate synthesis. It is used for UTIs, respiratory infections, and PCP prophylaxis.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Dihydrofolate reductase (TMP) and dihydropteroate synthase (SMX)',
      targetLocation: 'Bacterial folate pathway',
      simpleExplanation: 'Blocks two steps bacteria use to make folate, which they need to make DNA. Humans get folate from food, so we are not affected.',
      detailedMechanism: 'Sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase. Together they sequentially block folate synthesis, creating synergistic bactericidal effect.',
      mechanismSteps: [
        { order: 1, location: 'Bacterial cell', action: 'SMX blocks DHPS', result: 'Prevents dihydrofolate formation', timeframe: 'Minutes' },
        { order: 2, location: 'Bacterial cell', action: 'TMP blocks DHFR', result: 'Prevents tetrahydrofolate formation', timeframe: 'Minutes' },
        { order: 3, location: 'Cell', action: 'No folate available', result: 'DNA synthesis stops', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Bacterial', effect: 'Bactericidal synergy', mechanism: 'Sequential blockade', clinicalRelevance: 'Broad spectrum', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-4 hours',
      durationOfEffect: '12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '90-100%', route: ['oral', 'IV'], factors: ['Excellent absorption'], timeToePeak: '1-4 hours' },
      distribution: { volumeOfDistribution: 'TMP 1.3 L/kg, SMX 0.2 L/kg', proteinBinding: 'TMP 45%, SMX 70%', tissueDistribution: ['Lung', 'Prostate', 'Middle ear', 'CSF'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2C9'], activeMetabolites: [], geneticVariability: 'Slow acetylators have higher sulfa levels', drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: 'TMP 10h, SMX 10h',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Uncomplicated UTI', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'PCP prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'CA-MRSA skin infections', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute otitis media', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '1 DS tablet (160/800 mg)', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 15-30', adjustment: 'Half dose', rationale: 'Renal clearance' },
        { condition: 'CrCl < 15', adjustment: 'Avoid', rationale: 'Accumulation' },
      ],
      maxDose: '320/1600 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Maintain adequate hydration', 'Take with water'] },
    },
    adverseEffects: [
      { name: 'Rash', frequency: 'common', severity: 'mild', mechanism: 'Sulfa hypersensitivity', management: 'Discontinue if severe', reversible: true, onsetTiming: '1-2 weeks' },
      { name: 'Hyperkalemia', frequency: 'common', severity: 'moderate', mechanism: 'TMP blocks ENaC like amiloride', management: 'Monitor K+ especially with ACE-I/ARB', reversible: true, onsetTiming: 'Days' },
      { name: 'Stevens-Johnson syndrome', frequency: 'rare', severity: 'life-threatening', mechanism: 'Severe hypersensitivity', management: 'Immediate discontinuation', reversible: true, onsetTiming: '1-3 weeks' },
      { name: 'Bone marrow suppression', frequency: 'uncommon', severity: 'moderate', mechanism: 'Folate antagonism', management: 'Monitor CBC in prolonged use', reversible: true, onsetTiming: 'Weeks' },
    ],
    interactions: [
      { interactingDrug: 'Warfarin', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Inhibits CYP2C9', effect: 'Increased INR/bleeding', management: 'Monitor INR closely; may need to reduce warfarin' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both are antifolates', effect: 'Bone marrow toxicity', management: 'Avoid combination' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive hyperkalemia', effect: 'Dangerous K+ elevation', management: 'Monitor potassium' },
    ],
    contraindications: [
      { condition: 'Sulfa allergy', type: 'absolute', reason: 'Cross-reactivity' },
      { condition: 'Pregnancy (first trimester)', type: 'relative', reason: 'Neural tube defects' },
      { condition: 'Severe hepatic disease', type: 'relative', reason: 'Increased toxicity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Teratogenic in first trimester, kernicterus risk at term', recommendation: 'Avoid in first and third trimester', pregnancyCategory: 'D' },
      { population: 'geriatric', consideration: 'Higher hyperkalemia and bone marrow toxicity risk', recommendation: 'Monitor K+ and CBC closely' },
    ],
    monitoring: [
      { parameter: 'Potassium', frequency: 'Baseline and during therapy', rationale: 'TMP causes hyperkalemia' },
      { parameter: 'Creatinine', frequency: 'Baseline', rationale: 'TMP falsely elevates creatinine without affecting GFR' },
      { parameter: 'CBC', frequency: 'For prolonged therapy', rationale: 'Bone marrow suppression' },
    ],
    patientEducation: ['Drink plenty of fluids', 'Avoid excessive sun exposure', 'Stop if you develop rash', 'Report sore throat or fever'],
    clinicalPearls: ['First-line for UTI and PCP prophylaxis', 'TMP component raises creatinine without affecting true GFR', 'Causes hyperkalemia like a potassium-sparing diuretic', 'Significant warfarin interaction - monitor INR closely'],
  },

  // Propranolol - Beta Blocker
  {
    id: 'propranolol',
    genericName: 'Propranolol',
    brandNames: ['Inderal', 'InnoPran'],
    drugClass: 'Non-selective Beta Blocker',
    category: 'cardiovascular',
    overview: 'Propranolol is a non-selective beta blocker used for hypertension, tremor, migraine prevention, and performance anxiety. It blocks both beta-1 and beta-2 receptors.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Beta-1 and Beta-2 adrenergic receptors',
      targetLocation: 'Heart, blood vessels, bronchi, liver',
      simpleExplanation: 'Blocks adrenaline effects throughout the body, slowing heart rate and reducing blood pressure and tremor.',
      detailedMechanism: 'Non-selectively blocks beta-adrenergic receptors, reducing heart rate, contractility, and renin release (beta-1), while also blocking bronchodilation and glycogenolysis (beta-2).',
      mechanismSteps: [
        { order: 1, location: 'Beta receptors', action: 'Competitive antagonism', result: 'Blocks catecholamine binding', timeframe: 'Minutes' },
        { order: 2, location: 'Heart', action: 'Beta-1 blockade', result: 'Decreased HR and contractility', timeframe: 'Minutes' },
        { order: 3, location: 'Systemic', action: 'Reduced sympathetic tone', result: 'Decreased BP and tremor', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Negative chronotropic/inotropic', mechanism: 'Beta-1 blockade', clinicalRelevance: 'HR and BP control', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Bronchoconstriction', mechanism: 'Beta-2 blockade', clinicalRelevance: 'Avoid in asthma', desiredOrAdverse: 'adverse' },
        { system: 'Neurological', effect: 'Reduced tremor', mechanism: 'Peripheral beta blockade', clinicalRelevance: 'Essential tremor treatment', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '30 minutes to 1 hour',
      durationOfEffect: '6-12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '25% (high first-pass)', route: ['oral', 'IV'], factors: ['Food increases absorption'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '4 L/kg', proteinBinding: '90%', tissueDistribution: ['Wide', 'Highly lipophilic'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6', 'CYP1A2'], activeMetabolites: ['4-hydroxypropranolol'], geneticVariability: 'CYP2D6 polymorphism affects levels', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (metabolites)', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '3-6 hours',
      timeToSteadyState: '1-2 days',
    },
    indications: [
      { condition: 'Essential tremor', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Migraine prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Performance anxiety', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Thyrotoxicosis symptoms', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '40-80 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose', rationale: 'Extensive hepatic metabolism' },
        { condition: 'Performance anxiety', adjustment: '10-40 mg PRN', rationale: 'One-time use' },
      ],
      maxDose: '640 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not stop abruptly', 'Extended-release available'] },
    },
    adverseEffects: [
      { name: 'Bradycardia', frequency: 'common', severity: 'moderate', mechanism: 'Beta-1 blockade', management: 'Monitor HR', reversible: true, onsetTiming: 'Early' },
      { name: 'Fatigue', frequency: 'common', severity: 'mild', mechanism: 'Reduced cardiac output', management: 'Often improves over time', reversible: true, onsetTiming: 'Early' },
      { name: 'Bronchospasm', frequency: 'uncommon', severity: 'severe', mechanism: 'Beta-2 blockade', management: 'Contraindicated in asthma', reversible: true, onsetTiming: 'Variable' },
      { name: 'Cold extremities', frequency: 'common', severity: 'mild', mechanism: 'Peripheral vasoconstriction', management: 'Usually tolerable', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Verapamil/diltiazem', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive cardiac depression', effect: 'Bradycardia, heart block', management: 'Avoid combination or use with caution' },
      { interactingDrug: 'Clonidine', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Rebound hypertension if clonidine stopped', effect: 'Hypertensive crisis', management: 'Stop beta blocker first' },
      { interactingDrug: 'Insulin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Masks hypoglycemia symptoms', effect: 'Delayed recognition of low blood sugar', management: 'Monitor glucose closely in diabetics' },
    ],
    contraindications: [
      { condition: 'Asthma/COPD', type: 'absolute', reason: 'Bronchospasm from beta-2 blockade', alternative: 'Cardioselective beta blocker' },
      { condition: 'Heart block (2nd/3rd degree)', type: 'absolute', reason: 'Further conduction delay' },
      { condition: 'Decompensated heart failure', type: 'absolute', reason: 'Negative inotropic effect' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'May cause fetal bradycardia and hypoglycemia', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'More sensitive to bradycardia', recommendation: 'Start low, monitor carefully' },
    ],
    monitoring: [
      { parameter: 'Heart rate', frequency: 'At each visit', rationale: 'Avoid excessive bradycardia' },
      { parameter: 'Blood pressure', frequency: 'Regular', rationale: 'Therapeutic effect' },
    ],
    patientEducation: ['Do not stop suddenly - taper off', 'May mask low blood sugar symptoms if diabetic', 'Avoid if you have asthma', 'May cause fatigue initially'],
    clinicalPearls: ['Non-selective - contraindicated in asthma', 'Lipophilic - crosses BBB (CNS effects, migraine prevention)', 'Masks hypoglycemia symptoms in diabetics', 'Effective for performance anxiety at low PRN doses'],
  },

  // Nifedipine - Calcium Channel Blocker
  {
    id: 'nifedipine',
    genericName: 'Nifedipine',
    brandNames: ['Procardia', 'Adalat'],
    drugClass: 'Dihydropyridine Calcium Channel Blocker',
    category: 'cardiovascular',
    overview: 'Nifedipine is a calcium channel blocker that primarily relaxes blood vessels. It is used for hypertension and angina. Extended-release formulations are preferred.',
    mechanism: {
      type: 'ion-channel-blocker',
      target: 'L-type calcium channels',
      targetLocation: 'Vascular smooth muscle',
      simpleExplanation: 'Blocks calcium channels in blood vessel walls, causing vessels to relax and lower blood pressure.',
      detailedMechanism: 'Blocks L-type voltage-gated calcium channels in vascular smooth muscle, preventing calcium influx needed for contraction. Results in vasodilation, primarily in arterial beds, with minimal cardiac effects.',
      mechanismSteps: [
        { order: 1, location: 'Vascular smooth muscle', action: 'Blocks L-type Ca2+ channels', result: 'Decreased calcium influx', timeframe: 'Minutes' },
        { order: 2, location: 'Arterioles', action: 'Smooth muscle relaxation', result: 'Vasodilation', timeframe: 'Minutes to hours' },
        { order: 3, location: 'Systemic', action: 'Decreased peripheral resistance', result: 'Blood pressure reduction', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Cardiovascular', effect: 'Arterial vasodilation', mechanism: 'Calcium channel blockade', clinicalRelevance: 'BP reduction', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Reflex tachycardia', mechanism: 'Baroreceptor response', clinicalRelevance: 'Use extended-release to minimize', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '20 minutes (immediate release), 2-3 hours (extended release)',
      durationOfEffect: '6-8 hours (IR), 24 hours (ER)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '45-70%', route: ['oral'], factors: ['Grapefruit increases levels'], timeToePeak: '30 min (IR), 6 hours (ER)' },
      distribution: { volumeOfDistribution: '0.8-1.4 L/kg', proteinBinding: '92-98%', tissueDistribution: ['Wide'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Renal (metabolites)', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '2 hours (IR), 7 hours (ER)',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Use extended-release only' },
      { condition: 'Chronic stable angina', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Raynaud phenomenon', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '30-60 mg', frequency: 'Once daily', route: 'Oral (extended-release)' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Start 30 mg daily', rationale: 'CYP3A4 metabolism' },
      ],
      maxDose: '120 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Swallow extended-release whole - do not crush', 'Avoid grapefruit juice'] },
    },
    adverseEffects: [
      { name: 'Peripheral edema', frequency: 'very-common', severity: 'mild', mechanism: 'Precapillary dilation', management: 'Reduce dose; does not respond to diuretics', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation', management: 'Usually improves with continued use', reversible: true, onsetTiming: 'Early' },
      { name: 'Flushing', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation', management: 'Use extended-release', reversible: true, onsetTiming: 'Early' },
      { name: 'Reflex tachycardia', frequency: 'common', severity: 'moderate', mechanism: 'Baroreceptor reflex', management: 'Use extended-release; may add beta blocker', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased nifedipine levels', effect: 'Excessive hypotension', management: 'Avoid or reduce dose' },
      { interactingDrug: 'Grapefruit juice', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4 inhibition', effect: 'Increased levels/hypotension', management: 'Avoid grapefruit' },
      { interactingDrug: 'Beta blockers', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Enhanced BP lowering', management: 'Monitor; often used together beneficially' },
    ],
    contraindications: [
      { condition: 'Cardiogenic shock', type: 'absolute', reason: 'Further reduces cardiac output' },
      { condition: 'Immediate-release for hypertension', type: 'absolute', reason: 'Rapid BP drop causes reflex tachycardia and ischemia' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Used for tocolysis and preeclampsia', recommendation: 'May be used in pregnancy', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'More sensitive to hypotension', recommendation: 'Start at lower dose' },
    ],
    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Regular', rationale: 'Therapeutic effect and hypotension' },
      { parameter: 'Peripheral edema', frequency: 'Each visit', rationale: 'Common side effect' },
    ],
    patientEducation: ['Swallow extended-release whole', 'Avoid grapefruit juice', 'Report excessive swelling', 'Ghost tablet in stool is normal (ER shell)'],
    clinicalPearls: ['NEVER use immediate-release for hypertension - dangerous BP swings', 'Peripheral edema is due to vasodilation, not fluid retention - diuretics do not help', 'Dihydropyridine = vascular selective (unlike verapamil/diltiazem)', 'Grapefruit interaction significant'],
  },

  // Pregabalin - Anticonvulsant/Nerve Pain
  {
    id: 'pregabalin',
    genericName: 'Pregabalin',
    brandNames: ['Lyrica'],
    drugClass: 'Gabapentinoid',
    category: 'neurological',
    overview: 'Pregabalin is used for neuropathic pain, fibromyalgia, and seizures. It is related to gabapentin but has more predictable absorption and is a controlled substance.',
    mechanism: {
      type: 'ion-channel-blocker',
      target: 'Alpha-2-delta subunit of voltage-gated calcium channels',
      targetLocation: 'Central nervous system neurons',
      simpleExplanation: 'Calms overactive nerves by reducing the release of pain signals in the nervous system.',
      detailedMechanism: 'Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing calcium influx and subsequent release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P.',
      mechanismSteps: [
        { order: 1, location: 'CNS neurons', action: 'Binds alpha-2-delta subunit', result: 'Reduced Ca2+ channel trafficking', timeframe: 'Days' },
        { order: 2, location: 'Presynaptic terminal', action: 'Decreased calcium influx', result: 'Reduced neurotransmitter release', timeframe: 'Ongoing' },
        { order: 3, location: 'Pain pathways', action: 'Dampened signaling', result: 'Reduced pain perception', timeframe: '1-2 weeks' },
      ],
      physiologicalEffects: [
        { system: 'Nervous', effect: 'Reduced neuronal excitability', mechanism: 'Calcium channel modulation', clinicalRelevance: 'Pain relief and seizure control', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 weeks for pain; may be faster for anxiety',
      durationOfEffect: '8-12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '>90%', route: ['oral'], factors: ['Food slows but does not reduce absorption'], timeToePeak: '1.5 hours' },
      distribution: { volumeOfDistribution: '0.5 L/kg', proteinBinding: '0%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Negligible', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (98% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '6 hours',
      timeToSteadyState: '24-48 hours',
    },
    indications: [
      { condition: 'Diabetic neuropathy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Postherpetic neuralgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Fibromyalgia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Partial seizures (adjunct)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Generalized anxiety disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Approved in EU' },
    ],
    dosing: {
      usualDose: { amount: '150-300 mg', frequency: 'Divided BID or TID', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 30-60', adjustment: 'Max 300 mg/day', rationale: 'Renal clearance' },
        { condition: 'CrCl 15-30', adjustment: 'Max 150 mg/day', rationale: 'Renal clearance' },
        { condition: 'CrCl <15', adjustment: 'Max 75 mg/day', rationale: 'Renal clearance' },
      ],
      maxDose: '600 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not stop abruptly - taper over 1 week'] },
    },
    adverseEffects: [
      { name: 'Dizziness', frequency: 'very-common', severity: 'mild', mechanism: 'CNS depression', management: 'Start low, titrate slowly', reversible: true, onsetTiming: 'Early' },
      { name: 'Somnolence', frequency: 'very-common', severity: 'mild', mechanism: 'CNS depression', management: 'Often improves; take at bedtime', reversible: true, onsetTiming: 'Early' },
      { name: 'Weight gain', frequency: 'common', severity: 'mild', mechanism: 'Unclear - possibly appetite increase', management: 'Diet and exercise', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Peripheral edema', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'May need to discontinue', reversible: true, onsetTiming: 'Weeks' },
    ],
    interactions: [
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Increased drowsiness', management: 'Use caution' },
      { interactingDrug: 'Opioids', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS/respiratory depression', effect: 'Overdose risk', management: 'FDA warning - use lowest doses' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Animal studies show risks', recommendation: 'Avoid if possible', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Renally excreted unchanged', recommendation: 'Must adjust dose by CrCl' },
      { population: 'geriatric', consideration: 'More sensitive to CNS effects', recommendation: 'Start lower, go slower' },
    ],
    monitoring: [
      { parameter: 'Pain/symptoms', frequency: 'Regular visits', rationale: 'Assess efficacy' },
      { parameter: 'Renal function', frequency: 'Baseline and periodic', rationale: 'Dose adjustment needed' },
      { parameter: 'Signs of misuse', frequency: 'Ongoing', rationale: 'Schedule V controlled substance' },
    ],
    patientEducation: ['Do not stop suddenly', 'May cause dizziness - avoid driving initially', 'Report swelling or weight gain', 'Schedule V controlled - potential for misuse'],
    clinicalPearls: ['Schedule V controlled substance (gabapentin is not federally scheduled)', 'More predictable absorption than gabapentin (linear)', 'Must adjust dose for renal impairment', 'FDA warning about respiratory depression with opioids'],
  },

  // Risperidone - Atypical Antipsychotic
  {
    id: 'risperidone',
    genericName: 'Risperidone',
    brandNames: ['Risperdal'],
    drugClass: 'Atypical Antipsychotic',
    category: 'psychiatric',
    overview: 'Risperidone is an atypical antipsychotic used for schizophrenia, bipolar disorder, and irritability in autism. It has both dopamine and serotonin blocking properties.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Dopamine D2 and Serotonin 5-HT2A receptors',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms.',
      detailedMechanism: 'Potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. The 5-HT2A antagonism modulates dopamine release in the prefrontal cortex and may reduce extrapyramidal side effects compared to typical antipsychotics.',
      mechanismSteps: [
        { order: 1, location: 'Mesolimbic pathway', action: 'D2 antagonism', result: 'Reduces positive symptoms', timeframe: 'Days to weeks' },
        { order: 2, location: 'Prefrontal cortex', action: '5-HT2A antagonism', result: 'May improve negative/cognitive symptoms', timeframe: 'Weeks' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antipsychotic effect', mechanism: 'D2 blockade', clinicalRelevance: 'Symptom control', desiredOrAdverse: 'desired' },
        { system: 'Endocrine', effect: 'Hyperprolactinemia', mechanism: 'D2 blockade in tuberoinfundibular pathway', clinicalRelevance: 'Galactorrhea, amenorrhea', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-2 weeks',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '70%', route: ['oral', 'intramuscular'], factors: ['Food does not affect'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '1-2 L/kg', proteinBinding: '90%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6'], activeMetabolites: ['9-hydroxyrisperidone (paliperidone)'], geneticVariability: 'CYP2D6 poor metabolizers have higher parent drug levels', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (70%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '20 hours (parent + metabolite)',
      timeToSteadyState: '5-6 days',
    },
    indications: [
      { condition: 'Schizophrenia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar mania', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Irritability in autism', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '2-6 mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal/hepatic impairment', adjustment: 'Start 0.5 mg BID, titrate slowly', rationale: 'Decreased clearance' },
        { condition: 'Elderly/debilitated', adjustment: 'Start 0.5 mg BID', rationale: 'Increased sensitivity' },
      ],
      maxDose: '16 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Long-acting injection (Risperdal Consta) available'] },
    },
    adverseEffects: [
      { name: 'EPS/akathisia', frequency: 'common', severity: 'moderate', mechanism: 'D2 blockade in nigrostriatal pathway', management: 'Dose reduction; anticholinergics', reversible: true, onsetTiming: 'Early' },
      { name: 'Hyperprolactinemia', frequency: 'very-common', severity: 'moderate', mechanism: 'D2 blockade in pituitary', management: 'May need to switch agents', reversible: true, onsetTiming: 'Early' },
      { name: 'Weight gain', frequency: 'common', severity: 'moderate', mechanism: 'H1/5-HT2C antagonism', management: 'Diet, exercise, monitoring', reversible: true, onsetTiming: 'Weeks to months' },
      { name: 'Orthostatic hypotension', frequency: 'common', severity: 'mild', mechanism: 'Alpha-1 blockade', management: 'Rise slowly; titrate dose', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'CYP2D6 inhibitors (fluoxetine)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased risperidone levels', effect: 'Enhanced effects/toxicity', management: 'May need dose reduction' },
      { interactingDrug: 'Carbamazepine', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP3A4 induction', effect: 'Decreased risperidone levels', management: 'May need dose increase' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Black box warning for dementia-related psychosis', recommendation: 'Not approved for dementia psychosis', pregnancyCategory: '' },
      { population: 'pregnancy', consideration: 'Extrapyramidal symptoms in neonates', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
    ],
    monitoring: [
      { parameter: 'EPS assessment', frequency: 'Each visit initially', rationale: 'Higher EPS risk than other atypicals' },
      { parameter: 'Prolactin (if symptoms)', frequency: 'As needed', rationale: 'Highest prolactin elevation of atypicals' },
      { parameter: 'Metabolic parameters', frequency: 'Baseline and annually', rationale: 'Weight, glucose, lipids' },
    ],
    patientEducation: ['Rise slowly to avoid dizziness', 'Report muscle stiffness or restlessness', 'May affect menstrual cycle or cause breast changes', 'Regular monitoring needed'],
    clinicalPearls: ['Highest prolactin elevation of all atypicals', 'Active metabolite is paliperidone (Invega)', 'More EPS than other atypicals at higher doses', 'Long-acting injection useful for adherence'],
  },

  // Olanzapine - Atypical Antipsychotic
  {
    id: 'olanzapine',
    genericName: 'Olanzapine',
    brandNames: ['Zyprexa'],
    drugClass: 'Atypical Antipsychotic',
    category: 'psychiatric',
    overview: 'Olanzapine is an atypical antipsychotic effective for schizophrenia and bipolar disorder. It has broad receptor binding and significant metabolic side effects.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Multiple receptors: D2, 5-HT2A, H1, M1, alpha-1',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Blocks multiple brain receptors including dopamine and serotonin to reduce psychotic symptoms.',
      detailedMechanism: 'Antagonist at dopamine D2, serotonin 5-HT2A/2C, histamine H1, muscarinic M1, and alpha-1 adrenergic receptors. Broad binding profile explains both efficacy and side effect profile.',
      mechanismSteps: [
        { order: 1, location: 'Mesolimbic pathway', action: 'D2 antagonism', result: 'Reduces positive symptoms', timeframe: 'Days to weeks' },
        { order: 2, location: 'Multiple sites', action: 'Multi-receptor blockade', result: 'Broad efficacy and side effects', timeframe: 'Variable' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Antipsychotic', mechanism: 'D2/5-HT2A blockade', clinicalRelevance: 'Symptom control', desiredOrAdverse: 'desired' },
        { system: 'Metabolic', effect: 'Weight gain, diabetes risk', mechanism: 'H1/5-HT2C blockade', clinicalRelevance: 'Metabolic syndrome', desiredOrAdverse: 'adverse' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'H1 blockade', clinicalRelevance: 'Can be beneficial for agitation', desiredOrAdverse: 'both' },
      ],
      onsetOfAction: 'Hours for sedation; 1-2 weeks for antipsychotic effect',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '60%', route: ['oral', 'intramuscular'], factors: ['Food does not affect'], timeToePeak: '6 hours (oral), 15-45 min (IM)' },
      distribution: { volumeOfDistribution: '1000 L', proteinBinding: '93%', tissueDistribution: ['Extensive tissue distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP1A2', 'UGT'], activeMetabolites: [], geneticVariability: 'Smoking induces CYP1A2', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (57%) and fecal (30%)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '30-38 hours',
      timeToSteadyState: '7 days',
    },
    indications: [
      { condition: 'Schizophrenia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar disorder (mania/maintenance)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar depression (with fluoxetine)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute agitation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IM formulation' },
    ],
    dosing: {
      usualDose: { amount: '10-20 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly/debilitated', adjustment: 'Start 5 mg/day', rationale: 'Increased sensitivity' },
        { condition: 'Smokers', adjustment: 'May need higher doses', rationale: 'CYP1A2 induction' },
      ],
      maxDose: '20 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['ODT available for patients with swallowing issues', 'IM for acute agitation'] },
    },
    adverseEffects: [
      { name: 'Weight gain', frequency: 'very-common', severity: 'severe', mechanism: 'H1/5-HT2C antagonism', management: 'Counsel on diet/exercise before starting', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Metabolic syndrome', frequency: 'common', severity: 'severe', mechanism: 'Multiple mechanisms', management: 'Monitor glucose, lipids; may need to switch', reversible: true, onsetTiming: 'Months' },
      { name: 'Sedation', frequency: 'very-common', severity: 'mild', mechanism: 'H1 blockade', management: 'Take at bedtime; often improves', reversible: true, onsetTiming: 'Early' },
      { name: 'Orthostatic hypotension', frequency: 'common', severity: 'mild', mechanism: 'Alpha-1 blockade', management: 'Rise slowly', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Fluvoxamine', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'CYP1A2 inhibition', effect: 'Greatly increased olanzapine levels', management: 'Avoid or use with great caution' },
      { interactingDrug: 'Smoking', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP1A2 induction', effect: 'Decreased olanzapine levels', management: 'May need higher doses in smokers; watch for toxicity if they quit' },
      { interactingDrug: 'Benzodiazepines', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Respiratory depression (with IM)', management: 'Do not use IM olanzapine with IM benzos' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'geriatric', consideration: 'Black box warning for dementia-related psychosis', recommendation: 'Not approved for dementia psychosis' },
      { population: 'pregnancy', consideration: 'Excessive weight gain, gestational diabetes', recommendation: 'Use alternatives if possible', pregnancyCategory: 'C' },
    ],
    monitoring: [
      { parameter: 'Weight', frequency: 'Each visit for 6 months, then quarterly', rationale: 'Highest weight gain of antipsychotics' },
      { parameter: 'Fasting glucose', frequency: 'Baseline, 12 weeks, annually', rationale: 'Diabetes risk' },
      { parameter: 'Fasting lipids', frequency: 'Baseline, 12 weeks, annually', rationale: 'Dyslipidemia' },
      { parameter: 'Blood pressure', frequency: 'Each visit initially', rationale: 'Orthostatic hypotension' },
    ],
    patientEducation: ['Will likely cause weight gain - diet and exercise important from start', 'Take at bedtime due to sedation', 'Smokers may need dose adjustment if they quit', 'Regular blood tests needed'],
    clinicalPearls: ['Highest metabolic side effects of atypicals (with clozapine)', 'IM form should NOT be given with IM benzodiazepines - respiratory depression risk', 'Smokers need higher doses - watch when they quit', 'Very effective but reserve for cases where metabolic risk is acceptable'],
  },

  // Lamotrigine - Mood Stabilizer/Anticonvulsant
  {
    id: 'lamotrigine',
    genericName: 'Lamotrigine',
    brandNames: ['Lamictal'],
    drugClass: 'Anticonvulsant/Mood Stabilizer',
    category: 'neurological',
    overview: 'Lamotrigine is used for seizures and bipolar maintenance. It is particularly effective for bipolar depression and is weight-neutral with good tolerability.',
    mechanism: {
      type: 'ion-channel-blocker',
      target: 'Voltage-gated sodium channels',
      targetLocation: 'Neurons',
      simpleExplanation: 'Stabilizes overactive nerve cells by blocking sodium channels, reducing both seizures and mood swings.',
      detailedMechanism: 'Inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic release of glutamate and aspartate. May also affect calcium channels.',
      mechanismSteps: [
        { order: 1, location: 'Neuronal membrane', action: 'Blocks sodium channels', result: 'Stabilizes membrane', timeframe: 'Minutes' },
        { order: 2, location: 'Presynaptic terminal', action: 'Reduces glutamate release', result: 'Decreased excitation', timeframe: 'Ongoing' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Mood stabilization', mechanism: 'Glutamate modulation', clinicalRelevance: 'Prevents depressive episodes', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Anticonvulsant', mechanism: 'Sodium channel blockade', clinicalRelevance: 'Seizure prevention', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '2-8 weeks (mood effects)',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '98%', route: ['oral'], factors: ['Food does not affect'], timeToePeak: '1-5 hours' },
      distribution: { volumeOfDistribution: '1.1 L/kg', proteinBinding: '55%', tissueDistribution: ['Wide'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['UGT1A4 (glucuronidation)'], activeMetabolites: [], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Renal (94%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '25-33 hours',
      timeToSteadyState: '5-7 days (varies with concomitant drugs)',
    },
    indications: [
      { condition: 'Bipolar maintenance (depression prevention)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Partial seizures', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Generalized seizures', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Lennox-Gastaut syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '200 mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'With valproate', adjustment: 'Start 25 mg every other day, max 100-200 mg/day', rationale: 'Valproate doubles lamotrigine levels' },
        { condition: 'With carbamazepine/phenytoin', adjustment: 'Start 50 mg daily, target 300-500 mg/day', rationale: 'Inducers halve lamotrigine levels' },
      ],
      maxDose: '400-500 mg/day (depends on concomitant meds)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['MUST titrate slowly to prevent rash', 'Chewable and ODT available'] },
    },
    adverseEffects: [
      { name: 'Rash', frequency: 'common', severity: 'mild', mechanism: 'Hypersensitivity', management: 'Slow titration prevents; stop if occurs', reversible: true, onsetTiming: 'First 2-8 weeks' },
      { name: 'Stevens-Johnson syndrome', frequency: 'rare', severity: 'life-threatening', mechanism: 'Severe hypersensitivity', management: 'STOP immediately - risk highest with rapid titration', reversible: true, onsetTiming: 'First 8 weeks' },
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Often improves', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Valproate', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Inhibits glucuronidation', effect: 'Doubles lamotrigine levels', management: 'Halve lamotrigine dose; very slow titration' },
      { interactingDrug: 'Carbamazepine', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Induces glucuronidation', effect: 'Halves lamotrigine levels', management: 'May need to double lamotrigine dose' },
      { interactingDrug: 'Oral contraceptives', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Bidirectional interaction', effect: 'OCs lower lamotrigine; lamotrigine may lower OC efficacy', management: 'Monitor; adjust during pill-free week' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Risk of severe rash' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Levels drop significantly; possible cleft palate risk', recommendation: 'Use lowest effective dose; monitor levels', pregnancyCategory: 'C' },
      { population: 'pediatric', consideration: 'Higher rash risk especially with valproate', recommendation: 'Very slow titration essential' },
    ],
    monitoring: [
      { parameter: 'Rash assessment', frequency: 'During titration period', rationale: 'SJS risk' },
      { parameter: 'Drug levels', frequency: 'Optional; more useful in epilepsy', rationale: 'Wide therapeutic range for bipolar' },
    ],
    patientEducation: ['STOP and call doctor immediately for any rash', 'Must start at very low dose and increase slowly', 'Do not restart without medical supervision if stopped', 'Effective for preventing depression, less so for mania'],
    clinicalPearls: ['Main bipolar drug for depression prevention (not mania)', 'SLOW titration mandatory to prevent SJS (takes 6+ weeks to reach therapeutic dose)', 'Valproate doubles levels - must adjust dose', 'Weight-neutral and well-tolerated overall'],
  },

  // Clonazepam - Benzodiazepine
  {
    id: 'clonazepam',
    genericName: 'Clonazepam',
    brandNames: ['Klonopin'],
    drugClass: 'Benzodiazepine',
    category: 'psychiatric',
    overview: 'Clonazepam is a long-acting benzodiazepine used for panic disorder, seizures, and anxiety. It has high potency and a long half-life.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'GABA-A receptors (positive allosteric modulator)',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Enhances the calming effects of GABA, a natural brain chemical, reducing anxiety and preventing seizures.',
      detailedMechanism: 'Binds to a specific site on GABA-A receptors, increasing the frequency of chloride channel opening when GABA binds. This enhances inhibitory neurotransmission, reducing neuronal excitability.',
      mechanismSteps: [
        { order: 1, location: 'GABA-A receptor', action: 'Binds benzodiazepine site', result: 'Increases GABA affinity', timeframe: 'Minutes' },
        { order: 2, location: 'Chloride channel', action: 'Increased opening frequency', result: 'Neuronal hyperpolarization', timeframe: 'Minutes' },
        { order: 3, location: 'CNS', action: 'Enhanced inhibition', result: 'Anxiolysis, anticonvulsant effect', timeframe: 'Minutes to hour' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Anxiolysis', mechanism: 'GABA enhancement', clinicalRelevance: 'Panic and anxiety relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Anticonvulsant', mechanism: 'GABA enhancement', clinicalRelevance: 'Seizure control', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'GABA enhancement', clinicalRelevance: 'Can be limiting', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '20-60 minutes',
      durationOfEffect: '6-12 hours (clinical); half-life much longer',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '90%', route: ['oral'], factors: ['Food may slow absorption'], timeToePeak: '1-4 hours' },
      distribution: { volumeOfDistribution: '1.5-4.4 L/kg', proteinBinding: '85%', tissueDistribution: ['Wide CNS distribution'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: ['7-aminoclonazepam'], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '30-40 hours',
      timeToSteadyState: '5-7 days',
    },
    indications: [
      { condition: 'Panic disorder', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'SSRIs preferred first-line' },
      { condition: 'Seizure disorders', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Anxiety disorders', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '0.5-2 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 0.25 mg BID', rationale: 'Increased sensitivity' },
        { condition: 'Hepatic impairment', adjustment: 'Use lower doses', rationale: 'Decreased clearance' },
      ],
      maxDose: '20 mg/day (seizures); 4 mg/day (panic)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not stop abruptly after prolonged use', 'ODT available'] },
    },
    adverseEffects: [
      { name: 'Sedation/drowsiness', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Often improves; avoid driving', reversible: true, onsetTiming: 'Early' },
      { name: 'Cognitive impairment', frequency: 'common', severity: 'moderate', mechanism: 'CNS depression', management: 'Use lowest effective dose', reversible: true, onsetTiming: 'Ongoing' },
      { name: 'Physical dependence', frequency: 'common', severity: 'moderate', mechanism: 'GABA receptor adaptation', management: 'Taper slowly if discontinuing', reversible: true, onsetTiming: 'Weeks of use' },
      { name: 'Paradoxical disinhibition', frequency: 'rare', severity: 'moderate', mechanism: 'Unknown', management: 'Discontinue', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Opioids', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Additive CNS/respiratory depression', effect: 'Overdose death', management: 'FDA black box warning - avoid combination' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Severe sedation, respiratory depression', management: 'Avoid alcohol' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreased metabolism', effect: 'Increased sedation', management: 'Monitor for excess sedation' },
    ],
    contraindications: [
      { condition: 'Acute narrow-angle glaucoma', type: 'absolute', reason: 'May worsen glaucoma' },
      { condition: 'Severe respiratory depression', type: 'absolute', reason: 'Further respiratory depression' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Floppy infant syndrome, neonatal withdrawal', recommendation: 'Avoid especially in third trimester', pregnancyCategory: 'D' },
      { population: 'geriatric', consideration: 'Falls risk, cognitive impairment, paradoxical reactions', recommendation: 'Generally avoid; if necessary, use very low doses', pregnancyCategory: '' },
    ],
    monitoring: [
      { parameter: 'Sedation/cognitive function', frequency: 'Each visit', rationale: 'Common side effects' },
      { parameter: 'Signs of dependence/misuse', frequency: 'Ongoing', rationale: 'Schedule IV controlled' },
    ],
    patientEducation: ['Do not stop suddenly - severe withdrawal possible', 'Avoid alcohol completely', 'Do not drive until you know how it affects you', 'Do not combine with opioids'],
    clinicalPearls: ['Long half-life makes it useful for panic but also harder to discontinue', 'High potency - 0.5 mg equivalent to ~10 mg diazepam', 'FDA black box warning for opioid combination', 'Benzodiazepines are NOT first-line for anxiety - try SSRIs first'],
  },

  // Diazepam - Benzodiazepine
  {
    id: 'diazepam',
    genericName: 'Diazepam',
    brandNames: ['Valium'],
    drugClass: 'Benzodiazepine',
    category: 'psychiatric',
    overview: 'Diazepam is a long-acting benzodiazepine used for anxiety, muscle spasms, alcohol withdrawal, and seizures. It is the prototypical benzodiazepine.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'GABA-A receptors (positive allosteric modulator)',
      targetLocation: 'Central nervous system',
      simpleExplanation: 'Enhances the calming effects of GABA in the brain, reducing anxiety, relaxing muscles, and preventing seizures.',
      detailedMechanism: 'Binds to a specific site on GABA-A receptors, increasing the frequency of chloride channel opening when GABA binds. This enhances inhibitory neurotransmission throughout the CNS.',
      mechanismSteps: [
        { order: 1, location: 'GABA-A receptor', action: 'Binds benzodiazepine site', result: 'Allosteric modulation', timeframe: 'Minutes' },
        { order: 2, location: 'Chloride channel', action: 'Increased opening frequency', result: 'Neuronal hyperpolarization', timeframe: 'Minutes' },
        { order: 3, location: 'CNS', action: 'Enhanced inhibition', result: 'Anxiolysis, muscle relaxation, anticonvulsant', timeframe: 'Minutes' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Anxiolysis', mechanism: 'GABA enhancement', clinicalRelevance: 'Anxiety relief', desiredOrAdverse: 'desired' },
        { system: 'Musculoskeletal', effect: 'Muscle relaxation', mechanism: 'Spinal cord effects', clinicalRelevance: 'Spasm relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Anticonvulsant', mechanism: 'GABA enhancement', clinicalRelevance: 'Seizure termination', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '15-30 minutes (oral); 1-5 minutes (IV)',
      durationOfEffect: '6-8 hours (clinical effect); very long elimination half-life',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '90%', route: ['oral', 'IV', 'rectal'], factors: ['Food slows absorption'], timeToePeak: '0.5-1.5 hours' },
      distribution: { volumeOfDistribution: '1-3 L/kg', proteinBinding: '98%', tissueDistribution: ['Highly lipophilic - rapid CNS entry'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2C19', 'CYP3A4'], activeMetabolites: ['Desmethyldiazepam (t1/2 ~100h)', 'Oxazepam', 'Temazepam'], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '20-100 hours (including active metabolites)',
      timeToSteadyState: '1-2 weeks',
    },
    indications: [
      { condition: 'Alcohol withdrawal', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Anxiety disorders', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Muscle spasms', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Status epilepticus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'IV or rectal' },
    ],
    dosing: {
      usualDose: { amount: '2-10 mg', frequency: 'Two to four times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Start 2 mg once or twice daily', rationale: 'Increased sensitivity, accumulation' },
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose significantly', rationale: 'Impaired metabolism of long half-life metabolites' },
      ],
      maxDose: '40 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['IV for status epilepticus', 'Rectal gel (Diastat) for seizure emergencies'] },
    },
    adverseEffects: [
      { name: 'Sedation', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Use lowest effective dose', reversible: true, onsetTiming: 'Early' },
      { name: 'Anterograde amnesia', frequency: 'common', severity: 'mild', mechanism: 'CNS effects', management: 'Expected with use', reversible: true, onsetTiming: 'During use' },
      { name: 'Physical dependence', frequency: 'common', severity: 'moderate', mechanism: 'GABA receptor downregulation', management: 'Taper slowly', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Paradoxical agitation (elderly)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Unknown', management: 'Discontinue', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Opioids', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Additive CNS/respiratory depression', effect: 'Overdose risk', management: 'FDA black box warning - avoid combination' },
      { interactingDrug: 'Alcohol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive CNS depression', effect: 'Severe sedation/death', management: 'Contraindicated together' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Decreased metabolism', effect: 'Prolonged effect', management: 'Monitor closely' },
    ],
    contraindications: [
      { condition: 'Acute narrow-angle glaucoma', type: 'absolute', reason: 'May worsen' },
      { condition: 'Myasthenia gravis', type: 'relative', reason: 'May worsen weakness' },
      { condition: 'Severe respiratory insufficiency', type: 'absolute', reason: 'Respiratory depression' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Teratogenic in first trimester; floppy infant syndrome; neonatal withdrawal', recommendation: 'Avoid', pregnancyCategory: 'D' },
      { population: 'geriatric', consideration: 'Very long half-life leads to accumulation; falls, confusion, paradoxical reactions', recommendation: 'Avoid if possible - Beers criteria' },
      { population: 'hepatic-impairment', consideration: 'Metabolism significantly impaired', recommendation: 'Use alternatives like lorazepam, oxazepam' },
    ],
    monitoring: [
      { parameter: 'Mental status', frequency: 'Each visit', rationale: 'Sedation, confusion' },
      { parameter: 'Falls risk', frequency: 'Especially in elderly', rationale: 'Major concern' },
    ],
    patientEducation: ['Do not stop suddenly after prolonged use', 'Avoid alcohol completely', 'Do not drive or operate machinery', 'Very long-acting - effects may persist'],
    clinicalPearls: ['Very long half-life (including metabolites up to 100h) - accumulates', 'Avoid in elderly - Beers criteria drug', 'Good for alcohol withdrawal due to long action and cross-tolerance', 'IV is first-line for status epilepticus (along with lorazepam)'],
  },

  // Allopurinol - Gout Prevention
  {
    id: 'allopurinol',
    genericName: 'Allopurinol',
    brandNames: ['Zyloprim', 'Aloprim'],
    drugClass: 'Xanthine Oxidase Inhibitor',
    category: 'musculoskeletal',
    overview: 'Allopurinol lowers uric acid levels to prevent gout attacks and kidney stones. It is not used for acute gout treatment.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Xanthine oxidase',
      targetLocation: 'Liver and GI tract',
      simpleExplanation: 'Blocks the enzyme that makes uric acid, lowering blood levels to prevent gout crystals from forming.',
      detailedMechanism: 'Inhibits xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. This reduces uric acid production. Its metabolite oxypurinol also inhibits xanthine oxidase.',
      mechanismSteps: [
        { order: 1, location: 'Liver/GI', action: 'Inhibits xanthine oxidase', result: 'Blocks uric acid synthesis', timeframe: 'Hours' },
        { order: 2, location: 'Blood', action: 'Uric acid levels fall', result: 'Reduced crystal formation', timeframe: 'Days to weeks' },
        { order: 3, location: 'Joints/kidneys', action: 'Crystal dissolution', result: 'Reduced gout attacks', timeframe: 'Months' },
      ],
      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Decreased uric acid', mechanism: 'Enzyme inhibition', clinicalRelevance: 'Gout prevention', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 weeks to lower uric acid',
      durationOfEffect: '24-48 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '80-90%', route: ['oral', 'IV'], factors: ['Food does not significantly affect'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '1.6 L/kg', proteinBinding: 'Minimal', tissueDistribution: ['Wide'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['Xanthine oxidase'], activeMetabolites: ['Oxypurinol (t1/2 15-30h)'], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '1-2 hours (parent); 15-30 hours (oxypurinol)',
      timeToSteadyState: '1-2 weeks',
    },
    indications: [
      { condition: 'Chronic gout (urate-lowering)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Recurrent calcium oxalate stones', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Tumor lysis syndrome prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '100-300 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 10-20', adjustment: 'Max 200 mg/day', rationale: 'Accumulation of oxypurinol' },
        { condition: 'CrCl <10', adjustment: 'Max 100 mg/day or every other day', rationale: 'Severe accumulation' },
      ],
      maxDose: '800 mg/day',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Start low and titrate to uric acid goal', 'Take with food to reduce GI upset'] },
    },
    adverseEffects: [
      { name: 'Acute gout flare', frequency: 'common', severity: 'moderate', mechanism: 'Urate mobilization', management: 'Prophylaxis with colchicine or NSAID for 3-6 months', reversible: true, onsetTiming: 'Early (first weeks to months)' },
      { name: 'Rash', frequency: 'common', severity: 'mild', mechanism: 'Hypersensitivity', management: 'Stop if occurs - may progress', reversible: true, onsetTiming: 'First weeks' },
      { name: 'DRESS/SJS/TEN', frequency: 'rare', severity: 'life-threatening', mechanism: 'Severe hypersensitivity (HLA-B*5801)', management: 'Immediate discontinuation; may be fatal', reversible: false, onsetTiming: 'First 2 months' },
      { name: 'GI upset', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Take with food', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Azathioprine/6-mercaptopurine', interactionType: 'pharmacokinetic', severity: 'contraindicated', mechanism: 'Allopurinol inhibits metabolism', effect: 'Life-threatening myelosuppression', management: 'Reduce azathioprine dose by 75% or avoid' },
      { interactingDrug: 'Ampicillin/amoxicillin', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Unknown', effect: 'Increased rash risk', management: 'Monitor for rash' },
      { interactingDrug: 'ACE inhibitors', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Unknown', effect: 'Increased hypersensitivity risk', management: 'Monitor closely' },
    ],
    contraindications: [
      { condition: 'Acute gout attack', type: 'relative', reason: 'May worsen - do not start during acute flare' },
      { condition: 'Previous severe hypersensitivity', type: 'absolute', reason: 'Life-threatening reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use only if clearly needed', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Oxypurinol accumulates', recommendation: 'Reduce dose based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Uric acid level', frequency: '2-5 weeks after dose change, then periodic', rationale: 'Titrate to goal <6 mg/dL', actionThreshold: 'Target <6 mg/dL' },
      { parameter: 'Renal function', frequency: 'Periodic', rationale: 'Dose adjustment needed' },
      { parameter: 'Rash', frequency: 'First 2 months especially', rationale: 'DRESS/SJS risk' },
    ],
    patientEducation: ['Do not start during a gout attack', 'May trigger gout flares when starting - take preventive medication', 'Stop immediately and call doctor for any rash', 'Takes weeks to months to see full benefit'],
    clinicalPearls: ['NEVER start during acute gout - can worsen', 'Start low (100 mg), go slow - titrate q2-5 weeks', 'HLA-B*5801 testing recommended in high-risk ethnicities (Korean, Han Chinese, Thai)', 'Azathioprine interaction is life-threatening - must reduce azathioprine dose'],
  },

  // Colchicine - Gout Treatment
  {
    id: 'colchicine',
    genericName: 'Colchicine',
    brandNames: ['Colcrys', 'Mitigare'],
    drugClass: 'Anti-inflammatory (Gout)',
    category: 'musculoskeletal',
    overview: 'Colchicine treats acute gout attacks and prevents gout flares. It works by reducing inflammation caused by urate crystals. It has a narrow therapeutic window.',
    mechanism: {
      type: 'other',
      target: 'Microtubules',
      targetLocation: 'Inflammatory cells',
      simpleExplanation: 'Prevents inflammatory cells from responding to gout crystals, reducing swelling and pain.',
      detailedMechanism: 'Binds to tubulin, disrupting microtubule assembly. This inhibits neutrophil migration, phagocytosis, and inflammasome activation, reducing the inflammatory response to urate crystals.',
      mechanismSteps: [
        { order: 1, location: 'Neutrophils', action: 'Binds tubulin', result: 'Inhibits microtubule formation', timeframe: 'Hours' },
        { order: 2, location: 'Inflammatory cells', action: 'Blocks migration', result: 'Reduced inflammation at joint', timeframe: 'Hours to days' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Anti-inflammatory', mechanism: 'Inhibits neutrophil function', clinicalRelevance: 'Gout symptom relief', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '12-24 hours',
      durationOfEffect: '24-48 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '45%', route: ['oral'], factors: ['Food may delay absorption'], timeToePeak: '0.5-2 hours' },
      distribution: { volumeOfDistribution: '5-8 L/kg', proteinBinding: '39%', tissueDistribution: ['Concentrates in leukocytes'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Hepatobiliary (10-20% renal)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '27-31 hours',
      timeToSteadyState: '4-5 days',
    },
    indications: [
      { condition: 'Acute gout flare', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Gout flare prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Familial Mediterranean fever', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Pericarditis', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '1.2 mg then 0.6 mg one hour later', frequency: 'For acute flare; 0.6 mg daily for prophylaxis', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl <30', adjustment: 'Reduce dose; avoid repeated courses', rationale: 'Accumulation' },
        { condition: 'Hepatic impairment', adjustment: 'Reduce dose; use with caution', rationale: 'Decreased metabolism' },
      ],
      maxDose: '1.8 mg per attack (new dosing); 0.6 mg BID prophylaxis',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Low-dose regimen now standard - old high-dose regimens are toxic'] },
    },
    adverseEffects: [
      { name: 'Diarrhea', frequency: 'very-common', severity: 'mild', mechanism: 'GI toxicity', management: 'Dose-limiting; use low-dose regimen', reversible: true, onsetTiming: 'Early' },
      { name: 'Nausea/vomiting', frequency: 'common', severity: 'mild', mechanism: 'GI toxicity', management: 'Take with food', reversible: true, onsetTiming: 'Early' },
      { name: 'Bone marrow suppression', frequency: 'rare', severity: 'severe', mechanism: 'Toxic to dividing cells', management: 'Monitor CBC in long-term use', reversible: true, onsetTiming: 'Chronic' },
      { name: 'Myopathy/neuropathy', frequency: 'rare', severity: 'severe', mechanism: 'Microtubule disruption', management: 'Especially with statins/CYP3A4 inhibitors', reversible: true, onsetTiming: 'Chronic' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4/P-gp inhibitors (clarithromycin)', interactionType: 'pharmacokinetic', severity: 'contraindicated', mechanism: 'Greatly increased colchicine levels', effect: 'Fatal colchicine toxicity', management: 'Avoid combination or significantly reduce dose' },
      { interactingDrug: 'Statins', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive myopathy risk', effect: 'Rhabdomyolysis', management: 'Monitor for muscle symptoms' },
    ],
    contraindications: [
      { condition: 'Severe renal AND hepatic impairment', type: 'absolute', reason: 'No elimination pathway' },
      { condition: 'Concurrent strong CYP3A4/P-gp inhibitors', type: 'absolute', reason: 'Fatal toxicity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Potential teratogen', recommendation: 'Use only if clearly needed', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Increased toxicity risk', recommendation: 'Reduce dose; avoid repeated courses' },
    ],
    monitoring: [
      { parameter: 'CBC', frequency: 'Periodic with long-term use', rationale: 'Bone marrow toxicity' },
      { parameter: 'Renal/hepatic function', frequency: 'Baseline and periodic', rationale: 'Dose adjustment' },
    ],
    patientEducation: ['Stop if you develop diarrhea', 'New low-dose regimen is as effective and safer', 'Report muscle pain or weakness', 'Many drug interactions - tell doctor all medications'],
    clinicalPearls: ['Low-dose (1.2 mg + 0.6 mg) is now standard - old high-dose regimens are obsolete and dangerous', 'Narrow therapeutic window - toxicity common with old dosing', 'Clarithromycin interaction is FATAL - never combine', 'Also used for pericarditis prophylaxis'],
  },

  // Finasteride - 5-alpha Reductase Inhibitor
  {
    id: 'finasteride',
    genericName: 'Finasteride',
    brandNames: ['Proscar', 'Propecia'],
    drugClass: '5-alpha Reductase Inhibitor',
    category: 'urologic',
    overview: 'Finasteride treats BPH and male pattern baldness by blocking conversion of testosterone to DHT. It shrinks the prostate and may slow hair loss.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: '5-alpha reductase type II',
      targetLocation: 'Prostate, hair follicles, skin',
      simpleExplanation: 'Blocks the enzyme that converts testosterone to DHT, a hormone that causes prostate growth and hair loss.',
      detailedMechanism: 'Competitively inhibits 5-alpha reductase type II, reducing conversion of testosterone to dihydrotestosterone (DHT). Reduces prostate DHT by ~80%, serum DHT by 70%.',
      mechanismSteps: [
        { order: 1, location: 'Prostate/follicles', action: 'Inhibits 5-alpha reductase', result: 'Blocks DHT formation', timeframe: 'Hours' },
        { order: 2, location: 'Prostate', action: 'DHT levels drop', result: 'Prostate shrinkage over months', timeframe: '3-6 months' },
      ],
      physiologicalEffects: [
        { system: 'Genitourinary', effect: 'Prostate shrinkage', mechanism: 'DHT reduction', clinicalRelevance: 'BPH symptom relief', desiredOrAdverse: 'desired' },
        { system: 'Integumentary', effect: 'Hair regrowth/retention', mechanism: 'DHT reduction in follicles', clinicalRelevance: 'Hair loss treatment', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '3-6 months for BPH; 6-12 months for hair',
      durationOfEffect: 'Requires continuous use',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '65%', route: ['oral'], factors: ['Food does not affect'], timeToePeak: '2 hours' },
      distribution: { volumeOfDistribution: '76 L', proteinBinding: '90%', tissueDistribution: ['Crosses BBB (minimal)'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Fecal (57%) and renal (39%)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '6-8 hours (young); up to 8+ hours (elderly)',
      timeToSteadyState: '1-2 weeks',
    },
    indications: [
      { condition: 'Benign prostatic hyperplasia', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: '5 mg dose' },
      { condition: 'Male pattern baldness', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: '1 mg dose' },
    ],
    dosing: {
      usualDose: { amount: '5 mg (BPH) or 1 mg (hair loss)', frequency: 'Once daily', route: 'Oral' },
      adjustments: [],
      maxDose: '5 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Women should not handle crushed/broken tablets if pregnant'] },
    },
    adverseEffects: [
      { name: 'Sexual dysfunction', frequency: 'common', severity: 'moderate', mechanism: 'DHT reduction', management: 'May improve with continued use or discontinuation', reversible: true, onsetTiming: 'Early' },
      { name: 'Decreased libido', frequency: 'common', severity: 'mild', mechanism: 'DHT reduction', management: 'Discuss with patient before starting', reversible: true, onsetTiming: 'Variable' },
      { name: 'Gynecomastia', frequency: 'uncommon', severity: 'mild', mechanism: 'Altered hormone balance', management: 'May persist; rare', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'No significant interactions', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Minimal CYP involvement', effect: 'Low interaction potential', management: 'No adjustments needed' },
    ],
    contraindications: [
      { condition: 'Women (especially pregnant)', type: 'absolute', reason: 'Teratogenic - causes male fetal abnormalities' },
      { condition: 'Children', type: 'absolute', reason: 'Not indicated' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Contraindicated in women', recommendation: 'Do not handle broken tablets', pregnancyCategory: 'X' },
    ],
    monitoring: [
      { parameter: 'PSA', frequency: 'Before and during therapy', rationale: 'Lowers PSA by ~50% - doubles raw value for comparison' },
    ],
    patientEducation: ['Takes 3-6 months to see benefit', 'Lowers PSA - tell doctor you are on this medication', 'Women who are or may become pregnant should not handle broken tablets', 'Sexual side effects possible'],
    clinicalPearls: ['Reduces PSA by ~50% - must double measured PSA', 'Takes 6+ months for full effect on BPH', 'Post-finasteride syndrome controversial but reported', '1 mg and 5 mg are different indications'],
  },

  // Sildenafil - PDE5 Inhibitor
  {
    id: 'sildenafil',
    genericName: 'Sildenafil',
    brandNames: ['Viagra', 'Revatio'],
    drugClass: 'PDE5 Inhibitor',
    category: 'urologic',
    overview: 'Sildenafil treats erectile dysfunction and pulmonary arterial hypertension by relaxing blood vessel smooth muscle. It requires sexual stimulation to work for ED.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Phosphodiesterase type 5 (PDE5)',
      targetLocation: 'Corpus cavernosum, pulmonary vasculature',
      simpleExplanation: 'Blocks an enzyme that breaks down a chemical (cGMP) that relaxes blood vessels, improving blood flow where needed.',
      detailedMechanism: 'Selectively inhibits PDE5, preventing degradation of cGMP. In the corpus cavernosum, this enhances nitric oxide-mediated vasodilation during sexual stimulation. In pulmonary arteries, reduces pulmonary vascular resistance.',
      mechanismSteps: [
        { order: 1, location: 'Vascular smooth muscle', action: 'Inhibits PDE5', result: 'cGMP accumulates', timeframe: 'Minutes' },
        { order: 2, location: 'Corpus cavernosum/pulmonary arteries', action: 'Smooth muscle relaxation', result: 'Vasodilation', timeframe: 'Minutes to hour' },
      ],
      physiologicalEffects: [
        { system: 'Genitourinary', effect: 'Improved erection', mechanism: 'Increased penile blood flow', clinicalRelevance: 'ED treatment', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Pulmonary vasodilation', mechanism: 'Reduced pulmonary vascular resistance', clinicalRelevance: 'PAH treatment', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '30-60 minutes',
      durationOfEffect: '4-5 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '40%', route: ['oral'], factors: ['High-fat meals delay absorption'], timeToePeak: '30-120 minutes' },
      distribution: { volumeOfDistribution: '105 L', proteinBinding: '96%', tissueDistribution: ['Limited'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4', 'CYP2C9'], activeMetabolites: ['N-desmethyl sildenafil'], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Fecal (80%) and renal (13%)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '4 hours',
      timeToSteadyState: '1-2 days (PAH dosing)',
    },
    indications: [
      { condition: 'Erectile dysfunction', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Pulmonary arterial hypertension', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Revatio brand' },
    ],
    dosing: {
      usualDose: { amount: '50 mg (ED); 20 mg TID (PAH)', frequency: 'PRN 1 hour before (ED); TID (PAH)', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic impairment', adjustment: 'Start 25 mg', rationale: 'Decreased clearance' },
        { condition: 'CrCl <30', adjustment: 'Start 25 mg', rationale: 'Increased levels' },
        { condition: 'CYP3A4 inhibitors', adjustment: 'Start 25 mg', rationale: 'Increased levels' },
      ],
      maxDose: '100 mg/dose (ED); 20 mg TID (PAH)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['High-fat meal may delay onset for ED', 'Take 30-60 min before activity'] },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'very-common', severity: 'mild', mechanism: 'Vasodilation', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Flushing', frequency: 'common', severity: 'mild', mechanism: 'Vasodilation', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Visual disturbances (blue tinge)', frequency: 'uncommon', severity: 'mild', mechanism: 'PDE6 cross-reactivity', management: 'Usually transient', reversible: true, onsetTiming: 'During use' },
      { name: 'Priapism', frequency: 'rare', severity: 'severe', mechanism: 'Prolonged vasodilation', management: 'Seek emergency care if erection >4 hours', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Nitrates', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Synergistic hypotension', effect: 'Severe, potentially fatal hypotension', management: 'ABSOLUTE contraindication - no exception' },
      { interactingDrug: 'Alpha blockers', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive hypotension', effect: 'Significant orthostatic hypotension', management: 'Stabilize on alpha blocker first; start sildenafil 25 mg' },
      { interactingDrug: 'CYP3A4 inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased sildenafil levels', effect: 'Enhanced effects and side effects', management: 'Start with 25 mg' },
    ],
    contraindications: [
      { condition: 'Concurrent nitrate therapy', type: 'absolute', reason: 'Fatal hypotension' },
      { condition: 'Recent MI or stroke', type: 'relative', reason: 'Cardiovascular risk of sexual activity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Not indicated in women', recommendation: 'Category B but not for this indication', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Start with lower doses', recommendation: 'Start 25 mg' },
    ],
    monitoring: [
      { parameter: 'Blood pressure', frequency: 'Especially with antihypertensives', rationale: 'Additive hypotension' },
      { parameter: 'Vision changes', frequency: 'As needed', rationale: 'Rare but serious' },
    ],
    patientEducation: ['NEVER take with nitrates (nitroglycerin)', 'Requires sexual stimulation to work', 'Seek help for erection lasting >4 hours', 'Wait 24 hours after sildenafil before taking nitrates'],
    clinicalPearls: ['Nitrate contraindication is ABSOLUTE - wait 24h after sildenafil', 'Different brands for different indications (Viagra=ED, Revatio=PAH)', 'Food delays but does not reduce absorption', 'Also cross-reacts slightly with PDE6 (visual changes)'],
  },

  // Diphenhydramine - Antihistamine
  {
    id: 'diphenhydramine',
    genericName: 'Diphenhydramine',
    brandNames: ['Benadryl', 'ZzzQuil'],
    drugClass: 'First-Generation Antihistamine',
    category: 'immunologic',
    overview: 'Diphenhydramine is a first-generation antihistamine used for allergies, insomnia, and motion sickness. It is sedating and has anticholinergic effects.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Histamine H1 receptors',
      targetLocation: 'CNS and peripheral tissues',
      simpleExplanation: 'Blocks histamine, the chemical that causes allergy symptoms. Also causes drowsiness by acting on the brain.',
      detailedMechanism: 'Competitive antagonist at H1 histamine receptors, blocking histamine-mediated effects. Crosses BBB extensively, causing sedation. Also has anticholinergic, antiserotonergic, and local anesthetic properties.',
      mechanismSteps: [
        { order: 1, location: 'H1 receptors', action: 'Competitive antagonism', result: 'Blocks histamine binding', timeframe: 'Minutes' },
        { order: 2, location: 'CNS', action: 'Blocks central H1 receptors', result: 'Sedation', timeframe: 'Minutes to hour' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Antihistamine', mechanism: 'H1 blockade', clinicalRelevance: 'Allergy relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'Central H1 blockade', clinicalRelevance: 'Sleep aid or side effect', desiredOrAdverse: 'both' },
        { system: 'Autonomic', effect: 'Anticholinergic', mechanism: 'Muscarinic blockade', clinicalRelevance: 'Dry mouth, urinary retention', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '15-30 minutes',
      durationOfEffect: '4-6 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '40-60%', route: ['oral', 'IV', 'topical'], factors: ['Food does not significantly affect'], timeToePeak: '1-4 hours' },
      distribution: { volumeOfDistribution: '3-4 L/kg', proteinBinding: '80-85%', tissueDistribution: ['Widely distributed', 'Crosses BBB'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6'], activeMetabolites: [], geneticVariability: 'CYP2D6 polymorphism affects levels', drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '2-10 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Second-gen preferred due to less sedation' },
      { condition: 'Insomnia (short-term)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Motion sickness', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Acute dystonia', approvalStatus: 'off-label', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '25-50 mg', frequency: 'Every 4-6 hours as needed', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: 'Avoid if possible', rationale: 'High anticholinergic burden' },
      ],
      maxDose: '300 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Do not use for long-term sleep'] },
    },
    adverseEffects: [
      { name: 'Sedation', frequency: 'very-common', severity: 'moderate', mechanism: 'Central H1 blockade', management: 'Take at bedtime; do not drive', reversible: true, onsetTiming: 'Early' },
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic', management: 'Sip water', reversible: true, onsetTiming: 'Early' },
      { name: 'Urinary retention', frequency: 'uncommon', severity: 'moderate', mechanism: 'Anticholinergic', management: 'Avoid in BPH', reversible: true, onsetTiming: 'Variable' },
      { name: 'Confusion (elderly)', frequency: 'common', severity: 'moderate', mechanism: 'Anticholinergic', management: 'Avoid in elderly', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive sedation', effect: 'Excessive drowsiness', management: 'Avoid combination' },
      { interactingDrug: 'Other anticholinergics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Increased anticholinergic toxicity', management: 'Avoid in elderly' },
    ],
    contraindications: [
      { condition: 'Narrow-angle glaucoma', type: 'absolute', reason: 'Anticholinergic may worsen' },
      { condition: 'Urinary retention/severe BPH', type: 'relative', reason: 'May worsen' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Probably safe but crosses placenta', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'High anticholinergic burden - Beers criteria', recommendation: 'Avoid - use second-generation antihistamines' },
    ],
    monitoring: [
      { parameter: 'Sedation level', frequency: 'As needed', rationale: 'May impair function' },
      { parameter: 'Anticholinergic effects', frequency: 'In elderly', rationale: 'Falls, confusion risk' },
    ],
    patientEducation: ['Causes drowsiness - do not drive', 'Not for long-term sleep use', 'Avoid alcohol', 'Many OTC products contain this - check labels'],
    clinicalPearls: ['Beers criteria - avoid in elderly due to anticholinergic burden', 'First-gen antihistamines cause sedation (unlike cetirizine, loratadine)', 'Useful for acute dystonia from antipsychotics', 'Tolerance develops to sedation but not antihistamine effect'],
  },

  // Loratadine - Second-Generation Antihistamine
  {
    id: 'loratadine',
    genericName: 'Loratadine',
    brandNames: ['Claritin', 'Alavert'],
    drugClass: 'Second-Generation Antihistamine',
    category: 'immunologic',
    overview: 'Loratadine is a non-sedating antihistamine for allergic rhinitis and urticaria. It does not significantly cross the blood-brain barrier.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Histamine H1 receptors',
      targetLocation: 'Peripheral tissues',
      simpleExplanation: 'Blocks histamine that causes allergy symptoms, without making you drowsy.',
      detailedMechanism: 'Selective peripheral H1 receptor antagonist with minimal CNS penetration. Blocks histamine-mediated effects on smooth muscle, vasculature, and sensory nerves without significant sedation.',
      mechanismSteps: [
        { order: 1, location: 'Peripheral H1 receptors', action: 'Competitive antagonism', result: 'Blocks histamine effects', timeframe: 'Hours' },
        { order: 2, location: 'Airways/skin', action: 'Reduced inflammation', result: 'Symptom relief', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Antihistamine (non-sedating)', mechanism: 'Peripheral H1 blockade', clinicalRelevance: 'Allergy relief without drowsiness', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-3 hours',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '40%', route: ['oral'], factors: ['Food increases bioavailability'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '119 L', proteinBinding: '97-99%', tissueDistribution: ['Peripheral; minimal CNS'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4', 'CYP2D6'], activeMetabolites: ['Desloratadine (Clarinex)'], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal and fecal', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '8 hours (parent); 28 hours (metabolite)',
      timeToSteadyState: '5 days',
    },
    indications: [
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic urticaria', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '10 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Hepatic/renal impairment', adjustment: '10 mg every other day', rationale: 'Decreased clearance' },
      ],
      maxDose: '10 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['May take with or without food', 'ODT available'] },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'Variable' },
      { name: 'Fatigue', frequency: 'uncommon', severity: 'mild', mechanism: 'Minimal; at higher doses', management: 'Usually mild', reversible: true, onsetTiming: 'Variable' },
      { name: 'Dry mouth', frequency: 'uncommon', severity: 'mild', mechanism: 'Mild anticholinergic', management: 'Sip water', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Increased loratadine levels', effect: 'Minimal clinical significance', management: 'No adjustment needed at standard doses' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'No evidence of harm', recommendation: 'Preferred antihistamine in pregnancy', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Safe; non-anticholinergic', recommendation: 'Preferred over first-gen antihistamines' },
    ],
    monitoring: [
      { parameter: 'Symptom relief', frequency: 'As needed', rationale: 'Assess efficacy' },
    ],
    patientEducation: ['Take once daily', 'Non-drowsy but some people may have mild fatigue', 'Available over the counter', 'Safe for long-term use'],
    clinicalPearls: ['Second-generation = non-sedating', 'Active metabolite is desloratadine (Clarinex)', 'Preferred in elderly (no anticholinergic effects)', 'OTC - often first-line for allergies'],
  },

  // Enoxaparin - Low Molecular Weight Heparin
  {
    id: 'enoxaparin',
    genericName: 'Enoxaparin',
    brandNames: ['Lovenox'],
    drugClass: 'Low Molecular Weight Heparin (LMWH)',
    category: 'hematologic',
    overview: 'Enoxaparin is an injectable anticoagulant used for DVT prevention and treatment, and acute coronary syndromes. It is given subcutaneously.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Antithrombin III (potentiates)',
      targetLocation: 'Blood coagulation cascade',
      simpleExplanation: 'Enhances the body\'s natural blood thinner (antithrombin) to prevent and treat blood clots.',
      detailedMechanism: 'Binds to antithrombin III, accelerating its inhibition of factor Xa (primarily) and thrombin. Higher anti-Xa:anti-IIa ratio (3:1) compared to unfractionated heparin. More predictable anticoagulation.',
      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Binds antithrombin III', result: 'Conformational change', timeframe: 'Minutes' },
        { order: 2, location: 'Coagulation cascade', action: 'Enhanced factor Xa inhibition', result: 'Anticoagulation', timeframe: 'Minutes' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Factor Xa inhibition', clinicalRelevance: 'Prevents/treats clots', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '3-5 hours to peak anti-Xa activity',
      durationOfEffect: '12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '92% (SC)', route: ['subcutaneous', 'IV'], factors: ['SC injection site does not significantly affect'], timeToePeak: '3-5 hours' },
      distribution: { volumeOfDistribution: '4.3 L (based on anti-Xa)', proteinBinding: 'Low', tissueDistribution: ['Primarily intravascular'], crossesBBB: false, crossesPlacenta: false },
      metabolism: { primarySite: 'Liver (partial)', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '4-5 hours',
      timeToSteadyState: '2 days',
    },
    indications: [
      { condition: 'DVT prophylaxis (surgical)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'DVT/PE treatment', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'NSTEMI/UA', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '40 mg (prophylaxis); 1 mg/kg (treatment)', frequency: 'Daily (prophylaxis); Q12h (treatment)', route: 'Subcutaneous' },
      adjustments: [
        { condition: 'CrCl <30', adjustment: '30 mg daily (prophylaxis); 1 mg/kg daily (treatment)', rationale: 'Accumulation' },
        { condition: 'Obesity', adjustment: 'Use actual body weight up to 144 kg; consider anti-Xa monitoring', rationale: 'Variable response' },
      ],
      maxDose: 'Weight-based for treatment',
      administration: { route: 'Subcutaneous', withFood: 'either', specialInstructions: ['Inject into abdominal fat', 'Do not expel air bubble', 'Rotate sites'] },
    },
    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Monitor; protamine partially reverses', reversible: true, onsetTiming: 'Variable' },
      { name: 'Injection site reactions', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Rotate sites', reversible: true, onsetTiming: 'Early' },
      { name: 'Heparin-induced thrombocytopenia (HIT)', frequency: 'rare', severity: 'severe', mechanism: 'Antibody-mediated', management: 'Stop immediately; use alternative anticoagulant', reversible: true, onsetTiming: 'Days 5-10' },
      { name: 'Osteoporosis (long-term)', frequency: 'rare', severity: 'moderate', mechanism: 'Bone metabolism effects', management: 'Less than UFH', reversible: false, onsetTiming: 'Months' },
    ],
    interactions: [
      { interactingDrug: 'Other anticoagulants/antiplatelets', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive bleeding risk', effect: 'Increased hemorrhage', management: 'Use with caution; often combined intentionally' },
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Platelet inhibition + anticoagulation', effect: 'Increased bleeding', management: 'Use caution' },
    ],
    contraindications: [
      { condition: 'Active major bleeding', type: 'absolute', reason: 'Will worsen bleeding' },
      { condition: 'History of HIT', type: 'absolute', reason: 'Cross-reactivity' },
      { condition: 'Severe thrombocytopenia', type: 'relative', reason: 'Bleeding risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Does not cross placenta; preferred anticoagulant in pregnancy', recommendation: 'Safe to use', pregnancyCategory: 'B' },
      { population: 'renal-impairment', consideration: 'Accumulates', recommendation: 'Reduce dose if CrCl <30; consider anti-Xa monitoring' },
    ],
    monitoring: [
      { parameter: 'Platelets', frequency: 'Baseline then periodic', rationale: 'HIT surveillance' },
      { parameter: 'Anti-Xa levels', frequency: 'If needed (renal impairment, obesity, pregnancy)', rationale: 'Assess anticoagulation' },
      { parameter: 'Creatinine', frequency: 'Baseline and periodic', rationale: 'Dose adjustment' },
    ],
    patientEducation: ['Inject at 90-degree angle into belly fat', 'Do not rub injection site', 'Report unusual bleeding or bruising', 'Tell doctors/dentists you are on blood thinner'],
    clinicalPearls: ['More predictable than UFH - no routine monitoring needed in most cases', 'CrCl <30 requires dose reduction - accumulates', 'Lower HIT risk than unfractionated heparin', 'Protamine only partially reverses (~60%)'],
  },

  // Heparin - Anticoagulant
  {
    id: 'heparin',
    genericName: 'Heparin',
    brandNames: ['Hep-Lock'],
    drugClass: 'Unfractionated Heparin',
    category: 'hematologic',
    overview: 'Heparin is an injectable anticoagulant used IV for acute anticoagulation. It requires monitoring and is rapidly reversible with protamine.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Antithrombin III (potentiates)',
      targetLocation: 'Blood coagulation cascade',
      simpleExplanation: 'Greatly enhances the body\'s natural blood thinner to rapidly prevent clots.',
      detailedMechanism: 'Binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa), factor Xa, and other serine proteases by 1000-fold. Equal anti-IIa and anti-Xa activity (1:1 ratio).',
      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Binds antithrombin III', result: '1000-fold increase in activity', timeframe: 'Seconds' },
        { order: 2, location: 'Coagulation cascade', action: 'Inhibits thrombin and Xa', result: 'Rapid anticoagulation', timeframe: 'Minutes' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Thrombin and Xa inhibition', clinicalRelevance: 'Prevents clot propagation', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: 'Immediate (IV)',
      durationOfEffect: '2-6 hours (dose-dependent)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '~30% (SC); 100% (IV)', route: ['IV', 'subcutaneous'], factors: ['IV preferred for therapeutic anticoagulation'], timeToePeak: 'Immediate (IV)' },
      distribution: { volumeOfDistribution: '40-70 mL/kg', proteinBinding: 'High', tissueDistribution: ['Intravascular'], crossesBBB: false, crossesPlacenta: false },
      metabolism: { primarySite: 'Liver/RES', enzymes: ['Heparinase'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Reticuloendothelial', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '30-150 minutes (dose-dependent)',
      timeToSteadyState: 'Variable',
    },
    indications: [
      { condition: 'Acute VTE treatment', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Acute coronary syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Cardiopulmonary bypass', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Hemodialysis anticoagulation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '80 units/kg bolus then 18 units/kg/hr', frequency: 'Continuous infusion (adjust by aPTT)', route: 'IV' },
      adjustments: [
        { condition: 'aPTT-based nomogram', adjustment: 'Per protocol (usually target aPTT 60-80 seconds)', rationale: 'Maintain therapeutic range' },
      ],
      maxDose: 'Protocol-driven',
      administration: { route: 'IV', withFood: 'either', specialInstructions: ['Requires aPTT monitoring q6h initially', 'Use weight-based dosing'] },
    },
    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Protamine reverses completely', reversible: true, onsetTiming: 'Variable' },
      { name: 'HIT (Type II)', frequency: 'uncommon', severity: 'severe', mechanism: 'Antibody against heparin-PF4 complex', management: 'Stop all heparin; use alternative anticoagulant', reversible: true, onsetTiming: 'Days 5-10' },
      { name: 'Osteoporosis', frequency: 'uncommon', severity: 'moderate', mechanism: 'Osteoclast activation', management: 'With prolonged use', reversible: false, onsetTiming: 'Months' },
    ],
    interactions: [
      { interactingDrug: 'Other anticoagulants', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive effect', effect: 'Bleeding', management: 'Monitor closely when transitioning' },
      { interactingDrug: 'Antiplatelets', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive bleeding risk', effect: 'Increased hemorrhage', management: 'Often used together intentionally' },
    ],
    contraindications: [
      { condition: 'Active major bleeding', type: 'absolute', reason: 'Will worsen' },
      { condition: 'History of HIT', type: 'absolute', reason: 'Can precipitate again' },
      { condition: 'Severe thrombocytopenia', type: 'relative', reason: 'Bleeding risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Does not cross placenta', recommendation: 'Safe; used for VTE in pregnancy', pregnancyCategory: 'C' },
    ],
    monitoring: [
      { parameter: 'aPTT', frequency: 'Q6h until stable, then daily', rationale: 'Therapeutic monitoring', actionThreshold: '60-80 seconds typically' },
      { parameter: 'Platelets', frequency: 'Every 2-3 days', rationale: 'HIT surveillance' },
      { parameter: 'Hemoglobin', frequency: 'Daily', rationale: 'Bleeding detection' },
    ],
    patientEducation: ['Report any unusual bleeding', 'Hospital-administered medication', 'Blood tests needed frequently', 'Rapidly reversible if needed'],
    clinicalPearls: ['Requires aPTT monitoring - not "fire and forget"', 'Protamine completely reverses (1 mg per 100 units)', 'Higher HIT risk than LMWH', 'Short half-life = good for procedures/surgery'],
  },

  // Dabigatran - Direct Thrombin Inhibitor
  {
    id: 'dabigatran',
    genericName: 'Dabigatran',
    brandNames: ['Pradaxa'],
    drugClass: 'Direct Thrombin Inhibitor (DOAC)',
    category: 'hematologic',
    overview: 'Dabigatran is an oral anticoagulant for atrial fibrillation and VTE. It directly inhibits thrombin and has a specific reversal agent.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Thrombin (factor IIa)',
      targetLocation: 'Coagulation cascade',
      simpleExplanation: 'Directly blocks thrombin, the enzyme that converts fibrinogen to fibrin clots.',
      detailedMechanism: 'Competitive, reversible, direct inhibitor of both free and clot-bound thrombin. Does not require antithrombin as a cofactor. Prevents fibrin formation and thrombin-mediated activation of other coagulation factors.',
      mechanismSteps: [
        { order: 1, location: 'Blood', action: 'Directly binds thrombin active site', result: 'Blocks thrombin activity', timeframe: 'Hours' },
        { order: 2, location: 'Coagulation cascade', action: 'Prevents fibrin formation', result: 'Anticoagulation', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Hematologic', effect: 'Anticoagulation', mechanism: 'Direct thrombin inhibition', clinicalRelevance: 'Stroke prevention, VTE treatment', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-2 hours',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '3-7% (prodrug)', route: ['oral'], factors: ['Food delays but does not affect extent; must swallow capsule whole'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '50-70 L', proteinBinding: '35%', tissueDistribution: ['Moderate'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Plasma (esterases)', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (80%)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '12-17 hours',
      timeToSteadyState: '3 days',
    },
    indications: [
      { condition: 'Stroke prevention in non-valvular AFib', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'DVT/PE treatment', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'VTE prophylaxis (hip replacement)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '150 mg', frequency: 'Twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'CrCl 30-50', adjustment: '150 mg BID (AFib) or 110 mg BID if high bleeding risk', rationale: 'Moderate renal impairment' },
        { condition: 'CrCl 15-30', adjustment: '75 mg BID (AFib only in US)', rationale: 'Severe renal impairment' },
        { condition: 'CrCl <15', adjustment: 'Avoid', rationale: 'Contraindicated' },
        { condition: 'With P-gp inhibitors', adjustment: 'Reduce dose or avoid', rationale: 'Increased levels' },
      ],
      maxDose: '150 mg BID',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Swallow capsule whole - do not open/crush', 'Take with full glass of water'] },
    },
    adverseEffects: [
      { name: 'Bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Anticoagulation', management: 'Idarucizumab (Praxbind) reverses', reversible: true, onsetTiming: 'Variable' },
      { name: 'Dyspepsia', frequency: 'common', severity: 'mild', mechanism: 'Tartaric acid in capsule', management: 'Take with food; may need to switch agents', reversible: true, onsetTiming: 'Early' },
      { name: 'GI bleeding', frequency: 'common', severity: 'moderate', mechanism: 'Local anticoagulant effect in GI tract', management: 'Higher than warfarin; consider alternatives', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'P-gp inhibitors (dronedarone)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased dabigatran absorption', effect: 'Increased bleeding risk', management: 'Dose reduction or avoid' },
      { interactingDrug: 'P-gp inducers (rifampin)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Decreased absorption', effect: 'Reduced efficacy', management: 'Avoid combination' },
    ],
    contraindications: [
      { condition: 'Mechanical heart valve', type: 'absolute', reason: 'Inferior to warfarin - increased events' },
      { condition: 'CrCl <15 (or <30 for VTE)', type: 'absolute', reason: 'Accumulation' },
      { condition: 'Active pathological bleeding', type: 'absolute', reason: 'Will worsen' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Crosses placenta; limited data', recommendation: 'Avoid; use LMWH', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'Higher bleeding risk', recommendation: 'Assess renal function; use with caution >75 years' },
      { population: 'renal-impairment', consideration: '80% renal elimination', recommendation: 'Dose reduce or avoid based on CrCl' },
    ],
    monitoring: [
      { parameter: 'Renal function', frequency: 'Baseline then at least annually', rationale: 'Dose adjustment' },
      { parameter: 'Hemoglobin/symptoms', frequency: 'As needed', rationale: 'Bleeding detection' },
    ],
    patientEducation: ['Swallow capsules whole - never open or crush', 'Take twice daily at same times', 'Keep in original container (moisture-sensitive)', 'Reversal agent available if major bleeding occurs'],
    clinicalPearls: ['Only DOAC with specific reversal agent (idarucizumab)', 'Higher GI bleeding than warfarin', 'Renal function critical - 80% renally eliminated', 'Contraindicated with mechanical valves (RE-ALIGN trial)'],
  },

  // Budesonide - Inhaled Corticosteroid
  {
    id: 'budesonide',
    genericName: 'Budesonide',
    brandNames: ['Pulmicort', 'Entocort', 'Rhinocort'],
    drugClass: 'Corticosteroid',
    category: 'respiratory',
    overview: 'Budesonide is a corticosteroid available as inhaler, nasal spray, or oral formulation. The inhaled form is first-line for asthma maintenance.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'Glucocorticoid receptors',
      targetLocation: 'Airway epithelium and immune cells',
      simpleExplanation: 'Reduces inflammation in the airways to prevent asthma symptoms and attacks.',
      detailedMechanism: 'Binds to cytoplasmic glucocorticoid receptors, translocates to nucleus, and modulates gene transcription. Decreases inflammatory cell infiltration, cytokine production, and airway hyperresponsiveness.',
      mechanismSteps: [
        { order: 1, location: 'Target cells', action: 'Binds glucocorticoid receptor', result: 'Receptor activation', timeframe: 'Minutes' },
        { order: 2, location: 'Nucleus', action: 'Alters gene transcription', result: 'Anti-inflammatory proteins produced', timeframe: 'Hours to days' },
        { order: 3, location: 'Airways', action: 'Reduced inflammation', result: 'Improved asthma control', timeframe: 'Days to weeks' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Anti-inflammatory', mechanism: 'Reduced airway inflammation', clinicalRelevance: 'Asthma control', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '24 hours to 1-2 weeks for full effect',
      durationOfEffect: '12-24 hours per dose',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '~10% (inhaled, reaches systemic); 9-15% (oral-Entocort)', route: ['inhaled', 'nasal', 'oral'], factors: ['First-pass metabolism limits systemic exposure'], timeToePeak: '0.5-10 hours (varies by route)' },
      distribution: { volumeOfDistribution: '183-301 L', proteinBinding: '85-90%', tissueDistribution: ['Concentrates in airways (inhaled)'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (60%) and fecal', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '2-3 hours',
      timeToSteadyState: '1-2 weeks',
    },
    indications: [
      { condition: 'Asthma maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Inhaled' },
      { condition: 'Allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Nasal spray' },
      { condition: 'Crohn\'s disease (ileal/right colon)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Entocort' },
    ],
    dosing: {
      usualDose: { amount: '180-360 mcg (inhaled); 9 mg (oral Entocort)', frequency: 'Twice daily (inhaled); once daily (oral)', route: 'Inhaled or oral' },
      adjustments: [
        { condition: 'Hepatic impairment (oral)', adjustment: 'Reduce dose', rationale: 'CYP3A4 metabolism' },
      ],
      maxDose: '720 mcg/day (inhaled)',
      administration: { route: 'Inhaled', withFood: 'either', specialInstructions: ['Rinse mouth after inhaled use', 'Use spacer if MDI; Pulmicort Flexhaler is DPI'] },
    },
    adverseEffects: [
      { name: 'Oral candidiasis', frequency: 'common', severity: 'mild', mechanism: 'Local immunosuppression', management: 'Rinse mouth after use; use spacer', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Dysphonia', frequency: 'common', severity: 'mild', mechanism: 'Local steroid effect', management: 'Rinse mouth; spacer use', reversible: true, onsetTiming: 'Variable' },
      { name: 'Growth suppression (pediatric)', frequency: 'uncommon', severity: 'moderate', mechanism: 'Systemic absorption', management: 'Use lowest effective dose; monitor height', reversible: true, onsetTiming: 'Chronic' },
    ],
    interactions: [
      { interactingDrug: 'CYP3A4 inhibitors (ketoconazole)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased systemic exposure', effect: 'Increased steroid effects', management: 'Avoid prolonged use together' },
    ],
    contraindications: [
      { condition: 'Status asthmaticus', type: 'absolute', reason: 'Not for acute rescue' },
      { condition: 'Primary treatment of acute attack', type: 'absolute', reason: 'Not a bronchodilator' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Preferred inhaled steroid in pregnancy', recommendation: 'Continue for asthma control', pregnancyCategory: 'B' },
      { population: 'pediatric', consideration: 'May affect growth velocity', recommendation: 'Use lowest effective dose; monitor growth' },
    ],
    monitoring: [
      { parameter: 'Asthma control', frequency: 'Regular visits', rationale: 'Adjust dose to lowest effective' },
      { parameter: 'Growth (pediatric)', frequency: 'Regular intervals', rationale: 'Potential suppression' },
    ],
    patientEducation: ['Use regularly, not for acute attacks', 'Rinse mouth and spit after each use', 'May take weeks for full effect', 'Do not stop suddenly if on long-term'],
    clinicalPearls: ['First-line maintenance therapy for persistent asthma', 'Rinse mouth to prevent thrush', 'Oral form (Entocort) has high first-pass metabolism - less systemic effect', 'Preferred ICS in pregnancy'],
  },

  // Tiotropium - Long-Acting Anticholinergic
  {
    id: 'tiotropium',
    genericName: 'Tiotropium',
    brandNames: ['Spiriva'],
    drugClass: 'Long-Acting Muscarinic Antagonist (LAMA)',
    category: 'respiratory',
    overview: 'Tiotropium is a once-daily inhaled bronchodilator for COPD and asthma maintenance. It blocks acetylcholine in airway smooth muscle.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Muscarinic M3 receptors',
      targetLocation: 'Airway smooth muscle',
      simpleExplanation: 'Blocks a nerve signal (acetylcholine) that causes airway muscle to tighten, keeping airways open.',
      detailedMechanism: 'Long-acting muscarinic antagonist with slow dissociation from M3 receptors. Blocks acetylcholine-mediated bronchoconstriction and mucus secretion. Kinetic selectivity for M3 over M2 receptors.',
      mechanismSteps: [
        { order: 1, location: 'Airway smooth muscle', action: 'Blocks M3 receptors', result: 'Prevents bronchoconstriction', timeframe: 'Hours' },
        { order: 2, location: 'Airways', action: 'Sustained receptor blockade', result: '24-hour bronchodilation', timeframe: '24 hours' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'M3 antagonism', clinicalRelevance: 'Improved airflow', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced mucus secretion', mechanism: 'Cholinergic blockade', clinicalRelevance: 'Reduced symptoms', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '30 minutes',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '19.5% (inhaled)', route: ['inhaled'], factors: ['Systemic absorption from lungs and GI'], timeToePeak: '5 minutes (local); 5-7 days (systemic steady state)' },
      distribution: { volumeOfDistribution: '32 L/kg', proteinBinding: '72%', tissueDistribution: ['Lungs primarily'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver (minor)', enzymes: ['CYP2D6', 'CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (74%)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '5-6 days (terminal)',
      timeToSteadyState: '2-3 weeks',
    },
    indications: [
      { condition: 'COPD maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Asthma maintenance (add-on)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Spiriva Respimat' },
    ],
    dosing: {
      usualDose: { amount: '18 mcg (HandiHaler) or 2.5 mcg (Respimat)', frequency: 'Once daily', route: 'Inhaled' },
      adjustments: [],
      maxDose: '18 mcg/day (HandiHaler); 5 mcg/day (Respimat)',
      administration: { route: 'Inhaled', withFood: 'either', specialInstructions: ['Use device correctly - different techniques for HandiHaler vs Respimat', 'Take at same time daily'] },
    },
    adverseEffects: [
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic', management: 'Usually mild; sip water', reversible: true, onsetTiming: 'Early' },
      { name: 'Constipation', frequency: 'uncommon', severity: 'mild', mechanism: 'Anticholinergic', management: 'Fiber, fluids', reversible: true, onsetTiming: 'Variable' },
      { name: 'Urinary retention', frequency: 'uncommon', severity: 'moderate', mechanism: 'Anticholinergic', management: 'Caution in BPH', reversible: true, onsetTiming: 'Variable' },
      { name: 'Paradoxical bronchospasm', frequency: 'rare', severity: 'severe', mechanism: 'Hypersensitivity', management: 'Discontinue', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Other anticholinergics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Increased anticholinergic side effects', management: 'Avoid if possible' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity to atropine or derivatives', type: 'absolute', reason: 'Cross-reactivity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Use if benefits outweigh risks', pregnancyCategory: 'C' },
      { population: 'geriatric', consideration: 'May have more anticholinergic sensitivity', recommendation: 'Monitor for urinary retention, constipation' },
    ],
    monitoring: [
      { parameter: 'Lung function', frequency: 'Periodic', rationale: 'Assess response' },
      { parameter: 'COPD symptoms', frequency: 'Regular visits', rationale: 'Efficacy assessment' },
    ],
    patientEducation: ['Use once daily at the same time', 'Not for acute breathing problems', 'Learn correct inhaler technique', 'Report difficulty urinating'],
    clinicalPearls: ['First-line maintenance for COPD (GOLD guidelines)', 'Once-daily dosing improves adherence', 'LAMA + LABA (e.g., tiotropium + formoterol) more effective than either alone', 'Two formulations: HandiHaler (powder) and Respimat (mist)'],
  },

  // Ipratropium - Short-Acting Anticholinergic
  {
    id: 'ipratropium',
    genericName: 'Ipratropium',
    brandNames: ['Atrovent'],
    drugClass: 'Short-Acting Muscarinic Antagonist (SAMA)',
    category: 'respiratory',
    overview: 'Ipratropium is an inhaled bronchodilator for COPD and acute asthma (with beta-agonist). It is also used as a nasal spray for rhinitis.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'Muscarinic M3 receptors',
      targetLocation: 'Airway smooth muscle',
      simpleExplanation: 'Blocks nerve signals that cause airway muscles to tighten, helping you breathe easier.',
      detailedMechanism: 'Competitive antagonist at muscarinic receptors in bronchial smooth muscle. Blocks acetylcholine-induced bronchoconstriction and mucus hypersecretion. Quaternary amine - does not cross BBB.',
      mechanismSteps: [
        { order: 1, location: 'Airway smooth muscle', action: 'Blocks muscarinic receptors', result: 'Prevents bronchoconstriction', timeframe: 'Minutes' },
        { order: 2, location: 'Airways', action: 'Smooth muscle relaxation', result: 'Bronchodilation', timeframe: '15-30 minutes' },
      ],
      physiologicalEffects: [
        { system: 'Respiratory', effect: 'Bronchodilation', mechanism: 'Muscarinic blockade', clinicalRelevance: 'Acute relief', desiredOrAdverse: 'desired' },
        { system: 'Respiratory', effect: 'Reduced secretions', mechanism: 'Cholinergic blockade', clinicalRelevance: 'Symptom relief', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '15-30 minutes',
      durationOfEffect: '4-6 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '2-3% (inhaled)', route: ['inhaled', 'nasal'], factors: ['Minimal systemic absorption'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '176 L', proteinBinding: '0-9%', tissueDistribution: ['Lungs primarily'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver (esterases)', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '2 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'COPD maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'LAMA preferred for maintenance' },
      { condition: 'Acute asthma exacerbation (with SABA)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false, notes: 'Nasal spray' },
    ],
    dosing: {
      usualDose: { amount: '2 puffs (17 mcg each) or nebulizer 500 mcg', frequency: 'Every 4-6 hours', route: 'Inhaled' },
      adjustments: [],
      maxDose: '12 puffs/day (MDI); 2000 mcg/day (nebulizer)',
      administration: { route: 'Inhaled', withFood: 'either', specialInstructions: ['Often combined with albuterol (Combivent, DuoNeb)', 'Shake MDI before use'] },
    },
    adverseEffects: [
      { name: 'Dry mouth', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic', management: 'Usually mild', reversible: true, onsetTiming: 'Early' },
      { name: 'Cough', frequency: 'common', severity: 'mild', mechanism: 'Airway irritation', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Paradoxical bronchospasm', frequency: 'rare', severity: 'severe', mechanism: 'Hypersensitivity', management: 'Discontinue', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Other anticholinergics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive effects', effect: 'Increased side effects', management: 'Caution' },
    ],
    contraindications: [
      { condition: 'Soy or peanut allergy (MDI)', type: 'absolute', reason: 'Contains soy lecithin' },
      { condition: 'Atropine hypersensitivity', type: 'absolute', reason: 'Related compound' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Minimal systemic absorption', recommendation: 'Probably safe', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'May have more anticholinergic sensitivity', recommendation: 'Use standard doses' },
    ],
    monitoring: [
      { parameter: 'Symptom relief', frequency: 'As needed', rationale: 'Assess efficacy' },
    ],
    patientEducation: ['Can be used regularly or as needed', 'Often combined with albuterol', 'Not as fast as albuterol for acute symptoms', 'Nasal spray may cause nosebleeds'],
    clinicalPearls: ['Slower onset than albuterol - use together for acute attacks', 'Combivent = ipratropium + albuterol', 'Does not cross BBB (quaternary amine) - fewer CNS effects than atropine', 'First-choice addition to SABA for severe asthma exacerbations'],
  },

  // Methotrexate - Disease-Modifying Agent
  {
    id: 'methotrexate',
    genericName: 'Methotrexate',
    brandNames: ['Trexall', 'Rheumatrex', 'Otrexup'],
    drugClass: 'DMARD/Antimetabolite',
    category: 'immunologic',
    overview: 'Methotrexate is a cornerstone treatment for rheumatoid arthritis and other autoimmune diseases. It is also used in oncology at higher doses.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Dihydrofolate reductase (DHFR)',
      targetLocation: 'Cells (especially rapidly dividing)',
      simpleExplanation: 'Blocks folate metabolism, which reduces immune cell activity and inflammation.',
      detailedMechanism: 'Inhibits dihydrofolate reductase, blocking conversion of dihydrofolate to tetrahydrofolate needed for purine and thymidine synthesis. At low doses used in RA, also increases adenosine release (anti-inflammatory).',
      mechanismSteps: [
        { order: 1, location: 'Cells', action: 'Inhibits DHFR', result: 'Folate depletion', timeframe: 'Hours' },
        { order: 2, location: 'Immune cells', action: 'Reduced proliferation and adenosine release', result: 'Anti-inflammatory effect', timeframe: 'Weeks' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Immunomodulation', mechanism: 'Reduced lymphocyte proliferation', clinicalRelevance: 'Disease modification', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '3-6 weeks for RA',
      durationOfEffect: 'Requires continuous use',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '60-70% (oral); higher if SC', route: ['oral', 'subcutaneous', 'intramuscular'], factors: ['Food delays but does not reduce absorption'], timeToePeak: '1-2 hours' },
      distribution: { volumeOfDistribution: '0.4-0.8 L/kg', proteinBinding: '50%', tissueDistribution: ['Retained in hepatocytes and RBCs'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver and cells', enzymes: ['Polyglutamation'], activeMetabolites: ['Methotrexate polyglutamates'], drugInteractionRisk: 'high' },
      excretion: { primaryRoute: 'Renal (80-90% unchanged)', adjustmentNeeded: { renal: true, hepatic: true } },
      halfLife: '3-10 hours (dose-dependent)',
      timeToSteadyState: 'Weeks (polyglutamates)',
    },
    indications: [
      { condition: 'Rheumatoid arthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Psoriasis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Psoriatic arthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Ectopic pregnancy', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '7.5-25 mg', frequency: 'ONCE WEEKLY', route: 'Oral or SC' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Reduce dose; avoid if CrCl <30', rationale: 'Renal elimination' },
        { condition: 'Hepatic impairment', adjustment: 'Avoid in active liver disease', rationale: 'Hepatotoxicity risk' },
      ],
      maxDose: '25 mg/week (RA)',
      administration: { route: 'Oral or SC', withFood: 'either', specialInstructions: ['ONCE WEEKLY only - daily dosing is fatal', 'Take folic acid 1 mg daily to reduce side effects'] },
    },
    adverseEffects: [
      { name: 'GI upset/nausea', frequency: 'common', severity: 'mild', mechanism: 'Folate antagonism', management: 'Folic acid supplementation; take with food', reversible: true, onsetTiming: 'Early' },
      { name: 'Hepatotoxicity', frequency: 'uncommon', severity: 'severe', mechanism: 'Drug accumulation in liver', management: 'Monitor LFTs; avoid alcohol', reversible: true, onsetTiming: 'Variable' },
      { name: 'Bone marrow suppression', frequency: 'uncommon', severity: 'severe', mechanism: 'Folate antagonism', management: 'Monitor CBC; folic acid', reversible: true, onsetTiming: 'Variable' },
      { name: 'Pneumonitis', frequency: 'rare', severity: 'severe', mechanism: 'Hypersensitivity', management: 'Stop drug; may need steroids', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal clearance', effect: 'Methotrexate toxicity', management: 'Avoid NSAIDs or use with caution' },
      { interactingDrug: 'TMP-SMX', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both antifolates', effect: 'Severe bone marrow suppression', management: 'Avoid combination' },
      { interactingDrug: 'Proton pump inhibitors', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced renal clearance', effect: 'Increased MTX levels', management: 'Monitor closely' },
    ],
    contraindications: [
      { condition: 'Pregnancy', type: 'absolute', reason: 'Teratogenic and abortifacient', alternative: 'Discontinue 3 months before conception' },
      { condition: 'Alcoholism/liver disease', type: 'absolute', reason: 'Hepatotoxicity' },
      { condition: 'Immunodeficiency', type: 'relative', reason: 'Further immunosuppression' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Absolutely contraindicated - causes birth defects and abortion', recommendation: 'Stop 3 months before trying to conceive', pregnancyCategory: 'X' },
      { population: 'renal-impairment', consideration: 'Renally cleared', recommendation: 'Reduce dose or avoid if CrCl <30' },
    ],
    monitoring: [
      { parameter: 'CBC with differential', frequency: 'Baseline, monthly x3, then q3 months', rationale: 'Bone marrow suppression' },
      { parameter: 'LFTs', frequency: 'Baseline, monthly x3, then q3 months', rationale: 'Hepatotoxicity' },
      { parameter: 'Creatinine', frequency: 'Baseline and periodic', rationale: 'Renal clearance' },
      { parameter: 'Chest X-ray', frequency: 'Baseline', rationale: 'Pulmonary toxicity risk' },
    ],
    patientEducation: ['ONCE WEEKLY ONLY - not daily', 'Take folic acid daily as prescribed', 'Avoid alcohol', 'Avoid pregnancy - use contraception', 'Report fever, cough, mouth sores'],
    clinicalPearls: ['FATAL if taken daily instead of weekly - critical patient education', 'Anchor drug for RA - used first, biologics added to it', 'Folic acid 1 mg daily reduces side effects without reducing efficacy', 'SC administration has better bioavailability and less GI upset than oral'],
  },

  // Hydroxychloroquine - DMARD/Antimalarial
  {
    id: 'hydroxychloroquine',
    genericName: 'Hydroxychloroquine',
    brandNames: ['Plaquenil'],
    drugClass: 'DMARD/Antimalarial',
    category: 'immunologic',
    overview: 'Hydroxychloroquine is used primarily for autoimmune diseases like lupus and rheumatoid arthritis. It has a very slow onset but excellent long-term safety profile.',
    mechanism: {
      type: 'other',
      target: 'Multiple immune pathways',
      targetLocation: 'Lysosomes and immune cells',
      simpleExplanation: 'Accumulates in cells and interferes with immune cell signaling, reducing inflammation.',
      detailedMechanism: 'Raises lysosomal pH, interfering with antigen processing and MHC class II presentation. Also inhibits Toll-like receptors and reduces pro-inflammatory cytokine production.',
      mechanismSteps: [
        { order: 1, location: 'Lysosomes', action: 'Accumulates and raises pH', result: 'Impaired antigen processing', timeframe: 'Days-weeks' },
        { order: 2, location: 'Immune cells', action: 'Inhibits TLR signaling', result: 'Reduced cytokine production', timeframe: 'Weeks-months' },
      ],
      physiologicalEffects: [
        { system: 'Immune', effect: 'Immunomodulation', mechanism: 'Multiple anti-inflammatory effects', clinicalRelevance: 'Disease control in lupus/RA', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '2-6 months',
      durationOfEffect: 'Requires continuous use',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '70-80%', route: ['oral'], factors: ['Food increases absorption'], timeToePeak: '3-4 hours' },
      distribution: { volumeOfDistribution: 'Very large (extensive tissue binding)', proteinBinding: '40%', tissueDistribution: ['Skin', 'Eyes', 'Liver', 'Spleen'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2D6', 'CYP3A4'], activeMetabolites: ['Desethylhydroxychloroquine'], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (20-25% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '40-50 days',
      timeToSteadyState: '6 months',
    },
    indications: [
      { condition: 'Systemic lupus erythematosus', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Rheumatoid arthritis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Malaria prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '200-400 mg', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Reduce dose', rationale: 'Accumulation risk' },
        { condition: 'Weight-based', adjustment: '≤5 mg/kg/day ideal body weight', rationale: 'Reduces retinal toxicity risk' },
      ],
      maxDose: '400 mg/day',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Take with food or milk'] },
    },
    adverseEffects: [
      { name: 'Retinal toxicity', frequency: 'rare', severity: 'severe', mechanism: 'Drug accumulation in retina', management: 'Annual eye exams after 5 years; stop if detected', reversible: false, onsetTiming: 'After years of use' },
      { name: 'GI upset', frequency: 'common', severity: 'mild', mechanism: 'Local irritation', management: 'Take with food', reversible: true, onsetTiming: 'Early' },
      { name: 'Skin hyperpigmentation', frequency: 'uncommon', severity: 'mild', mechanism: 'Drug deposition', management: 'Usually reversible if stopped', reversible: true, onsetTiming: 'Months-years' },
      { name: 'Cardiomyopathy', frequency: 'very-rare', severity: 'severe', mechanism: 'Direct cardiotoxicity', management: 'Monitor; discontinue if suspected', reversible: false, onsetTiming: 'After years' },
    ],
    interactions: [
      { interactingDrug: 'Tamoxifen', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both affect retina', effect: 'Increased retinal toxicity risk', management: 'More frequent eye monitoring' },
      { interactingDrug: 'Digoxin', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased digoxin levels', effect: 'Digoxin toxicity risk', management: 'Monitor digoxin levels' },
    ],
    contraindications: [
      { condition: 'Pre-existing retinal disease', type: 'relative', reason: 'Increased toxicity risk' },
      { condition: 'G6PD deficiency', type: 'relative', reason: 'Hemolysis risk (though less than chloroquine)' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Can be continued - important for lupus control', recommendation: 'Continue during pregnancy for lupus', pregnancyCategory: 'Compatible' },
      { population: 'breastfeeding', consideration: 'Low levels in milk', recommendation: 'Generally acceptable' },
    ],
    monitoring: [
      { parameter: 'Ophthalmologic exam', frequency: 'Baseline, then annually after 5 years', rationale: 'Retinal toxicity screening' },
      { parameter: 'Visual field testing', frequency: 'Annually after 5 years', rationale: 'Early detection of toxicity' },
    ],
    patientEducation: ['Very slow onset - takes months to work', 'Annual eye exams critical after 5 years', 'One of the safest DMARDs for pregnancy', 'Do not stop during lupus flares'],
    clinicalPearls: ['Should NEVER be stopped in lupus - even in remission', 'Retinal toxicity risk increases after 5 years and cumulative dose >1000g', 'Weight-based dosing (≤5 mg/kg IBW) reduces retinal risk', 'Very long half-life - takes 6 months to reach steady state'],
  },

  // Lithium - Mood Stabilizer
  {
    id: 'lithium',
    genericName: 'Lithium',
    brandNames: ['Lithobid', 'Eskalith'],
    drugClass: 'Mood Stabilizer',
    category: 'psychiatric',
    overview: 'Lithium is the gold standard for bipolar disorder, particularly for preventing manic episodes and reducing suicide risk. It has a narrow therapeutic window requiring careful monitoring.',
    mechanism: {
      type: 'other',
      target: 'Multiple intracellular signaling pathways',
      targetLocation: 'Neurons',
      simpleExplanation: 'Stabilizes mood by affecting how brain cells communicate and respond to stress.',
      detailedMechanism: 'Inhibits inositol monophosphatase, affecting phosphoinositide signaling. Also inhibits GSK-3β, affecting gene expression, neuroplasticity, and circadian rhythms. Neuroprotective effects through multiple pathways.',
      mechanismSteps: [
        { order: 1, location: 'Neurons', action: 'Inhibits inositol recycling and GSK-3β', result: 'Altered intracellular signaling', timeframe: 'Days' },
        { order: 2, location: 'Brain', action: 'Modulates gene expression and neuroplasticity', result: 'Mood stabilization', timeframe: 'Weeks' },
      ],
      physiologicalEffects: [
        { system: 'CNS', effect: 'Mood stabilization', mechanism: 'Multiple pathways', clinicalRelevance: 'Prevents mania and depression', desiredOrAdverse: 'desired' },
        { system: 'Renal', effect: 'Nephrogenic DI', mechanism: 'Inhibits ADH response', clinicalRelevance: 'Polyuria, polydipsia', desiredOrAdverse: 'adverse' },
        { system: 'Thyroid', effect: 'Hypothyroidism', mechanism: 'Inhibits T4 release', clinicalRelevance: 'May need thyroid supplementation', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1-3 weeks',
      durationOfEffect: 'Requires continuous use',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '95-100%', route: ['oral'], factors: ['Food slows but does not reduce absorption'], timeToePeak: '1-3 hours (immediate release)' },
      distribution: { volumeOfDistribution: '0.7-1.0 L/kg', proteinBinding: '0%', tissueDistribution: ['Throughout body water'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Not metabolized', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (95% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '18-24 hours',
      timeToSteadyState: '5-7 days',
    },
    indications: [
      { condition: 'Bipolar disorder - mania', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar disorder - maintenance', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bipolar depression (augmentation)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '600-1800 mg', frequency: 'Divided BID-TID', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Reduce dose significantly', rationale: 'Renal elimination only' },
        { condition: 'Elderly', adjustment: 'Start lower, go slower', rationale: 'Reduced renal function' },
      ],
      maxDose: 'Based on serum levels, not mg',
      administration: { route: 'Oral', withFood: 'with-food', specialInstructions: ['Take with food', 'Maintain consistent salt and fluid intake'] },
    },
    adverseEffects: [
      { name: 'Tremor', frequency: 'very-common', severity: 'mild', mechanism: 'CNS effect', management: 'Beta-blocker (propranolol) if needed', reversible: true, onsetTiming: 'Early' },
      { name: 'Polyuria/Polydipsia', frequency: 'common', severity: 'moderate', mechanism: 'Nephrogenic DI', management: 'Monitor renal function; may persist', reversible: false, onsetTiming: 'Weeks-months' },
      { name: 'Hypothyroidism', frequency: 'common', severity: 'moderate', mechanism: 'Inhibits thyroid hormone release', management: 'Monitor TSH; add levothyroxine', reversible: true, onsetTiming: 'Months' },
      { name: 'Weight gain', frequency: 'common', severity: 'moderate', mechanism: 'Metabolic effects', management: 'Diet/exercise', reversible: true, onsetTiming: 'Months' },
      { name: 'Lithium toxicity', frequency: 'uncommon', severity: 'life-threatening', mechanism: 'Narrow therapeutic window', management: 'Hydration, dialysis if severe', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'NSAIDs', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal lithium clearance', effect: 'Lithium toxicity', management: 'Avoid NSAIDs or monitor levels closely' },
      { interactingDrug: 'ACE inhibitors/ARBs', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Reduced renal lithium clearance', effect: 'Lithium toxicity', management: 'Monitor levels; may need dose reduction' },
      { interactingDrug: 'Thiazide diuretics', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Increased lithium reabsorption', effect: 'Lithium toxicity', management: 'Use loop diuretics instead if needed' },
    ],
    contraindications: [
      { condition: 'Severe renal impairment', type: 'absolute', reason: 'Cannot excrete lithium' },
      { condition: 'Severe dehydration', type: 'absolute', reason: 'Toxicity risk' },
      { condition: 'Sodium depletion', type: 'absolute', reason: 'Toxicity risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Risk of Ebstein anomaly (cardiac) - though lower than previously thought', recommendation: 'Discuss risks/benefits; fetal echocardiogram if used', pregnancyCategory: 'D' },
      { population: 'breastfeeding', consideration: 'Present in breast milk', recommendation: 'Generally avoid or monitor infant closely' },
      { population: 'renal-impairment', consideration: 'Renally eliminated', recommendation: 'Significantly reduce dose; frequent monitoring' },
    ],
    monitoring: [
      { parameter: 'Lithium level', frequency: '5-7 days after dose change, then q3-6 months', rationale: 'Narrow therapeutic window (0.6-1.2 mEq/L)', actionThreshold: '>1.2 mEq/L' },
      { parameter: 'Creatinine/eGFR', frequency: 'Baseline, then q6-12 months', rationale: 'Renal toxicity monitoring' },
      { parameter: 'TSH', frequency: 'Baseline, then q6-12 months', rationale: 'Hypothyroidism monitoring' },
      { parameter: 'Calcium', frequency: 'Annually', rationale: 'Hyperparathyroidism risk' },
    ],
    patientEducation: ['Maintain consistent salt and fluid intake', 'Signs of toxicity: severe tremor, confusion, vomiting, diarrhea', 'Avoid NSAIDs (ibuprofen, naproxen) - use acetaminophen', 'Do not stop suddenly', 'Get blood levels checked regularly'],
    clinicalPearls: ['Only mood stabilizer with anti-suicide evidence', 'Toxicity at levels >1.5, severe >2.0 mEq/L', 'Dehydration, NSAIDs, and ACE-I are common causes of toxicity', 'Long-term use can cause nephrogenic DI and CKD'],
  },

  // Dapagliflozin - SGLT2 Inhibitor
  {
    id: 'dapagliflozin',
    genericName: 'Dapagliflozin',
    brandNames: ['Farxiga', 'Forxiga'],
    drugClass: 'SGLT2 Inhibitor',
    category: 'endocrine',
    overview: 'Dapagliflozin is a newer diabetes medication that works by causing glucose excretion in urine. It has revolutionized treatment due to cardiovascular and kidney protective effects.',
    mechanism: {
      type: 'transporter-inhibitor',
      target: 'Sodium-glucose cotransporter 2 (SGLT2)',
      targetLocation: 'Proximal tubule of kidney',
      simpleExplanation: 'Blocks sugar reabsorption in the kidney, causing excess sugar to be eliminated in urine.',
      detailedMechanism: 'Inhibits SGLT2 in the proximal tubule, which normally reabsorbs ~90% of filtered glucose. Results in glucosuria, natriuresis, and mild diuresis. Also reduces preload and afterload on heart.',
      mechanismSteps: [
        { order: 1, location: 'Kidney proximal tubule', action: 'Blocks SGLT2', result: 'Reduced glucose reabsorption', timeframe: 'Hours' },
        { order: 2, location: 'Urine', action: 'Glucose excretion', result: '50-80g glucose/day lost in urine', timeframe: 'Immediate' },
      ],
      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Glucose lowering', mechanism: 'Glucosuria', clinicalRelevance: 'A1c reduction ~0.5-0.8%', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'Heart failure protection', mechanism: 'Reduced preload and afterload', clinicalRelevance: 'Major CV benefits', desiredOrAdverse: 'desired' },
        { system: 'Renal', effect: 'Kidney protection', mechanism: 'Tubuloglomerular feedback', clinicalRelevance: 'Slows CKD progression', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '2 hours (glucosuria)',
      durationOfEffect: '24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '78%', route: ['oral'], factors: ['Food does not significantly affect'], timeToePeak: '2 hours' },
      distribution: { volumeOfDistribution: '118 L', proteinBinding: '91%', tissueDistribution: ['Kidney', 'Liver'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['UGT1A9 (glucuronidation)'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Renal (75%)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '12.9 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Type 2 diabetes', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Heart failure (HFrEF)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'With or without diabetes' },
      { condition: 'Chronic kidney disease', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'With or without diabetes' },
    ],
    dosing: {
      usualDose: { amount: '10 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'eGFR <25 (for diabetes)', adjustment: 'Glycemic benefit limited', rationale: 'Less glucose filtered' },
        { condition: 'Heart failure/CKD', adjustment: 'Can use down to eGFR 25', rationale: 'Non-glycemic benefits persist' },
      ],
      maxDose: '10 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Take in the morning'] },
    },
    adverseEffects: [
      { name: 'Genital mycotic infections', frequency: 'common', severity: 'mild', mechanism: 'Glucosuria creates favorable environment', management: 'Good hygiene; antifungal if needed', reversible: true, onsetTiming: 'Weeks' },
      { name: 'Urinary tract infections', frequency: 'common', severity: 'mild', mechanism: 'Glucosuria', management: 'Treat as usual', reversible: true, onsetTiming: 'Variable' },
      { name: 'Polyuria', frequency: 'common', severity: 'mild', mechanism: 'Osmotic diuresis', management: 'Usually improves with time', reversible: true, onsetTiming: 'Early' },
      { name: 'Euglycemic DKA', frequency: 'rare', severity: 'life-threatening', mechanism: 'Ketogenesis without high glucose', management: 'Stop drug; treat DKA', reversible: true, onsetTiming: 'Variable' },
      { name: 'Fournier gangrene', frequency: 'very-rare', severity: 'life-threatening', mechanism: 'Genitourinary infection', management: 'Emergency surgery', reversible: false, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Loop diuretics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive diuresis', effect: 'Volume depletion', management: 'May need to reduce diuretic dose' },
      { interactingDrug: 'Insulin/Sulfonylureas', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive glucose lowering', effect: 'Hypoglycemia risk', management: 'May need to reduce insulin dose' },
    ],
    contraindications: [
      { condition: 'Type 1 diabetes', type: 'absolute', reason: 'DKA risk' },
      { condition: 'Dialysis', type: 'absolute', reason: 'No benefit' },
      { condition: 'Frequent UTIs or genital infections', type: 'relative', reason: 'Increased infection risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Not recommended - may affect fetal kidney', recommendation: 'Avoid; use insulin', pregnancyCategory: 'Not recommended' },
      { population: 'geriatric', consideration: 'Higher risk of volume depletion', recommendation: 'Monitor volume status' },
    ],
    monitoring: [
      { parameter: 'eGFR', frequency: 'Baseline, then periodically', rationale: 'Renal function' },
      { parameter: 'Signs of DKA', frequency: 'Ongoing patient awareness', rationale: 'Can occur without high glucose' },
      { parameter: 'Volume status', frequency: 'Early in therapy', rationale: 'Diuretic effect' },
    ],
    patientEducation: ['May cause genital yeast infections - maintain good hygiene', 'Increases urination', 'Know signs of DKA even if blood sugar normal: nausea, vomiting, abdominal pain', 'Hold during acute illness, surgery, or dehydration', 'Major heart and kidney benefits beyond diabetes'],
    clinicalPearls: ['Use for cardio-renal protection even in non-diabetics now', 'Continue in HF/CKD down to eGFR 25', 'Hold before surgery (DKA risk)', 'Consider "sick day rules" education'],
  },

  // Semaglutide - GLP-1 Receptor Agonist
  {
    id: 'semaglutide',
    genericName: 'Semaglutide',
    brandNames: ['Ozempic', 'Wegovy', 'Rybelsus'],
    drugClass: 'GLP-1 Receptor Agonist',
    category: 'endocrine',
    overview: 'Semaglutide is a highly effective medication for type 2 diabetes and weight loss. It mimics a natural hormone that regulates blood sugar and appetite.',
    mechanism: {
      type: 'receptor-agonist',
      target: 'GLP-1 receptor',
      targetLocation: 'Pancreas, brain, GI tract',
      simpleExplanation: 'Mimics a natural hormone that increases insulin, decreases glucagon, slows digestion, and reduces appetite.',
      detailedMechanism: 'GLP-1 analog resistant to DPP-4 degradation. Activates GLP-1 receptors causing glucose-dependent insulin secretion, suppressed glucagon, delayed gastric emptying, and central satiety signals.',
      mechanismSteps: [
        { order: 1, location: 'Pancreas', action: 'GLP-1 receptor activation', result: 'Glucose-dependent insulin release', timeframe: 'Hours' },
        { order: 2, location: 'Brain', action: 'Hypothalamic GLP-1 receptors', result: 'Reduced appetite', timeframe: 'Days-weeks' },
        { order: 3, location: 'GI tract', action: 'Delayed gastric emptying', result: 'Early satiety', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Metabolic', effect: 'Glucose lowering', mechanism: 'Insulin and glucagon effects', clinicalRelevance: 'A1c reduction 1-1.5%', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Appetite suppression', mechanism: 'Central GLP-1 receptors', clinicalRelevance: '10-15% weight loss', desiredOrAdverse: 'desired' },
        { system: 'Cardiovascular', effect: 'CV protection', mechanism: 'Multiple pathways', clinicalRelevance: 'Reduced MACE', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: 'Days (glucose), weeks (weight)',
      durationOfEffect: '7 days (injection)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '89% (SC); ~1% (oral with enhancer)', route: ['subcutaneous', 'oral'], factors: ['Oral requires fasting'], timeToePeak: '1-3 days (SC)' },
      distribution: { volumeOfDistribution: '12.5 L', proteinBinding: '>99%', tissueDistribution: ['Plasma'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Proteolytic degradation', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Urine and feces', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '7 days (allows weekly dosing)',
      timeToSteadyState: '4-5 weeks',
    },
    indications: [
      { condition: 'Type 2 diabetes', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Chronic weight management (Wegovy)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Cardiovascular risk reduction', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '0.25-2 mg', frequency: 'Once weekly (SC)', route: 'Subcutaneous' },
      adjustments: [
        { condition: 'Initiation', adjustment: 'Start 0.25 mg weekly, titrate monthly', rationale: 'GI tolerability' },
        { condition: 'Weight management', adjustment: 'Titrate to 2.4 mg weekly', rationale: 'Higher dose for weight loss' },
      ],
      maxDose: '2 mg/week (diabetes), 2.4 mg/week (weight)',
      administration: { route: 'Subcutaneous (or oral for Rybelsus)', withFood: 'either', specialInstructions: ['SC: Any time of day, with or without food', 'Oral: 30 min before food with ≤4 oz water'] },
    },
    adverseEffects: [
      { name: 'Nausea', frequency: 'very-common', severity: 'mild', mechanism: 'Delayed gastric emptying', management: 'Slow titration; usually improves', reversible: true, onsetTiming: 'Early' },
      { name: 'Vomiting', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Slow titration; small meals', reversible: true, onsetTiming: 'Early' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'GI effects', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Pancreatitis', frequency: 'rare', severity: 'severe', mechanism: 'Unknown', management: 'Stop drug permanently', reversible: true, onsetTiming: 'Variable' },
      { name: 'Gallbladder disease', frequency: 'uncommon', severity: 'moderate', mechanism: 'Rapid weight loss', management: 'Standard management', reversible: true, onsetTiming: 'Months' },
    ],
    interactions: [
      { interactingDrug: 'Insulin/Sulfonylureas', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive glucose lowering', effect: 'Hypoglycemia', management: 'Reduce insulin dose when starting' },
      { interactingDrug: 'Oral medications', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Delayed gastric emptying', effect: 'Altered absorption timing', management: 'Usually not clinically significant' },
    ],
    contraindications: [
      { condition: 'Personal/family history of medullary thyroid carcinoma', type: 'absolute', reason: 'C-cell tumor risk in animals' },
      { condition: 'MEN 2 syndrome', type: 'absolute', reason: 'Thyroid cancer risk' },
      { condition: 'History of pancreatitis', type: 'relative', reason: 'Pancreatitis risk' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Not recommended', recommendation: 'Discontinue 2 months before pregnancy', pregnancyCategory: 'Not recommended' },
      { population: 'renal-impairment', consideration: 'No dose adjustment needed', recommendation: 'Use caution in severe due to GI symptoms and dehydration risk' },
    ],
    monitoring: [
      { parameter: 'A1c/Blood glucose', frequency: 'Every 3 months', rationale: 'Glycemic efficacy' },
      { parameter: 'Weight', frequency: 'Monthly during titration', rationale: 'Primary endpoint for weight indication' },
      { parameter: 'Signs of pancreatitis', frequency: 'Ongoing', rationale: 'Rare but serious' },
    ],
    patientEducation: ['GI side effects improve with time - slow titration helps', 'Once weekly injection (any day, any time)', 'Store in refrigerator', 'Do not use if pregnant or planning pregnancy', 'Report severe abdominal pain immediately'],
    clinicalPearls: ['Most effective agent for A1c and weight currently available', 'Weekly dosing improves adherence', 'GI side effects usually diminish after 4-8 weeks', 'Thyroid cancer warning based on rodent data - unclear human relevance'],
  },

  // Vancomycin - Glycopeptide Antibiotic
  {
    id: 'vancomycin',
    genericName: 'Vancomycin',
    brandNames: ['Vancocin', 'Firvanq'],
    drugClass: 'Glycopeptide Antibiotic',
    category: 'antimicrobial',
    overview: 'Vancomycin is a critical antibiotic for serious gram-positive infections, especially MRSA. It requires IV administration for systemic infections but oral for C. diff.',
    mechanism: {
      type: 'cell-wall-inhibitor',
      target: 'D-Ala-D-Ala terminus of peptidoglycan precursors',
      targetLocation: 'Bacterial cell wall',
      simpleExplanation: 'Binds to building blocks of bacterial cell wall, preventing the wall from being built and killing the bacteria.',
      detailedMechanism: 'Binds to D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors, preventing transglycosylation and transpeptidation. Results in defective cell wall synthesis and bacterial lysis.',
      mechanismSteps: [
        { order: 1, location: 'Cell wall precursors', action: 'Binds D-Ala-D-Ala', result: 'Blocks precursor incorporation', timeframe: 'Minutes' },
        { order: 2, location: 'Cell wall', action: 'Prevents cross-linking', result: 'Defective cell wall and lysis', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Infectious', effect: 'Bactericidal', mechanism: 'Cell wall destruction', clinicalRelevance: 'Kills gram-positive bacteria', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: 'Hours to days clinically',
      durationOfEffect: 'Dose-dependent',
    },
    pharmacokinetics: {
      absorption: { bioavailability: 'Poor oral (systemic); oral works locally for C. diff', route: ['intravenous', 'oral (for C. diff)'], factors: ['IV only for systemic infections'], timeToePeak: 'End of infusion (IV)' },
      distribution: { volumeOfDistribution: '0.4-1 L/kg', proteinBinding: '50%', tissueDistribution: ['Most tissues', 'Poor CNS penetration unless inflamed'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Not metabolized', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (90% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '4-6 hours (normal renal function); prolonged in renal impairment',
      timeToSteadyState: '24-36 hours',
    },
    indications: [
      { condition: 'MRSA infections', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'C. difficile colitis (oral)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Endocarditis (gram-positive)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Meningitis (with third-gen cephalosporin)', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '15-20 mg/kg', frequency: 'Every 8-12 hours', route: 'IV' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: 'Extend interval based on CrCl; use levels', rationale: 'Renally eliminated' },
        { condition: 'Obesity', adjustment: 'Use actual body weight', rationale: 'Altered Vd' },
        { condition: 'C. diff (oral)', adjustment: '125-500 mg QID', rationale: 'Local effect only' },
      ],
      maxDose: 'Based on trough levels',
      administration: { route: 'IV (slow infusion over 1+ hour)', withFood: 'either', specialInstructions: ['Infuse over at least 1 hour to prevent Red Man Syndrome', 'Oral does not treat systemic infections'] },
    },
    adverseEffects: [
      { name: 'Red Man Syndrome', frequency: 'common', severity: 'moderate', mechanism: 'Histamine release from rapid infusion', management: 'Slow infusion rate; antihistamines', reversible: true, onsetTiming: 'During infusion' },
      { name: 'Nephrotoxicity', frequency: 'common', severity: 'moderate', mechanism: 'Direct renal tubular toxicity', management: 'Monitor trough levels and creatinine', reversible: true, onsetTiming: 'Days to weeks' },
      { name: 'Ototoxicity', frequency: 'uncommon', severity: 'severe', mechanism: 'Cochlear damage', management: 'Monitor levels; avoid with other ototoxic drugs', reversible: false, onsetTiming: 'Variable' },
      { name: 'Thrombocytopenia', frequency: 'uncommon', severity: 'moderate', mechanism: 'Immune-mediated', management: 'Monitor platelets; discontinue if severe', reversible: true, onsetTiming: 'Days to weeks' },
    ],
    interactions: [
      { interactingDrug: 'Aminoglycosides', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive nephro/ototoxicity', effect: 'Increased renal and hearing damage risk', management: 'Avoid if possible; monitor closely' },
      { interactingDrug: 'Loop diuretics', interactionType: 'pharmacodynamic', severity: 'moderate', mechanism: 'Additive ototoxicity', effect: 'Hearing loss risk', management: 'Monitor audiometry if prolonged use' },
    ],
    contraindications: [
      { condition: 'Known vancomycin allergy', type: 'absolute', reason: 'Hypersensitivity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Use when needed - no clear teratogenicity', recommendation: 'Use for serious infections when needed', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Renally eliminated', recommendation: 'Adjust dose; trough-based dosing' },
      { population: 'geriatric', consideration: 'Often have renal impairment', recommendation: 'Frequent level monitoring' },
    ],
    monitoring: [
      { parameter: 'Vancomycin trough', frequency: 'Before 4th dose, then per protocol', rationale: 'Goal 10-20 mcg/mL (or AUC-based)', actionThreshold: '<10 (ineffective), >20 (toxicity risk)' },
      { parameter: 'Creatinine', frequency: 'Every 2-3 days initially', rationale: 'Nephrotoxicity monitoring' },
      { parameter: 'CBC', frequency: 'Weekly', rationale: 'Thrombocytopenia monitoring' },
    ],
    patientEducation: ['Tell nurse if itching, flushing during infusion (Red Man Syndrome)', 'Requires blood tests to check levels', 'Complete full course even if feeling better', 'Report ringing in ears'],
    clinicalPearls: ['Red Man Syndrome is NOT an allergy - slow the infusion', 'ORAL vancomycin does NOT treat systemic infections', 'AUC-based dosing now preferred over trough-only', 'Loading dose of 25-30 mg/kg for severe infections'],
  },

  // Acetazolamide - Carbonic Anhydrase Inhibitor
  {
    id: 'acetazolamide',
    genericName: 'Acetazolamide',
    brandNames: ['Diamox'],
    drugClass: 'Carbonic Anhydrase Inhibitor',
    category: 'neurological',
    overview: 'Acetazolamide has diverse uses including altitude sickness prevention, glaucoma, and certain seizures. It works by inhibiting carbonic anhydrase throughout the body.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'Carbonic anhydrase',
      targetLocation: 'Kidney, eye, brain, RBCs',
      simpleExplanation: 'Blocks an enzyme that helps control acid-base balance, leading to increased urine output and reduced fluid pressure in eyes and brain.',
      detailedMechanism: 'Inhibits carbonic anhydrase, reducing bicarbonate reabsorption in proximal tubule (diuresis), decreasing aqueous humor production (lower IOP), and causing respiratory alkalosis that aids altitude adaptation.',
      mechanismSteps: [
        { order: 1, location: 'Kidney', action: 'Inhibits proximal tubule CA', result: 'Bicarbonate diuresis', timeframe: 'Hours' },
        { order: 2, location: 'Eye', action: 'Reduces aqueous humor production', result: 'Lower intraocular pressure', timeframe: 'Hours' },
        { order: 3, location: 'Brain', action: 'Reduces CSF production', result: 'Lower intracranial pressure', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Renal', effect: 'Bicarbonate diuresis', mechanism: 'Inhibits HCO3 reabsorption', clinicalRelevance: 'Metabolic acidosis', desiredOrAdverse: 'both' },
        { system: 'Eye', effect: 'Reduced IOP', mechanism: 'Less aqueous humor', clinicalRelevance: 'Glaucoma treatment', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Anticonvulsant', mechanism: 'Unclear; possibly acidosis', clinicalRelevance: 'Some seizure types', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-4 hours (oral)',
      durationOfEffect: '8-12 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '>90%', route: ['oral', 'intravenous'], factors: ['Well absorbed'], timeToePeak: '1-4 hours' },
      distribution: { volumeOfDistribution: '0.2 L/kg', proteinBinding: '70-90%', tissueDistribution: ['RBCs', 'Kidney', 'Eye'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Not metabolized', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Renal (100% unchanged)', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '10-15 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Acute mountain sickness prevention', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Glaucoma', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: false },
      { condition: 'Idiopathic intracranial hypertension', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: true },
      { condition: 'Epilepsy (adjunct)', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '250-1000 mg', frequency: 'Daily in divided doses', route: 'Oral' },
      adjustments: [
        { condition: 'Altitude sickness prophylaxis', adjustment: '125-250 mg BID starting 1 day before ascent', rationale: 'Prophylactic dosing' },
        { condition: 'Renal impairment', adjustment: 'Reduce dose or avoid', rationale: 'Renally eliminated; metabolic acidosis worsens' },
      ],
      maxDose: '1000 mg/day',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['May cause tingling in fingers/toes'] },
    },
    adverseEffects: [
      { name: 'Paresthesias', frequency: 'very-common', severity: 'mild', mechanism: 'Electrolyte changes', management: 'Usually tolerable; dose-related', reversible: true, onsetTiming: 'Early' },
      { name: 'Metabolic acidosis', frequency: 'common', severity: 'moderate', mechanism: 'Bicarbonate wasting', management: 'Monitor; tolerance develops', reversible: true, onsetTiming: 'Days' },
      { name: 'Hypokalemia', frequency: 'common', severity: 'moderate', mechanism: 'Increased K excretion', management: 'Monitor potassium', reversible: true, onsetTiming: 'Days' },
      { name: 'Kidney stones', frequency: 'uncommon', severity: 'moderate', mechanism: 'Alkaline urine, hypocitraturia', management: 'Hydration; may need to stop', reversible: true, onsetTiming: 'Weeks-months' },
      { name: 'Sulfa allergy reaction', frequency: 'rare', severity: 'severe', mechanism: 'Sulfonamide structure', management: 'Avoid in sulfa allergy', reversible: true, onsetTiming: 'Days' },
    ],
    interactions: [
      { interactingDrug: 'Aspirin (high dose)', interactionType: 'pharmacokinetic', severity: 'major', mechanism: 'Displaces acetazolamide and increases CNS penetration', effect: 'Toxicity of both', management: 'Avoid combination' },
      { interactingDrug: 'Lithium', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Increased lithium excretion', effect: 'Decreased lithium levels', management: 'Monitor lithium' },
    ],
    contraindications: [
      { condition: 'Sulfonamide allergy', type: 'relative', reason: 'Cross-reactivity possible' },
      { condition: 'Severe hepatic disease', type: 'absolute', reason: 'Can precipitate hepatic encephalopathy' },
      { condition: 'Severe renal disease', type: 'absolute', reason: 'Worsens acidosis' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Teratogenic in animals', recommendation: 'Avoid in first trimester', pregnancyCategory: 'C' },
      { population: 'renal-impairment', consideration: 'Renally eliminated', recommendation: 'Avoid in severe impairment' },
    ],
    monitoring: [
      { parameter: 'Electrolytes', frequency: 'Baseline, then periodically', rationale: 'Hypokalemia, acidosis' },
      { parameter: 'Bicarbonate', frequency: 'Periodic', rationale: 'Metabolic acidosis monitoring' },
    ],
    patientEducation: ['Tingling in hands/feet is common and expected', 'Drink plenty of fluids', 'May make carbonated drinks taste flat', 'Start before climbing to altitude, not during symptoms'],
    clinicalPearls: ['Tolerance to diuretic effect develops in days', 'Paresthesias are expected - not a reason to stop', 'Structurally related to sulfonamides - use caution with sulfa allergy', 'Makes carbonated beverages taste bad (blocks CO2 sensing)'],
  },

  // Fexofenadine - Second-Generation Antihistamine
  {
    id: 'fexofenadine',
    genericName: 'Fexofenadine',
    brandNames: ['Allegra'],
    drugClass: 'Second-Generation Antihistamine',
    category: 'respiratory',
    overview: 'Fexofenadine is a non-sedating antihistamine used for allergies. It is the active metabolite of terfenadine without the cardiac risks.',
    mechanism: {
      type: 'receptor-antagonist',
      target: 'H1 histamine receptor',
      targetLocation: 'Peripheral tissues',
      simpleExplanation: 'Blocks histamine from causing allergy symptoms like sneezing, itching, and runny nose.',
      detailedMechanism: 'Selective peripheral H1-receptor antagonist. Does not significantly cross the BBB, resulting in minimal sedation. Blocks histamine-induced vascular permeability, smooth muscle contraction, and itch sensation.',
      mechanismSteps: [
        { order: 1, location: 'H1 receptors', action: 'Competitive antagonism', result: 'Blocked histamine effects', timeframe: '1-3 hours' },
      ],
      physiologicalEffects: [
        { system: 'Immune/Respiratory', effect: 'Reduced allergic symptoms', mechanism: 'H1 blockade', clinicalRelevance: 'Symptom relief', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-3 hours',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '33%', route: ['oral'], factors: ['Fruit juice reduces absorption by 30-40%'], timeToePeak: '1-3 hours' },
      distribution: { volumeOfDistribution: '5.8 L/kg', proteinBinding: '60-70%', tissueDistribution: ['Peripheral'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Minimal hepatic metabolism', enzymes: ['~5% by CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Feces (80%) and urine (11%) mostly unchanged', adjustmentNeeded: { renal: true, hepatic: false } },
      halfLife: '14 hours',
      timeToSteadyState: '2-3 days',
    },
    indications: [
      { condition: 'Seasonal allergic rhinitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Chronic idiopathic urticaria', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '60 mg BID or 180 mg once daily', frequency: 'Once or twice daily', route: 'Oral' },
      adjustments: [
        { condition: 'Renal impairment', adjustment: '60 mg once daily', rationale: 'Reduced clearance' },
        { condition: 'Pediatric', adjustment: 'Age-based dosing', rationale: 'Different formulations' },
      ],
      maxDose: '180 mg/day',
      administration: { route: 'Oral', withFood: 'without-food', specialInstructions: ['Avoid taking with fruit juice'] },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually tolerable', reversible: true, onsetTiming: 'Variable' },
      { name: 'Drowsiness', frequency: 'uncommon', severity: 'mild', mechanism: 'Minimal CNS penetration', management: 'Much less than first-gen antihistamines', reversible: true, onsetTiming: 'Variable' },
      { name: 'Nausea', frequency: 'uncommon', severity: 'mild', mechanism: 'GI effect', management: 'Take with food if needed (despite label)', reversible: true, onsetTiming: 'Early' },
    ],
    interactions: [
      { interactingDrug: 'Fruit juices (apple, orange, grapefruit)', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Inhibit OATP transporters reducing absorption', effect: 'Reduced fexofenadine levels by 30-40%', management: 'Avoid taking with fruit juice' },
      { interactingDrug: 'Erythromycin', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Inhibits P-glycoprotein efflux', effect: 'Increased fexofenadine levels', management: 'Usually not clinically significant' },
    ],
    contraindications: [
      { condition: 'Known hypersensitivity', type: 'absolute', reason: 'Allergic reaction' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but appears safe', recommendation: 'Use if needed; cetirizine preferred by some', pregnancyCategory: 'C' },
      { population: 'breastfeeding', consideration: 'Small amounts in milk', recommendation: 'Generally acceptable' },
      { population: 'geriatric', consideration: 'May need renal adjustment', recommendation: 'Check renal function' },
    ],
    monitoring: [
      { parameter: 'Symptom control', frequency: 'As needed', rationale: 'Efficacy assessment' },
    ],
    patientEducation: ['Does not typically cause drowsiness', 'Avoid taking with fruit juice - take with water', 'Can be taken daily during allergy season', 'Available over the counter'],
    clinicalPearls: ['Least sedating of the second-gen antihistamines', 'No cardiac effects (unlike its parent terfenadine)', 'Fruit juice interaction is clinically significant - take with water', 'Can safely use in pilots and other professions requiring alertness'],
  },

  // Polyethylene Glycol - Osmotic Laxative
  {
    id: 'polyethylene-glycol',
    genericName: 'Polyethylene Glycol 3350',
    brandNames: ['Miralax', 'GlycoLax', 'GoLYTELY'],
    drugClass: 'Osmotic Laxative',
    category: 'gastrointestinal',
    overview: 'PEG 3350 is a gentle osmotic laxative commonly used for constipation. It works by drawing water into the stool, making it softer and easier to pass.',
    mechanism: {
      type: 'other',
      target: 'Intestinal water content',
      targetLocation: 'Colon',
      simpleExplanation: 'Holds water in the intestine, making stool softer and easier to pass.',
      detailedMechanism: 'Large, non-absorbable molecule that creates osmotic gradient in the intestinal lumen, drawing water into the colon. Increases stool volume and promotes peristalsis without significant electrolyte disturbance.',
      mechanismSteps: [
        { order: 1, location: 'Intestine', action: 'Creates osmotic gradient', result: 'Water drawn into lumen', timeframe: '1-3 days' },
        { order: 2, location: 'Colon', action: 'Increased stool water content', result: 'Softer stool and easier passage', timeframe: '1-3 days' },
      ],
      physiologicalEffects: [
        { system: 'GI', effect: 'Increased stool frequency and softness', mechanism: 'Osmotic water retention', clinicalRelevance: 'Constipation relief', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '1-3 days (chronic constipation); hours (bowel prep)',
      durationOfEffect: 'Duration of use',
    },
    pharmacokinetics: {
      absorption: { bioavailability: 'Essentially 0% - not absorbed', route: ['oral'], factors: ['Not absorbed'], timeToePeak: 'N/A' },
      distribution: { volumeOfDistribution: 'N/A - not absorbed', proteinBinding: 'N/A', tissueDistribution: ['GI tract only'], crossesBBB: false, crossesPlacenta: false },
      metabolism: { primarySite: 'Not metabolized', enzymes: [], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Feces (unchanged)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: 'N/A - not absorbed',
      timeToSteadyState: 'N/A',
    },
    indications: [
      { condition: 'Chronic constipation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Bowel preparation', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true, notes: 'Higher volumes with electrolytes' },
      { condition: 'Fecal impaction', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '17 g', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Bowel prep', adjustment: 'Large volume solutions (GoLYTELY)', rationale: 'Complete cleansing needed' },
        { condition: 'Pediatric', adjustment: '0.5-1 g/kg/day', rationale: 'Weight-based dosing' },
      ],
      maxDose: '17 g/day for chronic use (higher for bowel prep)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['Mix in 8 oz of any beverage', 'Tasteless and odorless'] },
    },
    adverseEffects: [
      { name: 'Bloating', frequency: 'common', severity: 'mild', mechanism: 'Osmotic effect', management: 'Usually improves with time', reversible: true, onsetTiming: 'Early' },
      { name: 'Cramping', frequency: 'uncommon', severity: 'mild', mechanism: 'Increased peristalsis', management: 'Reduce dose', reversible: true, onsetTiming: 'Early' },
      { name: 'Diarrhea', frequency: 'uncommon', severity: 'mild', mechanism: 'Excessive effect', management: 'Reduce dose or skip doses', reversible: true, onsetTiming: 'Variable' },
    ],
    interactions: [
      { interactingDrug: 'Minimal interactions', interactionType: 'pharmacokinetic', severity: 'minor', mechanism: 'Not absorbed', effect: 'None significant', management: 'No specific precautions needed' },
    ],
    contraindications: [
      { condition: 'Known bowel obstruction', type: 'absolute', reason: 'Could worsen obstruction' },
      { condition: 'Ileus', type: 'absolute', reason: 'Need bowel motility' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Not absorbed - very safe', recommendation: 'First-line for constipation in pregnancy', pregnancyCategory: 'C (but not absorbed)' },
      { population: 'pediatric', consideration: 'Well-studied in children', recommendation: 'Safe and effective' },
      { population: 'geriatric', consideration: 'Gentle and well-tolerated', recommendation: 'Good choice for elderly' },
    ],
    monitoring: [
      { parameter: 'Bowel function', frequency: 'Ongoing', rationale: 'Efficacy assessment' },
    ],
    patientEducation: ['May take 1-3 days to work', 'Mix in any beverage - tasteless', 'Safe for long-term use', 'Drink adequate fluids', 'Not habit-forming'],
    clinicalPearls: ['Gentle and non-habit forming - safe for long-term use', 'First-line for chronic constipation in most guidelines', 'Not absorbed - extremely safe profile', 'Works better with adequate hydration'],
  },

  // Cyclobenzaprine - Muscle Relaxant
  {
    id: 'cyclobenzaprine',
    genericName: 'Cyclobenzaprine',
    brandNames: ['Flexeril', 'Amrix'],
    drugClass: 'Skeletal Muscle Relaxant',
    category: 'musculoskeletal',
    overview: 'Cyclobenzaprine is a centrally-acting muscle relaxant used for short-term relief of muscle spasm. It is structurally related to tricyclic antidepressants.',
    mechanism: {
      type: 'other',
      target: 'Central nervous system',
      targetLocation: 'Brainstem',
      simpleExplanation: 'Acts in the brain to reduce muscle spasm signals, providing relief from painful muscle tightness.',
      detailedMechanism: 'Acts primarily at brainstem level to reduce tonic somatic motor activity. Does not act directly on muscle or neuromuscular junction. Structurally and pharmacologically related to tricyclic antidepressants.',
      mechanismSteps: [
        { order: 1, location: 'Brainstem', action: 'Reduces motor neuron activity', result: 'Decreased muscle tone', timeframe: 'Hours' },
      ],
      physiologicalEffects: [
        { system: 'Musculoskeletal', effect: 'Muscle relaxation', mechanism: 'Central motor depression', clinicalRelevance: 'Spasm relief', desiredOrAdverse: 'desired' },
        { system: 'CNS', effect: 'Sedation', mechanism: 'Central nervous system depression', clinicalRelevance: 'Often limits daytime use', desiredOrAdverse: 'adverse' },
      ],
      onsetOfAction: '1 hour',
      durationOfEffect: '12-24 hours',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '33-55%', route: ['oral'], factors: ['Food does not significantly affect'], timeToePeak: '4 hours (IR); 7-8 hours (ER)' },
      distribution: { volumeOfDistribution: 'Large', proteinBinding: '93%', tissueDistribution: ['CNS', 'Muscle'], crossesBBB: true, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP3A4', 'CYP1A2', 'CYP2D6'], activeMetabolites: [], drugInteractionRisk: 'moderate' },
      excretion: { primaryRoute: 'Urine (mostly as metabolites)', adjustmentNeeded: { renal: false, hepatic: true } },
      halfLife: '18 hours (range 8-37 hours)',
      timeToSteadyState: '3-4 days',
    },
    indications: [
      { condition: 'Acute musculoskeletal pain with spasm', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: false },
      { condition: 'Fibromyalgia (low dose)', approvalStatus: 'off-label', evidenceLevel: 'moderate', firstLine: false },
    ],
    dosing: {
      usualDose: { amount: '5-10 mg', frequency: 'Three times daily', route: 'Oral' },
      adjustments: [
        { condition: 'Elderly', adjustment: '5 mg TID; avoid ER formulation', rationale: 'Increased sensitivity, longer half-life' },
        { condition: 'Hepatic impairment', adjustment: 'Start low, use with caution', rationale: 'Hepatically metabolized' },
      ],
      maxDose: '30 mg/day (IR) or 30 mg/day (ER)',
      administration: { route: 'Oral', withFood: 'either', specialInstructions: ['May cause drowsiness - take at bedtime if possible'] },
    },
    adverseEffects: [
      { name: 'Drowsiness', frequency: 'very-common', severity: 'moderate', mechanism: 'CNS depression', management: 'Take at bedtime; avoid driving', reversible: true, onsetTiming: 'Early' },
      { name: 'Dry mouth', frequency: 'very-common', severity: 'mild', mechanism: 'Anticholinergic effect', management: 'Sip water, sugarless gum', reversible: true, onsetTiming: 'Early' },
      { name: 'Dizziness', frequency: 'common', severity: 'mild', mechanism: 'CNS effect', management: 'Rise slowly', reversible: true, onsetTiming: 'Early' },
      { name: 'Constipation', frequency: 'common', severity: 'mild', mechanism: 'Anticholinergic effect', management: 'Fiber, fluids', reversible: true, onsetTiming: 'Days' },
    ],
    interactions: [
      { interactingDrug: 'MAO inhibitors', interactionType: 'pharmacodynamic', severity: 'contraindicated', mechanism: 'Structurally similar to TCAs', effect: 'Serotonin syndrome, hyperpyrexia', management: 'Do not use within 14 days of MAOI' },
      { interactingDrug: 'CNS depressants', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Additive sedation', effect: 'Excessive sedation', management: 'Use caution; reduce doses' },
      { interactingDrug: 'Tramadol', interactionType: 'pharmacodynamic', severity: 'major', mechanism: 'Both affect serotonin', effect: 'Seizure risk, serotonin syndrome', management: 'Use with caution' },
    ],
    contraindications: [
      { condition: 'Recent MI or arrhythmias', type: 'absolute', reason: 'TCA-like cardiac effects' },
      { condition: 'Heart failure', type: 'relative', reason: 'Anticholinergic effects' },
      { condition: 'Use with MAOIs', type: 'absolute', reason: 'Serious interactions' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data', recommendation: 'Avoid if possible', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Increased sensitivity, anticholinergic effects', recommendation: 'Avoid - on Beers list' },
      { population: 'hepatic-impairment', consideration: 'Hepatically metabolized', recommendation: 'Use lower doses' },
    ],
    monitoring: [
      { parameter: 'Symptom relief', frequency: 'After 2-3 weeks', rationale: 'Limit use to 2-3 weeks' },
      { parameter: 'Sedation level', frequency: 'Ongoing', rationale: 'Safety concern' },
    ],
    patientEducation: ['Causes drowsiness - do not drive until you know how it affects you', 'Not for long-term use (2-3 weeks max)', 'Avoid alcohol', 'May cause dry mouth', 'Best taken at bedtime due to sedation'],
    clinicalPearls: ['Limit use to 2-3 weeks - not for chronic use', 'Structurally similar to TCAs - similar side effects and interactions', 'On Beers list - avoid in elderly', '5 mg TID may be as effective as 10 mg TID with less sedation', 'Often used at bedtime for both muscle relaxation and sleep'],
  },

  // Pantoprazole - Proton Pump Inhibitor
  {
    id: 'pantoprazole',
    genericName: 'Pantoprazole',
    brandNames: ['Protonix'],
    drugClass: 'Proton Pump Inhibitor',
    category: 'gastrointestinal',
    overview: 'Pantoprazole is a PPI used to reduce stomach acid. It is commonly used for GERD, ulcers, and in hospital settings for stress ulcer prophylaxis.',
    mechanism: {
      type: 'enzyme-inhibitor',
      target: 'H+/K+-ATPase (proton pump)',
      targetLocation: 'Gastric parietal cells',
      simpleExplanation: 'Blocks the final step of acid production in the stomach, providing powerful acid suppression.',
      detailedMechanism: 'Irreversibly inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells. Blocks the final step of acid production regardless of stimulus.',
      mechanismSteps: [
        { order: 1, location: 'Stomach', action: 'Prodrug converted to active form in acidic canaliculus', result: 'Binds covalently to proton pump', timeframe: 'Minutes' },
        { order: 2, location: 'Parietal cell', action: 'Irreversible enzyme inhibition', result: 'Acid secretion blocked until new pumps synthesized', timeframe: 'Hours to days' },
      ],
      physiologicalEffects: [
        { system: 'GI', effect: 'Reduced gastric acid', mechanism: 'Proton pump inhibition', clinicalRelevance: 'GERD/ulcer healing', desiredOrAdverse: 'desired' },
      ],
      onsetOfAction: '2.5 hours (antisecretory effect)',
      durationOfEffect: '24+ hours (despite short half-life due to irreversible binding)',
    },
    pharmacokinetics: {
      absorption: { bioavailability: '77%', route: ['oral', 'intravenous'], factors: ['Enteric-coated to prevent gastric degradation'], timeToePeak: '2-3 hours' },
      distribution: { volumeOfDistribution: '11-23 L', proteinBinding: '98%', tissueDistribution: ['Parietal cells'], crossesBBB: false, crossesPlacenta: true },
      metabolism: { primarySite: 'Liver', enzymes: ['CYP2C19', 'CYP3A4'], activeMetabolites: [], drugInteractionRisk: 'low' },
      excretion: { primaryRoute: 'Urine (71%)', adjustmentNeeded: { renal: false, hepatic: false } },
      halfLife: '1 hour',
      timeToSteadyState: '3-5 days (for maximal acid suppression)',
    },
    indications: [
      { condition: 'GERD', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Erosive esophagitis', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Zollinger-Ellison syndrome', approvalStatus: 'FDA-approved', evidenceLevel: 'high', firstLine: true },
      { condition: 'Stress ulcer prophylaxis', approvalStatus: 'FDA-approved', evidenceLevel: 'moderate', firstLine: true },
    ],
    dosing: {
      usualDose: { amount: '40 mg', frequency: 'Once daily', route: 'Oral' },
      adjustments: [
        { condition: 'Erosive esophagitis maintenance', adjustment: '20-40 mg daily', rationale: 'Lower dose may suffice' },
        { condition: 'Zollinger-Ellison', adjustment: '40 mg BID, titrate up', rationale: 'Higher doses often needed' },
      ],
      maxDose: '240 mg/day (Zollinger-Ellison)',
      administration: { route: 'Oral or IV', withFood: 'without-food', specialInstructions: ['Take 30-60 minutes before breakfast', 'Do not crush or chew tablets'] },
    },
    adverseEffects: [
      { name: 'Headache', frequency: 'common', severity: 'mild', mechanism: 'Unknown', management: 'Usually transient', reversible: true, onsetTiming: 'Early' },
      { name: 'Diarrhea', frequency: 'common', severity: 'mild', mechanism: 'Altered gut flora', management: 'Usually tolerable', reversible: true, onsetTiming: 'Variable' },
      { name: 'C. difficile infection', frequency: 'uncommon', severity: 'severe', mechanism: 'Altered stomach pH and gut flora', management: 'Stop PPI; treat infection', reversible: true, onsetTiming: 'Variable' },
      { name: 'Hypomagnesemia', frequency: 'rare', severity: 'moderate', mechanism: 'Reduced intestinal absorption', management: 'Check Mg with long-term use', reversible: true, onsetTiming: 'Months-years' },
      { name: 'Increased fracture risk', frequency: 'rare', severity: 'moderate', mechanism: 'Reduced calcium absorption', management: 'Use lowest effective dose', reversible: false, onsetTiming: 'Years' },
    ],
    interactions: [
      { interactingDrug: 'Clopidogrel', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'CYP2C19 inhibition reduces clopidogrel activation', effect: 'Potentially reduced antiplatelet effect', management: 'Pantoprazole has less CYP2C19 effect than omeprazole - may be preferred' },
      { interactingDrug: 'Methotrexate', interactionType: 'pharmacokinetic', severity: 'moderate', mechanism: 'Reduced renal clearance', effect: 'Increased methotrexate levels', management: 'Monitor; may need to hold PPI' },
    ],
    contraindications: [
      { condition: 'Known PPI allergy', type: 'absolute', reason: 'Hypersensitivity' },
    ],
    specialPopulations: [
      { population: 'pregnancy', consideration: 'Limited data but appears safe', recommendation: 'Use if needed', pregnancyCategory: 'B' },
      { population: 'geriatric', consideration: 'Long-term risks (fractures, infections)', recommendation: 'Use lowest dose for shortest duration' },
    ],
    monitoring: [
      { parameter: 'Symptom control', frequency: 'After 4-8 weeks', rationale: 'Reassess need for continued therapy' },
      { parameter: 'Magnesium', frequency: 'Annually with long-term use', rationale: 'Hypomagnesemia risk' },
    ],
    patientEducation: ['Take 30-60 minutes before eating', 'Do not crush or chew tablets', 'Not for immediate heartburn relief - takes days for full effect', 'Long-term use has some risks - use lowest effective dose'],
    clinicalPearls: ['Lower CYP2C19 inhibition than omeprazole - preferred with clopidogrel', 'IV form commonly used for stress ulcer prophylaxis', 'Enteric coating is essential - do not crush', 'Antisecretory effect outlasts plasma half-life due to irreversible binding'],
  },

];

// ============================================
// Common Drug Interactions Database
// ============================================

export const COMMON_INTERACTIONS: DrugInteraction[] = [
  {
    interactingDrug: 'Warfarin + NSAIDs',
    interactionType: 'pharmacodynamic',
    severity: 'major',
    mechanism: 'NSAIDs inhibit platelet function and cause GI ulceration; combined with anticoagulation greatly increases bleeding risk',
    effect: 'Significantly increased risk of GI and other bleeding',
    management: 'Avoid combination if possible. If necessary, use PPI prophylaxis and monitor closely.',
  },
  {
    interactingDrug: 'Statins + Grapefruit',
    interactionType: 'pharmacokinetic',
    severity: 'moderate',
    mechanism: 'Grapefruit inhibits CYP3A4 in gut wall, increasing statin absorption',
    effect: 'Increased statin levels, increased myopathy risk',
    management: 'Avoid grapefruit with simvastatin, lovastatin. Less concern with atorvastatin (limited), minimal with pravastatin, rosuvastatin.',
  },
  {
    interactingDrug: 'ACE Inhibitors + Potassium supplements',
    interactionType: 'pharmacodynamic',
    severity: 'major',
    mechanism: 'ACE inhibitors decrease aldosterone, reducing potassium excretion. Adding potassium compounds the effect.',
    effect: 'Hyperkalemia risk',
    management: 'Monitor potassium levels. Usually avoid routine K supplementation with ACE-I. Be cautious with salt substitutes.',
  },
  {
    interactingDrug: 'SSRIs + MAOIs',
    interactionType: 'pharmacodynamic',
    severity: 'contraindicated',
    mechanism: 'Both increase serotonin. MAOIs prevent serotonin breakdown while SSRIs prevent reuptake.',
    effect: 'Serotonin syndrome - potentially fatal',
    management: 'Never combine. Wait 2 weeks after stopping SSRI (5 weeks for fluoxetine) before starting MAOI.',
  },
  {
    interactingDrug: 'Methotrexate + NSAIDs',
    interactionType: 'pharmacokinetic',
    severity: 'major',
    mechanism: 'NSAIDs reduce renal blood flow and compete for tubular secretion',
    effect: 'Increased methotrexate levels and toxicity',
    management: 'Avoid NSAIDs with high-dose methotrexate. Caution with low-dose methotrexate.',
  },
  {
    interactingDrug: 'Opioids + Benzodiazepines',
    interactionType: 'pharmacodynamic',
    severity: 'major',
    mechanism: 'Both cause CNS and respiratory depression',
    effect: 'Increased sedation, respiratory depression, overdose death',
    management: 'Avoid combination when possible. If necessary, use lowest effective doses. FDA black box warning.',
  },
  {
    interactingDrug: 'Digoxin + Amiodarone',
    interactionType: 'pharmacokinetic',
    severity: 'major',
    mechanism: 'Amiodarone inhibits P-glycoprotein and reduces renal clearance of digoxin',
    effect: 'Digoxin levels can double, increasing toxicity risk',
    management: 'Reduce digoxin dose by 50% when starting amiodarone. Monitor levels.',
  },
];

// ============================================
// Helper Functions
// ============================================

export function getDrugById(id: string): DrugEducation | undefined {
  return DRUGS.find(d => d.id === id);
}

export function getDrugByName(name: string): DrugEducation | undefined {
  const nameLower = name.toLowerCase();
  return DRUGS.find(d =>
    d.genericName.toLowerCase() === nameLower ||
    d.brandNames.some(bn => bn.toLowerCase() === nameLower)
  );
}

export function getDrugClassById(id: string): DrugClassEducation | undefined {
  return DRUG_CLASSES.find(dc => dc.id === id);
}

export function getDrugsByCategory(category: string): DrugEducation[] {
  return DRUGS.filter(d => d.category === category);
}

export function getInteractionsForDrug(drugName: string): DrugInteraction[] {
  const nameLower = drugName.toLowerCase();
  return COMMON_INTERACTIONS.filter(i =>
    i.interactingDrug.toLowerCase().includes(nameLower)
  );
}

export function getAllDrugClasses(): DrugClassEducation[] {
  return DRUG_CLASSES;
}
